column_name,broad_id,name,dose,screen_id,topFeature,feature_type,drug_category,moa_biomarkers,target,disease.area,indication,phase,bimodality_coef,Cor,hub_url,group,BM,x,y
BRD-A00055058-001-01-0::2.325889319::MTS004,BRD-A00055058-001-01-0,RS-0481,2.325889319,MTS004,Exp_TMEM221 (ENSG00000188051),GE,targeted cancer,immunostimulant,,,,Phase 2,0.342304606792274,0.0978978088055,RS-0481,,,0,0
BRD-A00077618-236-07-6::2.5::HTS,BRD-A00077618-236-07-6,8-bromo-cGMP,2.5,HTS,MIRNA_hsa-miR-199a-5p,MIRNA,noncancer,PKA activator,PRKG1,,,Preclinical,0.278782101151995,0.174358582763,8-bromo-cGMP,,,0,0
BRD-A00100033-001-08-9::2.5::HTS,BRD-A00100033-001-08-9,nifurtimox,2.5,HTS,CN_RNF216 (54476),CN,noncancer,DNA inhibitor,,infectious disease,"Chagas disease, African trypanosomiasis",Launched,0.299738637548386,0.0600884676485,nifurtimox,,,0,0
BRD-A00147595-001-01-5::2.5::HTS,BRD-A00147595-001-01-5,balaglitazone,2.5,HTS,CRISPR_PRSS48 (345062),AVANA_PUBLIC_18Q2,noncancer,"insulin sensitizer, PPAR receptor partial agonist",PPARG,,,Phase 3,0.288898845477852,0.0251805818322,balaglitazone,,,0,0
BRD-A00218260-001-03-4::2.5::HTS,BRD-A00218260-001-03-4,flutrimazole,2.5,HTS,METHYL_TAF1C,METHYL,noncancer,sterol demethylase inhibitor,,infectious disease,mycosis,Launched,0.281539554076653,0.0643244921527,flutrimazole,,,0,0
BRD-A00376169-001-01-6::2.5::HTS,BRD-A00376169-001-01-6,KBG,2.5,HTS,PROT_YB-1,PROT,targeted cancer,neprilysin inhibitor,MME,,,Phase 2,0.27491635228033,0.0175174330405,KBG,,,0,0
BRD-A00520476-001-07-4::2.5::HTS,BRD-A00520476-001-07-4,otenzepad,2.5,HTS,DEM2_LCN1 (3933),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,Phase 3,0.30056243228619,0.013886736378,otenzepad,,,0,0
BRD-A00546892-001-02-6::2.5::HTS,BRD-A00546892-001-02-6,biperiden,2.5,HTS,PROT_Heregulin,PROT,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",neurology/psychiatry,Parkinson's Disease,Launched,0.261509664955737,0.0783067930406,biperiden,,,0,0
BRD-A00578795-001-04-3::2.5::HTS,BRD-A00578795-001-04-3,zaltoprofen,2.5,HTS,LIN_glioma,LIN,noncancer,cyclooxygenase inhibitor,,"endocrinology, neurology/psychiatry","fever, pain relief",Launched,0.28902070756892,0.0660065497937,zaltoprofen,,,0,0
BRD-A00758722-001-04-9::2.5::HTS,BRD-A00758722-001-04-9,noretynodrel,2.5,HTS,Exp_RPL29P19 (ENSG00000224594),GE,noncancer,progestogen hormone,PGR,endocrinology,contraceptive,Launched,0.23943797568297603,0.085776645268,noretynodrel,,,0,0
BRD-A00827783-001-24-6::2.5::HTS,BRD-A00827783-001-24-6,dyphylline,2.5,HTS,PROT_Rab25,PROT,noncancer,"adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B",pulmonary,"asthma, bronchitis, emphysema",Launched,0.24853696005575102,0.0859260327243,dyphylline,,,0,0
BRD-A00842753-001-01-9::2.5::MTS004,BRD-A00842753-001-01-9,oleuropein,2.5,MTS004,Exp_RPL12P33 (ENSG00000244585),GE,targeted cancer,estrogen receptor agonist,GPER1,,,Phase 2,0.26027940248208103,0.0843166003699,oleuropein,,,0,0
BRD-A00993607-003-24-6::2.5::HTS,BRD-A00993607-003-24-6,alprenolol,2.5,HTS,DEM2_RAB4B (53916),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A",cardiology,angina pectoris,Launched,0.254055988533761,0.0682015343886,alprenolol,,,0,0
BRD-A01098288-001-02-9::2.5::HTS,BRD-A01098288-001-02-9,azelnidipine,2.5,HTS,DEM2_DDX19A (55308),DEMETER2_COM,noncancer,calcium channel blocker,CACNA1C,cardiology,hypertension,Launched,0.280398762761693,0.100692658138,azelnidipine,,,0,0
BRD-A01412266-001-01-0::2.5::HTS,BRD-A01412266-001-01-0,hydroxypropyl-beta-cyclodextrin,2.5,HTS,MIRNA_hsa-miR-1977,MIRNA,noncancer,,,,,Phase 2,0.259112949472745,-0.00983786997047,hydroxypropyl-beta-cyclodextrin,,,0,0
BRD-A01493904-003-12-1::2.5::HTS,BRD-A01493904-003-12-1,WB-4101,2.5,HTS,MIRNA_hsa-miR-296-3p,MIRNA,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A",,,Preclinical,0.30473357104525606,0.0570348920631,WB-4101,,,0,0
BRD-A01563671-001-02-7::2.5::HTS,BRD-A01563671-001-02-7,cleviprex,2.5,HTS,CN_CTAGE7P (119437),CN,noncancer,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1S",cardiology,hypertension,Launched,0.234880885713215,0.0556785127533,cleviprex,,,0,0
BRD-A01593789-001-03-1::2.5::HTS,BRD-A01593789-001-03-1,chlormadinone-acetate,2.5,HTS,METHYL_MIR3918,METHYL,noncancer,5 alpha reductase inhibitor,PGR,endocrinology,"hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea",Launched,0.26003706676335997,0.0295315278177,chlormadinone-acetate,,,0,0
BRD-A01636364-003-15-1::2.5::HTS,BRD-A01636364-003-15-1,bupivacaine,2.5,HTS,DEM2_TM4SF19 (116211),DEMETER2_COM,noncancer,sodium channel blocker,"KCNA5, PTGER1, SCN10A, SCN4A",neurology/psychiatry,"peripheral nerve block, caudal epidural block, lumbar epidural block",Launched,0.276882689104544,0.145048242711,bupivacaine,,,0,0
BRD-A01643550-001-04-9::2.5::HTS,BRD-A01643550-001-04-9,prednisolone-acetate,2.5,HTS,Exp_BHLHE41 (ENSG00000123095),GE,noncancer,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.271068644222136,0.244093999812,prednisolone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2781512119393608,4.0846858785388624,-2.481163187136203
BRD-A01907367-001-01-7::2.5::HTS,BRD-A01907367-001-01-7,FK-33-824,2.5,HTS,DEM2_DDI2 (84301),DEMETER2_COM,noncancer,opioid receptor agonist,OPRM1,,,Phase 2,0.27867320963062,0.133709077667,FK-33-824,,,0,0
BRD-A02006392-001-16-4::2.5::HTS,BRD-A02006392-001-16-4,nitrendipine,2.5,HTS,METHYL_CENPM,METHYL,noncancer,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CACNG1, KCNN4",cardiology,hypertension,Launched,0.33060067524680603,0.0315055896471,nitrendipine,,,0,0
BRD-A02180903-001-04-5::2.5::HTS,BRD-A02180903-001-04-5,betamethasone,2.5,HTS,PROT_53BP1,PROT,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.23296290580891502,0.134934559687,betamethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.2514294844168785,-3.9944578680181633,-2.8736801297440664
BRD-A02232681-001-01-8::2.5::MTS004,BRD-A02232681-001-01-8,isoleucine,2.5,MTS004,CN_MSH2 (4436),CN,noncancer,,"ACADSB, BCAT1, BCAT2, IARS, IARS2",,,Launched,0.254743215696174,0.0521711626932,isoleucine,,,0,0
BRD-A02710418-003-11-8::2.5::HTS,BRD-A02710418-003-11-8,meptazinol,2.5,HTS,Exp_HGSNAT (ENSG00000165102),GE,noncancer,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief,Launched,0.30011789350869605,0.110012323242,meptazinol,,,0,0
BRD-A02743701-001-03-6::2.5::HTS,BRD-A02743701-001-03-6,cilnidipine,2.5,HTS,CN_BTNL3 (10917),CN,noncancer,calcium channel blocker,CACNA1B,cardiology,hypertension,Launched,0.251448241790204,0.0259917378489,cilnidipine,,,0,0
BRD-A02759312-003-24-5::2.5::HTS,BRD-A02759312-003-24-5,betaxolol,2.5,HTS,CRISPR_PHF14 (9678),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.228153759167469,0.0997950757804,betaxolol,,,0,0
BRD-A02990301-003-06-6::2.5::HTS,BRD-A02990301-003-06-6,lofexidine,2.5,HTS,METHYL_MIR3134,METHYL,noncancer,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,opioid withdrawal,Launched,0.272907562424677,0.0925288184371,lofexidine,,,0,0
BRD-A03061970-003-07-3::2.5::HTS,BRD-A03061970-003-07-3,alizapride,2.5,HTS,DEM2_NES (10763),DEMETER2_COM,noncancer,dopamine receptor antagonist,DRD2,gastroenterology,nausea,Launched,0.259155637344053,0.058950956971,alizapride,,,0,0
BRD-A03216249-003-24-3::2.5::HTS,BRD-A03216249-003-24-3,mepivacaine,2.5,HTS,Exp_RPE (ENSG00000197713),GE,noncancer,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,Launched,0.331160302299495,0.11729555076,mepivacaine,,,0,0
BRD-A03359064-001-02-3::2.5::HTS,BRD-A03359064-001-02-3,ICI-89406,2.5,HTS,PROT_mTOR,PROT,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",,,Phase 1,0.265526173227236,0.0821831953059,ICI-89406,,,0,0
BRD-A03623303-045-09-5::2.5::HTS,BRD-A03623303-045-09-5,metoprolol,2.5,HTS,RMUTmis_CCDC11 (0),MUTmis,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction",Launched,0.251710983735179,0.119763981875,metoprolol,,,0,0
BRD-A03880619-001-01-0::2.5::HTS,BRD-A03880619-001-01-0,bismuth-subcitrate-potassium,2.5,HTS,METABOL_C36:4 PC-A,METABOL,noncancer,,,gastroenterology,duodenal ulcer disease,Launched,0.321799539201006,0.109907890101,bismuth-subcitrate-potassium,,,0,0
BRD-A03932035-004-04-3::2.5::HTS,BRD-A03932035-004-04-3,methscopolamine,2.5,HTS,CN_CLPSL2 (389383),CN,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.295096433596605,0.151228638227,methscopolamine,OTHER,0.2948187242922233,4.208507489017701,-2.27903722546979
BRD-A04203391-001-08-3::2.5::HTS,BRD-A04203391-001-08-3,piricapiron,2.5,HTS,METHYL_MFSD9,METHYL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,,,Phase 2,0.261860940712461,0.0164486418696,piricapiron,,,0,0
BRD-A04252265-003-01-4::2.5::HTS,BRD-A04252265-003-01-4,eperisone,2.5,HTS,MUTpool_RRBP1 (6238),MUTpool,noncancer,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,"amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury",Launched,0.345123102249932,-0.0337886100974,eperisone,,,0,0
BRD-A04322457-003-17-9::2.5::HTS,BRD-A04322457-003-17-9,isoprenaline,2.5,HTS,CRISPR_TRIT1 (54802),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, MAPK1, PIK3R1, PIK3R2, PIK3R3","cardiology, pulmonary","bradycardia, heart block, asthma",Launched,0.266777157955691,0.168856778086,isoprenaline,,,0,0
BRD-A04327189-001-15-1::2.5::HTS,BRD-A04327189-001-15-1,synephrine,2.5,HTS,CRISPR_NUP35 (129401),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,ADRA1A,,,Launched,0.286482906499788,0.0896846634005,synephrine,,,0,0
BRD-A04327189-003-03-3::2.5::HTS,BRD-A04327189-003-03-3,synephrine,2.5,HTS,DEM2_UCK2 (7371),DEMETER2_COM,noncancer,adrenergic receptor agonist,ADRA1A,,,Launched,0.226941664261665,0.0718095403333,synephrine,,,0,0
BRD-A04352665-001-05-3::2.5::HTS,BRD-A04352665-001-05-3,maraviroc,2.5,HTS,DEM2_LY6H (4062),DEMETER2_COM,noncancer,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.31141944125530896,0.130843218832,maraviroc,,,0,0
BRD-A04447196-001-01-8::2.5::MTS004,BRD-A04447196-001-01-8,gepefrine,2.5,MTS004,METHYL_PTPRM,METHYL,noncancer,adrenergic receptor agonist,,cardiology,hypotension,Launched,0.28012290719120697,0.10434596325,gepefrine,,,0,0
BRD-A04497688-001-04-2::2.5::HTS,BRD-A04497688-001-04-2,trilostane,2.5,HTS,PROT_HER2,PROT,noncancer,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,"ESR1, ESR2, HSD3B1, HSD3B2",endocrinology,Cushing's syndrome,Launched,0.3149705737516911,0.0911807933754,trilostane,,,0,0
BRD-A04506385-001-01-2::2.5::HTS,BRD-A04506385-001-01-2,stepronin,2.5,HTS,RMUTmis_EFCAB3 (146779),MUTmis,noncancer,mucolytic agent,,,,Launched,0.30148145337805105,-0.00730177006124,stepronin,,,0,0
BRD-A04553218-050-16-2::2.5::HTS,BRD-A04553218-050-16-2,chlorphenamine,2.5,HTS,METHYL_NDFIP1,METHYL,noncancer,histamine receptor antagonist,"HRH1, SLC6A2, SLC6A3, SLC6A4",allergy,"allergic rhinitis, urticaria",Launched,0.285784170260461,0.0753165343587,chlorphenamine,,,0,0
BRD-A04661934-001-02-9::2.5::HTS,BRD-A04661934-001-02-9,2-PMDQ,2.5,HTS,DEM2_NSDHL (50814),DEMETER2_COM,noncancer,adrenergic receptor antagonist,ADRA1A,,,Preclinical,0.291620766584141,0.0532382100899,2-PMDQ,,,0,0
BRD-A04971881-003-01-3::2.65294603::MTS004,BRD-A04971881-003-01-3,cloranolol,2.65294603,MTS004,MIRNA_hsa-miR-145,MIRNA,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,Launched,0.222508113501731,0.0964759911627,cloranolol,,,0,0
BRD-A05186015-003-19-8::2.5::HTS,BRD-A05186015-003-19-8,bupropion,2.5,HTS,PROT_IRS1,PROT,noncancer,dopamine uptake inhibitor,"CHRNA3, SLC6A2, SLC6A3",neurology/psychiatry,depression,Launched,0.24210623884173002,0.069418629089,bupropion,,,0,0
BRD-A05334458-001-02-8::2.5::HTS,BRD-A05334458-001-02-8,lisofylline,2.5,HTS,METHYL_PECAM1,METHYL,noncancer,"interleukin receptor antagonist, STAT inhibitor",,,,Phase 2,0.25228224851384196,0.0151667342274,lisofylline,,,0,0
BRD-A05457250-001-08-4::2.5::HTS,BRD-A05457250-001-08-4,BAY-K-8644-(+/-),2.5,HTS,MIRNA_hsa-miR-128,MIRNA,noncancer,L-type calcium channel activator,,,,Preclinical,0.30542262416595,0.0547910512296,BAY-K-8644-(+/-),,,0,0
BRD-A05515753-001-03-2::2.5::HTS,BRD-A05515753-001-03-2,erdosteine,2.5,HTS,Exp_FAM85B (ENSG00000253893),GE,noncancer,mucolytic agent,,"pulmonary, infectious disease","bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections",Launched,0.28043810343495,0.101417834823,erdosteine,,,0,0
BRD-A05523972-001-01-5::2.5::HTS,BRD-A05523972-001-01-5,telmesteine,2.5,HTS,METHYL_RNU6-19P,METHYL,noncancer,mucolytic agent,,,,Launched,0.33991379194798305,0.0640221687727,telmesteine,,,0,0
BRD-A05674712-001-06-0::2.5::HTS,BRD-A05674712-001-06-0,"mevalonic-d,-l-acid-lactone",2.5,HTS,METHYL_MIR4799,METHYL,noncancer,,,,,Preclinical,0.288730066809507,0.103674499688,"mevalonic-d,-l-acid-lactone",,,0,0
BRD-A05729358-001-02-0::2.5::HTS,BRD-A05729358-001-02-0,CPCCOEt,2.5,HTS,CRISPR_ARID3C (138715),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,GRM1,,,Preclinical,0.27293538987634397,0.0401963100568,CPCCOEt,,,0,0
BRD-A05906449-004-01-1::2.5::HTS,BRD-A05906449-004-01-1,lappaconite,2.5,HTS,CN_PPP1R13B (23368),CN,noncancer,sodium channel blocker,,,,Phase 2,0.23021767599926896,0.0767603822291,lappaconite,,,0,0
BRD-A06352418-001-25-9::2.5::HTS,BRD-A06352418-001-25-9,terfenadine,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,noncancer,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",,,Withdrawn,0.372539460786562,0.249776551866,terfenadine,OTHER,0.3717834120171954,4.767394034675579,0.15047812552173667
BRD-A06352508-001-03-7::2.5::HTS,BRD-A06352508-001-03-7,SB-218078,2.5,HTS,Exp_ZBED4 (ENSG00000100426),GE,noncancer,CHK inhibitor,CHEK1,,,Preclinical,0.37856787455488206,0.284481844365,SB-218078,OTHER,0.3793704851734718,3.2210403616844285,-3.210230541083342
BRD-A06390036-001-04-6::2.5::HTS,BRD-A06390036-001-04-6,hydroquinidine,2.5,HTS,DEM2_GATA5 (140628),DEMETER2_COM,noncancer,antiarrhythmic,,cardiology,cardiac arrythmia,Launched,0.237725886031263,0.0672464748601,hydroquinidine,,,0,0
BRD-A06426627-001-03-5::2.5::HTS,BRD-A06426627-001-03-5,diclazuril,2.5,HTS,PROT_p38_pT180_Y182,PROT,noncancer,antiprotozoal agent,,infectious disease,equine protozoal myeloencephalitis (EPM),Launched,0.26868804883505804,0.0934215868279,diclazuril,,,0,0
BRD-A06627858-236-03-0::2.5::HTS,BRD-A06627858-236-03-0,monensin,2.5,HTS,DEM2_RRM2 (6241),DEMETER2_COM,noncancer,bacterial permeability inducer,,,,Launched,0.400473788935259,0.104196870879,monensin,OTHER,0.3956594975151236,3.891417097435754,-0.4123144878998773
BRD-A06771424-004-01-7::2.5::HTS,BRD-A06771424-004-01-7,anisotropine,2.5,HTS,CN_DNAJC24 (120526),CN,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.308885678025907,0.0877101128363,anisotropine,,,0,0
BRD-A06916187-001-02-9::2.5::HTS,BRD-A06916187-001-02-9,CPI-613,2.5,HTS,METHYL_UCKL1,METHYL,targeted cancer,pyruvate dehydrogenase inhibitor,PDHA1,,,Phase 2,0.28287111251403396,0.0756190013977,CPI-613,,,0,0
BRD-A06935312-001-04-3::2.5::HTS,BRD-A06935312-001-04-3,fusidic-acid,2.5,HTS,Exp_UTRN (ENSG00000152818),GE,noncancer,bacterial 30S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV),Launched,0.306133918403832,0.119308950361,fusidic-acid,,,0,0
BRD-A07000685-001-04-4::2.5::HTS,BRD-A07000685-001-04-4,hydrocortisone-hemisuccinate,2.5,HTS,Exp_CPNE7 (ENSG00000178773),GE,noncancer,,,,,Phase 2/Phase 3,0.296849521622794,0.170038998261,hydrocortisone-hemisuccinate,OTHER,0.29830070987221435,-4.19754975772237,-2.4954077135202843
BRD-A07164067-001-01-2::2.5::HTS,BRD-A07164067-001-01-2,meluadrine,2.5,HTS,CN_ANKRD20A12P (100874392),CN,noncancer,,,,,Preclinical,0.248851787600168,0.0882639259937,meluadrine,,,0,0
BRD-A07207424-001-13-2::2.5::HTS,BRD-A07207424-001-13-2,Ro-20-1724,2.5,HTS,METABOL_C18:0 SM,METABOL,noncancer,phosphodiesterase inhibitor,"PDE3A, PDE4A, PDE4B, PDE4C, PDE4D",,,Preclinical,0.27710877991895394,0.0236882937463,Ro-20-1724,,,0,0
BRD-A07395371-003-10-0::2.5::HTS,BRD-A07395371-003-10-0,esmolol,2.5,HTS,CRISPR_CILP2 (148113),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,ADRB1,cardiology,"ventricular tachycardia (VT), hypertension",Launched,0.30502601929852097,0.103038020322,esmolol,,,0,0
BRD-A07440155-003-25-4::2.5::HTS,BRD-A07440155-003-25-4,labetalol,2.5,HTS,METABOL_5-adenosylhomocysteine,METABOL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2",cardiology,hypertension,Launched,0.24145849602935698,0.0343980885822,labetalol,,,0,0
BRD-A07563059-035-01-3::2.5::HTS,BRD-A07563059-035-01-3,bopindolol,2.5,HTS,DEM2_SNRNP25 (79622),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3, HTR1A, HTR1B",cardiology,"hypertension, coronary artery disease (CAD)",Launched,0.3044799060374939,0.025212936172,bopindolol,,,0,0
BRD-A07600638-060-05-2::2.5::HTS,BRD-A07600638-060-05-2,meclocycline-sulfosalicylate,2.5,HTS,MIRNA_hsa-miR-765,MIRNA,noncancer,bacterial 50S ribosomal subunit inhibitor,,"dermatology, infectious disease","acne vulgaris (AV), skin infections",Launched,0.272438280032031,0.0584606018236,meclocycline-sulfosalicylate,,,0,0
BRD-A07704283-001-01-3::2.5::HTS,BRD-A07704283-001-01-3,isofloxythepin,2.5,HTS,Exp_IFNA1 (ENSG00000197919),GE,noncancer,dopamine receptor antagonist,,,,Phase 2,0.253197285884531,0.0241668418808,isofloxythepin,,,0,0
BRD-A07780951-001-08-9::2.5::HTS,BRD-A07780951-001-08-9,metaproterenol,2.5,HTS,METABOL_C14:0 SM,METABOL,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, asthma, bronchitis, emphysema",Launched,0.24446746595692803,0.0939147165712,metaproterenol,,,0,0
BRD-A07780951-065-10-0::2.58::HTS,BRD-A07780951-065-10-0,metaproterenol,2.58,HTS,METABOL_C56:7 TAG,METABOL,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, asthma, bronchitis, emphysema",Launched,0.24446746595692803,0.0939147165712,metaproterenol,,,0,0
BRD-A07815743-001-01-1::2.5::HTS,BRD-A07815743-001-01-1,kakonein,2.5,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,"GABA receptor antagonist, serotonin receptor antagonist",,,,Phase 2,0.275423709819625,0.110764901689,kakonein,,,0,0
BRD-A07870296-001-07-4::2.5::HTS,BRD-A07870296-001-07-4,bicuculline-(+),2.5,HTS,CRISPR_LIMK1 (3984),AVANA_PUBLIC_18Q2,noncancer,GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1",,,Preclinical,0.28527682117805,0.046902174341,bicuculline-(+),,,0,0
BRD-A07893380-213-01-7::2.5::HTS,BRD-A07893380-213-01-7,vigabatrin,2.5,HTS,CRISPR_PTGIR (5739),AVANA_PUBLIC_18Q2,noncancer,GABA aminotransferase inhibitor,"ABAT, GABBR1, SLC32A1",neurology/psychiatry,"seizures, spasms",Launched,0.28231108361579904,0.114296269944,vigabatrin,,,0,0
BRD-A07932845-050-15-8::2.5::HTS,BRD-A07932845-050-15-8,metitepine,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,anti-HCVE2,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,Preclinical,0.254859243100661,0.0250479098672,metitepine,,,0,0
BRD-A07947329-001-01-4::2.5::HTS,BRD-A07947329-001-01-4,buparvaquone,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,antiprotozoal agent,,,,Launched,0.279457064835823,0.0497613915364,buparvaquone,,,0,0
BRD-A07986123-001-02-8::2.5::HTS,BRD-A07986123-001-02-8,galeterone,2.5,HTS,MIRNA_bkv-miR-B1-3p+jcv-miR-J1-3p,MIRNA,targeted cancer,androgen receptor modulator,"AR, CYP17A1",,,Phase 3,0.21098756064132101,0.0623138486793,galeterone,,,0,0
BRD-A08079565-001-01-8::2.5::HTS,BRD-A08079565-001-01-8,CDBA,2.5,HTS,Exp_IL1RL1 (ENSG00000115602),GE,noncancer,,,,,Phase 3,0.25696805408102397,0.134820226406,CDBA,,,0,0
BRD-A08187463-001-12-9::2.5::HTS,BRD-A08187463-001-12-9,racecadotril,2.5,HTS,CRISPR_DDX54 (79039),AVANA_PUBLIC_18Q2,noncancer,enkephalinase inhibitor,MME,gastroenterology,diarrhea,Launched,0.24934950853441198,0.188954683875,racecadotril,OTHER,0.2543878572124845,3.577779438082326,-3.4084684146132864
BRD-A08255417-001-14-7::2.5::HTS,BRD-A08255417-001-14-7,famprofazone,2.5,HTS,Exp_C11orf1 (ENSG00000137720),GE,noncancer,cyclooxygenase inhibitor,,,,Preclinical,0.295305208434381,0.107541548696,famprofazone,,,0,0
BRD-A08302182-001-01-7::2.5::HTS,BRD-A08302182-001-01-7,etonogestrel,2.5,HTS,PROT_Notch1,PROT,noncancer,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,Launched,0.29160907486453697,0.0970357939053,etonogestrel,,,0,0
BRD-A08316590-001-01-3::2.5::MTS004,BRD-A08316590-001-01-3,broxaterol,2.5,MTS004,METHYL_UHRF1,METHYL,noncancer,adrenergic receptor agonist,ADRB2,,,Phase 3,0.330483668817963,0.0750678126128,broxaterol,,,0,0
BRD-A08545410-003-07-8::2.38::HTS,BRD-A08545410-003-07-8,doxycycline,2.38,HTS,Exp_TLK1 (ENSG00000198586),GE,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.318156085433,doxycycline,OTHER,0.3420057965483333,0.8740520866360991,-3.3417040499545383
BRD-A08545410-003-08-6::2.5::HTS,BRD-A08545410-003-08-6,doxycycline,2.5,HTS,PROT_SETD2_Caution,PROT,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.298347328622,doxycycline,,,0,0
BRD-A08545410-311-01-8::2.5::HTS,BRD-A08545410-311-01-8,doxycycline,2.5,HTS,PROT_MEK1_pS217_S221,PROT,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.298347328622,doxycycline,,,0,0
BRD-A08545410-311-03-4::2.5::HTS,BRD-A08545410-311-03-4,doxycycline,2.5,HTS,Exp_DHX33 (ENSG00000005100),GE,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.318156085433,doxycycline,OTHER,0.3703244333477465,3.5120235404513935,-1.810881107936196
BRD-A08660406-001-05-9::2.5::HTS,BRD-A08660406-001-05-9,iodixanol,2.5,HTS,CRISPR_BST2 (684),AVANA_PUBLIC_18Q2,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.23296496616267603,0.101391723811,iodixanol,,,0,0
BRD-A08715367-001-01-7::2.87::HTS,BRD-A08715367-001-01-7,L-Theanine,2.87,HTS,RMUTdmg_APC (324),MUTdmg,noncancer,glutamate receptor antagonist,,,,Launched,0.295753791753079,0.0507006065237,L-Theanine,,,0,0
BRD-A08772153-001-02-4::2.500028879::MTS004,BRD-A08772153-001-02-4,SQ-109,2.500028879,MTS004,PROT_Lck,PROT,noncancer,bacterial cell wall synthesis inhibitor,FDFT1,,,Phase 3,0.256997361213395,0.140496637104,SQ-109,,,0,0
BRD-A08840375-001-01-3::2.5::HTS,BRD-A08840375-001-01-3,CID-5458317,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,MAP kinase phosphatase inhibitor,MAPK3,,,Preclinical,0.359445440436363,0.300612010789,CID-5458317,OTHER,0.3619909741147855,4.362019787181293,-1.243830546899216
BRD-A09056319-003-07-7::2.5::HTS,BRD-A09056319-003-07-7,alfuzosin,2.5,HTS,DEM2_PTGS2 (5743),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2",urology,benign prostatic hyperplasia (BPH),Launched,0.26749025588173103,0.112819911232,alfuzosin,,,0,0
BRD-A09062839-003-10-0::2.5::HTS,BRD-A09062839-003-10-0,amyleine,2.5,HTS,CN_BPGM (669),CN,noncancer,local anesthetic,,,,Preclinical,0.351024101951291,0.0615291628361,amyleine,,,0,0
BRD-A09094913-065-01-0::2.5::HTS,BRD-A09094913-065-01-0,strychnine,2.5,HTS,Exp_CCL26 (ENSG00000006606),GE,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB",,,Preclinical,0.28517745722317306,0.0971933015399,strychnine,,,0,0
BRD-A09349126-001-10-7::2.5::HTS,BRD-A09349126-001-10-7,norethindrone-acetate,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor agonist,,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",Launched,0.29272130528231,0.222152263377,norethindrone-acetate,OTHER,0.31465478336721364,3.3585804777898773,-0.5267401073815754
BRD-A09370961-001-01-0::2.5::HTS,BRD-A09370961-001-01-0,ioxilan,2.5,HTS,METHYL_TOLLIP,METHYL,noncancer,radiopaque medium,,radiology,angiography,Launched,0.16791337880444898,-0.0745915752122,ioxilan,,,0,0
BRD-A09467419-003-22-4::2.5::HTS,BRD-A09467419-003-22-4,mebeverine,2.5,HTS,Exp_NAT2 (ENSG00000156006),GE,noncancer,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,Launched,0.237284233066842,0.051692831062,mebeverine,,,0,0
BRD-A09472452-015-23-4::2.5::HTS,BRD-A09472452-015-23-4,flecainide,2.5,HTS,CN_HYI (81888),CN,noncancer,sodium channel blocker,"KCNA5, KCNA7, SCN4A, SCN5A",cardiology,"ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias",Launched,0.278896853041899,0.113385724405,flecainide,,,0,0
BRD-A09533288-003-31-2::2.5::HTS,BRD-A09533288-003-31-2,verapamil,2.5,HTS,DEM2_TREML1 (340205),DEMETER2_COM,noncancer,calcium channel blocker,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4",cardiology,hypertension,Launched,0.196555941424909,0.10071139238,verapamil,,,0,0
BRD-A09722536-002-18-0::2.5::HTS,BRD-A09722536-002-18-0,cyclophosphamide,2.5,HTS,METHYL_HLTF,METHYL,chemo,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer",Launched,0.29302803774054603,0.0991798410685,cyclophosphamide,,,0,0
BRD-A09735281-001-02-5::2.5::HTS,BRD-A09735281-001-02-5,boceprevir,2.5,HTS,METABOL_C38:5 PC,METABOL,noncancer,HCV inhibitor,"CMA1, CTSA, CTSF, CTSK, CTSL, CTSS",infectious disease,hepatitis C,Launched,0.35723125370243697,0.0924546370155,boceprevir,,,0,0
BRD-A09828896-004-11-0::2.5::HTS,BRD-A09828896-004-11-0,SKF-81297,2.5,HTS,METHYL_LOC100287944,METHYL,noncancer,dopamine receptor agonist,"DRD1, DRD5",,,Preclinical,0.324769479848333,0.0723250466234,SKF-81297,,,0,0
BRD-A09911125-001-01-4::2.5::MTS004,BRD-A09911125-001-01-4,prolylleucylglycinamide,2.5,MTS004,Exp_MMRN1 (ENSG00000138722),GE,noncancer,melanocyte-stimulating hormone release inhibitor,,,,Phase 2,0.28925945592378305,0.160314985904,prolylleucylglycinamide,,,0,0
BRD-A09925278-003-05-6::2.5::HTS,BRD-A09925278-003-05-6,etilefrine,2.5,HTS,CRISPR_SH2D6 (284948),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRA1A, ADRB1","neurology/psychiatry, otolaryngology, endocrinology, pulmonary","headache, nasal congestion, fever, cough suppressant, common cold",Launched,0.33203229454680105,0.151984606972,etilefrine,,,0,0
BRD-A10039652-001-01-2::2.5::HTS,BRD-A10039652-001-01-2,tipranavir,2.5,HTS,PROT_Syk,PROT,noncancer,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.26065751273810894,0.0821532513972,tipranavir,,,0,0
BRD-A10070317-003-28-3::2.5::HTS,BRD-A10070317-003-28-3,propranolol,2.5,HTS,DEM2_NSMCE1 (197370),DEMETER2_COM,noncancer,adrenergic receptor antagonist,,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache",Launched,0.314747475745617,0.0255752494704,propranolol,,,0,0
BRD-A10111329-001-04-6::2.5::HTS,BRD-A10111329-001-04-6,adenosine-phosphate,2.5,HTS,METHYL_STK17B,METHYL,targeted cancer,adenosine receptor agonist,"ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4",,,Launched,0.24097065719481897,0.0726657724324,adenosine-phosphate,,,0,0
BRD-A10188456-001-04-9::2.5::MTS004,BRD-A10188456-001-04-9,dexamethasone,2.5,MTS004,Exp_ZNF211 (ENSG00000121417),GE,noncancer,glucocorticoid receptor agonist,"ANXA1, NOS2, NR0B1, NR3C1, NR3C2","endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.27827415345917,0.084433800779,dexamethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.28577897236204713,2.448911165308005,4.67544394056798
BRD-A10420615-001-04-4::2.5::HTS,BRD-A10420615-001-04-4,cyclopiazonic-acid,2.5,HTS,DEM2_CAVIN1 (284119),DEMETER2_COM,noncancer,ATPase inhibitor,ATP2A1,,,Preclinical,0.31713624306412797,0.0364329221886,cyclopiazonic-acid,,,0,0
BRD-A10523515-001-07-9::2.5::HTS,BRD-A10523515-001-07-9,GSK429286A,2.5,HTS,METHYL_MAFF,METHYL,noncancer,rho associated kinase inhibitor,ROCK1,,,Preclinical,0.328886007593595,0.131647938081,GSK429286A,OTHER,0.3228598583889897,2.9786857677649867,-3.463061656813526
BRD-A10652366-238-04-1::2.5::HTS,BRD-A10652366-238-04-1,fosfomycin,2.5,HTS,Exp_SPI1 (ENSG00000066336),GE,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections,Launched,0.27990139811057,0.133377130568,fosfomycin,,,0,0
BRD-A10662413-043-11-2::2.5::HTS,BRD-A10662413-043-11-2,prenylamine,2.5,HTS,METHYL_ZBTB20,METHYL,noncancer,calcium channel blocker,"CALM1, MYLK2",,,Withdrawn,0.235703819298684,0.0443788459983,prenylamine,,,0,0
BRD-A10739734-003-10-6::2.5::HTS,BRD-A10739734-003-10-6,efaroxan,2.5,HTS,CN_SVIL (6840),CN,noncancer,adrenergic receptor antagonist,ADORA2A,,,Phase 2,0.284721232863494,0.0574916948626,efaroxan,,,0,0
BRD-A10773072-001-03-4::2.496712929::MTS004,BRD-A10773072-001-03-4,glycerol-monolaurate,2.496712929,MTS004,MIRNA_hsa-miR-140-5p,MIRNA,noncancer,beta lactamase inhibitor,,,,Launched,0.261985953695613,0.100260630124,glycerol-monolaurate,,,0,0
BRD-A10903566-003-07-7::2.5::HTS,BRD-A10903566-003-07-7,imiloxan,2.5,HTS,DEM2_ITGA2 (3673),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRA2A, ADRA2B",,,Phase 1,0.273496003478559,0.092030156442,imiloxan,OTHER,0.2710347045560559,2.9206716865435527,-0.4589869985434363
BRD-A10967948-003-06-3::2.5::HTS,BRD-A10967948-003-06-3,granisetron,2.5,HTS,MUTpool_NYAP2 (57624),MUTpool,noncancer,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting",Launched,0.245431357581953,0.108175743474,granisetron,,,0,0
BRD-A10977446-001-12-1::2.5::HTS,BRD-A10977446-001-12-1,carvedilol,2.5,HTS,CRISPR_DSCR3 (10311),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension",Launched,0.232315819966776,0.0706785998375,carvedilol,,,0,0
BRD-A11070335-236-02-1::2.5::HTS,BRD-A11070335-236-02-1,carbazochrome,2.5,HTS,PROT_STAT5-alpha,PROT,noncancer,,,hematology,hemorrhage,Launched,0.291510924535555,0.0807764596818,carbazochrome,,,0,0
BRD-A11132253-001-08-2::2.5::HTS,BRD-A11132253-001-08-2,nadide,2.5,HTS,RMUTdmg_PKHD1L1 (93035),MUTdmg,noncancer,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",,,Launched,0.158226830858608,0.0176776935851,nadide,,,0,0
BRD-A11551002-001-04-6::2.5::HTS,BRD-A11551002-001-04-6,dehydrocholate-acid,2.5,HTS,MIRNA_hsa-miR-548k,MIRNA,noncancer,,,,,Preclinical,0.2537480734264,0.0788804968583,dehydrocholate-acid,OTHER,0.26597813066278314,5.413891857349695,1.5683104372657897
BRD-A11662333-001-03-3::2.5::HTS,BRD-A11662333-001-03-3,meparfylon,2.5,HTS,METHYL_C10orf88,METHYL,noncancer,,,,,Preclinical,0.26992686847293,0.0931558105056,meparfylon,,,0,0
BRD-A11731518-001-01-7::2.5::HTS,BRD-A11731518-001-01-7,BAY-85-8050,2.5,HTS,CRISPR_POGLUT1 (56983),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 1,0.25793260682667,0.207485337818,BAY-85-8050,,,0,0
BRD-A11776908-065-01-5::2.5::HTS,BRD-A11776908-065-01-5,enilconazole,2.5,HTS,Exp_TMEM253 (ENSG00000232070),GE,noncancer,sterol demethylase inhibitor,"CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2",infectious disease,skin infections,Launched,0.276123336940312,0.163036011894,enilconazole,,,0,0
BRD-A11813248-003-02-4::2.5::HTS,BRD-A11813248-003-02-4,AM-92016,2.5,HTS,Exp_TRHDE (ENSG00000072657),GE,noncancer,potassium channel blocker,GRIN1,,,Preclinical,0.271582967124858,0.0360699415902,AM-92016,,,0,0
BRD-A11990600-001-03-4::2.5::HTS,BRD-A11990600-001-03-4,lorazepam,2.5,HTS,METABOL_C36:2 DAG,METABOL,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,Launched,0.22640770593706197,0.169805546897,lorazepam,,,0,0
BRD-A12077521-003-01-5::2.5::HTS,BRD-A12077521-003-01-5,cefepime,2.5,HTS,CN_LILRA6 (79168),CN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, urinary tract infections, skin infections, intra-abdominal infections",Launched,0.236300605421732,0.0373386630785,cefepime,,,0,0
BRD-A12230535-001-06-7::2.5::HTS,BRD-A12230535-001-06-7,nutlin-3,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,"MDM2, TP53",,,Preclinical,0.383159005772464,0.508204663257,nutlin-3,MDM INHIBITOR,0.3890998760191139,3.1553676467612863,-1.9277548013360024
BRD-A12237696-001-04-2::2.5::HTS,BRD-A12237696-001-04-2,L-Citrulline,2.5,HTS,PROT_Cyclin_E2_Caution,PROT,noncancer,nitric oxide stimulant,"ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6","cardiology, urology","hypertension, erectile dysfunction",Launched,0.20065914404114604,0.0931687804991,L-Citrulline,,,0,0
BRD-A12417644-001-07-6::2.31::HTS,BRD-A12417644-001-07-6,usniacin-(+),2.31,HTS,METABOL_C22:6 LPC,METABOL,targeted cancer,MAP kinase activator,PTPN1,,,Preclinical,0.263778804327987,0.120846302257,usniacin-(+),,,0,0
BRD-A12454076-001-01-9::2.5::HTS,BRD-A12454076-001-01-9,L-Hydroxyproline,2.5,HTS,MIRNA_hsa-miR-1178,MIRNA,noncancer,,,,,Launched,0.29591841958043197,0.0374272442229,L-Hydroxyproline,,,0,0
BRD-A12896037-001-04-3::2.5::HTS,BRD-A12896037-001-04-3,cisapride,2.5,HTS,CRISPR_BFSP1 (631),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor agonist,"HTR2A, HTR3A, HTR4, KCNH2",,,Withdrawn,0.177807205641296,0.181399110614,cisapride,,,0,0
BRD-A12994259-001-02-1::2.5::HTS,BRD-A12994259-001-02-1,pomalidomide,2.5,HTS,METHYL_MKRN3,METHYL,targeted cancer,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Launched,0.19584876572436102,0.11608845229,pomalidomide,,,0,0
BRD-A13084692-001-17-3::2.5::HTS,BRD-A13084692-001-17-3,troglitazone,2.5,HTS,METHYL_AKR7L,METHYL,targeted cancer,"insulin sensitizer, PPAR receptor agonist","ACSL4, ESRRA, ESRRG, PPARG, SERPINE1, SLC29A1, TRPM3",,,Withdrawn,0.26068954349742995,0.116186809107,troglitazone,,,0,0
BRD-A13116749-003-01-6::2.713967431::MTS004,BRD-A13116749-003-01-6,mabuterol,2.713967431,MTS004,Exp_NEDD9 (ENSG00000111859),GE,noncancer,adrenergic receptor agonist,ADRB2,,,Launched,0.271736836135994,0.0933792078104,mabuterol,,,0,0
BRD-A13133631-001-04-0::2.5::HTS,BRD-A13133631-001-04-0,fluorometholone,2.5,HTS,METABOL_AMP,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,Launched,0.31992846357641996,0.0893830347405,fluorometholone,GLUCOCORTICOID RECEPTOR AGONIST,0.3197261178940481,-1.3734734686143342,-2.8639436817060027
BRD-A13188892-066-21-5::2.5::HTS,BRD-A13188892-066-21-5,doxazosin,2.5,HTS,CRISPR_PRKD1 (5587),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension",Launched,0.262752390800667,0.0547330594155,doxazosin,,,0,0
BRD-A13323580-001-04-8::2.5::HTS,BRD-A13323580-001-04-8,perillyl-alcohol,2.5,HTS,CN_QRSL1 (55278),CN,targeted cancer,"apoptosis stimulant, farnesyltransferase inhibitor",FNTA,,,Phase 2,0.328499254005392,0.0963417110071,perillyl-alcohol,,,0,0
BRD-A13561534-003-02-0::2.5::HTS,BRD-A13561534-003-02-0,ornithine,2.5,HTS,DEM2_TMEM2 (23670),DEMETER2_COM,noncancer,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",,,Launched,0.274003735481769,0.0215405698072,ornithine,,,0,0
BRD-A13946108-001-17-1::2.5::HTS,BRD-A13946108-001-17-1,sulindac,2.5,HTS,MIRNA_hsa-miR-1283,MIRNA,noncancer,cyclooxygenase inhibitor,"AKR1B1, MAPK3, PPARD, PTGDR2, PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis, ankylosing spondylitis",Launched,0.256841825777179,0.0447547723516,sulindac,,,0,0
BRD-A13964793-001-02-6::2.5::HTS,BRD-A13964793-001-02-6,TC1,2.5,HTS,METABOL_hippurate,METABOL,noncancer,beta-secretase inhibitor,BACE1,,,Preclinical,0.22510393601921902,0.048176045102,TC1,,,0,0
BRD-A14208071-004-19-8::2.5::HTS,BRD-A14208071-004-19-8,oxyphenonium,2.5,HTS,METHYL_DPCD,METHYL,noncancer,cholinergic receptor antagonist,CHRM1,gastroenterology,peptic ulcer disease (PUD),Launched,0.283642075283293,0.0529389758449,oxyphenonium,,,0,0
BRD-A14240607-003-26-1::2.5::HTS,BRD-A14240607-003-26-1,octopamine,2.5,HTS,RMUTmis_WFIKKN1 (117166),MUT,noncancer,trace amine associated receptor agonist,"F10, TAAR1",,,Preclinical,0.28330495134585304,-0.0258548088145,octopamine,,,0,0
BRD-A14262390-065-01-8::2.5::HTS,BRD-A14262390-065-01-8,guanadrel,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,adrenergic inhibitor,SLC6A2,cardiology,hypertension,Launched,0.211440371083946,0.0622886234835,guanadrel,,,0,0
BRD-A14316475-001-02-3::2.5::HTS,BRD-A14316475-001-02-3,SN-6,2.5,HTS,METABOL_C34:1 PC,METABOL,noncancer,sodium/calcium exchange inhibitor,,,,Preclinical,0.22343957547259,0.0784484756947,SN-6,,,0,0
BRD-A14344385-001-03-2::2.5::HTS,BRD-A14344385-001-03-2,IDRA-21,2.5,HTS,METABOL_choline,METABOL,noncancer,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,Preclinical,0.39530659156795706,0.104528729836,IDRA-21,OTHER,0.38559279107084005,2.8775123618909304,0.4442996985250132
BRD-A14395271-074-17-8::2.5::HTS,BRD-A14395271-074-17-8,mesoridazine,2.5,HTS,DEM2_CARHSP1 (23589),DEMETER2_COM,noncancer,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.269437071779133,0.0587641934228,mesoridazine,,,0,0
BRD-A14574269-051-02-2::2.5::HTS,BRD-A14574269-051-02-2,UB-165,2.5,HTS,MIRNA_hsa-miR-1266,MIRNA,noncancer,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNB2",,,Preclinical,0.23698293250273803,0.0421149338796,UB-165,,,0,0
BRD-A14577621-001-01-5::2.5::MTS004,BRD-A14577621-001-01-5,peficitinib,2.5,MTS004,PROT_PR,PROT,noncancer,JAK inhibitor,"JAK1, JAK2, JAK3",,,Phase 3,0.300712950604539,0.191426220133,peficitinib,OTHER,0.3048608545654597,1.3195945262989706,-2.9084508730779213
BRD-A14886633-001-01-6::2.5::HTS,BRD-A14886633-001-01-6,norgestrel,2.5,HTS,Exp_VPS51 (ENSG00000149823),GE,noncancer,progesterone receptor agonist,PGR,endocrinology,contraceptive,Launched,0.23522826089436102,0.153614414655,norgestrel,,,0,0
BRD-A14941520-051-01-0::2.5::HTS,BRD-A14941520-051-01-0,dofequidar,2.5,HTS,CN_PSMB10 (5699),CN,targeted cancer,"MRP inhibitor, P glycoprotein inhibitor",ABCB1,,,Phase 3,0.264816749910138,0.0865132119586,dofequidar,,,0,0
BRD-A14966924-003-07-7::2.5::HTS,BRD-A14966924-003-07-7,alaproclate,2.5,HTS,METHYL_MIR5692B,METHYL,noncancer,serotonin receptor antagonist,SLC6A4,,,Phase 2,0.264705358241507,0.0617710245338,alaproclate,,,0,0
BRD-A15035311-001-01-8::2.5::HTS,BRD-A15035311-001-01-8,diadenosine-tetraphosphate,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,adenosine kinase inhibitor,"P2RY13, P2RY2",,,Phase 1,0.32974603572618105,0.134523836163,diadenosine-tetraphosphate,,,0,0
BRD-A15202882-003-02-7::2.5::HTS,BRD-A15202882-003-02-7,milnacipran,2.5,HTS,METABOL_anthranilic acid,METABOL,noncancer,serotonin-norepinephrine reuptake inhibitor (SNRI),"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A4",rheumatology,fibromyalgia,Launched,0.17168562179150498,0.0899552440652,milnacipran,,,0,0
BRD-A15297126-001-04-3::2.5::HTS,BRD-A15297126-001-04-3,fluocinolone-acetonide,2.5,HTS,RMUTmis_TTN (7273),MUTmis,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,Launched,0.267551082485177,0.0485881319275,fluocinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.26712513995403325,-1.6013649146834004,-3.0045613238666373
BRD-A15397381-001-02-5::2.5::HTS,BRD-A15397381-001-02-5,L-Cystine,2.5,HTS,PROT_Beclin_Caution,PROT,noncancer,,"CTNS, SLC3A1, SLC7A11, SLC7A9",,,Launched,0.326255431930844,0.0261830061137,L-Cystine,,,0,0
BRD-A15415227-003-02-9::2.5::HTS,BRD-A15415227-003-02-9,GW-1929,2.5,HTS,DEM2_GPR83 (10888),DEMETER2_COM,noncancer,PPAR receptor agonist,PPARG,,,Preclinical,0.257698032199816,0.158135397181,GW-1929,,,0,0
BRD-A15435692-003-02-3::2.5::HTS,BRD-A15435692-003-02-3,BMY-14802,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,sigma receptor antagonist,HTR1A,,,Phase 2,0.274738178032838,0.00263843325293,BMY-14802,,,0,0
BRD-A15530910-001-02-1::2.5::HTS,BRD-A15530910-001-02-1,SDZ-21009,2.5,HTS,DEM2_GRID2 (2895),DEMETER2_COM,noncancer,"adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A, HTR1B",,,Preclinical,0.305026633335232,0.102708539906,SDZ-21009,,,0,0
BRD-A15687940-001-05-6::2.5::MTS004,BRD-A15687940-001-05-6,clofedanol,2.5,MTS004,METHYL_MIR6838,METHYL,noncancer,histamine receptor antagonist,HRH1,pulmonary,cough suppressant,Launched,0.29241178862612205,0.1335493498,clofedanol,,,0,0
BRD-A15739803-001-01-0::2.726366321::MTS004,BRD-A15739803-001-01-0,polythiazide,2.726366321,MTS004,METHYL_LOC100130950,METHYL,noncancer,sodium/chloride cotransporter inhibitor,SLC12A3,"cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension",Launched,0.285661179069524,0.0725261052307,polythiazide,,,0,0
BRD-A15909516-001-06-6::2.5::HTS,BRD-A15909516-001-06-6,rebamipide,2.5,HTS,CRISPR_EXD3 (54932),AVANA_PUBLIC_18Q2,noncancer,free radical scavenger,FPR1,gastroenterology,"peptic ulcer disease (PUD), gastritis",Launched,0.260138797112339,0.117079347354,rebamipide,,,0,0
BRD-A15931911-001-03-8::2.5::HTS,BRD-A15931911-001-03-8,bucladesine,2.5,HTS,CN_LAYN (143903),CN,noncancer,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,Launched,0.27178957924825103,0.100536429656,bucladesine,,,0,0
BRD-A16263897-001-06-6::2.5::MTS004,BRD-A16263897-001-06-6,misonidazole,2.5,MTS004,METABOL_alpha-ketoglutarate,METABOL,noncancer,,,,,Phase 3,0.26552908717553997,0.109316804074,misonidazole,,,0,0
BRD-A16296925-001-01-3::2.5::HTS,BRD-A16296925-001-01-3,indobufen,2.5,HTS,CN_PCSK6 (5046),CN,noncancer,"cyclooxygenase inhibitor, platelet aggregation inhibitor","PTGS1, PTGS2",hematology,thrombosis,Launched,0.20235753894845496,0.0472599697084,indobufen,,,0,0
BRD-A16350940-001-01-9::2.5::HTS,BRD-A16350940-001-01-9,doramectin,2.5,HTS,Exp_THRAP3 (ENSG00000054118),GE,noncancer,,,infectious disease,gastrointestinal roundworms,Launched,0.267807979183255,0.178090525947,doramectin,,,0,0
BRD-A16439188-001-01-1::2.5::HTS,BRD-A16439188-001-01-1,quinestrol,2.5,HTS,RMUTmis_ESX1 (80712),MUT,noncancer,estrogen receptor agonist,ESR1,endocrinology,menopause,Launched,0.23450797622192998,0.0695141810659,quinestrol,,,0,0
BRD-A16665823-001-02-0::2.5::HTS,BRD-A16665823-001-02-0,butoconazole,2.5,HTS,CN_SH3RF3 (344558),CN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis,Launched,0.2226641766231,0.0723971996093,butoconazole,,,0,0
BRD-A16694057-001-06-8::2.5::HTS,BRD-A16694057-001-06-8,BADGE,2.5,HTS,METHYL_SYCP2,METHYL,targeted cancer,PPAR receptor antagonist,PPARG,,,Preclinical,0.24060124008366196,0.0954347843872,BADGE,,,0,0
BRD-A16700644-003-04-4::2.5::HTS,BRD-A16700644-003-04-4,isoxsuprine,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",Launched,0.31787019667260696,0.156637041301,isoxsuprine,OTHER,0.31583826689713546,5.256050297205043,-1.9074369908212263
BRD-A16997652-001-02-3::2.5::HTS,BRD-A16997652-001-02-3,protirelin,2.5,HTS,CRISPR_NFAT5 (10725),AVANA_PUBLIC_18Q2,noncancer,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,Launched,0.20703637692497898,0.113369319176,protirelin,,,0,0
BRD-A17009129-001-01-3::2.499993124::MTS004,BRD-A17009129-001-01-3,isavuconazole,2.499993124,MTS004,Exp_SPIRE1 (ENSG00000134278),GE,noncancer,cytochrome P450 inhibitor,CYP3A4,,,Phase 3,0.20898915871017198,0.0558829957496,isavuconazole,,,0,0
BRD-A17300716-001-01-5::2.5::HTS,BRD-A17300716-001-01-5,dehydroacetic-acid,2.5,HTS,CN_SMG1 (23049),CN,noncancer,,,,,Preclinical,0.271523640164429,0.045704238476,dehydroacetic-acid,,,0,0
BRD-A17407635-001-04-0::2.5::HTS,BRD-A17407635-001-04-0,alclometasone-dipropionate,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"CYP3A4, NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.27156941087696695,0.224079896149,alclometasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2499515226624148,-3.829309794183389,-2.971086957641285
BRD-A17411484-001-11-9::2.5::HTS,BRD-A17411484-001-11-9,carprofen,2.5,HTS,METHYL_RMDN2,METHYL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,osteoarthritis,Launched,0.298724833962812,0.0593044747639,carprofen,,,0,0
BRD-A17428743-003-09-0::2.5::HTS,BRD-A17428743-003-09-0,BW-723C86,2.5,HTS,PROT_Annexin_VII,PROT,noncancer,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.273246878235827,0.0653000913289,BW-723C86,,,0,0
BRD-A17453586-003-02-3::2.5::HTS,BRD-A17453586-003-02-3,MDL-72832,2.5,HTS,Exp_PDE6G (ENSG00000185527),GE,noncancer,serotonin receptor agonist,HTR1A,,,Preclinical,0.26245510690935897,0.112179834927,MDL-72832,,,0,0
BRD-A17462676-003-11-6::2.5::HTS,BRD-A17462676-003-11-6,bambuterol,2.5,HTS,CN_MAU2 (23383),CN,noncancer,adrenergic receptor agonist,"ADRB2, BCHE",pulmonary,asthma,Launched,0.31277264961293605,0.0271828318599,bambuterol,,,0,0
BRD-A17655518-001-24-4::2.5::HTS,BRD-A17655518-001-24-4,ibuprofen,2.5,HTS,CRISPR_HSPA13 (6782),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental","headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache",Launched,0.267385736619364,0.0433545135877,ibuprofen,,,0,0
BRD-A17846016-001-13-9::2.5::HTS,BRD-A17846016-001-13-9,trolox,2.5,HTS,Exp_PRPS2 (ENSG00000101911),GE,noncancer,antioxidant,,,,Launched,0.30475781836370197,0.141533862393,trolox,,,0,0
BRD-A17883755-001-06-1::2.5::HTS,BRD-A17883755-001-06-1,lenalidomide,2.5,HTS,CN_FOLH1 (2346),CN,targeted cancer,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Launched,0.2783225556163689,0.0846999694901,lenalidomide,,,0,0
BRD-A18043272-001-09-9::2.5::HTS,BRD-A18043272-001-09-9,phensuximide,2.5,HTS,DEM2_INCA1 (388324),DEMETER2_COM,noncancer,succinimide antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,Launched,0.30910250108288,-0.0207506145123,phensuximide,,,0,0
BRD-A18056626-003-22-3::2.5::HTS,BRD-A18056626-003-22-3,methacholine,2.5,HTS,CRISPR_WDR3 (10885),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor agonist,"CHRM2, CHRM3, CHRM4",pulmonary,bronchial hyperresponsiveness diagnostic,Launched,0.255401166725308,0.0988150368845,methacholine,,,0,0
BRD-A18233884-003-02-7::2.5::HTS,BRD-A18233884-003-02-7,bevantolol,2.5,HTS,DEM2_CACNA1E (777),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRB1, ADRB2",cardiology,"angina pectoris, hypertension",Launched,0.252397158969766,0.0727201045045,bevantolol,,,0,0
BRD-A18396475-001-15-3::2.56::HTS,BRD-A18396475-001-15-3,malic-acid,2.56,HTS,MUTpool_ZFAND4 (93550),MUTpool,noncancer,,"CS, ME2, PKD2L1",,,Launched,0.309049921567037,0.0731645662827,malic-acid,,,0,0
BRD-A18611368-001-01-5::2.5::HTS,BRD-A18611368-001-01-5,tazobactam,2.5,HTS,MIRNA_kshv-miR-K12-10a+kshv-miR-K12-10b,MIRNA,noncancer,beta lactamase inhibitor,,infectious disease,pneumonia,Launched,0.284634200963818,0.115867505269,tazobactam,,,0,0
BRD-A18627414-001-04-9::2.5::HTS,BRD-A18627414-001-04-9,cyanocobalamin,2.5,HTS,METHYL_LOC101927027,METHYL,noncancer,"methylmalonyl CoA mutase stimulant, vitamin B","MMAA, MMACHC, MTHFR, MTR, MTRR, MUT","hematology, infectious disease, gastroenterology","anemia, fish tapeworm infestation, celiac disease",Launched,0.31641703993394,0.00834442044559,cyanocobalamin,,,0,0
BRD-A18696154-003-22-6::2.5::HTS,BRD-A18696154-003-22-6,idazoxan,2.5,HTS,MIRNA_hsa-miR-744,MIRNA,noncancer,adrenergic receptor antagonist,ADRA2A,,,Phase 3,0.235893396204268,0.0312198166254,idazoxan,,,0,0
BRD-A18763547-300-05-5::2.5::HTS,BRD-A18763547-300-05-5,BAX-channel-blocker,2.5,HTS,CRISPR_SLFN12L (100506736),AVANA_PUBLIC_18Q2,noncancer,cytochrome C release inhibitor,BAX,,,Preclinical,0.239506034268302,0.126085658391,BAX-channel-blocker,,,0,0
BRD-A18795974-004-07-3::2.5::HTS,BRD-A18795974-004-07-3,7-hydroxy-DPAT,2.5,HTS,METHYL_MIR4322,METHYL,noncancer,dopamine receptor agonist,"DRD2, DRD3",,,Preclinical,0.28458683890442105,0.0358787728502,7-hydroxy-DPAT,,,0,0
BRD-A18992208-003-02-7::2.5::MTS004,BRD-A18992208-003-02-7,lercanidipine,2.5,MTS004,DEM2_COLEC10 (10584),DEMETER2_COM,noncancer,calcium channel blocker,"CACNA2D1, CACNG1",cardiology,hypertension,Launched,0.337204977865961,0.110838373549,lercanidipine,,,0,0
BRD-A19053834-050-09-5::2.5::MTS004,BRD-A19053834-050-09-5,clorotepine,2.5,MTS004,DEM2_AADAT (51166),DEMETER2_COM,noncancer,"dopamine receptor antagonist, adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6",neurology/psychiatry,psychosis,Launched,0.28858826596679105,0.0210223320804,clorotepine,,,0,0
BRD-A19102171-066-01-4::2.5::HTS,BRD-A19102171-066-01-4,naltriben,2.5,HTS,CN_FLJ16171 (441116),CN,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.28871155310317304,0.0838123882953,naltriben,,,0,0
BRD-A19195498-050-14-1::2.5::HTS,BRD-A19195498-050-14-1,trimipramine,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR3A, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.25686329013335196,0.0826494347492,trimipramine,,,0,0
BRD-A19585813-003-03-3::2.5::HTS,BRD-A19585813-003-03-3,methylphenidate,2.5,HTS,MUTpool_GRB14 (2888),MUTpool,noncancer,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",Launched,0.27907307306871504,0.0386395239591,methylphenidate,,,0,0
BRD-A19633847-050-32-1::2.5::HTS,BRD-A19633847-050-32-1,perhexiline,2.5,HTS,METABOL_C18:1 LPE,METABOL,noncancer,carnitine palmitoyltransferase inhibitor,"CPT1A, CPT2",cardiology,angina pectoris,Launched,0.302797902861593,0.145069169967,perhexiline,,,0,0
BRD-A19661776-003-27-6::2.5::HTS,BRD-A19661776-003-27-6,mianserin,2.5,HTS,PROT_AR,PROT,noncancer,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.275512455520408,0.123608429584,mianserin,,,0,0
BRD-A19736161-001-06-7::2.5::HTS,BRD-A19736161-001-06-7,ondansetron,2.5,HTS,DEM2_TMEM245 (23731),DEMETER2_COM,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR3A, HTR3B, HTR4, OPRM1",gastroenterology,"nausea, vomiting",Launched,0.281196356872398,0.0122143492923,ondansetron,,,0,0
BRD-A19777893-236-01-9::2.596350183::MTS004,BRD-A19777893-236-01-9,menadione-bisulfite,2.596350183,MTS004,METHYL_SHB,METHYL,noncancer,vitamin K,"GGCX, VKORC1, VKORC1L1",,,Phase 2,0.262509876308345,0.275592214622,menadione-bisulfite,,,0,0
BRD-A19795905-001-08-0::2.5::HTS,BRD-A19795905-001-08-0,atovaquone,2.5,HTS,METABOL_glucuronate,METABOL,noncancer,mitochondrial electron transport inhibitor,DHODH,infectious disease,pneumonia,Launched,0.319680947464286,0.145504640883,atovaquone,,,0,0
BRD-A19952358-001-11-3::2.5::HTS,BRD-A19952358-001-11-3,closantel,2.5,HTS,MIRNA_hsa-miR-148a,MIRNA,noncancer,"chitinase inhibitor, NFkB pathway inhibitor",,infectious disease,liver flukes,Launched,0.26658678073254,0.0856434010179,closantel,,,0,0
BRD-A19958636-065-04-4::2.5::HTS,BRD-A19958636-065-04-4,tuaminoheptane,2.5,HTS,METHYL_FTX,METHYL,noncancer,,,otolaryngology,nasal congestion,Launched,0.287328201849365,0.145436400592,tuaminoheptane,,,0,0
BRD-A20119038-003-07-8::2.5::HTS,BRD-A20119038-003-07-8,mecamylamine,2.5,HTS,Exp_STX10 (ENSG00000104915),GE,noncancer,acetylcholine receptor antagonist,"CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7",cardiology,hypertension,Launched,0.240663304346303,0.133094139868,mecamylamine,,,0,0
BRD-A20239487-001-24-9::2.5::HTS,BRD-A20239487-001-24-9,atenolol-(+/-),2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris",Launched,0.301366216416878,0.0942759277572,atenolol-(+/-),,,0,0
BRD-A20348246-001-15-8::2.5::HTS,BRD-A20348246-001-15-8,chlormezanone,2.5,HTS,DEM2_GRID1 (2894),DEMETER2_COM,noncancer,GABA receptor modulator,"GABRA1, TSPO",,,Withdrawn,0.295353498833961,0.0211320355564,chlormezanone,,,0,0
BRD-A20550616-001-02-9::2.5::HTS,BRD-A20550616-001-02-9,halothane,2.5,HTS,METHYL_PIDD1,METHYL,noncancer,glutamate receptor antagonist,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GNG2, GRIN2A, GRIN3A, GRIN3B, KCNJ3, KCNJ6, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9, KCNMA1, KCNN4, MT-ND1, NPSR1, RHO",neurology/psychiatry,general anaesthetic,Launched,0.338357219496477,0.0247735032172,halothane,,,0,0
BRD-A20644369-001-08-6::2.5::HTS,BRD-A20644369-001-08-6,canrenone,2.5,HTS,DEM2_SMARCC1 (6599),DEMETER2_COM,noncancer,mineralocorticoid receptor antagonist,NR3C2,,,Withdrawn,0.211014637728659,0.0792848436673,canrenone,,,0,0
BRD-A20758144-001-04-5::2.5::HTS,BRD-A20758144-001-04-5,prasterone-acetate,2.5,HTS,MIRNA_hsa-miR-875-5p,MIRNA,noncancer,,,,,Preclinical,0.25405200695117397,0.0881671412484,prasterone-acetate,,,0,0
BRD-A20781140-001-01-7::2.5::HTS,BRD-A20781140-001-01-7,plovamer-acetate,2.5,HTS,METHYL_ZFAND6,METHYL,noncancer,,"TAT, TH, YARS, YARS2",,,Phase 2,0.24117222857028303,0.0669424337059,plovamer-acetate,,,0,0
BRD-A20839672-003-01-5::2.5::HTS,BRD-A20839672-003-01-5,cefmenoxime,2.5,HTS,RMUTmis_OR2L13 (284521),MUTmis,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.19105327317352,0.0365632971669,cefmenoxime,,,0,0
BRD-A21276153-001-01-1::2.5::HTS,BRD-A21276153-001-01-1,"2,6-dimethylpiperidine",2.5,HTS,DEM2_OTX1 (5013),DEMETER2_COM,noncancer,,,,,Preclinical,0.235681900419323,0.0611869073125,"2,6-dimethylpiperidine",,,0,0
BRD-A21280314-001-06-8::2.5::MTS004,BRD-A21280314-001-06-8,nifenalol,2.5,MTS004,Exp_WDR36 (ENSG00000134987),GE,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",,,Launched,0.307517708639698,0.148905557316,nifenalol,,,0,0
BRD-A21446384-001-01-1::2.5::MTS004,BRD-A21446384-001-01-1,xibenolol,2.5,MTS004,CN_SLC25A37 (51312),CN,noncancer,adrenergic receptor antagonist,,,,Phase 3,0.293803683800974,0.0496731659367,xibenolol,,,0,0
BRD-A21474126-001-01-6::2.5::MTS004,BRD-A21474126-001-01-6,methoxyphenamine,2.5,MTS004,DEM2_KLF1 (10661),DEMETER2_COM,noncancer,adrenergic receptor agonist,,pulmonary,asthma,Launched,0.254082731594159,0.0746555293925,methoxyphenamine,,,0,0
BRD-A21544762-303-01-5::2.5::MTS004,BRD-A21544762-303-01-5,pipecuronium,2.5,MTS004,METHYL_GPER1,METHYL,noncancer,neuromuscular blocker,"CHRM2, CHRM3, CHRNA2",neurology/psychiatry,anesthetic,Launched,0.290047599225713,0.0599033066407,pipecuronium,,,0,0
BRD-A21607826-003-05-1::2.5::HTS,BRD-A21607826-003-05-1,medetomidine,2.5,HTS,Exp_MMD (ENSG00000108960),GE,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,sedative,Launched,0.29333998305344106,0.215355881982,medetomidine,OTHER,0.2873659903864457,-4.62539830225892,-2.221766813443298
BRD-A21858158-001-23-5::2.5::HTS,BRD-A21858158-001-23-5,praziquantel,2.5,HTS,CRISPR_COX19 (90639),AVANA_PUBLIC_18Q2,noncancer,anthelmintic agent,,infectious disease,"gastrointestinal parasites, cystic hydatid disease, schistosomiasis",Launched,0.309907922384355,0.130865060006,praziquantel,,,0,0
BRD-A22032524-074-06-5::2.5::HTS,BRD-A22032524-074-06-5,amlodipine,2.5,HTS,PROT_eEF2K,PROT,noncancer,calcium channel blocker,"CA1, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1, CACNA2D3, CACNB1, CACNB2, SMPD1",cardiology,"hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)",Launched,0.216719499181787,0.0416767076299,amlodipine,,,0,0
BRD-A22081593-001-11-1::2.5::HTS,BRD-A22081593-001-11-1,sulmazole,2.5,HTS,DEM2_RRAS2 (22800),DEMETER2_COM,noncancer,adenosine receptor antagonist,,,,Phase 1,0.23848731669787898,0.117223055171,sulmazole,OTHER,0.22459751923044616,4.905857982028984,-0.9774052993016559
BRD-A22106989-001-05-0::2.5::HTS,BRD-A22106989-001-05-0,phenothrin,2.5,HTS,PROT_MEK1,PROT,noncancer,,,infectious disease,lice,Launched,0.28800298604599395,0.107631403453,phenothrin,,,0,0
BRD-A22143024-231-03-8::2.5::HTS,BRD-A22143024-231-03-8,estropipate,2.5,HTS,CRISPR_AGMO (392636),AVANA_PUBLIC_18Q2,noncancer,estrogen receptor agonist,"ESR1, ESR2","orthopedics, endocrinology, obstetrics/gynecology","osteoporosis, menopause, vaginal atrophy, hypoestrogenism",Launched,0.283218447962099,0.0243927149536,estropipate,,,0,0
BRD-A22152765-003-10-0::2.5::HTS,BRD-A22152765-003-10-0,tridihexethyl,2.5,HTS,MIRNA_hsa-miR-28-5p,MIRNA,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3","gastroenterology, ophthalmology","peptic ulcer disease (PUD), nystagmus",Launched,0.25791507959664,0.118188515593,tridihexethyl,,,0,0
BRD-A22256192-003-22-7::2.5::HTS,BRD-A22256192-003-22-7,terazosin,2.5,HTS,MIRNA_hsa-miR-599,MIRNA,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension",Launched,0.247143719742564,0.119895840116,terazosin,,,0,0
BRD-A22267103-003-13-1::2.5::HTS,BRD-A22267103-003-13-1,drofenine,2.5,HTS,MIRNA_hsa-miR-651,MIRNA,noncancer,,,neurology/psychiatry,spasms,Launched,0.271131222726613,0.00712597614792,drofenine,,,0,0
BRD-A22305049-003-13-6::2.5::HTS,BRD-A22305049-003-13-6,benfluorex,2.5,HTS,DEM2_ATP6V1B2 (526),DEMETER2_COM,noncancer,gluconeogenesis inhibitor,HMGCR,,,Withdrawn,0.32324693159408396,0.0378350230839,benfluorex,,,0,0
BRD-A22642447-001-01-9::2.5::HTS,BRD-A22642447-001-01-9,licarbazepine,2.5,HTS,CRISPR_TET2 (54790),AVANA_PUBLIC_18Q2,noncancer,voltage-gated sodium channel blocker,SCN5A,,,Phase 3,0.2700377541799,0.0902841532587,licarbazepine,,,0,0
BRD-A22707317-001-10-8::2.5::HTS,BRD-A22707317-001-10-8,SB-205384,2.5,HTS,Exp_IL11 (ENSG00000095752),GE,noncancer,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",,,Preclinical,0.363898484611004,0.219163325785,SB-205384,OTHER,0.3638094881507075,0.08167318961813458,-3.9113312280022257
BRD-A22769835-300-05-7::2.5::HTS,BRD-A22769835-300-05-7,homochlorcyclizine,2.5,HTS,PROT_TIGAR,PROT,noncancer,antihistamine,HRH1,allergy,allergic rhinitis,Launched,0.271463504962156,0.099378520492,homochlorcyclizine,,,0,0
BRD-A22844106-001-26-0::2.5::HTS,BRD-A22844106-001-26-0,tenoxicam,2.5,HTS,METABOL_3-methyladipate/pimelate,METABOL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, orthopedics","rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis",Launched,0.31407440237565004,0.0578518422366,tenoxicam,,,0,0
BRD-A23067620-300-01-3::2.5::HTS,BRD-A23067620-300-01-3,itraconazole,2.5,HTS,PROT_CD49b,PROT,noncancer,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis",Launched,0.41114490355887207,0.172492514237,itraconazole,OTHER,0.35735383702404233,0.4874523959958715,-3.0777876996431903
BRD-A23072235-050-18-5::2.5::HTS,BRD-A23072235-050-18-5,pheniramine,2.5,HTS,METHYL_ESPNP,METHYL,noncancer,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",Launched,0.20535942684869896,0.091147808793,pheniramine,,,0,0
BRD-A23124853-001-01-4::2.5::MTS004,BRD-A23124853-001-01-4,PF-06463922,2.5,MTS004,METHYL_CCDC114,METHYL,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, FES, ROS1",,,Phase 2,0.384674107112566,0.0628354942545,PF-06463922,OTHER,0.3838837703658879,-1.222473332029074,0.3643322287044497
BRD-A23127772-001-02-3::2.5::HTS,BRD-A23127772-001-02-3,sclareol,2.5,HTS,DEM2_LRP10 (26020),DEMETER2_COM,noncancer,,,,,Preclinical,0.30738025306982303,0.0309081889072,sclareol,OTHER,0.29144273978849,-4.9388672764263095,-0.9396195222167164
BRD-A23359898-003-10-0::2.5::HTS,BRD-A23359898-003-10-0,sibutramine,2.5,HTS,CRISPR_IRGM (345611),AVANA_PUBLIC_18Q2,noncancer,serotonin-norepinephrine reuptake inhibitor (SNRI),"SLC6A2, SLC6A3, SLC6A4",,,Withdrawn,0.30317543245846396,0.12581416928,sibutramine,,,0,0
BRD-A23418262-001-01-5::2.519094866::MTS004,BRD-A23418262-001-01-5,floctafenine,2.519094866,MTS004,Exp_SHANK1 (ENSG00000161681),GE,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Launched,0.262160465322739,0.166271665591,floctafenine,,,0,0
BRD-A23603052-001-03-2::2.5::HTS,BRD-A23603052-001-03-2,rifampin,2.5,HTS,Exp_P4HA1 (ENSG00000122884),GE,noncancer,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis",Launched,0.269106341109085,0.0297552793181,rifampin,,,0,0
BRD-A24122750-001-03-7::2.5::HTS,BRD-A24122750-001-03-7,saclofen,2.5,HTS,MIRNA_hsa-miR-518f,MIRNA,noncancer,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,Preclinical,0.27444895515926504,0.0939150636015,saclofen,,,0,0
BRD-A24191444-046-02-1::2.5::HTS,BRD-A24191444-046-02-1,ifenprodil,2.5,HTS,DEM2_ORM1 (5004),DEMETER2_COM,noncancer,"adrenergic receptor antagonist, glutamate receptor antagonist","GRIN1, GRIN2B",,,Launched,0.31927680688716803,0.0772875055717,ifenprodil,,,0,0
BRD-A24191444-046-03-9::2.4::HTS,BRD-A24191444-046-03-9,ifenprodil,2.4,HTS,METHYL_FHOD3,METHYL,noncancer,"adrenergic receptor antagonist, glutamate receptor antagonist","GRIN1, GRIN2B",,,Launched,0.31927680688716803,0.106670864394,ifenprodil,,,0,0
BRD-A24228527-213-01-9::2.5::HTS,BRD-A24228527-213-01-9,ofloxacin,2.5,HTS,Exp_MEF2C (ENSG00000081189),GE,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, otolaryngology, gastroenterology, endocrinology","respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections",Launched,0.23046927333811,0.0827328996337,ofloxacin,,,0,0
BRD-A24297246-001-03-9::2.5::HTS,BRD-A24297246-001-03-9,troleandomycin,2.5,HTS,Exp_FAM3B (ENSG00000183844),GE,noncancer,protein synthesis inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, tonsillitis, sinusitis",Launched,0.28978135446910497,0.077778277007,troleandomycin,,,0,0
BRD-A24397426-001-10-4::2.5::HTS,BRD-A24397426-001-10-4,nadifloxacin,2.5,HTS,MIRNA_hsa-miR-1245,MIRNA,noncancer,bacterial DNA gyrase inhibitor,,"dermatology, infectious disease","acne vulgaris (AV), skin infections",Launched,0.337015813230073,0.0653757628231,nadifloxacin,,,0,0
BRD-A24514565-001-09-7::2.5::HTS,BRD-A24514565-001-09-7,warfarin,2.5,HTS,Exp_ZP3 (ENSG00000188372),GE,noncancer,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",Launched,0.22953998603228604,0.123159285539,warfarin,,,0,0
BRD-A24543851-001-05-7::2.5::HTS,BRD-A24543851-001-05-7,nornicotine,2.5,HTS,METHYL_SFXN3,METHYL,noncancer,acetylcholine receptor agonist,,,,Preclinical,0.287608154285272,0.112663729002,nornicotine,,,0,0
BRD-A24560335-300-01-2::2.5::HTS,BRD-A24560335-300-01-2,efatutazone,2.5,HTS,METABOL_C18:0 SM,METABOL,targeted cancer,PPAR receptor agonist,PPARG,,,Phase 2,0.29728248493266196,0.094171709687,efatutazone,,,0,0
BRD-A24587114-066-22-5::2.5::HTS,BRD-A24587114-066-22-5,isoetharine,2.5,HTS,METHYL_GRB10,METHYL,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma",Launched,0.241146561610795,0.0933437867308,isoetharine,,,0,0
BRD-A24857382-001-03-4::2.488183422::MTS004,BRD-A24857382-001-03-4,N-acetyl-tyrosine,2.488183422,MTS004,Exp_EXO5 (ENSG00000164002),GE,noncancer,,,,,Launched,0.32690178543436604,0.0122833180959,N-acetyl-tyrosine,,,0,0
BRD-A25004090-001-08-4::2.5::HTS,BRD-A25004090-001-08-4,erastin,2.5,HTS,Exp_MARCH4 (ENSG00000144583),GE,targeted cancer,ion channel antagonist,VDAC2,,,Preclinical,0.554889438458167,0.335722005971,erastin,OTHER,0.553829500723355,-1.019885127456999,0.4800375810710249
BRD-A25143711-001-02-2::2.5::HTS,BRD-A25143711-001-02-2,hydrocortisone-valerate,2.5,HTS,PROT_XRCC1_Caution,PROT,noncancer,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,Launched,0.250831679847372,0.106584108993,hydrocortisone-valerate,GLUCOCORTICOID RECEPTOR AGONIST,0.2503317293969236,-4.1593119742875135,-2.885341482148596
BRD-A25234499-001-18-3::2.5::HTS,BRD-A25234499-001-18-3,aminoglutethimide,2.5,HTS,CRISPR_ENTPD5 (957),AVANA_PUBLIC_18Q2,targeted cancer,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer",Launched,0.2936772122291,-0.00538645146012,aminoglutethimide,,,0,0
BRD-A25569250-001-03-3::2.5::HTS,BRD-A25569250-001-03-3,KI-16425,2.5,HTS,Exp_HM13-AS1 (ENSG00000230613),GE,targeted cancer,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",,,Preclinical,0.298090505424073,0.0765911220071,KI-16425,OTHER,0.29554580489761,3.611332209280232,-1.5117771532640851
BRD-A25608658-001-01-1::2.5::HTS,BRD-A25608658-001-01-1,narasin,2.5,HTS,Exp_BARD1 (ENSG00000138376),GE,noncancer,antiprotozoal agent,,infectious disease,coccidiosis,Launched,0.3294545051276,0.199310517863,narasin,OTHER,0.3295815713714193,4.655487319449608,-0.6863243834066082
BRD-A25619068-003-03-4::2.5::HTS,BRD-A25619068-003-03-4,fadrozole,2.5,HTS,MIRNA_hsa-miR-125a-5p,MIRNA,targeted cancer,aromatase inhibitor,"CYP11B1, CYP19A1",oncology,breast cancer,Launched,0.32982023274760197,0.0926529945234,fadrozole,,,0,0
BRD-A25800195-001-02-2::2.5::HTS,BRD-A25800195-001-02-2,L-Cysteinesulfinic-acid,2.5,HTS,DEM2_LHFPL6 (10186),DEMETER2_COM,noncancer,glutamate receptor agonist,"GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2",,,Preclinical,0.25647733062514605,0.0473089496134,L-Cysteinesulfinic-acid,,,0,0
BRD-A26032986-050-02-1::2.5::HTS,BRD-A26032986-050-02-1,zaldaride,2.5,HTS,Exp_FAM149A (ENSG00000109794),GE,noncancer,calmodulin antagonist,CALM1,,,Phase 3,0.31739792273579803,0.165659278521,zaldaride,,,0,0
BRD-A26334849-001-06-2::2.5::HTS,BRD-A26334849-001-06-2,propafenone,2.5,HTS,MIRNA_kshv-miR-K12-11,MIRNA,noncancer,antiarrhythmic,"ADRB1, ADRB2, KCNA5, KCNH2, SCN5A",cardiology,"atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias",Launched,0.24901678359615198,0.0754467123493,propafenone,,,0,0
BRD-A26384407-001-25-1::2.5::HTS,BRD-A26384407-001-25-1,chlorthalidone,2.5,HTS,METHYL_KAAG1,METHYL,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA4, CA7, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure",Launched,0.232673738389428,0.0500004970012,chlorthalidone,,,0,0
BRD-A26387268-050-04-4::2.5::HTS,BRD-A26387268-050-04-4,ergonovine,2.5,HTS,Exp_SMTNL2 (ENSG00000188176),GE,noncancer,"adrenergic receptor agonist, serotonin receptor agonist","ADRA1A, HTR1E",hematology,postpartum hemorrhage (PPH),Launched,0.309723229251441,0.107970586836,ergonovine,,,0,0
BRD-A26503646-001-16-6::2.5::HTS,BRD-A26503646-001-16-6,formestane,2.5,HTS,CRISPR_TGFBR2 (7048),AVANA_PUBLIC_18Q2,targeted cancer,aromatase inhibitor,CYP19A1,oncology,breast cancer,Launched,0.26257421579315,0.0571039259765,formestane,,,0,0
BRD-A26690767-066-01-9::2.5::HTS,BRD-A26690767-066-01-9,saquinavir,2.5,HTS,CN_VWA3A (146177),CN,noncancer,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.272626188161731,0.0562960252393,saquinavir,,,0,0
BRD-A26711594-003-10-6::2.5::HTS,BRD-A26711594-003-10-6,nicardipine,2.5,HTS,METHYL_FOXO1,METHYL,noncancer,calcium channel blocker,"ADORA3, ADRA1A, ADRA1B, ADRA1D, CACNA1C, CACNA1D, CACNA2D1, CACNB2, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, PDE1A, PDE1B",cardiology,"chronic stable angina, hypertension",Launched,0.224899370821466,0.0881354203524,nicardipine,,,0,0
BRD-A26845397-051-01-9::2.5::HTS,BRD-A26845397-051-01-9,isamoltane,2.5,HTS,MIRNA_hsa-miR-548e,MIRNA,noncancer,adrenergic receptor antagonist,"HTR1A, HTR1B",,,Phase 1,0.244971791961139,0.00746032624357,isamoltane,,,0,0
BRD-A27143604-001-02-0::2.5::HTS,BRD-A27143604-001-02-0,diarylpropionitrile,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,targeted cancer,estrogen receptor agonist,ESR2,,,Preclinical,0.247282623791228,0.0121100398095,diarylpropionitrile,,,0,0
BRD-A27274504-001-01-6::2.400106631::MTS004,BRD-A27274504-001-01-6,butofilolol,2.400106631,MTS004,METABOL_C36:1 PC,METABOL,noncancer,adrenergic receptor antagonist,,,,Phase 2,0.31381788688353496,0.103395505015,butofilolol,,,0,0
BRD-A27290375-330-01-1::2.5::HTS,BRD-A27290375-330-01-1,atropine,2.5,HTS,CRISPR_NSUN2 (54888),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,"cycloplegia, mydriasis, amblyopia",Launched,0.25795210438315197,0.108554991613,atropine,,,0,0
BRD-A27370296-001-03-0::2.5::HTS,BRD-A27370296-001-03-0,cyclandelate,2.5,HTS,CN_IGFL3 (388555),CN,noncancer,calcium channel blocker,"CACNA2D1, CES1","cardiology, rheumatology","claudication, arteriosclerosis, Raynaud's disease",Launched,0.22950488751296,0.063636509242,cyclandelate,,,0,0
BRD-A27732521-003-08-3::2.5::HTS,BRD-A27732521-003-08-3,tolperisone,2.5,HTS,METHYL_CD248,METHYL,noncancer,voltage-gated sodium channel blocker,"CYP2C19, CYP2D6","neurology/psychiatry, infectious disease, rheumatology, cardiology","muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease",Launched,0.21869449331825,-0.00700797150754,tolperisone,,,0,0
BRD-A27883417-300-01-6::2.5::HTS,BRD-A27883417-300-01-6,alexidine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,phosphatidylglycerophosphatase inhibitor,PTPMT1,,,Preclinical,0.3751389187655739,0.33594370131,alexidine,OTHER,0.37551841338850106,3.4676148277539616,-2.082755954636646
BRD-A27887842-001-04-0::2.5::HTS,BRD-A27887842-001-04-0,prednisolone,2.5,HTS,RMUTmis_POLRMT (5442),MUT,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.24512680526184696,0.0263133044824,prednisolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2443795585207873,-1.2808761348108684,-2.6770004020617035
BRD-A27924917-001-03-3::2.5::HTS,BRD-A27924917-001-03-3,2-hydroxysaclofen,2.5,HTS,DEM2_FBXL20 (84961),DEMETER2_COM,noncancer,GABA receptor antagonist,"GABBR1, GABBR2",,,Preclinical,0.24548552216267802,0.0849460416553,2-hydroxysaclofen,,,0,0
BRD-A28044053-001-01-7::2.5::HTS,BRD-A28044053-001-01-7,arotinolol,2.5,HTS,MIRNA_hsa-miR-1259,MIRNA,noncancer,adrenergic receptor antagonist,ADRB3,"cardiology, neurology/psychiatry","hypertension, tremors",Launched,0.21988975444665695,0.0293473895862,arotinolol,,,0,0
BRD-A28301258-001-03-0::2.5::HTS,BRD-A28301258-001-03-0,salinomycin,2.5,HTS,Exp_BNIP3P1 (ENSG00000197358),GE,noncancer,,,infectious disease,coccidiosis,Launched,0.35680304171722493,0.300172560108,salinomycin,OTHER,0.33738213852498666,4.714299994132405,-0.9879237967745876
BRD-A28301258-001-04-8::2.5::HTS,BRD-A28301258-001-04-8,salinomycin,2.5,HTS,Exp_KRT7 (ENSG00000135480),GE,noncancer,,,infectious disease,coccidiosis,Launched,0.35680304171722493,0.300172560108,salinomycin,OTHER,0.35485184233060496,4.672176273305377,-1.3264773775671563
BRD-A28318179-003-08-5::2.5::HTS,BRD-A28318179-003-08-5,aminomethyltransferase,2.5,HTS,PROT_Src,PROT,noncancer,nitric oxide synthase inhibitor,NOS2,,,Preclinical,0.28618478201632397,0.059379006836,aminomethyltransferase,,,0,0
BRD-A28329383-001-02-1::2.5::HTS,BRD-A28329383-001-02-1,MTPG,2.5,HTS,METHYL_LRIG1,METHYL,noncancer,glutamate receptor antagonist,"GRM2, GRM3",,,Preclinical,0.251871648370033,0.0487723288598,MTPG,,,0,0
BRD-A28545468-003-16-6::2.5::HTS,BRD-A28545468-003-16-6,selegiline,2.5,HTS,METABOL_C22:6 LPC,METABOL,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,Parkinson's Disease,Launched,0.29425103675686104,0.0326905366594,selegiline,,,0,0
BRD-A28856712-003-26-0::2.5::HTS,BRD-A28856712-003-26-0,tetrahydrozoline,2.5,HTS,METHYL_MAPKAPK3,METHYL,noncancer,adrenergic receptor agonist,,ophthalmology,eye irritation,Launched,0.225083028337245,0.0939521274451,tetrahydrozoline,,,0,0
BRD-A28887267-001-19-3::2.5::HTS,BRD-A28887267-001-19-3,proxyphylline,2.5,HTS,METABOL_serine,METABOL,noncancer,,,pulmonary,asthma,Launched,0.270957303967577,0.0782936979983,proxyphylline,,,0,0
BRD-A28940325-001-24-0::2.5::HTS,BRD-A28940325-001-24-0,trichlormethiazide,2.5,HTS,MIRNA_hsa-miR-146b-5p,MIRNA,noncancer,chloride channel blocker,"ATP1A1, CA1, CA2, CA4, SLC12A1, SLC12A3",cardiology,"hypertension, edema",Launched,0.295469671027336,0.0803315946373,trichlormethiazide,,,0,0
BRD-A28958257-001-01-2::2.5::HTS,BRD-A28958257-001-01-2,centpropazine,2.5,HTS,PROT_Fibronectin,PROT,noncancer,inositol monophosphatase inhibitor,,,,Phase 3,0.31541760300913,0.10617507713,centpropazine,,,0,0
BRD-A28970875-300-04-9::2.5::HTS,BRD-A28970875-300-04-9,puromycin,2.5,HTS,CN_NPIPA1 (9284),CN,noncancer,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,Preclinical,0.312073865584097,0.0771097501342,puromycin,OTHER,0.3729673329273601,3.9844286959104864,-1.2002721585893852
BRD-A29111201-001-04-8::2.5::HTS,BRD-A29111201-001-04-8,ethisterone,2.5,HTS,METABOL_lactate,METABOL,noncancer,progestogen hormone,TYR,,,Launched,0.262847053419417,0.0875074056362,ethisterone,,,0,0
BRD-A29260609-003-26-0::2.5::HTS,BRD-A29260609-003-26-0,acebutolol,2.5,HTS,PROT_Smad3,PROT,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, ventricular arrhythmias",Launched,0.27295224482290903,0.108682653903,acebutolol,,,0,0
BRD-A29281099-003-03-2::2.5::HTS,BRD-A29281099-003-03-2,clorprenaline,2.5,HTS,Exp_LINC00639 (ENSG00000259070),GE,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,asthma,Launched,0.290819906153387,0.0275339122218,clorprenaline,,,0,0
BRD-A29289453-001-04-7::2.5::HTS,BRD-A29289453-001-04-7,PCA-4248,2.5,HTS,DEM2_RPL22 (6146),DEMETER2_COM,noncancer,platelet activating factor receptor antagonist,PTAFR,,,Phase 1,0.31711951394431503,0.0790200991806,PCA-4248,,,0,0
BRD-A29349577-001-23-0::2.5::HTS,BRD-A29349577-001-23-0,dropropizine,2.5,HTS,MIRNA_hsa-miR-610,MIRNA,noncancer,antitussive,,pulmonary,cough suppressant,Launched,0.30527410160890806,0.0615282187479,dropropizine,,,0,0
BRD-A29426959-050-13-2::2.5::HTS,BRD-A29426959-050-13-2,carbinoxamine,2.5,HTS,MIRNA_hsa-miR-130a,MIRNA,noncancer,histamine receptor antagonist,HRH1,"allergy, ophthalmology, otolaryngology, dermatology","allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism",Launched,0.29592716496852,0.176486513003,carbinoxamine,,,0,0
BRD-A29485665-001-12-8::2.5::HTS,BRD-A29485665-001-12-8,bicalutamide,2.5,HTS,METHYL_RASA1,METHYL,targeted cancer,androgen receptor antagonist,AR,oncology,prostate cancer,Launched,0.277696478272359,0.0365590263483,bicalutamide,,,0,0
BRD-A29520968-001-02-7::2.5::HTS,BRD-A29520968-001-02-7,acifran,2.5,HTS,Exp_TACC1 (ENSG00000147526),GE,noncancer,cholesterol inhibitor,"HCAR2, HCAR3",,,Phase 3,0.26070593863185,0.0597787805609,acifran,,,0,0
BRD-A29623586-001-01-3::2.5::HTS,BRD-A29623586-001-01-3,anisodamine,2.5,HTS,RMUTmis_CNTNAP4 (85445),MUTmis,noncancer,lipid peroxidase inhibitor,ADRA1A,,,Phase 3,0.29071677439384497,0.0118870229491,anisodamine,,,0,0
BRD-A29644307-050-17-0::2.5::HTS,BRD-A29644307-050-17-0,nomifensine,2.5,HTS,METHYL_FBXO46,METHYL,noncancer,"dopamine uptake inhibitor, noradrenaline uptake inhibitor","DRD2, MAOA, MAOB, MPO, SLC6A2, SLC6A3",,,Withdrawn,0.23092374928803197,0.0505288625049,nomifensine,,,0,0
BRD-A29700858-304-01-8::2.5::HTS,BRD-A29700858-304-01-8,carbenoxolone,2.5,HTS,RMUTmis_ATAD2 (29028),MUTmis,noncancer,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation",Launched,0.292906237610628,0.0390641402449,carbenoxolone,,,0,0
BRD-A29700858-304-02-6::2.5::HTS,BRD-A29700858-304-02-6,carbenoxolone,2.5,HTS,CRISPR_CAMK2G (818),AVANA_PUBLIC_18Q2,noncancer,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation",Launched,0.300933389833311,0.111480180448,carbenoxolone,,,0,0
BRD-A29731977-001-04-5::2.5::HTS,BRD-A29731977-001-04-5,17-hydroxyprogesterone-caproate,2.5,HTS,METABOL_2-deoxycytidine,METABOL,targeted cancer,progesterone receptor agonist,"AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR",,,Launched,0.257386119331321,0.148981223355,17-hydroxyprogesterone-caproate,,,0,0
BRD-A29734509-011-13-6::2.5::HTS,BRD-A29734509-011-13-6,disopyramide,2.5,HTS,MUTpool_SLFN13 (146857),MUTpool,noncancer,sodium channel blocker,"CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A",cardiology,"ventricular tachycardia (VT), ventricular arrhythmias",Launched,0.22694609018636103,0.0894098165336,disopyramide,,,0,0
BRD-A29844814-300-01-5::2.5::HTS,BRD-A29844814-300-01-5,ABT-202,2.5,HTS,METABOL_C32:1 PC,METABOL,noncancer,acetylcholine receptor agonist,,,,Phase 1,0.204403913436933,0.124944293354,ABT-202,,,0,0
BRD-A29854054-236-12-6::2.5::HTS,BRD-A29854054-236-12-6,lorglumide,2.5,HTS,CRISPR_CPEB2 (132864),AVANA_PUBLIC_18Q2,noncancer,CCK receptor antagonist,"CCKAR, CCKBR",,,Phase 1,0.267635376801423,0.0306597538188,lorglumide,,,0,0
BRD-A29944538-003-08-3::2.5::HTS,BRD-A29944538-003-08-3,proxodolol,2.5,HTS,PROT_DJ-1,PROT,noncancer,adrenergic receptor antagonist,,,,Launched,0.28069972337708304,0.0165510897323,proxodolol,,,0,0
BRD-A30051119-002-01-8::2.5::HTS,BRD-A30051119-002-01-8,amikacin,2.5,HTS,DEM2_EAF1 (85403),DEMETER2_COM,noncancer,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.19134669676130897,0.0328867416505,amikacin,,,0,0
BRD-A30205217-001-11-2::2.5::HTS,BRD-A30205217-001-11-2,ethotoin,2.5,HTS,CRISPR_TUBB3 (10381),AVANA_PUBLIC_18Q2,noncancer,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.264840681059768,0.105900077405,ethotoin,,,0,0
BRD-A30403214-001-03-3::0.25::HTS,BRD-A30403214-001-03-3,edelfosine,0.25,HTS,DEM2_TBC1D7-LOC100130357 (107080638),DEMETER2_COM,targeted cancer,phospholipase inhibitor,,,,Phase 2,0.29227100627463504,0.0643541691098,edelfosine,,,0,0
BRD-A30582499-003-05-1::2.5::HTS,BRD-A30582499-003-05-1,tiletamine,2.5,HTS,METABOL_heptanoylcarnitine,METABOL,noncancer,glutamate receptor antagonist,,neurology/psychiatry,anesthetic,Launched,0.24610751340250198,0.0713675172214,tiletamine,,,0,0
BRD-A30590053-003-02-9::2.5::HTS,BRD-A30590053-003-02-9,MR-16728,2.5,HTS,Exp_CKM (ENSG00000104879),GE,noncancer,acetylcholine release enhancer,,,,Preclinical,0.216974625530935,0.0625152068156,MR-16728,,,0,0
BRD-A30655177-001-14-0::2.5::HTS,BRD-A30655177-001-14-0,LFM-A13,2.5,HTS,CRISPR_OR10A3 (26496),AVANA_PUBLIC_18Q2,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,Preclinical,0.28443344173089297,0.078711584359,LFM-A13,,,0,0
BRD-A30693873-003-12-8::2.5::HTS,BRD-A30693873-003-12-8,diperodon,2.5,HTS,METHYL_GRPR,METHYL,noncancer,local anesthetic,,,,Preclinical,0.207745163661847,0.0606299910749,diperodon,,,0,0
BRD-A30703952-201-01-2::2.5::HTS,BRD-A30703952-201-01-2,ganglioside-gm1,2.5,HTS,CN_CLEC2D (29121),CN,targeted cancer,,,,,Phase 2,0.24306737096341502,0.0889280458779,ganglioside-gm1,,,0,0
BRD-A30774155-001-01-2::2.499990706::MTS004,BRD-A30774155-001-01-2,efinaconazole,2.499990706,MTS004,CRISPR_APBA1 (320),AVANA_PUBLIC_18Q2,noncancer,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis,Launched,0.281244608983698,0.107114017176,efinaconazole,,,0,0
BRD-A30815329-001-10-5::2.5::HTS,BRD-A30815329-001-10-5,felodipine,2.5,HTS,METABOL_taurodeoxycholate/taurochenodeoxycholate,METABOL,noncancer,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CALM1, CFTR, NR3C2, PDE1A, PDE1B, TNNC1, TNNC2",cardiology,hypertension,Launched,0.23502943985708497,0.0991451027396,felodipine,,,0,0
BRD-A30886737-001-02-9::2.5::HTS,BRD-A30886737-001-02-9,florfenicol,2.5,HTS,DEM2_TBL3 (10607),DEMETER2_COM,noncancer,protein synthesis inhibitor,,pulmonary,bovine respiratory disease (BRD),Launched,0.33042686841219604,0.0429728691066,florfenicol,OTHER,0.3318209446503185,1.7831089538191516,-2.7697292557034703
BRD-A30984645-001-01-5::2.5::HTS,BRD-A30984645-001-01-5,GDC-0834,2.5,HTS,METABOL_C18:2 SM,METABOL,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,Phase 1,0.313420219424549,0.0828479318803,GDC-0834,,,0,0
BRD-A31095847-001-02-3::2.5::HTS,BRD-A31095847-001-02-3,mozavaptan,2.5,HTS,Exp_TMEM255B (ENSG00000184497),GE,noncancer,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,Launched,0.437146057017644,0.272205507131,mozavaptan,OTHER,0.4333184152117917,4.745712724788285,-3.928497318835463
BRD-A31159102-003-30-4::2.5::HTS,BRD-A31159102-003-30-4,fluoxetine,2.5,HTS,RMUTmis_COL5A2 (1290),MUTmis,noncancer,selective serotonin reuptake inhibitor (SSRI),"ANO1, HTR2B, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder",Launched,0.251200088453265,0.0296883588965,fluoxetine,,,0,0
BRD-A31362467-065-01-3::2.499984736::MTS004,BRD-A31362467-065-01-3,capreomycin,2.499984736,MTS004,PROT_HER2_pY1248_Caution,PROT,noncancer,protein synthesis inhibitor,,infectious disease,tuberculosis,Launched,0.23694820398796,0.0410164474801,capreomycin,,,0,0
BRD-A31454688-001-01-6::2.5::HTS,BRD-A31454688-001-01-6,monostearin,2.5,HTS,DEM2_TYMS (7298),DEMETER2_COM,noncancer,,,,,Preclinical,0.302660013463693,0.102757121354,monostearin,,,0,0
BRD-A31521121-001-26-4::2.5::HTS,BRD-A31521121-001-26-4,methocarbamol,2.5,HTS,CN_ACER2 (340485),CN,noncancer,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,Launched,0.23196118785281897,0.0566202861946,methocarbamol,,,0,0
BRD-A31564021-001-01-8::2.5::HTS,BRD-A31564021-001-01-8,isoflurane,2.5,HTS,CN_ZNF582-AS1 (386758),CN,noncancer,inhaled anaesthetic,"ATP2C1, ATP5D, CALM1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9",neurology/psychiatry,general anaesthetic,Launched,0.270145397077132,0.0236072299539,isoflurane,,,0,0
BRD-A31800922-003-25-1::2.5::HTS,BRD-A31800922-003-25-1,procyclidine,2.5,HTS,METHYL_MIR6769B,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,"parkinsonism, Parkinson's Disease, akathisia, dystonia",Launched,0.257267603392183,-0.0403253513911,procyclidine,,,0,0
BRD-A31811760-001-06-7::2.5::HTS,BRD-A31811760-001-06-7,miltefosine,2.5,HTS,METHYL_FRAT2,METHYL,noncancer,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis,Launched,0.30651196680630605,0.128095498435,miltefosine,,,0,0
BRD-A31990649-304-02-3::2.5::HTS,BRD-A31990649-304-02-3,adenosine-triphosphate,2.5,HTS,MUTpool_WDR66 (144406),MUTpool,noncancer,adenosine receptor agonist,"ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7",,,Phase 2,0.234990562520843,0.0852735205672,adenosine-triphosphate,,,0,0
BRD-A32172948-001-07-6::2.5::HTS,BRD-A32172948-001-07-6,methiopril,2.5,HTS,METHYL_LRRC61,METHYL,noncancer,angiotensin converting enzyme inhibitor,ACE,,,Phase 2,0.30328773730475606,0.104116184678,methiopril,,,0,0
BRD-A32269193-001-01-5::2.5::HTS,BRD-A32269193-001-01-5,VGX-1027,2.5,HTS,MIRNA_hsa-miR-653,MIRNA,noncancer,tumor necrosis factor receptor antagonist,TLR4,,,Phase 1,0.346954840532266,0.0333851486198,VGX-1027,,,0,0
BRD-A32505112-001-04-4::2.5::HTS,BRD-A32505112-001-04-4,trandolapril,2.5,HTS,CRISPR_DOC2A (8448),AVANA_PUBLIC_18Q2,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction",Launched,0.306303188712756,0.133666826775,trandolapril,,,0,0
BRD-A32597168-001-03-6::2.5::HTS,BRD-A32597168-001-03-6,letosteine,2.5,HTS,METHYL_LTA,METHYL,noncancer,mucolytic agent,,"pulmonary, infectious disease","bronchitis, pneumonia",Launched,0.19132447742960698,0.0887100870339,letosteine,,,0,0
BRD-A32673558-003-03-9::2.5::HTS,BRD-A32673558-003-03-9,aceclidine,2.5,HTS,DEM2_PRKACG (5568),DEMETER2_COM,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,glaucoma,Launched,0.276915225314437,0.0927261702335,aceclidine,,,0,0
BRD-A33168282-003-18-0::2.5::HTS,BRD-A33168282-003-18-0,sotalol,2.5,HTS,Exp_BAP1 (ENSG00000163930),GE,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, KCNH2",cardiology,"atrial fibrillation (AF), ventricular arrhythmias",Launched,0.314713375835872,0.0950644856638,sotalol,,,0,0
BRD-A33352494-316-01-6::2.499995956::MTS004,BRD-A33352494-316-01-6,oritavancin,2.499995956,MTS004,MIRNA_hsa-miR-509-5p,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections,Launched,0.17715315482046398,0.100677875273,oritavancin,,,0,0
BRD-A33447119-001-10-8::2.5::HTS,BRD-A33447119-001-10-8,oxfendazole,2.5,HTS,CRISPR_HMGA2 (8091),AVANA_PUBLIC_18Q2,noncancer,anthelmintic agent,,infectious disease,"lungworms, tapeworm, gastrointestinal roundworms",Launched,0.236963676560962,0.0817299724034,oxfendazole,,,0,0
BRD-A33479817-003-03-7::2.490825408::MTS004,BRD-A33479817-003-03-7,terodiline,2.490825408,MTS004,METHYL_ATXN7L2,METHYL,noncancer,cholinergic receptor antagonist,,,,Phase 3,0.249649843975023,0.101755551307,terodiline,,,0,0
BRD-A33514596-003-01-2::2.5::HTS,BRD-A33514596-003-01-2,N-benzylnaltrindole,2.5,HTS,DEM2_PTGDR2 (11251),DEMETER2_COM,noncancer,opioid receptor antagonist,,,,Preclinical,0.274939976123255,0.0953184418501,N-benzylnaltrindole,,,0,0
BRD-A33692381-001-01-9::2.5::HTS,BRD-A33692381-001-01-9,zidovudine,2.5,HTS,Exp_SLC13A3 (ENSG00000158296),GE,noncancer,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,"human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)",Launched,0.284627831766783,0.0810804894826,zidovudine,,,0,0
BRD-A33697453-008-02-4::2.5::HTS,BRD-A33697453-008-02-4,fenticonazole,2.5,HTS,CRISPR_HEATR5B (54497),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis,Launched,0.29222142493274794,-0.008580259475,fenticonazole,,,0,0
BRD-A33711280-003-03-1::2.5::HTS,BRD-A33711280-003-03-1,metixene,2.5,HTS,CN_COL20A1 (57642),CN,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",neurology/psychiatry,Parkinson's Disease,Launched,0.289435922006702,0.107412532816,metixene,,,0,0
BRD-A33894669-065-01-9::2.312630829::MTS004,BRD-A33894669-065-01-9,hexoprenaline,2.312630829,MTS004,PROT_Gab2,PROT,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,asthma,Launched,0.28064754658426394,0.133466976659,hexoprenaline,,,0,0
BRD-A34006693-001-15-4::2.5::HTS,BRD-A34006693-001-15-4,suprofen,2.5,HTS,DEM2_NRAS (4893),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Withdrawn,0.233242647195042,0.0254876351644,suprofen,,,0,0
BRD-A34205397-001-04-5::2.5::HTS,BRD-A34205397-001-04-5,suloctidil,2.5,HTS,CRISPR_PTPDC1 (138639),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,,,,Withdrawn,0.297520775463942,0.0939864628211,suloctidil,,,0,0
BRD-A34255068-001-34-5::2.5::HTS,BRD-A34255068-001-34-5,rolipram,2.5,HTS,Exp_DEFA5 (ENSG00000164816),GE,noncancer,phosphodiesterase inhibitor,,,,Phase 3,0.272012870822298,0.0938492968887,rolipram,,,0,0
BRD-A34358106-003-01-6::2.5::HTS,BRD-A34358106-003-01-6,sarpogrelate,2.5,HTS,MIRNA_ebv-miR-BART3,MIRNA,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C","endocrinology, cardiology, rheumatology","diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease",Launched,0.24933445230489898,0.109355084161,sarpogrelate,,,0,0
BRD-A34603619-001-01-9::2.427905848::MTS004,BRD-A34603619-001-01-9,tropesin,2.427905848,MTS004,Exp_CCIN (ENSG00000185972),GE,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.31589180670371003,0.0495404386443,tropesin,,,0,0
BRD-A34716233-004-03-5::2.5::HTS,BRD-A34716233-004-03-5,AMPA-(RS),2.5,HTS,DEM2_ZNF397 (84307),DEMETER2_COM,noncancer,glutamate receptor agonist,GRIN1,,,Preclinical,0.27826524278438697,0.0807928809357,AMPA-(RS),,,0,0
BRD-A34751532-001-06-9::2.5::HTS,BRD-A34751532-001-06-9,homosalate,2.5,HTS,Exp_TDH (ENSG00000154316),GE,noncancer,HSP inducer,,,,Preclinical,0.265771143652061,0.00778019663048,homosalate,,,0,0
BRD-A34788695-003-10-2::2.375699424::MTS004,BRD-A34788695-003-10-2,tetracycline,2.375699424,MTS004,Exp_VTI1A (ENSG00000151532),GE,noncancer,bacterial 30S ribosomal subunit inhibitor,PRNP,"infectious disease, dermatology","respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis",Launched,0.31928125625657106,0.0971283129183,tetracycline,,,0,0
BRD-A35379661-001-04-6::2.5::HTS,BRD-A35379661-001-04-6,sphingosylphosphorylcholine,2.5,HTS,CRISPR_CDV3 (55573),AVANA_PUBLIC_18Q2,targeted cancer,gene expression stimulant,GPR12,,,Preclinical,0.303528663195036,0.122745265296,sphingosylphosphorylcholine,,,0,0
BRD-A35588707-001-05-5::2.5::HTS,BRD-A35588707-001-05-5,teniposide,2.5,HTS,DEM2_CDX4 (1046),DEMETER2_COM,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.37919941860096795,0.116999470995,teniposide,TOPOISOMERASE INHIBITOR,0.3770620959138941,5.136812739337668,-1.212969451617493
BRD-A35623999-001-05-7::2.5::HTS,BRD-A35623999-001-05-7,CGP-37157,2.5,HTS,Exp_SEC1P (ENSG00000232871),GE,noncancer,"mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor",SLC8A1,,,Preclinical,0.306154183921513,0.057514796755,CGP-37157,,,0,0
BRD-A35667010-001-01-8::2.5::MTS004,BRD-A35667010-001-01-8,propylhexedrine,2.5,MTS004,CRISPR_CEBPG (1054),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"SLC18A2, TAAR1","otolaryngology, endocrinology, allergy","nasal congestion, fever, allergic rhinitis",Launched,0.283865731262295,0.084203878524,propylhexedrine,,,0,0
BRD-A35868371-005-01-6::2.5::HTS,BRD-A35868371-005-01-6,troventol,2.5,HTS,MIRNA_hsa-miR-196a,MIRNA,noncancer,,,,,Phase 1,0.23059599749484602,0.0863681992186,troventol,,,0,0
BRD-A35912562-001-02-8::2.5::HTS,BRD-A35912562-001-02-8,pregnenolone-succinate,2.5,HTS,Exp_NR3C1 (ENSG00000113580),GE,noncancer,GABA receptor negative allosteric modulator,,,,Preclinical,0.282762803842306,0.137482929874,pregnenolone-succinate,,,0,0
BRD-A35989968-001-04-2::2.5::HTS,BRD-A35989968-001-04-2,megestrol-acetate,2.5,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,progesterone receptor agonist,"NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia",Launched,0.29416903568179803,0.140760120341,megestrol-acetate,,,0,0
BRD-A36010170-001-04-0::2.5::HTS,BRD-A36010170-001-04-0,amcinonide,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"ANXA1, NR3C1",dermatology,corticosteroid-responsive dermatoses,Launched,0.23188904445577105,0.0663565883012,amcinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2349389758109275,-3.7547086082488312,-3.1594781087701005
BRD-A36074203-003-07-6::2.5::HTS,BRD-A36074203-003-07-6,remacemide,2.5,HTS,METHYL_MB21D1,METHYL,noncancer,glutamate receptor antagonist,GRIN1,,,Phase 3,0.281959572713728,0.0772372425782,remacemide,,,0,0
BRD-A36217750-001-16-3::2.5::HTS,BRD-A36217750-001-16-3,sulfinpyrazone,2.5,HTS,METHYL_MAFA,METHYL,noncancer,uricosuric blocker,"ABCC1, ABCC2, FPR1, SLC22A12",rheumatology,gout,Launched,0.290975530979505,0.0898175155739,sulfinpyrazone,,,0,0
BRD-A36267905-003-18-4::2.5::HTS,BRD-A36267905-003-18-4,buphenine,2.5,HTS,PROT_PRDX1,PROT,noncancer,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,Launched,0.22368450000425896,0.132805002757,buphenine,,,0,0
BRD-A36318220-001-08-8::2.5::HTS,BRD-A36318220-001-08-8,necrostatin-1,2.5,HTS,Exp_PPEF1 (ENSG00000086717),GE,noncancer,RIPK inhibitor,RIPK1,,,Preclinical,0.275741899715299,0.18729075821,necrostatin-1,OTHER,0.2931778488530141,-1.5667912971760298,0.9338314970107922
BRD-A36456202-001-01-3::2.5::HTS,BRD-A36456202-001-01-3,colistin-b-sulfate,2.5,HTS,Exp_KIAA1033 (ENSG00000136051),GE,noncancer,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections,Launched,0.232773388680494,0.107425856836,colistin-b-sulfate,OTHER,0.235077072261803,3.759020505572123,2.969991172381225
BRD-A37288617-003-02-2::2.5::HTS,BRD-A37288617-003-02-2,amfepramone,2.5,HTS,METHYL_C1D,METHYL,noncancer,adrenergic receptor agonist,"SLC6A2, SLC6A3",endocrinology,obesity,Launched,0.262872077600693,0.0220480853786,amfepramone,,,0,0
BRD-A37347161-003-02-6::2.5::HTS,BRD-A37347161-003-02-6,BRL-52537,2.5,HTS,METABOL_hypoxanthine,METABOL,noncancer,opioid receptor agonist,OPRK1,,,Preclinical,0.28907259276607694,0.0860866833533,BRL-52537,,,0,0
BRD-A37390343-003-03-5::2.5::HTS,BRD-A37390343-003-03-5,amorolfine,2.5,HTS,METABOL_phosphocreatine,METABOL,noncancer,membrane integrity inhibitor,,infectious disease,onychomycosis,Launched,0.234392784083286,0.0215613102343,amorolfine,,,0,0
BRD-A37441042-003-04-8::2.5::HTS,BRD-A37441042-003-04-8,tulobuterol,2.5,HTS,METABOL_glycodeoxycholate/glycochenodeoxycholate,METABOL,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,asthma,Launched,0.264399735019007,0.0560767283851,tulobuterol,,,0,0
BRD-A37492983-001-10-3::2.5::HTS,BRD-A37492983-001-10-3,iocetamic-acid,2.5,HTS,METHYL_PARP2,METHYL,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.21320178266730397,0.135843473705,iocetamic-acid,,,0,0
BRD-A37704979-001-10-7::2.5::HTS,BRD-A37704979-001-10-7,SB-203580,2.5,HTS,Exp_FAM198A (ENSG00000144649),GE,noncancer,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF",,,Preclinical,0.23405131966207798,0.194464296484,SB-203580,,,0,0
BRD-A38076815-003-10-3::2.5::HTS,BRD-A38076815-003-10-3,glafenine,2.5,HTS,DEM2_RTN4IP1 (84816),DEMETER2_COM,noncancer,DeltaF508-CFTR Correctors,CFTR,,,Withdrawn,0.27899409880437703,0.0710568878638,glafenine,,,0,0
BRD-A38218502-001-01-2::2.5::HTS,BRD-A38218502-001-01-2,metenkephalin,2.5,HTS,CRISPR_VANGL2 (57216),AVANA_PUBLIC_18Q2,targeted cancer,immunostimulant,OPRD1,,,Phase 2,0.28994183783996696,0.175556040484,metenkephalin,,,0,0
BRD-A38350138-001-04-9::2.5::HTS,BRD-A38350138-001-04-9,ketoconazole,2.5,HTS,METHYL_HECTD2-AS1,METHYL,noncancer,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,Launched,0.31491650359566,0.0884652482768,ketoconazole,,,0,0
BRD-A38706605-001-01-2::2.5::MTS004,BRD-A38706605-001-01-2,dromostanolone-propionate,2.5,MTS004,CRISPR_AKR1C4 (1109),AVANA_PUBLIC_18Q2,targeted cancer,androgen receptor modulator,AR,oncology,breast cancer,Launched,0.323242323354931,0.00475920895929,dromostanolone-propionate,,,0,0
BRD-A38747044-001-02-3::2.5::HTS,BRD-A38747044-001-02-3,KU14R,2.5,HTS,CRISPR_SUPV3L1 (6832),AVANA_PUBLIC_18Q2,noncancer,imidazoline receptor antagonist,,,,Preclinical,0.293464987595806,0.113969072919,KU14R,,,0,0
BRD-A39052811-048-11-0::2.5::HTS,BRD-A39052811-048-11-0,mosapride,2.5,HTS,PROT_beta-Catenin_pT41_S45,PROT,noncancer,serotonin receptor agonist,HTR4,gastroenterology,"hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome",Launched,0.26040130986048604,0.0721160243125,mosapride,,,0,0
BRD-A39189014-003-22-7::2.5::HTS,BRD-A39189014-003-22-7,methoxamine,2.5,HTS,METHYL_MIR3134,METHYL,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,Launched,0.273949380378323,0.0260398150349,methoxamine,,,0,0
BRD-A39230911-001-10-2::2.5::HTS,BRD-A39230911-001-10-2,chlorphensin-carbamate,2.5,HTS,METABOL_C14:0 SM,METABOL,noncancer,muscle relaxant,,,,Preclinical,0.329014794956997,0.0814503336438,chlorphensin-carbamate,,,0,0
BRD-A39255369-001-03-1::2.5::HTS,BRD-A39255369-001-03-1,DCPIB,2.5,HTS,PROT_Collagen_VI,PROT,noncancer,"chloride channel blocker, gap junction modulator, glutamate inhibitor",SLC1A2,,,Preclinical,0.29685459378517304,-0.0026946538486,DCPIB,,,0,0
BRD-A39390670-236-10-7::2.5::HTS,BRD-A39390670-236-10-7,rabeprazole,2.5,HTS,DEM2_STRA8 (346673),DEMETER2_COM,noncancer,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome",Launched,0.29809940680564095,0.0739658085655,rabeprazole,,,0,0
BRD-A39791822-001-05-1::2.5::HTS,BRD-A39791822-001-05-1,hydroxyprogesterone,2.5,HTS,DEM2_RAB10 (10890),DEMETER2_COM,noncancer,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth,Launched,0.259964049569853,0.0888063736471,hydroxyprogesterone,,,0,0
BRD-A39935389-001-05-9::2.5::HTS,BRD-A39935389-001-05-9,teroxirone,2.5,HTS,Exp_TCF3 (ENSG00000071564),GE,chemo,DNA inhibitor,,,,Phase 1,0.427347237303427,0.34809309168,teroxirone,OTHER,0.4239447960060244,3.2984245384970907,-3.547386607776501
BRD-A40084411-003-07-7::2.5::HTS,BRD-A40084411-003-07-7,CGP-12177,2.5,HTS,DEM2_ZNF850 (342892),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,Phase 1,0.28457904606710305,0.141931421657,CGP-12177,,,0,0
BRD-A40302156-001-01-9::2.503151999::MTS004,BRD-A40302156-001-01-9,A-33903,2.503151999,MTS004,PROT_PKC-delta_pS664,PROT,noncancer,,,,,Phase 2,0.292321351451337,0.175933105997,A-33903,,,0,0
BRD-A40413915-003-01-2::2.5::HTS,BRD-A40413915-003-01-2,NTNCB,2.5,HTS,MIRNA_hsa-miR-18a,MIRNA,noncancer,neuropeptide receptor antagonist,NPY5R,,,Preclinical,0.269168302569327,0.127617057451,NTNCB,,,0,0
BRD-A40546373-001-01-8::2.500029443::MTS004,BRD-A40546373-001-01-8,morinidazole,2.500029443,MTS004,MIRNA_ebv-miR-BART1-3p,MIRNA,noncancer,other antibiotic,CYP51A1,,,Launched,0.232254911627624,0.131540915304,morinidazole,,,0,0
BRD-A40639672-234-18-0::2.5::HTS,BRD-A40639672-234-18-0,ketorolac,2.5,HTS,DEM2_SGPP2 (130367),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.26826647517644303,0.0620210564062,ketorolac,,,0,0
BRD-A40777960-001-04-2::2.5::HTS,BRD-A40777960-001-04-2,aminohydroxybutyric-acid,2.5,HTS,Exp_PLAC1 (ENSG00000170965),GE,noncancer,,,neurology/psychiatry,epilepsy,Launched,0.22843533302789698,0.0506856248204,aminohydroxybutyric-acid,,,0,0
BRD-A40787240-066-04-6::2.5::HTS,BRD-A40787240-066-04-6,gemifloxacin,2.5,HTS,CRISPR_MYLIP (29116),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA gyrase inhibitor,,"pulmonary, infectious disease","bronchitis, pneumonia",Launched,0.28718726188759003,0.0183543161267,gemifloxacin,,,0,0
BRD-A40940854-001-01-1::2.5::HTS,BRD-A40940854-001-01-1,ibuproxam,2.5,HTS,CRISPR_RAB6A (5870),AVANA_PUBLIC_18Q2,noncancer,"cyclooxygenase inhibitor, prostaglandin inhibitor",ALOX5,"endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief",Launched,0.268641969749881,0.153760293388,ibuproxam,OTHER,0.2845167858179711,-4.240728681158864,-1.308169545938452
BRD-A41304429-001-14-8::2.5::HTS,BRD-A41304429-001-14-8,practolol,2.5,HTS,PROT_TAZ,PROT,noncancer,adrenergic receptor antagonist,ADRB1,,,Withdrawn,0.255571685312528,0.0896111792092,practolol,,,0,0
BRD-A41385909-001-01-3::2.5::HTS,BRD-A41385909-001-01-3,bornyl-acetate,2.5,HTS,PROT_MEK1,PROT,noncancer,,,,,Preclinical,0.32850059268541804,0.0802839469582,bornyl-acetate,,,0,0
BRD-A41450521-075-10-8::2.5::HTS,BRD-A41450521-075-10-8,tosufloxacin,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.23503700955930198,-0.0123910378835,tosufloxacin,,,0,0
BRD-A41451487-001-11-2::2.5::HTS,BRD-A41451487-001-11-2,PK-11195,2.5,HTS,Exp_PQBP1 (ENSG00000102103),GE,noncancer,benzodiazepine receptor antagonist,TSPO,,,Phase 1,0.312427171644375,0.053493786283,PK-11195,,,0,0
BRD-A41692738-001-07-6::2.5::HTS,BRD-A41692738-001-07-6,TGX-221,2.5,HTS,CRISPR_CCM2 (83605),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CB, PIK3CD",,,Preclinical,0.345430091765597,0.195565592227,TGX-221,,,0,0
BRD-A41698174-003-12-0::2.499982171::MTS004,BRD-A41698174-003-12-0,bacampicillin,2.499982171,MTS004,DEM2_PRRG4 (79056),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections",Launched,0.364919911351664,0.0436743191348,bacampicillin,,,0,0
BRD-A41714661-001-02-0::2.5::HTS,BRD-A41714661-001-02-0,bilobalide,2.5,HTS,PROT_N-Cadherin,PROT,noncancer,GABA receptor modulator,"GLRA1, GLRA2, GLRB, HTR3A, HTR3B",,,Preclinical,0.23898766034584898,0.0956067918115,bilobalide,,,0,0
BRD-A41774846-001-01-4::2.5::HTS,BRD-A41774846-001-01-4,algestone-acetophenide,2.5,HTS,CRISPR_FOXP2 (93986),AVANA_PUBLIC_18Q2,noncancer,,,endocrinology,contraceptive,Launched,0.25133818094986604,0.1687344873,algestone-acetophenide,,,0,0
BRD-A41995253-001-04-5::2.5::HTS,BRD-A41995253-001-04-5,brucine,2.5,HTS,CRISPR_DDA1 (79016),AVANA_PUBLIC_18Q2,noncancer,glycine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,Preclinical,0.26642531545323106,0.0604197336669,brucine,,,0,0
BRD-A42167015-003-10-2::2.5::HTS,BRD-A42167015-003-10-2,carteolol,2.5,HTS,CN_NTSR1 (4923),CN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.20265010594057803,0.0565344560497,carteolol,,,0,0
BRD-A42270467-001-04-4::2.5::HTS,BRD-A42270467-001-04-4,tenatoprazole,2.5,HTS,METHYL_HCP5,METHYL,noncancer,ATPase inhibitor,IDO1,,,Phase 2,0.22314475196358,0.125132815278,tenatoprazole,,,0,0
BRD-A42423104-001-01-4::2.495664958::MTS004,BRD-A42423104-001-01-4,benproperine,2.495664958,MTS004,Exp_CD52 (ENSG00000169442),GE,noncancer,antitussive,SCN5A,pulmonary,cough suppressant,Launched,0.267055779533393,0.0751562748646,benproperine,,,0,0
BRD-A42553870-001-14-3::2.5::HTS,BRD-A42553870-001-14-3,L-152804,2.5,HTS,Exp_GABRB1 (ENSG00000163288),GE,noncancer,neuropeptide receptor antagonist,NPY5R,,,Preclinical,0.217765735071371,0.0603443078101,L-152804,,,0,0
BRD-A42571354-300-12-0::2.5::HTS,BRD-A42571354-300-12-0,cetirizine,2.5,HTS,METABOL_2-deoxyadenosine,METABOL,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.26307818674635497,0.157138052001,cetirizine,,,0,0
BRD-A42628519-001-12-4::2.5::HTS,BRD-A42628519-001-12-4,iopanic-acid,2.5,HTS,CN_RBM15B (29890),CN,noncancer,thyroid hormone inhibitor,,,,Preclinical,0.28544234848933303,0.0994367104629,iopanic-acid,,,0,0
BRD-A42699921-001-02-8::2.5::HTS,BRD-A42699921-001-02-8,teriflunomide,2.5,HTS,CN_PPP1R12A (4659),CN,noncancer,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,Launched,0.266132197835524,0.0973166570309,teriflunomide,,,0,0
BRD-A42699921-001-03-6::2.6::HTS,BRD-A42699921-001-03-6,teriflunomide,2.6,HTS,CN_CDH3 (1001),CN,noncancer,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,Launched,0.266132197835524,0.0973166570309,teriflunomide,OTHER,0.19408000079740528,3.94919330919986,-1.8085930604005367
BRD-A42746051-001-02-9::2.5::HTS,BRD-A42746051-001-02-9,melengestrol-acetate,2.5,HTS,DEM2_CLPB (81570),DEMETER2_COM,noncancer,progesterone receptor agonist,,,,Preclinical,0.24393560159670002,0.170729518114,melengestrol-acetate,OTHER,0.2641039383927454,-4.229356985495588,-2.677341821397996
BRD-A42759514-001-20-5::2.5::HTS,BRD-A42759514-001-20-5,ornidazole,2.5,HTS,METHYL_PRMT5,METHYL,noncancer,antiprotozoal agent,,infectious disease,protozoan infection,Launched,0.26062507765099,0.0722327135509,ornidazole,,,0,0
BRD-A42881122-001-01-1::2.648380541::MTS004,BRD-A42881122-001-01-1,cyamemazine,2.648380541,MTS004,DEM2_CEACAM6 (4680),DEMETER2_COM,noncancer,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C, HTR7",neurology/psychiatry,"schizophrenia, anxiety",Launched,0.276370383839236,0.0860606007812,cyamemazine,,,0,0
BRD-A43082461-001-06-3::2.5::HTS,BRD-A43082461-001-06-3,linalool,2.5,HTS,METABOL_C52:3 TAG,METABOL,noncancer,anticonvulsant,,,,Phase 1,0.319022059609666,0.110825240854,linalool,,,0,0
BRD-A43082555-001-01-1::2.5::HTS,BRD-A43082555-001-01-1,loxoprofen,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist",PTGS2,neurology/psychiatry,pain relief,Launched,0.288685335118467,0.115818086122,loxoprofen,,,0,0
BRD-A43082555-001-02-9::2.5::HTS,BRD-A43082555-001-02-9,loxoprofen,2.5,HTS,METABOL_C18:0 SM,METABOL,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist",PTGS2,neurology/psychiatry,pain relief,Launched,0.288685335118467,0.115818086122,loxoprofen,,,0,0
BRD-A43435802-001-02-0::2.5::HTS,BRD-A43435802-001-02-0,mercaptosuccinic-acid,2.5,HTS,Exp_MYLK-AS2 (ENSG00000250174),GE,noncancer,,,,,Launched,0.297780939980666,0.0488480805125,mercaptosuccinic-acid,,,0,0
BRD-A43598550-001-09-4::2.5::HTS,BRD-A43598550-001-09-4,3-alpha-Hydroxy-5-beta-androstan-17-one,2.5,HTS,METABOL_C50:0 TAG,METABOL,noncancer,,,,,Preclinical,0.2459290090325,0.0515763048699,3-alpha-Hydroxy-5-beta-androstan-17-one,,,0,0
BRD-A43671941-003-11-9::2.5::HTS,BRD-A43671941-003-11-9,oxprenolol,2.5,HTS,CN_MEP1B (4225),CN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",Launched,0.34656153331725004,0.0615564212452,oxprenolol,,,0,0
BRD-A43809092-003-02-1::2.5::HTS,BRD-A43809092-003-02-1,clobutinol,2.5,HTS,MIRNA_hsa-miR-1301,MIRNA,noncancer,antitussive,,,,Withdrawn,0.281074600279981,0.0727066081129,clobutinol,,,0,0
BRD-A43882281-001-15-5::2.5::HTS,BRD-A43882281-001-15-5,pinacidil,2.5,HTS,MIRNA_hsa-miR-452,MIRNA,noncancer,"ATP channel activator, potassium channel activator","ABCC8, ABCC9",cardiology,hypertension,Launched,0.264547020109753,0.0794737316874,pinacidil,,,0,0
BRD-A43885598-001-08-1::2.5::HTS,BRD-A43885598-001-08-1,SID-7969543,2.5,HTS,Exp_NR0B1 (ENSG00000169297),GE,noncancer,steroidogenic factor antagonist,NR5A1,,,Preclinical,0.21714390353263002,0.211471203257,SID-7969543,,,0,0
BRD-A43930669-003-02-8::2.5::HTS,BRD-A43930669-003-02-8,L-368899,2.5,HTS,CRISPR_RCOR2 (283248),AVANA_PUBLIC_18Q2,noncancer,oxytocin receptor antagonist,"AVPR1A, AVPR2, OXTR",,,Phase 1,0.25383154989861,0.105074135156,L-368899,,,0,0
BRD-A44008656-036-25-8::2.5::HTS,BRD-A44008656-036-25-8,doxylamine,2.5,HTS,METABOL_C38:6 PC,METABOL,noncancer,histamine receptor antagonist,"CHRM1, HRH1",neurology/psychiatry,sedative,Launched,0.28198154544605397,0.0960471799236,doxylamine,,,0,0
BRD-A44090213-001-25-6::2.5::HTS,BRD-A44090213-001-25-6,indoprofen,2.5,HTS,CRISPR_NDUFS1 (4719),AVANA_PUBLIC_18Q2,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",,,Withdrawn,0.30122509174959494,0.0592233387446,indoprofen,,,0,0
BRD-A44133049-003-07-8::2.5::HTS,BRD-A44133049-003-07-8,azasetron,2.5,HTS,Exp_NCF1C (ENSG00000165178),GE,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B",infectious disease,genitial herpes,Launched,0.22960395586596102,0.0904336898698,azasetron,,,0,0
BRD-A44181516-001-01-8::2.666476303::MTS004,BRD-A44181516-001-01-8,flumecinol,2.666476303,MTS004,PROT_E-Cadherin,PROT,noncancer,,,,,Launched,0.298734289328878,0.076267209249,flumecinol,,,0,0
BRD-A44188509-001-01-2::2.639346634::MTS004,BRD-A44188509-001-01-2,AZD1446,2.639346634,MTS004,MIRNA_hsa-miR-1274b,MIRNA,noncancer,acetylcholine receptor agonist,"CHRNA4, CHRNB2",,,Phase 2,0.26263326300974305,0.143719325228,AZD1446,,,0,0
BRD-A44448661-001-04-8::2.5::HTS,BRD-A44448661-001-04-8,pentobarbital,2.5,HTS,METHYL_LINC01564,METHYL,noncancer,"barbiturate antiepileptic, GABA receptor modulator","CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",,,Withdrawn,0.287948086003412,0.103563688317,pentobarbital,,,0,0
BRD-A44500574-001-01-8::2.5::HTS,BRD-A44500574-001-01-8,FLI-06,2.5,HTS,Exp_CNKSR1 (ENSG00000142675),GE,targeted cancer,notch signaling inhibitor,,,,Preclinical,0.514217598009914,0.397976711727,FLI-06,OTHER,0.515268979202938,4.960814368292168,-1.5735214304016094
BRD-A44511856-001-01-4::2.499987042::MTS004,BRD-A44511856-001-01-4,ginsenoside-rg3,2.499987042,MTS004,Exp_MTHFD1P1 (ENSG00000231831),GE,noncancer,"angiogenesis inhibitor, apoptosis stimulant",KCNH2,,,Launched,0.286256111049303,0.0906081496908,ginsenoside-rg3,,,0,0
BRD-A44696962-001-01-4::2.5::HTS,BRD-A44696962-001-01-4,acetyl-11-keto-beta-boswellic-acid,2.5,HTS,MIRNA_hsa-miR-211,MIRNA,targeted cancer,lipoxygenase inhibitor,"HSD11B1, HSD11B2",,,Phase 2,0.23343906273972,0.0236638248266,acetyl-11-keto-beta-boswellic-acid,,,0,0
BRD-A44863528-001-13-2::2.5::HTS,BRD-A44863528-001-13-2,proglumide,2.5,HTS,MIRNA_hsa-miR-634,MIRNA,noncancer,CCK receptor antagonist,"CCKAR, CCKBR",,,Withdrawn,0.272142671808719,0.0215113106431,proglumide,,,0,0
BRD-A44936478-001-01-1::2.5::HTS,BRD-A44936478-001-01-1,cephalosporin-c-zn,2.5,HTS,DEM2_POLQ (10721),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,,,Preclinical,0.337497045099563,0.0343546441134,cephalosporin-c-zn,,,0,0
BRD-A45044890-236-02-3::2.5::HTS,BRD-A45044890-236-02-3,methylprednisolone-sodium-succinate,2.5,HTS,Exp_PLAC4 (ENSG00000225745),GE,noncancer,glucocorticoid receptor agonist,,"endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry","hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis",Launched,0.271640844934811,0.109015270929,methylprednisolone-sodium-succinate,GLUCOCORTICOID RECEPTOR AGONIST,0.28481891260487674,-4.534260512954382,-2.617096617543868
BRD-A45107007-001-03-4::2.5::HTS,BRD-A45107007-001-03-4,salubrinal,2.5,HTS,Exp_USP32P1 (ENSG00000188933),GE,noncancer,eukaryotic translation initiation factor inhibitor,EIF2S1,,,Preclinical,0.311624551815693,0.0467061172804,salubrinal,,,0,0
BRD-A45153512-001-01-0::2.5::HTS,BRD-A45153512-001-01-0,bimatoprost,2.5,HTS,METHYL_PFKFB3,METHYL,noncancer,prostanoid receptor agonist,"AKR1C3, PTGER1, PTGER3, PTGFR",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.24157301227050898,0.0533056771012,bimatoprost,,,0,0
BRD-A45498368-001-07-1::2.5::HTS,BRD-A45498368-001-07-1,WYE-125132,2.5,HTS,METHYL_MIR6825,METHYL,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.33176117688545304,0.032434197946,WYE-125132,MTOR INHIBITOR,0.32275503765631397,2.715883771004011,-0.5580620836692529
BRD-A45543382-001-10-0::2.5::HTS,BRD-A45543382-001-10-0,metrizamide,2.5,HTS,DEM2_AMOTL2 (51421),DEMETER2_COM,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.296774828281964,0.115316384499,metrizamide,,,0,0
BRD-A45869167-001-10-0::2.5::HTS,BRD-A45869167-001-10-0,sal003,2.5,HTS,CRISPR_XYLT1 (64131),AVANA_PUBLIC_18Q2,noncancer,eukaryotic translation initiation factor inhibitor,EIF2A,,,Preclinical,0.250855442875406,0.128731108535,sal003,,,0,0
BRD-A45889380-300-07-1::2.5::HTS,BRD-A45889380-300-07-1,mepacrine,2.5,HTS,CRISPR_UCP1 (7350),AVANA_PUBLIC_18Q2,noncancer,"cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator","PLA2G1B, PLA2G4A, PLA2G6, PLCL1",infectious disease,giardiasis,Launched,0.368938447738219,0.325602912477,mepacrine,OTHER,0.3545248048383378,-4.6472550626602445,-1.1846000449411584
BRD-A46066006-004-22-6::2.5::HTS,BRD-A46066006-004-22-6,clidinium,2.5,HTS,CRISPR_SLC34A1 (6569),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM3",gastroenterology,"peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis",Launched,0.265725860627749,0.162774586956,clidinium,,,0,0
BRD-A46179541-311-02-0::2.5::HTS,BRD-A46179541-311-02-0,doxapram,2.5,HTS,METABOL_alpha-ketoglutarate,METABOL,noncancer,potassium channel blocker,"KCNK3, KCNK9","pulmonary, neurology/psychiatry","respiratory depression, central nervous system depression, acute hypercapnia (AHC)",Launched,0.27376094986028304,0.172265760788,doxapram,,,0,0
BRD-A46186775-369-02-0::2.5::HTS,BRD-A46186775-369-02-0,hydrocortisone-phosphate,2.5,HTS,Exp_FGF8 (ENSG00000107831),GE,targeted cancer,,"ANXA1, NOS2, NR3C1","pulmonary, gastroenterology, hematologic malignancy, ophthalmology","asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis",Launched,0.270316922770734,0.135273730552,hydrocortisone-phosphate,OTHER,0.2683180557059145,-3.788223676671652,-2.9367906989805554
BRD-A46335897-003-27-8::2.499949994::MTS004,BRD-A46335897-003-27-8,promethazine,2.499949994,MTS004,METABOL_C34:1 PC,METABOL,noncancer,histamine receptor antagonist,"ADRA1A, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A","neurology/psychiatry, allergy","sedative, allergic rhinitis",Launched,0.25507272040929896,0.115321023851,promethazine,,,0,0
BRD-A46393198-003-16-6::2.5::HTS,BRD-A46393198-003-16-6,tetramisole,2.5,HTS,METABOL_phosphocreatine,METABOL,noncancer,immunostimulant,,infectious disease,gastrointestinal parasites,Launched,0.253238333930567,0.056600637472,tetramisole,,,0,0
BRD-A46813902-001-01-6::2.5::HTS,BRD-A46813902-001-01-6,iododexetimide,2.5,HTS,MIRNA_hsv2-miR-H2,MIRNA,noncancer,acetylcholine receptor antagonist,,,,Phase 2,0.31130837970015,0.0369818284149,iododexetimide,,,0,0
BRD-A46876182-003-02-8::2.5::HTS,BRD-A46876182-003-02-8,levobunolol-(+/-),2.5,HTS,RMUTmis_SV2C (22987),MUTmis,noncancer,adrenergic receptor antagonist,,,,Preclinical,0.299802533458869,0.00880641403577,levobunolol-(+/-),,,0,0
BRD-A47342814-003-01-8::2.5::HTS,BRD-A47342814-003-01-8,naltrindole,2.5,HTS,CRISPR_NAT1 (9),AVANA_PUBLIC_18Q2,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.23557946931053697,0.0363411033409,naltrindole,,,0,0
BRD-A47364545-003-02-6::2.5::HTS,BRD-A47364545-003-02-6,SK&F-10047-(+),2.5,HTS,MIRNA_hsa-miR-137,MIRNA,noncancer,sigma receptor agonist,SIGMAR1,,,Phase 1,0.251925683596935,0.0349169559759,SK&F-10047-(+),,,0,0
BRD-A47449001-004-13-7::2.5::HTS,BRD-A47449001-004-13-7,ipratropium,2.5,HTS,CN_UGT2B17 (7367),CN,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema",Launched,0.253549233464892,0.0962765748523,ipratropium,,,0,0
BRD-A47494775-003-11-3::2.5::HTS,BRD-A47494775-003-11-3,dipivefrine,2.5,HTS,Exp_ATP6V1G1P4 (ENSG00000233343),GE,noncancer,adrenergic receptor agonist,"ACHE, ADRA1A, ADRA2A, ADRB2, BCHE",ophthalmology,"glaucoma, intraocular pressure",Launched,0.228741313469043,0.0793114620534,dipivefrine,,,0,0
BRD-A47598013-004-16-0::2.5::HTS,BRD-A47598013-004-16-0,citalopram,2.5,HTS,CRISPR_TMPRSS11A (339967),AVANA_PUBLIC_18Q2,noncancer,selective serotonin reuptake inhibitor (SSRI),"SLC6A2, SLC6A4",neurology/psychiatry,depression,Launched,0.285142017325832,0.180495685492,citalopram,,,0,0
BRD-A47706533-001-02-6::2.5::HTS,BRD-A47706533-001-02-6,buthionine-sulfoximine,2.5,HTS,METHYL_LOC101928994,METHYL,targeted cancer,glutathione transferase inhibitor,GCLM,,,Phase 1,0.21536760205596897,0.0257814091638,buthionine-sulfoximine,,,0,0
BRD-A47790386-001-03-6::2.61::HTS,BRD-A47790386-001-03-6,balofloxacin,2.61,HTS,CN_NIPAL4 (348938),CN,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.28971821529244896,-0.00520530947861,balofloxacin,,,0,0
BRD-A47884604-051-01-2::2.5::HTS,BRD-A47884604-051-01-2,cyanopindolol,2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,adrenergic receptor antagonist,"ADRB1, HTR1A, HTR1D",,,Phase 2,0.24322959507578898,0.0781062474407,cyanopindolol,,,0,0
BRD-A47953250-001-01-7::2.5::HTS,BRD-A47953250-001-01-7,ecamsule-triethanolamine,2.5,HTS,Exp_MYCN (ENSG00000134323),GE,noncancer,,,dermatology,"skin protectant, sunscreen lotion",Launched,0.304386592866114,0.242722064287,ecamsule-triethanolamine,OTHER,0.31376966058444605,4.847888718572559,-1.5597131367672477
BRD-A48015106-004-08-9::2.5::HTS,BRD-A48015106-004-08-9,8-hydroxy-DPAT,2.5,HTS,CN_ROMO1 (140823),CN,noncancer,serotonin receptor agonist,"CDK1, CHEK1, CHEK2, GSK3B, HTR5A, HTR7, LCK, MAPK14, MARK1, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",,,Preclinical,0.185957120158865,0.0762864878652,8-hydroxy-DPAT,,,0,0
BRD-A48180038-003-24-3::2.5::HTS,BRD-A48180038-003-24-3,trihexyphenidyl,2.5,HTS,MIRNA_hsa-miR-126,MIRNA,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",neurology/psychiatry,parkinsonism,Launched,0.305922089967695,0.115104942171,trihexyphenidyl,,,0,0
BRD-A48237631-001-04-8::2.5::HTS,BRD-A48237631-001-04-8,mitomycin-c,2.5,HTS,PROT_XBP1_Caution,PROT,chemo,"DNA alkylating agent, DNA synthesis inhibitor",,oncology,"pancreatic cancer, gastric adenocarcinoma",Launched,0.398034889751289,0.253098043655,mitomycin-c,OTHER,0.3855028116154386,4.450207263728165,-0.9814233876031808
BRD-A48261811-001-08-1::2.5::HTS,BRD-A48261811-001-08-1,argatroban,2.5,HTS,CRISPR_METTL2A (339175),AVANA_PUBLIC_18Q2,noncancer,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT),Launched,0.225436707243612,0.0744880809564,argatroban,,,0,0
BRD-A48300215-001-04-8::2.5::HTS,BRD-A48300215-001-04-8,ajmaline,2.5,HTS,CN_TOM1L1 (10040),CN,noncancer,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),Launched,0.297566504742312,0.114503787445,ajmaline,,,0,0
BRD-A48376327-003-01-5::2.426818202::MTS004,BRD-A48376327-003-01-5,igmesine,2.426818202,MTS004,Exp_SLC16A13 (ENSG00000174327),GE,noncancer,sigma receptor agonist,SIGMAR1,,,Phase 2,0.334482314012901,0.1085553872,igmesine,,,0,0
BRD-A48420483-001-02-3::2.5::MTS004,BRD-A48420483-001-02-3,bupranolol,2.5,MTS004,CN_HLA-DQA1 (3117),CN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3","cardiology, ophthalmology","hypertension, glaucoma",Launched,0.28928170006979903,0.142334321369,bupranolol,,,0,0
BRD-A48430263-003-17-2::2.5::HTS,BRD-A48430263-003-17-2,pioglitazone,2.5,HTS,PROT_p21,PROT,noncancer,"insulin sensitizer, PPAR receptor agonist","PPARG, TRPM3",endocrinology,diabetes mellitus,Launched,0.29552071342009695,0.0108708398572,pioglitazone,,,0,0
BRD-A48720949-001-04-0::2.5::HTS,BRD-A48720949-001-04-0,testosterone-propionate,2.5,HTS,CRISPR_HTR3E (285242),AVANA_PUBLIC_18Q2,targeted cancer,androgen receptor agonist,AR,,,Launched,0.24833251450038396,0.0635695188158,testosterone-propionate,,,0,0
BRD-A48938994-001-14-1::2.5::MTS004,BRD-A48938994-001-14-1,monoctanoin,2.5,MTS004,Exp_CYP2B6 (ENSG00000197408),GE,noncancer,,,gastroenterology,gallstones,Launched,0.32076317907444396,0.108750946632,monoctanoin,,,0,0
BRD-A49035384-003-28-9::2.39::HTS,BRD-A49035384-003-28-9,methacycline,2.39,HTS,MIRNA_hsa-miR-1266,MIRNA,noncancer,protein synthesis inhibitor,,pulmonary,bronchitis,Launched,0.368897447376822,0.0956589545942,methacycline,OTHER,0.3681165530854047,0.7052493202039496,-3.2335308304114263
BRD-A49035384-003-30-5::2.5::HTS,BRD-A49035384-003-30-5,methacycline,2.5,HTS,METABOL_C20:4 LPE,METABOL,noncancer,protein synthesis inhibitor,,pulmonary,bronchitis,Launched,0.26939726632468697,0.0562962722924,methacycline,,,0,0
BRD-A49046702-003-08-3::2.5::HTS,BRD-A49046702-003-08-3,SKF-89976A,2.5,HTS,MIRNA_hsv1-miR-H2-3p,MIRNA,noncancer,GABA uptake inhibitor,SLC6A1,,,Preclinical,0.278081033287375,-0.014924955792,SKF-89976A,,,0,0
BRD-A49160188-003-12-7::2.5::HTS,BRD-A49160188-003-12-7,donepezil,2.5,HTS,METHYL_SERTAD4-AS1,METHYL,noncancer,acetylcholinesterase inhibitor,"ACHE, HTR2A",neurology/psychiatry,Alzheimer's disease,Launched,0.253012623354354,0.151538744057,donepezil,,,0,0
BRD-A49172652-001-27-1::2.5::HTS,BRD-A49172652-001-27-1,lansoprazole,2.5,HTS,CRISPR_SRL (6345),AVANA_PUBLIC_18Q2,noncancer,ATPase inhibitor,"ATP4A, ATP4B",gastroenterology,heartburn,Launched,0.27091825764308397,0.0300191886761,lansoprazole,,,0,0
BRD-A49225603-045-10-0::2.5::HTS,BRD-A49225603-045-10-0,alimemazine,2.5,HTS,Exp_EGLN3 (ENSG00000129521),GE,noncancer,histamine receptor agonist,HRH1,neurology/psychiatry,sedative,Launched,0.313755494858674,0.0804335551281,alimemazine,,,0,0
BRD-A49358627-001-14-6::2.5::HTS,BRD-A49358627-001-14-6,ciprofibrate,2.5,HTS,DEM2_RECQL4 (9401),DEMETER2_COM,noncancer,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,Launched,0.25343698690426303,0.0448221992919,ciprofibrate,OTHER,0.2605795308086503,-4.351295433660701,-2.84990018984212
BRD-A49399758-015-01-8::2.5::HTS,BRD-A49399758-015-01-8,desmopressin-acetate,2.5,HTS,MIRNA_hsa-miR-601,MIRNA,noncancer,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR","endocrinology, urology","central diabetes insipidus, nocturnal enuresis",Launched,0.279075544880778,0.0384235756553,desmopressin-acetate,,,0,0
BRD-A49447682-001-02-4::2.5::HTS,BRD-A49447682-001-02-4,desoximetasone,2.5,HTS,Exp_TDP1 (ENSG00000042088),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.258881574170255,0.170268838183,desoximetasone,GLUCOCORTICOID RECEPTOR AGONIST,0.25781441816172723,-3.905086271088084,-3.0259383463894127
BRD-A49544621-003-02-8::2.5::HTS,BRD-A49544621-003-02-8,AC-7954-(+/-),2.5,HTS,Exp_F12 (ENSG00000131187),GE,noncancer,urotensin receptor agonist,UTS2R,,,Preclinical,0.271938254982018,0.0498547007837,AC-7954-(+/-),,,0,0
BRD-A49622760-001-01-9::2.5::HTS,BRD-A49622760-001-01-9,faropenem,2.5,HTS,METHYL_HLF,METHYL,noncancer,lactamase inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis",Launched,0.327429018564758,0.0513993234852,faropenem,,,0,0
BRD-A49765801-001-04-1::2.5::HTS,BRD-A49765801-001-04-1,fludroxycortide,2.5,HTS,CRISPR_ALMS1 (7840),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",Launched,0.270833195198176,0.0319603999344,fludroxycortide,GLUCOCORTICOID RECEPTOR AGONIST,0.2663099218639568,-1.8618724999724447,-3.1110282370776368
BRD-A49838158-001-01-1::2.5::HTS,BRD-A49838158-001-01-1,phenprocoumon,2.5,HTS,METABOL_SDMA/ADMA,METABOL,noncancer,vitamin K antagonist,VKORC1,hematology,"thrombosis, pulmonary embolism (PE)",Launched,0.24469611603184,0.13394068336,phenprocoumon,,,0,0
BRD-A49906757-004-09-8::2.5::HTS,BRD-A49906757-004-09-8,scopolamine-n-oxide,2.5,HTS,CRISPR_CCNY (219771),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI",,,Preclinical,0.217848765691339,0.092176750679,scopolamine-n-oxide,,,0,0
BRD-A50028488-001-01-6::2.5::HTS,BRD-A50028488-001-01-6,TCS2002,2.5,HTS,Exp_CHST5 (ENSG00000135702),GE,noncancer,glycogen synthase kinase inhibitor,GSK3B,,,Preclinical,0.24576805866524104,0.118649810831,TCS2002,,,0,0
BRD-A50049929-001-01-9::2.5::HTS,BRD-A50049929-001-01-9,oxazepam,2.5,HTS,DEM2_NCBP2 (22916),DEMETER2_COM,noncancer,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,Launched,0.31746265541525703,0.125531070659,oxazepam,,,0,0
BRD-A50064262-001-04-7::2.5::HTS,BRD-A50064262-001-04-7,flumethasone-pivalate,2.5,HTS,Exp_CCDC22 (ENSG00000101997),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",,,Launched,0.23069904610372802,0.0804697195723,flumethasone-pivalate,GLUCOCORTICOID RECEPTOR AGONIST,0.2347117512131857,-1.680618461277095,-2.8892472019315965
BRD-A50157456-065-20-6::2.5::HTS,BRD-A50157456-065-20-6,terbutaline,2.5,HTS,METABOL_1-methylnicotinamide,METABOL,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema",Launched,0.26091050395056603,0.207969523098,terbutaline,,,0,0
BRD-A50311610-300-10-4::2.5::HTS,BRD-A50311610-300-10-4,meclizine,2.5,HTS,Exp_TNFRSF21 (ENSG00000146072),GE,noncancer,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness",Launched,0.251281899297547,0.123344739317,meclizine,OTHER,0.25378577155349913,5.762441574146704,-0.0553740451110154
BRD-A50675490-001-01-0::2.412483069::MTS004,BRD-A50675490-001-01-0,carazolol,2.412483069,MTS004,PROT_Fibronectin,PROT,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,"angina pectoris, cardiac arrythmia, hypertension, myocardial infarction",Launched,0.282065876046623,0.262060668743,carazolol,,,0,0
BRD-A50675702-001-07-1::2.5::HTS,BRD-A50675702-001-07-1,fipronil,2.5,HTS,CN_FANCC (2176),CN,noncancer,"chloride channel blocker, GABA gated chloride channel blocker",,,,Launched,0.230880378127231,0.103277981693,fipronil,,,0,0
BRD-A50684349-003-02-9::2.5::HTS,BRD-A50684349-003-02-9,fenoldopam,2.5,HTS,CN_UNC5D (137970),CN,noncancer,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD4, DRD5",cardiology,hypertension,Launched,0.28105061679976096,0.0474136519899,fenoldopam,,,0,0
BRD-A50737080-001-03-0::2.5::HTS,BRD-A50737080-001-03-0,CGK-733,2.5,HTS,CRISPR_MICA (100507436),AVANA_PUBLIC_18Q2,targeted cancer,"ATM kinase inhibitor, ATR kinase inhibitor","ATM, ATR",,,Preclinical,0.280537172695401,0.0564414610023,CGK-733,,,0,0
BRD-A50764878-003-02-8::2.5::HTS,BRD-A50764878-003-02-8,MDL-73005EF,2.5,HTS,Exp_LINC00539 (ENSG00000224429),GE,noncancer,serotonin receptor antagonist,HTR1A,,,Phase 1,0.30542157540433196,0.131783508406,MDL-73005EF,,,0,0
BRD-A50922295-001-01-3::2.5::HTS,BRD-A50922295-001-01-3,valganciclovir,2.5,HTS,METHYL_ESD,METHYL,noncancer,DNA synthesis inhibitor,,infectious disease,cytomegalovirus (CMV),Launched,0.268133277239871,0.0969476679687,valganciclovir,,,0,0
BRD-A50998626-001-02-1::2.5::HTS,BRD-A50998626-001-02-1,palomid-529,2.5,HTS,MIRNA_hsa-miR-219-2-3p,MIRNA,targeted cancer,"AKT inhibitor, mTOR inhibitor",MTOR,,,Phase 1,0.302865508314584,0.0956194092147,palomid-529,,,0,0
BRD-A51078674-003-01-0::2.5::HTS,BRD-A51078674-003-01-0,diclofensine,2.5,HTS,CN_TMEM257 (9142),CN,noncancer,dopamine reuptake inhibitor,"DRD1, MAOA, MAOB",,,Phase 3,0.300584055835703,0.0539084798738,diclofensine,,,0,0
BRD-A51355958-003-01-9::2.5::HTS,BRD-A51355958-003-01-9,nebracetam,2.5,HTS,MIRNA_hcmv-miR-US5-1,MIRNA,noncancer,acetylcholine receptor agonist,CHRM1,,,Phase 3,0.29499327219071897,0.102300544554,nebracetam,,,0,0
BRD-A51382177-236-03-0::2.5::HTS,BRD-A51382177-236-03-0,fosinopril,2.5,HTS,DEM2_TRIM5 (85363),DEMETER2_COM,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",Launched,0.257369154499383,0.107254709795,fosinopril,,,0,0
BRD-A51407134-001-01-9::2.5::HTS,BRD-A51407134-001-01-9,2-octyldodecan-1-ol,2.5,HTS,LIN_central_nervous_system,LIN,noncancer,,,,,Preclinical,0.271208967248807,0.105556965551,2-octyldodecan-1-ol,,,0,0
BRD-A51571244-001-01-9::2.5::HTS,BRD-A51571244-001-01-9,hypoestoxide,2.5,HTS,Exp_TFAP4 (ENSG00000090447),GE,targeted cancer,IKK inhibitor,"IKBKB, IL1B, TNF",,,Phase 1,0.336114385656543,0.220481457194,hypoestoxide,OTHER,0.3336078829627073,0.4299899341117226,-4.018798263667413
BRD-A51713165-003-02-6::2.5::HTS,BRD-A51713165-003-02-6,3-CPMT,2.5,HTS,DEM2_CD99 (4267),DEMETER2_COM,noncancer,dopamine reuptake inhibitor,,,,Preclinical,0.31093964259086104,0.0147911033859,3-CPMT,,,0,0
BRD-A51714012-003-13-6::2.5::HTS,BRD-A51714012-003-13-6,venlafaxine,2.5,HTS,CRISPR_KRT1 (3848),AVANA_PUBLIC_18Q2,noncancer,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)","SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder",Launched,0.202736349221228,0.100490959528,venlafaxine,,,0,0
BRD-A51747092-003-03-0::2.5::HTS,BRD-A51747092-003-03-0,moprolol,2.5,HTS,Exp_ARHGAP10 (ENSG00000071205),GE,noncancer,adrenergic receptor antagonist,,"cardiology, ophthalmology, neurology/psychiatry","hypertension, glaucoma, anxiety",Launched,0.29176743106722197,0.0527293261952,moprolol,,,0,0
BRD-A51820102-008-28-9::2.5::HTS,BRD-A51820102-008-28-9,econazole,2.5,HTS,PROT_c-Kit,PROT,noncancer,"lanosterol demethylase inhibitor, sterol demethylase inhibitor","CYP51A1, NPY1R, NPY2R, TRPM2, TRPV5",infectious disease,"tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis",Launched,0.284643142116714,0.0981436449125,econazole,,,0,0
BRD-A51829654-003-07-7::2.5::HTS,BRD-A51829654-003-07-7,BRL-15572,2.5,HTS,Exp_CETP (ENSG00000087237),GE,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",,,Preclinical,0.22723470812305,0.062839898127,BRL-15572,,,0,0
BRD-A51831848-001-01-7::2.5::HTS,BRD-A51831848-001-01-7,enflurane,2.5,HTS,METHYL_PLA2G4A,METHYL,noncancer,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, KCNN4",,,Launched,0.343258945240772,0.0569982210754,enflurane,,,0,0
BRD-A51964809-003-12-6::2.5::HTS,BRD-A51964809-003-12-6,halofantrine,2.5,HTS,MIRNA_kshv-miR-K12-8,MIRNA,noncancer,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,Launched,0.331688581295445,0.0956183401133,halofantrine,OTHER,0.32072928441981563,4.457228245113086,-2.3243021721629287
BRD-A52460047-001-01-3::2.5::HTS,BRD-A52460047-001-01-3,methylatropine-nitrate,2.5,HTS,CRISPR_WNT6 (7475),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,CHRM1,,,Preclinical,0.241197863512849,0.0392342185862,methylatropine-nitrate,,,0,0
BRD-A52588987-004-08-2::2.5::HTS,BRD-A52588987-004-08-2,SKF-83566,2.5,HTS,METHYL_MAP2K2,METHYL,noncancer,dopamine receptor antagonist,"DRD1, DRD5",,,Preclinical,0.27354156539061697,0.0220089791198,SKF-83566,,,0,0
BRD-A52660433-066-02-1::2.5::HTS,BRD-A52660433-066-02-1,tetrindole,2.5,HTS,PROT_Bid_Caution,PROT,noncancer,monoamine oxidase inhibitor,MAOA,,,Phase 3,0.23040835288140804,0.123416976342,tetrindole,,,0,0
BRD-A52922642-001-03-7::2.5::HTS,BRD-A52922642-001-03-7,gallopamil,2.5,HTS,MIRNA_hsa-miR-508-5p,MIRNA,noncancer,L-type calcium channel blocker,ATP2A2,cardiology,"hypertension, cardiac arrythmia",Launched,0.25541628272189104,0.0791380513365,gallopamil,,,0,0
BRD-A53037217-001-02-0::2.5::HTS,BRD-A53037217-001-02-0,BTZ043-racemate,2.5,HTS,METABOL_glucose,METABOL,noncancer,DPRE1 inhibitor,,,,Preclinical,0.235815221089998,0.0693423121779,BTZ043-racemate,,,0,0
BRD-A53037300-001-01-0::2.5::HTS,BRD-A53037300-001-01-0,2-fluoro-2-deoxy-D-galactose,2.5,HTS,Exp_ODAM (ENSG00000109205),GE,targeted cancer,,LCT,,,Phase 1,0.193356053817251,0.0417144583372,2-fluoro-2-deoxy-D-galactose,,,0,0
BRD-A53077924-001-01-2::2.499990763::MTS004,BRD-A53077924-001-01-2,tianeptine,2.499990763,MTS004,CRISPR_CCDC101 (112869),AVANA_PUBLIC_18Q2,noncancer,selective serotonin reuptake enhancer (SSRE),"OPRD1, OPRK1, OPRM1","neurology/psychiatry, pulmonary, gastroenterology","depression, asthma, irritable bowel syndrome",Launched,0.25665410264271,0.107174443797,tianeptine,,,0,0
BRD-A53134341-001-03-2::2.5::HTS,BRD-A53134341-001-03-2,Ro-106-9920,2.5,HTS,Exp_ITGA7 (ENSG00000135424),GE,noncancer,NFkB pathway inhibitor,,,,Preclinical,0.357985482786965,0.185123874296,Ro-106-9920,NFKB PATHWAY INHIBITOR,0.3623236306765081,3.4610383821207287,-2.473321398398526
BRD-A53151380-001-01-2::2.5::HTS,BRD-A53151380-001-01-2,prednisolone-tebutate,2.5,HTS,Exp_PLAC4 (ENSG00000225745),GE,noncancer,anti-inflammatory agent,,,,Launched,0.259792198942927,0.109089870812,prednisolone-tebutate,OTHER,0.2553093600452119,-4.17886907205028,-2.8823916192921013
BRD-A53539450-004-01-7::2.5::HTS,BRD-A53539450-004-01-7,neo-gilurytmal,2.5,HTS,METHYL_MIR200B,METHYL,noncancer,,,,,Launched,0.30047097976193393,0.14743735695,neo-gilurytmal,,,0,0
BRD-A53561827-004-23-1::2.5::HTS,BRD-A53561827-004-23-1,pipenzolate,2.5,HTS,PROT_IGFBP2,PROT,noncancer,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms,Launched,0.254408053994572,0.0476628844665,pipenzolate,,,0,0
BRD-A53566267-001-01-9::2.5::HTS,BRD-A53566267-001-01-9,anecortave-acetate,2.5,HTS,PROT_Smad1,PROT,noncancer,angiogenesis inhibitor,,ophthalmology,macular degeneration,Launched,0.28638829391611104,0.105670441101,anecortave-acetate,,,0,0
BRD-A53576514-048-14-3::2.5::HTS,BRD-A53576514-048-14-3,orphenadrine,2.5,HTS,METHYL_NAAA,METHYL,noncancer,acetylcholine receptor antagonist,"GRIN1, GRIN2D, GRIN3A, GRIN3B, HRH1, SCN10A, SLC6A2",neurology/psychiatry,muscle pain,Launched,0.265814583773876,0.0433017073795,orphenadrine,,,0,0
BRD-A53813595-001-01-8::2.5::HTS,BRD-A53813595-001-01-8,PGL5001,2.5,HTS,CRISPR_SRRD (402055),AVANA_PUBLIC_18Q2,noncancer,JNK inhibitor,"MAPK10, MAPK8, MAPK9",,,Phase 2,0.338119878604468,0.0545253176611,PGL5001,,,0,0
BRD-A53951045-004-01-6::2.5::HTS,BRD-A53951045-004-01-6,butylscopolamine-bromide,2.5,HTS,RMUThot_TP53 (7157),MUThot,noncancer,cholinergic receptor antagonist,,gastroenterology,abdominal pain,Launched,0.21711732540794898,0.0527109795545,butylscopolamine-bromide,,,0,0
BRD-A53952395-003-25-1::2.5::HTS,BRD-A53952395-003-25-1,prilocaine,2.5,HTS,METHYL_PGRMC2,METHYL,noncancer,local anesthetic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,anesthetic,Launched,0.240001242579238,0.108097967341,prilocaine,,,0,0
BRD-A54236247-003-04-3::2.5::HTS,BRD-A54236247-003-04-3,ephedrine-(racemic),2.5,HTS,Exp_TMEM214 (ENSG00000119777),GE,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA2A","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity",Launched,0.284077157802052,0.0592694284163,ephedrine-(racemic),,,0,0
BRD-A54275602-001-01-0::2.5::HTS,BRD-A54275602-001-01-0,lanoconazole,2.5,HTS,PROT_Smad1,PROT,noncancer,sterol demethylase inhibitor,,infectious disease,fungal infection,Launched,0.291686787944479,0.157957315542,lanoconazole,,,0,0
BRD-A54490543-066-11-9::2.5::HTS,BRD-A54490543-066-11-9,pirlindole,2.5,HTS,DEM2_TUBB4A (10382),DEMETER2_COM,noncancer,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Launched,0.31177973990105895,0.0846036763028,pirlindole,,,0,0
BRD-A54927599-001-16-9::2.5::HTS,BRD-A54927599-001-16-9,KF-38789,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,P selectin inhibitor,SELP,,,Preclinical,0.409613876894231,0.341430521739,KF-38789,OTHER,0.410646235898906,5.629864562105608,-3.048246387084584
BRD-A55272860-001-15-3::2.5::HTS,BRD-A55272860-001-15-3,sulpiride,2.5,HTS,CN_POU3F4 (5456),CN,noncancer,dopamine receptor antagonist,,neurology/psychiatry,"schizophrenia, schizophrenia",Launched,0.28206932350791497,0.0320688617637,sulpiride,,,0,0
BRD-A55312468-001-04-7::1.24::HTS,BRD-A55312468-001-04-7,k-strophanthidin,1.24,HTS,METHYL_LTBP4,METHYL,targeted cancer,ATPase inhibitor,ATP1A1,,,Phase 2,0.33991981339639193,0.336750266431,k-strophanthidin,OTHER,0.3508652461380069,5.638307541334004,-1.8691733852377888
BRD-A55393291-001-09-9::2.5::HTS,BRD-A55393291-001-09-9,testosterone,2.5,HTS,DEM2_CRTC3 (64784),DEMETER2_COM,noncancer,androgen receptor agonist,AR,endocrinology,hypogonadism,Launched,0.25389463942062096,0.0828838713144,testosterone,,,0,0
BRD-A55416093-001-06-4::2.5::MTS004,BRD-A55416093-001-06-4,colforsin,2.5,MTS004,DEM2_ARL8A (127829),DEMETER2_COM,targeted cancer,adenylyl cyclase activator,"ADCY2, ADCY5",,,Phase 2,0.291713922456788,0.0980944377618,colforsin,OTHER,0.2908400544826458,2.8073679767442887,0.7899574698261496
BRD-A55424491-001-19-9::2.5::HTS,BRD-A55424491-001-19-9,methotrexate,2.5,HTS,PROT_ASNS,PROT,chemo,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis",Launched,0.332646997346747,0.245486515292,methotrexate,OTHER,0.3352486217159817,4.135891606461302,-2.290373193022844
BRD-A55455283-001-01-3::2.5::HTS,BRD-A55455283-001-01-3,"2-ethyl-1,3-hexanediol",2.5,HTS,PROT_Syk,PROT,noncancer,,,,,Preclinical,0.31151908474609197,0.069845576907,"2-ethyl-1,3-hexanediol",,,0,0
BRD-A55464252-001-01-2::2.5::HTS,BRD-A55464252-001-01-2,3-(4-methylbenzylidene)camphor,2.5,HTS,Exp_SFTPA1 (ENSG00000122852),GE,noncancer,endocrine disruptor,,dermatology,sunscreen lotion,Launched,0.30797373881401396,0.119106082561,3-(4-methylbenzylidene)camphor,,,0,0
BRD-A55469827-001-07-4::2.5::HTS,BRD-A55469827-001-07-4,mephenesin,2.5,HTS,DEM2_DDX5 (1655),DEMETER2_COM,noncancer,muscle relaxant,,neurology/psychiatry,muscle relaxant,Launched,0.23249429070898,0.0192442107816,mephenesin,,,0,0
BRD-A55484088-050-02-5::2.5::HTS,BRD-A55484088-050-02-5,BNTX,2.5,HTS,PROT_Caveolin-1,PROT,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.358296794656537,0.324684528841,BNTX,OTHER,0.35971424474068003,5.802200168905524,-1.6962769285860275
BRD-A55664972-236-02-6::2.5::HTS,BRD-A55664972-236-02-6,sodium-tetradecyl-sulfate,2.5,HTS,METHYL_LGMN,METHYL,noncancer,,"PROC, PROS1",dermatology,"varicose veins, varicose veins",Launched,0.274557974028918,0.0203915968544,sodium-tetradecyl-sulfate,,,0,0
BRD-A55913614-316-09-6::2.5::HTS,BRD-A55913614-316-09-6,primaquine,2.5,HTS,METABOL_butyrylcarnitine/isobutyrylcarnitine,METABOL,noncancer,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,Launched,0.323676616523346,0.0688824133168,primaquine,,,0,0
BRD-A55962179-001-22-1::2.5::HTS,BRD-A55962179-001-22-1,omeprazole,2.5,HTS,DEM2_SEMA4D (10507),DEMETER2_COM,noncancer,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,Launched,0.315911589471287,0.0921536893255,omeprazole,,,0,0
BRD-A56085258-001-01-8::2.5::HTS,BRD-A56085258-001-01-8,LGX818,2.5,HTS,Exp_RAB38 (ENSG00000123892),GE,targeted cancer,RAF inhibitor,BRAF,,,Phase 3,0.44810961682059897,0.567752462194,LGX818,RAF INHIBITOR,0.4300122222666944,1.08224664660821,-3.0961365755080847
BRD-A56152450-001-02-0::2.5::HTS,BRD-A56152450-001-02-0,dimercaprol,2.5,HTS,PROT_Bad_pS112,PROT,noncancer,chelating agent,,neurology/psychiatry,metal toxicity,Launched,0.26907010877492105,0.0913813785235,dimercaprol,,,0,0
BRD-A56241705-003-01-2::2.639158457::MTS004,BRD-A56241705-003-01-2,trimethoquinol,2.639158457,MTS004,DEM2_SHH (6469),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRB2, ADRB3",,,Launched,0.29335765840290806,0.12047523018,trimethoquinol,,,0,0
BRD-A56359832-001-11-1::2.5::HTS,BRD-A56359832-001-11-1,zileuton,2.5,HTS,MIRNA_hsa-miR-2115,MIRNA,noncancer,"leukotriene synthesis inhibitor, lipoxygenase inhibitor",ALOX5,pulmonary,asthma,Launched,0.28815501138106603,0.0266632127869,zileuton,,,0,0
BRD-A56371469-001-03-3::2.5::HTS,BRD-A56371469-001-03-3,AGI-5198,2.5,HTS,DEM2_PCDHGA5 (56110),DEMETER2_COM,targeted cancer,isocitrate dehydrogenase inhibitor,IDH1,,,Preclinical,0.291237949295783,0.0902190164833,AGI-5198,,,0,0
BRD-A56592690-001-04-3::2.5::HTS,BRD-A56592690-001-04-3,PX-12,2.5,HTS,MIRNA_hsa-miR-934,MIRNA,targeted cancer,thioredoxin inhibitor,"TXN, TXNRD1",,,Phase 2,0.221056676251738,-0.00602016062387,PX-12,,,0,0
BRD-A56613951-004-01-1::2.642522873::MTS004,BRD-A56613951-004-01-1,valethamate,2.642522873,MTS004,DEM2_RNF24 (11237),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM4, CHRM5",obstetrics/gynecology,labor induction,Launched,0.293775467563086,0.056771816419,valethamate,,,0,0
BRD-A56675431-001-12-3::2.5::HTS,BRD-A56675431-001-12-3,althiazide,2.5,HTS,DEM2_PKM (5315),DEMETER2_COM,noncancer,diuretic,,cardiology,hypertension,Launched,0.325502050568515,0.0334384017616,althiazide,,,0,0
BRD-A56858165-001-04-4::2.5::HTS,BRD-A56858165-001-04-4,cefadroxil,2.5,HTS,DEM2_USP4 (7375),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,"SLC15A1, SLC15A2, SLC22A6, SLC22A8","infectious disease, otolaryngology","urinary tract infections, skin infections, tonsillitis, pharyngitis",Launched,0.292335400207409,0.0676238392324,cefadroxil,,,0,0
BRD-A56892734-001-09-4::2.5::MTS004,BRD-A56892734-001-09-4,omeprazole-magnesium,2.5,MTS004,METHYL_TMPO-AS1,METHYL,noncancer,proton pump inhibitor,"ATP4A, ATP4B",gastroenterology,"gastroesophageal reflux disease (GERD), heartburn",Launched,0.27929133212247303,0.108180859046,omeprazole-magnesium,,,0,0
BRD-A56987319-001-12-9::2.5::HTS,BRD-A56987319-001-12-9,SQ-22536,2.5,HTS,CRISPR_NOTCH1 (4851),AVANA_PUBLIC_18Q2,noncancer,adenylyl cyclase inhibitor,ADCY1,,,Preclinical,0.273062807116565,0.110285318941,SQ-22536,,,0,0
BRD-A57133233-003-11-0::2.5::HTS,BRD-A57133233-003-11-0,chlorcyclizine,2.5,HTS,Exp_ACAP3 (ENSG00000131584),GE,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.257210907843012,0.0381728358846,chlorcyclizine,,,0,0
BRD-A57382968-001-29-0::2.5::HTS,BRD-A57382968-001-29-0,piroxicam,2.5,HTS,Exp_JMJD1C (ENSG00000171988),GE,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis",Launched,0.27091738212953104,0.126885684674,piroxicam,,,0,0
BRD-A57592049-001-01-6::2.5::HTS,BRD-A57592049-001-01-6,methsuximide,2.5,HTS,METABOL_C24:0 SM,METABOL,noncancer,T-type calcium channel binder,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,Launched,0.257828063263716,0.0388113781875,methsuximide,,,0,0
BRD-A57798112-001-03-7::2.5::HTS,BRD-A57798112-001-03-7,PD-318088,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Preclinical,0.47407218195218,0.550297958437,PD-318088,MEK INHIBITOR,0.4702692636768581,0.4422520244508662,4.773551654541441
BRD-A57798559-004-02-3::2.5::HTS,BRD-A57798559-004-02-3,bicuculline-methochloride-(-),2.5,HTS,PROT_Syk,PROT,noncancer,GABA receptor antagonist,,,,Preclinical,0.244421458552025,0.0966506418758,bicuculline-methochloride-(-),,,0,0
BRD-A57900429-003-05-8::2.5::HTS,BRD-A57900429-003-05-8,hydrastinine,2.5,HTS,METABOL_phosphocreatine,METABOL,noncancer,haemostatic agent,,,,Preclinical,0.26948077654694896,0.0759330642483,hydrastinine,,,0,0
BRD-A57957888-001-08-0::2.5::HTS,BRD-A57957888-001-08-0,citiolone,2.5,HTS,PROT_PRAS40_pT246,PROT,noncancer,"lipotropic, mucolytic agent",,,,Preclinical,0.30824262847266903,0.127365791234,citiolone,,,0,0
BRD-A58048407-001-18-8::2.5::HTS,BRD-A58048407-001-18-8,nimodipine,2.5,HTS,CRISPR_AJAP1 (55966),AVANA_PUBLIC_18Q2,noncancer,calcium channel blocker,"AHR, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CFTR, NR3C2",hematology,hemorrhage,Launched,0.29844015752161307,0.0746489213535,nimodipine,,,0,0
BRD-A58193911-003-18-7::2.5::HTS,BRD-A58193911-003-18-7,oxyphencyclimine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.305076954654226,0.454095750641,oxyphencyclimine,OTHER,0.3049603988486184,4.327038686397928,-1.7594429380107002
BRD-A58564983-001-04-6::2.5::HTS,BRD-A58564983-001-04-6,selamectin,2.5,HTS,METHYL_LOC284865,METHYL,noncancer,nematocide,,infectious disease,flea control,Launched,0.261718894342982,0.107021180694,selamectin,,,0,0
BRD-A58947127-001-01-6::2.5::MTS004,BRD-A58947127-001-01-6,AMG319,2.5,MTS004,CRISPR_ROCK1 (6093),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,PIK3CD,,,Phase 2,0.34014505856635496,0.241144604937,AMG319,,,0,0
BRD-A58955223-001-03-8::2.5::HTS,BRD-A58955223-001-03-8,sulforaphane,2.5,HTS,METHYL_PDE4C,METHYL,targeted cancer,"anticancer agent, aryl hydrocarbon receptor antagonist",NFE2L2,,,Phase 2,0.259888075028523,0.0524833116157,sulforaphane,,,0,0
BRD-A59001851-001-02-1::2.5::HTS,BRD-A59001851-001-02-1,ginkgolide-b,2.5,HTS,METHYL_C1orf198,METHYL,noncancer,platelet activating factor receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",,,Phase 3,0.260102128089927,0.0874860336034,ginkgolide-b,,,0,0
BRD-A59174698-003-18-5::2.5::HTS,BRD-A59174698-003-18-5,ritodrine,2.5,HTS,METHYL_LINC00578,METHYL,noncancer,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,Launched,0.29064676676658696,0.053695356209,ritodrine,,,0,0
BRD-A59198242-003-02-9::2.5::HTS,BRD-A59198242-003-02-9,viloxazine,2.5,HTS,METABOL_C34:1 PC,METABOL,noncancer,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression,Launched,0.20442079605366603,0.114651615704,viloxazine,,,0,0
BRD-A59303141-001-10-4::2.5::HTS,BRD-A59303141-001-10-4,quinethazone,2.5,HTS,Exp_CDK5RAP2 (ENSG00000136861),GE,noncancer,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,Launched,0.23683017708403098,0.117518286564,quinethazone,,,0,0
BRD-A59337442-051-05-3::2.5::HTS,BRD-A59337442-051-05-3,xamoterol,2.5,HTS,DEM2_PSG11 (5680),DEMETER2_COM,noncancer,adrenergic receptor agonist,ADRB1,,,Phase 3,0.262698149059993,0.0886852857031,xamoterol,,,0,0
BRD-A59378440-001-01-3::2.499948202::MTS004,BRD-A59378440-001-01-3,butylphthalide,2.499948202,MTS004,METABOL_C56:8 TAG,METABOL,noncancer,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke,Launched,0.325392397694443,0.0943336668382,butylphthalide,,,0,0
BRD-A59413292-001-08-2::2.5::HTS,BRD-A59413292-001-08-2,dexpanthenol,2.5,HTS,METHYL_ABHD16B,METHYL,noncancer,,,gastroenterology,paralytic ileus,Launched,0.290496844380138,0.090110142942,dexpanthenol,,,0,0
BRD-A59709458-001-01-8::2.5::HTS,BRD-A59709458-001-01-8,PHCCC,2.5,HTS,CRISPR_THAP7 (80764),AVANA_PUBLIC_18Q2,targeted cancer,glutamate receptor agonist,"GRM1, GRM4",,,Preclinical,0.296673936618544,0.0686657269571,PHCCC,,,0,0
BRD-A59825838-326-01-4::2.499983757::MTS004,BRD-A59825838-326-01-4,netilmicin,2.499983757,MTS004,METABOL_C38:2 PC,METABOL,noncancer,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.255451725908496,0.113643554116,netilmicin,,,0,0
BRD-A59961917-001-01-0::2.5::MTS004,BRD-A59961917-001-01-0,BQ-123,2.5,MTS004,METABOL_glutamate,METABOL,noncancer,endothelin receptor antagonist,EDNRA,,,Phase 2,0.315139350597542,0.204132842848,BQ-123,,,0,0
BRD-A60197193-001-14-6::2.5::HTS,BRD-A60197193-001-14-6,amisulpride,2.5,HTS,MIRNA_hsa-miR-608,MIRNA,noncancer,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia",Launched,0.33459233381682596,0.0659782654923,amisulpride,,,0,0
BRD-A60498477-001-01-2::2.508127434::MTS004,BRD-A60498477-001-01-2,tolamolol,2.508127434,MTS004,Exp_FLCN (ENSG00000154803),GE,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,Phase 3,0.280369078169796,0.215818006953,tolamolol,,,0,0
BRD-A60594020-034-01-1::2.5::HTS,BRD-A60594020-034-01-1,8-hydroxy-PIPAT,2.5,HTS,CRISPR_TTYH1 (57348),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor ligand,"DRD2, DRD3",,,Preclinical,0.233025170038755,0.116146398758,8-hydroxy-PIPAT,,,0,0
BRD-A60786380-412-01-5::2.5::HTS,BRD-A60786380-412-01-5,sodium-stibogluconate,2.5,HTS,MUTpool_FHOD3 (80206),MUTpool,noncancer,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,Launched,0.290816732137286,0.0320797473505,sodium-stibogluconate,,,0,0
BRD-A61154809-001-15-9::2.5::HTS,BRD-A61154809-001-15-9,gliclazide,2.5,HTS,DEM2_SKP1 (6500),DEMETER2_COM,noncancer,"ATP channel blocker, insulin secretagogue","ABCC8, VEGFA",endocrinology,diabetes mellitus,Launched,0.23341801199020198,-0.00628580724373,gliclazide,,,0,0
BRD-A61194565-003-27-0::2.5::HTS,BRD-A61194565-003-27-0,benserazide,2.5,HTS,Exp_SNAP25-AS1 (ENSG00000227906),GE,noncancer,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,Launched,0.24428001977549502,0.00648231692384,benserazide,,,0,0
BRD-A61221616-001-04-3::2.5::HTS,BRD-A61221616-001-04-3,medroxyprogesterone-acetate,2.5,HTS,Exp_NME4 (ENSG00000103202),GE,noncancer,progesterone receptor agonist,,endocrinology,contraceptive,Launched,0.24596394979130498,0.136262791848,medroxyprogesterone-acetate,,,0,0
BRD-A61392169-001-02-7::2.5::HTS,BRD-A61392169-001-02-7,eliprodil,2.5,HTS,DEM2_SEC1P (653677),DEMETER2_COM,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2B",,,Phase 3,0.298166227048817,0.0497885295905,eliprodil,,,0,0
BRD-A61633223-001-02-8::2.678394161::MTS004,BRD-A61633223-001-02-8,ulifloxacin,2.678394161,MTS004,METABOL_choline,METABOL,noncancer,,,,,Launched,0.298459954203864,0.0943517529704,ulifloxacin,,,0,0
BRD-A61676498-001-06-6::2.5::HTS,BRD-A61676498-001-06-6,climbazole,2.5,HTS,Exp_VHL (ENSG00000134086),GE,noncancer,enzyme inducer,,dermatology,"dandruff, eczema",Launched,0.280318350871056,0.129702048938,climbazole,,,0,0
BRD-A61793559-001-15-6::2.5::HTS,BRD-A61793559-001-15-6,metolazone,2.5,HTS,CRISPR_NUP93 (9688),AVANA_PUBLIC_18Q2,noncancer,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension",Launched,0.26423130205870005,0.112908799648,metolazone,,,0,0
BRD-A61850409-001-10-7::2.5::HTS,BRD-A61850409-001-10-7,alpha-tochopheryl-acetate,2.5,HTS,PROT_c-Jun_pS73,PROT,noncancer,antioxidant,,endocrinology,vitamin E deficiency,Launched,0.28708121837066497,0.151956096025,alpha-tochopheryl-acetate,,,0,0
BRD-A62021152-003-03-4::2.5::HTS,BRD-A62021152-003-03-4,WAY-161503,2.5,HTS,CRISPR_CDNF (441549),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor agonist,HTR2C,,,Preclinical,0.319116665065862,0.103530836154,WAY-161503,,,0,0
BRD-A62057054-001-03-1::2.5::HTS,BRD-A62057054-001-03-1,MDL-11939,2.5,HTS,Exp_GRM2 (ENSG00000164082),GE,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Phase 2,0.30016363451639505,-0.0237093699873,MDL-11939,,,0,0
BRD-A62071884-001-04-6::2.5::HTS,BRD-A62071884-001-04-6,siguazodan,2.5,HTS,RMUTmis_ARHGAP39 (80728),MUTmis,noncancer,phosphodiesterase inhibitor,PDE3A,,,Phase 1,0.265288109283092,0.0584742847811,siguazodan,,,0,0
BRD-A62197763-001-01-1::2.532450362::MTS004,BRD-A62197763-001-01-1,enciprazine,2.532450362,MTS004,CN_BCRP3 (644165),CN,noncancer,GABA receptor modulator,GABRA1,,,Phase 3,0.31187580644073803,0.0987682344271,enciprazine,,,0,0
BRD-A62209527-001-04-5::2.5::HTS,BRD-A62209527-001-04-5,ZM-226600,2.5,HTS,DEM2_PNPLA8 (50640),DEMETER2_COM,noncancer,Kir6 channel (KATP) activator,,,,Preclinical,0.27733362039193205,0.0787086133634,ZM-226600,,,0,0
BRD-A62421304-004-18-9::2.5::HTS,BRD-A62421304-004-18-9,mepenzolate,2.5,HTS,DEM2_CYP2F1 (1572),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.29242340616937607,0.124562136829,mepenzolate,,,0,0
BRD-A62428732-300-06-3::2.5::HTS,BRD-A62428732-300-06-3,hydroxyzine,2.5,HTS,CN_ROCK1 (6093),CN,noncancer,antihistamine,HRH1,"neurology/psychiatry, allergy, dermatology","anxiety, urticaria, itching, dermatosis, anxiety, urticaria, itching, dermatosis",Launched,0.268430075937908,0.0944445425018,hydroxyzine,,,0,0
BRD-A62731508-001-05-8::2.5::HTS,BRD-A62731508-001-05-8,cortisone,2.5,HTS,PROT_GATA3,PROT,noncancer,glucocorticoid receptor agonist,NR3C1,"gastroenterology, rheumatology, dermatology","ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema",Launched,0.293760577707892,0.0844564924854,cortisone,,,0,0
BRD-A63310107-001-04-8::2.5::HTS,BRD-A63310107-001-04-8,miglitol,2.5,HTS,RMUTmis_KIAA1239 (0),MUTmis,noncancer,glucosidase inhibitor,"GAA, GANAB, GANC, MGAM",endocrinology,diabetes mellitus,Launched,0.21855249569327304,0.123215563416,miglitol,,,0,0
BRD-A63431791-001-01-9::2.5::MTS004,BRD-A63431791-001-01-9,sulbactam-pivoxil,2.5,MTS004,PROT_HER3_pY1289_Caution,PROT,noncancer,beta lactamase inhibitor,,infectious disease,skin infections,Launched,0.243424026157083,0.0764122266845,sulbactam-pivoxil,,,0,0
BRD-A63444178-001-01-5::2.5::HTS,BRD-A63444178-001-01-5,ME0328,2.5,HTS,CRISPR_EIF2AK3 (9451),AVANA_PUBLIC_18Q2,targeted cancer,PARP inhibitor,PARP3,,,Preclinical,0.29681361833250797,0.155411628015,ME0328,,,0,0
BRD-A63546914-003-02-0::2.5::HTS,BRD-A63546914-003-02-0,Ro-04-5595,2.5,HTS,CRISPR_LRRC45 (201255),AVANA_PUBLIC_18Q2,noncancer,,GRIN2B,,,Preclinical,0.27764099208965304,0.00793646236301,Ro-04-5595,,,0,0
BRD-A63675168-001-01-6::2.5::HTS,BRD-A63675168-001-01-6,brivudine,2.5,HTS,PROT_c-Met_pY1235,PROT,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,shingles,Launched,0.3243115377638,0.0540915487492,brivudine,,,0,0
BRD-A63752151-001-01-2::2.5::HTS,BRD-A63752151-001-01-2,fidarestat,2.5,HTS,CN_IL9 (3578),CN,noncancer,aldose reductase inhibitor,AKR1B1,,,Phase 3,0.28107523671899,0.0751277457826,fidarestat,,,0,0
BRD-A63780829-001-11-4::2.5::HTS,BRD-A63780829-001-11-4,hyperin,2.5,HTS,CN_PLD5 (200150),CN,targeted cancer,aldose reductase inhibitor,"ACE, AKR1B1",,,Preclinical,0.28915591742262603,0.0652428045922,hyperin,,,0,0
BRD-A64011898-001-01-0::2.5::HTS,BRD-A64011898-001-01-0,androstenone,2.5,HTS,DEM2_SLC22A20 (440044),DEMETER2_COM,noncancer,steroid,,,,Preclinical,0.27904575782707397,0.0428243228926,androstenone,,,0,0
BRD-A64092382-003-18-3::2.5::HTS,BRD-A64092382-003-18-3,mexiletine,2.5,HTS,RMUTmis_ZNF44 (51710),MUTmis,noncancer,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)",Launched,0.293748256449427,0.0868547589697,mexiletine,,,0,0
BRD-A64125466-236-04-6::2.5::HTS,BRD-A64125466-236-04-6,dehydrocholate,2.5,HTS,METHYL_DUSP27,METHYL,noncancer,,,,,Preclinical,0.29684130208429804,0.11252006312,dehydrocholate,,,0,0
BRD-A64173453-015-02-3::2.500011906::MTS004,BRD-A64173453-015-02-3,octreotide,2.500011906,MTS004,Exp_NEDD9 (ENSG00000111859),GE,targeted cancer,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5","gastroenterology, endocrinology, oncology","diarrhea, acromegaly, carcinoid tumors",Launched,0.35034149847581997,0.089526117991,octreotide,,,0,0
BRD-A64227845-004-09-3::2.5::HTS,BRD-A64227845-004-09-3,SKF-77434,2.5,HTS,RMUTmis_ATP1B2 (482),MUTmis,noncancer,dopamine receptor agonist,DRD1,,,Preclinical,0.25360263223977,0.089846714766,SKF-77434,,,0,0
BRD-A64406146-001-01-2::2.5::HTS,BRD-A64406146-001-01-2,timofibrate,2.5,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,"cholesterol inhibitor, lipase clearing factor inhibitor",LPL,,,Phase 2,0.282024846033718,0.0797521543087,timofibrate,,,0,0
BRD-A64553394-001-04-4::2.68::HTS,BRD-A64553394-001-04-4,DPI-201106,2.68,HTS,Exp_SERPINF1 (ENSG00000132386),GE,noncancer,sodium channel activator,ADRB2,,,Phase 2,0.29246950840735303,0.0680835534188,DPI-201106,,,0,0
BRD-A64610707-001-04-4::2.5::HTS,BRD-A64610707-001-04-4,pranoprofen,2.5,HTS,METABOL_thymidine,METABOL,noncancer,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,Launched,0.22925953032274302,0.112173242496,pranoprofen,,,0,0
BRD-A64698388-003-01-7::2.5::HTS,BRD-A64698388-003-01-7,levo-phencynonate,2.5,HTS,CRISPR_DVL2 (1856),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,CHRM1,,,Launched,0.274020281309719,0.115180340265,levo-phencynonate,,,0,0
BRD-A64743628-001-01-5::2.5::HTS,BRD-A64743628-001-01-5,isometheptene-mucate,2.5,HTS,PROT_PKC-pan_BetaII_pS660,PROT,noncancer,,"ADRA1A, SLC18A2",neurology/psychiatry,headache,Launched,0.23361172887499201,0.0587484358639,isometheptene-mucate,,,0,0
BRD-A64808605-003-02-7::2.5::HTS,BRD-A64808605-003-02-7,AH11110,2.5,HTS,CN_DOCK1 (1793),CN,noncancer,adrenergic receptor ligand,ADRA1B,,,Preclinical,0.27253548285485396,0.100464611017,AH11110,,,0,0
BRD-A64977602-001-15-9::2.5::HTS,BRD-A64977602-001-15-9,mirtazapine,2.5,HTS,CN_TCEB3CL2 (100506888),CN,noncancer,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD5, HRH1, HRH3, HTR2A, HTR2B, HTR2C, HTR3A, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.29143907940271996,0.148500809477,mirtazapine,,,0,0
BRD-A65013509-003-24-4::2.5::HTS,BRD-A65013509-003-24-4,oxybutynin,2.5,HTS,METHYL_BCL2L1,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",urology,urinary incontinence,Launched,0.22301520551370002,0.131890179679,oxybutynin,,,0,0
BRD-A65145453-001-06-1::2.5::HTS,BRD-A65145453-001-06-1,ATPA,2.5,HTS,Exp_RPL35P6 (ENSG00000244018),GE,noncancer,glutamate receptor agonist,"GRIA2, GRIK1",,,Preclinical,0.271110708316582,0.0409978424104,ATPA,,,0,0
BRD-A65248799-001-01-7::2.5::HTS,BRD-A65248799-001-01-7,EMD-53998,2.5,HTS,METABOL_C56:8 TAG,METABOL,noncancer,phosphodiesterase inhibitor,TNNC1,,,Phase 1,0.293069712568667,0.0667081921882,EMD-53998,,,0,0
BRD-A65280694-003-13-7::2.5::HTS,BRD-A65280694-003-13-7,molindone,2.5,HTS,PROT_Bcl-2,PROT,noncancer,dopamine receptor antagonist,"CHRM1, DRD2, HRH1, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.29564603827858,0.00277429375631,molindone,,,0,0
BRD-A65440446-001-04-1::2.5::HTS,BRD-A65440446-001-04-1,cimaterol,2.5,HTS,CN_CEP112 (201134),CN,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,Preclinical,0.252470200770397,0.0662550504129,cimaterol,,,0,0
BRD-A65449987-001-10-4::2.5::HTS,BRD-A65449987-001-10-4,flunisolide,2.5,HTS,PROT_TIGAR,PROT,noncancer,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,Launched,0.291438111720032,0.106927756216,flunisolide,OTHER,0.27591518255054204,-3.612857205544424,-3.0822506101470117
BRD-A65562236-001-01-2::2.499987842::MTS004,BRD-A65562236-001-01-2,solamargine,2.499987842,MTS004,CN_VSX1 (30813),CN,noncancer,apoptosis inhibitor,,,,Phase 3,0.19301155983186302,0.118176069364,solamargine,,,0,0
BRD-A65597028-003-07-3::2.5::HTS,BRD-A65597028-003-07-3,RX-821002,2.5,HTS,METABOL_aspartate,METABOL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",,,Preclinical,0.272117499036583,0.00318584092349,RX-821002,,,0,0
BRD-A65615053-003-02-2::2.5::HTS,BRD-A65615053-003-02-2,zacopride,2.5,HTS,Exp_GAPDHP70 (ENSG00000249489),GE,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B, HTR4, HTR5A",,,Phase 2,0.27953686807380895,0.0127346653298,zacopride,,,0,0
BRD-A65671304-001-07-5::2.5::HTS,BRD-A65671304-001-07-5,candesartan-cilextil,2.5,HTS,METHYL_TPM3,METHYL,noncancer,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,"hypertension, congestive heart failure",Launched,0.27994307595826196,0.0907745460514,candesartan-cilextil,,,0,0
BRD-A65683612-001-07-7::2.499972087::MTS004,BRD-A65683612-001-07-7,phenylpiracetam,2.499972087,MTS004,CRISPR_CTNNBIP1 (56998),AVANA_PUBLIC_18Q2,noncancer,noradrenaline uptake inhibitor,,neurology/psychiatry,"anxiety, fatigue, depression",Launched,0.323919494961022,0.21022696399,phenylpiracetam,,,0,0
BRD-A65767837-001-04-4::2.5::HTS,BRD-A65767837-001-04-4,hydrocortisone-acetate,2.5,HTS,CRISPR_EGLN3 (112399),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2",dermatology,corticosteroid-responsive dermatoses,Launched,0.21027418108644103,0.00840877311364,hydrocortisone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.21938335972098466,-3.911246520805953,-3.0282515161604504
BRD-A65797496-048-09-3::2.5::HTS,BRD-A65797496-048-09-3,deptropine,2.5,HTS,PROT_p27_pT157_Caution,PROT,noncancer,histamine receptor antagonist,HRH1,,,Preclinical,0.27316740134048,0.0138676220009,deptropine,,,0,0
BRD-A65818372-001-05-3::2.5::HTS,BRD-A65818372-001-05-3,ioversol,2.5,HTS,METHYL_FAM89A,METHYL,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.18236253770069502,0.0442816537289,ioversol,,,0,0
BRD-A66116161-001-02-3::2.5::HTS,BRD-A66116161-001-02-3,AM-1241,2.5,HTS,DEM2_TESK1 (7016),DEMETER2_COM,noncancer,cannabinoid receptor agonist,"CNR1, CNR2",,,Preclinical,0.298236083908865,0.100669987381,AM-1241,,,0,0
BRD-A66435872-332-01-8::2.5::HTS,BRD-A66435872-332-01-8,HTMT,2.5,HTS,CRISPR_PDCD6IP (10015),AVANA_PUBLIC_18Q2,noncancer,histamine receptor agonist,HRH4,,,Preclinical,0.30094718198483,0.11510946268,HTMT,,,0,0
BRD-A66869276-001-02-9::2.5::HTS,BRD-A66869276-001-02-9,diflorasone-diacetate,2.5,HTS,CN_RHD (6007),CN,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.27148731572457,0.123130090042,diflorasone-diacetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2683907881114175,-3.9989907665861137,-3.0849842251199675
BRD-A66920069-001-01-3::2.5::HTS,BRD-A66920069-001-01-3,fenigam,2.5,HTS,MIRNA_hsa-miR-1225-3p,MIRNA,noncancer,benzodiazepine receptor agonist,"GABBR1, GABBR2",neurology/psychiatry,"posttraumatic stress disorder, anxiety, depression",Launched,0.261009087873428,0.0640725915988,fenigam,,,0,0
BRD-A66966115-001-01-0::2.5::HTS,BRD-A66966115-001-01-0,NM107,2.5,HTS,CN_GPRC5B (51704),CN,noncancer,RNA polymerase inhibitor,,,,Phase 2,0.30722390621109197,0.121009785894,NM107,,,0,0
BRD-A67006024-001-04-8::2.5::HTS,BRD-A67006024-001-04-8,SNAP,2.5,HTS,CN_LOC653786 (653786),CN,targeted cancer,nitric oxide donor,PTPN1,,,Phase 2,0.321205018233879,0.131754505347,SNAP,,,0,0
BRD-A67060370-001-02-9::2.5::HTS,BRD-A67060370-001-02-9,albendazole-oxide,2.5,HTS,DEM2_TP63 (8626),DEMETER2_COM,noncancer,anthelmintic agent,,infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis",Launched,0.19627567694333103,0.0566557050794,albendazole-oxide,,,0,0
BRD-A67097164-001-18-7::2.5::HTS,BRD-A67097164-001-18-7,ifosfamide,2.5,HTS,MIRNA_hsa-miR-516a-3p,MIRNA,chemo,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis",Launched,0.258268397123361,0.0871389285762,ifosfamide,,,0,0
BRD-A67101513-001-03-7::2.5::HTS,BRD-A67101513-001-03-7,hygromycin-b,2.5,HTS,RMUTmis_DNAH8 (1769),MUTmis,noncancer,polypeptide synthesis inhibitor,,,,Preclinical,0.289423035298627,0.094542262114,hygromycin-b,,,0,0
BRD-A67181951-001-01-2::2.5::HTS,BRD-A67181951-001-01-2,gadobutrol,2.5,HTS,DEM2_DUSP5 (1847),DEMETER2_COM,noncancer,radiopaque medium,,radiology,MRI contrast agent,Launched,0.294073906614521,0.191929298815,gadobutrol,,,0,0
BRD-A67182178-001-01-7::2.5::MTS004,BRD-A67182178-001-01-7,toloxatone,2.5,MTS004,MIRNA_hsa-miR-885-5p,MIRNA,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,depression,Launched,0.364385151097331,0.173176446757,toloxatone,,,0,0
BRD-A67305656-001-01-5::2.5::MTS004,BRD-A67305656-001-01-5,spiramycin,2.5,MTS004,Exp_ZNF564 (ENSG00000249709),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,"toxoplasmosis, soft tissue infection",Launched,0.297050175152287,0.0384041243475,spiramycin,,,0,0
BRD-A67363467-001-01-3::2.5::HTS,BRD-A67363467-001-01-3,dihydrostreptomycin,2.5,HTS,METHYL_SH3TC2,METHYL,noncancer,bacterial 30S ribosomal subunit inhibitor,,,,Withdrawn,0.268701395129413,0.071713696184,dihydrostreptomycin,,,0,0
BRD-A67482312-001-02-6::2.5::HTS,BRD-A67482312-001-02-6,4-P-PDOT,2.5,HTS,CRISPR_THEGL (100506564),AVANA_PUBLIC_18Q2,noncancer,melatonin receptor antagonist,"MTNR1A, MTNR1B",,,Preclinical,0.328811930359796,0.0849980522465,4-P-PDOT,,,0,0
BRD-A67516570-001-02-8::2.5::HTS,BRD-A67516570-001-02-8,lafutidine,2.5,HTS,CRISPR_TMEM69 (51249),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",Launched,0.306848478550657,-0.00484932844704,lafutidine,,,0,0
BRD-A67521319-001-01-6::2.5::HTS,BRD-A67521319-001-01-6,pimonidazole,2.5,HTS,CN_HS3ST3A1 (9955),CN,targeted cancer,,,,,Phase 3,0.29494317593736796,0.037054482577,pimonidazole,,,0,0
BRD-A67616246-001-07-9::2.5::HTS,BRD-A67616246-001-07-9,levomequitazine,2.5,HTS,MIRNA_hsa-miR-643,MIRNA,noncancer,histamine receptor antagonist,HRH1,,,Phase 2,0.273739044717465,0.0986457237894,levomequitazine,,,0,0
BRD-A67748489-001-10-0::2.5::HTS,BRD-A67748489-001-10-0,K-858,2.5,HTS,DEM2_KIF11 (3832),DEMETER2_COM,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Preclinical,0.401745716160064,0.268859429532,K-858,OTHER,0.4097157628920486,4.925565049588563,-1.2386987951646873
BRD-A67862938-034-14-9::2.5::HTS,BRD-A67862938-034-14-9,naftidrofuryl,2.5,HTS,RMUTmis_SPATA2 (9825),MUT,noncancer,adrenergic receptor antagonist,,cardiology,claudication,Launched,0.22118600775264102,0.0897868682981,naftidrofuryl,,,0,0
BRD-A67975844-001-01-8::2.5::HTS,BRD-A67975844-001-01-8,NSC-405020,2.5,HTS,METABOL_serotonin,METABOL,noncancer,matrix metalloprotease inhibitor,MMP1,,,Preclinical,0.268418351680473,0.0739036585428,NSC-405020,,,0,0
BRD-A68083442-001-01-6::2.5::HTS,BRD-A68083442-001-01-6,pranidipine,2.5,HTS,METHYL_LOC101927243,METHYL,noncancer,calcium channel blocker,CACNA1C,,,Phase 2,0.319091724770939,0.0824007761193,pranidipine,OTHER,0.3271221624129245,0.5988982910775148,-3.3060392020473683
BRD-A68281735-001-18-6::0.25::HTS,BRD-A68281735-001-18-6,REV-5901,0.25,HTS,METHYL_UGT1A6,METHYL,noncancer,"leukotriene receptor antagonist, lipoxygenase inhibitor",ALOX5,,,Phase 2,0.28382827037204905,0.0991969907317,REV-5901,,,0,0
BRD-A68304895-003-02-2::2.5::HTS,BRD-A68304895-003-02-2,BTS-54505,2.5,HTS,Exp_CHD4 (ENSG00000111642),GE,noncancer,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,Withdrawn,0.325587395271007,0.0688965874874,BTS-54505,,,0,0
BRD-A68464583-001-02-5::2.5::HTS,BRD-A68464583-001-02-5,mazindol,2.5,HTS,Exp_C17orf89 (ENSG00000224877),GE,noncancer,"dopamine reuptake inhibitor, selective serotonin reuptake inhibitor (SSRI)","SLC6A2, SLC6A3, SLC6A4",genetics,duchenne muscular dystrophy (DMD),Launched,0.263440480972229,0.132127311879,mazindol,,,0,0
BRD-A68493689-001-01-9::2.5::HTS,BRD-A68493689-001-01-9,simeprevir,2.5,HTS,CRISPR_NLRP1 (22861),AVANA_PUBLIC_18Q2,noncancer,HCV inhibitor,"CYP1A2, CYP3A4",infectious disease,hepatitis C,Launched,0.30056906539588396,0.0440896789824,simeprevir,OTHER,0.2989765243969429,-3.889186605802033,-3.137476762158247
BRD-A68509429-003-03-9::2.5::HTS,BRD-A68509429-003-03-9,ethylnorepinephrine,2.5,HTS,METHYL_TBC1D28,METHYL,noncancer,bronchodilator,,,,Preclinical,0.271819755921307,0.204186561226,ethylnorepinephrine,,,0,0
BRD-A68589262-001-04-3::2.5::HTS,BRD-A68589262-001-04-3,troxipide,2.5,HTS,PROT_Bap1 c-4,PROT,noncancer,glucosamine synthetase stimulant,,gastroenterology,gastroesophageal reflux disease (GERD),Launched,0.29903594561309005,0.022739721618,troxipide,,,0,0
BRD-A68631409-001-05-4::2.5::HTS,BRD-A68631409-001-05-4,evodiamine,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,"ATPase inhibitor, TRPV agonist",TRPV1,,,Preclinical,0.346363834765176,0.282365933521,evodiamine,OTHER,0.34790409579280585,6.110594529393829,-2.087674762312325
BRD-A68723818-050-32-5::2.5::HTS,BRD-A68723818-050-32-5,brompheniramine,2.5,HTS,CN_MACROD2-AS1 (100379174),CN,noncancer,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1","allergy, otolaryngology","allergic rhinitis, common cold",Launched,0.240891521877545,0.0727856739261,brompheniramine,,,0,0
BRD-A68888262-003-15-1::2.5::HTS,BRD-A68888262-003-15-1,azelastine,2.5,HTS,DEM2_LRRC32 (2615),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,Launched,0.25654539297518897,0.105998583595,azelastine,,,0,0
BRD-A68942014-003-01-7::2.5::HTS,BRD-A68942014-003-01-7,amitifadine,2.5,HTS,METABOL_glutamine,METABOL,noncancer,serotonin transporter (SERT) inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,Phase 3,0.245812984993724,-0.0167763855036,amitifadine,,,0,0
BRD-A69275535-001-01-5::2.5::HTS,BRD-A69275535-001-01-5,pinitol,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,gamma secretase inhibitor,,,,Phase 2,0.31626747798561794,0.0419813035588,pinitol,,,0,0
BRD-A69636825-003-04-7::2.5::HTS,BRD-A69636825-003-04-7,diltiazem,2.5,HTS,METABOL_adenine,METABOL,noncancer,calcium channel blocker,"CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5",cardiology,"hypertension, angina pectoris",Launched,0.286828888063752,0.0288700132984,diltiazem,,,0,0
BRD-A69651145-003-07-2::2.5::HTS,BRD-A69651145-003-07-2,minocycline,2.5,HTS,DEM2_PTTG2 (10744),DEMETER2_COM,noncancer,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis",Launched,0.285123332364651,0.128535711614,minocycline,,,0,0
BRD-A69777949-001-24-2::2.5::HTS,BRD-A69777949-001-24-2,flumequine,2.5,HTS,LIN_gastric,LIN,noncancer,topoisomerase inhibitor,,infectious disease,urinary tract infections,Launched,0.259589903344946,0.0922256573948,flumequine,,,0,0
BRD-A69815203-001-07-6::2.5::HTS,BRD-A69815203-001-07-6,cyclosporin-a,2.5,HTS,Exp_RBM3 (ENSG00000102317),GE,noncancer,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis",Launched,0.328096024828078,0.139762653074,cyclosporin-a,OTHER,0.3443899978032907,1.1247724449702727,-3.0763924131734983
BRD-A69917777-065-02-2::2.5::HTS,BRD-A69917777-065-02-2,aminopentamide,2.5,HTS,Exp_PFDN1 (ENSG00000113068),GE,noncancer,acetylcholine receptor antagonist,CHRM1,gastroenterology,"acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea",Launched,0.324819420056162,0.102273408611,aminopentamide,,,0,0
BRD-A70083328-001-23-5::2.5::HTS,BRD-A70083328-001-23-5,secnidazole,2.5,HTS,MIRNA_hsa-miR-592,MIRNA,noncancer,"acetylcholinesterase inhibitor, microtubule inhibitor",,infectious disease,protozoan infection,Launched,0.26149961742062805,0.150109613892,secnidazole,,,0,0
BRD-A70083328-001-24-3::2.5::HTS,BRD-A70083328-001-24-3,secnidazole,2.5,HTS,MIRNA_hsa-miR-27b,MIRNA,noncancer,"acetylcholinesterase inhibitor, microtubule inhibitor",,infectious disease,protozoan infection,Launched,0.26149961742062805,0.150109613892,secnidazole,,,0,0
BRD-A70268693-050-01-2::2.5::HTS,BRD-A70268693-050-01-2,PG-9,2.5,HTS,METHYL_DCP1B,METHYL,noncancer,acetylcholine receptor agonist,,,,Preclinical,0.23933396746680602,0.0501846941601,PG-9,,,0,0
BRD-A70407468-001-02-0::2.5::HTS,BRD-A70407468-001-02-0,PSB-36,2.5,HTS,METABOL_thymidine,METABOL,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.295471647157865,0.0666757868651,PSB-36,,,0,0
BRD-A70649075-008-30-8::2.5::HTS,BRD-A70649075-008-30-8,sulconazole,2.5,HTS,Exp_TAF10 (ENSG00000166337),GE,noncancer,sterol demethylase inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.32301598105081497,0.172335999928,sulconazole,,,0,0
BRD-A70858459-001-01-7::2.5::HTS,BRD-A70858459-001-01-7,estramustine,2.5,HTS,MUTpool_MS4A12 (54860),MUTpool,chemo,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,Launched,0.26606143956341,0.0507984263938,estramustine,,,0,0
BRD-A70998768-004-01-1::2.5::HTS,BRD-A70998768-004-01-1,pinaverium,2.5,HTS,MIRNA_hsv2-miR-H2,MIRNA,noncancer,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome,Launched,0.27735302948930396,0.0569300338898,pinaverium,,,0,0
BRD-A71033472-003-23-9::2.5::HTS,BRD-A71033472-003-23-9,fendiline,2.5,HTS,PROT_DJ-1,PROT,noncancer,calcium channel blocker,HTR2B,,,Preclinical,0.32793469599799496,0.101467887303,fendiline,,,0,0
BRD-A71157293-003-10-0::2.5::HTS,BRD-A71157293-003-10-0,fursultiamine,2.5,HTS,CN_GPAT2 (150763),CN,noncancer,vitamin B,,,,Launched,0.238287771949372,0.0613760559879,fursultiamine,,,0,0
BRD-A71262238-001-08-4::2.5::HTS,BRD-A71262238-001-08-4,nafadotride,2.5,HTS,DEM2_TMEM256-PLSCR3&PLSCR3 (100529211&57048),DEMETER2_COM,noncancer,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",,,Preclinical,0.240051012830787,0.0636437316423,nafadotride,,,0,0
BRD-A71407503-001-01-8::2.5::HTS,BRD-A71407503-001-01-8,inimur,2.5,HTS,DEM2_UBE2S (27338),DEMETER2_COM,noncancer,other antifungal,,,,Launched,0.31744634823925,0.0316821513016,inimur,,,0,0
BRD-A71725768-001-01-3::2.5::HTS,BRD-A71725768-001-01-3,metoxibutropate,2.5,HTS,CRISPR_BTN3A1 (11119),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.29788400516353397,0.0610746230407,metoxibutropate,,,0,0
BRD-A71765060-001-01-4::2.5::MTS004,BRD-A71765060-001-01-4,picartamide,2.5,MTS004,CN_RAB11A (8766),CN,noncancer,H+/K+-ATPase inhibitor,ATP4A,,,Phase 2,0.314948168980046,0.103301730792,picartamide,,,0,0
BRD-A71774530-001-05-9::2.5::HTS,BRD-A71774530-001-05-9,lufenuron,2.5,HTS,METHYL_MIR483,METHYL,noncancer,chitin inhibitor,,infectious disease,flea control,Launched,0.30832180089008304,0.0606102071691,lufenuron,,,0,0
BRD-A72066420-001-04-5::2.5::HTS,BRD-A72066420-001-04-5,mifobate,2.5,HTS,METHYL_REC114,METHYL,noncancer,PPAR receptor antagonist,PPARG,,,Phase 2,0.271744659299274,0.0937195289672,mifobate,,,0,0
BRD-A72212290-300-01-4::2.5::HTS,BRD-A72212290-300-01-4,eprazinone,2.5,HTS,METHYL_LOC102724050,METHYL,noncancer,mucolytic agent,,pulmonary,bronchospasm,Launched,0.28632693704647494,-0.00000307298497747,eprazinone,,,0,0
BRD-A72297358-001-01-8::2.5::MTS004,BRD-A72297358-001-01-8,ozolinone,2.5,MTS004,PROT_eIF4E,PROT,noncancer,diuretic,,,,Phase 3,0.19858766611762402,0.104095177045,ozolinone,,,0,0
BRD-A72309220-001-04-1::2.5::HTS,BRD-A72309220-001-04-1,metergoline,2.5,HTS,METABOL_glutamine,METABOL,noncancer,"dopamine receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,Launched,0.298013804413503,0.0205710312609,metergoline,,,0,0
BRD-A72351335-001-04-5::2.463310717::MTS004,BRD-A72351335-001-04-5,misoprostol,2.463310717,MTS004,MIRNA_hsa-miR-23b,MIRNA,noncancer,prostanoid receptor agonist,"PTGER2, PTGER3, PTGER4, PTGIR",gastroenterology,duodenal ulcer disease,Launched,0.19667281690593302,0.159432787414,misoprostol,,,0,0
BRD-A72390365-001-15-2::2.5::HTS,BRD-A72390365-001-15-2,choline-alfoscerate,2.5,HTS,METABOL_aspartate,METABOL,noncancer,acetylcholine precursor,GM2A,,,Launched,0.278744430934662,0.0217850295257,choline-alfoscerate,,,0,0
BRD-A72401848-001-02-2::2.551316459::MTS004,BRD-A72401848-001-02-2,gadoteridol,2.551316459,MTS004,RMUThot_KRAS (3845),MUThot,noncancer,radiopaque medium,,radiology,MRI contrast agent,Launched,0.266124440537939,0.0852072213452,gadoteridol,,,0,0
BRD-A72483914-001-03-7::2.5::HTS,BRD-A72483914-001-03-7,spiroxatrine,2.5,HTS,Exp_GABRB1 (ENSG00000163288),GE,noncancer,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B",,,Preclinical,0.27795730963821,0.0326688458192,spiroxatrine,,,0,0
BRD-A72703248-003-04-9::2.5::HTS,BRD-A72703248-003-04-9,SKF-96365,2.5,HTS,Exp_TMEM255B (ENSG00000184497),GE,noncancer,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",,,Preclinical,0.368573255445981,0.279412183556,SKF-96365,OTHER,0.3672886590707028,4.957797857830569,-3.9615573520595335
BRD-A72711497-236-03-8::2.5::HTS,BRD-A72711497-236-03-8,lasalocid,2.5,HTS,Exp_TNFAIP6 (ENSG00000123610),GE,noncancer,bacterial permeability inducer,,infectious disease,coccidiosis,Launched,0.41789313366849495,0.298464772179,lasalocid,OTHER,0.4187306591097998,4.989558837890383,-1.0261818499298756
BRD-A72767275-003-01-6::2.5::HTS,BRD-A72767275-003-01-6,nalmefene,2.5,HTS,DEM2_PLS1 (5357),DEMETER2_COM,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",pulmonary,respiratory depression,Launched,0.265305708287625,0.0175580374149,nalmefene,,,0,0
BRD-A72988804-001-11-1::2.5::MTS004,BRD-A72988804-001-11-1,tiaprofenic-acid,2.5,MTS004,CRISPR_SEPHS2 (22928),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,rheumatoid arthritis,Launched,0.241928533034267,0.123602739652,tiaprofenic-acid,,,0,0
BRD-A73368467-003-17-6::2.5::HTS,BRD-A73368467-003-17-6,fexofenadine,2.5,HTS,DEM2_TRMT10C (54931),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",Launched,0.275925840371297,0.0859716452806,fexofenadine,,,0,0
BRD-A73385064-001-01-5::2.603473418::MTS004,BRD-A73385064-001-01-5,beclomethasone,2.603473418,MTS004,METABOL_C18:2 LPC,METABOL,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,Launched,0.287375935013944,0.0806721966091,beclomethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.2888130742587232,2.5661592919120544,4.600033987536116
BRD-A73427433-240-01-3::2.5::HTS,BRD-A73427433-240-01-3,adaprev,2.5,HTS,METABOL_heptanoylcarnitine,METABOL,noncancer,TGF beta receptor inhibitor,"IGF2R, M6PR",,,Phase 3,0.236823707405629,0.122649441699,adaprev,,,0,0
BRD-A73556557-001-06-4::2.5::HTS,BRD-A73556557-001-06-4,tagatose,2.5,HTS,CN_MYO6 (4646),CN,noncancer,phosphorylase inhibitor,PYGL,,,Phase 3,0.22525697591670896,0.0460545038761,tagatose,,,0,0
BRD-A73566563-001-01-6::2.5::MTS004,BRD-A73566563-001-01-6,tiprenolol,2.5,MTS004,CN_NANS (54187),CN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,Phase 2,0.32139569802103496,0.11542527617,tiprenolol,,,0,0
BRD-A73679382-236-01-8::2.499981367::MTS004,BRD-A73679382-236-01-8,MK-571,2.499981367,MTS004,CN_LOC100505812 (100505812),CN,noncancer,leukotriene receptor antagonist,"ABCC2, CYSLTR1",,,Phase 2,0.33936045260568,0.0423036822257,MK-571,,,0,0
BRD-A73709786-001-01-3::2.5::HTS,BRD-A73709786-001-01-3,LB-100,2.5,HTS,CN_PLEKHJ1 (55111),CN,targeted cancer,protein phosphatase inhibitor,,,,Phase 1,0.275849039150245,0.0209763754812,LB-100,,,0,0
BRD-A73871920-236-03-6::2.5::HTS,BRD-A73871920-236-03-6,nanchangmycin,2.5,HTS,METABOL_carnitine,METABOL,noncancer,other antibiotic,,,,Preclinical,0.390094488678488,0.168478454238,nanchangmycin,OTHER,0.37073360966936775,4.432035002060621,-0.5696516752481728
BRD-A73908300-001-06-7::2.5::HTS,BRD-A73908300-001-06-7,EX-527,2.5,HTS,PROT_Collagen_VI,PROT,noncancer,SIRT inhibitor,SIRT1,,,Phase 2,0.279811284550873,0.0928912746915,EX-527,,,0,0
BRD-A73930134-001-03-0::2.5::HTS,BRD-A73930134-001-03-0,5-hydroxytryptophan,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,neurotransmitter,"SLC36A1, SLC36A2",neurology/psychiatry,insomnia,Launched,0.30823789863003104,0.043124445288,5-hydroxytryptophan,,,0,0
BRD-A74208568-003-01-5::2.5::HTS,BRD-A74208568-003-01-5,CGP-54626,2.5,HTS,MIRNA_hsa-miR-1286,MIRNA,noncancer,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,Preclinical,0.292181885414937,0.0747501131357,CGP-54626,,,0,0
BRD-A74387232-001-02-5::2.5::HTS,BRD-A74387232-001-02-5,PMPA,2.5,HTS,DEM2_CCDC6 (8030),DEMETER2_COM,noncancer,glutamate receptor antagonist,FOLH1,,,Preclinical,0.289932680600759,0.0611134456651,PMPA,,,0,0
BRD-A74391928-051-01-3::2.5::HTS,BRD-A74391928-051-01-3,ibutilide,2.5,HTS,MUTpool_ADAMTS18 (170692),MUTpool,noncancer,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),Launched,0.299455848318661,0.0719365792167,ibutilide,,,0,0
BRD-A74391928-051-02-1::2.64::HTS,BRD-A74391928-051-02-1,ibutilide,2.64,HTS,MIRNA_hsa-miR-324-3p,MIRNA,noncancer,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),Launched,0.33043835813407296,0.0988018457125,ibutilide,,,0,0
BRD-A74667430-001-23-6::2.5::HTS,BRD-A74667430-001-23-6,etodolac,2.5,HTS,DEM2_CA9 (768),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2, RXRA",rheumatology,"osteoarthritis, rheumatoid arthritis",Launched,0.272617112990187,0.0975427023923,etodolac,,,0,0
BRD-A74765037-001-01-1::2.5::HTS,BRD-A74765037-001-01-1,estradiol-benzoate,2.5,HTS,Exp_RPL7AP28 (ENSG00000184139),GE,noncancer,contraceptive agent,ESR1,,,Preclinical,0.24722712618487197,0.0685926959537,estradiol-benzoate,,,0,0
BRD-A74914197-001-02-9::2.5::HTS,BRD-A74914197-001-02-9,pralatrexate,2.5,HTS,Exp_HMGN5 (ENSG00000198157),GE,targeted cancer,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Launched,0.37836061531506604,0.226859621975,pralatrexate,OTHER,0.37803310523795147,3.970053987944538,-2.8796677506861466
BRD-A74975734-004-09-9::2.5::MTS004,BRD-A74975734-004-09-9,homatropine,2.5,MTS004,CRISPR_KRTAP13-2 (337959),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CES1, CHRM1",ophthalmology,pupil dilation,Launched,0.274243255709021,0.224119419645,homatropine,,,0,0
BRD-A74975734-004-10-7::2.5::HTS,BRD-A74975734-004-10-7,homatropine,2.5,HTS,MIRNA_hsa-miR-365,MIRNA,noncancer,acetylcholine receptor antagonist,"CES1, CHRM1",ophthalmology,pupil dilation,Launched,0.27115561367310603,0.139590772262,homatropine,,,0,0
BRD-A74980173-001-11-9::2.5::HTS,BRD-A74980173-001-11-9,gatifloxacin,2.5,HTS,DEM2_BUD23 (114049),DEMETER2_COM,noncancer,bacterial DNA gyrase inhibitor,,,,Withdrawn,0.329879368454471,0.0278314445692,gatifloxacin,,,0,0
BRD-A75224450-001-02-4::2.662563322::MTS004,BRD-A75224450-001-02-4,ibuprofen-piconol,2.662563322,MTS004,METABOL_C22:6 CE,METABOL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.254427743280697,0.0533029659921,ibuprofen-piconol,,,0,0
BRD-A75369945-001-01-2::2.5::HTS,BRD-A75369945-001-01-2,vitamin-b12,2.5,HTS,METHYL_ANKRD20A5P,METHYL,noncancer,,,hematology,megaloblastic anemia,Launched,0.25211342929111996,0.105936223932,vitamin-b12,,,0,0
BRD-A75479906-001-02-4::2.5::HTS,BRD-A75479906-001-02-4,rimantadine,2.5,HTS,Exp_BEX5 (ENSG00000184515),GE,noncancer,"antiviral, RNA synthesis inhibitor",,infectious disease,influenza A virus infection,Launched,0.274307383592151,0.0635900372253,rimantadine,,,0,0
BRD-A75552914-001-15-0::2.5::HTS,BRD-A75552914-001-15-0,isoxicam,2.5,HTS,CRISPR_STAT2 (6773),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Withdrawn,0.226650243372459,0.0365897690936,isoxicam,,,0,0
BRD-A75726477-003-21-3::2.5::HTS,BRD-A75726477-003-21-3,clenbuterol,2.5,HTS,RMUTdmg_SMARCA2 (6595),MUTdmg,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",Launched,0.26910492413798,0.0184057022019,clenbuterol,,,0,0
BRD-A75769826-003-02-1::2.5::HTS,BRD-A75769826-003-02-1,SDM25N,2.5,HTS,CRISPR_S100A2 (6273),AVANA_PUBLIC_18Q2,noncancer,opioid receptor antagonist,OPRD1,,,Preclinical,0.24149300322657702,0.159490001619,SDM25N,,,0,0
BRD-A75817871-001-06-7::2.5::HTS,BRD-A75817871-001-06-7,blebbistatin-(+/-),2.5,HTS,Exp_NLRX1 (ENSG00000160703),GE,noncancer,ATPase inhibitor,MYH2,,,Preclinical,0.263114314652766,0.0604493782322,blebbistatin-(+/-),,,0,0
BRD-A75850590-213-01-0::2.5::HTS,BRD-A75850590-213-01-0,lomefloxacin,2.5,HTS,MUTpool_NBPF1 (55672),MUTpool,noncancer,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections",Launched,0.22695866059244602,0.0835413052734,lomefloxacin,,,0,0
BRD-A75919782-399-02-6::2.5::HTS,BRD-A75919782-399-02-6,leucovorin,2.5,HTS,METABOL_tryptophan,METABOL,targeted cancer,folate receptor ligand,TYMS,oncology,osteosarcoma,Launched,0.254347690450548,0.078487513299,leucovorin,,,0,0
BRD-A75975749-001-01-4::2.5::MTS004,BRD-A75975749-001-01-4,bafetinib,2.5,MTS004,CRISPR_BRAF (673),AVANA_PUBLIC_18Q2,targeted cancer,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",,,Phase 2,0.40215959882747204,0.475446185411,bafetinib,OTHER,0.3942299940242819,0.6674558015465467,4.217434375942652
BRD-A76533773-001-01-9::2.5::MTS004,BRD-A76533773-001-01-9,lisadimate,2.5,MTS004,METHYL_KCNS1,METHYL,noncancer,topical sunscreen agent,,dermatology,sunscreen lotion,Launched,0.32072799862948903,0.081104169648,lisadimate,,,0,0
BRD-A76672327-003-02-0::2.5::HTS,BRD-A76672327-003-02-0,clindamycin-palmitate,2.5,HTS,METHYL_LINC01194,METHYL,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections",Launched,0.27758359483540196,0.112133921618,clindamycin-palmitate,,,0,0
BRD-A77218119-001-03-5::2.5::HTS,BRD-A77218119-001-03-5,SYM-2206,2.5,HTS,Exp_ITGA10 (ENSG00000143127),GE,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,Preclinical,0.30329675292696,0.0876202480375,SYM-2206,,,0,0
BRD-A77291778-003-22-0::2.5::HTS,BRD-A77291778-003-22-0,cyclopentolate,2.5,HTS,PROT_Cyclin_E2_Caution,PROT,noncancer,acetylcholine receptor antagonist,CHRM1,ophthalmology,"mydriasis, cycloplegia",Launched,0.284266787541229,0.115383720068,cyclopentolate,,,0,0
BRD-A77577770-003-08-9::2.5::HTS,BRD-A77577770-003-08-9,palmitoylcarnitine,2.5,HTS,METHYL_MFSD9,METHYL,noncancer,protein kinase inhibitor,,,,Preclinical,0.30631567840939505,0.0625903279543,palmitoylcarnitine,,,0,0
BRD-A78093359-001-06-3::2.5::HTS,BRD-A78093359-001-06-3,MRS1845,2.5,HTS,CRISPR_PSKH1 (5681),AVANA_PUBLIC_18Q2,noncancer,calcium channel blocker,,,,Preclinical,0.29200958166915997,0.0354355728287,MRS1845,,,0,0
BRD-A78195072-001-06-2::2.5::HTS,BRD-A78195072-001-06-2,imexon,2.5,HTS,DEM2_PILRB (29990),DEMETER2_COM,targeted cancer,"apoptosis stimulant, ribonucleotide reductase inhibitor","RRM1, RRM2",,,Phase 2,0.24753117178556402,0.0777649481111,imexon,,,0,0
BRD-A78277353-001-01-9::2.492599937::MTS004,BRD-A78277353-001-01-9,metazosin,2.492599937,MTS004,CRISPR_MSH6 (2956),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,ADRA1A,,,Phase 2,0.303573108297512,0.211351333365,metazosin,,,0,0
BRD-A78322124-003-14-0::2.5::HTS,BRD-A78322124-003-14-0,dobutamine,2.5,HTS,CRISPR_RALGPS2 (55103),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2",cardiology,congestive heart failure,Launched,0.312995842124065,0.0962168010771,dobutamine,,,0,0
BRD-A78341343-001-01-6::2.5::HTS,BRD-A78341343-001-01-6,regadenoson,2.5,HTS,RMUTmis_ADAMTS12 (81792),MUTmis,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",radiology,myocardial perfusion imaging (MPI),Launched,0.31573396621687105,0.0150962739736,regadenoson,,,0,0
BRD-A78377521-001-05-5::2.5::HTS,BRD-A78377521-001-05-5,monastrol,2.5,HTS,METABOL_adenine,METABOL,targeted cancer,kinesin inhibitor,KIF11,,,Preclinical,0.287480387824832,0.0151175572717,monastrol,,,0,0
BRD-A78391468-001-02-8::2.5::HTS,BRD-A78391468-001-02-8,prednisolone-hemisuccinate,2.5,HTS,CRISPR_KIAA0586 (9786),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,,,Preclinical,0.269377669070041,0.138426429933,prednisolone-hemisuccinate,GLUCOCORTICOID RECEPTOR AGONIST,0.2657955746429717,-3.955027635797848,-3.136768384948647
BRD-A78588743-001-03-4::2.5::HTS,BRD-A78588743-001-03-4,editol,2.5,HTS,CRISPR_MBD1 (4152),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.23521131554178398,0.0212229689306,editol,,,0,0
BRD-A78723049-001-01-2::2.5::HTS,BRD-A78723049-001-01-2,cefotetan,2.5,HTS,DEM2_ASCC3 (10973),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis",Launched,0.21048909518923897,0.0228356601751,cefotetan,,,0,0
BRD-A78877355-001-03-0::2.5::HTS,BRD-A78877355-001-03-0,nefopam,2.5,HTS,Exp_PGM5 (ENSG00000154330),GE,noncancer,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,Launched,0.22797177506758898,0.104918792016,nefopam,,,0,0
BRD-A78952587-001-01-5::2.5::HTS,BRD-A78952587-001-01-5,A740003,2.5,HTS,CN_FANCC (2176),CN,noncancer,purinergic receptor antagonist,P2RX7,,,Preclinical,0.27925623014019796,0.046270994523,A740003,,,0,0
BRD-A78965079-036-01-8::2.640168331::MTS004,BRD-A78965079-036-01-8,tafenoquine,2.640168331,MTS004,METABOL_5-adenosylhomocysteine,METABOL,noncancer,antimalarial agent,,,,Phase 3,0.35247034426292606,0.10138836915,tafenoquine,OTHER,0.3526339131869369,1.470433896136603,-0.6652607651783929
BRD-A79052425-003-01-5::2.5::MTS004,BRD-A79052425-003-01-5,SIB-1553A,2.5,MTS004,METHYL_GTF3C6,METHYL,noncancer,acetylcholine receptor agonist,CHRNB4,,,Phase 2,0.271524168184671,0.075479247902,SIB-1553A,,,0,0
BRD-A79431551-001-01-1::2.5::HTS,BRD-A79431551-001-01-1,3-deazaadenosine,2.5,HTS,CN_AUTS2 (26053),CN,noncancer,adenosylhomocysteinase inhibitor,AHCY,,,Phase 2,0.25443407812242,0.126969805959,3-deazaadenosine,,,0,0
BRD-A79672927-001-20-7::2.5::HTS,BRD-A79672927-001-20-7,tropicamide,2.5,HTS,CRISPR_VHL (7428),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",ophthalmology,"mydriasis diagnostic, cycloplegia diagnostic",Launched,0.218197731650648,0.0901191210319,tropicamide,,,0,0
BRD-A79768653-001-12-0::2.5::HTS,BRD-A79768653-001-12-0,sirolimus,2.5,HTS,Exp_NBR1 (ENSG00000188554),GE,noncancer,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis",Launched,0.33544717133822805,0.290675351696,sirolimus,MTOR INHIBITOR,0.3389631866009944,0.6867315868482158,-1.6916955190674343
BRD-A79803969-003-16-1::2.5::HTS,BRD-A79803969-003-16-1,memantine,2.5,HTS,CRISPR_TAF8 (129685),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,"CHRFAM7A, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A",neurology/psychiatry,"Alzheimer's disease, senile dementia",Launched,0.235493597554228,0.0472281524869,memantine,,,0,0
BRD-A79981887-003-16-4::2.5::HTS,BRD-A79981887-003-16-4,midodrine,2.5,HTS,RMUTmis_LIPE (3991),MUTmis,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,Launched,0.2421500057541,0.0468026071989,midodrine,,,0,0
BRD-A80017228-001-25-7::2.5::HTS,BRD-A80017228-001-25-7,bendroflumethiazide,2.5,HTS,RMUTmis_SLC15A4 (121260),MUTmis,noncancer,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,Launched,0.23502928964897302,0.012310857166,bendroflumethiazide,,,0,0
BRD-A80213327-305-08-3::2.5::HTS,BRD-A80213327-305-08-3,NSC-23766,2.5,HTS,Exp_PRPF8 (ENSG00000174231),GE,noncancer,Ras GTPase inhibitor,,,,Preclinical,0.350109850406496,0.118687296738,NSC-23766,,,0,0
BRD-A80280426-001-03-8::2.43120883::MTS004,BRD-A80280426-001-03-8,AD-5467,2.43120883,MTS004,DEM2_RPL22L1 (200916),DEMETER2_COM,noncancer,aldose reductase inhibitor,AKR1B1,,,Phase 2,0.311730633879888,0.0233657865057,AD-5467,,,0,0
BRD-A80871782-004-06-9::2.5::HTS,BRD-A80871782-004-06-9,hydroxyamphetamine,2.5,HTS,CRISPR_ZNF668 (79759),AVANA_PUBLIC_18Q2,noncancer,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis,Launched,0.275932630773789,0.106576763055,hydroxyamphetamine,,,0,0
BRD-A80908310-003-13-8::2.5::HTS,BRD-A80908310-003-13-8,cloperastine,2.5,HTS,PROT_Porin,PROT,noncancer,antitussive,,pulmonary,cough suppressant,Launched,0.298690229715975,0.0700681937045,cloperastine,,,0,0
BRD-A81129465-001-03-8::2.5::HTS,BRD-A81129465-001-03-8,fenoprofen,2.5,HTS,MUTpool_GCNT4 (51301),MUTpool,noncancer,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.231467883362272,0.0920720897745,fenoprofen,,,0,0
BRD-A81233518-004-16-1::2.5::HTS,BRD-A81233518-004-16-1,glycopyrrolate,2.5,HTS,METABOL_malonylcarnitine,METABOL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),Launched,0.299308598083922,0.0908534020876,glycopyrrolate,,,0,0
BRD-A81370665-001-03-6::2.5::HTS,BRD-A81370665-001-03-6,BI-D1870,2.5,HTS,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",,,Preclinical,0.426651387072711,0.362541715801,BI-D1870,OTHER,0.4226988117712222,1.2651545501205264,-4.2663816374107215
BRD-A81513827-001-03-6::2.5::HTS,BRD-A81513827-001-03-6,saxagliptin,2.5,HTS,METABOL_C18:0 LPE,METABOL,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.239295528493996,0.0389340429692,saxagliptin,,,0,0
BRD-A81541225-001-06-8::2.5::HTS,BRD-A81541225-001-06-8,oligomycin-a,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,noncancer,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,,,Preclinical,0.33148976073063,0.290505275539,oligomycin-a,OTHER,0.3401273617088688,2.172754019186544,-2.5959425469420045
BRD-A81615860-003-01-7::2.5::HTS,BRD-A81615860-003-01-7,fenclonine-(+/-),2.5,HTS,CRISPR_PPP1R26 (9858),AVANA_PUBLIC_18Q2,noncancer,tryptophan hydroxylase inhibitor,"PAH, TPH1, TPH2",,,Preclinical,0.303849817315406,0.109852628485,fenclonine-(+/-),,,0,0
BRD-A82035391-001-02-7::2.5::HTS,BRD-A82035391-001-02-7,tolvaptan,2.5,HTS,PROT_SETD2_Caution,PROT,noncancer,vasopressin receptor antagonist,"AVPR1A, AVPR2","endocrinology, cardiology, gastroenterology","hyponatremia, congestive heart failure, hepatic cirrhosis",Launched,0.28112362807542896,0.0921602495057,tolvaptan,,,0,0
BRD-A82396632-008-29-0::2.5::HTS,BRD-A82396632-008-29-0,miconazole,2.5,HTS,METHYL_PTPRR,METHYL,noncancer,bacterial cell wall synthesis inhibitor,"KCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, NOS2, NOS3, TRPM2, TRPV5","infectious disease, neurology/psychiatry","yeast infection, itching",Launched,0.293140028094104,0.110272578978,miconazole,,,0,0
BRD-A82522119-001-01-7::2.5::HTS,BRD-A82522119-001-01-7,tibolone,2.5,HTS,LIN_glioma,LIN,noncancer,"androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist",ESR1,obstetrics/gynecology,endometriosis,Launched,0.237067364584382,-0.0391654862656,tibolone,,,0,0
BRD-A82772293-001-03-2::2.5::HTS,BRD-A82772293-001-03-2,mepazine,2.5,HTS,METABOL_glutamine,METABOL,targeted cancer,MALT1 inhibitor (JH),MALT1,,,Phase 2,0.278619217075987,0.0991778411353,mepazine,,,0,0
BRD-A83029242-001-05-3::2.5::HTS,BRD-A83029242-001-05-3,prasugrel,2.5,HTS,METABOL_1-methylnicotinamide,METABOL,noncancer,purinergic receptor antagonist,P2RY12,cardiology,"myocardial infarction, acute coronary syndrome (ACS)",Launched,0.23792371243178898,0.0435732651336,prasugrel,,,0,0
BRD-A83644949-236-01-6::2.5::HTS,BRD-A83644949-236-01-6,ardeparin,2.5,HTS,MIRNA_hsa-miR-887,MIRNA,noncancer,thrombin inhibitor,"SERPINC1, SERPIND1",,,Withdrawn,0.264485169608719,0.12622580598,ardeparin,,,0,0
BRD-A83650191-004-02-8::2.5::HTS,BRD-A83650191-004-02-8,A61603,2.5,HTS,CRISPR_NTSR1 (4923),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,ADRA1A,,,Preclinical,0.270086824415966,0.141796432721,A61603,,,0,0
BRD-A83802939-304-04-2::2.5::HTS,BRD-A83802939-304-04-2,dexamethasone-sodium-phosphate,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.282248717483595,0.0903172851705,dexamethasone-sodium-phosphate,GLUCOCORTICOID RECEPTOR AGONIST,0.2865963643212687,-4.075175736723643,-2.97255462882354
BRD-A83937277-001-10-5::2.5::HTS,BRD-A83937277-001-10-5,mephenytoin,2.5,HTS,RMUTmis_GAL3ST4 (79690),MUTmis,noncancer,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.25139869894439804,-0.0267364151322,mephenytoin,,,0,0
BRD-A84174393-236-07-1::2.5::HTS,BRD-A84174393-236-07-1,meloxicam,2.5,HTS,RMUTmis_SIRPG (55423),MUTmis,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis",Launched,0.264514655744848,0.113892883723,meloxicam,,,0,0
BRD-A84389633-001-05-7::2.5::HTS,BRD-A84389633-001-05-7,"tropanyl-3,5-dimethylbenzoate",2.5,HTS,MIRNA_hsa-miR-515-5p,MIRNA,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B",,,Preclinical,0.255667809227263,0.0597806280919,"tropanyl-3,5-dimethylbenzoate",,,0,0
BRD-A84481105-003-31-3::2.5::HTS,BRD-A84481105-003-31-3,thioridazine,2.5,HTS,DEM2_FGFR2 (2263),DEMETER2_COM,targeted cancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCNH2",,,Withdrawn,0.27879285559787204,0.0626893156853,thioridazine,,,0,0
BRD-A84575140-001-02-4::2.5::HTS,BRD-A84575140-001-02-4,pimobendan,2.5,HTS,METHYL_MANF,METHYL,noncancer,"calcium sensitizer, phosphodiesterase inhibitor",PDE3A,cardiology,congestive heart failure,Launched,0.287680288211029,0.0760334081652,pimobendan,,,0,0
BRD-A84687895-001-03-2::2.5::HTS,BRD-A84687895-001-03-2,nilvadipine,2.5,HTS,MUTpool_SFSWAP (6433),MUTpool,noncancer,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNA2D3, CACNB2",cardiology,"hypertension, cerebral artery occlusion",Launched,0.291265775355969,0.0182172382093,nilvadipine,,,0,0
BRD-A84810646-001-01-6::2.500007302::MTS004,BRD-A84810646-001-01-6,ginsenoside-rd,2.500007302,MTS004,PROT_Syk,PROT,noncancer,calcium channel blocker,,,,Phase 3,0.268446607837618,0.191235711681,ginsenoside-rd,,,0,0
BRD-A84907376-300-03-8::2.5::HTS,BRD-A84907376-300-03-8,alcuronium,2.5,HTS,CN_SNRNP27 (11017),CN,noncancer,muscle relaxant,"CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7",neurology/psychiatry,muscle relaxant,Launched,0.28302418445602695,0.0098732165797,alcuronium,,,0,0
BRD-A85025557-001-02-5::2.5::HTS,BRD-A85025557-001-02-5,NCS-382,2.5,HTS,METHYL_GOLGA5,METHYL,noncancer,GABA receptor antagonist,"GABBR1, GABBR2, SLC52A2",,,Preclinical,0.253418786664716,0.11344009045,NCS-382,,,0,0
BRD-A85216385-003-02-4::2.5::HTS,BRD-A85216385-003-02-4,3-alpha-bis-(4-fluorophenyl)-methoxytropane,2.5,HTS,PROT_Paxillin_Caution,PROT,noncancer,dopamine uptake inhibitor,"CHRM1, SLC6A2, SLC6A3, SLC6A4",,,Preclinical,0.29153350027326697,0.0703620630531,3-alpha-bis-(4-fluorophenyl)-methoxytropane,,,0,0
BRD-A85242401-001-12-3::2.5::HTS,BRD-A85242401-001-12-3,ascorbic-acid,2.5,HTS,PROT_HER2_pY1248_Caution,PROT,noncancer,antioxidant,"ALKBH2, ALKBH3, BBOX1, DBH, EGLN1, EGLN2, EGLN3, KDM5D, LCT, OGFOD1, OGFOD2, P3H1, P3H2, P3H3, P4HA1, P4HTM, PAM, PHYH, PLOD1, PLOD2, PLOD3, SLC23A1, SLC23A2, TMLHE",endocrinology,scurvy,Launched,0.243924863277325,0.0659623824881,ascorbic-acid,,,0,0
BRD-A85295731-001-06-4::2.500008824::MTS004,BRD-A85295731-001-06-4,tiopronin,2.500008824,MTS004,METABOL_2-deoxyadenosine,METABOL,noncancer,"chelating agent, reducing agent",,urology,kidney stones,Launched,0.30189040435724607,0.117144120447,tiopronin,,,0,0
BRD-A85472596-001-02-2::2.5::HTS,BRD-A85472596-001-02-2,L-670596,2.5,HTS,DEM2_KIF5B (3799),DEMETER2_COM,noncancer,prostanoid receptor antagonist,,,,Preclinical,0.282897694423614,0.0764830236531,L-670596,,,0,0
BRD-A85548292-001-01-8::2.5::HTS,BRD-A85548292-001-01-8,piketoprofen,2.5,HTS,CRISPR_OGFRL1 (79627),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,Launched,0.194419164510285,0.0571581379083,piketoprofen,,,0,0
BRD-A85587465-001-03-3::2.5::HTS,BRD-A85587465-001-03-3,bemesetron,2.5,HTS,METHYL_PIGT,METHYL,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B",,,Phase 3,0.28556701835482,0.0460212782667,bemesetron,,,0,0
BRD-A85651701-001-19-7::2.5::HTS,BRD-A85651701-001-19-7,clopamide,2.5,HTS,Exp_RNF222 (ENSG00000189051),GE,noncancer,sodium/chloride cotransporter inhibitor,,cardiology,hypertension,Launched,0.229299686256812,0.0854063536627,clopamide,,,0,0
BRD-A85667082-001-12-7::2.5::HTS,BRD-A85667082-001-12-7,fulvestrant,2.5,HTS,MIRNA_hsa-miR-551b,MIRNA,targeted cancer,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,Launched,0.32422661092918603,0.100816191203,fulvestrant,,,0,0
BRD-A85876464-001-01-5::2.5::HTS,BRD-A85876464-001-01-5,nibentan,2.5,HTS,CRISPR_CYP27A1 (1593),AVANA_PUBLIC_18Q2,noncancer,potassium channel blocker,,,,Phase 2,0.295324342920052,0.0458453943995,nibentan,,,0,0
BRD-A86044036-001-26-5::2.5::HTS,BRD-A86044036-001-26-5,flurbiprofen-(+/-),2.5,HTS,CN_KHDRBS3 (10656),CN,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.29096626027200895,0.11250362452,flurbiprofen-(+/-),,,0,0
BRD-A86216746-046-02-6::2.5::HTS,BRD-A86216746-046-02-6,varenicline,2.5,HTS,CRISPR_ZNF253 (56242),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNA6, CHRNA7",neurology/psychiatry,smoking cessation,Launched,0.27257781523527397,0.151120342487,varenicline,,,0,0
BRD-A86248581-001-01-4::2.5::HTS,BRD-A86248581-001-01-4,tetrahydrouridine,2.5,HTS,METABOL_C20:3 LPC,METABOL,targeted cancer,cytidine deaminase inhibitor,CDA,,,Phase 2,0.19161327964554298,0.0634936584145,tetrahydrouridine,,,0,0
BRD-A86354194-002-01-7::2.5::HTS,BRD-A86354194-002-01-7,L-(+)-Rhamnose-Monohydrate,2.5,HTS,RMUTmis_PRDM5 (11107),MUTmis,noncancer,,,,,Preclinical,0.28177566269663895,0.0368238216129,L-(+)-Rhamnose-Monohydrate,,,0,0
BRD-A86414188-003-01-5::2.5::HTS,BRD-A86414188-003-01-5,ractopamine,2.5,HTS,PROT_GSK3-alpha-beta,PROT,noncancer,adrenergic receptor agonist,,,,Launched,0.287694552207388,0.0854447614242,ractopamine,,,0,0
BRD-A86415025-050-01-0::2.5::HTS,BRD-A86415025-050-01-0,"1-(1,2-Diphenylethyl)piperidine-(+/-)",2.5,HTS,Exp_ZC3H12B (ENSG00000102053),GE,noncancer,glutamate receptor antagonist,,,,Preclinical,0.24230237251182501,0.0481356343764,"1-(1,2-Diphenylethyl)piperidine-(+/-)",,,0,0
BRD-A86619021-001-04-8::2.5::HTS,BRD-A86619021-001-04-8,andrographolide,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,tumor necrosis factor production inhibitor,NFKB1,,,Phase 2,0.33782508649216697,0.123245964655,andrographolide,OTHER,0.3378700553829307,0.4485964283873531,-3.893512169208916
BRD-A86665761-001-01-1::2.5::MTS004,BRD-A86665761-001-01-1,gabapentin-enacarbil,2.5,MTS004,PROT_VHL_Caution,PROT,noncancer,adrenergic receptor agonist,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8",neurology/psychiatry,"restless leg syndrome, postherpetic neuralgia",Launched,0.31232259044295,0.100031991016,gabapentin-enacarbil,,,0,0
BRD-A86871940-001-01-9::2.5::HTS,BRD-A86871940-001-01-9,nicaraven,2.5,HTS,CN_PCSK7 (9159),CN,noncancer,free radical scavenger,,,,Phase 3,0.26110134558746806,0.0530950662155,nicaraven,,,0,0
BRD-A87130939-001-07-9::2.5::HTS,BRD-A87130939-001-07-9,masoprocol,2.5,HTS,DEM2_BBX (56987),DEMETER2_COM,noncancer,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK),Launched,0.26681688775130397,0.0857996468423,masoprocol,,,0,0
BRD-A87435144-001-01-6::2.5::HTS,BRD-A87435144-001-01-6,AZD7545,2.5,HTS,CN_POLK (51426),CN,noncancer,pyruvate dehydrogenase kinase inhibitor,PDK1,,,Phase 1,0.30749620980627,0.129761113319,AZD7545,,,0,0
BRD-A87479750-001-02-7::2.5::HTS,BRD-A87479750-001-02-7,tenidap,2.5,HTS,CRISPR_KIAA1468 (57614),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"KCNJ4, PTGS1",,,Phase 3,0.26225537164003304,0.0954000191722,tenidap,,,0,0
BRD-A87673115-001-04-1::2.5::HTS,BRD-A87673115-001-04-1,moguisteine,2.5,HTS,Exp_ECM2 (ENSG00000106823),GE,noncancer,ATP-sensitive potassium channel inhibitor,,,,Phase 2,0.275341590723226,0.0660971498134,moguisteine,,,0,0
BRD-A87715314-003-14-4::2.5::HTS,BRD-A87715314-003-14-4,pronethalol,2.5,HTS,Exp_TAC3 (ENSG00000166863),GE,noncancer,adrenergic receptor antagonist,,,,Withdrawn,0.266735924914483,0.139759400832,pronethalol,,,0,0
BRD-A87983072-001-01-1::2.5::HTS,BRD-A87983072-001-01-1,benzotript,2.5,HTS,METHYL_TINAGL1,METHYL,noncancer,CCK receptor antagonist,"CCKAR, CCKBR",,,Phase 1,0.25022343686501,0.109086739815,benzotript,,,0,0
BRD-A88080608-001-04-2::2.5::HTS,BRD-A88080608-001-04-2,equilin,2.5,HTS,Exp_CRELD1 (ENSG00000163703),GE,noncancer,estrogen receptor agonist,HSD17B1,,,Preclinical,0.315929220447229,0.0591748986139,equilin,,,0,0
BRD-A88138582-001-04-8::2.5::HTS,BRD-A88138582-001-04-8,halcinonide,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.260581558217579,0.137338441879,halcinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2726816088208294,-1.7406042441211036,-2.90907220173186
BRD-A88254928-001-07-9::2.5::MTS004,BRD-A88254928-001-07-9,albuterol,2.5,MTS004,CRISPR_HABP2 (3026),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,asthma,Launched,0.227276335396178,0.130788542446,albuterol,,,0,0
BRD-A88369366-001-01-7::2.5::HTS,BRD-A88369366-001-01-7,trelagliptin,2.5,HTS,DEM2_TLK2 (11011),DEMETER2_COM,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.32649053787656895,0.0213180826557,trelagliptin,,,0,0
BRD-A88548664-004-02-7::2.5::HTS,BRD-A88548664-004-02-7,SKF-38393,2.5,HTS,MUTpool_ZNF229 (7772),MUTpool,noncancer,dopamine receptor agonist,"CALY, DRD1, DRD5",,,Preclinical,0.26138190555524,-0.0188422314185,SKF-38393,,,0,0
BRD-A88562598-001-01-7::2.500008795::MTS004,BRD-A88562598-001-01-7,degarelix,2.500008795,MTS004,MIRNA_ebv-miR-BART20-3p,MIRNA,targeted cancer,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer,Launched,0.305148167492315,0.0531110129869,degarelix,,,0,0
BRD-A88684804-001-04-3::2.5::HTS,BRD-A88684804-001-04-3,bucetin,2.5,HTS,METABOL_inositol,METABOL,noncancer,analgesic agent,,,,Withdrawn,0.270190087278373,0.132375636107,bucetin,,,0,0
BRD-A89082344-001-08-7::2.500026693::MTS004,BRD-A89082344-001-08-7,perifosine,2.500026693,MTS004,RMUThot_KRAS (3845),MUThot,targeted cancer,AKT inhibitor,AKT1,,,Phase 3,0.190429363189965,0.1633092204,perifosine,AKT INHIBITOR,0.21900427069592135,4.8178230361778684,1.7689863545946776
BRD-A89164055-001-03-3::2.5::HTS,BRD-A89164055-001-03-3,sorbinil,2.5,HTS,METHYL_DDX39A,METHYL,noncancer,aldose reductase inhibitor,AKR1B1,,,Phase 3,0.274313616848886,0.0438644441595,sorbinil,,,0,0
BRD-A89175223-051-14-8::2.5::HTS,BRD-A89175223-051-14-8,bisoprolol,2.5,HTS,CRISPR_QTRTD1 (79691),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,hypertension,Launched,0.284293522087541,0.103827293662,bisoprolol,,,0,0
BRD-A89196962-300-01-7::2.5::HTS,BRD-A89196962-300-01-7,dalargin,2.5,HTS,DEM2_ICOSLG (23308),DEMETER2_COM,noncancer,opioid receptor agonist,OPRM1,,,Phase 2,0.284667836518054,-0.0196252874696,dalargin,,,0,0
BRD-A89207210-001-01-6::2.378054241::MTS004,BRD-A89207210-001-01-6,terguride,2.378054241,MTS004,DEM2_ACYP2 (98),DEMETER2_COM,noncancer,"dopamine receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,Launched,0.29803968274660403,0.109160060608,terguride,,,0,0
BRD-A89337244-001-02-9::2.5::HTS,BRD-A89337244-001-02-9,PD-102807,2.5,HTS,RMUTmis_DZIP1 (22873),MUT,noncancer,acetylcholine receptor antagonist,CHRM4,,,Preclinical,0.292606434490722,0.0247642926982,PD-102807,,,0,0
BRD-A89585551-003-16-6::2.5::HTS,BRD-A89585551-003-16-6,mefloquine,2.5,HTS,PROT_PREX1,PROT,noncancer,"adenosine receptor antagonist, hemoglobin antagonist","ADORA2A, HBA1",infectious disease,malaria,Launched,0.241067850098018,0.0722093889212,mefloquine,,,0,0
BRD-A89594340-003-11-5::2.5::HTS,BRD-A89594340-003-11-5,carnitine-(D/L),2.5,HTS,Exp_ACOX2 (ENSG00000168306),GE,noncancer,,,,,Phase 3,0.24729773826569895,0.0839691189145,carnitine-(D/L),,,0,0
BRD-A89672324-001-03-0::2.5::HTS,BRD-A89672324-001-03-0,CGP-55845,2.5,HTS,PROT_GSK3-alpha-beta,PROT,noncancer,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,Preclinical,0.31447968684996097,0.0935015104235,CGP-55845,,,0,0
BRD-A90272038-001-01-7::2.5::HTS,BRD-A90272038-001-01-7,CGP-37849,2.5,HTS,RMUTmis_ZIC3 (7547),MUT,noncancer,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Phase 1,0.20041630128248103,-0.0187671124131,CGP-37849,,,0,0
BRD-A90515964-001-16-5::2.5::HTS,BRD-A90515964-001-16-5,guaifenesin,2.5,HTS,METABOL_C48:3 TAG,METABOL,noncancer,expectorant,,pulmonary,cough suppressant,Launched,0.288251317185557,0.0563836277858,guaifenesin,,,0,0
BRD-A90547603-001-02-5::2.5::HTS,BRD-A90547603-001-02-5,eptifibatide,2.5,HTS,Exp_ZNF449 (ENSG00000173275),GE,noncancer,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",Launched,0.25116386856760897,0.0541960885401,eptifibatide,,,0,0
BRD-A90551241-001-10-8::2.5::HTS,BRD-A90551241-001-10-8,lornoxicam,2.5,HTS,METHYL_LMAN2,METHYL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, neurology/psychiatry","osteoarthritis, sciata",Launched,0.26953288229742395,0.0166983764548,lornoxicam,,,0,0
BRD-A90625545-001-02-0::2.5::HTS,BRD-A90625545-001-02-0,clinofibrate,2.5,HTS,PROT_Collagen_VI,PROT,noncancer,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia,Launched,0.185449823346692,0.0662630276435,clinofibrate,,,0,0
BRD-A90695733-001-07-4::2.5::HTS,BRD-A90695733-001-07-4,manidipine,2.5,HTS,METHYL_MIR3650,METHYL,noncancer,calcium channel blocker,"CACNA1C, CACNA1D",cardiology,hypertension,Launched,0.252749677844176,0.0783675640786,manidipine,,,0,0
BRD-A90799790-001-19-9::2.5::HTS,BRD-A90799790-001-19-9,isradipine,2.5,HTS,CN_MIR3977 (100616297),CN,noncancer,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2",cardiology,hypertension,Launched,0.212088728290522,0.00116683221035,isradipine,,,0,0
BRD-A90926615-001-01-9::2.5::HTS,BRD-A90926615-001-01-9,adrafinil,2.5,HTS,METABOL_palmitoylcarnitine,METABOL,noncancer,adrenergic receptor agonist,,neurology/psychiatry,fatigue,Launched,0.27875917273881395,0.0794522957495,adrafinil,,,0,0
BRD-A91008255-003-24-8::2.5::HTS,BRD-A91008255-003-24-8,bepridil,2.5,HTS,PROT_Stathmin,PROT,noncancer,calcium channel blocker,"ATP1A1, CACNA1A, CACNA1H, CACNA2D2, CALM1, KCNQ1, KCNQ4, PDE1A, PDE1B, TNNC1",cardiology,angina pectoris,Launched,0.293857358137678,0.163306235542,bepridil,,,0,0
BRD-A91366704-001-01-9::2.5::HTS,BRD-A91366704-001-01-9,eprinomectin,2.5,HTS,PROT_PRDX1,PROT,noncancer,benzodiazepine receptor agonist,,infectious disease,"gastrointestinal roundworms, lungworms",Launched,0.294453496742563,0.0871273770479,eprinomectin,,,0,0
BRD-A91444184-300-01-9::2.5::MTS004,BRD-A91444184-300-01-9,buclizine,2.5,MTS004,CRISPR_H3F3A (3020),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,"CHRM1, HRH1",neurology/psychiatry,migraine headache,Launched,0.232215686733132,0.0210537438337,buclizine,,,0,0
BRD-A91452556-001-04-0::2.5::HTS,BRD-A91452556-001-04-0,estradiol-cypionate,2.5,HTS,PROT_Gab2,PROT,noncancer,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",Launched,0.27891816214577003,0.119439305895,estradiol-cypionate,,,0,0
BRD-A91699651-316-10-9::2.5::HTS,BRD-A91699651-316-10-9,chloroquine,2.5,HTS,MIRNA_hsa-miR-137,MIRNA,noncancer,antimalarial agent,"GSTA2, MRGPRX1, TLR9, TNF",infectious disease,"malaria, amebiasis",Launched,0.281473035474752,0.132757203196,chloroquine,,,0,0
BRD-A91728607-236-11-9::2.5::MTS004,BRD-A91728607-236-11-9,citicoline,2.5,MTS004,CRISPR_MSL2 (55167),AVANA_PUBLIC_18Q2,noncancer,"membrane permeability enhancer, glutathione transferase stimulant","ACHE, SLC1A2","neurology/psychiatry, ophthalmology","stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma",Launched,0.315990808138269,0.0654235753152,citicoline,,,0,0
BRD-A91733352-300-04-5::2.5::HTS,BRD-A91733352-300-04-5,camylofine-chlorhydrate,2.5,HTS,METABOL_C58:6 TAG,METABOL,noncancer,,,gastroenterology,abdominal pain,Launched,0.268103729085752,0.046483023388,camylofine-chlorhydrate,,,0,0
BRD-A91822151-001-05-0::2.5::HTS,BRD-A91822151-001-05-0,picrotin,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,GABA receptor antagonist,"GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB",,,Phase 2,0.374486786799187,0.0532187978127,picrotin,,,0,0
BRD-A91831168-003-02-5::2.5::HTS,BRD-A91831168-003-02-5,tetrahydropapaverine,2.5,HTS,DEM2_TGFB2 (7042),DEMETER2_COM,noncancer,,,,,Preclinical,0.28061259409124395,0.12513252006,tetrahydropapaverine,,,0,0
BRD-A92096630-001-02-8::2.5::HTS,BRD-A92096630-001-02-8,shikimic-acid,2.5,HTS,Exp_S100Z (ENSG00000171643),GE,noncancer,,,,,Preclinical,0.263141358494954,-0.0131102545956,shikimic-acid,,,0,0
BRD-A92177080-001-02-1::2.5::MTS004,BRD-A92177080-001-02-1,betamethasone-acetate,2.5,MTS004,CRISPR_LGR4 (55366),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.30055078212035996,0.035615938558,betamethasone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.3092618822892069,2.2144882201421794,4.612779046450769
BRD-A92262698-001-02-5::2.5::MTS004,BRD-A92262698-001-02-5,chlorphenesin,2.5,MTS004,CN_XPOT (11260),CN,noncancer,muscle relaxant,,neurology/psychiatry,"muscle relaxant, sedative",Launched,0.24076423260944396,0.0514536079837,chlorphenesin,,,0,0
BRD-A92341659-001-04-0::2.499993321::MTS004,BRD-A92341659-001-04-0,prulifloxacin,2.499993321,MTS004,METHYL_LOC100132735,METHYL,noncancer,bacterial DNA gyrase inhibitor,,"infectious disease, pulmonary, gastroenterology","urinary tract infections, bronchitis, diarrhea",Launched,0.34332050315716806,0.0922950845728,prulifloxacin,,,0,0
BRD-A92439610-001-05-7::2.5::HTS,BRD-A92439610-001-05-7,triamcinolone-acetonide,2.5,HTS,Exp_ZNF738 (ENSG00000172687),GE,noncancer,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.26241012502140804,0.116154610103,triamcinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2598257683931729,-2.731376049909671,-3.257181662183739
BRD-A92537424-001-04-7::2.5::HTS,BRD-A92537424-001-04-7,danazol,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",Launched,0.26946413143404896,0.202388169875,danazol,,,0,0
BRD-A92630576-050-24-1::2.5::HTS,BRD-A92630576-050-24-1,trimebutine,2.5,HTS,METABOL_C32:0 PC,METABOL,noncancer,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,Launched,0.28948078791763,0.0657375571191,trimebutine,,,0,0
BRD-A92670106-003-05-4::2.5::HTS,BRD-A92670106-003-05-4,tocainide,2.5,HTS,MIRNA_hsa-miR-509-5p,MIRNA,noncancer,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,Launched,0.28585910391225106,0.0643546472835,tocainide,,,0,0
BRD-A92800748-001-05-5::2.5::HTS,BRD-A92800748-001-05-5,tie2-kinase-inhibitor,2.5,HTS,Exp_SOST (ENSG00000167941),GE,targeted cancer,TIE tyrosine kinase inhibitor,"KDR, MAPK14",,,Preclinical,0.29654029760519895,0.0973483053992,tie2-kinase-inhibitor,,,0,0
BRD-A92826379-001-01-5::2.5::HTS,BRD-A92826379-001-01-5,lupanine,2.5,HTS,METABOL_NADP,METABOL,noncancer,sodium channel blocker,INS,,,Phase 1,0.28680990395163203,0.0185570944034,lupanine,,,0,0
BRD-A92872453-001-01-8::2.5::HTS,BRD-A92872453-001-01-8,N-acetylmannosamine,2.5,HTS,METHYL_ZC3H12D,METHYL,noncancer,,CHIT1,,,Phase 1,0.248953282891158,0.0574908306924,N-acetylmannosamine,,,0,0
BRD-A92933783-050-01-6::2.5::HTS,BRD-A92933783-050-01-6,SM-21,2.5,HTS,DEM2_TTC21A (199223),DEMETER2_COM,noncancer,sigma receptor antagonist,PGRMC1,,,Preclinical,0.29243113307808305,0.0629114095639,SM-21,,,0,0
BRD-A93000692-001-08-1::2.5::HTS,BRD-A93000692-001-08-1,ciglitazone,2.5,HTS,MIRNA_hsa-miR-324-5p,MIRNA,noncancer,PPAR receptor agonist,PPARG,,,Phase 2,0.238341280475993,0.0797701911881,ciglitazone,,,0,0
BRD-A93093700-001-02-9::2.5::HTS,BRD-A93093700-001-02-9,temazepam,2.5,HTS,PROT_MDMX_MDM4(BetIHC-00108)_Caution,PROT,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",,,Withdrawn,0.3600011123810671,0.114489693342,temazepam,OTHER,0.3585079249221297,4.224905136481254,-1.2836122566239485
BRD-A93353767-008-02-2::2.5::HTS,BRD-A93353767-008-02-2,isoconazole,2.5,HTS,METHYL_ULK4P3,METHYL,noncancer,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections,Launched,0.295874425340921,0.116290991597,isoconazole,,,0,0
BRD-A93407926-001-01-1::2.5::HTS,BRD-A93407926-001-01-1,allopurinol-riboside,2.5,HTS,RMUTmis_MADD (8567),MUT,noncancer,anti-leishmanial agent,,,,Phase 2,0.206377114064222,0.0551833593713,allopurinol-riboside,,,0,0
BRD-A93477898-001-04-2::2.5::HTS,BRD-A93477898-001-04-2,PETCM,2.5,HTS,CRISPR_URM1 (81605),AVANA_PUBLIC_18Q2,noncancer,caspase activator,CASP3,,,Preclinical,0.31942541827113696,0.114923944638,PETCM,,,0,0
BRD-A93683007-001-01-9::2.5::MTS004,BRD-A93683007-001-01-9,mabuprofen,2.5,MTS004,DEM2_APC (324),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,Launched,0.352414648920724,0.147556004808,mabuprofen,,,0,0
BRD-A93695607-322-02-5::2.47::HTS,BRD-A93695607-322-02-5,nicotine,2.47,HTS,RMUTmis_MYH7B (57644),MUTmis,noncancer,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,Launched,0.243561001339445,0.0959370705886,nicotine,,,0,0
BRD-A93699261-236-03-4::2.5::HTS,BRD-A93699261-236-03-4,sodium-danshensu,2.5,HTS,PROT_c-Met_pY1235,PROT,noncancer,,,,,Preclinical,0.292426233171129,0.016951968881,sodium-danshensu,,,0,0
BRD-A93964801-003-03-3::2.5::HTS,BRD-A93964801-003-03-3,clinafloxacin,2.5,HTS,METHYL_C1orf140,METHYL,noncancer,bacterial DNA gyrase inhibitor,,,,Phase 3,0.340753764513596,0.0603477941855,clinafloxacin,,,0,0
BRD-A94008949-001-01-9::2.5::HTS,BRD-A94008949-001-01-9,telithromycin,2.5,HTS,MIRNA_hsa-miR-718,MIRNA,noncancer,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7",infectious disease,pneumonia,Launched,0.259196375203464,0.0670834395157,telithromycin,,,0,0
BRD-A94033181-001-01-4::2.5::HTS,BRD-A94033181-001-01-4,AZD6765,2.5,HTS,METHYL_RCSD1,METHYL,noncancer,glutamate receptor antagonist,GRIN1,,,Phase 2,0.27428832147333604,0.167347474867,AZD6765,,,0,0
BRD-A94276798-001-01-4::2.5::HTS,BRD-A94276798-001-01-4,talinolol,2.5,HTS,Exp_PTPRD (ENSG00000153707),GE,noncancer,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,Launched,0.31266425602120196,0.105980963441,talinolol,,,0,0
BRD-A94323479-001-02-8::2.5::HTS,BRD-A94323479-001-02-8,ki16198,2.5,HTS,DEM2_ASB13 (79754),DEMETER2_COM,targeted cancer,lipoprotein antagonist,LPA,,,Preclinical,0.22114834828315696,0.0987218185008,ki16198,,,0,0
BRD-A94523291-304-02-7::2.5::HTS,BRD-A94523291-304-02-7,prednisolone-sodium-phosphate,2.5,HTS,CRISPR_KCNK13 (56659),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,"allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, asthma, meningitis, psoriatic arthritis, rheumatoid arthritis",Launched,0.267308155787252,0.0987601665087,prednisolone-sodium-phosphate,GLUCOCORTICOID RECEPTOR AGONIST,0.26501982067357444,-4.038814817705432,-2.9017224721044013
BRD-A94543220-001-24-7::2.5::HTS,BRD-A94543220-001-24-7,bifonazole,2.5,HTS,CRISPR_SCP2 (6342),AVANA_PUBLIC_18Q2,noncancer,sterol demethylase inhibitor,CYP2B6,infectious disease,"tinea pedis, tinea cruris",Launched,0.24759226653178,0.062596608258,bifonazole,,,0,0
BRD-A94624445-236-17-0::2.5::HTS,BRD-A94624445-236-17-0,bucladesine,2.5,HTS,CN_ASXL1 (171023),CN,noncancer,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,Launched,0.27674214379781603,0.0883488206738,bucladesine,,,0,0
BRD-A94709349-001-08-3::2.5::HTS,BRD-A94709349-001-08-3,metaxalone,2.5,HTS,PROT_MAPK_pT202_Y204,PROT,noncancer,muscle relaxant,,neurology/psychiatry,muscle pain,Launched,0.296114244126217,0.0920308995646,metaxalone,,,0,0
BRD-A94993966-001-04-4::2.5::HTS,BRD-A94993966-001-04-4,vildagliptin,2.5,HTS,RMUTmis_DNAH3 (55567),MUTmis,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.28020600650083805,0.044142569111,vildagliptin,,,0,0
BRD-A94993966-001-05-1::2.63::HTS,BRD-A94993966-001-05-1,vildagliptin,2.63,HTS,METHYL_ACVR2B-AS1,METHYL,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.252427305450464,0.167048923773,vildagliptin,,,0,0
BRD-A95121829-001-08-9::2.5::HTS,BRD-A95121829-001-08-9,ginkgolide-a,2.5,HTS,PROT_B-Raf_pS445,PROT,noncancer,GABA receptor antagonist,"GLRA1, GLRB",,,Preclinical,0.265683411695393,0.0674880291336,ginkgolide-a,,,0,0
BRD-A95340155-001-09-7::2.5::HTS,BRD-A95340155-001-09-7,methyclothiazide,2.5,HTS,DEM2_NKX2-1 (7080),DEMETER2_COM,noncancer,chloride reabsorption inhibitor,"CA1, CA2, CA4, SLC12A1, SLC12A3",cardiology,"hypertension, edema",Launched,0.226308314105619,0.0834694461644,methyclothiazide,,,0,0
BRD-A95602221-003-02-1::2.5::HTS,BRD-A95602221-003-02-1,celiprolol,2.5,HTS,RMUTdmg_PTEN (5728),MUTdmg,noncancer,adrenergic receptor antagonist,"ADRA2A, ADRB1, ADRB2",genetics,Ehlers-Danlos syndrome (EDS),Launched,0.228856721985775,0.0779121128047,celiprolol,,,0,0
BRD-A95696066-003-13-8::2.5::HTS,BRD-A95696066-003-13-8,nisoxetine,2.5,HTS,RMUTdmg_MACF1 (23499),MUTdmg,noncancer,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,Phase 1,0.29709729799159,0.0810811867265,nisoxetine,,,0,0
BRD-A95755460-001-01-3::2.5::HTS,BRD-A95755460-001-01-3,talarozole,2.5,HTS,RMUTmis_DNAH8 (1769),MUTmis,noncancer,cytochrome P450 inhibitor,CYP26A1,,,Phase 2,0.287793767056062,0.0239963978374,talarozole,,,0,0
BRD-A95869247-001-26-9::2.5::HTS,BRD-A95869247-001-26-9,indapamide,2.5,HTS,CRISPR_GRAMD1B (57476),AVANA_PUBLIC_18Q2,noncancer,thiazide diuretic,"KCNE1, KCNQ1, SLC12A3",cardiology,"hypertension, congestive heart failure",Launched,0.33174262562333195,0.113260824371,indapamide,,,0,0
BRD-A95886749-001-03-5::2.5::HTS,BRD-A95886749-001-03-5,colfosceril-palmitate,2.5,HTS,PROT_CD31,PROT,noncancer,pulmonary surfactant,,pulmonary,respiratory distress syndrome (RDS),Launched,0.17240272752932098,0.0385227400664,colfosceril-palmitate,,,0,0
BRD-A95939040-001-01-2::2.5::HTS,BRD-A95939040-001-01-2,sertaconazole,2.5,HTS,DEM2_BRD1 (23774),DEMETER2_COM,noncancer,sterol demethylase inhibitor,,infectious disease,tinea pedis,Launched,0.25634503095485,0.0380795353272,sertaconazole,,,0,0
BRD-A96292436-003-16-1::2.5::HTS,BRD-A96292436-003-16-1,eflornithine,2.5,HTS,METHYL_MLLT4-AS1,METHYL,noncancer,ornithine decarboxylase inhibitor,"ARG2, ODC1",dermatology,facial hair reduction,Launched,0.22927675256355498,0.104065959911,eflornithine,,,0,0
BRD-A96407378-001-15-1::2.5::HTS,BRD-A96407378-001-15-1,allantoin,2.5,HTS,DEM2_PDXK (8566),DEMETER2_COM,noncancer,cosmetic,,dermatology,skin protectant,Launched,0.22902005029719602,0.0251989888345,allantoin,,,0,0
BRD-A96456596-001-02-2::2.5::HTS,BRD-A96456596-001-02-2,FPL-55712,2.5,HTS,METHYL_TNPO2,METHYL,noncancer,leukotriene receptor antagonist,,,,Phase 1,0.223275053340931,0.043247547633,FPL-55712,,,0,0
BRD-A96466199-001-01-4::2.442131966::MTS004,BRD-A96466199-001-01-4,nuclomedone,2.442131966,MTS004,RMUTmis_PTCHD1 (139411),MUTmis,noncancer,immunosuppressant,,,,Phase 3,0.318677487968478,0.0932180845302,nuclomedone,,,0,0
BRD-A96485169-001-14-3::2.5::HTS,BRD-A96485169-001-14-3,EBPC,2.5,HTS,DEM2_LRFN1 (57622),DEMETER2_COM,noncancer,aldose reductase inhibitor,AKR1B1,,,Preclinical,0.224490022137177,0.0064846022248,EBPC,,,0,0
BRD-A96529864-001-01-3::2.5::HTS,BRD-A96529864-001-01-3,isosteviol,2.5,HTS,METABOL_C34:4 PC,METABOL,noncancer,,,,,Phase 2,0.313652859119872,0.0102725927952,isosteviol,,,0,0
BRD-A96977263-001-03-7::2.5::HTS,BRD-A96977263-001-03-7,M-14157,2.5,HTS,RMUTdmg_ERMAP (114625),MUTdmg,noncancer,ATP-sensitive potassium channel antagonist,KCNQ1,,,Phase 2,0.297919510794573,0.0829198247267,M-14157,,,0,0
BRD-A97104540-004-15-0::2.5::HTS,BRD-A97104540-004-15-0,fenoterol,2.5,HTS,PROT_eIF4E,PROT,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,Withdrawn,0.32610734788379103,0.123747197885,fenoterol,,,0,0
BRD-A97437073-050-14-5::2.5::HTS,BRD-A97437073-050-14-5,rosiglitazone,2.5,HTS,MIRNA_hsa-miR-561,MIRNA,noncancer,"insulin sensitizer, PPAR receptor agonist","ACSL4, FFAR1, PPARG, TRPC5, TRPM3",,,Withdrawn,0.274022920967287,0.115997790282,rosiglitazone,,,0,0
BRD-A97479839-003-13-3::2.5::HTS,BRD-A97479839-003-13-3,piperidolate,2.5,HTS,DEM2_ARFRP1 (10139),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms,Launched,0.28786346996236606,0.0647373572551,piperidolate,,,0,0
BRD-A97674275-001-11-8::2.5::HTS,BRD-A97674275-001-11-8,ranolazine,2.5,HTS,METABOL_glucose,METABOL,noncancer,sodium channel blocker,"SCN10A, SCN4A, SCN5A, SCN9A",cardiology,chronic stable angina,Launched,0.338424114658433,0.104576667203,ranolazine,,,0,0
BRD-A97701745-001-16-0::2.5::HTS,BRD-A97701745-001-16-0,pindolol,2.5,HTS,CRISPR_CHEK2 (11200),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,Launched,0.30042386993673803,0.128043200198,pindolol,,,0,0
BRD-A97730597-003-11-5::2.5::HTS,BRD-A97730597-003-11-5,hexylcaine,2.5,HTS,METABOL_C38:2 PC,METABOL,noncancer,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,local anesthetic,Launched,0.244632970856021,0.0313383042911,hexylcaine,,,0,0
BRD-A98174560-001-02-1::2.5::HTS,BRD-A98174560-001-02-1,chloralose,2.5,HTS,METHYL_LSM10,METHYL,noncancer,,,,,Preclinical,0.288376665587487,0.0965180060383,chloralose,,,0,0
BRD-A98299281-050-09-6::2.5::HTS,BRD-A98299281-050-09-6,"hydroxytacrine-maleate-(r,s)",2.5,HTS,DEM2_C6orf136 (221545),DEMETER2_COM,noncancer,cholinesterase inhibitor,ACHE,,,Preclinical,0.31732997299674,0.118985805516,"hydroxytacrine-maleate-(r,s)",,,0,0
BRD-A98378129-001-02-2::2.5::HTS,BRD-A98378129-001-02-2,talniflumate,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief,Launched,0.318454275145219,0.0958135043195,talniflumate,,,0,0
BRD-A98845662-036-03-7::2.5::HTS,BRD-A98845662-036-03-7,desvenlafaxine,2.5,HTS,PROT_Tuberin_pT1462,PROT,noncancer,serotonin-norepinephrine reuptake inhibitor (SNRI),"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.272729817068361,0.0836239952779,desvenlafaxine,,,0,0
BRD-A98990573-003-01-3::2.5::HTS,BRD-A98990573-003-01-3,epinastine,2.5,HTS,Exp_CNN2 (ENSG00000064666),GE,noncancer,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,Launched,0.27532856631165803,0.0464857016689,epinastine,,,0,0
BRD-A99117172-065-04-0::2.5::HTS,BRD-A99117172-065-04-0,hydroxychloroquine,2.5,HTS,METABOL_C48:2 TAG,METABOL,noncancer,antimalarial agent,"TLR7, TLR9",infectious disease,malaria,Launched,0.274852477923843,0.049036815554,hydroxychloroquine,,,0,0
BRD-A99388803-001-01-5::2.5::HTS,BRD-A99388803-001-01-5,metipranolol,2.5,HTS,DEM2_SSX1 (6756),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",,,Withdrawn,0.302824393639644,0.0952532618392,metipranolol,,,0,0
BRD-A99633051-001-07-0::2.5::HTS,BRD-A99633051-001-07-0,ethosuximide,2.5,HTS,METHYL_MYADML2,METHYL,noncancer,succinimide antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,epilepsy,Launched,0.268266109779078,0.0722202049247,ethosuximide,,,0,0
BRD-A99833829-003-27-1::2.5::HTS,BRD-A99833829-003-27-1,bethanechol,2.5,HTS,DEM2_SPTBN1 (6711),DEMETER2_COM,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",urology,urinary retention,Launched,0.28502016125700796,0.0867046586398,bethanechol,,,0,0
BRD-A99888680-001-04-6::2.5::HTS,BRD-A99888680-001-04-6,paliperidone,2.5,HTS,MIRNA_hsa-miR-9,MIRNA,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,Launched,0.286160527346938,0.0525562241825,paliperidone,,,0,0
BRD-A99899486-004-01-9::2.293696319::MTS004,BRD-A99899486-004-01-9,cimetropium,2.293696319,MTS004,Exp_ZDHHC3 (ENSG00000163812),GE,noncancer,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,Launched,0.279022461970999,0.0994992808104,cimetropium,,,0,0
BRD-A99939097-001-24-2::2.5::HTS,BRD-A99939097-001-24-2,carisoprodol,2.5,HTS,METABOL_uracil,METABOL,noncancer,acetylcholine receptor antagonist,CYP2C19,neurology/psychiatry,muscle relaxant,Launched,0.259849411198675,0.0540411201459,carisoprodol,,,0,0
BRD-K00077635-304-01-2::2.5::HTS,BRD-K00077635-304-01-2,estramustine-phosphate,2.5,HTS,DEM2_MAT1A (4143),DEMETER2_COM,chemo,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,Launched,0.292991837151153,0.00303281368118,estramustine-phosphate,,,0,0
BRD-K00091711-001-01-2::2.5::HTS,BRD-K00091711-001-01-2,RWJ-21757,2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,toll-like receptor agonist,TLR7,,,Phase 1,0.246345681402167,0.00823264473513,RWJ-21757,,,0,0
BRD-K00259736-001-16-4::2.5::HTS,BRD-K00259736-001-16-4,colchicine,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,noncancer,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever",Launched,0.42158284991051703,0.343206751193,colchicine,OTHER,0.4219535502522243,5.802952878740113,-2.4442728828490976
BRD-K00312224-001-09-5::2.5::HTS,BRD-K00312224-001-09-5,PPT,2.5,HTS,Exp_IGSF22 (ENSG00000179057),GE,noncancer,estrogen receptor agonist,ESR1,,,Preclinical,0.272501531491844,0.122591442056,PPT,,,0,0
BRD-K00317371-001-06-1::2.4::HTS,BRD-K00317371-001-06-1,RITA,2.4,HTS,Exp_SULT1A1 (ENSG00000196502),GE,targeted cancer,MDM inhibitor,MDM2,,,Preclinical,0.482510433982741,0.53822052441,RITA,MDM INHIBITOR,0.481484150573667,4.346613295519049,-0.5283717008040485
BRD-K00337317-001-06-6::2.5::HTS,BRD-K00337317-001-06-6,NU-7441,2.5,HTS,DEM2_GABARAP (11337),DEMETER2_COM,targeted cancer,DNA dependent protein kinase inhibitor,PRKDC,,,Preclinical,0.31788052907100295,0.0486830039204,NU-7441,OTHER,0.33120153278735154,0.8738656443530392,-1.3646249517524778
BRD-K00405906-001-01-9::2.5::HTS,BRD-K00405906-001-01-9,phloroglucin,2.5,HTS,CRISPR_PAX9 (5083),AVANA_PUBLIC_18Q2,noncancer,,,,,Launched,0.20935036911459803,-0.0390387096623,phloroglucin,,,0,0
BRD-K00486786-001-02-2::2.5::HTS,BRD-K00486786-001-02-2,Ro-08-2750,2.5,HTS,DEM2_ARHGAP1 (392),DEMETER2_COM,targeted cancer,,NGF,,,Preclinical,0.256223725598638,0.0553690175044,Ro-08-2750,,,0,0
BRD-K00494077-066-01-9::2.5::HTS,BRD-K00494077-066-01-9,trovafloxacin,2.5,HTS,Exp_CHD4 (ENSG00000111642),GE,noncancer,bacterial DNA gyrase inhibitor,TOP2A,,,Withdrawn,0.168943707483948,0.154534315175,trovafloxacin,OTHER,0.1692810022745765,5.952380982710443,-2.2373062122547593
BRD-K00519864-341-03-3::2.39::HTS,BRD-K00519864-341-03-3,peramivir,2.39,HTS,CRISPR_LRP10 (26020),AVANA_PUBLIC_18Q2,noncancer,neuraminidase inhibitor,,infectious disease,influenza A virus infection,Launched,0.258016166006304,0.0456447767425,peramivir,,,0,0
BRD-K00521308-019-01-9::2.5::HTS,BRD-K00521308-019-01-9,ATN-161,2.5,HTS,DEM2_LSAMP (4045),DEMETER2_COM,targeted cancer,integrin antagonist,"ITGA5, ITGAV, ITGB1, ITGB3",,,Phase 2,0.30178077155474203,0.155033113131,ATN-161,,,0,0
BRD-K00531707-001-01-3::2.608376789::MTS004,BRD-K00531707-001-01-3,cinepazet,2.608376789,MTS004,Exp_CTDSP1 (ENSG00000144579),GE,noncancer,vasodilator,,,,Launched,0.260928044682962,0.114381938911,cinepazet,,,0,0
BRD-K00535541-001-05-5::2.5::HTS,BRD-K00535541-001-05-5,9-aminoacridine,2.5,HTS,Exp_NCAM1 (ENSG00000149294),GE,targeted cancer,,,,,Preclinical,0.234902473978447,0.249157675849,9-aminoacridine,OTHER,0.23469635012399406,4.087214726535483,-2.2385949178372826
BRD-K00535541-001-06-3::2.5::HTS,BRD-K00535541-001-06-3,9-aminoacridine,2.5,HTS,Exp_RAB34 (ENSG00000109113),GE,targeted cancer,,,,,Preclinical,0.234902473978447,0.249157675849,9-aminoacridine,OTHER,0.3224184335295563,4.397975443641274,-1.713675944202615
BRD-K00573984-003-01-5::2.5::HTS,BRD-K00573984-003-01-5,delapril,2.5,HTS,CN_PCDH15 (65217),CN,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,Launched,0.226681708328518,0.103940180728,delapril,,,0,0
BRD-K00610438-003-02-5::2.5::HTS,BRD-K00610438-003-02-5,altanserin,2.5,HTS,METHYL_ZNF335,METHYL,noncancer,serotonin receptor antagonist,HTR2A,,,Phase 2,0.21512270924789897,0.0390761344086,altanserin,,,0,0
BRD-K00615600-001-12-9::2.5::HTS,BRD-K00615600-001-12-9,AG-14361,2.5,HTS,CRISPR_DMXL2 (23312),AVANA_PUBLIC_18Q2,targeted cancer,PARP inhibitor,PARP1,,,Preclinical,0.327893169892989,0.16530097783,AG-14361,,,0,0
BRD-K00627859-003-03-7::2.5::HTS,BRD-K00627859-003-03-7,tubastatin-a,2.5,HTS,METHYL_LINC00242,METHYL,targeted cancer,HDAC inhibitor,HDAC6,,,Preclinical,0.310470717054294,0.160675839337,tubastatin-a,,,0,0
BRD-K00634421-001-01-0::2.500042819::MTS004,BRD-K00634421-001-01-0,brivaracetam,2.500042819,MTS004,Exp_ABCB1 (ENSG00000085563),GE,noncancer,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,Launched,0.323872047859926,0.465960524775,brivaracetam,OTHER,0.3296973809765913,5.376514918336286,-3.662398854983669
BRD-K00662280-001-09-4::2.5::HTS,BRD-K00662280-001-09-4,CL-218872,2.5,HTS,MUTpool_ZNF442 (79973),MUTpool,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",,,Phase 1,0.239116554652452,0.0947444749343,CL-218872,,,0,0
BRD-K00673382-001-18-9::2.5::HTS,BRD-K00673382-001-18-9,famotidine,2.5,HTS,METABOL_inosine,METABOL,noncancer,histamine receptor antagonist,HRH2,gastroenterology,heartburn,Launched,0.251573771945973,0.0701582038288,famotidine,,,0,0
BRD-K00674894-001-01-4::2.5::HTS,BRD-K00674894-001-01-4,orteronel,2.5,HTS,MIRNA_hsa-miR-584,MIRNA,targeted cancer,"androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor",CYP17A1,,,Phase 3,0.29467702496436,0.0562255545739,orteronel,,,0,0
BRD-K00739965-001-01-9::2.675904798::MTS004,BRD-K00739965-001-01-9,guacetisal,2.675904798,MTS004,METABOL_C36:2 PC,METABOL,noncancer,immunosuppressant,,,,Launched,0.22322144281991396,0.106161187005,guacetisal,,,0,0
BRD-K00911143-001-01-9::2.5::HTS,BRD-K00911143-001-01-9,brexpiprazole,2.5,HTS,MIRNA_hsa-miR-939,MIRNA,noncancer,dopamine receptor partial agonist,DRD2,neurology/psychiatry,"depression, schizophrenia",Launched,0.255480641971341,0.0542071927041,brexpiprazole,,,0,0
BRD-K00911807-003-01-2::2.5::HTS,BRD-K00911807-003-01-2,D-Phenylalanine,2.5,HTS,DEM2_EFEMP2 (30008),DEMETER2_COM,noncancer,enkephalinase inhibitor,"CCBL1, CRH, HCAR3",,,Preclinical,0.275279383724445,0.138218525189,D-Phenylalanine,,,0,0
BRD-K00938507-001-17-8::2.5::HTS,BRD-K00938507-001-17-8,sulfamethoxypyridazine,2.5,HTS,METHYL_GUCY2GP,METHYL,noncancer,bacterial antifolate,,,,Withdrawn,0.291288396318081,0.156875284187,sulfamethoxypyridazine,,,0,0
BRD-K01029106-001-01-4::2.52::HTS,BRD-K01029106-001-01-4,picolinic-acid,2.52,HTS,PROT_Annexin_VII,PROT,noncancer,chelating agent,,,,Phase 2,0.304544535229472,-0.0212456768617,picolinic-acid,,,0,0
BRD-K01039503-001-01-2::2.5::HTS,BRD-K01039503-001-01-2,sofalcone,2.5,HTS,CRISPR_PRRT2 (112476),AVANA_PUBLIC_18Q2,noncancer,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD),Launched,0.30448408130368704,0.0371151162967,sofalcone,,,0,0
BRD-K01095011-001-15-9::2.5::HTS,BRD-K01095011-001-15-9,finasteride,2.5,HTS,CN_GUSBP4 (375513),CN,noncancer,5 alpha reductase inhibitor,"AKR1D1, SRD5A1, SRD5A2",endocrinology,androgenetic alopecia,Launched,0.33009855154046597,0.0670722930886,finasteride,,,0,0
BRD-K01109406-001-03-7::2.5::HTS,BRD-K01109406-001-03-7,nitisinone,2.5,HTS,PROT_P-Cadherin_Caution,PROT,noncancer,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,Launched,0.29256773635060496,0.0980346173565,nitisinone,,,0,0
BRD-K01174345-001-01-9::2.5::HTS,BRD-K01174345-001-01-9,anamorelin,2.5,HTS,DEM2_ARHGAP1 (392),DEMETER2_COM,targeted cancer,growth hormone secretagogue receptor agonist,GHSR,,,Phase 3,0.26592555917586697,0.0656926739192,anamorelin,,,0,0
BRD-K01244426-236-12-1::2.5::HTS,BRD-K01244426-236-12-1,cloxacillin,2.5,HTS,METABOL_thiamine,METABOL,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,Launched,0.250152779045033,0.139413134998,cloxacillin,,,0,0
BRD-K01291782-001-01-1::2.50002964::MTS004,BRD-K01291782-001-01-1,molidustat,2.50002964,MTS004,Exp_MT1G (ENSG00000125144),GE,noncancer,hypoxia inducible factor inhibitor,EGLN2,,,Phase 2,0.30336150260866196,0.211722297452,molidustat,HIF PROLYL HYDROXYLASE,0.302959284557636,-7.3970286529636144,0.762834257421692
BRD-K01292756-001-25-0::2.5::HTS,BRD-K01292756-001-25-0,pimozide,2.5,HTS,PROT_Dvl3,PROT,noncancer,dopamine receptor antagonist,"CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2",neurology/psychiatry,Tourette's disorder,Launched,0.29220235128932104,0.0446337887778,pimozide,,,0,0
BRD-K01294196-001-01-5::2.5::HTS,BRD-K01294196-001-01-5,sucrose-octaacetate,2.5,HTS,METHYL_CCDC15,METHYL,noncancer,,,,,Preclinical,0.25078060640637395,0.0759467706122,sucrose-octaacetate,,,0,0
BRD-K01295354-001-02-8::2.5::HTS,BRD-K01295354-001-02-8,uric-acid,2.5,HTS,CRISPR_GOLPH3 (64083),AVANA_PUBLIC_18Q2,noncancer,,PYGL,,,Phase 3,0.275564527513653,0.0706824563389,uric-acid,,,0,0
BRD-K01377300-001-01-1::2.5::HTS,BRD-K01377300-001-01-1,CZC24832,2.5,HTS,METHYL_C2orf68,METHYL,noncancer,PI3K inhibitor,PIK3CG,,,Preclinical,0.273464101642996,0.0627213949465,CZC24832,,,0,0
BRD-K01493881-001-29-4::2.5::HTS,BRD-K01493881-001-29-4,apigenin,2.5,HTS,DEM2_KAT2A (2648),DEMETER2_COM,targeted cancer,"casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1",,,Preclinical,0.236620451031216,0.105008185836,apigenin,,,0,0
BRD-K01507359-001-22-9::2.5::HTS,BRD-K01507359-001-22-9,rifampin,2.5,HTS,CRISPR_RAB34 (83871),AVANA_PUBLIC_18Q2,noncancer,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis",Launched,0.31450749851379606,0.230508272932,rifampin,OTHER,0.3177120343287302,3.4008914455406534,-2.4518940296822125
BRD-K01567962-001-23-0::2.5::HTS,BRD-K01567962-001-23-0,pyrazolanthrone,2.5,HTS,CN_FOXO3 (2309),CN,targeted cancer,JNK inhibitor,"MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK",,,Preclinical,0.27199592846936105,0.0939362302847,pyrazolanthrone,,,0,0
BRD-K01577834-001-15-1::2.5::HTS,BRD-K01577834-001-15-1,adenosine,2.5,HTS,METHYL_GUF1,METHYL,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4",cardiology,Wolff-Parkinson-White Syndrome (WPW),Launched,0.23496448187962699,-0.0456680116777,adenosine,,,0,0
BRD-K01614093-001-02-6::2.5::HTS,BRD-K01614093-001-02-6,dihydromyricetin,2.5,HTS,CRISPR_MS4A13 (503497),AVANA_PUBLIC_18Q2,targeted cancer,,,,,Preclinical,0.260532710326188,0.0999530987617,dihydromyricetin,,,0,0
BRD-K01624185-001-05-7::2.5::HTS,BRD-K01624185-001-05-7,maltobionic-acid,2.5,HTS,Exp_NPPC (ENSG00000163273),GE,noncancer,matrix metalloprotease inhibitor,,dermatology,cosmetic,Launched,0.31181881412615997,0.17773795057,maltobionic-acid,OTHER,0.3111491397543104,7.168750069180082,-2.0207417585839336
BRD-K01638814-011-01-4::2.587084236::MTS004,BRD-K01638814-011-01-4,rilmenidine,2.587084236,MTS004,CRISPR_BUB1B (701),AVANA_PUBLIC_18Q2,noncancer,"adrenergic receptor agonist, imidazoline receptor agonist",ADRA2A,cardiology,hypertension,Launched,0.27874483425818,0.142796740003,rilmenidine,,,0,0
BRD-K01649396-003-07-1::2.5::HTS,BRD-K01649396-003-07-1,indatraline,2.5,HTS,METABOL_adenine,METABOL,noncancer,norepinephrine transporter inhibitor,"MAOA, MAOB",,,Preclinical,0.281351418376603,0.0429536501942,indatraline,,,0,0
BRD-K01653460-001-01-1::2.5::HTS,BRD-K01653460-001-01-1,chlorindanol,2.5,HTS,CRISPR_ZSCAN22 (342945),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.193598046745504,0.0978660277461,chlorindanol,,,0,0
BRD-K01662324-001-01-8::2.618953925::MTS004,BRD-K01662324-001-01-8,priralfinamide,2.618953925,MTS004,METHYL_ATRN,METHYL,noncancer,sodium channel blocker,CACNA1B,,,Phase 3,0.19725696109527,0.0536749194166,priralfinamide,,,0,0
BRD-K01663662-003-20-2::2.5::HTS,BRD-K01663662-003-20-2,diphenidol,2.5,HTS,Exp_DOK2 (ENSG00000147443),GE,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,vertigo,Launched,0.259454384868669,0.0554406916007,diphenidol,,,0,0
BRD-K01666412-001-02-0::2.5::MTS004,BRD-K01666412-001-02-0,L-proline,2.5,MTS004,Exp_C19orf70 (ENSG00000174917),GE,noncancer,glutamate receptor agonist,"EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7",,,Launched,0.258058392422787,0.0493773173342,L-proline,,,0,0
BRD-K01669786-001-02-2::2.5::HTS,BRD-K01669786-001-02-2,triapine,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,chemo,ribonucleotide reductase inhibitor,"RRM1, RRM2",,,Phase 2,0.3681833069553,0.310476896842,triapine,OTHER,0.3672013495591196,4.1800233780681735,-2.520943152076069
BRD-K01674964-300-06-3::2.5::HTS,BRD-K01674964-300-06-3,histamine,2.5,HTS,METABOL_inositol,METABOL,noncancer,histamine receptor agonist,"HRH1, HRH2, HRH3, HRH4",allergy,allergic rhinitis,Launched,0.275931298301311,0.115258184705,histamine,,,0,0
BRD-K01683783-001-02-6::2.5::HTS,BRD-K01683783-001-02-6,TAK-901,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,Aurora kinase inhibitor,AURKB,,,Phase 1,0.340299958233312,0.428379884634,TAK-901,AURORA KINASE INHIBITOR,0.3417370161140996,4.156913556272688,-1.6860975397639884
BRD-K01773083-001-01-4::2.303758671::MTS004,BRD-K01773083-001-01-4,denotivir,2.303758671,MTS004,MIRNA_hsa-miR-214,MIRNA,noncancer,antiviral,,infectious disease,"virus herpes simplex (HSV), skin infections",Launched,0.29562166735836104,0.142466228794,denotivir,,,0,0
BRD-K01773560-001-02-4::2.59::HTS,BRD-K01773560-001-02-4,UNC2250,2.59,HTS,Exp_SMU1 (ENSG00000122692),GE,targeted cancer,MER tyrosine kinase inhibitor,MERTK,,,Preclinical,0.33563903360348807,0.315544851698,UNC2250,OTHER,0.33661057869565425,3.540361056549917,-4.150718362561591
BRD-K01815685-001-15-5::2.5::HTS,BRD-K01815685-001-15-5,indole-3-carbinol,2.5,HTS,METABOL_C36:2 DAG,METABOL,noncancer,"aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor",AHR,,,Phase 2/Phase 3,0.257793842068885,0.0276048915066,indole-3-carbinol,,,0,0
BRD-K01824921-001-18-5::2.5::HTS,BRD-K01824921-001-18-5,DPCPX,2.5,HTS,DEM2_DIDO1 (11083),DEMETER2_COM,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Phase 1,0.26094715411003305,0.140221869331,DPCPX,,,0,0
BRD-K01868942-003-02-7::2.5::HTS,BRD-K01868942-003-02-7,RS-23597-190,2.5,HTS,RMUTmis_LAMA3 (3909),MUTmis,noncancer,serotonin receptor antagonist,HTR4,,,Preclinical,0.250648710567199,0.0818305904832,RS-23597-190,,,0,0
BRD-K01902415-001-11-7::2.5::HTS,BRD-K01902415-001-11-7,pirinixic-acid,2.5,HTS,PROT_cIAP_Caution,PROT,noncancer,PPAR receptor agonist,PPARA,,,Preclinical,0.260634164867602,0.0873633669874,pirinixic-acid,,,0,0
BRD-K01942991-005-08-2::2.5::HTS,BRD-K01942991-005-08-2,oxotremorine-m,2.5,HTS,Exp_HS3ST5 (ENSG00000249853),GE,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,Preclinical,0.26870495580576004,0.114241292073,oxotremorine-m,,,0,0
BRD-K01950558-001-14-7::2.5::HTS,BRD-K01950558-001-14-7,succinylsulfathiazole,2.5,HTS,DEM2_CLDN6 (9074),DEMETER2_COM,noncancer,dihydrofolate reductase inhibitor,DHFR,,,Phase 2,0.31927167447988203,0.000552816366348,succinylsulfathiazole,,,0,0
BRD-K01980392-003-11-6::2.5::HTS,BRD-K01980392-003-11-6,guvacine,2.5,HTS,DEM2_APTX (54840),DEMETER2_COM,noncancer,GABA uptake inhibitor,"SLC6A1, SLC6A11, SLC6A12, SLC6A13",,,Preclinical,0.256088907263008,0.02844130947,guvacine,,,0,0
BRD-K01995783-001-01-6::2.5::HTS,BRD-K01995783-001-01-6,AMG-9810,2.5,HTS,Exp_STK39 (ENSG00000198648),GE,noncancer,TRPV antagonist,TRPV1,,,Preclinical,0.298784277208152,0.177550184318,AMG-9810,,,0,0
BRD-K02017404-300-06-2::2.5::HTS,BRD-K02017404-300-06-2,NVP-BSK805,2.5,HTS,Exp_LINC00211 (ENSG00000237803),GE,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.27307025148796105,0.0351583249629,NVP-BSK805,OTHER,0.2699548766099145,0.4731946242507176,-2.690008456375316
BRD-K02079473-001-01-3::2.5::HTS,BRD-K02079473-001-01-3,oxatomide,2.5,HTS,MIRNA_hsa-miR-423-3p,MIRNA,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.287725899562586,0.136434216389,oxatomide,,,0,0
BRD-K02113016-001-15-4::2.5::HTS,BRD-K02113016-001-15-4,olaparib,2.5,HTS,Exp_KDM2B (ENSG00000089094),GE,targeted cancer,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,Launched,0.38269064337114705,0.276169329376,olaparib,OTHER,0.3787662727731039,2.465286319244268,-4.124437188738591
BRD-K02123250-001-06-7::2.5::HTS,BRD-K02123250-001-06-7,JNJ-38877605,2.5,HTS,CRISPR_TCF7L2 (6934),AVANA_PUBLIC_18Q2,targeted cancer,tyrosine kinase inhibitor,MET,,,Phase 1,0.296740671158829,0.0775604158397,JNJ-38877605,,,0,0
BRD-K02152879-414-02-1::2.500013375::MTS004,BRD-K02152879-414-02-1,sivelestat,2.500013375,MTS004,METABOL_CMP,METABOL,noncancer,elastase inhibitor,"CELA1, ELANE",pulmonary,acute lung injury,Launched,0.13796616203536802,0.125298712591,sivelestat,,,0,0
BRD-K02241333-001-02-7::2.5::HTS,BRD-K02241333-001-02-7,CHIR-124,2.5,HTS,Exp_ZFP3 (ENSG00000180787),GE,noncancer,CHK inhibitor,CHEK1,,,Preclinical,0.417469477659745,0.181323306438,CHIR-124,OTHER,0.41617280655093103,5.671232967953338,-0.19473710696980276
BRD-K02265150-001-26-5::2.5::HTS,BRD-K02265150-001-26-5,amoxapine,2.5,HTS,METABOL_pantothenate,METABOL,noncancer,norepinephrine reputake inhibitor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.29910237935838696,0.114989609758,amoxapine,,,0,0
BRD-K02275692-300-02-6::2.499989889::MTS004,BRD-K02275692-300-02-6,cefotiam,2.499989889,MTS004,METHYL_MIF-AS1,METHYL,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections",Launched,0.303350142362643,0.0779202655102,cefotiam,,,0,0
BRD-K02292852-001-02-1::2.5::HTS,BRD-K02292852-001-02-1,cefoperazone,2.5,HTS,CRISPR_FXYD3 (5349),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.260742833601635,0.0280691714029,cefoperazone,,,0,0
BRD-K02314383-001-01-3::2.5::HTS,BRD-K02314383-001-01-3,epitiostanol,2.5,HTS,Exp_ADAMTS4 (ENSG00000158859),GE,noncancer,androgen receptor agonist,AR,,,Launched,0.22486642100166102,0.0972890015082,epitiostanol,,,0,0
BRD-K02389548-001-02-5::2.5::HTS,BRD-K02389548-001-02-5,RG2833,2.5,HTS,METHYL_LEKR1,METHYL,noncancer,HDAC inhibitor,"HDAC1, HDAC3",,,Phase 1,0.28851080817984803,0.192221674876,RG2833,HDAC INHIBITOR,0.2993314863206562,-1.0101233201151083,-2.436020908684833
BRD-K02404261-001-16-7::2.5::HTS,BRD-K02404261-001-16-7,caffeine,2.5,HTS,PROT_cIAP_Caution,PROT,noncancer,"adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3",neurology/psychiatry,"fatigue, drowsiness, fatigue, drowsiness",Launched,0.23703697741513396,0.0190364425969,caffeine,,,0,0
BRD-K02407574-001-09-7::2.5::HTS,BRD-K02407574-001-09-7,parbendazole,2.5,HTS,Exp_SNRNP40 (ENSG00000060688),GE,noncancer,tubulin polymerization inhibitor,TUBB,,,Preclinical,0.39207434140786895,0.352066470481,parbendazole,TUBULIN POLYMERIZATION INHIBITOR,0.3952633423353972,5.925110594848253,-2.7629474544309818
BRD-K02464583-001-02-2::2.5::HTS,BRD-K02464583-001-02-2,ethyl-paraben,2.5,HTS,CN_CNNM2 (54805),CN,noncancer,,,,,Preclinical,0.243649332048244,-0.0256947362497,ethyl-paraben,,,0,0
BRD-K02475039-001-01-0::2.5::HTS,BRD-K02475039-001-01-0,ethopabate,2.5,HTS,Exp_SPRR2D (ENSG00000163216),GE,noncancer,antiprotozoal agent,,infectious disease,coccidiosis,Launched,0.244763367966738,0.073188468488,ethopabate,,,0,0
BRD-K02501528-001-01-1::2.5::HTS,BRD-K02501528-001-01-1,S18986,2.5,HTS,DEM2_ADGRB3 (577),DEMETER2_COM,noncancer,glutamate receptor modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,Phase 2,0.30760108038851297,0.084141562429,S18986,,,0,0
BRD-K02528732-001-02-4::2.425128585::MTS004,BRD-K02528732-001-02-4,fluorometholone-acetate,2.425128585,MTS004,PROT_RBM15,PROT,noncancer,,NR3C1,ophthalmology,eye inflammation,Launched,0.28515563158477897,0.0661487329481,fluorometholone-acetate,OTHER,0.2760338338838659,2.3330753449669825,4.726276745234582
BRD-K02554563-001-01-6::2.5::MTS004,BRD-K02554563-001-01-6,PF-05190457,2.5,MTS004,METABOL_asparagine,METABOL,noncancer,growth hormone secretagogue receptor inverse agonist,GHSR,,,Phase 2,0.298521183406261,0.12306792508,PF-05190457,,,0,0
BRD-K02594908-001-16-4::2.5::HTS,BRD-K02594908-001-16-4,sulfanilamide,2.5,HTS,CRISPR_FAM196B (100131897),AVANA_PUBLIC_18Q2,noncancer,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,Launched,0.310341655311943,0.0686269827552,sulfanilamide,,,0,0
BRD-K02637541-001-18-0::2.5::HTS,BRD-K02637541-001-18-0,celecoxib,2.5,HTS,METABOL_inositol,METABOL,noncancer,cyclooxygenase inhibitor,"CA12, PDPK1, PTGS2","rheumatology, endocrinology","osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)",Launched,0.2950552639788189,0.183613623126,celecoxib,,,0,0
BRD-K02703275-001-07-5::2.5::HTS,BRD-K02703275-001-07-5,gedunin,2.5,HTS,DEM2_MRPL19 (9801),DEMETER2_COM,targeted cancer,HSP inhibitor,HSP90AA1,,,Preclinical,0.258751950945076,0.108677044996,gedunin,,,0,0
BRD-K02715688-001-02-1::2.5::HTS,BRD-K02715688-001-02-1,"hydrastine-(1r,-9s)",2.5,HTS,CRISPR_STOX1 (219736),AVANA_PUBLIC_18Q2,noncancer,tyrosine hydroxylase inhibitor,,,,Preclinical,0.331293972726237,0.105923931198,"hydrastine-(1r,-9s)",,,0,0
BRD-K02729857-001-01-9::2.50244046::MTS004,BRD-K02729857-001-01-9,phenylbenzimidazole-sulfonic-acid,2.50244046,MTS004,CN_CPNE4 (131034),CN,noncancer,,,dermatology,sunscreen lotion,Launched,0.252595155792557,0.0634028004545,phenylbenzimidazole-sulfonic-acid,,,0,0
BRD-K02733959-236-07-7::2.5::HTS,BRD-K02733959-236-07-7,cefuroxime,2.5,HTS,MIRNA_hsa-miR-455-3p,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.251236935930433,0.106140390531,cefuroxime,,,0,0
BRD-K02750403-001-01-4::2.499962046::MTS004,BRD-K02750403-001-01-4,piboserod,2.499962046,MTS004,PROT_4E-BP1_pS65,PROT,noncancer,serotonin receptor antagonist,"HTR2B, HTR4",,,Phase 2,0.300527623991371,0.171702198646,piboserod,,,0,0
BRD-K02764365-001-13-6::2.5::HTS,BRD-K02764365-001-13-6,methiazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,anthelmintic agent,,,,Preclinical,0.426491390323564,0.277707361124,methiazole,OTHER,0.425116372200637,5.2537625466143005,-3.3986095099003863
BRD-K02816415-001-01-9::2.5::HTS,BRD-K02816415-001-01-9,CRT0044876,2.5,HTS,DEM2_ARHGAP1 (392),DEMETER2_COM,noncancer,,,,,Preclinical,0.30238337256101,0.0911022831039,CRT0044876,,,0,0
BRD-K02898090-001-02-7::2.5::HTS,BRD-K02898090-001-02-7,kifunensine,2.5,HTS,PROT_beta-Catenin_pT41_S45,PROT,noncancer,mannosidase inhibitor,"MAN1B1, MAN2A1",,,Phase 1,0.325385740175779,0.0192908398765,kifunensine,,,0,0
BRD-K02900412-001-11-3::2.5::HTS,BRD-K02900412-001-11-3,clofoctol,2.5,HTS,Exp_MINOS1P2 (ENSG00000270714),GE,noncancer,protein synthesis inhibitor,,infectious disease,gram-positive bacterial infections,Launched,0.254842472728529,0.0734866345821,clofoctol,,,0,0
BRD-K02908048-003-06-4::2.5::HTS,BRD-K02908048-003-06-4,preclamol,2.5,HTS,MIRNA_hsa-miR-125a-3p,MIRNA,noncancer,dopamine receptor agonist,DRD2,,,Phase 2,0.32444859965425105,0.0960203937855,preclamol,,,0,0
BRD-K02943813-001-01-9::2.5::HTS,BRD-K02943813-001-01-9,dasabuvir,2.5,HTS,MIRNA_hsa-miR-498,MIRNA,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.24715468020971998,0.0244936640272,dasabuvir,,,0,0
BRD-K02950022-001-02-9::2.5::HTS,BRD-K02950022-001-02-9,BMS-299897,2.5,HTS,PROT_Bak_Caution,PROT,noncancer,gamma secretase inhibitor,,,,Phase 1,0.27584692967974606,0.0938132180243,BMS-299897,,,0,0
BRD-K02953697-001-09-2::2.5::HTS,BRD-K02953697-001-09-2,naringin,2.5,HTS,PROT_CD49b,PROT,noncancer,cytochrome P450 inhibitor,SLCO1A2,,,Preclinical,0.284783793341708,0.0271193318252,naringin,,,0,0
BRD-K02965346-001-07-5::2.5::HTS,BRD-K02965346-001-07-5,SU-11274,2.5,HTS,METABOL_cotinine,METABOL,targeted cancer,"hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor",MET,,,Preclinical,0.227018187785451,0.0917727076059,SU-11274,OTHER,0.2264569448892105,-5.760503135214508,1.4240516444900346
BRD-K02965577-001-03-4::0.25::HTS,BRD-K02965577-001-03-4,secalciferol,0.25,HTS,DEM2_POC1A (25886),DEMETER2_COM,noncancer,vitamin D receptor agonist,VDR,critical care,bone fracture,Launched,0.318469636015895,0.0475132337543,secalciferol,,,0,0
BRD-K02988401-001-01-2::2.5::MTS004,BRD-K02988401-001-01-2,UNC0737,2.5,MTS004,Exp_RN7SKP296 (ENSG00000223117),GE,noncancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.37202967655506897,0.204264667054,UNC0737,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.37084548629275305,1.9053473956031617,-0.7341238846406903
BRD-K02995728-003-01-9::2.499993866::MTS004,BRD-K02995728-003-01-9,quinagolide,2.499993866,MTS004,METABOL_phosphocreatine,METABOL,noncancer,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia,Launched,0.26307921156919895,-0.00277600933632,quinagolide,,,0,0
BRD-K03063480-001-05-8::2.5::HTS,BRD-K03063480-001-05-8,PF-477736,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.39892247342584997,0.340072271555,PF-477736,OTHER,0.4022879513272519,4.466507721716564,-2.075202987648929
BRD-K03063480-001-06-6::2.42::HTS,BRD-K03063480-001-06-6,PF-477736,2.42,HTS,Exp_EDA2R (ENSG00000131080),GE,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.39892247342584997,0.340072271555,PF-477736,OTHER,0.38542512748200203,5.1093303795768135,-1.0992658670078743
BRD-K03095347-001-06-1::2.5::HTS,BRD-K03095347-001-06-1,levosimendan,2.5,HTS,METABOL_fructose/glucose/galactose,METABOL,noncancer,calcium sensitizer,"KCNJ11, KCNJ8, PDE3A, TNNC1",cardiology,congestive heart failure,Launched,0.26910636462207804,0.0423405226824,levosimendan,,,0,0
BRD-K03109492-001-02-2::2.5::HTS,BRD-K03109492-001-02-2,NSC-663284,2.5,HTS,Exp_GSTP1 (ENSG00000084207),GE,targeted cancer,CDC inhibitor,"CDC25A, CDC25B, CDC25C",,,Preclinical,0.4195528109153979,0.408758870024,NSC-663284,OTHER,0.4247105291719364,4.610982088248291,-1.3067170953052014
BRD-K03155172-001-02-2::2.5::HTS,BRD-K03155172-001-02-2,GSK3787,2.5,HTS,DEM2_C3AR1 (719),DEMETER2_COM,noncancer,PPAR receptor antagonist,PPARD,,,Preclinical,0.23141686272590198,0.0607755916058,GSK3787,,,0,0
BRD-K03164761-001-02-1::2.5::HTS,BRD-K03164761-001-02-1,thiazovivin,2.5,HTS,PROT_Rab25,PROT,noncancer,rho associated kinase inhibitor,,,,Preclinical,0.323522236167967,0.175402389452,thiazovivin,OTHER,0.30848027687676244,5.707630636708772,1.1419376756397088
BRD-K03165895-001-01-9::2.499970324::MTS004,BRD-K03165895-001-01-9,elafibranor,2.499970324,MTS004,PROT_Src_pY527,PROT,targeted cancer,PPAR receptor agonist,"PPARA, PPARD",,,Phase 3,0.360801210300386,0.147246313944,elafibranor,,,0,0
BRD-K03194791-001-04-8::2.5::HTS,BRD-K03194791-001-04-8,roflumilast,2.5,HTS,PROT_ACVRL1_Caution,PROT,noncancer,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis",Launched,0.33794421794061197,0.0668386909617,roflumilast,,,0,0
BRD-K03243820-001-23-8::2.37::HTS,BRD-K03243820-001-23-8,trifluridine,2.37,HTS,Exp_SUPT16H (ENSG00000092201),GE,chemo,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.380651665025111,3.94309177253663,-3.2388711987940795
BRD-K03243820-001-25-3::2.5::HTS,BRD-K03243820-001-25-3,trifluridine,2.5,HTS,Exp_LTA4H (ENSG00000111144),GE,chemo,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.3722083043224055,3.6622341566390015,-3.5348063957589293
BRD-K03273112-001-01-8::2.5::HTS,BRD-K03273112-001-01-8,1-azakenpaullone,2.5,HTS,DEM2_EIF4G1 (1981),DEMETER2_COM,noncancer,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",,,Preclinical,0.31249779704499103,0.11581208668,1-azakenpaullone,OTHER,0.2883579127463332,-2.2131831267628503,0.9137911309308936
BRD-K03289018-001-02-7::2.5::HTS,BRD-K03289018-001-02-7,CCT137690,2.5,HTS,Exp_KCNMB3 (ENSG00000171121),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.35895843164284297,0.32739649773,CCT137690,AURORA KINASE INHIBITOR,0.3551666459992621,3.9347986028060764,-0.95746212578706
BRD-K03289534-001-01-4::2.5::HTS,BRD-K03289534-001-01-4,lersivirine,2.5,HTS,MIRNA_ebv-miR-BART6-3p,MIRNA,noncancer,non-nucleoside reverse transcriptase inhibitor,,,,Phase 2,0.20507072692932002,0.0168575277125,lersivirine,,,0,0
BRD-K03294269-001-08-0::2.5::HTS,BRD-K03294269-001-08-0,NU6027,2.5,HTS,Exp_GSR (ENSG00000104687),GE,targeted cancer,CDK inhibitor,"CCNA2, CDK2",,,Preclinical,0.3778694362565321,0.358654954709,NU6027,CDK INHIBITOR,0.3755856809360565,1.1411434825106117,1.0918575444708023
BRD-K03301001-003-02-5::2.5::HTS,BRD-K03301001-003-02-5,A-7,2.5,HTS,CRISPR_CSTB (1476),AVANA_PUBLIC_18Q2,noncancer,calmodulin antagonist,,,,Preclinical,0.24420171217648398,0.120224014409,A-7,,,0,0
BRD-K03353589-236-01-4::2.5::HTS,BRD-K03353589-236-01-4,ecabet,2.5,HTS,Exp_UNC5B (ENSG00000107731),GE,noncancer,"gastrin inhibitor, urease inhibitor",NOXO1,ophthalmology,dry eye syndrome,Launched,0.25371477504331197,0.103585689838,ecabet,,,0,0
BRD-K03384561-001-02-7::2.5::HTS,BRD-K03384561-001-02-7,roquinimex,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,targeted cancer,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",,,,Phase 3,0.31553332803267303,0.156806646878,roquinimex,,,0,0
BRD-K03390685-001-01-7::2.5::HTS,BRD-K03390685-001-01-7,cobimetinib,2.5,HTS,Exp_C1QL1 (ENSG00000131094),GE,targeted cancer,MEK inhibitor,,oncology,melanoma,Launched,0.41442344925464003,0.543088474306,cobimetinib,MEK INHIBITOR,0.4142149861256813,0.33070752536389003,4.870681702366238
BRD-K03406345-001-27-8::2.5::HTS,BRD-K03406345-001-27-8,azacitidine,2.5,HTS,Exp_RGS16 (ENSG00000143333),GE,chemo,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)",Launched,0.28150666963459803,0.221953077311,azacitidine,OTHER,0.28087446088451673,3.541024658647161,-2.7336075755949456
BRD-K03449891-001-08-6::2.5::HTS,BRD-K03449891-001-08-6,foretinib,2.5,HTS,PROT_XBP1_Caution,PROT,targeted cancer,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",,,Phase 2,0.371140239492623,0.262552969348,foretinib,VEGFR INHIBITOR,0.3773544967210353,4.7496658738714155,-1.5614888317262945
BRD-K03503561-001-01-4::2.339952449::MTS004,BRD-K03503561-001-01-4,ravuconazole,2.339952449,MTS004,DEM2_ARPC1A (10552),DEMETER2_COM,noncancer,sterol demethylase inhibitor,,,,Phase 2,0.356641819885948,0.155704180721,ravuconazole,,,0,0
BRD-K03504028-001-07-6::2.5::HTS,BRD-K03504028-001-07-6,amygdalin,2.5,HTS,DEM2_TBC1D9B (23061),DEMETER2_COM,targeted cancer,caspase activator,CASP3,,,Phase 2,0.264557360620266,0.00064710303665,amygdalin,,,0,0
BRD-K03549949-001-01-0::2.5::HTS,BRD-K03549949-001-01-0,XL388,2.5,HTS,DEM2_STK19 (8859),DEMETER2_COM,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.35385696725801097,0.205035831207,XL388,MTOR INHIBITOR,0.35122344440715403,0.9294631199936776,-1.4546738964700272
BRD-K03564313-001-03-3::2.5::HTS,BRD-K03564313-001-03-3,DMNB,2.5,HTS,Exp_RN7SL105P (ENSG00000243704),GE,noncancer,DNA dependent protein kinase inhibitor,,,,Preclinical,0.27724801463497495,0.0837580060655,DMNB,,,0,0
BRD-K03739921-001-06-8::2.5::HTS,BRD-K03739921-001-06-8,hypoxanthine,2.5,HTS,Exp_SPHK2 (ENSG00000063176),GE,noncancer,PARP inhibitor,PNP,,,Preclinical,0.32897684778525604,0.102684398178,hypoxanthine,,,0,0
BRD-K03765900-001-01-9::2.499986292::MTS004,BRD-K03765900-001-01-9,XL-647,2.499986292,MTS004,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",,,Phase 3,0.4449515305581721,0.53038806092,XL-647,EGFR INHIBITOR,0.4423696251612983,1.2941219405176367,-4.7272797385165966
BRD-K03894385-001-01-1::2.500025266::MTS004,BRD-K03894385-001-01-1,MK-6096,2.500025266,MTS004,PROT_eIF4E,PROT,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Phase 2,0.295223542579454,0.140727793796,MK-6096,,,0,0
BRD-K04111260-001-10-0::2.5::HTS,BRD-K04111260-001-10-0,raclopride,2.5,HTS,MIRNA_hsa-miR-375,MIRNA,noncancer,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",,,Launched,0.26373086175661803,0.0726622281925,raclopride,,,0,0
BRD-K04176066-001-08-3::2.5::HTS,BRD-K04176066-001-08-3,bergenin,2.5,HTS,MUTpool_VASH1 (22846),MUTpool,noncancer,interleukin inhibitor,"IL1B, TNF",,,Preclinical,0.30026251703504603,0.0892666597226,bergenin,,,0,0
BRD-K04185004-003-11-9::2.5::HTS,BRD-K04185004-003-11-9,oxybuprocaine,2.5,HTS,MIRNA_hsa-miR-608,MIRNA,noncancer,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic,Launched,0.253500089978315,0.123857051148,oxybuprocaine,,,0,0
BRD-K04196797-001-24-4::2.5::HTS,BRD-K04196797-001-24-4,oxcarbazepine,2.5,HTS,RMUTdmg_TARBP1 (6894),MUTdmg,noncancer,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.265258936233727,0.0422285704361,oxcarbazepine,,,0,0
BRD-K04264130-001-01-4::2.5::HTS,BRD-K04264130-001-01-4,favipiravir,2.5,HTS,CRISPR_IST1 (9798),AVANA_PUBLIC_18Q2,noncancer,RNA polymerase inhibitor,,,,Phase 3,0.264435698593902,0.0927340312138,favipiravir,,,0,0
BRD-K04394237-001-03-7::2.49::HTS,BRD-K04394237-001-03-7,drospirenone,2.49,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,Launched,0.414833385463885,0.211123461697,drospirenone,OTHER,0.4197150458414303,-3.582083994485957,-0.7984976856575852
BRD-K04394237-001-06-0::2.5::HTS,BRD-K04394237-001-06-0,drospirenone,2.5,HTS,Exp_TNNC1 (ENSG00000114854),GE,noncancer,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,Launched,0.414833385463885,0.211123461697,drospirenone,,,0,0
BRD-K04430056-236-02-1::2.5::HTS,BRD-K04430056-236-02-1,7-nitroindazole,2.5,HTS,Exp_COX10 (ENSG00000006695),GE,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,Preclinical,0.319361694262145,0.149524910925,7-nitroindazole,OTHER,0.31887262790806786,3.2916774324393256,-0.5863895366671588
BRD-K04497194-001-02-1::2.5::HTS,BRD-K04497194-001-02-1,lithocholic-acid,2.5,HTS,MUTpool_XPNPEP2 (7512),MUTpool,targeted cancer,"FXR antagonist, vitamin D receptor agonist","GPBAR1, NR1H4, NR1I2, VDR",,,Preclinical,0.224822085899957,0.0695241448613,lithocholic-acid,,,0,0
BRD-K04568635-300-01-4::2.5::HTS,BRD-K04568635-300-01-4,octenidine,2.5,HTS,Exp_ABCC3 (ENSG00000108846),GE,noncancer,membrane integrity inhibitor,,,,Launched,0.356782624217653,0.365087717223,octenidine,OTHER,0.3570362947725316,3.638474337248665,-1.6736673911131446
BRD-K04603573-376-01-3::2.542651982::MTS004,BRD-K04603573-376-01-3,"1,12-Besm",2.542651982,MTS004,Exp_ABLIM1 (ENSG00000099204),GE,targeted cancer,polyamine biosynthesis inhibitor,,,,Phase 2,0.3376194570024289,0.252284762543,"1,12-Besm",OTHER,0.3411587639979148,-3.761769334110193,-1.426486240668147
BRD-K04622161-001-02-3::2.5::HTS,BRD-K04622161-001-02-3,YO-01027,2.5,HTS,Exp_SSR4P1 (ENSG00000235374),GE,noncancer,gamma secretase inhibitor,,,,Preclinical,0.29360414402922497,0.0739547252182,YO-01027,,,0,0
BRD-K04623885-001-07-5::2.5::HTS,BRD-K04623885-001-07-5,BIBR-1532,2.5,HTS,Exp_C22orf46 (ENSG00000184208),GE,targeted cancer,telomerase inhibitor,TERT,,,Preclinical,0.299362425972442,0.0681671686322,BIBR-1532,,,0,0
BRD-K04643877-001-03-2::2.633096501::MTS004,BRD-K04643877-001-03-2,perzinfotel,2.633096501,MTS004,CRISPR_ETS2 (2114),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B",,,Phase 2,0.307233871074454,0.111252998775,perzinfotel,,,0,0
BRD-K04657451-001-01-0::2.5::HTS,BRD-K04657451-001-01-0,D-delta-Tocopherol,2.5,HTS,MIRNA_hsa-miR-1281,MIRNA,noncancer,,,,,Launched,0.25509198262480803,0.10876663619,D-delta-Tocopherol,,,0,0
BRD-K04691817-001-01-8::2.5::HTS,BRD-K04691817-001-01-8,AGI-6780,2.5,HTS,MIRNA_hsa-miR-450b-3p,MIRNA,targeted cancer,isocitrate dehydrogenase inhibitor,IDH2,,,Preclinical,0.282663320476388,0.142923791266,AGI-6780,,,0,0
BRD-K04701033-001-04-7::2.499987566::MTS004,BRD-K04701033-001-04-7,VE-822,2.499987566,MTS004,Exp_LBR (ENSG00000143815),GE,targeted cancer,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",,,Phase 2,0.361566975001654,0.33195152746,VE-822,OTHER,0.3613074433910049,5.0790161841347095,-2.6736121558974446
BRD-K04704168-003-14-3::2.5::HTS,BRD-K04704168-003-14-3,clemizole,2.5,HTS,METHYL_TIGIT,METHYL,noncancer,HCV inhibitor,,allergy,allergic rhinitis,Launched,0.27621261696396804,0.10278877696,clemizole,,,0,0
BRD-K04710043-001-17-8::2.5::MTS004,BRD-K04710043-001-17-8,hexamethylenebisacetamide,2.5,MTS004,Exp_HOXA7 (ENSG00000122592),GE,targeted cancer,"AKT inhibitor, differentiation inducer, NFKB pathway inhibitor",AKT1,,,Phase 2,0.305739767282464,0.0550841811175,hexamethylenebisacetamide,,,0,0
BRD-K04804440-001-09-5::2.5::HTS,BRD-K04804440-001-09-5,ciprofloxacin,2.5,HTS,MIRNA_hsa-miR-147,MIRNA,noncancer,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis,Launched,0.297994754990907,0.0246273083913,ciprofloxacin,,,0,0
BRD-K04833372-001-06-2::2.5::HTS,BRD-K04833372-001-06-2,GSK1904529A,2.5,HTS,Exp_HSF2 (ENSG00000025156),GE,targeted cancer,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",,,Preclinical,0.326243589281663,0.137021825162,GSK1904529A,OTHER,0.3274430805622233,0.9318535054566256,-3.3809891456397123
BRD-K04851519-001-06-8::2.5::HTS,BRD-K04851519-001-06-8,aloe-emodin,2.5,HTS,DEM2_NSMCE1 (197370),DEMETER2_COM,noncancer,anticancer agent,CASP8,,,Preclinical,0.257445584826535,0.0401638078425,aloe-emodin,,,0,0
BRD-K04923131-001-15-4::2.5::HTS,BRD-K04923131-001-15-4,GSK-3-inhibitor-IX,2.5,HTS,Exp_QSOX2 (ENSG00000165661),GE,targeted cancer,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",,,Preclinical,0.39302375838269504,0.241526968344,GSK-3-inhibitor-IX,OTHER,0.3897712563070901,-2.1910431025325803,0.844123172018082
BRD-K04956647-003-02-5::2.5::HTS,BRD-K04956647-003-02-5,nebivolol,2.5,HTS,LIN_upper_aerodigestive,LIN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,hypertension,Launched,0.269584482869911,0.0597189206882,nebivolol,,,0,0
BRD-K04993719-001-01-7::2.5::HTS,BRD-K04993719-001-01-7,LY2334737,2.5,HTS,DEM2_TFEC (22797),DEMETER2_COM,chemo,"antitumor agent, ribonucleotide reductase inhibitor",,,,Phase 1,0.456722875665507,0.179442760519,LY2334737,OTHER,0.4541989570203829,-3.4122554221205306,-0.8753729409748812
BRD-K05048137-001-03-9::1.57::HTS,BRD-K05048137-001-03-9,phytosphingosine,1.57,HTS,MUTpool_GAS2L3 (283431),MUTpool,noncancer,,,,,Phase 1,0.28092467938316,-0.0111342276075,phytosphingosine,,,0,0
BRD-K05104363-001-10-0::2.5::HTS,BRD-K05104363-001-10-0,PD-184352,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",,,Phase 2,0.4249449059285039,0.442763304083,PD-184352,MEK INHIBITOR,0.4246853743277095,0.6235357895053986,4.476836369656759
BRD-K05151076-001-02-6::2.5::HTS,BRD-K05151076-001-02-6,ZK-164015,2.5,HTS,CRISPR_CDH17 (1015),AVANA_PUBLIC_18Q2,noncancer,estrogen receptor antagonist,"ESR1, ESR2",,,Preclinical,0.275848920306137,0.00611645395718,ZK-164015,,,0,0
BRD-K05181084-003-03-7::2.5::HTS,BRD-K05181084-003-03-7,NGB-2904,2.5,HTS,CRISPR_RELL2 (285613),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor antagonist,DRD3,,,Preclinical,0.286427796052034,0.177778952327,NGB-2904,,,0,0
BRD-K05236810-001-19-0::2.5::HTS,BRD-K05236810-001-19-0,luteolin,2.5,HTS,LIN_Ewings_sarcoma,LIN,noncancer,glucosidase inhibitor,TOP1,,,Phase 2,0.271969715627621,0.178716431944,luteolin,,,0,0
BRD-K05361803-001-03-9::2.5::HTS,BRD-K05361803-001-03-9,SC-10,2.5,HTS,CN_MIR4439 (100616207),CN,noncancer,protein kinase activator,PRKCA,,,Preclinical,0.316368090732151,0.0491727482954,SC-10,,,0,0
BRD-K05395900-322-05-4::2.5::HTS,BRD-K05395900-322-05-4,nicotine,2.5,HTS,PROT_Rb_pS807_S811,PROT,noncancer,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,Launched,0.310684668164706,0.0571697899666,nicotine,,,0,0
BRD-K05434375-001-06-5::2.5::HTS,BRD-K05434375-001-06-5,HA-1004,2.5,HTS,Exp_WBP5 (ENSG00000185222),GE,noncancer,calcium channel blocker,,,,Phase 2,0.236921666455669,0.145997305958,HA-1004,,,0,0
BRD-K05444225-001-01-7::2.5::HTS,BRD-K05444225-001-01-7,E7449,2.5,HTS,CN_FAM181B (220382),CN,targeted cancer,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",,,Phase 1/Phase 2,0.281027587887354,0.109249152786,E7449,OTHER,0.2801350794594549,2.5345378817457087,0.11279200866895026
BRD-K05446112-001-01-8::2.5::HTS,BRD-K05446112-001-01-8,ledipasvir,2.5,HTS,Exp_TMEM155 (ENSG00000164112),GE,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.28663729464144605,0.29331498732,ledipasvir,OTHER,0.2857906099907198,-5.455122198422616,-1.0131222945200786
BRD-K05464208-001-05-7::2.5::HTS,BRD-K05464208-001-05-7,JX-401,2.5,HTS,METHYL_ZNF248,METHYL,noncancer,p38 MAPK inhibitor,MAPK14,,,Preclinical,0.288415138668693,0.0794890490921,JX-401,,,0,0
BRD-K05524748-003-04-4::2.5::HTS,BRD-K05524748-003-04-4,dronedarone,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),Launched,0.209844795982416,0.161198997608,dronedarone,OTHER,0.2278436243559641,2.501787834981454,-3.91695675528948
BRD-K05528470-305-02-2::2.5::HTS,BRD-K05528470-305-02-2,L-745870,2.5,HTS,CRISPR_NPIPA7 (101059938),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7",,,Preclinical,0.20840839263020702,0.180671229642,L-745870,,,0,0
BRD-K05619559-001-12-7::2.5::HTS,BRD-K05619559-001-12-7,tobramycin,2.5,HTS,METHYL_TLK1,METHYL,noncancer,bacterial 30S ribosomal subunit inhibitor,,infectious disease,"bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections",Launched,0.313408327171116,0.0755806119812,tobramycin,,,0,0
BRD-K05638300-001-01-2::2.5::HTS,BRD-K05638300-001-01-2,sevoflurane,2.5,HTS,PROT_Annexin 1,PROT,noncancer,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,Launched,0.280166554116029,-0.00681848959305,sevoflurane,,,0,0
BRD-K05658747-001-02-9::2.5::HTS,BRD-K05658747-001-02-9,raltegravir,2.5,HTS,CN_SLC4A7 (9497),CN,noncancer,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.27521175952024396,0.0749415492473,raltegravir,,,0,0
BRD-K05673000-236-12-1::2.5::HTS,BRD-K05673000-236-12-1,dicloxacillin,2.5,HTS,CRISPR_RHOA (387),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,Launched,0.24337332594666802,0.0904440370233,dicloxacillin,,,0,0
BRD-K05674516-001-01-7::2.5::HTS,BRD-K05674516-001-01-7,PSI-7976,2.5,HTS,MIRNA_hsa-miR-668,MIRNA,noncancer,HCV inhibitor,,,,Preclinical,0.25493029643053605,0.029655175968,PSI-7976,,,0,0
BRD-K05674516-001-02-5::2.5::HTS,BRD-K05674516-001-02-5,sofosbuvir,2.5,HTS,Exp_CCDC140 (ENSG00000163081),GE,noncancer,RNA polymerase inhibitor,,infectious disease,hepatitis C,Launched,0.295377119284697,0.117031262365,sofosbuvir,,,0,0
BRD-K05677083-001-05-4::2.5::HTS,BRD-K05677083-001-05-4,PACOCF3,2.5,HTS,METABOL_arachidonyl_carnitine,METABOL,noncancer,phospholipase inhibitor,PLA2G4A,,,Preclinical,0.292443817648806,0.0697543085354,PACOCF3,,,0,0
BRD-K05804044-001-06-0::2.5::HTS,BRD-K05804044-001-06-0,AZ-628,2.5,HTS,Exp_SPRY4 (ENSG00000187678),GE,targeted cancer,RAF inhibitor,"BRAF, RAF1",,,Preclinical,0.471543045631854,0.557943202955,AZ-628,RAF INHIBITOR,0.4677598573297166,0.5680648233775349,4.506307507371487
BRD-K05850076-001-01-5::2.5::HTS,BRD-K05850076-001-01-5,sotagliflozin,2.5,HTS,METABOL_C36:2 DAG,METABOL,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",,,Phase 3,0.263584614724362,0.0663964875893,sotagliflozin,,,0,0
BRD-K05858796-001-01-7::2.500017956::MTS004,BRD-K05858796-001-01-7,GSK2330672,2.500017956,MTS004,METABOL_2-hydroxyglutarate,METABOL,noncancer,bile acid transporter inhibitor,SLC10A2,,,Phase 2,0.264964251980247,0.12198133663,GSK2330672,,,0,0
BRD-K05878375-236-05-7::2.5::HTS,BRD-K05878375-236-05-7,sodium-butyrate,2.5,HTS,CRISPR_DCUN1D3 (123879),AVANA_PUBLIC_18Q2,targeted cancer,HDAC inhibitor,"BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8",,,Phase 2,0.306899727935324,0.0642506608905,sodium-butyrate,,,0,0
BRD-K05900209-001-03-4::2.47::HTS,BRD-K05900209-001-03-4,dexlansoprazole,2.47,HTS,MIRNA_hsa-miR-769-3p,MIRNA,noncancer,ATPase inhibitor,"ATP4A, ATP4B",gastroenterology,"gastroesophageal reflux disease (GERD), erosive esophagitis (EE)",Launched,0.334730577535851,0.0738397338127,dexlansoprazole,,,0,0
BRD-K05906022-001-05-1::2.5::HTS,BRD-K05906022-001-05-1,limonin,2.5,HTS,DEM2_PPP2R3A (5523),DEMETER2_COM,targeted cancer,HIV protease inhibitor,,,,Preclinical,0.282701358613851,0.116823106721,limonin,,,0,0
BRD-K05907307-001-07-1::2.5::HTS,BRD-K05907307-001-07-1,nonivamide,2.5,HTS,CN_JAK2 (3717),CN,noncancer,TRPV agonist,TRPV1,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain",Launched,0.3187110313785,0.0257113487221,nonivamide,,,0,0
BRD-K05919151-001-01-6::2.5::HTS,BRD-K05919151-001-01-6,dixanthogen,2.5,HTS,CN_LINC00632 (286411),CN,noncancer,,,,,Preclinical,0.24405331381466397,-0.00672825020021,dixanthogen,,,0,0
BRD-K05977355-001-19-0::2.5::HTS,BRD-K05977355-001-19-0,fluconazole,2.5,HTS,PROT_p70S6K_pT389,PROT,noncancer,sterol demethylase inhibitor,CYP51A1,infectious disease,"esophageal candidiasis, meningitis",Launched,0.28634098866475394,0.00510312365683,fluconazole,,,0,0
BRD-K06147391-300-06-8::2.5::HTS,BRD-K06147391-300-06-8,telenzepine,2.5,HTS,DEM2_LEFTY1 (10637),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CHRM1,,,Phase 3,0.275067821680212,0.101423637299,telenzepine,,,0,0
BRD-K06152156-001-01-8::2.5::HTS,BRD-K06152156-001-01-8,methoxyflurane,2.5,HTS,MIRNA_hsa-miR-1247,MIRNA,noncancer,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,Launched,0.276493220097143,0.105027745728,methoxyflurane,,,0,0
BRD-K06181161-048-15-1::2.5::HTS,BRD-K06181161-048-15-1,carbetapentane,2.5,HTS,PROT_MDM2_pS166,PROT,noncancer,acetylcholine receptor antagonist,CHRM2,"otolaryngology, pulmonary","common cold, nasal congestion, bronchitis",Launched,0.312694816833735,0.123378101997,carbetapentane,,,0,0
BRD-K06182768-001-02-3::2.5::MTS004,BRD-K06182768-001-02-3,A-366,2.5,MTS004,CN_EPN2-IT1 (100874309),CN,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.23203910183159698,0.114740275579,A-366,,,0,0
BRD-K06208435-003-08-2::2.5::HTS,BRD-K06208435-003-08-2,YS-035,2.5,HTS,RMUTmis_LRP1B (53353),MUTmis,noncancer,calcium channel blocker,,,,Preclinical,0.294375213012342,0.0310002250934,YS-035,,,0,0
BRD-K06221026-001-06-8::2.5::HTS,BRD-K06221026-001-06-8,DUP-697,2.5,HTS,MIRNA_hsa-miR-1261,MIRNA,noncancer,cyclooxygenase inhibitor,PTGS2,,,Phase 1,0.236701232392875,0.0116403853501,DUP-697,,,0,0
BRD-K06222852-001-03-2::2.5::HTS,BRD-K06222852-001-03-2,posaconazole,2.5,HTS,CRISPR_WDR24 (84219),AVANA_PUBLIC_18Q2,noncancer,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,Launched,0.323222216071676,0.0803309655141,posaconazole,OTHER,0.30053166239183376,2.509018745317019,-2.8246500111014106
BRD-K06234293-001-04-2::2.5::HTS,BRD-K06234293-001-04-2,LY364947,2.5,HTS,PROT_Caveolin-1,PROT,targeted cancer,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,,,Preclinical,0.33240407495702196,0.1405608521,LY364947,,,0,0
BRD-K06240250-001-01-6::2.5::HTS,BRD-K06240250-001-01-6,rilpivirine,2.5,HTS,Exp_FRG2B (ENSG00000225899),GE,noncancer,non-nucleoside reverse transcriptase inhibitor,"NR1I2, SCN10A",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.31695230945833297,0.116780718124,rilpivirine,,,0,0
BRD-K06273313-001-07-9::2.5::MTS004,BRD-K06273313-001-07-9,E-64,2.5,MTS004,METABOL_C18:0 SM,METABOL,noncancer,"cysteine protease inhibitor, calpain inhibitor",CTSS,,,Preclinical,0.263757819496599,0.0537726619283,E-64,,,0,0
BRD-K06294530-001-01-5::2.5::HTS,BRD-K06294530-001-01-5,UK-383367,2.5,HTS,PROT_C-Raf_pS338,PROT,noncancer,Procollagen C-Endopeptidase Inhibitors,BMP1,,,Phase 1,0.313084682104484,0.176036921602,UK-383367,OTHER,0.32690684432446565,-3.608441745296461,-0.8384278901686959
BRD-K06328344-015-01-7::2.500004254::MTS004,BRD-K06328344-015-01-7,bremelanotide,2.500004254,MTS004,Exp_ZBTB12 (ENSG00000204366),GE,noncancer,melanocortin receptor agonist,"MC1R, MC2R, MC3R, MC4R, MC5R",,,Phase 3,0.29527931594720097,0.0832041835572,bremelanotide,,,0,0
BRD-K06335600-003-20-7::2.5::HTS,BRD-K06335600-003-20-7,tizanidine,2.5,HTS,PROT_eEF2K,PROT,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, NISCH",neurology/psychiatry,spasms,Launched,0.28449518275474,0.0532098275396,tizanidine,,,0,0
BRD-K06357403-001-01-4::2.49996939::MTS004,BRD-K06357403-001-01-4,velneperit,2.49996939,MTS004,RMUTmis_PRDM7 (11105),MUTmis,noncancer,neuropeptide receptor antagonist,NPY5R,,,Phase 2,0.34259005703589396,-0.0661248506941,velneperit,,,0,0
BRD-K06388322-312-02-6::2.5::HTS,BRD-K06388322-312-02-6,pramipexole,2.5,HTS,METHYL_C6orf1,METHYL,noncancer,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,Parkinson's Disease,Launched,0.234153759247312,0.091387510118,pramipexole,,,0,0
BRD-K06388517-001-01-2::2.5::MTS004,BRD-K06388517-001-01-2,lofemizole,2.5,MTS004,Exp_ANKUB1 (ENSG00000206199),GE,noncancer,cyclooxygenase inhibitor,,,,Phase 3,0.284046362646867,0.0911411072586,lofemizole,,,0,0
BRD-K06408664-001-03-5::2.5::HTS,BRD-K06408664-001-03-5,fludrocortisone-acetate,2.5,HTS,PROT_RBM15,PROT,noncancer,,"AR, NR3C1, NR3C2",endocrinology,"Addison's disease, adrenogenital syndrome",Launched,0.30094976711311305,0.0830624949949,fludrocortisone-acetate,OTHER,0.2990600450696257,-2.0585320614330604,-2.9504377010889167
BRD-K06426971-001-02-7::2.5::HTS,BRD-K06426971-001-02-7,ryuvidine,2.5,HTS,Exp_PGD (ENSG00000142657),GE,noncancer,histone lysine methyltransferase inhibitor,"CDK2, CDK4",,,Preclinical,0.40780339200481497,0.37476396424,ryuvidine,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4080770292425621,3.94856715315891,-0.6531890747817841
BRD-K06455935-001-01-3::2.499992329::MTS004,BRD-K06455935-001-01-3,daprodustat,2.499992329,MTS004,Exp_NDRG1 (ENSG00000104419),GE,noncancer,hypoxia inducible factor inhibitor,EGLN1,,,Phase 3,0.346738581608312,0.355638845275,daprodustat,HIF PROLYL HYDROXYLASE,0.3479482812084938,-7.402190002526455,0.6919605281634054
BRD-K06467130-304-02-7::2.5::MTS004,BRD-K06467130-304-02-7,CL316243,2.5,MTS004,MIRNA_hsa-let-7a,MIRNA,noncancer,adrenergic receptor agonist,"ADRB3, UCP1, UCP2, UCP3",,,Phase 2,0.30011756785828997,0.063215418932,CL316243,,,0,0
BRD-K06502269-001-02-6::2.5::MTS004,BRD-K06502269-001-02-6,L-methionine,2.5,MTS004,METABOL_C34:4 PC,METABOL,noncancer,voltage-gated calcium channel ligand,,,,Launched,0.329844562076407,0.129205416164,L-methionine,,,0,0
BRD-K06519765-001-01-1::2.5::MTS004,BRD-K06519765-001-01-1,vinblastine,2.5,MTS004,Exp_TBPL1 (ENSG00000028839),GE,chemo,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma",Launched,0.374307588486506,0.402916330164,vinblastine,OTHER,0.3763534084842421,5.672617216773956,-3.807764284022219
BRD-K06542892-001-01-9::2.5::HTS,BRD-K06542892-001-01-9,ASP3026,2.5,HTS,METABOL_erythrose-4-phosphate,METABOL,targeted cancer,ALK tyrosine kinase receptor inhibitor,ALK,,,Phase 1,0.309770632755469,0.0538041189008,ASP3026,,,0,0
BRD-K06543683-066-02-1::2.5::HTS,BRD-K06543683-066-02-1,bisindolylmaleimide-ix,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",,,Preclinical,0.418383426722534,0.484855934981,bisindolylmaleimide-ix,OTHER,0.4161579288460412,4.2898232771182325,-2.5593926212919293
BRD-K06593056-001-04-8::2.5::HTS,BRD-K06593056-001-04-8,LE-135,2.5,HTS,DEM2_GINS1 (9837),DEMETER2_COM,noncancer,retinoid receptor agonist,RARB,,,Preclinical,0.243168478305041,0.0440125334873,LE-135,,,0,0
BRD-K06644925-001-03-0::2.5::HTS,BRD-K06644925-001-03-0,oleamide,2.5,HTS,MIRNA_hsa-miR-1976,MIRNA,noncancer,cannabinoid receptor agonist,"HTR7, PLA2G2A",,,Preclinical,0.326916709783892,0.0687308433648,oleamide,,,0,0
BRD-K06674495-334-03-2::2.5::HTS,BRD-K06674495-334-03-2,nafamostat,2.5,HTS,CRISPR_COPRS (55352),AVANA_PUBLIC_18Q2,noncancer,serine protease inhibitor,"ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7",,,Launched,0.22638142718660897,0.186989672378,nafamostat,,,0,0
BRD-K06749501-001-02-1::2.5::HTS,BRD-K06749501-001-02-1,GSK1838705A,2.5,HTS,Exp_ST6GAL1 (ENSG00000073849),GE,targeted cancer,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",,,Preclinical,0.33028622574550504,0.166291407194,GSK1838705A,OTHER,0.3749829292287016,2.157246285957804,-3.0445743924509414
BRD-K06753942-001-14-5::2.5::HTS,BRD-K06753942-001-14-5,nobiletin,2.5,HTS,DEM2_CALD1 (800),DEMETER2_COM,targeted cancer,MEK inhibitor,MAP2K1,,,Preclinical,0.307243806597652,0.0778531800475,nobiletin,,,0,0
BRD-K06762493-001-08-1::2.5::HTS,BRD-K06762493-001-08-1,isbufylline,2.5,HTS,CN_KCNK18 (338567),CN,noncancer,phosphodiesterase inhibitor,,,,Phase 2,0.254530587284544,0.047864769496,isbufylline,,,0,0
BRD-K06854232-001-19-9::2.5::HTS,BRD-K06854232-001-19-9,AM-580,2.5,HTS,METHYL_DDX60,METHYL,targeted cancer,retinoid receptor agonist,RARA,,,Preclinical,0.223762180462482,0.0574910433837,AM-580,,,0,0
BRD-K06858286-001-01-3::2.5::HTS,BRD-K06858286-001-01-3,cabazitaxel,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,chemo,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,Launched,0.419722438727628,0.226340289168,cabazitaxel,OTHER,0.4136556066589647,5.139944204404794,-2.4725478752576766
BRD-K06878038-001-18-6::2.5::HTS,BRD-K06878038-001-18-6,deferiprone,2.5,HTS,MIRNA_hsa-miR-486-3p,MIRNA,noncancer,chelating agent,UGT1A6,hematology,"transfusional hemosiderosis, thalassemia, iron overload",Launched,0.25584302656776303,0.0894991441827,deferiprone,,,0,0
BRD-K06883221-001-01-9::2.686662955::MTS004,BRD-K06883221-001-01-9,apratastat,2.686662955,MTS004,Exp_COPZ2 (ENSG00000005243),GE,noncancer,"matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9",,,Phase 2,0.304479187478029,0.0877732293531,apratastat,,,0,0
BRD-K06900071-001-01-2::2.5::HTS,BRD-K06900071-001-01-2,tebipenem,2.5,HTS,MIRNA_hsa-miR-1246,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,CNR1,"infectious disease, otolaryngology","pneumonia, otitis",Launched,0.272002438657298,0.0659832772162,tebipenem,,,0,0
BRD-K06902185-003-01-7::2.5::HTS,BRD-K06902185-003-01-7,minoxidil,2.5,HTS,CN_ANKRD27 (84079),CN,noncancer,"KATP activator, Kir6 channel (KATP) activator, vasodilator","ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1",endocrinology,androgenetic alopecia,Launched,0.28480824075894606,0.0680542006379,minoxidil,,,0,0
BRD-K06980535-003-25-9::2.5::HTS,BRD-K06980535-003-25-9,promazine,2.5,HTS,MIRNA_hsa-miR-138,MIRNA,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,Launched,0.232119132522098,0.129581213434,promazine,,,0,0
BRD-K07070922-001-01-4::2.5::MTS004,BRD-K07070922-001-01-4,PF-03049423,2.5,MTS004,PROT_INPP4B,PROT,noncancer,phosphodiesterase inhibitor,PDE5A,,,Phase 2,0.225384687212631,0.0881204887846,PF-03049423,,,0,0
BRD-K07106112-003-03-8::2.5::HTS,BRD-K07106112-003-03-8,BMS-599626,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",,,Phase 1,0.44817107663452505,0.458812662162,BMS-599626,EGFR INHIBITOR,0.4247440304764435,1.0136431900793197,-5.059065347105403
BRD-K07160047-001-01-3::2.5::HTS,BRD-K07160047-001-01-3,fiacitabine,2.5,HTS,CRISPR_MCL1 (4170),AVANA_PUBLIC_18Q2,noncancer,DNA synthesis inhibitor,,,,Phase 2,0.207513358979123,0.0259605049166,fiacitabine,,,0,0
BRD-K07166362-330-02-8::2.5::HTS,BRD-K07166362-330-02-8,streptomycin,2.5,HTS,RMUTmis_PCDHB5 (26167),MUTmis,noncancer,bacterial 30S ribosomal subunit inhibitor,,infectious disease,tuberculosis,Launched,0.237959572646767,0.0785698656374,streptomycin,,,0,0
BRD-K07202345-001-19-4::2.5::HTS,BRD-K07202345-001-19-4,frentizole,2.5,HTS,PROT_p21,PROT,noncancer,immunosuppressant,,,,Phase 1,0.284913461661134,0.0628684764163,frentizole,,,0,0
BRD-K07208025-001-29-7::2.5::HTS,BRD-K07208025-001-29-7,trimethoprim,2.5,HTS,PROT_eIF4G_Caution,PROT,noncancer,dihydrofolate reductase inhibitor,"DHFR, TYMS","infectious disease, gastroenterology","urinary tract infections, ear infections, diarrhea",Launched,0.259547837681992,0.021979818732,trimethoprim,,,0,0
BRD-K07220430-001-18-4::2.5::HTS,BRD-K07220430-001-18-4,cinnarazine,2.5,HTS,RMUThot_PIK3CA (5290),MUThot,noncancer,calcium channel blocker,,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome",Launched,0.286750208595682,0.0793900237764,cinnarazine,,,0,0
BRD-K07220430-001-19-2::2.5::HTS,BRD-K07220430-001-19-2,cinnarazine,2.5,HTS,METABOL_C56:3 TAG,METABOL,noncancer,calcium channel blocker,,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome",Launched,0.261194354659368,0.0836396926178,cinnarazine,,,0,0
BRD-K07237224-001-19-6::2.5::HTS,BRD-K07237224-001-19-6,moclobemide,2.5,HTS,PROT_Gab2,PROT,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,"depression, anxiety",Launched,0.263661524972009,0.115223235075,moclobemide,,,0,0
BRD-K07265709-003-05-6::2.61::HTS,BRD-K07265709-003-05-6,dexrazoxane,2.61,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,Launched,0.376644810533462,0.388675733791,dexrazoxane,OTHER,0.3758012866050104,5.041303594211862,-3.5743663961363947
BRD-K07283971-001-01-3::2.5::HTS,BRD-K07283971-001-01-3,oxyclozanide,2.5,HTS,METABOL_cAMP,METABOL,noncancer,,,infectious disease,fascioliasis,Launched,0.16760279879565199,0.070978035827,oxyclozanide,,,0,0
BRD-K07359318-001-03-9::2.45::HTS,BRD-K07359318-001-03-9,benfotiamine,2.45,HTS,Exp_MTX1 (ENSG00000173171),GE,noncancer,antioxidant,AGER,rheumatology,lumbago,Launched,0.32616502407237297,0.182540180827,benfotiamine,,,0,0
BRD-K07409305-001-01-1::2.391201575::MTS004,BRD-K07409305-001-01-1,Org-12962,2.391201575,MTS004,Exp_MT1H (ENSG00000205358),GE,noncancer,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",,,Phase 2,0.270581758814971,0.0358263079735,Org-12962,,,0,0
BRD-K07441213-001-18-9::2.5::HTS,BRD-K07441213-001-18-9,paroxypropione,2.5,HTS,METHYL_KIAA1467,METHYL,noncancer,gonadotropin inhibitor,,,,Launched,0.328147505161419,0.012242128117,paroxypropione,,,0,0
BRD-K07442505-001-03-6::2.5::HTS,BRD-K07442505-001-03-6,BAM7,2.5,HTS,CN_CDC42EP2 (10435),CN,targeted cancer,BAX activator,BAX,,,Preclinical,0.27929555381503496,0.08916865554,BAM7,,,0,0
BRD-K07487750-001-03-3::2.5::HTS,BRD-K07487750-001-03-3,WHI-P154,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",,,Preclinical,0.346733784424112,0.323532912014,WHI-P154,OTHER,0.3256891773590692,0.8241431519540047,-5.1683183824541015
BRD-K07507905-236-02-6::2.5::HTS,BRD-K07507905-236-02-6,BRL-37344,2.5,HTS,DEM2_NPR2 (4882),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,Phase 2,0.283183846968899,0.0277640393091,BRL-37344,,,0,0
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,Exp_UGT1A10 (ENSG00000242515),GE,targeted cancer,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,Launched,0.37832256278215104,0.460146229389,curcumin,OTHER,0.3789770977073541,4.075380820463593,-3.5193950398683675
BRD-K07612980-001-07-9::2.5::HTS,BRD-K07612980-001-07-9,sparfloxacin,2.5,HTS,RMUTmis_PALLD (23022),MUT,noncancer,bacterial DNA gyrase inhibitor,TOP2A,,,Withdrawn,0.28015195945863697,0.103313418135,sparfloxacin,,,0,0
BRD-K07625016-001-01-2::2.50703254::MTS004,BRD-K07625016-001-01-2,norethisterone-enanthate,2.50703254,MTS004,Exp_ZNF474 (ENSG00000164185),GE,noncancer,contraceptive agent,,endocrinology,contraceptive,Launched,0.33513707608377397,0.170448865522,norethisterone-enanthate,,,0,0
BRD-K07682953-001-01-8::2.499993276::MTS004,BRD-K07682953-001-01-8,palosuran,2.499993276,MTS004,PROT_NF2_Caution,PROT,noncancer,urotensin receptor antagonist,UTS2R,,,Phase 2,0.28482389126742796,0.123594264575,palosuran,,,0,0
BRD-K07691486-001-15-5::2.5::HTS,BRD-K07691486-001-15-5,roscovitine,2.5,HTS,METHYL_SNORD116-15,METHYL,targeted cancer,CDK inhibitor,"CDK2, CDK9",,,Phase 2,0.262911398170335,0.0726553577281,roscovitine,,,0,0
BRD-K07736136-001-04-6::2.51::HTS,BRD-K07736136-001-04-6,VX-702,2.51,HTS,DEM2_LOC107984562 (107984562),DEMETER2_COM,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",,,Phase 2,0.34140178356321604,0.00458742798252,VX-702,,,0,0
BRD-K07753030-003-17-6::2.5::HTS,BRD-K07753030-003-17-6,acecainide,2.5,HTS,METABOL_lactose,METABOL,noncancer,polarization inhibitor,SCN5A,,,Phase 3,0.25908225139462,-0.0246102587598,acecainide,,,0,0
BRD-K07762753-001-04-4::2.5::HTS,BRD-K07762753-001-04-4,aminopurvalanol-a,2.5,HTS,Exp_DCTN3 (ENSG00000137100),GE,targeted cancer,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",,,Preclinical,0.311502836085631,0.183284558968,aminopurvalanol-a,CDK INHIBITOR,0.3124725757388038,4.634481409922142,-2.1105525080986176
BRD-K07785030-001-01-6::2.29884119::MTS004,BRD-K07785030-001-01-6,7-keto-DHEA,2.29884119,MTS004,Exp_OSBP2 (ENSG00000184792),GE,noncancer,steroid,,,,Launched,0.28693824369623,0.147710583451,7-keto-DHEA,,,0,0
BRD-K07790550-001-01-6::2.500001908::MTS004,BRD-K07790550-001-01-6,mavoglurant,2.500001908,MTS004,METABOL_aconitate,METABOL,noncancer,glutamate receptor antagonist,GRM5,,,Phase 2,0.26308798951666,0.101015276116,mavoglurant,,,0,0
BRD-K07798980-001-01-9::2.5::HTS,BRD-K07798980-001-01-9,PSI-6130,2.5,HTS,Exp_NKX1-2 (ENSG00000229544),GE,noncancer,RNA polymerase inhibitor,,,,Phase 1,0.281000701462518,0.130937738916,PSI-6130,,,0,0
BRD-K07857022-002-01-1::2.5::HTS,BRD-K07857022-002-01-1,alvimopan,2.5,HTS,CN_SULT1A1 (6817),CN,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,postoperative ileus,Launched,0.23148398300111497,-0.00391733428954,alvimopan,,,0,0
BRD-K07881437-001-03-8::2.5::HTS,BRD-K07881437-001-03-8,danusertib,2.5,HTS,PROT_XBP1_Caution,PROT,targeted cancer,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,AURORA KINASE INHIBITOR,0.2837208582858569,4.649412073545898,-2.300150941263573
BRD-K07881437-001-04-6::2.41::HTS,BRD-K07881437-001-04-6,danusertib,2.41,HTS,PROT_HER3,PROT,targeted cancer,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,AURORA KINASE INHIBITOR,0.3831285169133298,4.807608421263585,-2.115120817832654
BRD-K07940445-310-02-9::2.5::HTS,BRD-K07940445-310-02-9,quinine,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,noncancer,hemozoin biocrystallization inhibitor,"GP9, KCNB2, KCNN4, SLC29A4",infectious disease,malaria,Launched,0.308409412717772,0.0987868504395,quinine,,,0,0
BRD-K07954936-001-01-3::2.5::HTS,BRD-K07954936-001-01-3,2-iminobiotin,2.5,HTS,CN_ZNF664-FAM101A (100533183),CN,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2",,,Phase 2,0.287930855198147,0.136691747384,2-iminobiotin,,,0,0
BRD-K07955840-001-02-3::2.5::HTS,BRD-K07955840-001-02-3,PF-05212384,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",,,Phase 2,0.382687800620755,0.564858659535,PF-05212384,MTOR INHIBITOR,0.3852296565502841,3.989082123526386,-1.4161922013574806
BRD-K08033334-003-04-3::2.5::HTS,BRD-K08033334-003-04-3,lincomycin,2.5,HTS,PROT_TFRC,PROT,noncancer,bacterial 30S ribosomal subunit inhibitor,,gastroenterology,enteritis,Launched,0.26586063326773895,0.0222308491783,lincomycin,,,0,0
BRD-K08037784-001-12-6::2.5::HTS,BRD-K08037784-001-12-6,arbutin,2.5,HTS,MUTpool_MAP3K9 (4293),MUTpool,noncancer,melanin inhibitor,TYR,,,Phase 2/Phase 3,0.208056417322299,0.117882508331,arbutin,,,0,0
BRD-K08078237-001-19-8::2.5::HTS,BRD-K08078237-001-19-8,tetrandrine,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,targeted cancer,calcium channel blocker,SLC6A3,,,Preclinical,0.39961950152674197,0.305633865108,tetrandrine,OTHER,0.3996904634177592,5.073194231686816,-0.8605365484963716
BRD-K08109215-001-06-4::2.5::HTS,BRD-K08109215-001-06-4,I-BET-762,2.5,HTS,PROT_p38_MAPK,PROT,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 2,0.30116579822616996,0.188425739311,I-BET-762,BROMODOMAIN INHIBITOR,0.2992486390162427,-0.3304865239185704,3.085886346552537
BRD-K08109516-001-07-8::2.5::HTS,BRD-K08109516-001-07-8,L-701324,2.5,HTS,RMUTmis_ATXN7L1 (222255),MUT,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Preclinical,0.258458621216774,0.0436453690954,L-701324,,,0,0
BRD-K08111240-001-02-8::2.5::HTS,BRD-K08111240-001-02-8,danoprevir,2.5,HTS,PROT_p62 Lck ligand_Caution,PROT,noncancer,HCV inhibitor,,,,Phase 2,0.267806858654475,0.0331899515967,danoprevir,,,0,0
BRD-K08111712-001-16-7::2.5::HTS,BRD-K08111712-001-16-7,chloramphenicol,2.5,HTS,CN_HRK (8739),CN,noncancer,bacterial 50S ribosomal subunit inhibitor,CD55,"infectious disease, endocrinology","meningitis, fever, cholera",Launched,0.299037796328363,0.0530793713712,chloramphenicol,,,0,0
BRD-K08188887-001-02-4::2.5::HTS,BRD-K08188887-001-02-4,astragaloside-a,2.5,HTS,CN_FBXO9 (26268),CN,noncancer,antiinflammatory agent,,,,Preclinical,0.388365569918682,0.0846092890962,astragaloside-a,,,0,0
BRD-K08206212-002-01-0::2.5::HTS,BRD-K08206212-002-01-0,entecavir,2.5,HTS,MUTpool_FAM189B (10712),MUTpool,noncancer,"DNA replication inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,hepatitis B,Launched,0.20189874922495898,0.0597220560327,entecavir,,,0,0
BRD-K08223200-001-01-1::2.5::HTS,BRD-K08223200-001-01-1,WAY-200070,2.5,HTS,Exp_PRKCH (ENSG00000027075),GE,noncancer,estrogen receptor agonist,"ERBB2, ERBB3, ERBB4, ESR2",,,Preclinical,0.30235612352846997,0.118366818102,WAY-200070,,,0,0
BRD-K08231299-001-08-1::2.5::HTS,BRD-K08231299-001-08-1,propoxur,2.5,HTS,CN_PI4KAP2 (375133),CN,noncancer,,,,,Launched,0.28216094059172897,0.0585718056571,propoxur,,,0,0
BRD-K08248804-001-01-8::2.5::HTS,BRD-K08248804-001-01-8,LCL-161,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, XIAP",,,Phase 2,0.443605934389414,0.367897107999,LCL-161,XIAP INHIBITOR,0.4449477833329341,4.875151993458472,-2.260915031304023
BRD-K08251020-001-01-0::2.5::HTS,BRD-K08251020-001-01-0,falecalcitriol,2.5,HTS,METHYL_S100A14,METHYL,noncancer,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,Launched,0.325355124773793,0.25658416568,falecalcitriol,VITAMIN D RECEPTOR AGONIST,0.3240369976895801,0.3068969909447711,-1.4454633341750212
BRD-K08252256-236-33-8::2.5::HTS,BRD-K08252256-236-33-8,diclofenac,2.5,HTS,CN_IGLL3P (91353),CN,noncancer,cyclooxygenase inhibitor,"AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A","rheumatology, neurology/psychiatry","rheumatoid arthritis, osteoarthritis, migraine headache",Launched,0.232369926615497,0.0623908662208,diclofenac,,,0,0
BRD-K08255599-365-01-1::2.656154742::MTS004,BRD-K08255599-365-01-1,frovatriptan,2.656154742,MTS004,CN_EPHA5-AS1 (100144602),CN,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D",neurology/psychiatry,migraine headache,Launched,0.312931003939863,0.0826875082854,frovatriptan,,,0,0
BRD-K08273968-001-19-0::2.5::HTS,BRD-K08273968-001-19-0,griseofulvin,2.5,HTS,DEM2_FOXN2 (3344),DEMETER2_COM,noncancer,tubulin polymerization inhibitor,KRT12,infectious disease,"ringworm, tinea pedis",Launched,0.31846055633046805,0.162684966945,griseofulvin,,,0,0
BRD-K08287586-001-14-3::2.5::HTS,BRD-K08287586-001-14-3,butyl-paraben,2.5,HTS,METABOL_C16:0 CE,METABOL,noncancer,DNA synthesis inhibitor,,,,Preclinical,0.27077290101683105,0.0676468322034,butyl-paraben,,,0,0
BRD-K08288352-001-03-6::2.5::HTS,BRD-K08288352-001-03-6,1-ethyl-2-pyrrolidone,2.5,HTS,CRISPR_OR5M9 (390162),AVANA_PUBLIC_18Q2,noncancer,transdermal absorption-enhancing compound,,,,Preclinical,0.22672478173795,0.0820876105464,1-ethyl-2-pyrrolidone,,,0,0
BRD-K08303368-001-10-0::2.5::HTS,BRD-K08303368-001-10-0,chlorpyrifos,2.5,HTS,DEM2_SERPINB10 (5273),DEMETER2_COM,noncancer,acetylcholinesterase inhibitor,ACHE,,,Launched,0.23839880149210396,0.148566905171,chlorpyrifos,,,0,0
BRD-K08356259-003-24-7::2.5::HTS,BRD-K08356259-003-24-7,xylometazoline,2.5,HTS,CRISPR_BRE (9577),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","otolaryngology, allergy","nasal congestion, allergic rhinitis",Launched,0.315093387589483,0.0778571217628,xylometazoline,,,0,0
BRD-K08493205-001-04-9::2.5::HTS,BRD-K08493205-001-04-9,salicyl-alcohol,2.5,HTS,MUTpool_MT-CYB (4519),MUTpool,noncancer,,,,,Preclinical,0.31327367254833,0.0925616977979,salicyl-alcohol,,,0,0
BRD-K08525451-003-05-2::2.5::HTS,BRD-K08525451-003-05-2,sarafloxacin,2.5,HTS,Exp_MT1H (ENSG00000205358),GE,noncancer,bacterial DNA gyrase inhibitor,,,,Launched,0.275684876441668,0.120655945685,sarafloxacin,OTHER,0.2754721164812623,3.8038578107247942,-1.0891570624673037
BRD-K08542803-001-03-1::0.8::HTS,BRD-K08542803-001-03-1,gambogic-acid,0.8,HTS,METHYL_CCNI2,METHYL,targeted cancer,caspase activator,BCL2,,,Phase 2,0.363980498623811,0.229874026189,gambogic-acid,OTHER,0.3704107553583408,3.9316486335822334,-0.9546035402306554
BRD-K08547377-394-03-5::2.5::HTS,BRD-K08547377-394-03-5,irinotecan,2.5,HTS,Exp_EDA2R (ENSG00000131080),GE,chemo,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,Launched,0.291528500539335,0.267568033885,irinotecan,TOPOISOMERASE INHIBITOR,0.29113542741333576,4.626762903016814,-2.589856350248934
BRD-K08586861-001-01-1::2.5::HTS,BRD-K08586861-001-01-1,ramatroban,2.5,HTS,PROT_beta-Catenin_pT41_S45,PROT,noncancer,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",Launched,0.222284497229115,0.0853215374027,ramatroban,OTHER,0.15583115451443838,5.3773527995164665,-0.8691576767590679
BRD-K08619574-334-05-4::2.5::HTS,BRD-K08619574-334-05-4,thioproperazine,2.5,HTS,LIN_lung_squamous,LIN,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.323860240898947,0.0822869384558,thioproperazine,,,0,0
BRD-K08619838-300-05-7::2.5::HTS,BRD-K08619838-300-05-7,tremorine,2.5,HTS,CN_HMOX1 (3162),CN,noncancer,acetylcholine receptor agonist,,,,Preclinical,0.326335256503412,0.0683728422626,tremorine,,,0,0
BRD-K08640512-003-02-3::2.5::HTS,BRD-K08640512-003-02-3,RS-100329,2.5,HTS,MIRNA_hsa-miR-486-3p,MIRNA,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1D",,,Preclinical,0.295418509617094,0.0898324925456,RS-100329,,,0,0
BRD-K08703257-001-12-1::2.5::HTS,BRD-K08703257-001-12-1,3-amino-benzamide,2.5,HTS,CN_HELLS (3070),CN,targeted cancer,PARP inhibitor,PARP1,,,Phase 2,0.256707578718196,0.0569622591773,3-amino-benzamide,,,0,0
BRD-K08791496-001-01-0::2.5::HTS,BRD-K08791496-001-01-0,fenaclon,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,,,,,Preclinical,0.312445461690734,0.0818760002503,fenaclon,,,0,0
BRD-K08799216-001-05-3::2.5::HTS,BRD-K08799216-001-05-3,pelitinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,EGFR inhibitor,EGFR,,,Phase 2,0.327475309570815,0.29880108215,pelitinib,EGFR INHIBITOR,0.3229821376454882,4.026639438102257,-1.7492747571805165
BRD-K08832567-001-11-5::2.5::HTS,BRD-K08832567-001-11-5,naringenin,2.5,HTS,DEM2_PPHLN1 (51535),DEMETER2_COM,targeted cancer,"aromatase inhibitor, TRPV antagonist","CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1",,,Phase 1,0.250544180241294,0.0544961969498,naringenin,,,0,0
BRD-K08837089-236-01-6::2.5::HTS,BRD-K08837089-236-01-6,actinoquinol,2.5,HTS,CN_LINC00925 (254559),CN,noncancer,,,,,Preclinical,0.29259387336448806,0.0816543042303,actinoquinol,,,0,0
BRD-K08859203-001-01-9::2.5::HTS,BRD-K08859203-001-01-9,DU-728,2.5,HTS,MIRNA_hsa-miR-583,MIRNA,targeted cancer,structural glycoprotein antagonist,"ITGA2B, ITGB3",,,Phase 1,0.25686872307404895,0.0531923409308,DU-728,,,0,0
BRD-K08864679-001-02-2::2.5::HTS,BRD-K08864679-001-02-2,fexaramine,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,FXR agonist,NR1H4,,,Preclinical,0.284814528349647,0.0836070378153,fexaramine,,,0,0
BRD-K08893438-001-04-9::2.52::HTS,BRD-K08893438-001-04-9,CCG-50014,2.52,HTS,CRISPR_TXNDC17 (84817),AVANA_PUBLIC_18Q2,noncancer,G protein signaling inhibitor,"RGS4, RGS8",,,Preclinical,0.355360204841318,0.221386236015,CCG-50014,,,0,0
BRD-K08924299-003-06-1::2.5::HTS,BRD-K08924299-003-06-1,palonosetron,2.5,HTS,CN_MYOM1 (8736),CN,noncancer,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting",Launched,0.311480984555682,0.0642631845188,palonosetron,,,0,0
BRD-K08953028-001-09-6::2.5::HTS,BRD-K08953028-001-09-6,U-0521,2.5,HTS,PROT_S6_pS235_S236,PROT,noncancer,catechol O methyltransferase inhibitor,COMT,,,Preclinical,0.26813126178547403,0.140919244537,U-0521,,,0,0
BRD-K08976401-001-18-5::2.5::HTS,BRD-K08976401-001-18-5,azelaic-acid,2.5,HTS,PROT_Beclin_Caution,PROT,noncancer,tyrosinase inhibitor,"AKR1D1, SRD5A2, TYR",dermatology,rosacea,Launched,0.263853890258341,0.0767787459314,azelaic-acid,,,0,0
BRD-K08996725-332-01-7::2.5::HTS,BRD-K08996725-332-01-7,zolantidine,2.5,HTS,PROT_JAK2,PROT,noncancer,histamine receptor antagonist,,,,Preclinical,0.3624253542741379,0.20257393044,zolantidine,OTHER,0.36608438485053535,2.683421157524275,-4.365336215249126
BRD-K08998509-001-02-4::2.5::HTS,BRD-K08998509-001-02-4,fananserin,2.5,HTS,METABOL_adenine,METABOL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,,,Phase 2,0.228022769840502,0.0028518065737,fananserin,,,0,0
BRD-K08999871-213-01-5::2.5::HTS,BRD-K08999871-213-01-5,pipemidic-acid,2.5,HTS,RMUTmis_RASAL3 (64926),MUTmis,noncancer,topoisomerase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.27499888404365597,0.153625416727,pipemidic-acid,,,0,0
BRD-K09090949-001-01-9::2.5::HTS,BRD-K09090949-001-01-9,"CP-945,598",2.5,HTS,METHYL_NR1H3,METHYL,noncancer,cannabinoid receptor antagonist,CNR1,,,Phase 3,0.25658612445524104,0.10945958112,"CP-945,598",OTHER,0.2005051085794207,3.456077590228372,-0.4283269609694593
BRD-K09126848-003-01-9::2.5::HTS,BRD-K09126848-003-01-9,nepicastat,2.5,HTS,DEM2_KLHL30 (377007),DEMETER2_COM,noncancer,dopamine beta hydroxylase inhibitor,DBH,,,Phase 2,0.28748807195537607,0.0520398689437,nepicastat,,,0,0
BRD-K09132007-001-07-5::2.5::HTS,BRD-K09132007-001-07-5,D-4476,2.5,HTS,RMUTdmg_TTF1 (7270),MUTdmg,noncancer,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",,,Preclinical,0.24482760762960698,0.0968304050692,D-4476,,,0,0
BRD-K09255212-001-16-6::2.5::HTS,BRD-K09255212-001-16-6,clioquinol,2.5,HTS,PROT_ATM,PROT,noncancer,chelating agent,OPRK1,,,Withdrawn,0.265212117116324,0.0527133769992,clioquinol,,,0,0
BRD-K09295674-001-09-8::2.5::HTS,BRD-K09295674-001-09-8,carzenide,2.5,HTS,PROT_MDMX_MDM4(BetIHC-00108)_Caution,PROT,noncancer,,"CA1, CA12, CA14, CA2, CA6, CA9",,,Preclinical,0.34161439780683694,0.0852003172276,carzenide,,,0,0
BRD-K09338665-001-07-1::2.5::HTS,BRD-K09338665-001-07-1,1-octanol,2.5,HTS,METABOL_C32:2 PC,METABOL,noncancer,,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1",,,Phase 2,0.301567885718604,0.0798674896717,1-octanol,,,0,0
BRD-K09353376-001-03-9::2.5::HTS,BRD-K09353376-001-03-9,tariquidar,2.5,HTS,Exp_SSTR2 (ENSG00000180616),GE,targeted cancer,P glycoprotein inhibitor,ABCB1,,,Phase 3,0.270235201822228,0.118616676751,tariquidar,,,0,0
BRD-K09372874-001-01-0::2.5::HTS,BRD-K09372874-001-01-0,merimepodib,2.5,HTS,Exp_MYLK (ENSG00000065534),GE,noncancer,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,,Phase 2,0.32617878499386,0.275649940659,merimepodib,OTHER,0.32594435564167384,3.847517653443197,-2.2761791500279647
BRD-K09397065-003-06-1::2.5::HTS,BRD-K09397065-003-06-1,SR-57227A,2.5,HTS,METABOL_anthranilic acid,METABOL,noncancer,serotonin receptor agonist,HTR3A,,,Phase 2,0.22812974482095896,0.027926397091,SR-57227A,,,0,0
BRD-K09416995-001-39-9::2.5::HTS,BRD-K09416995-001-39-9,lovastatin,2.5,HTS,Exp_TSKU (ENSG00000182704),GE,noncancer,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia",Launched,0.509039639666836,0.330185139721,lovastatin,HMGCR INHIBITOR,0.5153199239063254,1.7476398817897498,5.340249958634682
BRD-K09426783-300-01-0::2.5::HTS,BRD-K09426783-300-01-0,TAS-103,2.5,HTS,DEM2_USP1 (7398),DEMETER2_COM,chemo,topoisomerase inhibitor,TOP1,,,Phase 1,0.351838791701481,0.211791183243,TAS-103,TOPOISOMERASE INHIBITOR,0.3713923539283257,4.8271165627614385,-0.8988571339046123
BRD-K09436144-001-01-7::2.487366457::MTS004,BRD-K09436144-001-01-7,YM022,2.487366457,MTS004,DEM2_SAFB2 (9667),DEMETER2_COM,noncancer,CCK receptor antagonist,CCKBR,,,Phase 2,0.24101297572249397,0.0885456532487,YM022,,,0,0
BRD-K09443272-001-03-3::2.5::HTS,BRD-K09443272-001-03-3,PHA-680632,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.394879622964546,0.425459329737,PHA-680632,AURORA KINASE INHIBITOR,0.3971930737469404,4.328504927549684,-3.9034382471952753
BRD-K09471561-001-18-2::2.5::HTS,BRD-K09471561-001-18-2,levofloxacin,2.5,HTS,DEM2_NUP35 (129401),DEMETER2_COM,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, otolaryngology, pulmonary, urology","pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague",Launched,0.325822450844273,0.0511318220698,levofloxacin,,,0,0
BRD-K09537769-001-04-0::2.5::HTS,BRD-K09537769-001-04-0,NU-7026,2.5,HTS,METABOL_palmitoylcarnitine,METABOL,targeted cancer,"DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",PRKDC,,,Preclinical,0.271174566938797,0.0680850519485,NU-7026,,,0,0
BRD-K09549677-300-03-4::2.5::HTS,BRD-K09549677-300-03-4,mibefradil,2.5,HTS,METHYL_LINC01506,METHYL,noncancer,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",,,Withdrawn,0.23920572734448803,0.0263752937594,mibefradil,,,0,0
BRD-K09602097-001-13-6::2.5::HTS,BRD-K09602097-001-13-6,forskolin,2.5,HTS,CN_PCDHB8 (56128),CN,targeted cancer,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",,,Launched,0.31208613238169297,0.140043093851,forskolin,,,0,0
BRD-K09619322-001-03-8::2.5::HTS,BRD-K09619322-001-03-8,CD-1530,2.5,HTS,CN_GOLGA8T (653075),CN,noncancer,retinoid receptor agonist,RARG,,,Preclinical,0.231922567240614,0.175606220768,CD-1530,,,0,0
BRD-K09619578-001-01-3::2.5::HTS,BRD-K09619578-001-01-3,DS2-(806622),2.5,HTS,DEM2_MDM4 (4194),DEMETER2_COM,noncancer,,,,,Preclinical,0.28123601886553495,0.117612858438,DS2-(806622),,,0,0
BRD-K09635314-001-03-4::2.5::HTS,BRD-K09635314-001-03-4,m-3M3FBS,2.5,HTS,CRISPR_ZKSCAN8 (7745),AVANA_PUBLIC_18Q2,targeted cancer,,"PLCB2, PLCB3, PLCD1, PLCG1, PLCG2",,,Preclinical,0.30026645034144706,0.0844761404448,m-3M3FBS,,,0,0
BRD-K09659835-003-01-4::2.5::HTS,BRD-K09659835-003-01-4,loreclezole,2.5,HTS,CN_SENP6 (26054),CN,noncancer,benzodiazepine receptor agonist,"GABRB2, GABRB3",,,Phase 2,0.273199988758483,0.0309920509413,loreclezole,,,0,0
BRD-K09711437-001-04-3::2.5::HTS,BRD-K09711437-001-04-3,varespladib,2.5,HTS,DEM2_GOLGA4 (2803),DEMETER2_COM,noncancer,secretory phospholipase inhibitor,PLA2G2A,,,Phase 3,0.195168453548974,-0.0250629805105,varespladib,,,0,0
BRD-K09735259-001-01-3::2.500007896::MTS004,BRD-K09735259-001-01-3,elbasvir,2.500007896,MTS004,CRISPR_GRB10 (2887),AVANA_PUBLIC_18Q2,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.241895733235636,0.0573921971834,elbasvir,,,0,0
BRD-K09757388-065-04-0::2.5::HTS,BRD-K09757388-065-04-0,atazanavir,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.27204034805760896,0.0323647645531,atazanavir,,,0,0
BRD-K09778810-001-10-6::2.5::HTS,BRD-K09778810-001-10-6,FGIN-1-27,2.5,HTS,CRISPR_SH2D6 (284948),AVANA_PUBLIC_18Q2,noncancer,inositol monophosphatase inhibitor,TSPO,,,Preclinical,0.255888116936732,0.0490658872652,FGIN-1-27,,,0,0
BRD-K09785578-001-01-2::2.5::HTS,BRD-K09785578-001-01-2,bakuchiol,2.5,HTS,DEM2_NCSTN (23385),DEMETER2_COM,noncancer,DNA polymerase inhibitor,HIF1A,,,Phase 2,0.292335185742613,0.0117350818987,bakuchiol,,,0,0
BRD-K09821361-066-25-8::2.499990088::MTS004,BRD-K09821361-066-25-8,deferoxamine-mesylate,2.499990088,MTS004,CN_SPINT4 (391253),CN,noncancer,chelating agent,,hematology,"acute iron intoxication, iron overload",Launched,0.298398264005396,-0.0034634471225,deferoxamine-mesylate,OTHER,0.29791925480310205,-3.853495114918567,1.1642546665831366
BRD-K09877029-001-01-2::2.5::HTS,BRD-K09877029-001-01-2,VS-4718,2.5,HTS,Exp_CDKN2D (ENSG00000129355),GE,targeted cancer,focal adhesion kinase inhibitor,,,,Phase 1,0.316441479030099,0.273974549238,VS-4718,OTHER,0.31329037113625763,3.7852248126894494,-3.0133686052426256
BRD-K09900591-001-26-7::2.5::HTS,BRD-K09900591-001-26-7,caffeic-acid,2.5,HTS,Exp_LSM14A (ENSG00000257103),GE,noncancer,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",,,Preclinical,0.29957846204594607,0.129866838304,caffeic-acid,,,0,0
BRD-K09951645-001-06-8::2.5::HTS,BRD-K09951645-001-06-8,dabrafenib,2.5,HTS,DEM2_BRAF (673),DEMETER2_COM,targeted cancer,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,Launched,0.389754464300569,0.498900689281,dabrafenib,RAF INHIBITOR,0.3872259850587587,1.4995789029045268,3.6157406011155633
BRD-K10029415-005-06-9::2.5::HTS,BRD-K10029415-005-06-9,enisamium-iodide,2.5,HTS,PROT_Dvl3,PROT,noncancer,,,,,Launched,0.29176928864584195,0.0544942380714,enisamium-iodide,,,0,0
BRD-K10065684-001-07-4::2.5::HTS,BRD-K10065684-001-07-4,dantron,2.5,HTS,MUTpool_AGTPBP1 (23287),MUTpool,noncancer,laxative,,,,Withdrawn,0.358287190805148,-0.0238434826416,dantron,,,0,0
BRD-K10071630-001-01-0::2.5::HTS,BRD-K10071630-001-01-0,ertugliflozin,2.5,HTS,METHYL_MIR5100,METHYL,noncancer,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,Launched,0.284696636704232,0.11255913075,ertugliflozin,OTHER,0.2857294587432616,3.061609915564065,-2.649102293698066
BRD-K10176267-001-03-3::2.5::HTS,BRD-K10176267-001-03-3,L-701252,2.5,HTS,METHYL_CD4,METHYL,noncancer,glutamate receptor antagonist,GRIN1,,,Preclinical,0.28396218786863,0.0926050382962,L-701252,,,0,0
BRD-K10177585-003-02-4::2.5::HTS,BRD-K10177585-003-02-4,PSB-11,2.5,HTS,METHYL_QKI,METHYL,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA3",,,Preclinical,0.275989916981003,0.131083977859,PSB-11,,,0,0
BRD-K10196357-003-02-0::2.5::HTS,BRD-K10196357-003-02-0,besifloxacin,2.5,HTS,METHYL_NUDT8,METHYL,noncancer,bacterial DNA gyrase inhibitor,,ophthalmology,conjunctivitis,Launched,0.29941851159419297,0.0571678343766,besifloxacin,,,0,0
BRD-K10314788-003-12-7::2.5::HTS,BRD-K10314788-003-12-7,meclofenoxate,2.5,HTS,Exp_FOXD2 (ENSG00000186564),GE,noncancer,nootropic agent,,neurology/psychiatry,"senile dementia, Alzheimer's disease",Launched,0.29292054778890303,0.0652825857211,meclofenoxate,,,0,0
BRD-K10362825-001-03-4::2.5::HTS,BRD-K10362825-001-03-4,teniposide,2.5,HTS,DEM2_DHRS1 (115817),DEMETER2_COM,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.38298754958898606,0.163340900636,teniposide,TOPOISOMERASE INHIBITOR,0.3725798225354496,5.346628429557206,-0.5224288039204716
BRD-K10415035-001-04-4::2.5::MTS004,BRD-K10415035-001-04-4,tasuldine,2.5,MTS004,DEM2_AURKA (6790),DEMETER2_COM,noncancer,mucolytic agent,,,,Phase 3,0.329477686544758,0.157254604376,tasuldine,,,0,0
BRD-K10575656-034-01-0::2.5::HTS,BRD-K10575656-034-01-0,MRS3777,2.5,HTS,Exp_CYSLTR1 (ENSG00000173198),GE,noncancer,adenosine receptor antagonist,ADORA2A,,,Preclinical,0.24222461406593399,0.0252044720712,MRS3777,,,0,0
BRD-K10598093-303-06-1::2.5::HTS,BRD-K10598093-303-06-1,hexamethonium,2.5,HTS,METABOL_C54:1 TAG,METABOL,noncancer,cholinergic receptor antagonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6",,,Preclinical,0.27757201783710805,0.0704824657365,hexamethonium,,,0,0
BRD-K10667240-001-01-7::2.485820406::MTS004,BRD-K10667240-001-01-7,ethacizin,2.485820406,MTS004,Exp_FECH (ENSG00000066926),GE,noncancer,anticonvulsant,,cardiology,"ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)",Launched,0.29197779858612893,0.100211437846,ethacizin,,,0,0
BRD-K10670311-001-15-5::2.5::HTS,BRD-K10670311-001-15-5,sulfasalazine,2.5,HTS,PROT_Transglutaminase,PROT,noncancer,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,Launched,0.14894835496156,0.138142485909,sulfasalazine,,,0,0
BRD-K10671814-001-14-8::2.5::HTS,BRD-K10671814-001-14-8,sulfaphenazole,2.5,HTS,CRISPR_MORC1 (27136),AVANA_PUBLIC_18Q2,noncancer,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections,Launched,0.224300291681797,0.0749906421209,sulfaphenazole,,,0,0
BRD-K10673031-004-02-0::2.5::HTS,BRD-K10673031-004-02-0,S-Isopropylisothiourea,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,nitric oxide synthase inhibitor,NOS3,,,Preclinical,0.309594186292683,0.108754434701,S-Isopropylisothiourea,,,0,0
BRD-K10705233-001-02-2::2.5::HTS,BRD-K10705233-001-02-2,GW-405833,2.5,HTS,Exp_PRMT3 (ENSG00000185238),GE,noncancer,cannabinoid receptor agonist,CNR2,,,Preclinical,0.23245013687318,0.0374848590417,GW-405833,,,0,0
BRD-K10706131-046-03-6::2.5::HTS,BRD-K10706131-046-03-6,rivastigmine,2.5,HTS,PROT_ER-alpha_pS118,PROT,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,"Alzheimer's disease, Parkinson's Disease, senile dementia",Launched,0.26001219520234303,0.0972503237687,rivastigmine,,,0,0
BRD-K10759144-001-04-3::2.5::HTS,BRD-K10759144-001-04-3,xylose,2.5,HTS,CN_SYT1 (6857),CN,noncancer,,,,,Launched,0.241325290591347,0.113385673756,xylose,,,0,0
BRD-K10784860-003-02-3::2.5::HTS,BRD-K10784860-003-02-3,temocapril,2.5,HTS,CRISPR_ZNF44 (51710),AVANA_PUBLIC_18Q2,noncancer,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",Launched,0.35180172294022605,0.129796837099,temocapril,,,0,0
BRD-K10799896-001-26-2::2.5::HTS,BRD-K10799896-001-26-2,clobetasol-propionate,2.5,HTS,METHYL_ZNF71,METHYL,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.293026290538289,0.0873548591807,clobetasol-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2912176899445477,-1.9818466665009573,-3.1470636434458923
BRD-K10836013-001-01-3::2.5::HTS,BRD-K10836013-001-01-3,sitafloxacin,2.5,HTS,CRISPR_ANKRD13D (338692),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,buruli ulcer,Launched,0.23206394343123998,0.0558316784456,sitafloxacin,,,0,0
BRD-K10843433-001-22-7::2.5::HTS,BRD-K10843433-001-22-7,phenylbutazone,2.5,HTS,CN_THSD4 (79875),CN,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",,,Withdrawn,0.168665234616853,0.0592174556136,phenylbutazone,,,0,0
BRD-K10843433-001-23-5::2.58::HTS,BRD-K10843433-001-23-5,phenylbutazone,2.58,HTS,Exp_MRPL30 (ENSG00000185414),GE,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",,,Withdrawn,0.327875982187274,0.0711546379057,phenylbutazone,,,0,0
BRD-K10845183-304-01-6::2.5::HTS,BRD-K10845183-304-01-6,tiludronate,2.5,HTS,METHYL_ALX3,METHYL,noncancer,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,Launched,0.210589359003565,0.0340725053452,tiludronate,,,0,0
BRD-K10852020-001-04-5::2.5::HTS,BRD-K10852020-001-04-5,tolcapone,2.5,HTS,MIRNA_hsa-miR-204,MIRNA,noncancer,catechol O methyltransferase inhibitor,COMT,,,Withdrawn,0.22500655077611897,0.0773860663498,tolcapone,,,0,0
BRD-K10852020-001-05-2::2.57::HTS,BRD-K10852020-001-05-2,tolcapone,2.57,HTS,DEM2_ITSN1 (6453),DEMETER2_COM,noncancer,catechol O methyltransferase inhibitor,COMT,,,Withdrawn,0.301582392972297,0.129464755298,tolcapone,,,0,0
BRD-K10859802-001-01-0::2.5::HTS,BRD-K10859802-001-01-0,APD668,2.5,HTS,PROT_Lck,PROT,noncancer,glucose dependent insulinotropic receptor agonist,GPR119,,,Phase 1,0.211389827084077,0.0616033459119,APD668,,,0,0
BRD-K10878147-001-02-2::2.5::HTS,BRD-K10878147-001-02-2,OAC1,2.5,HTS,MIRNA_hsa-miR-1470,MIRNA,noncancer,Oct activator,,,,Preclinical,0.318796916807908,0.0434845308415,OAC1,,,0,0
BRD-K10906636-001-02-9::2.67::HTS,BRD-K10906636-001-02-9,silodosin,2.67,HTS,PROT_JNK_pT183_Y185,PROT,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),Launched,0.30013526667392604,0.165366743446,silodosin,,,0,0
BRD-K10961822-001-05-1::2.5::HTS,BRD-K10961822-001-05-1,latanoprost,2.5,HTS,Exp_OMP (ENSG00000254550),GE,noncancer,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",Launched,0.308548992801302,0.209526073675,latanoprost,OTHER,0.2962948535223808,4.153185950907941,-0.4203745111658312
BRD-K10974103-001-21-1::2.5::HTS,BRD-K10974103-001-21-1,diloxanide,2.5,HTS,METABOL_C36:1 PC,METABOL,noncancer,protein synthesis inhibitor,,infectious disease,amebiasis,Launched,0.23598233348463502,0.109464520288,diloxanide,,,0,0
BRD-K10990317-001-04-5::2.5::HTS,BRD-K10990317-001-04-5,clotiapine,2.5,HTS,METABOL_pantothenate,METABOL,noncancer,,,neurology/psychiatry,psychosis,Launched,0.292975192280626,0.0216050648594,clotiapine,,,0,0
BRD-K10995081-001-27-9::2.316458322::MTS004,BRD-K10995081-001-27-9,perphenazine,2.316458322,MTS004,LIN_thyroid,LIN,noncancer,dopamine receptor antagonist,"CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7","neurology/psychiatry, gastroenterology","schizophrenia, nausea, vomiting",Launched,0.30574681520135905,0.0880901091772,perphenazine,,,0,0
BRD-K11046126-001-02-0::2.5::HTS,BRD-K11046126-001-02-0,VUF10166,2.5,HTS,METHYL_ATP6V0E2-AS1,METHYL,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B",,,Preclinical,0.256954139740758,0.0548075540402,VUF10166,,,0,0
BRD-K11071038-001-01-7::2.5::HTS,BRD-K11071038-001-01-7,ICI-162846,2.5,HTS,Exp_R3HCC1 (ENSG00000104679),GE,noncancer,histamine receptor antagonist,HRH2,,,Phase 1,0.262199893222038,0.0318212911643,ICI-162846,,,0,0
BRD-K11073688-001-01-6::2.5::HTS,BRD-K11073688-001-01-6,CPI-1189,2.5,HTS,METHYL_STAM2,METHYL,noncancer,tumor necrosis factor release inhibitor,TNF,,,Phase 2,0.27056626442159804,-0.0521736769857,CPI-1189,,,0,0
BRD-K11094367-001-10-1::2.5::HTS,BRD-K11094367-001-10-1,acetanilide,2.5,HTS,METABOL_glutathione oxidized,METABOL,noncancer,hydrogen peroxide decomposition inhibitor,,,,Preclinical,0.259428815076242,0.112650172248,acetanilide,,,0,0
BRD-K11099631-001-07-6::2.5::HTS,BRD-K11099631-001-07-6,gadoterate-meglumine,2.5,HTS,METHYL_TNFSF13B,METHYL,noncancer,radiopaque medium,,radiology,MRI contrast agent,Launched,0.248670689214666,0.140686536441,gadoterate-meglumine,,,0,0
BRD-K11124378-001-04-6::2.5::HTS,BRD-K11124378-001-04-6,ceftibuten,2.5,HTS,DEM2_LAIR1 (3903),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,"pulmonary, otolaryngology","bronchitis, otitis, pharyngitis, tonsillitis",Launched,0.33121678074346395,0.116817852296,ceftibuten,,,0,0
BRD-K11129031-001-27-5::2.5::HTS,BRD-K11129031-001-27-5,gemfibrozil,2.5,HTS,MUTpool_MC5R (4161),MUTpool,noncancer,lipoprotein lipase activator,"LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1","endocrinology, cardiology","hyperlipidemia, coronary heart disease",Launched,0.173017753713044,0.0144632553362,gemfibrozil,,,0,0
BRD-K11153516-001-05-5::2.5::HTS,BRD-K11153516-001-05-5,iniparib,2.5,HTS,RMUThot_CDKN2A (1029),MUThot,targeted cancer,PARP inhibitor,PARP1,,,Phase 3,0.26755651974310396,0.0530514810994,iniparib,,,0,0
BRD-K11196887-001-21-2::2.5::HTS,BRD-K11196887-001-21-2,norfloxacin,2.5,HTS,DEM2_RAB33B (83452),DEMETER2_COM,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis",Launched,0.23477284467541895,0.0448983414915,norfloxacin,,,0,0
BRD-K11196887-001-22-0::2.49::HTS,BRD-K11196887-001-22-0,norfloxacin,2.49,HTS,METABOL_C36:4 PC-A,METABOL,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis",Launched,0.31997413584308804,0.0643080030749,norfloxacin,,,0,0
BRD-K11215326-001-03-7::2.31::HTS,BRD-K11215326-001-03-7,tazemetostat,2.31,HTS,CRISPR_KIAA1524 (57650),AVANA_PUBLIC_18Q2,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Phase 2,0.347130168122753,0.230977416761,tazemetostat,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3464881677782277,4.4241468812698255,-2.0046919044104925
BRD-K11244467-001-08-5::2.5::HTS,BRD-K11244467-001-08-5,ambazone,2.5,HTS,PROT_TIGAR,PROT,chemo,DNA damage inducer,,,,Phase 1,0.27989052986005,0.214388505873,ambazone,,,0,0
BRD-K11256763-001-01-5::2.5::MTS004,BRD-K11256763-001-01-5,niceritrol,2.5,MTS004,CRISPR_CALCOCO1 (57658),AVANA_PUBLIC_18Q2,noncancer,NAD precursor,,endocrinology,hyperlipidemia,Launched,0.247081779074394,0.162678606757,niceritrol,,,0,0
BRD-K11267252-001-04-4::2.5::HTS,BRD-K11267252-001-04-4,alectinib,2.5,HTS,PROT_JAK2,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),Launched,0.32881545868913203,0.179164304864,alectinib,OTHER,0.3232365058427085,5.560517825169137,-1.0651359222754304
BRD-K11292736-300-02-8::2.5::HTS,BRD-K11292736-300-02-8,ambenonium,2.5,HTS,CN_FANCC (2176),CN,noncancer,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,Launched,0.22827936706238003,0.0765223301567,ambenonium,,,0,0
BRD-K11399644-003-11-3::2.5::HTS,BRD-K11399644-003-11-3,phenformin,2.5,HTS,MUTpool_RGPD2 (729857),MUTpool,noncancer,AMPK activator,"KCNJ8, PRKAA1",,,Withdrawn,0.27215825085008,0.0694199768004,phenformin,,,0,0
BRD-K11411329-001-01-3::2.5::HTS,BRD-K11411329-001-01-3,NOV-002,2.5,HTS,METABOL_C54:6 TAG,METABOL,noncancer,,"GSR, GSTM2",,,Phase 3,0.23042340940858602,0.0303128828412,NOV-002,,,0,0
BRD-K11433652-001-17-0::2.5::HTS,BRD-K11433652-001-17-0,aspirin,2.5,HTS,MIRNA_hsa-miR-584,MIRNA,noncancer,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain",Launched,0.233967071096434,0.105833443465,aspirin,,,0,0
BRD-K11443721-003-01-6::2.403980733::MTS004,BRD-K11443721-003-01-6,NE-100,2.403980733,MTS004,Exp_AP2S1 (ENSG00000042753),GE,noncancer,sigma receptor antagonist,SIGMAR1,,,Phase 2,0.301920912537896,0.101377291435,NE-100,,,0,0
BRD-K11452913-001-01-9::2.5000112::MTS004,BRD-K11452913-001-01-9,evatanepag,2.5000112,MTS004,METABOL_C18:2 LPC,METABOL,noncancer,prostaglandin inhibitor,"PTGER2, PTGER4",,,Phase 2,0.297608156674319,0.0637808052369,evatanepag,,,0,0
BRD-K11463116-304-03-5::2.500052374::MTS004,BRD-K11463116-304-03-5,eprodisate,2.500052374,MTS004,MIRNA_hsa-miR-485-5p,MIRNA,noncancer,"antiamyloidogenic agent, amyloid protein inhibitor",SAA1,,,Phase 3,0.276314072993193,0.0935954919031,eprodisate,,,0,0
BRD-K11510141-001-01-8::2.5::HTS,BRD-K11510141-001-01-8,teprenone,2.5,HTS,CN_LINC00883 (344595),CN,noncancer,mucus protecting agent,,dermatology,cosmetic,Launched,0.284616673431353,0.0143184454683,teprenone,,,0,0
BRD-K11558771-001-13-9::2.5::HTS,BRD-K11558771-001-13-9,droxinostat,2.5,HTS,Exp_DPP6 (ENSG00000130226),GE,noncancer,HDAC inhibitor,"HDAC6, HDAC8",,,Preclinical,0.268445317477519,0.112906440969,droxinostat,,,0,0
BRD-K11590034-002-03-4::2.49::HTS,BRD-K11590034-002-03-4,morin,2.49,HTS,MIRNA_hsa-miR-632,MIRNA,noncancer,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",,,Preclinical,0.23518409812841895,0.0319553569779,morin,,,0,0
BRD-K11595419-001-01-4::2.5::HTS,BRD-K11595419-001-01-4,dipeptamin,2.5,HTS,CRISPR_GPCPD1 (56261),AVANA_PUBLIC_18Q2,noncancer,,,,,Launched,0.22073310416081,0.0601298365548,dipeptamin,,,0,0
BRD-K11630072-001-13-2::2.5::HTS,BRD-K11630072-001-13-2,carmofur,2.5,HTS,PROT_HSP70_Caution,PROT,targeted cancer,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer",Launched,0.325861016843475,0.286782765024,carmofur,OTHER,0.3244132441740765,3.9483386588459055,-2.10117994265139
BRD-K11631773-001-10-8::2.58::HTS,BRD-K11631773-001-10-8,sesamin,2.58,HTS,MIRNA_hsa-miR-744,MIRNA,noncancer,NFkB pathway inhibitor,,,,Preclinical,0.24092090355337198,0.066409125383,sesamin,,,0,0
BRD-K11636097-001-03-1::2.5::HTS,BRD-K11636097-001-03-1,JNJ-7706621,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,targeted cancer,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",,,Preclinical,0.3428053162825301,0.278923923122,JNJ-7706621,CDK INHIBITOR,0.3427143878190421,4.6700754433425455,-3.0302143160272617
BRD-K11640013-001-15-8::2.5::HTS,BRD-K11640013-001-15-8,sulfamethazine,2.5,HTS,DEM2_ZCCHC14 (23174),DEMETER2_COM,noncancer,PABA antagonist,,gastroenterology,"enteritis, enteritis",Launched,0.25936203931411,0.0751579935436,sulfamethazine,,,0,0
BRD-K11640013-236-10-1::2.5::HTS,BRD-K11640013-236-10-1,sulfamethazine,2.5,HTS,METABOL_C22:6 LPC,METABOL,noncancer,PABA antagonist,,gastroenterology,"enteritis, enteritis",Launched,0.25936203931411,0.117220578656,sulfamethazine,,,0,0
BRD-K11663430-001-02-3::2.5::HTS,BRD-K11663430-001-02-3,pyroxamide,2.5,HTS,PROT_CD49b,PROT,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 1,0.32908914400531797,0.0674064010255,pyroxamide,HDAC INHIBITOR,0.3285536723799529,7.1740379932256255,-2.1646096547919003
BRD-K11672787-001-01-5::2.5::HTS,BRD-K11672787-001-01-5,rostafuroxine,2.5,HTS,METABOL_creatine,METABOL,noncancer,ATPase inhibitor,ATP1A1,,,Phase 2,0.27275875896935897,0.0792159625214,rostafuroxine,,,0,0
BRD-K11717138-001-30-3::2.5::HTS,BRD-K11717138-001-30-3,benzbromarone,2.5,HTS,CRISPR_OR2M3 (127062),AVANA_PUBLIC_18Q2,noncancer,chloride channel blocker,ABCC1,rheumatology,gout,Launched,0.271684415406848,0.119921949078,benzbromarone,,,0,0
BRD-K11742128-003-23-4::2.5::HTS,BRD-K11742128-003-23-4,triprolidine,2.5,HTS,PROT_HER3,PROT,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.28393578952606396,0.168076061446,triprolidine,,,0,0
BRD-K11756522-001-09-9::2.5::HTS,BRD-K11756522-001-09-9,furazolidone,2.5,HTS,CRISPR_IREB2 (3658),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA inhibitor,,"gastroenterology, infectious disease","diarrhea, enteritis, cholera",Launched,0.268432822711553,0.122691353647,furazolidone,,,0,0
BRD-K11792081-001-01-4::2.500009305::MTS004,BRD-K11792081-001-01-4,ABT-639,2.500009305,MTS004,CRISPR_CCDC37 (348807),AVANA_PUBLIC_18Q2,noncancer,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I",,,Phase 2,0.22827209082322103,0.0410234386946,ABT-639,,,0,0
BRD-K11796549-001-04-5::2.5::HTS,BRD-K11796549-001-04-5,NBQX,2.5,HTS,METABOL_urate,METABOL,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B",,,Preclinical,0.294877219380987,0.0600875376492,NBQX,,,0,0
BRD-K11851476-003-01-7::2.499993171::MTS004,BRD-K11851476-003-01-7,pardoprunox,2.499993171,MTS004,Exp_ABCB1 (ENSG00000085563),GE,noncancer,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",,,Phase 3,0.393002187788966,0.431069360903,pardoprunox,OTHER,0.39620888229269213,5.337860056534098,-3.793736336661188
BRD-K11853856-001-01-7::2.5::HTS,BRD-K11853856-001-01-7,PJ-34,2.5,HTS,CRISPR_EFR3A (23167),AVANA_PUBLIC_18Q2,targeted cancer,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",,,Preclinical,0.271474636226419,0.123994190024,PJ-34,,,0,0
BRD-K11900042-001-14-4::2.5::HTS,BRD-K11900042-001-14-4,methylthiouracil,2.5,HTS,DEM2_DUSP8 (1850),DEMETER2_COM,noncancer,,,endocrinology,hyperthyroidism,Launched,0.22840199976136,0.0834479208634,methylthiouracil,,,0,0
BRD-K11911061-003-11-9::2.5::HTS,BRD-K11911061-003-11-9,GR-127935,2.5,HTS,METABOL_glutamine,METABOL,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",,,Preclinical,0.354061873781313,0.113084303127,GR-127935,,,0,0
BRD-K11973162-003-01-8::2.5::HTS,BRD-K11973162-003-01-8,tipiracil,2.5,HTS,PROT_Caveolin-1,PROT,targeted cancer,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Launched,0.19880449239056502,0.135036950491,tipiracil,OTHER,0.20515140136704405,5.354970185194693,2.362733336399501
BRD-K12014493-001-02-2::2.5::HTS,BRD-K12014493-001-02-2,betaine,2.5,HTS,METHYL_ULBP3,METHYL,noncancer,nitric oxide donor,,metabolism,homocystinuria,Launched,0.305511079334922,-0.0457441150298,betaine,,,0,0
BRD-K12040459-001-06-0::2.5::HTS,BRD-K12040459-001-06-0,AT7867,2.5,HTS,Exp_IL6R (ENSG00000160712),GE,targeted cancer,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",,,Preclinical,0.36208107519315,0.379387021143,AT7867,AKT INHIBITOR,0.3682857341712445,3.2961172557476868,-3.687938112136143
BRD-K12047401-001-01-5::2.5::HTS,BRD-K12047401-001-01-5,palifosfamide,2.5,HTS,DEM2_DHX37 (57647),DEMETER2_COM,chemo,DNA alkylating agent,,,,Phase 3,0.30042476625649606,0.119073333205,palifosfamide,,,0,0
BRD-K12068470-001-04-1::2.5::HTS,BRD-K12068470-001-04-1,LY2608204,2.5,HTS,METHYL_TMEM144,METHYL,noncancer,glucokinase activator,GCK,,,Phase 2,0.306268481318422,0.0595305085991,LY2608204,,,0,0
BRD-K12079898-001-02-6::2.5::HTS,BRD-K12079898-001-02-6,PD-160170,2.5,HTS,DEM2_OASL (8638),DEMETER2_COM,noncancer,neuropeptide receptor antagonist,NPY1R,,,Preclinical,0.275257456659873,0.146093866899,PD-160170,,,0,0
BRD-K12102668-001-25-5::2.5::HTS,BRD-K12102668-001-25-5,nialamide,2.5,HTS,CN_FGF17 (8822),CN,noncancer,monoamine oxidase inhibitor,"COMT, MAOA, MAOB",,,Withdrawn,0.280960773182709,0.0870334274052,nialamide,,,0,0
BRD-K12120659-305-02-2::2.5::HTS,BRD-K12120659-305-02-2,GR-144053,2.5,HTS,Exp_OR7E91P (ENSG00000205847),GE,noncancer,integrin antagonist,"ITGA2B, ITGB3",,,Preclinical,0.214011811932747,0.124343724214,GR-144053,,,0,0
BRD-K12184916-001-15-4::2.5::HTS,BRD-K12184916-001-15-4,NVP-BEZ235,2.5,HTS,Exp_PPP2CB (ENSG00000104695),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.34121656967012004,0.265464996979,NVP-BEZ235,MTOR INHIBITOR,0.3445319543727742,2.336388135743562,-1.100654595623761
BRD-K12219985-001-26-1::2.5::HTS,BRD-K12219985-001-26-1,glipizide,2.5,HTS,CN_SLC24A2 (25769),CN,noncancer,sulfonylurea,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,"diabetes mellitus, hyperglycemia",Launched,0.198847253729132,-0.0404938403997,glipizide,,,0,0
BRD-K12244279-001-05-8::2.5::HTS,BRD-K12244279-001-05-8,MEK1-2-inhibitor,2.5,HTS,RMUThot_BRAF (673),MUThot,noncancer,MEK inhibitor,MAP2K2,,,Preclinical,0.286036229903955,0.0842624219982,MEK1-2-inhibitor,MEK INHIBITOR,0.28583105209411963,-6.100342423924926,1.7658187412290598
BRD-K12251893-065-04-7::2.5::HTS,BRD-K12251893-065-04-7,vincristine,2.5,HTS,Exp_YWHAE (ENSG00000108953),GE,chemo,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.35551054409447796,0.222659440993,vincristine,TUBULIN POLYMERIZATION INHIBITOR,0.35890922744210524,5.750968346463982,-2.022256313645824
BRD-K12261274-001-02-4::2.499953183::MTS004,BRD-K12261274-001-02-4,zaltidine,2.499953183,MTS004,CRISPR_SACS (26278),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,HRH2,,,Phase 3,0.31410248983882105,0.167893066304,zaltidine,,,0,0
BRD-K12343256-001-08-9::2.5::HTS,BRD-K12343256-001-08-9,trametinib,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,Launched,0.406465000584262,0.548928642324,trametinib,MEK INHIBITOR,0.4048279408743857,0.33501276923196355,4.974271598475147
BRD-K12502280-001-08-0::2.5::HTS,BRD-K12502280-001-08-0,TG-101348,2.5,HTS,CRISPR_NCCRP1 (342897),AVANA_PUBLIC_18Q2,targeted cancer,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",,,Phase 3,0.28473987190713695,0.174616344486,TG-101348,OTHER,0.2884233313840727,0.7424202011856487,-2.9425849699761932
BRD-K12513978-001-24-1::2.5::HTS,BRD-K12513978-001-24-1,fenbufen,2.5,HTS,METHYL_MIR107,METHYL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.21969964551148397,0.108766648485,fenbufen,,,0,0
BRD-K12539416-001-01-4::2.5::HTS,BRD-K12539416-001-01-4,sulbutiamine,2.5,HTS,PROT_FRA1_Caution,PROT,noncancer,acetylcholine receptor antagonist,,neurology/psychiatry,asthenia,Launched,0.14464296894185097,0.0998091141241,sulbutiamine,,,0,0
BRD-K12539581-001-23-7::2.5::HTS,BRD-K12539581-001-23-7,nocodazole,2.5,HTS,Exp_PLGLB2 (ENSG00000125551),GE,targeted cancer,tubulin polymerization inhibitor,HPGDS,,,Preclinical,0.37131078964137604,0.0518694839367,nocodazole,TUBULIN POLYMERIZATION INHIBITOR,0.3650091859756092,4.9252568420971,-2.0098799199427297
BRD-K12568846-001-14-6::2.5::HTS,BRD-K12568846-001-14-6,amidopyrine,2.5,HTS,METHYL_LOC101928417,METHYL,noncancer,analgesic agent,,dermatology,dermatitis herpetiformis (DH),Launched,0.29179205965953303,0.0623967440183,amidopyrine,,,0,0
BRD-K12609457-001-03-1::2.5::HTS,BRD-K12609457-001-03-1,exalamide,2.5,HTS,METABOL_AMP,METABOL,noncancer,membrane permeability inhibitor,,,,Launched,0.22685325568167103,0.0611820755689,exalamide,,,0,0
BRD-K12614344-003-01-8::2.5::HTS,BRD-K12614344-003-01-8,CGS-21680,2.5,HTS,MIRNA_ebv-miR-BART11-3p,MIRNA,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.340504454664824,0.00598971247929,CGS-21680,,,0,0
BRD-K12630395-001-14-9::2.5::HTS,BRD-K12630395-001-14-9,harmane,2.5,HTS,PROT_GSK3-alpha-beta_pS21_S9,PROT,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",,,Preclinical,0.325378713573045,0.0970532149969,harmane,,,0,0
BRD-K12735121-001-01-4::2.5::HTS,BRD-K12735121-001-01-4,TG-100801,2.5,HTS,CRISPR_CWC27 (10283),AVANA_PUBLIC_18Q2,targeted cancer,"src inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, SRC",,,Phase 2,0.31814183459988,0.0547862965279,TG-100801,,,0,0
BRD-K12737986-001-01-4::2.5::HTS,BRD-K12737986-001-01-4,veliparib,2.5,HTS,PROT_Beclin_Caution,PROT,targeted cancer,PARP inhibitor,"PARP1, PARP2",,,Phase 3,0.291625894495093,0.000264571413488,veliparib,,,0,0
BRD-K12742203-003-01-7::2.512196931::MTS004,BRD-K12742203-003-01-7,moxaverine,2.512196931,MTS004,RMUTmis_ARPP21 (10777),MUTmis,noncancer,phosphodiesterase inhibitor,,neurology/psychiatry,spasms,Launched,0.269730490584893,0.111995853669,moxaverine,,,0,0
BRD-K12762134-001-06-2::2.5::HTS,BRD-K12762134-001-06-2,XAV-939,2.5,HTS,Exp_LINC00472 (ENSG00000233237),GE,targeted cancer,tankyrase inhibitor,"TNKS, TNKS2",,,Preclinical,0.33750790706581707,0.205146172479,XAV-939,OTHER,0.3342362287111818,-4.557079436065345,0.07283770236442955
BRD-K12787259-001-04-3::2.5::HTS,BRD-K12787259-001-04-3,CX-5461,2.5,HTS,Exp_HEATR1 (ENSG00000119285),GE,targeted cancer,RNA polymerase inhibitor,,,,Phase 1,0.33726960179167403,0.316719531732,CX-5461,OTHER,0.338163199894902,3.4669426188436976,-3.6476238556222333
BRD-K12807006-001-18-5::2.5::HTS,BRD-K12807006-001-18-5,kaempferol,2.5,HTS,Exp_KMO (ENSG00000117009),GE,targeted cancer,"bone resorption inhibitor, estrogen-related receptor inverse agonist","AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1",,,Preclinical,0.237538717635593,0.0776155289369,kaempferol,,,0,0
BRD-K12829205-003-02-8::2.5::HTS,BRD-K12829205-003-02-8,mechlorethamine,2.5,HTS,Exp_DDN (ENSG00000181418),GE,chemo,DNA inhibitor,,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma",Launched,0.385635241747264,0.375757868176,mechlorethamine,OTHER,0.3869383796560793,3.6805037081389465,-2.358975848207721
BRD-K12852738-001-01-2::2.584725941::MTS004,BRD-K12852738-001-01-2,veliflapon,2.584725941,MTS004,Exp_CCDC116 (ENSG00000161180),GE,noncancer,leukotriene synthesis inhibitor,ALOX5AP,,,Phase 3,0.247926976191767,0.119489214304,veliflapon,,,0,0
BRD-K12867552-001-04-7::2.5::HTS,BRD-K12867552-001-04-7,PCI-24781,2.5,HTS,METHYL_MIR4265,METHYL,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",,,Phase 1/Phase 2,0.386813395291418,0.15717804776,PCI-24781,HDAC INHIBITOR,0.3618524634124952,6.238271742037539,-0.492029941617552
BRD-K12885236-001-02-7::2.5::HTS,BRD-K12885236-001-02-7,dapivirine,2.5,HTS,Exp_TMEM69 (ENSG00000159596),GE,noncancer,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",,,Phase 3,0.351161970783729,0.226586628858,dapivirine,OTHER,0.3224853202762428,3.468560924651423,-1.5956684860882395
BRD-K12906202-001-06-2::2.5::MTS004,BRD-K12906202-001-06-2,carbendazim,2.5,MTS004,METABOL_C24:1 SM,METABOL,noncancer,"microtubule inhibitor, tubulin polymerization inhibitor","TP53, TUBB",infectious disease,fungicide,Launched,0.339417508799799,0.107834194472,carbendazim,,,0,0
BRD-K12932420-001-02-3::2.5::HTS,BRD-K12932420-001-02-3,YM-976,2.5,HTS,Exp_SLA (ENSG00000155926),GE,noncancer,phosphodiesterase inhibitor,PDE4A,,,Phase 1,0.30119165187653,0.0913850434522,YM-976,,,0,0
BRD-K12968785-001-13-3::2.5::HTS,BRD-K12968785-001-13-3,bergapten,2.5,HTS,DEM2_NARF (26502),DEMETER2_COM,targeted cancer,,,,,Preclinical,0.293995043761623,0.0648989384022,bergapten,,,0,0
BRD-K12994359-001-18-4::2.5::HTS,BRD-K12994359-001-18-4,valdecoxib,2.5,HTS,PROT_SETD2_Caution,PROT,noncancer,cyclooxygenase inhibitor,"CA12, PTGS2",,,Withdrawn,0.22961724098699696,0.0706396394753,valdecoxib,,,0,0
BRD-K13044802-213-20-7::2.5::HTS,BRD-K13044802-213-20-7,ciclopirox,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,noncancer,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,Launched,0.355873088668969,0.264431587481,ciclopirox,OTHER,0.35902740488371226,3.973128313061404,-2.5934557150668542
BRD-K13049116-001-05-7::2.5::HTS,BRD-K13049116-001-05-7,BMS-754807,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,IGF-1 inhibitor,"AKT1, IGF1R",,,Phase 2,0.40598626536087,0.250620086602,BMS-754807,OTHER,0.4030339740763488,3.7879060779073863,-3.1365538227192338
BRD-K13050303-001-17-3::2.5::HTS,BRD-K13050303-001-17-3,uridine,2.5,HTS,DEM2_CDKL1 (8814),DEMETER2_COM,noncancer,dopamine receptor agonist,"LSM6, TYMP",,,Phase 2,0.295296538080281,0.0148799932549,uridine,,,0,0
BRD-K13050303-001-18-1::2.5::HTS,BRD-K13050303-001-18-1,uridine,2.5,HTS,METABOL_homocysteine,METABOL,noncancer,dopamine receptor agonist,"LSM6, TYMP",,,Phase 2,0.249994768199728,0.0806766788392,uridine,,,0,0
BRD-K13050541-001-01-9::2.8::HTS,BRD-K13050541-001-01-9,acivicin,2.8,HTS,Exp_SLC7A5 (ENSG00000103257),GE,targeted cancer,gamma glutamyltransferase Inhibitors,CTPS1,,,Phase 2,0.36325696129268603,0.311570553809,acivicin,OTHER,0.3639229518677984,3.9902930479341854,-0.7685524658794844
BRD-K13060017-001-02-1::2.499994836::MTS004,BRD-K13060017-001-02-1,UNC0631,2.499994836,MTS004,METHYL_PLEKHO2,METHYL,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.38779862340593396,0.29295346794,UNC0631,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3939790645955226,4.344667709032758,-1.9956111507753145
BRD-K13078532-001-28-4::2.5::HTS,BRD-K13078532-001-28-4,hydrochlorothiazide,2.5,HTS,MIRNA_hsa-miR-27b,MIRNA,noncancer,thiazide diuretic,"CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3",cardiology,"hypertension, congestive heart failure",Launched,0.301759419731392,0.049673388991,hydrochlorothiazide,,,0,0
BRD-K13087974-001-02-5::2.5::HTS,BRD-K13087974-001-02-5,CGP-52411,2.5,HTS,CRISPR_FGFR2 (2263),AVANA_PUBLIC_18Q2,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.22841732081406999,0.109033228545,CGP-52411,,,0,0
BRD-K13094524-001-07-5::2.63::HTS,BRD-K13094524-001-07-5,PFI-1,2.63,HTS,CRISPR_APLP1 (333),AVANA_PUBLIC_18Q2,targeted cancer,bromodomain inhibitor,BRD4,,,Preclinical,0.38157120214294893,0.266638199536,PFI-1,BROMODOMAIN INHIBITOR,0.3996785263630317,-0.3543883184452394,3.200987968040427
BRD-K13112821-001-17-4::2.5::HTS,BRD-K13112821-001-17-4,artemisinin,2.5,HTS,CN_ZNF670-ZNF695 (100533111),CN,noncancer,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,Launched,0.36541727704959703,0.211390509824,artemisinin,OTHER,0.36387307723033896,1.7048980783978287,-3.214504362036555
BRD-K13167095-001-02-9::2.5::HTS,BRD-K13167095-001-02-9,AR-42,2.5,HTS,PROT_VEGFR2,PROT,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 1,0.442126157839965,0.0465548154316,AR-42,HDAC INHIBITOR,0.43223523994206375,6.026329152669554,-0.6505133907252163
BRD-K13169950-001-14-4::2.5::HTS,BRD-K13169950-001-14-4,NSC-3852,2.5,HTS,Exp_TBPL1 (ENSG00000028839),GE,targeted cancer,HDAC inhibitor,HDAC1,,,Preclinical,0.331516212075269,0.394564979747,NSC-3852,HDAC INHIBITOR,0.3341238133758708,4.958530857451478,-2.0624552595384342
BRD-K13183738-317-10-2::2.5::HTS,BRD-K13183738-317-10-2,pentamidine,2.5,HTS,Exp_SLC47A1 (ENSG00000142494),GE,noncancer,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,Launched,0.38662095358613796,0.387862016232,pentamidine,OTHER,0.3865069972529797,2.6081869835000373,-2.026545440738759
BRD-K13211965-003-02-8::2.5::HTS,BRD-K13211965-003-02-8,L-741742,2.5,HTS,Exp_LMF1 (ENSG00000103227),GE,noncancer,dopamine receptor antagonist,"DRD3, DRD4, SCN1A, SCN3A",,,Preclinical,0.331024899248385,0.0829132928112,L-741742,,,0,0
BRD-K13238168-001-02-0::2.5::HTS,BRD-K13238168-001-02-0,haloprogin,2.5,HTS,Exp_VCX3A (ENSG00000169059),GE,noncancer,other antifungal,,infectious disease,tinea pedis,Launched,0.325543387712705,0.0805962407583,haloprogin,,,0,0
BRD-K13238618-001-05-9::2.5::HTS,BRD-K13238618-001-05-9,carsalam,2.5,HTS,RMUTmis_UTRN (7402),MUTmis,noncancer,analgesic agent,,,,Preclinical,0.278355524309146,0.0305056367345,carsalam,,,0,0
BRD-K13249881-001-02-3::2.5::HTS,BRD-K13249881-001-02-3,piperazine,2.5,HTS,Exp_DANCR (ENSG00000226950),GE,noncancer,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,Launched,0.193561873659728,0.137196592661,piperazine,OTHER,0.19323644032625967,4.594821329068331,-2.080687162495044
BRD-K13261168-300-01-0::2.5::HTS,BRD-K13261168-300-01-0,quinelorane,2.5,HTS,Exp_BCRP2 (ENSG00000169668),GE,noncancer,dopamine receptor agonist,"DRD2, DRD3",,,Phase 3,0.255563804747267,0.136165244738,quinelorane,,,0,0
BRD-K13277760-001-01-2::2.5::MTS004,BRD-K13277760-001-01-2,rifamycin-sv,2.5,MTS004,DEM2_PIGO (84720),DEMETER2_COM,noncancer,RNA synthesis inhibitor,,,,Phase 3,0.365199774120985,0.119312320447,rifamycin-sv,,,0,0
BRD-K13296708-001-05-8::2.5::HTS,BRD-K13296708-001-05-8,rimonabant,2.5,HTS,CRISPR_SURF4 (6836),AVANA_PUBLIC_18Q2,noncancer,cannabinoid receptor antagonist,"CNR1, GPR55",,,Withdrawn,0.294682204788849,0.123304911752,rimonabant,,,0,0
BRD-K13302470-001-02-7::2.5::HTS,BRD-K13302470-001-02-7,KY02111,2.5,HTS,METHYL_SLC22A1,METHYL,noncancer,Wnt pathway inhibitor,DKK1,,,Preclinical,0.28529598307847803,0.0090489427759,KY02111,,,0,0
BRD-K13314656-001-01-0::2.5::HTS,BRD-K13314656-001-01-0,ebastine,2.5,HTS,PROT_Src_pY527,PROT,noncancer,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",Launched,0.380495503866438,0.147593637311,ebastine,,,0,0
BRD-K13356952-001-25-1::2.5::HTS,BRD-K13356952-001-25-1,methazolamide,2.5,HTS,CRISPR_FAM222B (55731),AVANA_PUBLIC_18Q2,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"glaucoma, intraocular pressure",Launched,0.28238988951069605,0.06431841792,methazolamide,,,0,0
BRD-K13387373-004-14-5::2.5::HTS,BRD-K13387373-004-14-5,thonzonium,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,ATPase inhibitor,,,,Launched,0.38955381784945897,0.470902073974,thonzonium,OTHER,0.3869897896603857,3.0333995385857557,-2.2502656295647867
BRD-K13394247-003-01-4::2.499991328::MTS004,BRD-K13394247-003-01-4,radafaxine,2.499991328,MTS004,METHYL_DNAH1,METHYL,noncancer,dopamine-norepinephrine reuptake inhibitor,SLC6A3,,,Phase 2,0.254110080948205,0.202961723349,radafaxine,,,0,0
BRD-K13409143-001-01-9::2.5::HTS,BRD-K13409143-001-01-9,isopropyl-myristate,2.5,HTS,METHYL_GRIPAP1,METHYL,noncancer,,,dermatology,cosmetic,Launched,0.321742416788566,0.0424603447657,isopropyl-myristate,OTHER,0.3229660012017448,1.5134084133747572,-1.7512955272542623
BRD-K13414800-001-01-3::2.499970601::MTS004,BRD-K13414800-001-01-3,vesnarinone,2.499970601,MTS004,Exp_SERPINB4 (ENSG00000206073),GE,noncancer,phosphodiesterase inhibitor,"KCNH2, PDE3A",cardiology,congestive heart failure,Launched,0.282812842070338,0.119612685908,vesnarinone,,,0,0
BRD-K13421763-001-06-2::2.5::HTS,BRD-K13421763-001-06-2,aminothiazole,2.5,HTS,DEM2_PRUNE2 (158471),DEMETER2_COM,noncancer,cyclin D inhibitor,NOS2,,,Preclinical,0.254625108291892,0.161347874151,aminothiazole,,,0,0
BRD-K13474508-001-01-2::2.5::HTS,BRD-K13474508-001-01-2,"L-655,708",2.5,HTS,DEM2_TULP3 (7289),DEMETER2_COM,noncancer,GABA receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRG2",,,Preclinical,0.258383786776469,0.0914924509666,"L-655,708",,,0,0
BRD-K13486660-001-01-0::2.5::HTS,BRD-K13486660-001-01-0,sulfacarbamide,2.5,HTS,PROT_JNK2_Caution,PROT,noncancer,,,,,Withdrawn,0.308173363131797,0.0455582039865,sulfacarbamide,,,0,0
BRD-K13495773-001-11-4::2.5::HTS,BRD-K13495773-001-11-4,creatinine,2.5,HTS,MIRNA_hsa-miR-96,MIRNA,noncancer,,,,,Preclinical,0.297013857337779,0.0862541068281,creatinine,,,0,0
BRD-K13511380-001-01-4::2.5::HTS,BRD-K13511380-001-01-4,naringin-dihydrochalcone,2.5,HTS,METHYL_PYGL,METHYL,noncancer,cytochrome P450 inhibitor,,,,Preclinical,0.270412682976001,0.0974087673668,naringin-dihydrochalcone,,,0,0
BRD-K13514097-001-05-3::2.5::HTS,BRD-K13514097-001-05-3,everolimus,2.5,HTS,Exp_FBLN1 (ENSG00000077942),GE,targeted cancer,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma",Launched,0.325673483684225,0.285059480134,everolimus,MTOR INHIBITOR,0.3239258224630583,0.9765448800234804,-1.79803941156674
BRD-K13533483-001-16-2::2.5::MTS004,BRD-K13533483-001-16-2,cyclosporine,2.5,MTS004,CN_TRIM32 (22954),CN,noncancer,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis",Launched,0.383068804770557,0.0503966574231,cyclosporine,OTHER,0.3811751572742466,2.8547977432446814,-0.7061593959277177
BRD-K13566078-001-02-3::2.5::HTS,BRD-K13566078-001-02-3,BMS-345541,2.5,HTS,Exp_GPX3 (ENSG00000211445),GE,targeted cancer,IKK inhibitor,"CHUK, IKBKB",,,Preclinical,0.360255229666415,0.186969702123,BMS-345541,OTHER,0.3573714518428191,5.595968672528417,-2.999342942970878
BRD-K13571841-001-14-4::2.5::HTS,BRD-K13571841-001-14-4,pepstatin,2.5,HTS,Exp_DCSTAMP (ENSG00000164935),GE,noncancer,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",,,Preclinical,0.294100846447226,0.0517485363988,pepstatin,,,0,0
BRD-K13606314-001-01-3::2.5::HTS,BRD-K13606314-001-01-3,P5091,2.5,HTS,Exp_LRRC49 (ENSG00000137821),GE,targeted cancer,ubiquitin specific protease inhibitor,USP7,,,Preclinical,0.425176890608056,0.250068608242,P5091,OTHER,0.4283035715908117,1.6308433984167934,1.231765252697152
BRD-K13619941-213-01-8::2.5::HTS,BRD-K13619941-213-01-8,aceglutamide,2.5,HTS,METHYL_PRG3,METHYL,noncancer,,,gastroenterology,peptic ulcer disease (PUD),Launched,0.28639067449043504,0.0419209855705,aceglutamide,,,0,0
BRD-K13646352-001-03-8::2.5::HTS,BRD-K13646352-001-03-8,midostaurin,2.5,HTS,MIRNA_hsa-miR-375,MIRNA,targeted cancer,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.358993650561106,0.262333430793,midostaurin,OTHER,0.3640559995471973,4.388920721349135,-1.51697061903397
BRD-K13664493-316-02-5::2.500014041::MTS004,BRD-K13664493-316-02-5,naphthoquine-phosphate,2.500014041,MTS004,Exp_MUC4 (ENSG00000145113),GE,noncancer,antimalarial agent,,,,Launched,0.309082159892898,0.135012964632,naphthoquine-phosphate,,,0,0
BRD-K13756951-001-01-4::2.5::HTS,BRD-K13756951-001-01-4,bitopertin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",,,Phase 3,0.40516880032875396,0.440927204996,bitopertin,OTHER,0.4034463636026648,4.997173004159649,-3.7439200909514887
BRD-K13769342-001-01-5::2.50001379::MTS004,BRD-K13769342-001-01-5,danirixin,2.50001379,MTS004,MIRNA_hsa-miR-558,MIRNA,noncancer,CC chemokine receptor antagonist,CXCR2,,,Phase 2,0.29858156457761,0.055701861779,danirixin,,,0,0
BRD-K13800121-001-01-5::2.5::HTS,BRD-K13800121-001-01-5,parecoxib,2.5,HTS,METABOL_choline,METABOL,noncancer,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief,Launched,0.307211841791415,0.104435392183,parecoxib,,,0,0
BRD-K13810148-311-03-2::2.5::HTS,BRD-K13810148-311-03-2,givinostat,2.5,HTS,CRISPR_BRD2 (6046),AVANA_PUBLIC_18Q2,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,Phase 2,0.450275692050925,0.131335631051,givinostat,HDAC INHIBITOR,0.4078393621714961,5.872543405785465,-0.6881788222050051
BRD-K13819402-003-10-2::2.4::HTS,BRD-K13819402-003-10-2,desoxypeganine,2.4,HTS,DEM2_FLOT1 (10211),DEMETER2_COM,noncancer,"acetylcholinesterase inhibitor, monoamine oxidase inhibitor",ACHE,,,Phase 1,0.29676911302605896,-0.0323781265185,desoxypeganine,,,0,0
BRD-K13829090-303-02-9::2.5::HTS,BRD-K13829090-303-02-9,IEM1460,2.5,HTS,CRISPR_EIF2AK3 (9451),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,GRIA2,,,Preclinical,0.300010575363979,0.00810172653456,IEM1460,,,0,0
BRD-K13926615-003-03-3::2.5::HTS,BRD-K13926615-003-03-3,vardenafil,2.5,HTS,DEM2_SPACA5&SPACA5B (389852&729201),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H",urology,erectile dysfunction,Launched,0.295617705408997,0.0234991839061,vardenafil,,,0,0
BRD-K13949769-001-01-7::2.5::HTS,BRD-K13949769-001-01-7,tenovin-6,2.5,HTS,METHYL_AGAP2-AS1,METHYL,targeted cancer,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",,,Preclinical,0.30744367784912396,0.132407574955,tenovin-6,OTHER,0.3178222532877105,2.7768326617965893,-3.6739737557992456
BRD-K13994703-003-15-8::2.5::HTS,BRD-K13994703-003-15-8,propranolol-(S),2.5,HTS,METHYL_HSD17B1,METHYL,targeted cancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3, HTR1A, HTR1B, HTR5A, SLC10A1",,,Preclinical,0.27803533161934496,0.0464278511534,propranolol-(S),,,0,0
BRD-K14003026-003-09-0::2.46::HTS,BRD-K14003026-003-09-0,ritodrine,2.46,HTS,PROT_MIG-6,PROT,noncancer,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,Launched,0.28810129301249104,0.0802453132971,ritodrine,,,0,0
BRD-K14109347-001-03-4::2.5::HTS,BRD-K14109347-001-03-4,LY2603618,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,CHK inhibitor,CHEK1,,,Phase 2,0.43790491305785706,0.283388030615,LY2603618,OTHER,0.40612419308907466,5.146764576013639,-0.9271317578562992
BRD-K14116214-001-09-6::2.5::HTS,BRD-K14116214-001-09-6,sulfamonomethoxine,2.5,HTS,RMUTmis_GLRA3 (8001),MUTmis,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.30859271575469,0.11082143474,sulfamonomethoxine,,,0,0
BRD-K14127446-005-22-7::2.5::HTS,BRD-K14127446-005-22-7,isopropamide-iodide,2.5,HTS,METHYL_COL18A1-AS1,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM3, CHRM4",gastroenterology,"peptic ulcer disease (PUD), gastrointestinal acidosis",Launched,0.281805345216461,0.119626245601,isopropamide-iodide,,,0,0
BRD-K14171291-001-01-4::2.499985403::MTS004,BRD-K14171291-001-01-4,omarigliptin,2.499985403,MTS004,PROT_Claudin-7,PROT,noncancer,dipeptidyl peptidase inhibitor,DPP4,,,Launched,0.27924266926101,0.208822166518,omarigliptin,,,0,0
BRD-K14175878-001-01-6::2.5::HTS,BRD-K14175878-001-01-6,MK-0812,2.5,HTS,PROT_XBP1_Caution,PROT,noncancer,CC chemokine receptor antagonist,CCR2,,,Phase 2,0.18289141858758398,0.041352536386,MK-0812,,,0,0
BRD-K14235254-001-01-2::2.5::HTS,BRD-K14235254-001-01-2,GTS21,2.5,HTS,PROT_p53_Caution,PROT,noncancer,cholinergic receptor agonist,CHRNA7,,,Phase 1/Phase 2,0.317067605077084,0.028238834327,GTS21,,,0,0
BRD-K14276241-001-01-2::2.49998187::MTS004,BRD-K14276241-001-01-2,daucosterol,2.49998187,MTS004,CN_SPOCD1 (90853),CN,targeted cancer,apoptosis stimulant,,,,Phase 2,0.26449487251107195,0.0581463526078,daucosterol,,,0,0
BRD-K14329163-001-03-9::2.5::HTS,BRD-K14329163-001-03-9,BAY-K-8644-(s)-(-),2.5,HTS,CRISPR_FAM110D (79927),AVANA_PUBLIC_18Q2,noncancer,L-type calcium channel activator,CACNA1C,,,Preclinical,0.372125005398861,0.100227778776,BAY-K-8644-(s)-(-),,,0,0
BRD-K14349461-003-13-1::2.5::HTS,BRD-K14349461-003-13-1,pyridoxine,2.5,HTS,CN_RGP1 (9827),CN,noncancer,vitamin B,"DDC, PDXK",metabolism,vitamin B6 deficiency,Launched,0.349476881754055,0.041088999265,pyridoxine,,,0,0
BRD-K14385366-001-04-4::2.59::HTS,BRD-K14385366-001-04-4,FG-4592,2.59,HTS,CRISPR_RELT (84957),AVANA_PUBLIC_18Q2,noncancer,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,,,Phase 3,0.354486151392349,0.157794792201,FG-4592,HIF PROLYL HYDROXYLASE,0.3075982876339975,-7.238441251734287,0.7566810241125346
BRD-K14395568-001-16-3::2.5::HTS,BRD-K14395568-001-16-3,NECA,2.5,HTS,Exp_SOX8 (ENSG00000005513),GE,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HSP90B1",,,Launched,0.264868702728465,0.081909214383,NECA,,,0,0
BRD-K14496212-066-04-8::2.5::HTS,BRD-K14496212-066-04-8,bromocriptine,2.5,HTS,DEM2_BCAR1 (9564),DEMETER2_COM,noncancer,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7","endocrinology, neurology/psychiatry","hyperprolactinemia, Parkinson's Disease, acromegaly",Launched,0.28539691802220596,-0.00233863764691,bromocriptine,,,0,0
BRD-K14529030-001-01-9::2.5::HTS,BRD-K14529030-001-01-9,meisoindigo,2.5,HTS,CRISPR_DYNLRB1 (83658),AVANA_PUBLIC_18Q2,targeted cancer,STAT inhibitor,STAT3,,,Phase 3,0.352935903885762,0.164592975409,meisoindigo,OTHER,0.3487733091041316,-1.8709779806976927,0.7266174419023008
BRD-K14560436-001-01-4::2.5::HTS,BRD-K14560436-001-01-4,TG-02,2.5,HTS,CN_SLC7A6 (9057),CN,targeted cancer,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",,,Phase 1,0.416665039453543,0.198016287339,TG-02,CDK INHIBITOR,0.41215569180391415,5.044221500614257,-0.7693097555773051
BRD-K14571191-001-01-6::2.5::MTS004,BRD-K14571191-001-01-6,zometapine,2.5,MTS004,Exp_IGHV4-59 (ENSG00000224373),GE,noncancer,,,,,Phase 2,0.302977454053784,0.133462458341,zometapine,,,0,0
BRD-K14618467-001-04-6::2.5::HTS,BRD-K14618467-001-04-6,IKK-16,2.5,HTS,MUTpool_THAP3 (90326),MUTpool,noncancer,IKK inhibitor,IKBKB,,,Preclinical,0.30226862251058506,0.223504168775,IKK-16,OTHER,0.3001428569243834,4.231819323058535,-1.5400106977272867
BRD-K14619660-001-01-5::2.5::HTS,BRD-K14619660-001-01-5,altrenogest,2.5,HTS,METABOL_C54:5 TAG,METABOL,noncancer,progestogen hormone,PGR,endocrinology,estrus,Launched,0.21977882148263,0.0541036885151,altrenogest,,,0,0
BRD-K14653796-001-01-1::2.5::HTS,BRD-K14653796-001-01-1,tasquinimod,2.5,HTS,CRISPR_CDK5R2 (8941),AVANA_PUBLIC_18Q2,targeted cancer,"angiogenesis inhibitor, S100A9 inhibitor",HDAC4,,,Phase 3,0.19385079203020997,0.0629406330983,tasquinimod,,,0,0
BRD-K14658796-003-01-6::2.368766292::MTS004,BRD-K14658796-003-01-6,drotaverine,2.368766292,MTS004,Exp_TRIM14 (ENSG00000106785),GE,noncancer,phosphodiesterase inhibitor,"CACNA1C, PDE4A",obstetrics/gynecology,labor induction,Launched,0.330355322360047,0.236985529942,drotaverine,OTHER,0.32872435590243737,5.4893068638904365,-0.2699826940888661
BRD-K14681867-001-01-6::2.5::MTS004,BRD-K14681867-001-01-6,somatostatin,2.5,MTS004,METHYL_BTF3L4,METHYL,noncancer,somatostatin receptor agonist,"OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5",hematology,hemorrhage,Launched,0.303891343616178,0.121282040326,somatostatin,,,0,0
BRD-K14704277-001-22-6::2.5::HTS,BRD-K14704277-001-22-6,cinoxacin,2.5,HTS,MIRNA_hsa-miR-339-5p,MIRNA,noncancer,topoisomerase inhibitor,,infectious disease,urinary tract infections,Launched,0.32312480173830394,0.185474817727,cinoxacin,,,0,0
BRD-K14705039-001-16-4::2.5::HTS,BRD-K14705039-001-16-4,sulfathiazole,2.5,HTS,MIRNA_hsa-miR-384,MIRNA,targeted cancer,dihydropteroate synthase inhibitor,,,,Launched,0.262319494885917,0.120860961327,sulfathiazole,,,0,0
BRD-K14711741-001-02-1::2.5::HTS,BRD-K14711741-001-02-1,PF-4708671,2.5,HTS,CN_PDPN (10630),CN,targeted cancer,ribosomal protein inhibitor,RPS6KB1,,,Preclinical,0.28176725342864695,0.0965512069673,PF-4708671,,,0,0
BRD-K14763542-001-02-3::2.5::HTS,BRD-K14763542-001-02-3,flurothyl,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,,,,,Preclinical,0.30719520486559004,0.0580218648302,flurothyl,,,0,0
BRD-K14765469-003-12-2::2.5::HTS,BRD-K14765469-003-12-2,vesamicol,2.5,HTS,CN_ATP7A (538),CN,noncancer,acetylcholinesterase inhibitor,SLC18A3,,,Preclinical,0.321134738452753,0.0553848290795,vesamicol,,,0,0
BRD-K14767410-001-02-3::2.5::HTS,BRD-K14767410-001-02-3,SC-560,2.5,HTS,METABOL_2-aminoadipate,METABOL,targeted cancer,cyclooxygenase inhibitor,PTGS1,,,Preclinical,0.304706072828192,0.0842361873706,SC-560,,,0,0
BRD-K14796088-003-26-8::2.5::HTS,BRD-K14796088-003-26-8,berberine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,LDL receptor activator,LDLR,,,Phase 2/Phase 3,0.34249593984868293,0.295339156992,berberine,OTHER,0.3424558995552177,2.724739603099648,-2.200329055215009
BRD-K14807180-001-02-5::2.5::HTS,BRD-K14807180-001-02-5,SB-221284,2.5,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.281535518536104,0.083388275903,SB-221284,,,0,0
BRD-K14870255-001-02-3::2.5::HTS,BRD-K14870255-001-02-3,R-428,2.5,HTS,CRISPR_PNPLA8 (50640),AVANA_PUBLIC_18Q2,targeted cancer,AXL kinase inhibitor,AXL,,,Phase 1,0.323921332099234,0.0766222307172,R-428,,,0,0
BRD-K14880289-001-02-2::2.5::HTS,BRD-K14880289-001-02-2,GW-501516,2.5,HTS,CRISPR_HAL (3034),AVANA_PUBLIC_18Q2,noncancer,PPAR receptor agonist,"PPARA, PPARD",,,Phase 2,0.29194244239885603,0.106062252834,GW-501516,,,0,0
BRD-K14920963-304-02-7::2.5::HTS,BRD-K14920963-304-02-7,erythrosine,2.5,HTS,MIRNA_hsa-miR-188-5p,MIRNA,noncancer,coloring agent,,,,Preclinical,0.263634825392312,0.120884117963,erythrosine,,,0,0
BRD-K14965640-001-12-4::2.5::HTS,BRD-K14965640-001-12-4,ibuprofen-(s),2.5,HTS,PROT_4E-BP1_pS65,PROT,noncancer,cyclooxygenase inhibitor,"ASIC1, BCL2, CFTR, FABP2, PLAT, PPARG, PTGS1, PTGS2, SLC5A8, THBD",,,Preclinical,0.280512421943872,0.0649081438912,ibuprofen-(s),,,0,0
BRD-K14991967-001-02-6::2.5::HTS,BRD-K14991967-001-02-6,GSK650394,2.5,HTS,CN_ARHGEF28 (64283),CN,targeted cancer,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",,,Preclinical,0.321801164666881,0.0853988388614,GSK650394,OTHER,0.32058229016981765,1.7035619458704645,-3.9857023396227347
BRD-K14993104-001-05-9::2.5::HTS,BRD-K14993104-001-05-9,bemegride,2.5,HTS,CRISPR_PLXNA2 (5362),AVANA_PUBLIC_18Q2,noncancer,chemoreceptor agonist,GABRA1,critical care,poison antidote,Launched,0.31113553764922197,0.0302582627492,bemegride,,,0,0
BRD-K15010214-364-02-7::2.5::HTS,BRD-K15010214-364-02-7,emedastine,2.5,HTS,DEM2_STAMBP (10617),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,Launched,0.269109523338835,0.0861093442298,emedastine,,,0,0
BRD-K15014948-001-10-3::2.500062642::MTS004,BRD-K15014948-001-10-3,tranexamic-acid,2.500062642,MTS004,CN_YWHAEP7 (284100),CN,noncancer,"antifibrinolytic, plasminogen activator inhibitor",PLG,hematology,hemophilia,Launched,0.277113211401158,0.145306626125,tranexamic-acid,,,0,0
BRD-K15025317-001-15-1::2.5::HTS,BRD-K15025317-001-15-1,BAY-11-7082,2.5,HTS,Exp_LAMTOR3 (ENSG00000109270),GE,noncancer,NFkB pathway inhibitor,RELA,,,Preclinical,0.317965843895433,0.205980159426,BAY-11-7082,NFKB PATHWAY INHIBITOR,0.3213906452490388,5.101642264119144,-1.3832818906798303
BRD-K15045219-001-01-8::2.5::HTS,BRD-K15045219-001-01-8,salazodine,2.5,HTS,CN_AKTIP (64400),CN,noncancer,,,,,Phase 2,0.272062669615757,0.0513450671701,salazodine,,,0,0
BRD-K15071410-001-01-1::2.5::HTS,BRD-K15071410-001-01-1,tiotidine,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,histamine receptor antagonist,HRH2,,,Phase 2,0.240440081682228,0.0745508804723,tiotidine,,,0,0
BRD-K15086322-050-01-3::2.5::HTS,BRD-K15086322-050-01-3,JNJ-10191584,2.5,HTS,DEM2_SP100 (6672),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH4,,,Preclinical,0.23110062699584197,0.119675191177,JNJ-10191584,,,0,0
BRD-K15108141-001-06-6::2.5::HTS,BRD-K15108141-001-06-6,gemcitabine,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,chemo,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer",Launched,0.340960428157479,0.249943274074,gemcitabine,OTHER,0.34141906861412313,4.831069482434648,-1.8557826700642612
BRD-K15164005-001-05-6::2.5::HTS,BRD-K15164005-001-05-6,apoptosis-activator-II,2.5,HTS,CRISPR_RAB10 (10890),AVANA_PUBLIC_18Q2,noncancer,carboxylesterase inhibitor,"BCHE, CES1",,,Preclinical,0.355602298171512,0.173607077267,apoptosis-activator-II,,,0,0
BRD-K15170068-001-03-2::2.89::HTS,BRD-K15170068-001-03-2,swainsonine,2.89,HTS,CN_LOC286189 (286189),CN,targeted cancer,alpha mannosidase inhibitor,MAN2A1,,,Phase 2,0.29393716320399704,0.0915963890888,swainsonine,,,0,0
BRD-K15179513-001-03-4::2.5::HTS,BRD-K15179513-001-03-4,NVP-ADW742,2.5,HTS,PROT_PTEN,PROT,targeted cancer,insulin growth factor receptor inhibitor,IGF1R,,,Preclinical,0.36085617938086706,0.105573574517,NVP-ADW742,OTHER,0.30201954406532106,-6.0336938481826285,2.6641402257861517
BRD-K15196155-001-02-3::2.5::HTS,BRD-K15196155-001-02-3,IBC-293,2.5,HTS,DEM2_TBC1D19 (55296),DEMETER2_COM,noncancer,hydroxycarboxylic acid receptor agonist,HCAR3,,,Preclinical,0.283683998839385,0.0776598755129,IBC-293,,,0,0
BRD-K15231341-001-01-5::2.5::HTS,BRD-K15231341-001-01-5,hemomex-s,2.5,HTS,RMUTmis_OR10G8 (219869),MUT,targeted cancer,,PPARG,,,Launched,0.30773615343871696,0.101028588503,hemomex-s,,,0,0
BRD-K15262564-001-15-0::2.500002693::MTS004,BRD-K15262564-001-15-0,mupirocin,2.500002693,MTS004,CN_ABCC8 (6833),CN,noncancer,isoleucyl-tRNA synthetase inhibitor,,infectious disease,impetigo,Launched,0.264073577187966,0.0508954820408,mupirocin,,,0,0
BRD-K15318383-201-01-5::2.5::HTS,BRD-K15318383-201-01-5,ammonium-glycyrrhizinate,2.5,HTS,METHYL_DGCR8,METHYL,noncancer,thrombin inhibitor,"HSD11B1, HSD11B2, SLCO1B1, SLCO1B3",dermatology,cosmetic,Launched,0.204682665391796,-0.0433701348059,ammonium-glycyrrhizinate,,,0,0
BRD-K15318909-001-10-5::2.5::HTS,BRD-K15318909-001-10-5,PRIMA1,2.5,HTS,Exp_KEL (ENSG00000197993),GE,targeted cancer,TP53 inhibitor,ACHE,,,Preclinical,0.28321230627246896,0.0244382732101,PRIMA1,,,0,0
BRD-K15327298-001-05-5::2.444207768::MTS004,BRD-K15327298-001-05-5,fmoc-l-leucine,2.444207768,MTS004,CN_TFAP2A-AS1 (100130275),CN,noncancer,PPAR receptor agonist,,,,Phase 2,0.303638930932895,0.18881767938,fmoc-l-leucine,,,0,0
BRD-K15337272-001-01-3::2.5::HTS,BRD-K15337272-001-01-3,C-751,2.5,HTS,MIRNA_hsa-miR-518f,MIRNA,noncancer,,,,,Preclinical,0.256961959950133,0.0946743990907,C-751,,,0,0
BRD-K15360631-325-01-4::2.404560312::MTS004,BRD-K15360631-325-01-4,dehydroepiandrosterone-sulfate,2.404560312,MTS004,METHYL_PBRM1,METHYL,noncancer,"androgen receptor agonist, estrogen receptor agonist","AR, ESR1, ESR2",endocrinology,menopause,Launched,0.24275157750662302,0.121281560943,dehydroepiandrosterone-sulfate,,,0,0
BRD-K15409150-001-05-8::2.5::HTS,BRD-K15409150-001-05-8,penfluridol,2.5,HTS,METHYL_CIART,METHYL,noncancer,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,Launched,0.26888325917211703,0.160002975964,penfluridol,OTHER,0.2754230643099099,3.7031220909043583,-0.22031852812098496
BRD-K15424032-001-03-6::2.5::HTS,BRD-K15424032-001-03-6,SB-228357,2.5,HTS,PROT_B-Raf_Caution,PROT,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.44793226917337897,0.156500642366,SB-228357,OTHER,0.4455826641253263,-0.028113562323769745,-3.1982292528693788
BRD-K15426076-001-01-2::2.5::HTS,BRD-K15426076-001-01-2,iguratimod,2.5,HTS,MIRNA_hsa-miR-521,MIRNA,noncancer,"cyclooxygenase inhibitor, NFkB pathway inhibitor",PTGS2,rheumatology,rheumatoid arthritis,Launched,0.18700235204059304,0.0104805739509,iguratimod,,,0,0
BRD-K15502390-001-20-9::2.5::HTS,BRD-K15502390-001-20-9,nevirapine,2.5,HTS,PROT_INPP4B,PROT,noncancer,non-nucleoside reverse transcriptase inhibitor,"CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.274851086158175,0.136119272239,nevirapine,,,0,0
BRD-K15507868-001-03-7::2.5::HTS,BRD-K15507868-001-03-7,tesaglitazar,2.5,HTS,CRISPR_ITPA (3704),AVANA_PUBLIC_18Q2,noncancer,"insulin sensitizer, PPAR receptor agonist","PPARA, PPARG",,,Phase 3,0.303985141248507,-0.0254885047839,tesaglitazar,,,0,0
BRD-K15519488-050-01-3::2.5::HTS,BRD-K15519488-050-01-3,CS-110266,2.5,HTS,CN_PGA4 (643847),CN,noncancer,dopamine receptor agonist,SLC6A3,,,Preclinical,0.288040607198141,0.0895464702111,CS-110266,,,0,0
BRD-K15563106-001-18-0::2.5::HTS,BRD-K15563106-001-18-0,phloretin,2.5,HTS,DEM2_LHFPL6 (10186),DEMETER2_COM,noncancer,sodium/glucose cotransporter inhibitor,"AQP9, CLCN3, SLC23A1",,,Launched,0.258732285294112,0.129381311318,phloretin,,,0,0
BRD-K15567136-003-27-2::2.5::HTS,BRD-K15567136-003-27-2,papaverine,2.5,HTS,Exp_SYT13 (ENSG00000019505),GE,noncancer,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",Launched,0.288342568012135,0.14726664477,papaverine,OTHER,0.28746773419000793,2.040441812505171,-2.202669252365336
BRD-K15588452-003-02-7::2.5::HTS,BRD-K15588452-003-02-7,R-96544,2.5,HTS,METHYL_USP28,METHYL,noncancer,serotonin receptor antagonist,HTR2A,,,Preclinical,0.30880911282339196,0.0626148102098,R-96544,,,0,0
BRD-K15600710-066-04-1::2.5::HTS,BRD-K15600710-066-04-1,obatoclax,2.5,HTS,METHYL_DGKD,METHYL,targeted cancer,BCL inhibitor,BCL2,,,Phase 3,0.37003700679398,0.0343672997725,obatoclax,OTHER,0.3724238803541881,4.804518881781472,-0.8283557647110906
BRD-K15691453-236-01-6::2.499981005::MTS004,BRD-K15691453-236-01-6,GSK2190915,2.499981005,MTS004,PROT_FRA1_Caution,PROT,noncancer,lipoxygenase inhibitor,ALOX5AP,,,Phase 2,0.292094170929671,0.0577012490415,GSK2190915,,,0,0
BRD-K15697815-001-16-2::2.5::HTS,BRD-K15697815-001-16-2,ursodiol,2.5,HTS,Exp_GAPDHP70 (ENSG00000249489),GE,noncancer,"nuclear factor erythroid derived, like (NRF2) activator",NR1H4,gastroenterology,gallstones,Launched,0.282191496855337,0.164656798398,ursodiol,,,0,0
BRD-K15766189-001-09-8::2.5::HTS,BRD-K15766189-001-09-8,cefdinir,2.5,HTS,CRISPR_KRT80 (144501),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis",Launched,0.26540869915814,0.0471144469722,cefdinir,,,0,0
BRD-K15791587-003-02-5::2.5::HTS,BRD-K15791587-003-02-5,L-733060,2.5,HTS,CN_HLA-B (3106),CN,noncancer,tachykinin antagonist,TACR1,,,Preclinical,0.312109160410203,0.0122712844507,L-733060,,,0,0
BRD-K15834839-001-02-3::2.5::HTS,BRD-K15834839-001-02-3,lobendazole,2.5,HTS,Exp_SEC31B (ENSG00000075826),GE,noncancer,anthelmintic agent,,,,Preclinical,0.22867794011463397,0.119302497739,lobendazole,,,0,0
BRD-K15868788-003-07-7::2.5::HTS,BRD-K15868788-003-07-7,SDZ-205-557,2.5,HTS,CRISPR_ANKRD13D (338692),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,"HTR3A, HTR3B",,,Preclinical,0.309696502454729,0.160721065444,SDZ-205-557,,,0,0
BRD-K15891719-001-05-1::2.45::HTS,BRD-K15891719-001-05-1,tenofovir,2.45,HTS,METHYL_TRAPPC12,METHYL,noncancer,"HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B",Launched,0.26875569043354997,-0.00645088666637,tenofovir,,,0,0
BRD-K15898725-001-01-7::2.5::HTS,BRD-K15898725-001-01-7,maytansinol-isobutyrate,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,,,,,Preclinical,0.38260056000243203,0.339536221147,maytansinol-isobutyrate,OTHER,0.3811845384802369,6.122465840644442,-2.511465164058854
BRD-K15916496-001-27-9::2.5::HTS,BRD-K15916496-001-27-9,clotrimazole,2.5,HTS,METHYL_KLHL28,METHYL,noncancer,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis",Launched,0.30103922568325503,0.0661143659493,clotrimazole,,,0,0
BRD-K15933101-003-06-1::2.5::HTS,BRD-K15933101-003-06-1,ropinirole,2.5,HTS,METABOL_C50:3 TAG,METABOL,noncancer,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome",Launched,0.25515717216475,0.00998498616868,ropinirole,,,0,0
BRD-K16037980-001-01-1::2.5::HTS,BRD-K16037980-001-01-1,Z160,2.5,HTS,Exp_RNF7P1 (ENSG00000239831),GE,noncancer,N-type calcium channel blocker,CACNA2D1,,,Phase 2,0.27566789629461796,0.0755253281631,Z160,,,0,0
BRD-K16077845-001-06-1::2.5::HTS,BRD-K16077845-001-06-1,fentiazac,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",Launched,0.28791595946494203,0.0685338532725,fentiazac,,,0,0
BRD-K16180792-001-01-7::2.5::MTS004,BRD-K16180792-001-01-7,bis(maltolato)oxovanadium(IV),2.5,MTS004,Exp_SLC26A2 (ENSG00000155850),GE,noncancer,tyrosine phosphatase inhibitor,PTPN1,,,Phase 2,0.472699909819384,0.619736235827,bis(maltolato)oxovanadium(IV),OTHER,0.47641199103346,1.7702534768880485,4.096371307036435
BRD-K16189898-003-03-3::2.5::HTS,BRD-K16189898-003-03-3,CHIR-99021,2.5,HTS,CN_ADAMTSL3 (57188),CN,noncancer,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",,,Preclinical,0.285384222317295,0.12448760177,CHIR-99021,OTHER,0.2901421277643567,-2.7071453080551757,0.9666302802847068
BRD-K16195444-003-26-0::2.5::HTS,BRD-K16195444-003-26-0,oxymetazoline,2.5,HTS,METHYL_SSUH2,METHYL,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,Launched,0.335814343748305,0.10339882106,oxymetazoline,,,0,0
BRD-K16277217-001-10-9::2.5::HTS,BRD-K16277217-001-10-9,piperacetazine,2.5,HTS,MUTpool_ULBP2 (80328),MUTpool,noncancer,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia,Launched,0.157728234153333,0.172511120722,piperacetazine,,,0,0
BRD-K16295392-003-01-3::2.5::HTS,BRD-K16295392-003-01-3,atrasentan,2.5,HTS,CRISPR_VCL (7414),AVANA_PUBLIC_18Q2,targeted cancer,endothelin receptor antagonist,EDNRA,,,Phase 3,0.29164277720851506,0.0884454463636,atrasentan,,,0,0
BRD-K16338837-001-02-6::2.5::HTS,BRD-K16338837-001-02-6,CCMI,2.5,HTS,Exp_C6orf25 (ENSG00000204420),GE,noncancer,acetylcholine receptor allosteric modulator,CHRNA7,,,Preclinical,0.301061795217133,0.0535043575124,CCMI,,,0,0
BRD-K16444452-001-09-1::2.5::HTS,BRD-K16444452-001-09-1,ibudilast,2.5,HTS,RMUTmis_KIAA2026 (158358),MUTmis,noncancer,"leukotriene receptor antagonist, phosphodiesterase inhibitor","IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","pulmonary, neurology/psychiatry","asthma, stroke",Launched,0.29866671212345197,0.0363239361205,ibudilast,,,0,0
BRD-K16474819-001-09-6::2.5::HTS,BRD-K16474819-001-09-6,metacetamol,2.5,HTS,CN_RASGRP3 (25780),CN,noncancer,analgesic agent,,,,Preclinical,0.293656578911142,0.128696463238,metacetamol,,,0,0
BRD-K16478699-001-09-2::2.5::HTS,BRD-K16478699-001-09-2,PLX-4720,2.5,HTS,DEM2_BRAF (673),DEMETER2_COM,targeted cancer,RAF inhibitor,"BRAF, KDR",,,Preclinical,0.35461275912986895,0.414495480983,PLX-4720,RAF INHIBITOR,0.3515845228819439,1.5685635426314568,3.147103146345177
BRD-K16484091-001-01-1::2.5::HTS,BRD-K16484091-001-01-1,metocurine,2.5,HTS,CRISPR_TUFM (7284),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM2, CHRNA2",neurology/psychiatry,muscle relaxant,Launched,0.266748773754778,0.0951484137285,metocurine,,,0,0
BRD-K16505263-003-02-9::2.49996754::MTS004,BRD-K16505263-003-02-9,forodesine,2.49996754,MTS004,Exp_SCAF11 (ENSG00000139218),GE,targeted cancer,purinergic receptor antagonist,PNP,,,Phase 2,0.23252824043835502,0.132306171423,forodesine,,,0,0
BRD-K16508793-001-05-9::2.5::HTS,BRD-K16508793-001-05-9,diazepam,2.5,HTS,Exp_PPA1 (ENSG00000180817),GE,noncancer,benzodiazepine receptor agonist,"ADRA1A, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",neurology/psychiatry,"generalized anxiety disorder (GAD), abstinence from alcohol, hallucinosis, tremors",Launched,0.316568276144883,0.14596122072,diazepam,,,0,0
BRD-K16542329-001-13-5::2.5::HTS,BRD-K16542329-001-13-5,zaprinast,2.5,HTS,MIRNA_hsa-miR-187,MIRNA,noncancer,phosphodiesterase inhibitor,"GPR35, PDE1A, PDE4D, PDE5A, PDE9A",,,Phase 2,0.311749532106973,0.0546005105666,zaprinast,,,0,0
BRD-K16546375-001-01-4::2.393310671::MTS004,BRD-K16546375-001-01-4,bicyclol,2.393310671,MTS004,CN_IMMP2L (83943),CN,noncancer,NFkB pathway inhibitor,"HSPA1A, HSPB1",,,Launched,0.265048731898002,0.0715147033203,bicyclol,,,0,0
BRD-K16551357-001-03-2::2.5::HTS,BRD-K16551357-001-03-2,evacetrapib,2.5,HTS,PROT_Src_pY527,PROT,noncancer,cholesteryl ester transfer protein inhibitor,CETP,,,Phase 3,0.355282526845651,0.123527353966,evacetrapib,OTHER,0.3614810603329596,0.5088452944818743,-3.4460505846432445
BRD-K16551401-003-03-4::2.5::HTS,BRD-K16551401-003-03-4,PNU-22394,2.5,HTS,CN_SNHG16 (100507246),CN,noncancer,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C, MAOA, MAOB",,,Phase 2,0.23742961076964003,0.0906576851099,PNU-22394,,,0,0
BRD-K16664969-001-03-3::2.5::HTS,BRD-K16664969-001-03-3,GTP-14564,2.5,HTS,Exp_CHTOP (ENSG00000160679),GE,targeted cancer,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",,,Preclinical,0.306188202151403,0.139715396369,GTP-14564,OTHER,0.30337297595092416,-1.2757643109296586,0.9203131718675964
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,OTHER,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K16732600-001-01-7::2.5::HTS,BRD-K16732600-001-01-7,MK-0893,2.5,HTS,METABOL_dCMP,METABOL,noncancer,glucagon receptor antagonist,GCGR,,,Phase 2,0.248202492845558,0.074981536872,MK-0893,,,0,0
BRD-K16757695-050-02-5::2.5::HTS,BRD-K16757695-050-02-5,PRX-08066,2.5,HTS,Exp_ITGAL (ENSG00000005844),GE,noncancer,serotonin receptor antagonist,HTR2B,,,Phase 2,0.329401203706107,0.163230664985,PRX-08066,,,0,0
BRD-K16758059-001-01-8::2.5::HTS,BRD-K16758059-001-01-8,perfluamine,2.5,HTS,MUTpool_COL5A2 (1290),MUTpool,noncancer,,,,,Launched,0.29982394376984695,0.000134948143873,perfluamine,,,0,0
BRD-K16761703-001-03-8::2.5::HTS,BRD-K16761703-001-03-8,sotrastaurin,2.5,HTS,PROT_p53_Caution,PROT,targeted cancer,PKC inhibitor,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ",,,Phase 2,0.295839649179545,0.13806970712,sotrastaurin,,,0,0
BRD-K16803204-001-01-6::2.5::HTS,BRD-K16803204-001-01-6,filgotinib,2.5,HTS,MIRNA_hsa-miR-485-5p,MIRNA,noncancer,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",,,Phase 2,0.31243968049265697,0.0708211804646,filgotinib,,,0,0
BRD-K16810791-001-01-0::2.5::HTS,BRD-K16810791-001-01-0,LGK-974,2.5,HTS,Exp_ARHGEF28 (ENSG00000214944),GE,targeted cancer,porcupine inhibitor,PORCN,,,Phase 2,0.32797863366631796,0.11443041891,LGK-974,,,0,0
BRD-K16898998-001-01-6::2.5::HTS,BRD-K16898998-001-01-6,bevirimat-dimeglumine,2.5,HTS,Exp_PGM1 (ENSG00000079739),GE,noncancer,HIV capsid assembly inhibitor,,,,Phase 2,0.286232674138819,0.0487636666354,bevirimat-dimeglumine,,,0,0
BRD-K17008822-303-02-1::2.5::HTS,BRD-K17008822-303-02-1,BD-1008,2.5,HTS,PROT_BRCA2_Caution,PROT,noncancer,sigma receptor antagonist,,,,Preclinical,0.31141421036758604,0.08697438933,BD-1008,,,0,0
BRD-K17016787-001-16-7::2.5::HTS,BRD-K17016787-001-16-7,estriol,2.5,HTS,METHYL_PEX6,METHYL,noncancer,estrogen receptor agonist,"ESR1, ESR2","endocrinology, obstetrics/gynecology, infectious disease","menopause, vaginal atrophy, urinary tract infections",Launched,0.273825824960552,0.0769779305364,estriol,,,0,0
BRD-K17026858-001-01-2::2.5::HTS,BRD-K17026858-001-01-2,pibenzimol,2.5,HTS,METABOL_C46:1 TAG,METABOL,targeted cancer,DNA inhibitor,,,,Phase 2,0.36932022813549603,0.147111758393,pibenzimol,OTHER,0.3689306652141264,3.3316336195182275,-3.891342888750433
BRD-K17068645-003-04-2::2.5::HTS,BRD-K17068645-003-04-2,bendamustine,2.5,HTS,DEM2_IMPDH2 (3615),DEMETER2_COM,chemo,DNA inhibitor,,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)",Launched,0.313597171291609,0.0393752861845,bendamustine,,,0,0
BRD-K17075857-001-17-6::2.5::HTS,BRD-K17075857-001-17-6,chloroxine,2.5,HTS,Exp_TRPC4 (ENSG00000133107),GE,noncancer,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff",Launched,0.286385349126523,0.178648217826,chloroxine,OTHER,0.3476702405048476,4.877226087164149,-2.7896100935729646
BRD-K17075857-001-18-4::2.5::HTS,BRD-K17075857-001-18-4,chloroxine,2.5,HTS,LIN_Ewings_sarcoma,LIN,noncancer,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff",Launched,0.286385349126523,0.186807257002,chloroxine,OTHER,0.2900225474501338,3.2548311945522816,-2.8612119155259355
BRD-K17203476-001-01-9::2.5::HTS,BRD-K17203476-001-01-9,LY2874455,2.5,HTS,Exp_PDXDC1 (ENSG00000179889),GE,targeted cancer,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",,,Phase 1,0.346517261019826,0.407566497911,LY2874455,OTHER,0.34749043103505245,3.457046067114806,-2.700743730793615
BRD-K17205817-001-06-1::2.5::HTS,BRD-K17205817-001-06-1,sulfametopyrazine,2.5,HTS,CRISPR_TNFRSF6B (8771),AVANA_PUBLIC_18Q2,noncancer,PABA antagonist,,infectious disease,"malaria, urinary tract infections, respiratory tract infections",Launched,0.25605115106919,0.0708059922387,sulfametopyrazine,,,0,0
BRD-K17223896-001-10-0::2.5::HTS,BRD-K17223896-001-10-0,chloroxylenol,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,ATP synthase inhibitor,,infectious disease,skin infections,Launched,0.22646573288270605,0.0797007807024,chloroxylenol,,,0,0
BRD-K17294426-050-12-3::2.5::HTS,BRD-K17294426-050-12-3,clebopride,2.5,HTS,METHYL_LOC101928851,METHYL,noncancer,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,Launched,0.296803062984976,0.144764275698,clebopride,,,0,0
BRD-K17295893-001-01-0::2.499987615::MTS004,BRD-K17295893-001-01-0,nastorazepide,2.499987615,MTS004,PROT_NF-kB-p65_pS536_Caution,PROT,targeted cancer,CCK receptor antagonist,CCKBR,,,Phase 2,0.307205944354036,0.120530882175,nastorazepide,,,0,0
BRD-K17368287-001-18-3::2.5::HTS,BRD-K17368287-001-18-3,adrenosterone,2.5,HTS,METHYL_SNX30,METHYL,noncancer,11-beta hydroxysteroid dehydrogenase inhibitor,"HSD11B1, HSD11B2",,,Preclinical,0.265595106698686,0.102408732536,adrenosterone,,,0,0
BRD-K17378184-300-05-9::2.5::HTS,BRD-K17378184-300-05-9,BP-897,2.5,HTS,CRISPR_ANKS6 (203286),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor agonist,"ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B",,,Phase 2,0.250512014572303,0.091653623035,BP-897,,,0,0
BRD-K17415526-001-03-5::2.5::HTS,BRD-K17415526-001-03-5,tyrphostin-AG-835,2.5,HTS,DEM2_ARID1B (57492),DEMETER2_COM,targeted cancer,protein tyrosine kinase inhibitor,EGFR,,,Preclinical,0.258191299684999,0.0529856577519,tyrphostin-AG-835,,,0,0
BRD-K17443395-065-02-2::2.5::HTS,BRD-K17443395-065-02-2,abacavir,2.5,HTS,CRISPR_CCDC51 (79714),AVANA_PUBLIC_18Q2,noncancer,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.28191587968128,0.0945706890656,abacavir,,,0,0
BRD-K17480742-001-01-1::2.5::MTS004,BRD-K17480742-001-01-1,delamanid,2.5,MTS004,Exp_NCF1C (ENSG00000165178),GE,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis,Launched,0.227075856652023,0.00386910824109,delamanid,,,0,0
BRD-K17497770-001-03-6::2.5::HTS,BRD-K17497770-001-03-6,butein,2.5,HTS,Exp_BEND5 (ENSG00000162373),GE,noncancer,"EGFR inhibitor, src inhibitor",ACE,,,Preclinical,0.34813140370888895,0.15719318392,butein,EGFR INHIBITOR,0.3463790579989863,-4.07822373954745,-1.1574521940062703
BRD-K17498618-344-02-6::2.5::HTS,BRD-K17498618-344-02-6,betaxolol,2.5,HTS,RMUTdmg_VWA3A (146177),MUTdmg,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.28354326144615,0.0577750841093,betaxolol,,,0,0
BRD-K17500877-001-02-1::2.5::HTS,BRD-K17500877-001-02-1,bropirimine,2.5,HTS,CRISPR_SAR1A (56681),AVANA_PUBLIC_18Q2,targeted cancer,interferon inducer,,,,Phase 3,0.292742146415626,0.0710776784915,bropirimine,,,0,0
BRD-K17513304-001-01-9::2.5::HTS,BRD-K17513304-001-01-9,firategrast,2.5,HTS,CRISPR_VENTX (27287),AVANA_PUBLIC_18Q2,noncancer,integrin antagonist,ITGA4,,,Phase 2,0.32342742836963106,0.0100664313149,firategrast,,,0,0
BRD-K17518951-001-03-0::2.5::HTS,BRD-K17518951-001-03-0,penicillamine-(D),2.5,HTS,METABOL_proline,METABOL,noncancer,chelating agent,,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria",Launched,0.309197146641066,0.060868413178,penicillamine-(D),,,0,0
BRD-K17555800-003-01-5::2.5::HTS,BRD-K17555800-003-01-5,talmapimod,2.5,HTS,METHYL_HCG23,METHYL,targeted cancer,p38 MAPK inhibitor,"MAPK11, MAPK14",,,Phase 2,0.35205391830124794,0.165456459532,talmapimod,OTHER,0.35256987476510426,4.713778794984255,-1.1472350766494164
BRD-K17561142-003-32-5::2.5::HTS,BRD-K17561142-003-32-5,amiodarone,2.5,HTS,PROT_SCD1,PROT,noncancer,potassium channel blocker,"ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2",cardiology,ventricular arrhythmias,Launched,0.31744609726658,0.0964038749743,amiodarone,,,0,0
BRD-K17565903-066-23-1::2.5::HTS,BRD-K17565903-066-23-1,pridinol,2.5,HTS,METABOL_C32:0 PC,METABOL,noncancer,muscle relaxant,,neurology/psychiatry,muscle relaxant,Launched,0.279937606018863,0.0342079529222,pridinol,,,0,0
BRD-K17610631-001-03-3::2.421190843::MTS004,BRD-K17610631-001-03-3,indisulam,2.421190843,MTS004,Exp_DCAF15 (ENSG00000132017),GE,targeted cancer,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",,,Phase 2,0.46505516054461504,0.393099327153,indisulam,CDK INHIBITOR,0.4724312219594145,5.324284690705121,-3.894970665490989
BRD-K17641316-001-04-8::2.500015146::MTS004,BRD-K17641316-001-04-8,decoquinate,2.500015146,MTS004,CN_PSMD3 (5709),CN,noncancer,antiprotozoal agent,,infectious disease,coccidiosis,Launched,0.308188928533509,0.113744009676,decoquinate,,,0,0
BRD-K17702546-001-03-2::2.5::HTS,BRD-K17702546-001-03-2,PD-168393,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, SRC",,,Preclinical,0.44722495178451793,0.537780071912,PD-168393,EGFR INHIBITOR,0.4503270312788369,0.9703824987247894,-5.1801434083536515
BRD-K17705806-003-04-4::2.5::HTS,BRD-K17705806-003-04-4,JTC-801,2.5,HTS,Exp_CDC42BPA (ENSG00000143776),GE,noncancer,opioid receptor antagonist,OPRL1,,,Phase 2,0.412423317049556,0.287741638325,JTC-801,OTHER,0.4041889699386277,4.434418447186978,-0.9393341705397305
BRD-K17743125-001-08-4::2.5::HTS,BRD-K17743125-001-08-4,belinostat,2.5,HTS,Exp_EN1 (ENSG00000163064),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Launched,0.42282490157331504,0.171561244731,belinostat,HDAC INHIBITOR,0.42531548719814294,6.257025435667624,-0.7786242497268265
BRD-K17743697-066-03-6::2.5::HTS,BRD-K17743697-066-03-6,KB-R7943,2.5,HTS,Exp_MLF1 (ENSG00000178053),GE,noncancer,sodium/calcium exchange inhibitor,"SLC8A1, TRPC3, TRPC5, TRPC6",,,Preclinical,0.31140151003086797,0.0657386841601,KB-R7943,,,0,0
BRD-K17774839-001-02-9::2.5::HTS,BRD-K17774839-001-02-9,JNJ-7777120,2.5,HTS,PROT_Tuberin,PROT,noncancer,histamine receptor antagonist,HRH4,,,Preclinical,0.292580255495765,0.0323251943854,JNJ-7777120,,,0,0
BRD-K17849083-001-31-1::2.5::HTS,BRD-K17849083-001-31-1,tranilast,2.5,HTS,Exp_BDKRB1 (ENSG00000100739),GE,noncancer,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,Launched,0.291514950822094,0.134774778611,tranilast,,,0,0
BRD-K17849083-001-32-9::2.43::HTS,BRD-K17849083-001-32-9,tranilast,2.43,HTS,METABOL_C40:6 PC,METABOL,noncancer,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,Launched,0.291514950822094,0.0854494723272,tranilast,,,0,0
BRD-K17850764-236-11-9::2.5::HTS,BRD-K17850764-236-11-9,cloprostenol-(+/-),2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,prostaglandin receptor agonist,"PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R",,,Launched,0.25558225263893397,0.139830800755,cloprostenol-(+/-),,,0,0
BRD-K17868609-001-05-0::2.5::HTS,BRD-K17868609-001-05-0,BRL-54443,2.5,HTS,DEM2_NUP153 (9972),DEMETER2_COM,noncancer,serotonin receptor agonist,"HTR1E, HTR1F",,,Preclinical,0.23622585163104395,0.0520866923231,BRL-54443,,,0,0
BRD-K17874705-300-03-2::2.5::HTS,BRD-K17874705-300-03-2,2-pyridylethylamine,2.5,HTS,Exp_HAPLN1 (ENSG00000145681),GE,noncancer,histamine receptor agonist,HRH1,,,Preclinical,0.28733762221766995,0.0953253222986,2-pyridylethylamine,,,0,0
BRD-K17894950-001-14-3::2.5::HTS,BRD-K17894950-001-14-3,indirubin,2.5,HTS,Exp_SLC19A2 (ENSG00000117479),GE,targeted cancer,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",,,Phase 2/Phase 3,0.301333802448029,0.157385178543,indirubin,CDK INHIBITOR,0.2983403988654041,-1.0704134924591613,0.9983716869621628
BRD-K17953908-001-01-7::2.5::HTS,BRD-K17953908-001-01-7,LY2886721,2.5,HTS,CRISPR_CYP2F1 (1572),AVANA_PUBLIC_18Q2,noncancer,beta-secretase inhibitor,BACE1,,,Phase 1/Phase 2,0.304530718432038,0.114838812207,LY2886721,,,0,0
BRD-K17977438-048-02-4::2.5::HTS,BRD-K17977438-048-02-4,oxelaidin,2.5,HTS,MIRNA_hsa-miR-143,MIRNA,noncancer,antitussive,,pulmonary,cough suppressant,Launched,0.229333474253455,0.00883718859231,oxelaidin,,,0,0
BRD-K17979676-001-01-2::2.5::HTS,BRD-K17979676-001-01-2,eprobemide,2.5,HTS,CRISPR_NFKB1 (4790),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Launched,0.293134302829961,0.0695733909355,eprobemide,OTHER,0.2717337199610915,-1.9939389567874564,-2.671419846923301
BRD-K18036262-001-02-8::2.5::HTS,BRD-K18036262-001-02-8,L-168049,2.5,HTS,PROT_Chk2_pT68_Caution,PROT,noncancer,glucagon receptor antagonist,GCGR,,,Preclinical,0.22701740937490103,0.119739804103,L-168049,,,0,0
BRD-K18059238-001-10-4::0.25::HTS,BRD-K18059238-001-10-4,gamma-linolenic-acid,0.25,HTS,MUTpool_NOTCH4 (4855),MUTpool,noncancer,"cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2",,,Phase 2,0.265656818387981,0.0736478283796,gamma-linolenic-acid,,,0,0
BRD-K18131774-001-17-6::2.5::HTS,BRD-K18131774-001-17-6,ethoxzolamide,2.5,HTS,CRISPR_VPS35 (55737),AVANA_PUBLIC_18Q2,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9","ophthalmology, gastroenterology","glaucoma, duodenal ulcer disease",Launched,0.239668864757273,0.0717891383003,ethoxzolamide,,,0,0
BRD-K18135438-001-14-2::2.5::MTS004,BRD-K18135438-001-14-2,chenodeoxycholic-acid,2.5,MTS004,CN_GCDH (2639),CN,noncancer,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones",Launched,0.283995020426904,0.151737854343,chenodeoxycholic-acid,,,0,0
BRD-K18135438-001-16-7::2.5::HTS,BRD-K18135438-001-16-7,chenodeoxycholic-acid,2.5,HTS,METABOL_C20:5 CE,METABOL,noncancer,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones",Launched,0.283995020426904,0.109308034851,chenodeoxycholic-acid,,,0,0
BRD-K18157228-001-01-7::2.5::HTS,BRD-K18157228-001-01-7,fdcyd,2.5,HTS,Exp_RNF224 (ENSG00000233198),GE,targeted cancer,DNA methyltransferase inhibitor,,,,Phase 2,0.362864250965426,0.234718363909,fdcyd,OTHER,0.3626240140925862,4.048640760278651,-2.394411232839825
BRD-K18163608-001-05-6::2.48::HTS,BRD-K18163608-001-05-6,HA14-1,2.48,HTS,Exp_IGHV3-42 (ENSG00000254228),GE,targeted cancer,BCL inhibitor,BCL2,,,Preclinical,0.32864633073631605,0.199773317995,HA14-1,,,0,0
BRD-K18172896-001-02-5::2.5::HTS,BRD-K18172896-001-02-5,eltanolone,2.5,HTS,CRISPR_LRSAM1 (90678),AVANA_PUBLIC_18Q2,noncancer,membrane integrity inhibitor,"GABRA1, GABRB2, GABRG2",,,Phase 3,0.283724813976982,0.10362626221,eltanolone,,,0,0
BRD-K18194590-065-08-0::2.5::HTS,BRD-K18194590-065-08-0,mephentermine,2.5,HTS,CRISPR_STAG1 (10274),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3",cardiology,hypotension,Launched,0.25511159458368904,0.104719587137,mephentermine,,,0,0
BRD-K18250272-003-11-0::2.5::HTS,BRD-K18250272-003-11-0,propoxycaine,2.5,HTS,CRISPR_SMYD3 (64754),AVANA_PUBLIC_18Q2,noncancer,local anesthetic,,neurology/psychiatry,anesthetic,Launched,0.16897185813001503,0.00683997589349,propoxycaine,,,0,0
BRD-K18316707-001-02-7::2.5::HTS,BRD-K18316707-001-02-7,O-1918,2.5,HTS,PROT_Stathmin,PROT,noncancer,cannabinoid receptor antagonist,,,,Preclinical,0.29854772934758506,0.043125530173,O-1918,,,0,0
BRD-K18323388-001-01-1::2.5::HTS,BRD-K18323388-001-01-1,uridine-triacetate,2.5,HTS,LIN_pancreas,LIN,noncancer,,,nephrology,orotic aciduria,Launched,0.285159456396123,0.135271692275,uridine-triacetate,,,0,0
BRD-K18324993-001-01-6::2.5::HTS,BRD-K18324993-001-01-6,budipine,2.5,HTS,CN_LOC100289361 (100289361),CN,noncancer,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease,Launched,0.27062854353295496,0.0679767074839,budipine,,,0,0
BRD-K18375018-376-02-3::2.5::HTS,BRD-K18375018-376-02-3,spermine,2.5,HTS,CN_SLC38A11 (151258),CN,targeted cancer,,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",,,Preclinical,0.36617085538799604,0.132977479975,spermine,OTHER,0.37046409924831736,3.7450376459558288,-2.22294322447475
BRD-K18424115-003-01-3::2.5::HTS,BRD-K18424115-003-01-3,TG-100572,2.5,HTS,METHYL_MAFF,METHYL,targeted cancer,"src inhibitor, VEGFR inhibitor","KDR, SRC",,,Preclinical,0.34769718685842405,0.113056931171,TG-100572,OTHER,0.3679078878218813,3.1967957758628835,-1.225139557985246
BRD-K18574842-236-17-7::2.5::HTS,BRD-K18574842-236-17-7,nafcillin,2.5,HTS,LIN_colorectal_MSI,LIN,noncancer,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,Launched,0.273344537676635,0.114447554634,nafcillin,,,0,0
BRD-K18574842-323-10-8::2.51::HTS,BRD-K18574842-323-10-8,nafcillin,2.51,HTS,LIN_glioma,LIN,noncancer,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,Launched,0.273344537676635,0.114447554634,nafcillin,,,0,0
BRD-K18613660-001-05-5::2.5::HTS,BRD-K18613660-001-05-5,mexeneone,2.5,HTS,MIRNA_hsa-miR-143,MIRNA,noncancer,,,,,Preclinical,0.22653438775173398,0.0351831065593,mexeneone,,,0,0
BRD-K18619710-001-14-4::2.5::HTS,BRD-K18619710-001-14-4,digoxigenin,2.5,HTS,PROT_TAZ,PROT,noncancer,steroid,,,,Preclinical,0.3386136487317,0.0922537714226,digoxigenin,OTHER,0.34395622000180986,4.548661631523352,-0.8931894425852679
BRD-K18673820-001-15-5::2.5::HTS,BRD-K18673820-001-15-5,folic-acid,2.5,HTS,CN_CPQ (10404),CN,noncancer,folate receptor ligand,"FOLR2, FOLR3, SLC19A1, SLC46A1",hematology,megaloblastic anemia,Launched,0.27851896027414,0.132150632621,folic-acid,,,0,0
BRD-K18678457-003-02-8::2.5::HTS,BRD-K18678457-003-02-8,ZD-7288,2.5,HTS,Exp_ANKRD63 (ENSG00000230778),GE,noncancer,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",,,Phase 2,0.244128346053011,0.0448189609318,ZD-7288,,,0,0
BRD-K18749874-003-08-9::2.5::MTS004,BRD-K18749874-003-08-9,melevodopa,2.5,MTS004,DEM2_TMEM191A (84222),DEMETER2_COM,noncancer,"dopamine precursor, dopamine receptor agonist",DDC,neurology/psychiatry,Parkinson's Disease,Launched,0.309668274424143,0.115377812319,melevodopa,,,0,0
BRD-K18772613-303-02-4::2.5::HTS,BRD-K18772613-303-02-4,benzoquinonium-dibromide,2.5,HTS,PROT_c-Kit,PROT,noncancer,cholinergic receptor antagonist,CHRNA1,,,Preclinical,0.292852309821002,0.0376650149565,benzoquinonium-dibromide,,,0,0
BRD-K18779551-003-07-8::2.5::HTS,BRD-K18779551-003-07-8,bifemelane,2.5,HTS,METHYL_SLC3A1,METHYL,noncancer,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia",Launched,0.321509090506089,0.0807245406812,bifemelane,,,0,0
BRD-K18787491-001-08-6::2.5::HTS,BRD-K18787491-001-08-6,U-0126,2.5,HTS,Exp_TTBK2 (ENSG00000128881),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.318333461407703,0.284682620627,U-0126,MEK INHIBITOR,0.3023027234116865,2.7949124311200864,-0.1306064330600245
BRD-K18834913-001-01-1::2.5::HTS,BRD-K18834913-001-01-1,LB42708,2.5,HTS,PROT_Gab2,PROT,targeted cancer,farnesyltransferase inhibitor,,,,Preclinical,0.34925758077114394,0.243224881919,LB42708,OTHER,0.3483686647713172,4.039475659274402,-2.9128860808306607
BRD-K18849474-001-04-4::2.61::HTS,BRD-K18849474-001-04-4,dalcetrapib,2.61,HTS,DEM2_PKM (5315),DEMETER2_COM,noncancer,cholesteryl ester transfer protein inhibitor,CETP,,,Phase 3,0.35053017640074,0.127294653436,dalcetrapib,,,0,0
BRD-K18850819-001-04-6::2.5::HTS,BRD-K18850819-001-04-6,MK-0752,2.5,HTS,CRISPR_GCNT3 (9245),AVANA_PUBLIC_18Q2,targeted cancer,gamma secretase inhibitor,,,,Phase 1/Phase 2,0.269675737005062,0.123851154017,MK-0752,,,0,0
BRD-K18898553-001-01-1::2.5::MTS004,BRD-K18898553-001-01-1,salvianolic-acid-B,2.5,MTS004,METHYL_LOC152578,METHYL,noncancer,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,,,Phase 2,0.221160330132946,0.128835370607,salvianolic-acid-B,,,0,0
BRD-K18905250-003-02-4::2.5::HTS,BRD-K18905250-003-02-4,ST-91,2.5,HTS,METABOL_glucuronate,METABOL,noncancer,adrenergic receptor agonist,,,,Preclinical,0.25482433743733,0.114530630311,ST-91,,,0,0
BRD-K18910433-001-36-6::2.58::HTS,BRD-K18910433-001-36-6,estradiol,2.58,HTS,DEM2_CRTC3 (64784),DEMETER2_COM,noncancer,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,Launched,0.224893378997988,0.213024787599,estradiol,,,0,0
BRD-K18910433-001-43-2::2.5::HTS,BRD-K18910433-001-43-2,estradiol,2.5,HTS,DEM2_YIF1B (90522),DEMETER2_COM,noncancer,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,Launched,0.224893378997988,0.213024787599,estradiol,,,0,0
BRD-K18922609-004-23-1::2.5::HTS,BRD-K18922609-004-23-1,neostigmine,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,Launched,0.24128080198435298,0.0875561340879,neostigmine,,,0,0
BRD-K18948558-001-01-9::2.5::HTS,BRD-K18948558-001-01-9,clevudine,2.5,HTS,DEM2_LOC641746 (641746),DEMETER2_COM,noncancer,DNA polymerase inhibitor,,infectious disease,hepatitis B,Launched,0.254711285834739,0.0892986981816,clevudine,,,0,0
BRD-K18961567-001-01-1::2.5::HTS,BRD-K18961567-001-01-1,LY2801653,2.5,HTS,METHYL_RAB34,METHYL,targeted cancer,MET inhibitor,MET,,,Phase 2,0.37134985290753,0.246230596673,LY2801653,OTHER,0.3792347833028255,5.6990205733970125,-1.9371622122607324
BRD-K19034817-001-01-4::2.5::HTS,BRD-K19034817-001-01-4,pacritinib,2.5,HTS,Exp_ZNF702P (ENSG00000242779),GE,targeted cancer,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",,,Phase 3,0.35450106985868796,0.309997170954,pacritinib,OTHER,0.3530889563001092,1.5216939223286627,-3.5390272598331998
BRD-K19061412-001-02-4::2.5::HTS,BRD-K19061412-001-02-4,mubritinib,2.5,HTS,Exp_FAM129B (ENSG00000136830),GE,targeted cancer,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,Phase 1,0.32595983396638395,0.254492096342,mubritinib,OTHER,0.3249953894820127,1.817624084248065,-2.8041325645179707
BRD-K19085898-001-01-8::2.5::HTS,BRD-K19085898-001-01-8,darapladib,2.5,HTS,PROT_4E-BP1_pS65,PROT,noncancer,phospholipase inhibitor,PLA2G7,,,Phase 3,0.261388877266154,0.144169215017,darapladib,,,0,0
BRD-K19111024-001-20-9::2.5::HTS,BRD-K19111024-001-20-9,clofibric-acid,2.5,HTS,METABOL_adenosine,METABOL,noncancer,PPAR receptor agonist,PPARA,,,Launched,0.22415022403289198,-0.0407438705288,clofibric-acid,,,0,0
BRD-K19136521-001-08-9::2.5::HTS,BRD-K19136521-001-08-9,indirubin-3-monoxime,2.5,HTS,METHYL_ABCA11P,METHYL,targeted cancer,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B",,,Preclinical,0.327613773413435,0.0323762403882,indirubin-3-monoxime,CDK INHIBITOR,0.3294411690100792,-2.3480012511918407,0.589359530325325
BRD-K19171642-001-02-3::2.5::HTS,BRD-K19171642-001-02-3,CP-91149,2.5,HTS,CN_ACYP2 (98),CN,noncancer,glycogen phosphorylase inhibitor,PYGL,,,Preclinical,0.25241329011774,0.0571286533786,CP-91149,,,0,0
BRD-K19180152-001-02-6::2.5::HTS,BRD-K19180152-001-02-6,meprobamate,2.5,HTS,DEM2_SREBF2 (6721),DEMETER2_COM,noncancer,,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,anxiety,Launched,0.243941612842338,0.0900240669194,meprobamate,,,0,0
BRD-K19203487-001-01-4::2.5::HTS,BRD-K19203487-001-01-4,SPP301,2.5,HTS,RMUThot_TP53 (7157),MUThot,noncancer,endothelin receptor antagonist,EDNRA,,,Phase 3,0.30616420576135306,0.0429035892219,SPP301,,,0,0
BRD-K19227686-001-18-6::2.5::HTS,BRD-K19227686-001-18-6,phenolphthalein,2.5,HTS,METABOL_sucrose,METABOL,noncancer,indicator dye,UGT1A9,,,Withdrawn,0.28946138560369,0.0948166373929,phenolphthalein,,,0,0
BRD-K19284129-001-02-6::2.5::HTS,BRD-K19284129-001-02-6,salvinorin-a,2.5,HTS,METHYL_GGA3,METHYL,noncancer,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",,,Phase 1,0.272235349109539,-0.0625630754766,salvinorin-a,,,0,0
BRD-K19295594-015-14-3::2.29::HTS,BRD-K19295594-015-14-3,gossypol,2.29,HTS,Exp_NR1D2 (ENSG00000174738),GE,targeted cancer,"BCL inhibitor, MCL1 inhibitor",BCL2,,,Phase 2,0.409211177989029,0.227636670808,gossypol,OTHER,0.40993181201097134,5.189436591077652,0.07548300230064564
BRD-K19309090-300-05-5::2.5::HTS,BRD-K19309090-300-05-5,SR-95639A,2.5,HTS,CN_BRD3 (8019),CN,noncancer,acetylcholine receptor agonist,CHRM1,,,Preclinical,0.28452163818437104,0.0567878703609,SR-95639A,,,0,0
BRD-K19318328-001-01-3::2.5::HTS,BRD-K19318328-001-01-3,FR-139317,2.5,HTS,Exp_DHRS2 (ENSG00000100867),GE,noncancer,endothelin receptor antagonist,EDNRA,,,Phase 1,0.291749277791833,0.0615445156798,FR-139317,,,0,0
BRD-K19333160-001-01-3::2.5::HTS,BRD-K19333160-001-01-3,RKI-1447,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",,,Preclinical,0.37359435683023495,0.320250707166,RKI-1447,OTHER,0.3732297192336484,3.31484074655142,-3.766803173021716
BRD-K19352500-070-12-4::2.5::HTS,BRD-K19352500-070-12-4,prochlorperazine,2.5,HTS,MIRNA_hsa-miR-620,MIRNA,noncancer,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4",gastroenterology,"nausea, vomiting",Launched,0.242399610974642,0.128819601197,prochlorperazine,,,0,0
BRD-K19388745-003-01-7::2.5::HTS,BRD-K19388745-003-01-7,colforsin-daproate,2.5,HTS,Exp_GRAMD4P8 (ENSG00000270930),GE,noncancer,adenylyl cyclase activator,,,,Launched,0.29439587027763897,0.0470326027386,colforsin-daproate,OTHER,0.2918816212626624,-3.699428689120477,0.13686775987278074
BRD-K19412355-001-01-0::2.5::HTS,BRD-K19412355-001-01-0,SB-242235,2.5,HTS,DEM2_GPR75 (10936),DEMETER2_COM,noncancer,p38 MAPK inhibitor,"HSPB1, MAPK14",,,Phase 1,0.27637965343337,0.107965424978,SB-242235,,,0,0
BRD-K19416115-001-05-3::2.5::HTS,BRD-K19416115-001-05-3,sitagliptin,2.5,HTS,DEM2_USP8 (9101),DEMETER2_COM,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.21738794327680397,0.0854499172338,sitagliptin,,,0,0
BRD-K19438463-001-05-5::2.5::HTS,BRD-K19438463-001-05-5,CNQX,2.5,HTS,CN_BTNL3 (10917),CN,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,Phase 1,0.292862582648606,0.120496205597,CNQX,,,0,0
BRD-K19456237-001-27-6::2.5::HTS,BRD-K19456237-001-27-6,piracetam,2.5,HTS,PROT_B-Raf_Caution,PROT,noncancer,acetylcholine receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",neurology/psychiatry,senile dementia,Launched,0.31109179333377,0.105200384237,piracetam,,,0,0
BRD-K19462402-003-24-6::2.5::HTS,BRD-K19462402-003-24-6,buflomedil,2.5,HTS,CN_MAP3K4 (4216),CN,noncancer,"adrenergic receptor antagonist, calcium channel blocker",ADRA1A,cardiology,peripheral artery disease (PAD),Launched,0.267498246649423,0.0575014849449,buflomedil,,,0,0
BRD-K19477839-001-07-6::2.5::HTS,BRD-K19477839-001-07-6,SGX523,2.5,HTS,Exp_LIPG (ENSG00000101670),GE,targeted cancer,hepatocyte growth factor receptor inhibitor,MET,,,Phase 1,0.276198592585991,0.127890456354,SGX523,,,0,0
BRD-K19507340-001-22-1::2.38::HTS,BRD-K19507340-001-22-1,megestrol-acetate,2.38,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,progesterone receptor agonist,"NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia",Launched,0.322575415942589,0.168250798047,megestrol-acetate,,,0,0
BRD-K19515365-001-02-6::2.33859482::MTS004,BRD-K19515365-001-02-6,bendazac,2.33859482,MTS004,PROT_ER-alpha_pS118,PROT,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",Launched,0.33705942013805,0.131007730198,bendazac,,,0,0
BRD-K19540840-001-09-4::2.5::HTS,BRD-K19540840-001-09-4,saracatinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,src inhibitor,"ABL1, LCK, SRC, YES1",,,Phase 2/Phase 3,0.39560446910944497,0.392162692398,saracatinib,OTHER,0.3961234739213966,1.3243000686551682,-4.466581854172591
BRD-K19601669-001-03-5::2.5::HTS,BRD-K19601669-001-03-5,ruxolitinib-(S),2.5,HTS,METHYL_DNAH7,METHYL,targeted cancer,JAK inhibitor,"JAK1, JAK2",,,Preclinical,0.26855269853832603,0.182254285751,ruxolitinib-(S),,,0,0
BRD-K19605405-001-02-7::2.5::HTS,BRD-K19605405-001-02-7,ZM-241385,2.5,HTS,Exp_CYP2C19 (ENSG00000165841),GE,targeted cancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.3055798386186239,0.148336149648,ZM-241385,OTHER,0.3014217157166892,-5.541378240375479,0.3577233292111668
BRD-K19615002-001-02-3::2.5::HTS,BRD-K19615002-001-02-3,creatine,2.5,HTS,CRISPR_IFNA4 (3441),AVANA_PUBLIC_18Q2,targeted cancer,,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",,,Launched,0.297303482106115,0.185367081808,creatine,OTHER,0.32862611284602383,3.823933580805087,-2.708204709618575
BRD-K19655798-001-01-9::2.5::HTS,BRD-K19655798-001-01-9,compound-401,2.5,HTS,METABOL_inosine,METABOL,noncancer,DNA dependent protein kinase inhibitor,"MTOR, PRKDC",,,Preclinical,0.26275013578756196,0.137008645143,compound-401,,,0,0
BRD-K19669037-001-01-1::2.5::HTS,BRD-K19669037-001-01-1,GGTI-298,2.5,HTS,DEM2_MIR21 (406991),DEMETER2_COM,targeted cancer,GGTase inhibitor,CDKN1A,,,Preclinical,0.27283216038068103,0.269914317187,GGTI-298,,,0,0
BRD-K19672466-001-02-3::2.5::HTS,BRD-K19672466-001-02-3,ethimizol,2.5,HTS,DEM2_FLRT1 (23769),DEMETER2_COM,noncancer,,,,,Phase 1,0.29692899260183503,0.111927983549,ethimizol,,,0,0
BRD-K19687926-379-07-4::2.5::HTS,BRD-K19687926-379-07-4,lapatinib,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,Launched,0.427739400427997,0.497752716732,lapatinib,EGFR INHIBITOR,0.4253178996391905,0.8516761282538033,-5.0643122326247765
BRD-K19741547-003-01-7::2.5::HTS,BRD-K19741547-003-01-7,vernakalant,2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF),Launched,0.17691351701833496,0.0913098049551,vernakalant,,,0,0
BRD-K19761926-001-02-8::2.5::HTS,BRD-K19761926-001-02-8,eplerenone,2.5,HTS,Exp_SLC10A6 (ENSG00000145283),GE,noncancer,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension",Launched,0.25342905633387397,0.084281958481,eplerenone,,,0,0
BRD-K19761926-001-03-6::2.45::HTS,BRD-K19761926-001-03-6,eplerenone,2.45,HTS,Exp_ZBTB4 (ENSG00000174282),GE,noncancer,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension",Launched,0.25342905633387397,0.084281958481,eplerenone,,,0,0
BRD-K19796430-001-05-6::2.5::HTS,BRD-K19796430-001-05-6,sonidegib,2.5,HTS,PROT_eEF2_Caution,PROT,targeted cancer,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),Launched,0.33261766226472,0.0875206925561,sonidegib,,,0,0
BRD-K19939891-001-05-4::2.5::HTS,BRD-K19939891-001-05-4,TIC10,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,targeted cancer,"AKT inhibitor, TRAIL modulator","AKT1, MAPK1",,,Phase 2,0.23027423972767602,0.0728374927796,TIC10,,,0,0
BRD-K19972289-001-01-4::2.5::HTS,BRD-K19972289-001-01-4,octinoxate,2.5,HTS,CRISPR_ZFP36L1 (677),AVANA_PUBLIC_18Q2,noncancer,,,dermatology,sunscreen lotion,Launched,0.295101460188862,0.0232552668162,octinoxate,,,0,0
BRD-K20001883-001-02-7::2.5::HTS,BRD-K20001883-001-02-7,apabetalone,2.5,HTS,Exp_HIF1A (ENSG00000100644),GE,noncancer,apolipoprotein expression enhancer,BRD3,,,Phase 3,0.311384168592765,0.224321593672,apabetalone,,,0,0
BRD-K20008181-001-01-3::2.5::HTS,BRD-K20008181-001-01-3,LCQ908,2.5,HTS,DEM2_CHD1 (1105),DEMETER2_COM,noncancer,diacylglycerol O acyltransferase inhibitor,DGAT1,,,Phase 3,0.344376260508791,0.140096070052,LCQ908,,,0,0
BRD-K20013301-001-02-6::2.5::HTS,BRD-K20013301-001-02-6,LY411575,2.5,HTS,Exp_FRG2B (ENSG00000225899),GE,noncancer,gamma secretase inhibitor,,,,Preclinical,0.264719985817342,0.124450528561,LY411575,,,0,0
BRD-K20075662-300-04-0::2.5::HTS,BRD-K20075662-300-04-0,betazole,2.5,HTS,MIRNA_hsa-miR-1973,MIRNA,noncancer,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic,Launched,0.311004121875982,0.0336623062055,betazole,,,0,0
BRD-K20079257-001-09-6::2.5::HTS,BRD-K20079257-001-09-6,rufinamide,2.5,HTS,CRISPR_PTAR1 (375743),AVANA_PUBLIC_18Q2,noncancer,voltage-gated sodium channel blocker,"GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.238909743160933,0.0323513064948,rufinamide,,,0,0
BRD-K20093108-001-02-3::2.5::MTS004,BRD-K20093108-001-02-3,BMS-587101,2.5,MTS004,METABOL_F1P/F6P/G1P/G6P,METABOL,noncancer,integrin antagonist,"ITGAL, ITGB2",,,Phase 2,0.30769837179686305,0.0839629295406,BMS-587101,,,0,0
BRD-K20141153-003-13-7::2.5::HTS,BRD-K20141153-003-13-7,atomoxetine,2.5,HTS,PROT_Syk,PROT,noncancer,norepinephrine transporter inhibitor,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD),Launched,0.291768166270454,0.0447246074563,atomoxetine,,,0,0
BRD-K20152659-001-04-6::2.5::HTS,BRD-K20152659-001-04-6,dihomo-gamma-linolenic-acid,2.5,HTS,MIRNA_hsa-miR-148a,MIRNA,noncancer,prostanoid receptor agonist,"PTGS1, PTGS2",,,Phase 2,0.245084365370247,0.124293154143,dihomo-gamma-linolenic-acid,,,0,0
BRD-K20168442-004-06-3::2.5::HTS,BRD-K20168442-004-06-3,vecuronium,2.5,HTS,CRISPR_CDH2 (1000),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant,Launched,0.259035212687303,0.0348562877573,vecuronium,,,0,0
BRD-K20285085-001-07-1::2.5::HTS,BRD-K20285085-001-07-1,R406,2.5,HTS,PROT_HER3,PROT,targeted cancer,SYK inhibitor,"RET, SYK",,,Phase 1,0.35756083669499206,0.318725344333,R406,OTHER,0.2710103437881689,1.649548236939805,-2.280522255801804
BRD-K20285085-074-04-5::2.5::HTS,BRD-K20285085-074-04-5,R406,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,SYK inhibitor,"RET, SYK",,,Phase 1,0.35756083669499206,0.318725344333,R406,OTHER,0.34234853238133084,1.6410558801775776,-2.754145449135673
BRD-K20290250-001-01-3::2.5::HTS,BRD-K20290250-001-01-3,BIX-02188,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,MEK inhibitor,MAP2K5,,,Preclinical,0.29041649244992,0.279139905283,BIX-02188,,,0,0
BRD-K20290250-001-02-1::2.38::HTS,BRD-K20290250-001-02-1,BIX-02188,2.38,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,MEK inhibitor,MAP2K5,,,Preclinical,0.29041649244992,0.279139905283,BIX-02188,,,0,0
BRD-K20313525-001-04-6::2.5::HTS,BRD-K20313525-001-04-6,rosmarinic-acid,2.5,HTS,MIRNA_hsa-miR-652,MIRNA,targeted cancer,GABA transaminase inhibitor,"MCL1, TYR",,,Launched,0.250214823071716,0.0732542445982,rosmarinic-acid,,,0,0
BRD-K20338176-001-17-7::2.5::HTS,BRD-K20338176-001-17-7,cefaclor,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis",Launched,0.274085739354685,0.108860151623,cefaclor,,,0,0
BRD-K20372197-001-03-1::2.5::HTS,BRD-K20372197-001-03-1,droxidopa,2.5,HTS,Exp_AGBL4 (ENSG00000186094),GE,noncancer,norepinephrine precursor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH","cardiology, neurology/psychiatry","hypertension, Parkinson's Disease",Launched,0.253506154735344,0.101009327064,droxidopa,,,0,0
BRD-K20417253-001-01-9::2.5::HTS,BRD-K20417253-001-01-9,oxiniacic-acid,2.5,HTS,DEM2_LTBP2 (4053),DEMETER2_COM,noncancer,,,,,Preclinical,0.266495186661091,0.110987223019,oxiniacic-acid,,,0,0
BRD-K20431737-001-08-1::2.5::HTS,BRD-K20431737-001-08-1,benzoylpas,2.5,HTS,Exp_SPAG4 (ENSG00000061656),GE,noncancer,,,,,Preclinical,0.265619707555575,0.0652880071949,benzoylpas,,,0,0
BRD-K20463415-300-01-4::2.499966791::MTS004,BRD-K20463415-300-01-4,LY2606368,2.499966791,MTS004,Exp_SH2B3 (ENSG00000111252),GE,targeted cancer,CHK inhibitor,CHEK1,,,Phase 2,0.39720057586176394,0.374800467523,LY2606368,OTHER,0.3962322992253286,1.559869641984971,0.07253993702210915
BRD-K20468903-001-01-6::2.49996519::MTS004,BRD-K20468903-001-01-6,BNC105,2.49996519,MTS004,Exp_TNFAIP8L1 (ENSG00000185361),GE,chemo,tubulin polymerization inhibitor,,,,Phase 2,0.389394983825307,0.345259496133,BNC105,TUBULIN POLYMERIZATION INHIBITOR,0.3912611631439378,5.9600468858070945,-3.5595601346598427
BRD-K20482099-001-09-4::2.5::HTS,BRD-K20482099-001-09-4,rutin,2.5,HTS,RMUTmis_PFKFB2 (5208),MUT,noncancer,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis",Launched,0.260628904319403,0.0959791023305,rutin,,,0,0
BRD-K20482099-001-11-0::2.5::HTS,BRD-K20482099-001-11-0,rutin,2.5,HTS,CN_MBD5 (55777),CN,noncancer,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis",Launched,0.260628904319403,0.0923359486911,rutin,,,0,0
BRD-K20545304-001-01-6::2.5::HTS,BRD-K20545304-001-01-6,bardoxolone,2.5,HTS,Exp_ITPKC (ENSG00000086544),GE,targeted cancer,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",,,Phase 1,0.42235265608303296,0.250468256329,bardoxolone,OTHER,0.4179730664902721,5.7350671509569695,-1.454616062603178
BRD-K20655524-003-12-0::2.5::HTS,BRD-K20655524-003-12-0,mefexamide,2.5,HTS,CN_ZNF521 (25925),CN,noncancer,psychoactive drug,,,,Preclinical,0.302984532246554,0.0552011582227,mefexamide,,,0,0
BRD-K20714604-003-02-9::2.5::HTS,BRD-K20714604-003-02-9,RS-56812,2.5,HTS,DEM2_GTF2H3 (2967),DEMETER2_COM,noncancer,serotonin receptor partial agonist,HTR3A,,,Preclinical,0.23699761691350896,0.141721098727,RS-56812,,,0,0
BRD-K20722021-001-02-1::2.5::HTS,BRD-K20722021-001-02-1,CEP-32496,2.5,HTS,Exp_CHST15 (ENSG00000182022),GE,targeted cancer,RAF inhibitor,"BRAF, RAF1",,,Phase 1/Phase 2,0.308278821202966,0.283343374638,CEP-32496,RAF INHIBITOR,0.30600524914152183,2.9260694379533896,-1.200258826223887
BRD-K20738689-001-01-2::2.5::HTS,BRD-K20738689-001-01-2,dazmegrel,2.5,HTS,CN_UPP2 (151531),CN,noncancer,thromboxane synthase inhibitor,TBXAS1,,,Phase 2,0.27090917428542605,0.0220145796049,dazmegrel,,,0,0
BRD-K20742498-003-02-9::2.5::HTS,BRD-K20742498-003-02-9,RS-39604,2.5,HTS,CN_GSR (2936),CN,noncancer,serotonin receptor antagonist,HTR4,,,Preclinical,0.318679654337062,0.080172767707,RS-39604,,,0,0
BRD-K20745393-003-01-0::2.5::HTS,BRD-K20745393-003-01-0,olprinone,2.5,HTS,PROT_Caveolin-1,PROT,noncancer,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,Launched,0.244635112955339,0.101706460367,olprinone,,,0,0
BRD-K20755323-001-05-9::2.5::HTS,BRD-K20755323-001-05-9,SKI-II,2.5,HTS,Exp_HMGB1P3 (ENSG00000250011),GE,targeted cancer,sphingosine kinase inhibitor,SPHK1,,,Preclinical,0.297936207996075,0.301076643425,SKI-II,OTHER,0.2954391345440127,-3.2046910741873216,-0.9587887894257454
BRD-K20897876-001-10-0::2.5::HTS,BRD-K20897876-001-10-0,castanospermine,2.5,HTS,Exp_RNF144A-AS1 (ENSG00000228203),GE,targeted cancer,glucosidase inhibitor,"GAA, GBA",,,Phase 2,0.285868131926682,0.0904381788401,castanospermine,,,0,0
BRD-K20920669-304-09-1::2.5::HTS,BRD-K20920669-304-09-1,cromoglicic-acid,2.5,HTS,Exp_MYLK-AS2 (ENSG00000250174),GE,noncancer,immunosuppressant,"KCNMA1, S100P","pulmonary, ophthalmology, allergy, gastroenterology","asthma, conjunctivitis, urticaria, ulcerative colitis",Launched,0.23534676462604198,0.0587098415509,cromoglicic-acid,,,0,0
BRD-K20958582-001-01-4::2.5::HTS,BRD-K20958582-001-01-4,TH-302,2.5,HTS,Exp_FAM149A (ENSG00000109794),GE,chemo,DNA alkylating agent,,,,Phase 3,0.38731767270773,0.294144559207,TH-302,OTHER,0.3864177941192776,5.7212964902700225,-2.648477246749315
BRD-K20995441-001-02-5::2.5::HTS,BRD-K20995441-001-02-5,U-54494A,2.5,HTS,CN_BAIAP2 (10458),CN,noncancer,opioid receptor agonist,OPRK1,,,Preclinical,0.30255550183860197,0.0695872610489,U-54494A,,,0,0
BRD-K21025364-001-04-9::2.5::HTS,BRD-K21025364-001-04-9,NVP-TAE226,2.5,HTS,METHYL_MIR4520-2,METHYL,targeted cancer,protein tyrosine kinase inhibitor,PTK2,,,Preclinical,0.363898736923841,0.361784518401,NVP-TAE226,OTHER,0.2728803893632428,4.7596335423220255,-1.2195479081294187
BRD-K21025364-001-05-6::2.44::HTS,BRD-K21025364-001-05-6,NVP-TAE226,2.44,HTS,METHYL_FAM83A,METHYL,targeted cancer,protein tyrosine kinase inhibitor,PTK2,,,Preclinical,0.363898736923841,0.361784518401,NVP-TAE226,OTHER,0.3671752269334696,4.503969758587428,-0.8793079239682253
BRD-K21071223-001-02-8::2.5::HTS,BRD-K21071223-001-02-8,VP-20629,2.5,HTS,PROT_CDK1,PROT,noncancer,beta amyloid antagonist,"PLA2G2E, SLC36A1",,,Phase 1,0.283637328271625,0.0867846823011,VP-20629,,,0,0
BRD-K21077415-001-01-5::2.656085278::MTS004,BRD-K21077415-001-01-5,AMG-319,2.656085278,MTS004,CRISPR_SARAF (51669),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,PIK3CD,,,Phase 2,0.293128334305823,0.146466147022,AMG-319,,,0,0
BRD-K21123171-001-02-9::2.5::HTS,BRD-K21123171-001-02-9,pramiracetam,2.5,HTS,METHYL_UBALD1,METHYL,noncancer,acetylcholine receptor agonist,,,,Launched,0.272537427282257,0.0267646451168,pramiracetam,,,0,0
BRD-K21152241-001-07-3::2.5082643::MTS004,BRD-K21152241-001-07-3,enoximone,2.5082643,MTS004,Exp_PDE3A (ENSG00000172572),GE,noncancer,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,Launched,0.35273656183092206,0.194488043982,enoximone,,,0,0
BRD-K21160401-065-01-0::2.5::HTS,BRD-K21160401-065-01-0,dextroamphetamine,2.5,HTS,Exp_MYOCD (ENSG00000141052),GE,noncancer,monoamine oxidase inhibitor,"ADRA1A, ADRA1B, SLC18A2, SLC6A2, SLC6A3, TAAR1",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",Launched,0.219391073931246,0.09444299426,dextroamphetamine,,,0,0
BRD-K21164796-001-02-8::2.5::HTS,BRD-K21164796-001-02-8,beta-naphthol,2.5,HTS,CN_CARD8 (22900),CN,noncancer,,,,,Preclinical,0.443177923920699,0.155249869807,beta-naphthol,OTHER,0.4460167270710404,4.368419821072877,0.8435769142780773
BRD-K21191422-001-01-5::2.499985534::MTS004,BRD-K21191422-001-01-5,selexipag,2.499985534,MTS004,Exp_DUSP12 (ENSG00000081721),GE,noncancer,"platelet aggregation inhibitor, IP1 prostacyclin receptor agonist",PTGIR,,,Phase 3,0.25700387984222894,0.064807210003,selexipag,,,0,0
BRD-K21237892-376-01-3::2.5::MTS004,BRD-K21237892-376-01-3,semapimod,2.5,MTS004,Exp_SYTL4 (ENSG00000102362),GE,targeted cancer,"cytokine production inhibitor, p38 MAPK inhibitor",MAPK14,,,Phase 2,0.340836888735062,0.142535336202,semapimod,,,0,0
BRD-K21283037-001-21-5::2.5::HTS,BRD-K21283037-001-21-5,riluzole,2.5,HTS,CRISPR_MEF2D (4209),AVANA_PUBLIC_18Q2,noncancer,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),Launched,0.29219884515551603,0.0951322726624,riluzole,OTHER,0.2822719543292831,5.43048800999063,-3.0876685576431693
BRD-K21295289-001-01-6::2.5::HTS,BRD-K21295289-001-01-6,senicapoc,2.5,HTS,METHYL_MEX3D,METHYL,noncancer,intermediate conductance potassium channel blocker,KCNN4,,,Phase 3,0.275621505118761,0.0103888319868,senicapoc,,,0,0
BRD-K21372554-003-01-7::2.5::HTS,BRD-K21372554-003-01-7,cefetamet-pivoxil,2.5,HTS,Exp_S100Z (ENSG00000171643),GE,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,Launched,0.255401938143596,0.0345417206203,cefetamet-pivoxil,,,0,0
BRD-K21396683-001-04-8::2.5::HTS,BRD-K21396683-001-04-8,marimastat,2.5,HTS,PROT_SCD1,PROT,targeted cancer,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",,,Phase 3,0.231290231274697,0.0790497258153,marimastat,,,0,0
BRD-K21450440-001-14-6::2.5::HTS,BRD-K21450440-001-14-6,benzthiazide,2.5,HTS,Exp_FOXD4L1 (ENSG00000184492),GE,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA4, CA9, SLC12A3",cardiology,"hypertension, edema",Launched,0.258339649239988,0.0636932706875,benzthiazide,,,0,0
BRD-K21452876-003-01-8::2.5::HTS,BRD-K21452876-003-01-8,chlorazanil,2.5,HTS,METHYL_ELFN1,METHYL,noncancer,,,,,Preclinical,0.29490034239974,0.0619795685048,chlorazanil,,,0,0
BRD-K21520694-236-02-6::2.5::HTS,BRD-K21520694-236-02-6,sulfacetamide,2.5,HTS,DEM2_USP4 (7375),DEMETER2_COM,noncancer,PABA antagonist,,ophthalmology,conjunctivitis,Launched,0.29272353150734903,0.146992025058,sulfacetamide,,,0,0
BRD-K21528677-001-02-8::2.44::HTS,BRD-K21528677-001-02-8,desonide,2.44,HTS,PROT_N-Cadherin,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,Launched,0.32094866222491397,0.155887145015,desonide,GLUCOCORTICOID RECEPTOR AGONIST,0.3175639725971348,-0.5946219975964909,-2.3652107690694257
BRD-K21528677-001-03-6::2.5::HTS,BRD-K21528677-001-03-6,desonide,2.5,HTS,PROT_RBM15,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,Launched,0.32094866222491397,0.155887145015,desonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2298288739810081,-2.2311041736343418,-3.267368875628283
BRD-K21547160-001-01-4::2.5::HTS,BRD-K21547160-001-01-4,sufentanil,2.5,HTS,CRISPR_VENTX (27287),AVANA_PUBLIC_18Q2,noncancer,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,Launched,0.28235848760908505,0.0116888672552,sufentanil,OTHER,0.23292624104207574,1.1653100337541469,-1.6265046080869414
BRD-K21548250-003-19-1::2.5::HTS,BRD-K21548250-003-19-1,moracizine,2.5,HTS,METHYL_MEIS2,METHYL,noncancer,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias,Launched,0.274062118073745,0.0459661676234,moracizine,,,0,0
BRD-K21565985-001-22-5::2.5::HTS,BRD-K21565985-001-22-5,xylazine,2.5,HTS,METHYL_CRNN,METHYL,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,Launched,0.29178725136263395,0.0361492647538,xylazine,,,0,0
BRD-K21612934-001-01-1::2.473727942::MTS004,BRD-K21612934-001-01-1,leteprinim,2.473727942,MTS004,DEM2_XPNPEP3 (63929),DEMETER2_COM,targeted cancer,nerve growth factor agonist,,,,Phase 2,0.24739303039821497,0.19287436584,leteprinim,,,0,0
BRD-K21615095-001-08-4::2.5::HTS,BRD-K21615095-001-08-4,acetohydroxamic-acid,2.5,HTS,Exp_CAAP1 (ENSG00000120159),GE,noncancer,urease inhibitor,MMP12,infectious disease,urinary tract infections,Launched,0.28620503919151197,0.00539519435645,acetohydroxamic-acid,,,0,0
BRD-K21670884-001-01-9::2.5::HTS,BRD-K21670884-001-01-9,cariporide,2.5,HTS,METHYL_FBXL3,METHYL,noncancer,sodium/hydrogen exchanger inhibitor,SLC9A1,,,Phase 3,0.305856840231437,-0.00145686934335,cariporide,,,0,0
BRD-K21672174-001-03-0::2.5::HTS,BRD-K21672174-001-03-0,Ro-28-1675,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,glucokinase activator,GCK,,,Preclinical,0.24735973078826604,0.0692169715746,Ro-28-1675,,,0,0
BRD-K21673112-003-01-3::2.5::HTS,BRD-K21673112-003-01-3,BF2.649,2.5,HTS,CRISPR_NCBP1 (4686),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,HRH3,,,Phase 3,0.260919086734262,0.0963579758323,BF2.649,,,0,0
BRD-K21718444-001-06-8::2.5::HTS,BRD-K21718444-001-06-8,KW-2449,2.5,HTS,CRISPR_ANKRD49 (54851),AVANA_PUBLIC_18Q2,targeted cancer,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",,,Phase 1,0.36775139743891905,0.380965291121,KW-2449,OTHER,0.35710734541267874,3.646363964724309,-3.7587140572181728
BRD-K21728777-001-02-3::2.5::HTS,BRD-K21728777-001-02-3,AMG900,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.36604230247668296,0.30971031726,AMG900,AURORA KINASE INHIBITOR,0.3668769243039424,4.0569067357653985,-3.112343970878338
BRD-K21733600-001-14-1::2.5::HTS,BRD-K21733600-001-14-1,rofecoxib,2.5,HTS,PROT_Smad3,PROT,targeted cancer,cyclooxygenase inhibitor,"ELN, PTGS2",,,Withdrawn,0.257225784510611,0.116349212064,rofecoxib,,,0,0
BRD-K21771665-304-04-2::2.5::HTS,BRD-K21771665-304-04-2,merbromin,2.5,HTS,METABOL_kynurenic acid,METABOL,noncancer,antiseptic,,infectious disease,first-aid antiseptic,Launched,0.361907551379052,0.0296182402327,merbromin,,,0,0
BRD-K21782625-001-02-4::2.5::HTS,BRD-K21782625-001-02-4,AMG458,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,MET inhibitor,MET,,,Preclinical,0.34165567034936706,0.221190233387,AMG458,,,0,0
BRD-K21782625-001-03-2::2.45::HTS,BRD-K21782625-001-03-2,AMG458,2.45,HTS,Exp_PCSK6 (ENSG00000140479),GE,targeted cancer,MET inhibitor,MET,,,Preclinical,0.34165567034936706,0.232785749234,AMG458,OTHER,0.3426418946540632,0.4588293877165983,-2.8146828055432245
BRD-K21867462-001-02-9::2.5::HTS,BRD-K21867462-001-02-9,GSK2816126,2.5,HTS,CRISPR_DOT1L (84444),AVANA_PUBLIC_18Q2,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Phase 1,0.2954066127859,0.11955020969,GSK2816126,,,0,0
BRD-K21884483-001-03-7::2.5::HTS,BRD-K21884483-001-03-7,mizolastine,2.5,HTS,DEM2_OGFOD1 (55239),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,allergy,"urticaria, allergic rhinitis",Launched,0.314520313712482,0.0601779112677,mizolastine,,,0,0
BRD-K21906513-001-04-0::2.36::HTS,BRD-K21906513-001-04-0,UNC669,2.36,HTS,CRISPR_UBALD2 (283991),AVANA_PUBLIC_18Q2,noncancer,L3MBTL antagonist,L3MBTL1,,,Preclinical,0.24422413769306797,0.0985781833128,UNC669,,,0,0
BRD-K21908111-001-01-8::2.5::HTS,BRD-K21908111-001-01-8,AZD1208,2.5,HTS,CN_OR4F21 (441308),CN,targeted cancer,Pim kinase inhibitor,"PIM1, PIM2, PIM3",,,Phase 1,0.222696107853258,0.1011609175,AZD1208,,,0,0
BRD-K21910317-001-12-3::2.5::HTS,BRD-K21910317-001-12-3,"2,4-dinitrophenol",2.5,HTS,Exp_CALN1 (ENSG00000183166),GE,noncancer,ATP synthase inhibitor,APP,,,Preclinical,0.28559994178136,0.0754297758414,"2,4-dinitrophenol",,,0,0
BRD-K21913543-001-02-4::2.5::HTS,BRD-K21913543-001-02-4,fluorescein,2.5,HTS,Exp_ANKH (ENSG00000154122),GE,noncancer,,SLC22A6,ophthalmology,ophthalmology diagnostic,Launched,0.295423185561085,0.0379950325191,fluorescein,,,0,0
BRD-K21937671-001-09-2::2.53::HTS,BRD-K21937671-001-09-2,loxistatin-acid,2.53,HTS,PROT_Smad1,PROT,noncancer,cysteine peptidase inhibitor,CTSB,,,Preclinical,0.298166168312993,0.0884366132752,loxistatin-acid,OTHER,0.3000678957730191,4.7899585808988085,-0.3008804996984256
BRD-K21937671-001-10-0::2.5::HTS,BRD-K21937671-001-10-0,loxistatin-acid,2.5,HTS,PROT_YB-1,PROT,noncancer,cysteine peptidase inhibitor,CTSB,,,Preclinical,0.298166168312993,0.0884366132752,loxistatin-acid,,,0,0
BRD-K22009844-001-12-5::2.5::HTS,BRD-K22009844-001-12-5,phenprobamate,2.5,HTS,CN_NOMO3 (408050),CN,noncancer,muscle relaxant,,neurology/psychiatry,"anxiety, muscle relaxant",Launched,0.27878530173828003,0.150528892492,phenprobamate,,,0,0
BRD-K22024824-001-03-7::2.5::HTS,BRD-K22024824-001-03-7,RG4733,2.5,HTS,MIRNA_hsa-miR-888,MIRNA,targeted cancer,gamma secretase inhibitor,PSEN1,,,Phase 2,0.30921475846971197,0.0590120031632,RG4733,,,0,0
BRD-K22025381-003-01-9::2.5::HTS,BRD-K22025381-003-01-9,U-18666A,2.5,HTS,Exp_RBBP8NL (ENSG00000130701),GE,noncancer,oxidosqualene cyclase inhibitor,,,,Preclinical,0.424582356324985,0.422143669921,U-18666A,OTHER,0.4214789963189672,0.2678321341436856,-3.553213758248935
BRD-K22031190-001-23-6::2.5::HTS,BRD-K22031190-001-23-6,diflunisal,2.5,HTS,MIRNA_hsa-miR-219-2-3p,MIRNA,noncancer,prostanoid receptor antagonist,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.29132797829233803,0.116775603519,diflunisal,,,0,0
BRD-K22064724-001-01-8::2.499989634::MTS004,BRD-K22064724-001-01-8,napabucasin,2.499989634,MTS004,METHYL_ZNF655,METHYL,targeted cancer,STAT inhibitor,STAT3,,,Phase 3,0.361867354908956,0.181072833101,napabucasin,OTHER,0.36042378172789896,2.1116386294983767,-0.036831189213115234
BRD-K22097830-001-01-9::2.5::HTS,BRD-K22097830-001-01-9,OCO-1112,2.5,HTS,Exp_NR1H4 (ENSG00000012504),GE,noncancer,cholesterol inhibitor,,,,Phase 2,0.244731158601458,0.138399458324,OCO-1112,,,0,0
BRD-K22134346-001-22-3::2.5::HTS,BRD-K22134346-001-22-3,simvastatin,2.5,HTS,Exp_TMEM45B (ENSG00000151715),GE,noncancer,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia",Launched,0.45577765016445004,0.428373350071,simvastatin,HMGCR INHIBITOR,0.4788054966982619,1.7748186592083377,5.302407706928071
BRD-K22134346-001-24-9::2.42::HTS,BRD-K22134346-001-24-9,simvastatin,2.42,HTS,Exp_ADAMTSL1 (ENSG00000178031),GE,noncancer,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia",Launched,0.45577765016445004,0.428373350071,simvastatin,HMGCR INHIBITOR,0.456255620169743,1.7539002621997932,4.845737253555429
BRD-K22193694-001-13-6::2.5::HTS,BRD-K22193694-001-13-6,dioxybenzone,2.5,HTS,METHYL_MTL5,METHYL,noncancer,topical sunscreen agent,,,,Preclinical,0.302031871151606,0.0881329494048,dioxybenzone,,,0,0
BRD-K22261391-001-01-2::2.5::HTS,BRD-K22261391-001-01-2,pirodavir,2.5,HTS,RMUTmis_PTPRQ (374462),MUTmis,noncancer,,,,,Phase 2,0.270531075335415,0.0362951187353,pirodavir,,,0,0
BRD-K22314899-001-02-4::2.5::HTS,BRD-K22314899-001-02-4,CH223191,2.5,HTS,CN_LINC00879 (255025),CN,noncancer,aryl hydrocarbon receptor antagonist,AHR,,,Preclinical,0.274536362181667,0.00657989964552,CH223191,,,0,0
BRD-K22356203-001-01-8::2.5::HTS,BRD-K22356203-001-01-8,IDO5L,2.5,HTS,PROT_p90RSK_pT573_Caution,PROT,targeted cancer,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,Preclinical,0.263544370339315,0.00170801593929,IDO5L,,,0,0
BRD-K22385716-001-02-5::2.5::HTS,BRD-K22385716-001-02-5,LY303511,2.5,HTS,CRISPR_WBSCR17 (64409),AVANA_PUBLIC_18Q2,targeted cancer,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",,,Preclinical,0.25455988571279103,0.152085799313,LY303511,,,0,0
BRD-K22482860-001-21-4::2.5::HTS,BRD-K22482860-001-21-4,dalfampridine,2.5,HTS,METABOL_histidine,METABOL,noncancer,potassium channel blocker,"KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2",neurology/psychiatry,multiple sclerosis,Launched,0.282261742130734,0.0991934935899,dalfampridine,,,0,0
BRD-K22503835-001-11-0::2.5::HTS,BRD-K22503835-001-11-0,scriptaid,2.5,HTS,Exp_KCNQ2 (ENSG00000075043),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,Preclinical,0.382011219305684,0.354841598089,scriptaid,HDAC INHIBITOR,0.3793499339376492,6.594070369332041,-1.5547706859577848
BRD-K22514639-001-05-7::2.500015058::MTS004,BRD-K22514639-001-05-7,EGF816,2.500015058,MTS004,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,EGFR,,,Phase 2,0.35722679656081296,0.333039939389,EGF816,EGFR INHIBITOR,0.35856790556925383,1.1927069784492328,-5.040163972963789
BRD-K22518984-001-01-8::2.5::MTS004,BRD-K22518984-001-01-8,metacresol,2.5,MTS004,METABOL_1-methylnicotinamide,METABOL,noncancer,,INS,,,Launched,0.24640077359769397,0.175736258327,metacresol,,,0,0
BRD-K22520627-001-01-7::2.5::HTS,BRD-K22520627-001-01-7,DVD-111,2.5,HTS,CRISPR_KATNA1 (11104),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 2,0.287663474078791,0.120096488152,DVD-111,,,0,0
BRD-K22525962-001-05-0::2.500010949::MTS004,BRD-K22525962-001-05-0,dihydrotestosterone,2.500010949,MTS004,MIRNA_hsa-miR-548k,MIRNA,noncancer,androgen receptor agonist,"AR, HSD17B1","neurology/psychiatry, endocrinology","tetany, hypoparathyroidism",Launched,0.245515849755593,0.0689240914567,dihydrotestosterone,,,0,0
BRD-K22588750-001-07-0::2.654665484::MTS004,BRD-K22588750-001-07-0,gidazepam,2.654665484,MTS004,DEM2_CDH2 (1000),DEMETER2_COM,noncancer,GABA benzodiazepine site receptor agonist,,,,Launched,0.260202431317701,0.148662688895,gidazepam,,,0,0
BRD-K22662435-001-18-3::2.5::HTS,BRD-K22662435-001-18-3,ganciclovir,2.5,HTS,CRISPR_ATP4A (495),AVANA_PUBLIC_18Q2,noncancer,DNA polymerase inhibitor,,infectious disease,cytomegalovirus (CMV),Launched,0.32992114071427303,0.0682014962293,ganciclovir,,,0,0
BRD-K22662435-001-19-1::2.5::HTS,BRD-K22662435-001-19-1,ganciclovir,2.5,HTS,CRISPR_HCN2 (610),AVANA_PUBLIC_18Q2,noncancer,DNA polymerase inhibitor,,infectious disease,cytomegalovirus (CMV),Launched,0.32992114071427303,0.0682014962293,ganciclovir,,,0,0
BRD-K22662557-300-01-7::2.5::HTS,BRD-K22662557-300-01-7,WIN-64338,2.5,HTS,CN_GOLGA4 (2803),CN,noncancer,bradykinin receptor antagonist,BDKRB2,,,Preclinical,0.229240257744244,0.0164307611146,WIN-64338,,,0,0
BRD-K22745370-003-02-3::2.5::HTS,BRD-K22745370-003-02-3,2-BFI,2.5,HTS,METABOL_thymine,METABOL,noncancer,imidazoline receptor ligand,"ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB",,,Preclinical,0.24720319950070102,0.0164212474299,2-BFI,,,0,0
BRD-K22749967-046-02-3::2.5::HTS,BRD-K22749967-046-02-3,ABT-239,2.5,HTS,CN_MIR876 (100126310),CN,noncancer,histamine receptor antagonist,"HRH1, HRH2, HRH3",,,Phase 1,0.28346436990396,0.0991269436641,ABT-239,,,0,0
BRD-K22822991-001-02-3::2.5::HTS,BRD-K22822991-001-02-3,odanacatib,2.5,HTS,DEM2_DMRT2 (10655),DEMETER2_COM,targeted cancer,cathepsin inhibitor,CTSK,,,Phase 3,0.312045574281954,0.0578858771708,odanacatib,,,0,0
BRD-K22861715-001-17-4::2.5::HTS,BRD-K22861715-001-17-4,chrysin,2.5,HTS,PROT_CD31,PROT,targeted cancer,breast cancer resistance protein inhibitor,"AKR1B1, CDK6, CYP19A1, CYP1B1",,,Phase 1,0.24694197768754697,0.0280202792237,chrysin,,,0,0
BRD-K22936972-003-23-6::2.5::HTS,BRD-K22936972-003-23-6,diphenylpyraline,2.5,HTS,METHYL_CLASP2,METHYL,noncancer,dopamine uptake inhibitor,"HRH1, SLC6A3",allergy,allergic rhinitis,Launched,0.32984988894561795,0.0337275529447,diphenylpyraline,,,0,0
BRD-K23067689-001-02-1::2.4::HTS,BRD-K23067689-001-02-1,zanamivir,2.4,HTS,METHYL_XKRX,METHYL,noncancer,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection,Launched,0.278419264114233,0.0388434268653,zanamivir,,,0,0
BRD-K23082237-003-01-5::2.5::HTS,BRD-K23082237-003-01-5,butaclamol,2.5,HTS,METHYL_PCDHGA6,METHYL,noncancer,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A",,,Phase 2,0.24253705233438197,0.0902722571458,butaclamol,,,0,0
BRD-K23163214-050-15-1::2.5::HTS,BRD-K23163214-050-15-1,dizocilpine-(-),2.5,HTS,METHYL_MIR5582,METHYL,noncancer,glutamate receptor antagonist,,,,Phase 1,0.24534656198090699,-0.0447899875049,dizocilpine-(-),,,0,0
BRD-K23190681-001-01-1::2.5::HTS,BRD-K23190681-001-01-1,AV-412,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,Phase 1,0.5083333568901189,0.571900460669,AV-412,OTHER,0.5081345043171889,1.3606726174701778,-4.624374015089041
BRD-K23204545-001-16-4::2.5::HTS,BRD-K23204545-001-16-4,busulfan,2.5,HTS,METHYL_MED1,METHYL,chemo,DNA inhibitor,,hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.264087536769463,0.177150982513,busulfan,,,0,0
BRD-K23228615-001-02-8::2.5::HTS,BRD-K23228615-001-02-8,GDC-0980,2.5,HTS,Exp_ELP3 (ENSG00000134014),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",,,Phase 2,0.30084307307744296,0.247061919705,GDC-0980,MTOR INHIBITOR,0.3032016771793324,2.9478329653309148,-1.33768074963867
BRD-K23248433-001-01-8::2.5::HTS,BRD-K23248433-001-01-8,camicinal,2.5,HTS,RMUThot_BRAF (673),MUThot,noncancer,motilin receptor agonist,MLNR,,,Phase 2,0.23649072305776603,0.179203029585,camicinal,,,0,0
BRD-K23301018-001-11-7::2.63::HTS,BRD-K23301018-001-11-7,broxyquinoline,2.63,HTS,PROT_PREX1,PROT,noncancer,antiprotozoal agent,,,,Phase 1,0.335827316931125,0.127387554167,broxyquinoline,OTHER,0.3199767330372933,-4.666869181288352,-0.08432336803919728
BRD-K23335153-300-02-5::2.5::HTS,BRD-K23335153-300-02-5,AMN-082,2.5,HTS,Exp_SLC30A2 (ENSG00000158014),GE,noncancer,glutamate receptor modulator,GRM7,,,Preclinical,0.297548801802547,0.112868600163,AMN-082,,,0,0
BRD-K23383398-001-09-9::2.5::HTS,BRD-K23383398-001-09-9,T-0901317,2.5,HTS,CRISPR_SMARCAL1 (50485),AVANA_PUBLIC_18Q2,noncancer,LXR agonist,"NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB",,,Preclinical,0.293593306456189,0.00703169020866,T-0901317,,,0,0
BRD-K23403298-003-01-9::2.5::HTS,BRD-K23403298-003-01-9,benzyldimethylhexadecylammonium,2.5,HTS,METABOL_inositol,METABOL,noncancer,cationic surfactant,,,,Preclinical,0.3518515567704771,0.0622848975108,benzyldimethylhexadecylammonium,,,0,0
BRD-K23541596-300-07-2::2.5::HTS,BRD-K23541596-300-07-2,dimaprit,2.5,HTS,CRISPR_MTTP (4547),AVANA_PUBLIC_18Q2,noncancer,histamine receptor agonist,"HRH2, HRH3, HRH4",,,Preclinical,0.252312924042993,0.0757998667688,dimaprit,,,0,0
BRD-K23566484-001-15-1::2.5::HTS,BRD-K23566484-001-15-1,nilutamide,2.5,HTS,MIRNA_hsa-miR-133a,MIRNA,targeted cancer,androgen receptor antagonist,AR,oncology,prostate cancer,Launched,0.25246166980900103,0.00740005739143,nilutamide,,,0,0
BRD-K23586533-001-03-6::2.5::HTS,BRD-K23586533-001-03-6,clindamycin,2.5,HTS,PROT_N-Cadherin,PROT,noncancer,protein synthesis inhibitor,,infectious disease,"respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections",Launched,0.232471054384326,0.0615752736651,clindamycin,,,0,0
BRD-K23647661-001-02-2::2.5::HTS,BRD-K23647661-001-02-2,volinanserin,2.5,HTS,MIRNA_hsa-miR-448,MIRNA,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C, KCNH2",,,Phase 3,0.22198276327759803,0.0892247988666,volinanserin,,,0,0
BRD-K23672206-001-01-4::2.5::HTS,BRD-K23672206-001-01-4,BCI-540,2.5,HTS,PROT_Akt,PROT,noncancer,glutamate receptor agonist,,,,Phase 2,0.269892355578287,0.110558779712,BCI-540,,,0,0
BRD-K23677682-003-01-2::2.5::HTS,BRD-K23677682-003-01-2,voreloxin,2.5,HTS,Exp_TBPL1 (ENSG00000028839),GE,chemo,topoisomerase inhibitor,TOP2A,,,Phase 3,0.368153569614973,0.333396416831,voreloxin,TOPOISOMERASE INHIBITOR,0.36981988523709936,3.952981369100298,-3.1991567334208373
BRD-K23728141-001-01-2::2.5::HTS,BRD-K23728141-001-01-2,tafamidis-meglumine,2.5,HTS,METHYL_APCDD1L-AS1,METHYL,noncancer,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP),Launched,0.32888876952022494,0.0757941013511,tafamidis-meglumine,,,0,0
BRD-K23779958-001-05-8::2.5::HTS,BRD-K23779958-001-05-8,dichlorvos,2.5,HTS,CRISPR_FYCO1 (79443),AVANA_PUBLIC_18Q2,noncancer,acetylcholinesterase inhibitor,,,,Launched,0.311890789622971,0.0642975456225,dichlorvos,,,0,0
BRD-K23791635-001-01-3::2.499966688::MTS004,BRD-K23791635-001-01-3,AFN-1252,2.499966688,MTS004,CN_ZNF229 (7772),CN,noncancer,FABI inhibitor,,,,Phase 2,0.28678848460506107,0.0422620966758,AFN-1252,,,0,0
BRD-K23848629-401-03-7::2.5::MTS004,BRD-K23848629-401-03-7,fosaprepitant-dimeglumine,2.5,MTS004,PROT_NF2_Caution,PROT,noncancer,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",Launched,0.34505665726561097,0.151931905704,fosaprepitant-dimeglumine,OTHER,0.33237151246240665,5.153118728645828,-3.8257793606284314
BRD-K23913458-001-20-7::2.5::HTS,BRD-K23913458-001-20-7,coumarin,2.5,HTS,CRISPR_MYO18B (84700),AVANA_PUBLIC_18Q2,noncancer,vitamin K antagonist,"CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6","gastroenterology, pulmonary","ulcerative colitis, asthma, celiac disease",Launched,0.28015549595128597,0.0672154284804,coumarin,,,0,0
BRD-K23925186-001-01-0::2.5::HTS,BRD-K23925186-001-01-0,oridonin,2.5,HTS,Exp_ST13P18 (ENSG00000234322),GE,targeted cancer,BCL inhibitor,BCL2,,,Preclinical,0.37804915182190796,0.258715241468,oridonin,OTHER,0.3706941071400224,1.0619830906808811,-3.798513317734717
BRD-K23925186-001-02-8::2.51::HTS,BRD-K23925186-001-02-8,oridonin,2.51,HTS,Exp_CCDC8 (ENSG00000169515),GE,targeted cancer,BCL inhibitor,BCL2,,,Preclinical,0.37804915182190796,0.258715241468,oridonin,OTHER,0.38219534452591497,5.712263031932813,0.7357492297463968
BRD-K23952234-236-01-8::2.5::HTS,BRD-K23952234-236-01-8,BMS-986020,2.5,HTS,CRISPR_AS3MT (57412),AVANA_PUBLIC_18Q2,noncancer,lysophosphatidic acid receptor antagonist,LPAR1,,,Phase 2,0.35194156215404,0.164643515958,BMS-986020,,,0,0
BRD-K23976833-001-01-0::2.5::HTS,BRD-K23976833-001-01-0,travoprost,2.5,HTS,CRISPR_PRTFDC1 (56952),AVANA_PUBLIC_18Q2,noncancer,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",Launched,0.317415521385243,0.160575566574,travoprost,,,0,0
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,OTHER,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K24048528-001-01-7::2.59::HTS,BRD-K24048528-001-01-7,abiraterone-acetate,2.59,HTS,CRISPR_MEIS3 (56917),AVANA_PUBLIC_18Q2,targeted cancer,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,Launched,0.281093243687021,0.102084034833,abiraterone-acetate,,,0,0
BRD-K24048528-001-02-5::2.5::HTS,BRD-K24048528-001-02-5,abiraterone-acetate,2.5,HTS,CRISPR_TP63 (8626),AVANA_PUBLIC_18Q2,targeted cancer,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,Launched,0.281093243687021,0.102084034833,abiraterone-acetate,,,0,0
BRD-K24084088-001-11-3::2.5::HTS,BRD-K24084088-001-11-3,paraxanthine,2.5,HTS,MIRNA_hsa-miR-324-3p,MIRNA,noncancer,adenosine receptor antagonist,,,,Phase 1,0.27725961313673103,0.0830874334635,paraxanthine,,,0,0
BRD-K24179883-001-16-7::2.5::HTS,BRD-K24179883-001-16-7,arsanilic-acid,2.5,HTS,MIRNA_hsa-miR-888,MIRNA,noncancer,,LYZ,,,Phase 1,0.256983797847892,0.024061903475,arsanilic-acid,,,0,0
BRD-K24187789-001-01-7::2.5::HTS,BRD-K24187789-001-01-7,VU0238429,2.5,HTS,Exp_YWHAE (ENSG00000108953),GE,noncancer,acetylcholine receptor allosteric modulator,CHRM5,,,Preclinical,0.38655377394478296,0.378965803544,VU0238429,OTHER,0.3879526085056925,5.321087347284803,-1.8688603692635288
BRD-K24201553-003-11-5::2.5::HTS,BRD-K24201553-003-11-5,SB-269970,2.5,HTS,CN_ATAD3C (219293),CN,noncancer,serotonin receptor antagonist,HTR7,,,Preclinical,0.268103165091837,0.0638047667656,SB-269970,,,0,0
BRD-K24219278-001-01-6::2.5::HTS,BRD-K24219278-001-01-6,amineptine,2.5,HTS,MIRNA_hsa-miR-483-3p,MIRNA,noncancer,dopamine receptor agonist,"SLC6A2, SLC6A4",,,Withdrawn,0.21901319879155698,0.112954243075,amineptine,,,0,0
BRD-K24221957-003-01-6::2.5::MTS004,BRD-K24221957-003-01-6,pralidoxime-chloride,2.5,MTS004,PROT_PRAS40_pT246,PROT,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",pulmonary,respiratory depression,Launched,0.329160440412803,0.102324784745,pralidoxime-chloride,,,0,0
BRD-K24227647-364-01-5::2.5::HTS,BRD-K24227647-364-01-5,TC2559,2.5,HTS,MIRNA_hsa-miR-1185,MIRNA,noncancer,acetylcholine receptor agonist,CHRNA4,,,Preclinical,0.280738111985269,0.110133488004,TC2559,,,0,0
BRD-K24242599-001-02-8::2.5::HTS,BRD-K24242599-001-02-8,GW-2580,2.5,HTS,Exp_LRAT (ENSG00000121207),GE,targeted cancer,cFMS kinase inhibitor,CSF1R,,,Preclinical,0.26108899294203,0.158925904092,GW-2580,,,0,0
BRD-K24255045-001-05-3::2.5::HTS,BRD-K24255045-001-05-3,fluoxymesterone,2.5,HTS,METABOL_inosine,METABOL,noncancer,androgen receptor modulator,"AR, ESR1, NR3C1, PRLR",endocrinology,hypogonadism,Launched,0.293341231970586,0.0854653692789,fluoxymesterone,,,0,0
BRD-K24258499-001-05-8::2.5::HTS,BRD-K24258499-001-05-8,vanillin,2.5,HTS,DEM2_TCTEX1D1 (200132),DEMETER2_COM,targeted cancer,,"ABAT, ALDH5A1",,,Preclinical,0.29700898983616497,0.0827789942163,vanillin,,,0,0
BRD-K24297741-001-05-2::2.5::HTS,BRD-K24297741-001-05-2,urethane,2.5,HTS,CRISPR_ME3 (10873),AVANA_PUBLIC_18Q2,noncancer,local anesthetic,,,,Preclinical,0.27217580543139497,0.148039007176,urethane,,,0,0
BRD-K24312986-001-01-2::2.5::HTS,BRD-K24312986-001-01-2,tecovirimat,2.5,HTS,CN_PKP2 (5318),CN,noncancer,orthopoxvirus egress inhibitor,,,,Phase 3,0.262350506307497,0.00314788097442,tecovirimat,,,0,0
BRD-K24443618-001-10-2::2.5::HTS,BRD-K24443618-001-10-2,etebenecid,2.5,HTS,RMUTmis_ABCC5 (10057),MUTmis,noncancer,uricosuric blocker,,,,Preclinical,0.277462440471354,0.0525542051091,etebenecid,,,0,0
BRD-K24452555-001-01-7::2.599377769::MTS004,BRD-K24452555-001-01-7,methylprednisolone-aceponate,2.599377769,MTS004,Exp_TDP1 (ENSG00000042088),GE,noncancer,"anti-inflammatory agent, glucocorticoid receptor agonist",NR3C1,"endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia",Launched,0.29275996176196506,0.0973387121175,methylprednisolone-aceponate,OTHER,0.2914846333032741,2.5343923036825817,4.622917974238021
BRD-K24476327-001-01-3::2.50002878::MTS004,BRD-K24476327-001-01-3,icaritin,2.50002878,MTS004,Exp_UNC119 (ENSG00000109103),GE,targeted cancer,PPAR receptor antagonist,PDE5A,,,Phase 2,0.266350215754617,0.00742001380469,icaritin,,,0,0
BRD-K24497734-001-01-6::2.499993902::MTS004,BRD-K24497734-001-01-6,setipiprant,2.499993902,MTS004,CRISPR_EDDM3B (64184),AVANA_PUBLIC_18Q2,noncancer,prostaglandin inhibitor,PTGDR2,,,Phase 3,0.277926450225391,0.128911208652,setipiprant,,,0,0
BRD-K24507548-001-01-8::2.5::HTS,BRD-K24507548-001-01-8,cintriamide,2.5,HTS,MIRNA_hsa-miR-181c,MIRNA,noncancer,,,,,Preclinical,0.264181321965461,0.0490106050941,cintriamide,,,0,0
BRD-K24548560-342-02-1::2.5::HTS,BRD-K24548560-342-02-1,evans-blue,2.5,HTS,METHYL_C17orf59,METHYL,targeted cancer,glutamate receptor negative allosteric modulator,"GRIA1, PTPN1",,,Launched,0.251690096069744,0.0910790026107,evans-blue,,,0,0
BRD-K24556098-001-16-7::2.45::HTS,BRD-K24556098-001-16-7,deoxycorticosterone-acetate,2.45,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progestogen hormone,NR3C2,,,Preclinical,0.377419025074719,0.166777654527,deoxycorticosterone-acetate,OTHER,0.3872461701822008,-4.024737480254147,-2.51521206586428
BRD-K24556098-001-19-1::2.5::HTS,BRD-K24556098-001-19-1,deoxycorticosterone-acetate,2.5,HTS,Exp_LINC00473 (ENSG00000223414),GE,noncancer,progestogen hormone,NR3C2,,,Preclinical,0.377419025074719,0.166777654527,deoxycorticosterone-acetate,,,0,0
BRD-K24556407-001-02-3::2.5::HTS,BRD-K24556407-001-02-3,ETP-46464,2.5,HTS,METHYL_MIR196B,METHYL,targeted cancer,ATR kinase inhibitor,,,,Preclinical,0.317804207896385,0.150655393393,ETP-46464,OTHER,0.3216088992754015,2.3350614033691506,-3.6065000540415513
BRD-K24566386-001-01-9::2.5::HTS,BRD-K24566386-001-01-9,SD-208,2.5,HTS,METABOL_cotinine,METABOL,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.308995368998367,0.176142693311,SD-208,OTHER,0.3062592579124751,5.009352676062903,1.052547884098973
BRD-K24576554-001-04-8::2.5::HTS,BRD-K24576554-001-04-8,AT-9283,2.5,HTS,Exp_CCDC64 (ENSG00000135127),GE,targeted cancer,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",,,Phase 2,0.39158450945863393,0.279954599041,AT-9283,AURORA KINASE INHIBITOR,0.3921450821221964,4.773124769567573,-1.0999671895146412
BRD-K24593301-001-02-3::2.54::HTS,BRD-K24593301-001-02-3,AZD3463,2.54,HTS,Exp_PLEKHD1 (ENSG00000175985),GE,targeted cancer,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",,,Preclinical,0.35039418432545605,0.179607051705,AZD3463,OTHER,0.3509052941184259,5.565302350391401,0.9082515657128948
BRD-K24601397-001-01-1::2.5::HTS,BRD-K24601397-001-01-1,phlorizin,2.5,HTS,Exp_CXCL5 (ENSG00000163735),GE,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",,,Preclinical,0.33014727091334495,0.0775957819521,phlorizin,OTHER,0.3307167890792496,-6.3598049242123125,0.43101863481446795
BRD-K24603946-001-02-1::2.5::HTS,BRD-K24603946-001-02-1,5-hydroxymethyl-tolterodine,2.5,HTS,METABOL_thyroxine,METABOL,noncancer,acetylcholine receptor antagonist,CHRM3,,,Phase 1,0.271952395269207,0.0769334731637,5-hydroxymethyl-tolterodine,,,0,0
BRD-K24610819-003-01-8::2.33438271::MTS004,BRD-K24610819-003-01-8,amibegron,2.33438271,MTS004,MIRNA_hsa-miR-193a-5p,MIRNA,noncancer,adrenergic receptor agonist,ADRB3,,,Phase 3,0.28369251222568503,0.111208874686,amibegron,,,0,0
BRD-K24616672-003-20-1::2.5::HTS,BRD-K24616672-003-20-1,procaine,2.5,HTS,CN_MIR568 (693153),CN,noncancer,HMGCR inhibitor,"CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3",neurology/psychiatry,anesthetic,Launched,0.27466760831320103,0.080778522436,procaine,,,0,0
BRD-K24666289-001-04-9::2.499988887::MTS004,BRD-K24666289-001-04-9,copanlisib,2.499988887,MTS004,Exp_ATP6V0E2-AS1 (ENSG00000204934),GE,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,follicular lymphoma,Launched,0.418081005437764,0.30219684814,copanlisib,PI3K INHIBITOR,0.4162811217191591,1.9539783954306211,-0.39326921151237615
BRD-K24689407-001-06-3::2.5::HTS,BRD-K24689407-001-06-3,3-bromo-7-nitroindazole,2.5,HTS,PROT_Caspase-8_Caution,PROT,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,Preclinical,0.299728554655695,0.0359327365938,3-bromo-7-nitroindazole,,,0,0
BRD-K24696047-001-02-3::2.5::HTS,BRD-K24696047-001-02-3,NVP-AEW541,2.5,HTS,PROT_TAZ,PROT,targeted cancer,IGF-1 inhibitor,"IGF1R, INSR",,,Preclinical,0.360269405759211,0.206282170681,NVP-AEW541,OTHER,0.3536428941732573,-3.5380001213920806,0.24363490015159384
BRD-K24697665-001-01-4::2.5::HTS,BRD-K24697665-001-01-4,bucillamine,2.5,HTS,DEM2_RBM15B (29890),DEMETER2_COM,noncancer,immunosuppressant,,rheumatology,rheumatoid arthritis,Launched,0.329624807257667,0.111622326149,bucillamine,,,0,0
BRD-K24715592-406-02-1::2.53::HTS,BRD-K24715592-406-02-1,ethacridine-lactate-monohydrate,2.53,HTS,Exp_SLC16A2 (ENSG00000147100),GE,noncancer,DNA intercalating agent,,,,Preclinical,0.43277682874016704,0.426247652757,ethacridine-lactate-monohydrate,OTHER,0.43360598751496665,4.991584904097858,-1.1732004086958585
BRD-K24723746-036-02-5::2.5::HTS,BRD-K24723746-036-02-5,solifenacin-succinate,2.5,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency",Launched,0.251419748874337,0.224953639963,solifenacin-succinate,OTHER,0.243193710439829,-3.74673112044919,-3.3055571943585127
BRD-K24771047-001-01-6::2.5::HTS,BRD-K24771047-001-01-6,ampalex,2.5,HTS,PROT_p70S6K_pT389,PROT,noncancer,glutamate receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,Phase 2,0.326639260452122,0.122115239894,ampalex,,,0,0
BRD-K24790130-001-07-1::2.5::HTS,BRD-K24790130-001-07-1,tricaprylin,2.5,HTS,METABOL_alpha-ketoglutarate,METABOL,noncancer,,,dermatology,cosmetic,Launched,0.28484509314449896,0.0808314661567,tricaprylin,,,0,0
BRD-K24820488-001-01-7::2.5::HTS,BRD-K24820488-001-01-7,CH-170,2.5,HTS,MIRNA_hsa-miR-877,MIRNA,noncancer,,,,,Phase 1,0.290374052561459,0.119376876433,CH-170,,,0,0
BRD-K24821794-001-01-4::2.5::HTS,BRD-K24821794-001-01-4,SGC-CBP30,2.5,HTS,Exp_GABRA5 (ENSG00000186297),GE,targeted cancer,bromodomain inhibitor,"CREBBP, EP300",,,Preclinical,0.270667175334122,0.135801773399,SGC-CBP30,,,0,0
BRD-K24844714-001-24-5::2.5::HTS,BRD-K24844714-001-24-5,5-fluorouracil,2.5,HTS,Exp_AP1S2 (ENSG00000182287),GE,chemo,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma",Launched,0.30726327127093,0.248197681586,5-fluorouracil,OTHER,0.3059102321857283,3.614795852759789,-2.8639220995733434
BRD-K24864897-001-01-0::2.5::MTS004,BRD-K24864897-001-01-0,JNJ-26990990,2.5,MTS004,MIRNA_hsa-miR-483-5p,MIRNA,noncancer,anticonvulsant,,,,Phase 2,0.33617585737751904,0.0565703738269,JNJ-26990990,,,0,0
BRD-K24869513-001-02-1::2.5::HTS,BRD-K24869513-001-02-1,CNX-2006,2.5,HTS,PROT_GSK3_pS9,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.33333894023249394,0.197554243353,CNX-2006,EGFR INHIBITOR,0.3171973699178206,0.9421808869711608,-5.066159200428287
BRD-K24943235-001-01-3::2.5::HTS,BRD-K24943235-001-01-3,grazoprevir,2.5,HTS,Exp_GAPDHP22 (ENSG00000234005),GE,noncancer,HCV inhibitor,,,,Launched,0.272153680372295,0.0905691779868,grazoprevir,,,0,0
BRD-K24968862-001-01-0::2.5::HTS,BRD-K24968862-001-01-0,SB-683698,2.5,HTS,CRISPR_NUP62 (23636),AVANA_PUBLIC_18Q2,noncancer,integrin antagonist,"ITGA4, ITGAV, ITGB1, ITGB7",,,Phase 1,0.25811334206083103,0.0288347771704,SB-683698,,,0,0
BRD-K25015158-001-01-2::2.5::HTS,BRD-K25015158-001-01-2,limaprost-alfadex,2.5,HTS,DEM2_RARG (5916),DEMETER2_COM,noncancer,prostanoid receptor agonist,PTGER1,cardiology,claudication,Launched,0.23957837155430603,0.0432441048357,limaprost-alfadex,,,0,0
BRD-K25029121-001-05-8::2.446932239::MTS004,BRD-K25029121-001-05-8,triclocarban,2.446932239,MTS004,Exp_PKIA (ENSG00000171033),GE,noncancer,other antibiotic,,,,Launched,0.301441954853532,0.115139827976,triclocarban,,,0,0
BRD-K25114078-003-08-1::2.5::HTS,BRD-K25114078-003-08-1,aminoguanidine,2.5,HTS,CRISPR_LGR4 (55366),AVANA_PUBLIC_18Q2,noncancer,nitric oxide synthase inhibitor,NOS2,,,Phase 3,0.294910294590916,0.0925576843062,aminoguanidine,,,0,0
BRD-K25140590-001-03-0::2.5::HTS,BRD-K25140590-001-03-0,CX-516,2.5,HTS,Exp_C12orf42 (ENSG00000179088),GE,noncancer,glutamate receptor modulator,,,,Phase 2/Phase 3,0.277866529501274,0.0509447424267,CX-516,,,0,0
BRD-K25146005-001-01-0::2.5::MTS004,BRD-K25146005-001-01-0,cis-urocanic acid,2.5,MTS004,METABOL_inosine,METABOL,targeted cancer,serotonin receptor agonist,HTR2A,,,Phase 2,0.29089049354350605,0.122979476677,cis-urocanic acid,,,0,0
BRD-K25154476-001-01-4::2.5::MTS004,BRD-K25154476-001-01-4,cinflumide,2.5,MTS004,CRISPR_MTHFR (4524),AVANA_PUBLIC_18Q2,noncancer,muscle relaxant,,,,Phase 2,0.21979035557658397,0.190445827105,cinflumide,,,0,0
BRD-K25186396-001-09-6::2.5::HTS,BRD-K25186396-001-09-6,tangeritin,2.5,HTS,DEM2_CSTF2 (1478),DEMETER2_COM,noncancer,cell cycle inhibitor,,,,Preclinical,0.25343749446915,0.104785356609,tangeritin,,,0,0
BRD-K25204779-001-01-1::2.5::HTS,BRD-K25204779-001-01-1,pritelivir,2.5,HTS,METABOL_C18:2 CE,METABOL,noncancer,helicase primase inhibitor,,,,Phase 2,0.290311663176301,0.075319370889,pritelivir,,,0,0
BRD-K25224017-001-25-0::2.5::HTS,BRD-K25224017-001-25-0,pirenperone,2.5,HTS,Exp_HS3ST5 (ENSG00000249853),GE,noncancer,serotonin receptor antagonist,"HTR2A, HTR7",,,Preclinical,0.270717293373655,0.041276376197,pirenperone,,,0,0
BRD-K25243230-001-01-2::2.5::MTS004,BRD-K25243230-001-01-2,oxytocin,2.5,MTS004,DEM2_REM2 (161253),DEMETER2_COM,noncancer,oxytocin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",obstetrics/gynecology,labor induction,Launched,0.31533461967812,0.149826340194,oxytocin,,,0,0
BRD-K25244359-066-03-4::2.68::HTS,BRD-K25244359-066-03-4,apatinib,2.68,HTS,MIRNA_hsa-miR-199a-5p,MIRNA,targeted cancer,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",,,Phase 3,0.37017729148818,0.157696655304,apatinib,RET TYROSINE KINASE INHIBITOR,0.367434370286835,0.6799202208958381,-3.124016944266457
BRD-K25279140-001-01-5::2.5::HTS,BRD-K25279140-001-01-5,MK-8745,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Preclinical,0.39392893612703495,0.241616916397,MK-8745,AURORA KINASE INHIBITOR,0.3953522750975241,4.461661659269818,-3.4983205556095918
BRD-K25311561-001-10-7::2.5::HTS,BRD-K25311561-001-10-7,KU-55933,2.5,HTS,Exp_KCNK6 (ENSG00000099337),GE,noncancer,ATM kinase inhibitor,"ATM, PRKDC",,,Preclinical,0.307257873710422,0.101806904628,KU-55933,,,0,0
BRD-K25312248-001-01-5::2.5::HTS,BRD-K25312248-001-01-5,matrine,2.5,HTS,DEM2_PARVA (55742),DEMETER2_COM,targeted cancer,opioid receptor agonist,OPRK1,,,Phase 2,0.309067522025,0.0557275048124,matrine,,,0,0
BRD-K25317177-065-01-4::2.5::HTS,BRD-K25317177-065-01-4,modaline,2.5,HTS,CN_BTNL8 (79908),CN,noncancer,,,,,Preclinical,0.260629103006694,0.0701828642891,modaline,,,0,0
BRD-K25340465-001-11-1::2.58::HTS,BRD-K25340465-001-11-1,OSI-930,2.58,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",,,Phase 1,0.362401395674544,0.312895010808,OSI-930,OTHER,0.3669385970000413,4.803720341507483,-2.1638536864048463
BRD-K25359048-001-02-6::2.5::HTS,BRD-K25359048-001-02-6,WZ811,2.5,HTS,CRISPR_ATP8B1 (5205),AVANA_PUBLIC_18Q2,targeted cancer,CC chemokine receptor antagonist,CXCR4,,,Preclinical,0.294586638106842,0.109731619897,WZ811,,,0,0
BRD-K25412176-001-01-9::2.5::HTS,BRD-K25412176-001-01-9,GSK2110183,2.5,HTS,Exp_AKT3 (ENSG00000117020),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.385126932206104,0.424869249604,GSK2110183,AKT INHIBITOR,0.3921378863473861,0.5371378515870229,-2.050139373623729
BRD-K25433859-003-25-4::2.5::HTS,BRD-K25433859-003-25-4,maprotiline,2.5,HTS,Exp_SUCNR1 (ENSG00000198829),GE,noncancer,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder",Launched,0.17544436402790603,0.122965761929,maprotiline,,,0,0
BRD-K25486274-300-01-0::2.5::HTS,BRD-K25486274-300-01-0,DRF053-(R),2.5,HTS,Exp_CHST4 (ENSG00000140835),GE,targeted cancer,CDK inhibitor,CSNK1A1,,,Preclinical,0.30385188802804,0.124596908143,DRF053-(R),,,0,0
BRD-K25494650-003-01-8::2.660853131::MTS004,BRD-K25494650-003-01-8,chlorproguanil,2.660853131,MTS004,METHYL_INSL4,METHYL,noncancer,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,Launched,0.3077437033859,0.105291257331,chlorproguanil,,,0,0
BRD-K25570267-001-01-4::2.436963824::MTS004,BRD-K25570267-001-01-4,ezutromid,2.436963824,MTS004,Exp_SOWAHD (ENSG00000187808),GE,noncancer,utrophin enhancer,UTRN,,,Phase 2,0.288381696538961,0.0808130512514,ezutromid,,,0,0
BRD-K25596805-001-01-8::2.5::HTS,BRD-K25596805-001-01-8,JNJ-16259685,2.5,HTS,RMUTmis_PTPN23 (25930),MUT,noncancer,glutamate receptor antagonist,GRM1,,,Preclinical,0.241701122124207,-0.0347639592057,JNJ-16259685,,,0,0
BRD-K25630527-001-03-8::2.5::HTS,BRD-K25630527-001-03-8,LY2784544,2.5,HTS,Exp_ZNF280C (ENSG00000056277),GE,noncancer,JAK inhibitor,"JAK2, JAK3",,,Phase 2,0.33593893163462696,0.341591148603,LY2784544,OTHER,0.34017091684850764,4.953970186770492,-3.000345598341473
BRD-K25649279-001-02-0::2.5::HTS,BRD-K25649279-001-02-0,2-iodomelatonin,2.5,HTS,CN_CFHR4 (10877),CN,noncancer,melatonin receptor agonist,"MTNR1A, MTNR1B, NQO2",,,Preclinical,0.258287809161319,0.00378631297702,2-iodomelatonin,,,0,0
BRD-K25650355-065-02-0::2.5::HTS,BRD-K25650355-065-02-0,physostigmine,2.5,HTS,METHYL_IDE,METHYL,noncancer,cholinesterase inhibitor,"ACHE, BCHE","cardiology, neurology/psychiatry, ophthalmology, gastroenterology","hypotension, Alzheimer's disease, glaucoma, gastroparesis",Launched,0.26977915275431397,0.0901299836993,physostigmine,,,0,0
BRD-K25690923-001-02-4::2.5::HTS,BRD-K25690923-001-02-4,4-iodo-6-phenylpyrimidine,2.5,HTS,PROT_Akt_pT308,PROT,targeted cancer,macrophage migration inhibiting factor inhibitor,MIF,,,Preclinical,0.28562081674497103,0.0791369453595,4-iodo-6-phenylpyrimidine,,,0,0
BRD-K25691735-001-09-5::2.5::HTS,BRD-K25691735-001-09-5,chuanxiongzine,2.5,HTS,CN_FZD1 (8321),CN,noncancer,,,,,Phase 2,0.288729887162938,0.164913079319,chuanxiongzine,,,0,0
BRD-K25723200-001-02-7::2.5::HTS,BRD-K25723200-001-02-7,azilsartan-medoxomil,2.5,HTS,MIRNA_hsa-miR-203,MIRNA,noncancer,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,Launched,0.257336832949092,0.0375445550498,azilsartan-medoxomil,,,0,0
BRD-K25835157-001-01-4::2.5::HTS,BRD-K25835157-001-01-4,PRT062070,2.5,HTS,Exp_TAB3 (ENSG00000157625),GE,targeted cancer,"JAK inhibitor, syk inhibitor",SYK,,,Phase 1,0.332487422556861,0.239260466531,PRT062070,OTHER,0.3283957173620561,2.5094831418339067,-3.5378665260610607
BRD-K25837718-001-03-8::2.5::HTS,BRD-K25837718-001-03-8,josamycin,2.5,HTS,MUTpool_ZNF335 (63925),MUTpool,noncancer,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis,Launched,0.30989139291924794,0.0877110019484,josamycin,,,0,0
BRD-K25875056-001-02-0::2.5::HTS,BRD-K25875056-001-02-0,SC-9,2.5,HTS,DEM2_ASPH (444),DEMETER2_COM,noncancer,protein tyrosine kinase activator,PRKCA,,,Preclinical,0.295513881729017,0.00142485528539,SC-9,,,0,0
BRD-K25943794-001-02-3::2.5::HTS,BRD-K25943794-001-02-3,blonanserin,2.5,HTS,MIRNA_hsa-miR-1298,MIRNA,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.286633384745196,0.0722972020873,blonanserin,,,0,0
BRD-K25970317-001-01-6::2.50000335::MTS004,BRD-K25970317-001-01-6,resibufogenin,2.50000335,MTS004,PROT_MIG-6,PROT,noncancer,Na/K-ATPase inhibitor,,,,Phase 2,0.385936607666272,0.404382683238,resibufogenin,OTHER,0.3885743938994004,5.347308393302672,-1.2403526897543098
BRD-K25991633-001-01-9::2.5::HTS,BRD-K25991633-001-01-9,BMS-649,2.5,HTS,Exp_STAB1 (ENSG00000010327),GE,noncancer,retinoid receptor agonist,RXRA,,,Preclinical,0.29262011706299296,0.108400615976,BMS-649,,,0,0
BRD-K26005076-001-12-8::2.5::HTS,BRD-K26005076-001-12-8,gramine,2.5,HTS,METHYL_THUMPD1,METHYL,noncancer,norepinephrine reputake inhibitor,,,,Preclinical,0.31323503747045695,0.0359162352348,gramine,,,0,0
BRD-K26011976-001-01-0::2.5::HTS,BRD-K26011976-001-01-0,licochalcone-a,2.5,HTS,DEM2_UBOX5 (22888),DEMETER2_COM,targeted cancer,topoisomerase inhibitor,PTPN1,,,Phase 3,0.31477169776005104,0.0628900574596,licochalcone-a,,,0,0
BRD-K26024145-001-01-9::2.5::MTS004,BRD-K26024145-001-01-9,desoxycorticosterone-pivalate,2.5,MTS004,CRISPR_STT3B (201595),AVANA_PUBLIC_18Q2,noncancer,corticosteroid agonist,NR3C2,endocrinology,Addison's disease,Launched,0.323205525064573,0.0162047201202,desoxycorticosterone-pivalate,,,0,0
BRD-K26026438-001-01-0::2.499979456::MTS004,BRD-K26026438-001-01-0,tucatinib,2.499979456,MTS004,Exp_PGAP3 (ENSG00000161395),GE,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 2,0.30537396083315504,0.358437592792,tucatinib,EGFR INHIBITOR,0.30374454143214663,1.0708324777907905,-5.122392906569769
BRD-K26060080-065-05-6::2.5::HTS,BRD-K26060080-065-05-6,adenine,2.5,HTS,DEM2_RAMP1 (10267),DEMETER2_COM,noncancer,protein synthesis stimulant,"ACACB, ACP1, APRT, MTAP, PECR, SRPK2",,,Preclinical,0.21875534358907997,0.111889913854,adenine,,,0,0
BRD-K26160755-003-02-6::2.5::HTS,BRD-K26160755-003-02-6,RS-45041-190,2.5,HTS,Exp_C7orf65 (ENSG00000221845),GE,noncancer,imidazoline receptor agonist,,,,Preclinical,0.252644416144286,0.0834432575875,RS-45041-190,,,0,0
BRD-K26168087-001-09-7::2.5::HTS,BRD-K26168087-001-09-7,magnolol,2.5,HTS,DEM2_HR (55806),DEMETER2_COM,targeted cancer,PPAR receptor agonist,"GABRA1, PPARG",,,Preclinical,0.309435741649022,0.0736930994257,magnolol,,,0,0
BRD-K26222048-001-01-7::2.5::HTS,BRD-K26222048-001-01-7,"trans-10,cis-12-Conjugated-linoleic-acid",2.5,HTS,METHYL_SCAP,METHYL,noncancer,,,,,Launched,0.283414317156237,0.0556080070098,"trans-10,cis-12-Conjugated-linoleic-acid",,,0,0
BRD-K26253904-001-01-5::2.5::HTS,BRD-K26253904-001-01-5,NMS-873,2.5,HTS,CRISPR_SDHB (6390),AVANA_PUBLIC_18Q2,targeted cancer,ATPase inhibitor,VCP,,,Preclinical,0.37773914423069,0.254342889045,NMS-873,OTHER,0.35374124062490003,2.551147923525896,-1.8409549587228755
BRD-K26262077-238-01-5::2.5::HTS,BRD-K26262077-238-01-5,acamprosate,2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,glutamate receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5",neurology/psychiatry,abstinence from alcohol,Launched,0.28306810944081107,0.0233138803037,acamprosate,,,0,0
BRD-K26305185-001-02-1::2.5::HTS,BRD-K26305185-001-02-1,K-Ras(G12C)-inhibitor-6,2.5,HTS,PROT_Src_pY416_Caution,PROT,noncancer,K-ras inhibitor,,,,Preclinical,0.29377571719930895,0.100832560641,K-Ras(G12C)-inhibitor-6,,,0,0
BRD-K26323068-001-01-8::2.5::MTS004,BRD-K26323068-001-01-8,leuprolide,2.5,MTS004,MIRNA_hsa-miR-190,MIRNA,targeted cancer,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer,Launched,0.312036592783763,0.0443766883381,leuprolide,,,0,0
BRD-K26325692-003-01-3::2.5::HTS,BRD-K26325692-003-01-3,API-001,2.5,HTS,METABOL_inositol,METABOL,targeted cancer,sigma receptor antagonist,SIGMAR1,,,Phase 2,0.283366027451345,0.0999304261553,API-001,,,0,0
BRD-K26341917-001-01-3::2.5::HTS,BRD-K26341917-001-01-3,L-ergothioneine,2.5,HTS,DEM2_ZFY (7544),DEMETER2_COM,noncancer,free radical scavenger,,,,Phase 2,0.260447374228133,0.0481340447803,L-ergothioneine,,,0,0
BRD-K26349472-001-01-3::2.5::HTS,BRD-K26349472-001-01-3,OG-L002,2.5,HTS,DEM2_S100A11 (6282),DEMETER2_COM,noncancer,histone lysine demethylase inhibitor,KDM1A,,,Preclinical,0.29965708788052503,0.0811545150571,OG-L002,,,0,0
BRD-K26373640-001-05-1::2.5::HTS,BRD-K26373640-001-05-1,IKK-2-inhibitor,2.5,HTS,PROT_Chk2,PROT,targeted cancer,"IKK inhibitor, SYK inhibitor",IKBKB,,,Preclinical,0.239555375049751,0.0971059181256,IKK-2-inhibitor,,,0,0
BRD-K26502378-001-07-9::2.5::HTS,BRD-K26502378-001-07-9,vanitiolide,2.5,HTS,CRISPR_TOPBP1 (11073),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.345593283679955,0.0136187948291,vanitiolide,,,0,0
BRD-K26530649-001-01-6::2.568078778::MTS004,BRD-K26530649-001-01-6,carboxypyridine-disulfide,2.568078778,MTS004,Exp_NUTF2 (ENSG00000102898),GE,targeted cancer,,,,,Phase 2,0.381068315607565,0.282730556228,carboxypyridine-disulfide,OTHER,0.38312352615568535,2.5752955992103788,-4.260729508020321
BRD-K26531771-001-01-4::2.5::HTS,BRD-K26531771-001-01-4,EPZ-5676,2.5,HTS,Exp_KRT23 (ENSG00000108244),GE,targeted cancer,histone lysine methyltransferase inhibitor,DOT1L,,,Phase 1,0.411219173948939,0.264567420168,EPZ-5676,,,0,0
BRD-K26531771-001-02-2::2.35::HTS,BRD-K26531771-001-02-2,EPZ-5676,2.35,HTS,Exp_FANCE (ENSG00000112039),GE,targeted cancer,histone lysine methyltransferase inhibitor,DOT1L,,,Phase 1,0.411219173948939,0.264567420168,EPZ-5676,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3873840940067252,1.6433725958133143,-3.8571715325420186
BRD-K26548821-003-10-5::2.5::HTS,BRD-K26548821-003-10-5,quinpirol-(-),2.5,HTS,Exp_RNF220 (ENSG00000187147),GE,noncancer,dopamine receptor agonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C",,,Phase 2,0.249697197799159,0.0653570905406,quinpirol-(-),,,0,0
BRD-K26573499-300-02-1::2.5::HTS,BRD-K26573499-300-02-1,DMAB-anabaseine,2.5,HTS,CRISPR_TRAF6 (7189),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,CHRNA7,,,Preclinical,0.27204507213603,0.0484494976943,DMAB-anabaseine,,,0,0
BRD-K26581543-001-01-6::2.5::HTS,BRD-K26581543-001-01-6,bifendate,2.5,HTS,Exp_DMRT1 (ENSG00000137090),GE,noncancer,,,,,Launched,0.255885853715696,0.121990216309,bifendate,,,0,0
BRD-K26603252-003-04-9::2.5::HTS,BRD-K26603252-003-04-9,PD-153035,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,EGFR inhibitor,"EGFR, KDR",,,Phase 1,0.432760301802387,0.510488932054,PD-153035,EGFR INHIBITOR,0.4272990396560319,1.06671992973089,-5.263855457378938
BRD-K26619122-001-02-1::2.5::HTS,BRD-K26619122-001-02-1,thiocolchicoside,2.5,HTS,PROT_p90RSK_Caution,PROT,noncancer,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,Launched,0.30465764435355397,0.0243231014645,thiocolchicoside,,,0,0
BRD-K26634012-001-04-9::2.5::HTS,BRD-K26634012-001-04-9,tilmicosin,2.5,HTS,PROT_p38_MAPK,PROT,noncancer,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bovine respiratory disease (BRD),Launched,0.264976111741965,0.0737918482103,tilmicosin,,,0,0
BRD-K26667523-001-02-5::2.5::HTS,BRD-K26667523-001-02-5,TAK-733,2.5,HTS,Exp_ETV4 (ENSG00000175832),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 1,0.414270339522114,0.464319045888,TAK-733,MEK INHIBITOR,0.41492268257847503,0.3347795300880411,5.01264951209501
BRD-K26701552-001-01-8::2.5::HTS,BRD-K26701552-001-01-8,tegobuvir,2.5,HTS,CRISPR_ZNF641 (121274),AVANA_PUBLIC_18Q2,noncancer,"HCV inhibitor, protease inhibitor",,,,Phase 3,0.27662456799718393,0.125183199534,tegobuvir,,,0,0
BRD-K26712974-001-01-5::2.5::HTS,BRD-K26712974-001-01-5,VX-765,2.5,HTS,CRISPR_TMEM127 (55654),AVANA_PUBLIC_18Q2,noncancer,caspase inhibitor,CASP1,,,Phase 2,0.185128918311834,0.130495104784,VX-765,,,0,0
BRD-K26739552-003-15-4::2.5::HTS,BRD-K26739552-003-15-4,fenspiride,2.5,HTS,CN_NETO1 (81832),CN,noncancer,bronchodilator,,"pulmonary, otolaryngology","asthma, otitis, sinusitis, rhinopharyngitis, laryngitis",Launched,0.29945516131898997,0.031833221077,fenspiride,,,0,0
BRD-K26756394-001-02-2::2.5::HTS,BRD-K26756394-001-02-2,VE-821,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,ATR kinase inhibitor,ATR,,,Preclinical,0.36993173366591603,0.24064598466,VE-821,OTHER,0.33391180459635345,2.8292846346516707,-3.4003694439740766
BRD-K26801045-001-02-9::2.5::HTS,BRD-K26801045-001-02-9,pipamperone,2.5,HTS,METABOL_C14:0 CE,METABOL,noncancer,dopamine receptor antagonist,"DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.277309073732329,0.0747337893523,pipamperone,,,0,0
BRD-K26807903-001-04-3::2.5::HTS,BRD-K26807903-001-04-3,aklomide,2.5,HTS,PROT_Cyclin_E2_Caution,PROT,noncancer,,,infectious disease,coccidiosis,Launched,0.27413692774662,0.153444622814,aklomide,,,0,0
BRD-K26813177-001-03-2::2.46430412::MTS004,BRD-K26813177-001-03-2,daltroban,2.46430412,MTS004,CN_D21S2088E (266917),CN,noncancer,thromboxane receptor antagonist,TBXA2R,,,Phase 3,0.23253877934255898,0.0935993066218,daltroban,,,0,0
BRD-K26818574-305-04-3::2.5::HTS,BRD-K26818574-305-04-3,BIX-01294,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.40725969092650205,0.368465692473,BIX-01294,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3675148473551251,4.562808201766867,-1.474052246887129
BRD-K26823213-001-02-9::2.5::HTS,BRD-K26823213-001-02-9,GW-842166,2.5,HTS,MIRNA_hsa-miR-2277,MIRNA,noncancer,cannabinoid receptor agonist,CNR2,,,Phase 2,0.333910867811485,0.0616532497841,GW-842166,,,0,0
BRD-K26824830-001-02-0::2.5::HTS,BRD-K26824830-001-02-0,azomycin-(2-nitroimidazole),2.5,HTS,CRISPR_NAA35 (60560),AVANA_PUBLIC_18Q2,noncancer,protein synthesis inhibitor,,,,Preclinical,0.33565187279496506,0.0388200600466,azomycin-(2-nitroimidazole),,,0,0
BRD-K26833429-001-02-8::2.5::HTS,BRD-K26833429-001-02-8,costunolide,2.5,HTS,RMUTmis_ZEB2 (9839),MUTmis,targeted cancer,telomerase inhibitor,,,,Preclinical,0.341114451715648,0.102904878112,costunolide,OTHER,0.3390352998443936,0.3866951967608897,-3.759837832003948
BRD-K26838195-075-04-9::2.5::HTS,BRD-K26838195-075-04-9,AST-1306,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.44592577938152395,0.466423065302,AST-1306,EGFR INHIBITOR,0.4380699003610072,0.9285657245855238,-5.163226386009617
BRD-K26862302-001-05-2::2.5::HTS,BRD-K26862302-001-05-2,diosmetin,2.5,HTS,DEM2_PUSL1 (126789),DEMETER2_COM,noncancer,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic,Launched,0.261539604893852,0.0340504057057,diosmetin,,,0,0
BRD-K26901728-001-06-2::2.5::HTS,BRD-K26901728-001-06-2,lumiracoxib,2.5,HTS,MIRNA_hsa-miR-1243,MIRNA,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Withdrawn,0.27869291485237896,0.0361863763508,lumiracoxib,,,0,0
BRD-K26989966-001-03-5::2.5::HTS,BRD-K26989966-001-03-5,UNC1999,2.5,HTS,LIN_melanoma,LIN,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.287382178571904,0.157677332617,UNC1999,,,0,0
BRD-K26997899-001-02-2::2.5::HTS,BRD-K26997899-001-02-2,D-64131,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,microtubule inhibitor,TUBB,,,Preclinical,0.41463185368126504,0.363413205794,D-64131,OTHER,0.4162983026775585,5.761099015592093,-3.099251771381436
BRD-K27061362-001-01-6::2.499998598::MTS004,BRD-K27061362-001-01-6,AMG-337,2.499998598,MTS004,DEM2_DZANK1 (55184),DEMETER2_COM,targeted cancer,MET inhibitor,MET,,,Phase 2,0.18111484976422898,0.115999979818,AMG-337,,,0,0
BRD-K27062708-001-23-1::2.5::HTS,BRD-K27062708-001-23-1,chlorotrianisene,2.5,HTS,Exp_ZDHHC20P1 (ENSG00000233916),GE,targeted cancer,estrogenic hormone,"ESR1, ESR2","endocrinology, oncology","menopause, prostate cancer",Launched,0.28396955374856603,0.0803736358234,chlorotrianisene,,,0,0
BRD-K27135764-001-08-7::2.5::HTS,BRD-K27135764-001-08-7,xanthone,2.5,HTS,CRISPR_ICT1 (3396),AVANA_PUBLIC_18Q2,noncancer,antimalarial agent,,,,Preclinical,0.23857721896938897,0.0411514173232,xanthone,,,0,0
BRD-K27141178-003-07-3::2.5::HTS,BRD-K27141178-003-07-3,SB-203186,2.5,HTS,RMUTdmg_CDKN2A (1029),MUTdmg,noncancer,serotonin receptor antagonist,HTR4,,,Preclinical,0.24133752680857604,0.0962380743056,SB-203186,,,0,0
BRD-K27168049-001-02-8::2.5::HTS,BRD-K27168049-001-02-8,SDZ-220-581,2.5,HTS,CN_RUFY1 (80230),CN,noncancer,glutamate receptor antagonist,GRIN1,,,Preclinical,0.230175119779137,0.0535656871453,SDZ-220-581,,,0,0
BRD-K27182532-001-02-3::2.5::HTS,BRD-K27182532-001-02-3,metatinib,2.5,HTS,CRISPR_SP6 (80320),AVANA_PUBLIC_18Q2,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,Phase 1,0.22905769749624397,0.127757134218,metatinib,OTHER,0.22869518339296316,5.6506094995852365,0.52798222767017
BRD-K27184429-300-01-3::2.5::HTS,BRD-K27184429-300-01-3,levocetirizine,2.5,HTS,MUTpool_ADAMTS18 (170692),MUTpool,noncancer,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",Launched,0.252905215144532,0.0472994192468,levocetirizine,,,0,0
BRD-K27204852-001-01-9::2.5::HTS,BRD-K27204852-001-01-9,balicatib,2.5,HTS,RMUThot_KRAS (3845),MUThot,noncancer,cathepsin inhibitor,CTSK,,,Phase 2,0.16583563565764903,0.00782226362955,balicatib,,,0,0
BRD-K27217864-001-22-3::2.5::HTS,BRD-K27217864-001-22-3,butamben,2.5,HTS,LIN_liver,LIN,noncancer,sodium channel blocker,,,,Withdrawn,0.31384623879136203,0.0525519803155,butamben,,,0,0
BRD-K27293958-001-01-5::2.450321909::MTS004,BRD-K27293958-001-01-5,tiaramide,2.450321909,MTS004,MIRNA_hsa-miR-202,MIRNA,noncancer,anti-inflammatory agent,,pulmonary,asthma,Launched,0.27697126201404604,0.151916577213,tiaramide,,,0,0
BRD-K27305650-001-16-6::2.5::HTS,BRD-K27305650-001-16-6,LY294002,2.5,HTS,Exp_FZD10-AS1 (ENSG00000250208),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor, DNA dependent protein kinase inhibitor, phosphodiesterase inhibitor, PLK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.234714927168851,0.0281617866664,LY294002,,,0,0
BRD-K27316855-001-13-3::2.44::HTS,BRD-K27316855-001-13-3,calcitriol,2.44,HTS,Exp_ZBP1 (ENSG00000124256),GE,noncancer,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis",Launched,0.353830391762423,0.257683808528,calcitriol,VITAMIN D RECEPTOR AGONIST,0.3349823708355824,0.3162279439853538,-1.601898815797414
BRD-K27316855-001-19-0::2.5::HTS,BRD-K27316855-001-19-0,calcitriol,2.5,HTS,Exp_TAS2R38 (ENSG00000257138),GE,noncancer,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis",Launched,0.353830391762423,0.257683808528,calcitriol,VITAMIN D RECEPTOR AGONIST,0.3286617749493958,0.4584585407418578,-1.3139100857088972
BRD-K27335680-001-10-0::2.5::HTS,BRD-K27335680-001-10-0,rhein,2.5,HTS,MIRNA_hsa-miR-493,MIRNA,targeted cancer,,HSP90AA1,,,Phase 1,0.25645583474807604,-0.00178658704479,rhein,,,0,0
BRD-K27351809-001-09-5::2.5::HTS,BRD-K27351809-001-09-5,nomegestrol-acetate,2.5,HTS,MUTpool_SRGAP3 (9901),MUTpool,noncancer,progesterone receptor agonist,PGR,endocrinology,contraceptive,Launched,0.26670203520533103,0.109568127826,nomegestrol-acetate,,,0,0
BRD-K27382019-418-01-9::2.5::HTS,BRD-K27382019-418-01-9,piperaquine-phosphate,2.5,HTS,METHYL_LNX1-AS1,METHYL,noncancer,antimalarial agent,,infectious disease,malaria,Launched,0.27311381790164,0.147081042257,piperaquine-phosphate,,,0,0
BRD-K27393415-001-01-0::2.5::HTS,BRD-K27393415-001-01-0,xipamide,2.5,HTS,MIRNA_hsa-miR-554,MIRNA,noncancer,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension",Launched,0.324442505064656,0.125585859345,xipamide,,,0,0
BRD-K27406233-001-07-7::2.5::HTS,BRD-K27406233-001-07-7,acetyl-l-leucine,2.5,HTS,PROT_JAK2,PROT,noncancer,,,neurology/psychiatry,vertigo,Launched,0.264052088939367,0.0564961906638,acetyl-l-leucine,,,0,0
BRD-K27515606-003-01-3::2.5::MTS004,BRD-K27515606-003-01-3,cefcapene-pivoxil,2.5,MTS004,LIN_glioma,LIN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, pneumonia, urinary tract infections",Launched,0.224216264332549,0.188002834447,cefcapene-pivoxil,,,0,0
BRD-K27625831-001-02-9::2.499990597::MTS004,BRD-K27625831-001-02-9,pleconaril,2.499990597,MTS004,METABOL_C48:3 TAG,METABOL,noncancer,,,,,Phase 3,0.27143387254367396,0.142468137813,pleconaril,,,0,0
BRD-K27721098-065-08-6::2.5::HTS,BRD-K27721098-065-08-6,clopidogrel,2.5,HTS,PROT_TSC1_Caution,PROT,noncancer,purinergic receptor antagonist,P2RY12,"cardiology, neurology/psychiatry","myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)",Launched,0.36418508879543604,0.014122474795,clopidogrel,,,0,0
BRD-K27737647-300-03-0::2.5::HTS,BRD-K27737647-300-03-0,H-89,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,PKA inhibitor,"GSG2, PKIA, PRKACA",,,Preclinical,0.280804876605127,0.094067049431,H-89,,,0,0
BRD-K27755542-001-01-6::2.49693186::MTS004,BRD-K27755542-001-01-6,PF-04937319,2.49693186,MTS004,CN_SMIM12 (113444),CN,noncancer,glucokinase activator,GCK,,,Phase 2,0.229016458409456,0.041891431805,PF-04937319,,,0,0
BRD-K27771035-001-02-5::2.5::HTS,BRD-K27771035-001-02-5,clindamycin-phosphate,2.5,HTS,CN_C10orf11 (83938),CN,noncancer,protein synthesis inhibitor,,obstetrics/gynecology,bacterial vaginosis,Launched,0.268886697609307,0.0803158904918,clindamycin-phosphate,,,0,0
BRD-K27798832-001-01-5::2.350625651::MTS004,BRD-K27798832-001-01-5,cefetamet,2.350625651,MTS004,MIRNA_hsa-miR-875-5p,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, pulmonary","ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections",Launched,0.28223443043764695,0.0848352724416,cefetamet,,,0,0
BRD-K27799744-001-02-8::2.52::HTS,BRD-K27799744-001-02-8,cyclovirobuxin-d,2.52,HTS,MIRNA_ebv-miR-BART1-3p,MIRNA,noncancer,calcium channel modulator,,,,Preclinical,0.29056439355975894,0.108902856675,cyclovirobuxin-d,OTHER,0.29825349542849355,4.400664270281839,-2.0939698165385234
BRD-K27853494-003-04-7::2.5::HTS,BRD-K27853494-003-04-7,"1s,2r-phenylpropanolamine",2.5,HTS,DEM2_ATP6V0B (533),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRB1, ADRB2, DRD1",,,Withdrawn,0.260429803959986,0.0637525813025,"1s,2r-phenylpropanolamine",,,0,0
BRD-K27871792-001-01-8::2.5::HTS,BRD-K27871792-001-01-8,flucloxacillin,2.5,HTS,CRISPR_NDC80 (10403),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, dermatology, gastroenterology","gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia",Launched,0.355442257098182,0.0439750013333,flucloxacillin,,,0,0
BRD-K27885593-001-06-8::2.500027849::MTS004,BRD-K27885593-001-06-8,corosolic-acid,2.500027849,MTS004,CRISPR_PCBD1 (5092),AVANA_PUBLIC_18Q2,targeted cancer,"PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1",,,Phase 2,0.302453624302681,0.054018549648,corosolic-acid,,,0,0
BRD-K27911943-001-02-8::2.5::HTS,BRD-K27911943-001-02-8,"chromanol-293B-(-)-[3R,4S]",2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,potassium channel blocker,,,,Preclinical,0.21775908111540998,0.100109984214,"chromanol-293B-(-)-[3R,4S]",,,0,0
BRD-K27938825-001-02-4::2.5::HTS,BRD-K27938825-001-02-4,ASA-404,2.5,HTS,METHYL_BRMS1,METHYL,targeted cancer,angiogenesis inhibitor,,,,Phase 3,0.273039836235885,0.144139811492,ASA-404,,,0,0
BRD-K27955832-001-02-9::2.5::HTS,BRD-K27955832-001-02-9,lomeguatrib,2.5,HTS,CN_ERBB4 (2066),CN,targeted cancer,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,Phase 2,0.31349332123547996,0.0543803197098,lomeguatrib,,,0,0
BRD-K28007504-051-01-2::2.5::HTS,BRD-K28007504-051-01-2,Ro-60-0175,2.5,HTS,PROT_ACVRL1_Caution,PROT,noncancer,,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.266748621606028,0.00361845090956,Ro-60-0175,,,0,0
BRD-K28029915-001-02-2::2.5::HTS,BRD-K28029915-001-02-2,dolasetron,2.5,HTS,Exp_CSF2RA (ENSG00000198223),GE,noncancer,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting",Launched,0.309315807443039,0.0769767664726,dolasetron,,,0,0
BRD-K28042756-001-01-9::5::HTS,BRD-K28042756-001-01-9,,5,HTS,MIRNA_hsa-miR-183,MIRNA,,,,,,,0.200093630770423,0.0141646979856,,,,0,0
BRD-K28061410-001-06-6::2.5::MTS004,BRD-K28061410-001-06-6,beta-lapachone,2.5,MTS004,Exp_KIF6 (ENSG00000164627),GE,chemo,topoisomerase inhibitor,TOP1,,,Phase 2,0.468077268349341,0.351562153896,beta-lapachone,TOPOISOMERASE INHIBITOR,0.4577214683426839,3.1813289787445767,-1.04892753886084
BRD-K28115081-001-02-7::2.5::HTS,BRD-K28115081-001-02-7,apafant,2.5,HTS,Exp_NLRP6 (ENSG00000174885),GE,noncancer,platelet activating factor receptor antagonist,PTAFR,,,Phase 3,0.24404113512596398,0.0307080792651,apafant,,,0,0
BRD-K28120222-001-08-4::2.5::HTS,BRD-K28120222-001-08-4,parthenolide-(alternate-stereo),2.5,HTS,DEM2_KATNA1 (11104),DEMETER2_COM,targeted cancer,NFkB pathway inhibitor,"IKBKB, RELA",,,Preclinical,0.31636248376425,0.134985767888,parthenolide-(alternate-stereo),NFKB PATHWAY INHIBITOR,0.30819213065780643,0.2946666536722525,-3.9436744333324736
BRD-K28121004-001-01-1::2.5::HTS,BRD-K28121004-001-01-1,N-acetylglycyl-D-glutamic-acid,2.5,HTS,MIRNA_ebv-miR-BART8,MIRNA,noncancer,glutamate receptor agonist,,,,Preclinical,0.292510791165885,0.0236176566574,N-acetylglycyl-D-glutamic-acid,,,0,0
BRD-K28143534-001-02-2::2.5::HTS,BRD-K28143534-001-02-2,cyproheptadine,2.5,HTS,PROT_TIGAR,PROT,noncancer,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism",Launched,0.18331460392298002,0.0667115998723,cyproheptadine,OTHER,0.18527525451520627,3.98022239932912,-0.3199052050155067
BRD-K28143534-003-25-9::2.5::HTS,BRD-K28143534-003-25-9,cyproheptadine,2.5,HTS,MIRNA_hsa-miR-15b,MIRNA,noncancer,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism",Launched,0.264916438935034,0.0591767564015,cyproheptadine,,,0,0
BRD-K28183345-003-11-4::2.5::HTS,BRD-K28183345-003-11-4,proguanil,2.5,HTS,Exp_CHI3L2 (ENSG00000064886),GE,noncancer,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,Launched,0.24018249289407298,0.179584772202,proguanil,,,0,0
BRD-K28192623-066-08-1::2.5::HTS,BRD-K28192623-066-08-1,spiradoline,2.5,HTS,CRISPR_RPL32 (6161),AVANA_PUBLIC_18Q2,noncancer,opioid receptor agonist,OPRK1,,,Phase 2,0.345054168841783,0.0682529708624,spiradoline,,,0,0
BRD-K28210218-236-08-1::2.5::HTS,BRD-K28210218-236-08-1,cephalothin,2.5,HTS,DEM2_LHX6 (26468),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, surgical prophylaxis",Launched,0.265683250499552,0.0848047359838,cephalothin,,,0,0
BRD-K28217197-001-01-4::2.5::HTS,BRD-K28217197-001-01-4,ganaxolone,2.5,HTS,DEM2_PTPN4 (5775),DEMETER2_COM,noncancer,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",,,Phase 3,0.26598101486868897,0.194963832296,ganaxolone,,,0,0
BRD-K28307902-001-21-7::2.5::HTS,BRD-K28307902-001-21-7,flutamide,2.5,HTS,CN_NMD3 (51068),CN,targeted cancer,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,Launched,0.157499044392517,0.0213934376363,flutamide,,,0,0
BRD-K28308851-303-01-8::2.5::HTS,BRD-K28308851-303-01-8,alpha-methylhistamine-dihydrobromide-(S)-(+),2.5,HTS,CRISPR_ALOX15B (247),AVANA_PUBLIC_18Q2,noncancer,histamine receptor agonist,HRH3,,,Preclinical,0.28009697615436896,0.0710207669291,alpha-methylhistamine-dihydrobromide-(S)-(+),,,0,0
BRD-K28343777-001-01-6::2.5::HTS,BRD-K28343777-001-01-6,20-hydroxyecdysone,2.5,HTS,DEM2_KCNJ5 (3762),DEMETER2_COM,noncancer,ecdysone receptor modulator,,,,Preclinical,0.3185784008871,0.0902123413123,20-hydroxyecdysone,,,0,0
BRD-K28352084-001-02-3::2.5::HTS,BRD-K28352084-001-02-3,CH5132799,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.38835376407003297,0.446512158108,CH5132799,PI3K INHIBITOR,0.37618184022541024,1.0241747672843324,-1.4979519393694385
BRD-K28360340-001-08-3::2.31::HTS,BRD-K28360340-001-08-3,TW-37,2.31,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, MCL1",,,Preclinical,0.365785940362567,0.261299105821,TW-37,OTHER,0.365762079995828,4.00675065652595,-2.3119939238008502
BRD-K28383148-001-01-4::2.5::HTS,BRD-K28383148-001-01-4,AP1903,2.5,HTS,CN_SUMF2 (25870),CN,targeted cancer,,,,,Phase 1/Phase 2,0.29152726446463106,0.105422820084,AP1903,,,0,0
BRD-K28392481-001-05-1::2.5::HTS,BRD-K28392481-001-05-1,AZD4547,2.5,HTS,PROT_Gab2,PROT,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",,,Phase 2/Phase 3,0.31272225581845503,0.142596612763,AZD4547,OTHER,0.3244328745494774,3.9734465047808536,-3.3427110148165244
BRD-K28405228-001-06-7::2.5::HTS,BRD-K28405228-001-06-7,mecarbinate,2.5,HTS,CRISPR_NFIX (4784),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.221065578559597,0.0379542277821,mecarbinate,,,0,0
BRD-K28428262-001-04-1::2.5::HTS,BRD-K28428262-001-04-1,brivanib,2.5,HTS,Exp_PRRX1 (ENSG00000116132),GE,targeted cancer,"FGFR inhibitor, VEGFR inhibitor","CYP3A4, FGFR1, FLT1, KCNH2, KDR",,,Phase 3,0.24246734083352497,0.129840524384,brivanib,,,0,0
BRD-K28442028-001-01-3::2.5::HTS,BRD-K28442028-001-01-3,R-1479,2.5,HTS,METHYL_HOXB2,METHYL,noncancer,HCV inhibitor,,,,Phase 1,0.259319286228894,0.0259925976349,R-1479,,,0,0
BRD-K28453807-003-11-2::2.5::HTS,BRD-K28453807-003-11-2,nitrocaramiphen,2.5,HTS,DEM2_HSP90B1 (7184),DEMETER2_COM,noncancer,cholinergic receptor antagonist,CHRM1,,,Preclinical,0.252565477132364,0.0601980275273,nitrocaramiphen,,,0,0
BRD-K28456624-001-01-1::2.5::HTS,BRD-K28456624-001-01-1,seocalcitol,2.5,HTS,Exp_NLGN2 (ENSG00000169992),GE,targeted cancer,vitamin D receptor agonist,VDR,,,Phase 3,0.269120133538698,0.131451413166,seocalcitol,VITAMIN D RECEPTOR AGONIST,0.2674568067876395,0.2841216371195492,-1.3921323621058614
BRD-K28492574-001-01-6::2.5::HTS,BRD-K28492574-001-01-6,piconol,2.5,HTS,MIRNA_hsa-miR-323-3p,MIRNA,noncancer,,,,,Preclinical,0.300782446244416,0.0609752717201,piconol,,,0,0
BRD-K28494619-001-28-2::2.5::HTS,BRD-K28494619-001-28-2,sulfamethoxazole,2.5,HTS,Exp_CELSR3 (ENSG00000008300),GE,noncancer,PABA antagonist,,"infectious disease, gastroenterology","pneumonia, enteritis, urinary tract infections",Launched,0.300496551092995,0.0858002466932,sulfamethoxazole,,,0,0
BRD-K28537285-001-01-8::2.499968715::MTS004,BRD-K28537285-001-01-8,chidamide,2.499968715,MTS004,METHYL_REXO1L2P,METHYL,targeted cancer,HDAC inhibitor,"HDAC10, HDAC3",,,Launched,0.34813180086304096,0.230016392726,chidamide,HDAC INHIBITOR,0.36001414422290295,6.839338277855022,-2.1168458679386766
BRD-K28542495-003-13-5::2.5::HTS,BRD-K28542495-003-13-5,benzydamine,2.5,HTS,PROT_Fibronectin,PROT,noncancer,prostanoid receptor antagonist,,"dental, otolaryngology","mouth inflammation, throat inflammation",Launched,0.264244083529163,0.108239547943,benzydamine,,,0,0
BRD-K28570407-001-02-0::2.5::HTS,BRD-K28570407-001-02-0,A-803467,2.5,HTS,DEM2_RRAGC (64121),DEMETER2_COM,noncancer,sodium channel blocker,SCN10A,,,Preclinical,0.24404184321139,0.182646150827,A-803467,,,0,0
BRD-K28578425-001-07-0::2.5::HTS,BRD-K28578425-001-07-0,cilostamide,2.5,HTS,CRISPR_L3HYPDH (112849),AVANA_PUBLIC_18Q2,targeted cancer,phosphodiesterase inhibitor,"PDE3A, PDE3B",,,Preclinical,0.272220320508359,0.0557086125834,cilostamide,,,0,0
BRD-K28595280-001-04-5::2.5::HTS,BRD-K28595280-001-04-5,meglumine,2.5,HTS,METHYL_FOXN3-AS1,METHYL,noncancer,excipient,,,,Launched,0.31498606618261304,0.0758165714671,meglumine,,,0,0
BRD-K28667793-001-28-1::2.5::HTS,BRD-K28667793-001-28-1,pyrazinamide,2.5,HTS,MUTpool_NPBWR2 (2832),MUTpool,noncancer,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis,Launched,0.269670475338513,0.0831508126049,pyrazinamide,,,0,0
BRD-K28687144-001-08-7::2.5::MTS004,BRD-K28687144-001-08-7,fosfosal,2.5,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,phosphodiesterase inhibitor,"PTGS1, PTGS2",,,Launched,0.331501634857167,0.116374889192,fosfosal,,,0,0
BRD-K28690501-001-02-1::2.5::HTS,BRD-K28690501-001-02-1,diosgenin,2.5,HTS,MIRNA_hsa-miR-526b,MIRNA,targeted cancer,steroid,,,,Preclinical,0.29056437894059806,0.0722471101607,diosgenin,,,0,0
BRD-K28761384-300-01-0::2.5::HTS,BRD-K28761384-300-01-0,zuclopenthixol,2.5,HTS,MIRNA_hsa-miR-211,MIRNA,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.272562707703175,0.0223061065437,zuclopenthixol,,,0,0
BRD-K28761891-001-10-1::2.5::HTS,BRD-K28761891-001-10-1,ramelteon,2.5,HTS,CRISPR_SPATA8 (145946),AVANA_PUBLIC_18Q2,noncancer,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,insomnia,Launched,0.330952731741472,0.117727856705,ramelteon,,,0,0
BRD-K28822270-001-01-1::2.5::HTS,BRD-K28822270-001-01-1,resminostat,2.5,HTS,Exp_SLC2A4 (ENSG00000181856),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",,,Phase 2,0.34802245594319003,0.271560047358,resminostat,HDAC INHIBITOR,0.3435685487570231,5.918415732720924,-1.251134799869365
BRD-K28824103-001-02-8::2.5::HTS,BRD-K28824103-001-02-8,genipin,2.5,HTS,PROT_Cyclin_B1,PROT,targeted cancer,choleretic agent,,,,Preclinical,0.4331398058052371,0.285367562364,genipin,OTHER,0.4303610560429579,2.646799421316816,-4.277394563311947
BRD-K28824103-001-04-4::2.5::HTS,BRD-K28824103-001-04-4,genipin,2.5,HTS,Exp_PLA2G4D (ENSG00000159337),GE,targeted cancer,choleretic agent,,,,Preclinical,0.4331398058052371,0.281419852603,genipin,,,0,0
BRD-K28849549-001-13-4::2.5::HTS,BRD-K28849549-001-13-4,mesalazine,2.5,HTS,METHYL_NFE2,METHYL,noncancer,"cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2",gastroenterology,"ulcerative colitis, inflammatory bowel disease",Launched,0.267704167852946,0.118810710357,mesalazine,,,0,0
BRD-K28861668-001-01-9::2.5::HTS,BRD-K28861668-001-01-9,A922500,2.5,HTS,PROT_ACC_pS79,PROT,noncancer,diacylglycerol O acyltransferase inhibitor,DGAT1,,,Preclinical,0.255342598208739,0.0726591952474,A922500,,,0,0
BRD-K28863208-001-02-0::2.5::HTS,BRD-K28863208-001-02-0,PNU-282987,2.5,HTS,DEM2_RING1 (6015),DEMETER2_COM,noncancer,cholinergic receptor agonist,CHRNA7,,,Preclinical,0.21460927888816397,0.110892902106,PNU-282987,,,0,0
BRD-K28907958-001-04-3::2.5::HTS,BRD-K28907958-001-04-3,CD-437,2.5,HTS,Exp_ZNF701 (ENSG00000167562),GE,targeted cancer,retinoid receptor agonist,RARG,,,Preclinical,0.33606310301041303,0.219447812612,CD-437,OTHER,0.33832541447311537,4.800914950092278,-1.5710142205255346
BRD-K28912512-001-23-2::2.5::HTS,BRD-K28912512-001-23-2,nicotinamide,2.5,HTS,CRISPR_SLC4A5 (57835),AVANA_PUBLIC_18Q2,noncancer,protein synthesis stimulant,"BST1, LDHA, PARP1, SIRT5",dermatology,acne vulgaris (AV),Launched,0.29246979147109003,0.136007039222,nicotinamide,,,0,0
BRD-K28936863-051-33-0::2.5::HTS,BRD-K28936863-051-33-0,ketotifen,2.5,HTS,MUTpool_UTS2R (2837),MUTpool,noncancer,"histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor","HRH1, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B, PGD",neurology/psychiatry,itching,Launched,0.269079597162649,0.0419259109025,ketotifen,,,0,0
BRD-K28965160-001-01-1::2.5::HTS,BRD-K28965160-001-01-1,BVD-523,2.5,HTS,Exp_ADORA1 (ENSG00000163485),GE,targeted cancer,MAP kinase inhibitor,,,,Phase 1/Phase 2,0.45469222464901904,0.494593790747,BVD-523,OTHER,0.4502816735615523,0.5172629685174357,4.619371065216948
BRD-K28971625-003-01-4::2.5::HTS,BRD-K28971625-003-01-4,ZD-7114,2.5,HTS,PROT_ASNS,PROT,noncancer,adrenergic receptor agonist,ADRB3,,,Phase 1,0.271075422056671,0.0792906201022,ZD-7114,,,0,0
BRD-K28982731-001-01-6::2.5::HTS,BRD-K28982731-001-01-6,emoxipin,2.5,HTS,CRISPR_DENND4A (10260),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 2,0.22607279288219698,0.0707663048681,emoxipin,,,0,0
BRD-K29133151-001-03-2::2.5::HTS,BRD-K29133151-001-03-2,"ICI-185,282",2.5,HTS,Exp_NCF1B (ENSG00000182487),GE,noncancer,thromboxane receptor antagonist,,,,Phase 1,0.288804511243729,0.193058632287,"ICI-185,282",,,0,0
BRD-K29173907-001-09-2::2.5::HTS,BRD-K29173907-001-09-2,isoflupredone-acetate,2.5,HTS,CRISPR_ANP32A (8125),AVANA_PUBLIC_18Q2,noncancer,,NR3C1,,,Preclinical,0.28879779885535,0.128919867488,isoflupredone-acetate,OTHER,0.28704743755613155,-3.770662409879262,-3.2953498341799614
BRD-K29220403-001-10-8::2.5::HTS,BRD-K29220403-001-10-8,eszopiclone,2.5,HTS,MIRNA_hsa-miR-1321,MIRNA,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,insomnia,Launched,0.305164958915905,0.0824163973329,eszopiclone,,,0,0
BRD-K29254801-001-14-7::2.5::HTS,BRD-K29254801-001-14-7,thiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,,JAK2,ophthalmology,contact dermatitis,Launched,0.4005659825417279,0.339556085055,thiram,OTHER,0.40081095712550413,3.794117274647835,-1.3094434346348018
BRD-K29322660-001-01-9::2.5::HTS,BRD-K29322660-001-01-9,edoxaban,2.5,HTS,Exp_FIBP (ENSG00000172500),GE,noncancer,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)",Launched,0.266554952336052,0.103679639574,edoxaban,,,0,0
BRD-K29359156-001-30-1::2.5::HTS,BRD-K29359156-001-30-1,ebselen,2.5,HTS,MUTpool_MANBA (4126),MUTpool,noncancer,"cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor",ALB,,,Phase 2/Phase 3,0.282401254744963,0.0744886512459,ebselen,,,0,0
BRD-K29392254-001-02-2::2.5::HTS,BRD-K29392254-001-02-2,pantothenic-acid,2.5,HTS,Exp_CNN2P4 (ENSG00000213816),GE,noncancer,coenzyme A precursor,,,,Launched,0.22897290074875698,0.0661995557676,pantothenic-acid,,,0,0
BRD-K29395450-001-06-8::2.5::HTS,BRD-K29395450-001-06-8,PIK-93,2.5,HTS,CRISPR_ZNF689 (115509),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PI4KB, PIK3C3, PIK3CG",,,Preclinical,0.36168119494936496,0.208511414279,PIK-93,PI3K INHIBITOR,0.3633863383670989,0.7101886765763821,-1.3442657074484619
BRD-K29458283-001-29-9::2.5::HTS,BRD-K29458283-001-29-9,chlorambucil,2.5,HTS,METHYL_TTC30A,METHYL,chemo,DNA inhibitor,,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",Launched,0.393402883194635,0.161218377385,chlorambucil,OTHER,0.3854771305561472,3.882225857855918,-2.517342141890687
BRD-K29462201-001-01-9::2.5::HTS,BRD-K29462201-001-01-9,deserpidine,2.5,HTS,DEM2_FNTA (2339),DEMETER2_COM,noncancer,angiotensin converting enzyme inhibitor,"ACE, SLC18A2",cardiology,hypertension,Launched,0.276259608759344,0.0752695200023,deserpidine,OTHER,0.2833473131162669,-4.853193437151722,-0.1001675149016088
BRD-K29530284-001-06-2::2.5::HTS,BRD-K29530284-001-06-2,amlexanox,2.5,HTS,PROT_eIF4E,PROT,noncancer,histamine receptor modulator,"FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13","dental, pulmonary, ophthalmology, allergy","aphthous ulcers, asthma, conjunctivitis, allergic rhinitis",Launched,0.259918626572318,0.140401818789,amlexanox,,,0,0
BRD-K29542628-001-03-9::2.5::HTS,BRD-K29542628-001-03-9,1-naphthyl-PP1,2.5,HTS,DEM2_DDX18 (8886),DEMETER2_COM,targeted cancer,src inhibitor,SRC,,,Preclinical,0.259928355881448,0.0262416402658,1-naphthyl-PP1,,,0,0
BRD-K29546239-001-02-3::2.5::HTS,BRD-K29546239-001-02-3,SNC-80,2.5,HTS,PROT_Heregulin,PROT,noncancer,,OPRD1,,,Preclinical,0.285037203224395,-0.00340038625129,SNC-80,,,0,0
BRD-K29570907-001-07-3::2.420672872::MTS004,BRD-K29570907-001-07-3,sulmetozine,2.420672872,MTS004,METHYL_AUNIP,METHYL,noncancer,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD),Launched,0.28383472392197995,0.0831352620535,sulmetozine,,,0,0
BRD-K29582115-066-01-2::2.5::HTS,BRD-K29582115-066-01-2,ziprasidone,2.5,HTS,Exp_RCN1 (ENSG00000049449),GE,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.307232779222948,0.0752920305461,ziprasidone,,,0,0
BRD-K29582677-300-10-6::2.5::HTS,BRD-K29582677-300-10-6,flunarizine,2.5,HTS,DEM2_GTF3C3 (9330),DEMETER2_COM,noncancer,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1","neurology/psychiatry, cardiology","migraine headache, vertigo, peripheral artery disease (PAD)",Launched,0.27397389167596303,0.115129024674,flunarizine,,,0,0
BRD-K29626940-001-01-5::2.682001852::MTS004,BRD-K29626940-001-01-5,imidafenacin,2.682001852,MTS004,MIRNA_hsv1-miR-H1,MIRNA,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM3",neurology/psychiatry,"spasms, spasms",Launched,0.277973342762424,0.0290211504858,imidafenacin,,,0,0
BRD-K29653726-001-13-4::2.5::HTS,BRD-K29653726-001-13-4,topiramate,2.5,HTS,METHYL_TWIST1,METHYL,noncancer,"carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist","CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, migraine headache",Launched,0.34642490584712105,0.131363242488,topiramate,,,0,0
BRD-K29656036-001-02-5::2.5::HTS,BRD-K29656036-001-02-5,MK-8245,2.5,HTS,Exp_IL7R (ENSG00000168685),GE,noncancer,stearoyl-CoA desaturase inhibitor,SCD,,,Phase 2,0.427129417306045,0.272506180001,MK-8245,OTHER,0.4271523510278273,0.11754908459947427,-3.984743531058157
BRD-K29668683-300-02-2::2.5::HTS,BRD-K29668683-300-02-2,BD-1063,2.5,HTS,METABOL_C48:3 TAG,METABOL,noncancer,sigma receptor antagonist,SIGMAR1,,,Preclinical,0.245826644560469,0.0270005315511,BD-1063,,,0,0
BRD-K29673530-001-05-4::2.5::HTS,BRD-K29673530-001-05-4,hypericin,2.5,HTS,METHYL_C14orf183,METHYL,targeted cancer,tyrosine kinase inhibitor,,,,Phase 2,0.333692137076718,0.0508886462309,hypericin,,,0,0
BRD-K29713308-001-01-7::2.5::HTS,BRD-K29713308-001-01-7,mebhydrolin,2.5,HTS,CN_TEK (7010),CN,noncancer,antihistamine,,allergy,"allergic rhinitis, urticaria",Launched,0.274339757082205,0.0564451804251,mebhydrolin,,,0,0
BRD-K29713308-077-04-1::2.5::HTS,BRD-K29713308-077-04-1,"mebhydroline-1,5-naphtalenedisulfonate",2.5,HTS,METHYL_MFSD2A,METHYL,noncancer,,,,,Preclinical,0.274339757082205,0.143205840075,"mebhydroline-1,5-naphtalenedisulfonate",,,0,0
BRD-K29735307-001-02-9::2.5::HTS,BRD-K29735307-001-02-9,ostarine,2.5,HTS,LIN_liver,LIN,targeted cancer,androgen receptor modulator,AR,,,Phase 3,0.26386186961512803,0.0548718084488,ostarine,,,0,0
BRD-K29812331-011-01-7::2.472474424::MTS004,BRD-K29812331-011-01-7,dimemorfan,2.472474424,MTS004,CN_VWA3A (146177),CN,noncancer,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant,Launched,0.246982993857385,0.0512597737414,dimemorfan,,,0,0
BRD-K29834313-001-01-4::2.5::HTS,BRD-K29834313-001-01-4,myricitrin,2.5,HTS,CN_INTS3 (65123),CN,noncancer,PKC inhibitor,"NOS1, PRKCA",,,Preclinical,0.28378945394361893,0.0158571097558,myricitrin,,,0,0
BRD-K29895144-001-01-0::2.5::HTS,BRD-K29895144-001-01-0,SKLB1002,2.5,HTS,METHYL_SYNPO2L,METHYL,targeted cancer,VEGFR inhibitor,KDR,,,Preclinical,0.284488382015333,0.061670661482,SKLB1002,,,0,0
BRD-K29905972-001-06-3::2.5::HTS,BRD-K29905972-001-06-3,axitinib,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),Launched,0.340687193794764,0.320944722315,axitinib,OTHER,0.34224498067386994,3.5341995082138533,-3.3919041857006613
BRD-K29918010-003-04-1::2.5::HTS,BRD-K29918010-003-04-1,glucosamine,2.5,HTS,CRISPR_RHBDD2 (57414),AVANA_PUBLIC_18Q2,noncancer,glycosylated protein precursor,"IFNG, IL1B, MMP9, NFKB2, TNF","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis, joint pain, backache",Launched,0.283957360138197,0.119112029347,glucosamine,,,0,0
BRD-K29950728-048-17-4::2.5::HTS,BRD-K29950728-048-17-4,clomifene,2.5,HTS,CRISPR_TCF7L2 (6934),AVANA_PUBLIC_18Q2,noncancer,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,Launched,0.265456518311105,0.105278588179,clomifene,,,0,0
BRD-K29968218-001-03-2::2.5::HTS,BRD-K29968218-001-03-2,KX2-391,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,"src inhibitor, tubulin polymerization inhibitor",SRC,,,Phase 2,0.397407500559846,0.334663716673,KX2-391,OTHER,0.39573840199389615,5.91990323244767,-2.416818323557817
BRD-K30019776-003-01-5::2.5::HTS,BRD-K30019776-003-01-5,dexfosfoserine,2.5,HTS,CRISPR_SULT1E1 (6783),AVANA_PUBLIC_18Q2,noncancer,membrane integrity inhibitor,"CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2",,,Preclinical,0.23797678117863,0.0508191854562,dexfosfoserine,,,0,0
BRD-K30020243-051-02-5::2.5::HTS,BRD-K30020243-051-02-5,aliskiren-hemifumarate,2.5,HTS,Exp_GLYATL1 (ENSG00000166840),GE,noncancer,renin inhibitor,REN,cardiology,hypertension,Launched,0.284257313679907,0.108724435446,aliskiren-hemifumarate,,,0,0
BRD-K30114692-001-15-9::2.5::HTS,BRD-K30114692-001-15-9,methenamine,2.5,HTS,METHYL_ALKBH8,METHYL,noncancer,bacterial DNA inhibitor,,infectious disease,urinary tract infections,Launched,0.316007507488176,0.0180362148406,methenamine,,,0,0
BRD-K30126819-304-02-7::2.5::HTS,BRD-K30126819-304-02-7,dimesna,2.5,HTS,METABOL_C18:2 LPC,METABOL,noncancer,tubulin polymerization inhibitor,,,,Phase 3,0.257559833446657,0.0539801108749,dimesna,,,0,0
BRD-K30159788-001-01-9::2.49998123::MTS004,BRD-K30159788-001-01-9,RSV604,2.49998123,MTS004,CRISPR_PRPH (5630),AVANA_PUBLIC_18Q2,noncancer,RSV replication inhibitor,,,,Phase 2,0.22732746680717603,0.149355754356,RSV604,,,0,0
BRD-K30213273-001-01-6::2.5::HTS,BRD-K30213273-001-01-6,fenofibric-acid,2.5,HTS,METABOL_C18:1 SM,METABOL,noncancer,cytochrome P450 inhibitor,"CLCN1, PPARA",cardiology,dyslipidemia,Launched,0.26152183668807505,0.0825341913596,fenofibric-acid,,,0,0
BRD-K30237152-300-02-5::2.5::HTS,BRD-K30237152-300-02-5,1400W,2.5,HTS,CRISPR_ZNF18 (7566),AVANA_PUBLIC_18Q2,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,Preclinical,0.306352120055896,0.132648304501,1400W,,,0,0
BRD-K30240666-051-15-9::2.5::HTS,BRD-K30240666-051-15-9,clemastine,2.5,HTS,METHYL_ACOT6,METHYL,noncancer,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",Launched,0.289020748512823,0.0376143621565,clemastine,,,0,0
BRD-K30331124-001-01-7::2.5::HTS,BRD-K30331124-001-01-7,ASC-J9,2.5,HTS,Exp_RPRML (ENSG00000179673),GE,targeted cancer,androgen receptor enhancer,AR,,,Phase 2,0.248381201528847,0.132279576061,ASC-J9,,,0,0
BRD-K30373883-001-02-8::2.5::HTS,BRD-K30373883-001-02-8,dutasteride,2.5,HTS,CN_FAM90A10P (441328),CN,noncancer,5 alpha reductase inhibitor,"SRD5A1, SRD5A2",urology,benign prostatic hyperplasia (BPH),Launched,0.308358333696073,0.0523849785899,dutasteride,,,0,0
BRD-K30374899-001-09-3::2.5::HTS,BRD-K30374899-001-09-3,mannitol-D,2.5,HTS,PROT_XBP1_Caution,PROT,noncancer,diuretic,,"neurology/psychiatry, ophthalmology, gastroenterology","intracranial pressure, intraocular pressure, constipation",Launched,0.22199623584108,0.0162657125022,mannitol-D,,,0,0
BRD-K30421593-050-04-9::2.5::HTS,BRD-K30421593-050-04-9,timolol,2.5,HTS,MIRNA_hsa-miR-1254,MIRNA,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"ocular hypertension, glaucoma",Launched,0.266100860822704,0.0224867170789,timolol,,,0,0
BRD-K30431096-004-01-3::2.5::HTS,BRD-K30431096-004-01-3,domiphen,2.5,HTS,METHYL_HGD,METHYL,noncancer,,,,,Preclinical,0.36565700575642296,0.100502262781,domiphen,OTHER,0.3640408958266119,3.137800784900292,-2.2768948312080135
BRD-K30466858-001-09-6::2.5::HTS,BRD-K30466858-001-09-6,ellagic-acid,2.5,HTS,METHYL_PTPLAD1,METHYL,targeted cancer,"glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor","CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK",,,Phase 2,0.268502719484761,0.0660422224821,ellagic-acid,,,0,0
BRD-K30480208-001-18-5::2.5::HTS,BRD-K30480208-001-18-5,torasemide,2.5,HTS,RMUTmis_ALK (238),MUT,noncancer,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension",Launched,0.29649962100776,0.0657814600483,torasemide,,,0,0
BRD-K30485548-050-01-6::2.479775098::MTS004,BRD-K30485548-050-01-6,sumanirole,2.479775098,MTS004,METABOL_pipecolic acid,METABOL,noncancer,dopamine receptor agonist,DRD2,,,Phase 3,0.272433963053153,0.104193544742,sumanirole,,,0,0
BRD-K30519779-001-03-1::2.5::HTS,BRD-K30519779-001-03-1,homoquinolinic-acid,2.5,HTS,MIRNA_hsa-miR-27a,MIRNA,noncancer,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Preclinical,0.27877074064138896,0.082784220103,homoquinolinic-acid,,,0,0
BRD-K30550578-001-01-3::2.5::HTS,BRD-K30550578-001-01-3,PF-04620110,2.5,HTS,CRISPR_TICAM1 (148022),AVANA_PUBLIC_18Q2,noncancer,diacylglycerol O acyltransferase inhibitor,DGAT1,,,Phase 1,0.282619085030251,0.162799227696,PF-04620110,,,0,0
BRD-K30553453-001-13-2::2.5::HTS,BRD-K30553453-001-13-2,hesperetin,2.5,HTS,DEM2_GABRR3 (200959),DEMETER2_COM,targeted cancer,ACAT inhibitor,"DGAT1, MTTP, SOAT1, SOAT2",,,Launched,0.256232805104591,0.142127649678,hesperetin,,,0,0
BRD-K30563334-001-02-9::2.5::HTS,BRD-K30563334-001-02-9,rifabutin,2.5,HTS,Exp_BAP1 (ENSG00000163930),GE,noncancer,protein synthesis inhibitor,"HSP90AA1, HSP90B1",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.278563846789322,0.155528606302,rifabutin,,,0,0
BRD-K30572193-001-02-0::2.5::HTS,BRD-K30572193-001-02-0,CTEP,2.5,HTS,METHYL_CITED2,METHYL,noncancer,glutamate receptor antagonist,GRM5,,,Preclinical,0.303033206636148,0.0379606199616,CTEP,,,0,0
BRD-K30577245-001-04-3::2.5::HTS,BRD-K30577245-001-04-3,docetaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)",Launched,0.373500390599039,0.25555168675,docetaxel,TUBULIN POLYMERIZATION INHIBITOR,0.3200138251347359,6.165900811579388,-1.8610676981893064
BRD-K30577245-341-01-9::2.5::HTS,BRD-K30577245-341-01-9,docetaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)",Launched,0.373500390599039,0.25555168675,docetaxel,TUBULIN POLYMERIZATION INHIBITOR,0.3753999016741466,5.027236624014705,-1.4301151028779646
BRD-K30634073-046-01-0::2.5::HTS,BRD-K30634073-046-01-0,levallorphan,2.5,HTS,CN_PHF21B (112885),CN,noncancer,opioid antagonist,"CHRNA2, OPRM1",pulmonary,respiratory depression,Launched,0.33333256686291496,0.0447043367521,levallorphan,,,0,0
BRD-K30649484-003-13-7::2.5::HTS,BRD-K30649484-003-13-7,mafenide,2.5,HTS,Exp_ZFAND2A (ENSG00000178381),GE,noncancer,carbonic anhydrase inhibitor,"CA12, CA14, CA2, CA4, CA6, CA9",infectious disease,"first-aid antibiotic, skin infections",Launched,0.265928255323429,0.118223719806,mafenide,,,0,0
BRD-K30652337-004-02-1::2.5::HTS,BRD-K30652337-004-02-1,eletriptan,2.5,HTS,METABOL_lactose,METABOL,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,Launched,0.274408828830477,0.0808970655082,eletriptan,,,0,0
BRD-K30685142-001-15-4::2.5::HTS,BRD-K30685142-001-15-4,levothyroxine,2.5,HTS,DEM2_LAMB3 (3914),DEMETER2_COM,noncancer,thyroid hormone stimulant,"THRA, THRB",endocrinology,myxedema coma,Launched,0.282911488416777,0.114641892008,levothyroxine,,,0,0
BRD-K30707190-001-04-1::2.5::HTS,BRD-K30707190-001-04-1,PNU-74654,2.5,HTS,METHYL_ZBTB20,METHYL,targeted cancer,beta-catenin inhibitor,"CTNNB1, TCF4",,,Preclinical,0.27498929949073897,0.1380124593,PNU-74654,,,0,0
BRD-K30758549-001-01-8::2.5::HTS,BRD-K30758549-001-01-8,isopropyl-palmitate,2.5,HTS,MIRNA_hsa-miR-657,MIRNA,noncancer,cosmetic moisturizer,,dermatology,cosmetic,Launched,0.31386681535737393,0.0857644919958,isopropyl-palmitate,,,0,0
BRD-K30764557-001-01-5::2.5::MTS004,BRD-K30764557-001-01-5,miocamycin,2.5,MTS004,Exp_IGFL4 (ENSG00000204869),GE,noncancer,other antibiotic,,infectious disease,"urinary tract infections, chlamydia",Launched,0.30672633451422804,0.11458004113,miocamycin,,,0,0
BRD-K30867024-003-03-3::2.5::HTS,BRD-K30867024-003-03-3,SB-216641,2.5,HTS,MIRNA_hsa-miR-760,MIRNA,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,Preclinical,0.40201028818670204,0.104074752122,SB-216641,OTHER,0.3966323975235743,1.0145996646890487,-2.4339608529227394
BRD-K30933884-001-01-0::2.5::HTS,BRD-K30933884-001-01-0,UNBS-5162,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,CC chemokine receptor antagonist,,,,Phase 1,0.503728812451808,0.462857398265,UNBS-5162,OTHER,0.5055852577161933,3.1258046329141917,-4.251114945360008
BRD-K30977212-001-02-8::2.5::HTS,BRD-K30977212-001-02-8,PIK-293,2.5,HTS,PROT_Collagen_VI,PROT,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Preclinical,0.270066812830823,0.0855843990019,PIK-293,,,0,0
BRD-K30990140-003-02-4::2.5::HTS,BRD-K30990140-003-02-4,FR-122047,2.5,HTS,CRISPR_PBK (55872),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,,,,Preclinical,0.251081197493664,0.153369381598,FR-122047,,,0,0
BRD-K31054881-300-04-7::2.5::HTS,BRD-K31054881-300-04-7,BMY-7378,2.5,HTS,DEM2_IQGAP1 (8826),DEMETER2_COM,noncancer,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A",,,Preclinical,0.2773988725565639,0.0859115412911,BMY-7378,,,0,0
BRD-K31086665-005-04-6::2.5::HTS,BRD-K31086665-005-04-6,NH125,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,eukaryotic translation elongation factor 2 inhibitor,,,,Preclinical,0.312206159320351,0.31232444094,NH125,OTHER,0.3120689225871371,3.985445109735719,-1.6220628130240424
BRD-K31092604-003-03-5::2.5::HTS,BRD-K31092604-003-03-5,donitriptan,2.5,HTS,DEM2_GPR37 (2861),DEMETER2_COM,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6",,,Phase 2,0.261586400301922,0.0367244939768,donitriptan,,,0,0
BRD-K31111078-001-04-2::2.5::HTS,BRD-K31111078-001-04-2,dimethyl-fumarate,2.5,HTS,CRISPR_CAPSL (133690),AVANA_PUBLIC_18Q2,noncancer,"nuclear factor erythroid derived, like (NRF2) activator",KEAP1,neurology/psychiatry,multiple sclerosis,Launched,0.20200052614563302,0.17434348067,dimethyl-fumarate,,,0,0
BRD-K31135544-001-07-0::2.5::HTS,BRD-K31135544-001-07-0,IB-MECA,2.5,HTS,PROT_TIGAR,PROT,targeted cancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Phase 3,0.266747429911698,0.0561096221143,IB-MECA,,,0,0
BRD-K31283835-048-04-4::2.5::HTS,BRD-K31283835-048-04-4,tofacitinib,2.5,HTS,CRISPR_AVL9 (23080),AVANA_PUBLIC_18Q2,noncancer,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",rheumatology,rheumatoid arthritis,Launched,0.289423959791533,0.140511400585,tofacitinib,,,0,0
BRD-K31309378-001-01-5::2.5::HTS,BRD-K31309378-001-01-5,lucitanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,Phase 2,0.3929726761430539,0.349685559839,lucitanib,OTHER,0.3927501337186822,2.3923401357074705,-1.4849731669084938
BRD-K31313613-003-04-2::2.5::HTS,BRD-K31313613-003-04-2,BS-181,2.5,HTS,PROT_Beclin_Caution,PROT,targeted cancer,CDK inhibitor,CDK7,,,Preclinical,0.258870492305642,0.104483326571,BS-181,,,0,0
BRD-K31339321-001-03-6::2.5::HTS,BRD-K31339321-001-03-6,lirimilast,2.5,HTS,METHYL_SLC1A4,METHYL,noncancer,phosphodiesterase inhibitor,,,,Phase 2,0.28753856961390695,0.104478215126,lirimilast,,,0,0
BRD-K31385749-003-01-3::2.5::HTS,BRD-K31385749-003-01-3,ivabradine,2.5,HTS,RMUTmis_ADRA1A (148),MUTmis,noncancer,"HCN channel antagonist, potassium channel blocker, sodium channel blocker","HCN1, HCN3, HCN4",cardiology,angina pectoris,Launched,0.23828065356491,0.0717521774374,ivabradine,,,0,0
BRD-K31417912-001-01-9::2.499995989::MTS004,BRD-K31417912-001-01-9,PF-3274167,2.499995989,MTS004,DEM2_RRAGC (64121),DEMETER2_COM,noncancer,oxytocin receptor antagonist,"AVPR1A, OXTR",,,Phase 2,0.262415031789895,0.156039775672,PF-3274167,,,0,0
BRD-K31468676-237-01-8::2.5::HTS,BRD-K31468676-237-01-8,oxonic-acid,2.5,HTS,DEM2_APOOL (139322),DEMETER2_COM,noncancer,uricase inhibitor,,,,Preclinical,0.18343356219932802,0.059823868558,oxonic-acid,,,0,0
BRD-K31476763-001-01-5::2.5::HTS,BRD-K31476763-001-01-5,AZD9668,2.5,HTS,CRISPR_CSTF1 (1477),AVANA_PUBLIC_18Q2,noncancer,elastase inhibitor,ELANE,,,Phase 2,0.40848270358337896,0.235871369078,AZD9668,OTHER,0.35006780042554403,4.066789464799645,-3.0490843724072985
BRD-K31491153-003-05-9::2.5::HTS,BRD-K31491153-003-05-9,1-phenylbiguanide,2.5,HTS,DEM2_MMRN2 (79812),DEMETER2_COM,noncancer,serotonin receptor agonist,"HTR3A, HTR3B",,,Preclinical,0.319026804756896,0.0789194912685,1-phenylbiguanide,,,0,0
BRD-K31495718-001-01-1::2.5::HTS,BRD-K31495718-001-01-1,AZD7687,2.5,HTS,Exp_BAP1 (ENSG00000163930),GE,noncancer,diacylglycerol O acyltransferase inhibitor,DGAT1,,,Phase 1,0.30296031679819896,0.0867406284184,AZD7687,,,0,0
BRD-K31519811-001-02-2::2.5::HTS,BRD-K31519811-001-02-2,PF-02545920,2.5,HTS,DEM2_HSPA8 (3312),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,PDE10A,,,Phase 2,0.323800632314393,0.0266736857902,PF-02545920,,,0,0
BRD-K31553034-001-03-0::2.5::HTS,BRD-K31553034-001-03-0,zibotentan,2.5,HTS,METHYL_NXT1,METHYL,targeted cancer,endothelin receptor antagonist,EDNRA,,,Phase 3,0.25872019166814497,0.144233625567,zibotentan,,,0,0
BRD-K31560319-001-01-5::2.5::HTS,BRD-K31560319-001-01-5,olvanil,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,TRPV agonist,"CNR1, GPR119, TRPV1",,,Preclinical,0.36979166994586204,0.0293044281829,olvanil,,,0,0
BRD-K31627533-001-09-5::2.5::HTS,BRD-K31627533-001-09-5,rimexolone,2.5,HTS,CRISPR_SLC19A1 (6573),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,Launched,0.309402841604276,0.1076601938,rimexolone,GLUCOCORTICOID RECEPTOR AGONIST,0.3104141890206382,-1.9828873110800969,-3.098194298867352
BRD-K31633810-003-02-8::2.5::HTS,BRD-K31633810-003-02-8,DAU-5884,2.5,HTS,Exp_SLC2A14 (ENSG00000173262),GE,noncancer,acetylcholine receptor antagonist,CHRM3,,,Preclinical,0.251555559778409,0.0725228604412,DAU-5884,,,0,0
BRD-K31682896-001-24-0::2.5::HTS,BRD-K31682896-001-24-0,sulfamethizole,2.5,HTS,METABOL_C48:3 TAG,METABOL,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.28003766293873805,0.0654612632912,sulfamethizole,,,0,0
BRD-K31698212-001-02-9::2.5::HTS,BRD-K31698212-001-02-9,icotinib,2.5,HTS,Exp_EGFR (ENSG00000146648),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.35067050013004397,0.298859125169,icotinib,EGFR INHIBITOR,0.3445224455852446,1.2632169200016734,-4.8960343770435575
BRD-K31731454-237-02-5::2.5::HTS,BRD-K31731454-237-02-5,pemirolast,2.5,HTS,CRISPR_FAM76A (199870),AVANA_PUBLIC_18Q2,noncancer,mediator release inhibitor,HRH1,pulmonary,asthma,Launched,0.25000209312501603,0.111287414848,pemirolast,,,0,0
BRD-K31802667-001-01-9::2.530781625::MTS004,BRD-K31802667-001-01-9,JNJ-37822681,2.530781625,MTS004,DEM2_WDR48 (57599),DEMETER2_COM,noncancer,dopamine receptor antagonist,DRD2,,,Phase 2,0.27623372061152,0.0107832842363,JNJ-37822681,,,0,0
BRD-K31812033-003-11-0::2.5::HTS,BRD-K31812033-003-11-0,levobunolol,2.5,HTS,METHYL_CLIC6,METHYL,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension",Launched,0.28461179948618703,0.0687184198375,levobunolol,,,0,0
BRD-K31841515-001-07-8::2.5::HTS,BRD-K31841515-001-07-8,oxypurinol,2.5,HTS,CRISPR_WWC1 (23286),AVANA_PUBLIC_18Q2,noncancer,xanthine oxidase inhibitor,XDH,,,Phase 2/Phase 3,0.315865707225729,0.0360631929097,oxypurinol,,,0,0
BRD-K31843556-001-04-1::2.5::HTS,BRD-K31843556-001-04-1,T-0070907,2.5,HTS,METHYL_MSANTD3-TMEFF1,METHYL,noncancer,PPAR receptor antagonist,PPARG,,,Preclinical,0.23449790669626103,0.0538917000643,T-0070907,,,0,0
BRD-K31866293-001-01-6::2.5::HTS,BRD-K31866293-001-01-6,TAK-632,2.5,HTS,Exp_CHST15 (ENSG00000182022),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.39234576780911495,0.467082193446,TAK-632,RAF INHIBITOR,0.38893095634520697,0.682512945067741,4.273751896626126
BRD-K31920458-001-23-6::2.5::HTS,BRD-K31920458-001-23-6,mestranol,2.5,HTS,METHYL_MIR6878,METHYL,noncancer,estrogen receptor agonist,ESR1,endocrinology,contraceptive,Launched,0.286242037243768,0.0796524092807,mestranol,,,0,0
BRD-K31928526-001-02-1::2.5::HTS,BRD-K31928526-001-02-1,barasertib,2.5,HTS,Exp_RCOR2 (ENSG00000167771),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Phase 2/Phase 3,0.343978207981335,0.26548781931,barasertib,AURORA KINASE INHIBITOR,0.344694962171153,4.115935773880047,-3.445905733788486
BRD-K32007074-001-02-9::3.16::HTS,BRD-K32007074-001-02-9,enocitabine,3.16,HTS,MUTpool_ZNF711 (7552),MUTpool,chemo,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",,,Launched,0.276591421832281,0.0956375748906,enocitabine,OTHER,0.2794283781471642,4.2389972107935225,-0.7898665017277167
BRD-K32021043-001-14-3::2.5::HTS,BRD-K32021043-001-14-3,sulfachlorpyridazine,2.5,HTS,CRISPR_CRHR2 (1395),AVANA_PUBLIC_18Q2,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.31208053159965304,0.0686845747817,sulfachlorpyridazine,,,0,0
BRD-K32101625-001-01-6::2.5::HTS,BRD-K32101625-001-01-6,LX1031,2.5,HTS,MIRNA_hsa-miR-520d-3p,MIRNA,noncancer,tryptophan hydroxylase inhibitor,TPH1,,,Phase 2,0.34330615390254,0.0314404084808,LX1031,,,0,0
BRD-K32107296-001-16-9::2.5::HTS,BRD-K32107296-001-16-9,temozolomide,2.5,HTS,METHYL_LMF1,METHYL,chemo,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma",Launched,0.294030367702562,0.104684182298,temozolomide,,,0,0
BRD-K32164935-001-30-8::2.5::HTS,BRD-K32164935-001-30-8,tolazamide,2.5,HTS,CN_FAM19A2 (338811),CN,noncancer,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,Launched,0.32175714929933896,0.0854646700326,tolazamide,,,0,0
BRD-K32218650-001-01-6::2.5::HTS,BRD-K32218650-001-01-6,MBX-2982,2.5,HTS,METHYL_LOC101928940,METHYL,noncancer,glucose dependent insulinotropic receptor agonist,GPR119,,,Phase 2,0.274583110612233,0.0535905249797,MBX-2982,,,0,0
BRD-K32247306-001-29-4::2.5::HTS,BRD-K32247306-001-29-4,primidone,2.5,HTS,Exp_TRGV6 (ENSG00000226212),GE,noncancer,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.271635578588662,0.0429881083836,primidone,,,0,0
BRD-K32256160-001-01-9::2.499998021::MTS004,BRD-K32256160-001-01-9,solithromycin,2.499998021,MTS004,MIRNA_hsa-miR-137,MIRNA,noncancer,protein synthesis inhibitor,,,,Phase 3,0.296962693751036,0.227684096465,solithromycin,,,0,0
BRD-K32273377-001-17-9::2.5::HTS,BRD-K32273377-001-17-9,sulfadiazine,2.5,HTS,MIRNA_hsa-miR-605,MIRNA,noncancer,bacterial antifolate,,"infectious disease, ophthalmology","malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid",Launched,0.298934488560969,0.103734271045,sulfadiazine,,,0,0
BRD-K32285926-001-02-1::2.5::HTS,BRD-K32285926-001-02-1,AMG-208,2.5,HTS,METHYL_CALB1,METHYL,targeted cancer,tyrosine kinase inhibitor,MET,,,Phase 1,0.28180184393518,0.131010283354,AMG-208,,,0,0
BRD-K32289541-001-01-0::2.5::HTS,BRD-K32289541-001-01-0,EHop-016,2.5,HTS,RMUTmis_KIF2B (84643),MUTmis,targeted cancer,Ras GTPase inhibitor,"RAC1, RAC3",,,Preclinical,0.25852425474213897,-0.0574186360649,EHop-016,,,0,0
BRD-K32292990-001-03-6::2.5::HTS,BRD-K32292990-001-03-6,CGP-53353,2.5,HTS,CRISPR_SRSF12 (135295),AVANA_PUBLIC_18Q2,targeted cancer,"EGFR inhibitor, PKC inhibitor","EGFR, PRKCB",,,Preclinical,0.28094986119516807,0.10114407272,CGP-53353,,,0,0
BRD-K32311154-001-01-0::2.5::HTS,BRD-K32311154-001-01-0,nifekalant,2.5,HTS,DEM2_CENPF (1063),DEMETER2_COM,noncancer,potassium channel blocker,,cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)",Launched,0.283460362958783,0.103383186756,nifekalant,,,0,0
BRD-K32318651-001-23-7::2.5::HTS,BRD-K32318651-001-23-7,acyclovir,2.5,HTS,CRISPR_DDX31 (64794),AVANA_PUBLIC_18Q2,noncancer,DNA polymerase inhibitor,PNP,infectious disease,"genitial herpes, shingles, chicken pox",Launched,0.29226272201506603,0.0364856404276,acyclovir,,,0,0
BRD-K32318651-001-24-5::2.5::HTS,BRD-K32318651-001-24-5,acyclovir,2.5,HTS,RMUTmis_GTF3C1 (2975),MUTmis,noncancer,DNA polymerase inhibitor,PNP,infectious disease,"genitial herpes, shingles, chicken pox",Launched,0.261812641170871,0.0964923539013,acyclovir,,,0,0
BRD-K32372024-001-01-0::2.5::HTS,BRD-K32372024-001-01-0,D-7193,2.5,HTS,CN_PCDH17 (27253),CN,noncancer,,,,,Phase 2,0.28775937318188105,0.10584157974,D-7193,,,0,0
BRD-K32405725-001-02-8::2.5::HTS,BRD-K32405725-001-02-8,etomoxir,2.5,HTS,METHYL_FNDC7,METHYL,noncancer,carnitine palmitoyltransferase inhibitor,CPT1A,,,Phase 2,0.27179969671097404,0.00793697911812,etomoxir,,,0,0
BRD-K32501161-300-06-2::2.5::HTS,BRD-K32501161-300-06-2,vanoxerine,2.5,HTS,MIRNA_hsa-miR-515-5p,MIRNA,noncancer,dopamine uptake inhibitor,SLC6A3,,,Phase 3,0.247589044717197,0.115202455886,vanoxerine,,,0,0
BRD-K32572029-001-04-4::2.5::HTS,BRD-K32572029-001-04-4,orotic-acid,2.5,HTS,Exp_IFITM4P (ENSG00000235821),GE,noncancer,,DHODH,,,Phase 2,0.23752739577634804,-0.0517862964127,orotic-acid,,,0,0
BRD-K32730239-001-01-0::2.5::HTS,BRD-K32730239-001-01-0,SU3327,2.5,HTS,Exp_ABCC1 (ENSG00000103222),GE,noncancer,JNK inhibitor,MAPK8,,,Preclinical,0.343122713819,0.416842992728,SU3327,OTHER,0.3486617695142661,4.346254591983551,-1.6396705772133318
BRD-K32744045-001-31-2::2.5::HTS,BRD-K32744045-001-31-2,disulfiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,Launched,0.41909359351696507,0.385017397154,disulfiram,OTHER,0.41989092976234177,3.733317542020092,-1.597935388096854
BRD-K32768103-051-02-6::2.5::HTS,BRD-K32768103-051-02-6,vonoprazan,2.5,HTS,METHYL_CC2D1B,METHYL,noncancer,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD),Launched,0.25390251586244894,0.0143815103216,vonoprazan,,,0,0
BRD-K32804101-001-01-8::2.5::MTS004,BRD-K32804101-001-01-8,valrocemide,2.5,MTS004,METHYL_TNFRSF19,METHYL,noncancer,,,,,Phase 2,0.27935827468888397,0.091192766937,valrocemide,,,0,0
BRD-K32821942-001-21-3::2.5::HTS,BRD-K32821942-001-21-3,azathioprine,2.5,HTS,Exp_CAD (ENSG00000084774),GE,noncancer,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis",Launched,0.33892268094694505,0.234087532194,azathioprine,OTHER,0.3382316419620231,3.6619139241322434,-3.953704927607121
BRD-K32830106-001-02-6::2.5::HTS,BRD-K32830106-001-02-6,guanfacine,2.5,HTS,DEM2_OAT (4942),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,Launched,0.264656070019532,0.127509600055,guanfacine,,,0,0
BRD-K32830106-003-20-4::2.5::HTS,BRD-K32830106-003-20-4,guanfacine,2.5,HTS,METHYL_HLTF,METHYL,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,Launched,0.264656070019532,0.0706333899958,guanfacine,,,0,0
BRD-K32842773-434-01-8::2.5::MTS004,BRD-K32842773-434-01-8,pemetrexed,2.5,MTS004,Exp_TIGIT (ENSG00000181847),GE,targeted cancer,"dihydrofolate reductase inhibitor, thymidylate synthase inhibitor","ATIC, DHFR, GART, TYMS",oncology,"non-small cell lung cancer (NSCLC), mesothelioma",Launched,0.329596515580604,0.145991309188,pemetrexed,OTHER,0.3290545890871922,3.664497843882424,-3.220893509417129
BRD-K32847234-065-04-6::2.5::HTS,BRD-K32847234-065-04-6,sparteine-sulfate,2.5,HTS,Exp_FUT11 (ENSG00000196968),GE,noncancer,,,,,Launched,0.224300755963976,0.117686607367,sparteine-sulfate,,,0,0
BRD-K32891457-001-15-5::2.719791572::MTS004,BRD-K32891457-001-15-5,cortodoxone,2.719791572,MTS004,CN_OR4K15 (81127),CN,noncancer,androgen receptor antagonist,AR,,,Phase 3,0.298189288157758,0.0981881089677,cortodoxone,,,0,0
BRD-K32977963-001-05-0::2.5::HTS,BRD-K32977963-001-05-0,eugenol,2.5,HTS,CN_PGA4 (643847),CN,noncancer,androgen receptor antagonist,AR,dental,toothache,Launched,0.301513233141651,0.0918300107331,eugenol,,,0,0
BRD-K33082088-001-03-3::2.5::HTS,BRD-K33082088-001-03-3,retapamulin,2.5,HTS,CRISPR_HIST1H4H (8365),AVANA_PUBLIC_18Q2,noncancer,protein synthesis inhibitor,,infectious disease,impetigo,Launched,0.33968623462184494,0.138291443075,retapamulin,,,0,0
BRD-K33127281-001-05-6::2.5::HTS,BRD-K33127281-001-05-6,adapalene,2.5,HTS,Exp_ZNF674 (ENSG00000251192),GE,noncancer,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),Launched,0.36904519768391,0.233677823201,adapalene,OTHER,0.3635975067078575,3.1709125200711807,-2.861526684331369
BRD-K33131085-001-07-2::2.644499841::MTS004,BRD-K33131085-001-07-2,gentiopicrin,2.644499841,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,glutamate receptor downregulator,GRIN2B,,,Phase 3,0.28836926041905603,0.116135731837,gentiopicrin,OTHER,0.28762549686130234,2.4183123786405183,4.797475539094362
BRD-K33133047-001-01-8::2.5::MTS004,BRD-K33133047-001-01-8,dapiprazole,2.5,MTS004,METHYL_FCGRT,METHYL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",ophthalmology,mydriasis,Launched,0.269372474429223,0.0360501806564,dapiprazole,,,0,0
BRD-K33141550-003-05-7::2.5::HTS,BRD-K33141550-003-05-7,L-NAME,2.5,HTS,DEM2_IFRD2 (7866),DEMETER2_COM,noncancer,nitric oxide synthase inhibitor,NOS3,,,Phase 2/Phase 3,0.296423232429529,0.100949993663,L-NAME,,,0,0
BRD-K33151569-003-09-7::2.5::HTS,BRD-K33151569-003-09-7,deoxyepinephrine,2.5,HTS,PROT_Smad1,PROT,noncancer,"adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2",,,Preclinical,0.26320459276972197,0.111961146178,deoxyepinephrine,,,0,0
BRD-K33183200-303-02-4::2.5::HTS,BRD-K33183200-303-02-4,imetit,2.5,HTS,CN_MICU1 (10367),CN,noncancer,histamine receptor agonist,"HRH3, HRH4",,,Preclinical,0.272785817845746,0.0430285653751,imetit,,,0,0
BRD-K33211335-004-01-7::2.5::HTS,BRD-K33211335-004-01-7,dextromethorphan,2.5,HTS,PROT_Smad4,PROT,noncancer,"glutamate receptor antagonist, sigma receptor agonist","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4",pulmonary,cough suppressant,Launched,0.28392346819769604,0.0669133678826,dextromethorphan,,,0,0
BRD-K33219225-001-01-9::2.5::HTS,BRD-K33219225-001-01-9,allylisothiocyanate,2.5,HTS,DEM2_ABCA3 (21),DEMETER2_COM,noncancer,TRPV agonist,TRPA1,,,Preclinical,0.263809463803584,0.0100970594192,allylisothiocyanate,,,0,0
BRD-K33226500-001-01-0::2.5::HTS,BRD-K33226500-001-01-0,indinavir,2.5,HTS,METHYL_SHF,METHYL,noncancer,HIV protease inhibitor,"CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.253929220701033,-0.0180746970437,indinavir,,,0,0
BRD-K33240821-001-06-2::2.50000539::MTS004,BRD-K33240821-001-06-2,plerixafor,2.50000539,MTS004,MIRNA_hsa-miR-296-5p,MIRNA,targeted cancer,CC chemokine receptor antagonist,"ACKR3, CCR4, CXCR4",hematologic malignancy,"non-Hodgkin lymphoma (NHL), multiple myeloma",Launched,0.266970657401689,0.0761400665835,plerixafor,,,0,0
BRD-K33245965-001-03-4::2.50001558::MTS004,BRD-K33245965-001-03-4,BMS-833923,2.50001558,MTS004,Exp_GLYATL1 (ENSG00000166840),GE,targeted cancer,smoothened receptor antagonist,SMO,,,Phase 2,0.305759507229064,0.0952898458542,BMS-833923,,,0,0
BRD-K33251802-001-01-3::2.5::HTS,BRD-K33251802-001-01-3,miglustat,2.5,HTS,PROT_Bax,PROT,noncancer,Glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,Launched,0.267211399872008,0.0707453635681,miglustat,,,0,0
BRD-K33379087-001-07-5::2.5::HTS,BRD-K33379087-001-07-5,tivantinib,2.5,HTS,Exp_TCOF1 (ENSG00000070814),GE,targeted cancer,tyrosine kinase inhibitor,MET,,,Phase 3,0.4408612872920539,0.251904243218,tivantinib,OTHER,0.44582229502099385,5.092937202827745,-2.8863365440960163
BRD-K33396764-001-08-7::0.25::HTS,BRD-K33396764-001-08-7,alpha-linolenic-acid,0.25,HTS,PROT_MEK1_pS217_S221,PROT,noncancer,omega 3 fatty acid stimulant,"ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1",,,Phase 3,0.26812880101657505,0.0685548625272,alpha-linolenic-acid,,,0,0
BRD-K33425534-001-12-5::2.5::HTS,BRD-K33425534-001-12-5,exemestane,2.5,HTS,DEM2_CEP250 (11190),DEMETER2_COM,targeted cancer,aromatase inhibitor,CYP19A1,oncology,breast cancer,Launched,0.25032666204519,0.0737058701153,exemestane,,,0,0
BRD-K33453211-003-11-5::2.5::HTS,BRD-K33453211-003-11-5,levocabastine,2.5,HTS,METABOL_NAD,METABOL,noncancer,histamine receptor antagonist,"HRH1, NTSR2",ophthalmology,conjunctivitis,Launched,0.257139474645087,0.0435570481408,levocabastine,,,0,0
BRD-K33459542-001-07-4::2.5::HTS,BRD-K33459542-001-07-4,ditolylguanidine,2.5,HTS,METABOL_C52:2 TAG,METABOL,noncancer,sigma receptor agonist,"GRIN1, GRIN2A, GRIN2B, SIGMAR1",,,Preclinical,0.29021410406827697,0.101548489772,ditolylguanidine,,,0,0
BRD-K33483813-001-10-0::2.5::HTS,BRD-K33483813-001-10-0,actarit,2.5,HTS,METABOL_creatinine,METABOL,noncancer,interleukin receptor agonist,,rheumatology,rheumatoid arthritis,Launched,0.301396698290233,0.0238612331018,actarit,,,0,0
BRD-K33510429-001-03-1::2.5::HTS,BRD-K33510429-001-03-1,vanillylacetone,2.5,HTS,Exp_TGFBR2 (ENSG00000163513),GE,noncancer,,,,,Preclinical,0.265427964455486,0.0820067116083,vanillylacetone,,,0,0
BRD-K33583600-001-16-1::2.5::HTS,BRD-K33583600-001-16-1,isoliquiritigenin,2.5,HTS,METHYL_EIF2AK3,METHYL,targeted cancer,guanylate cyclase activator,GABBR1,,,Preclinical,0.19598902602263604,0.10558897691,isoliquiritigenin,,,0,0
BRD-K33588785-001-01-9::2.5::HTS,BRD-K33588785-001-01-9,obidoxime,2.5,HTS,METABOL_isoleucine,METABOL,noncancer,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",Launched,0.25522420565466003,0.0528758435214,obidoxime,,,0,0
BRD-K33610132-001-02-9::2.5::HTS,BRD-K33610132-001-02-9,rociletinib,2.5,HTS,Exp_TET3 (ENSG00000187605),GE,targeted cancer,EGFR inhibitor,EGFR,,,Phase 3,0.337357749914565,0.337756462072,rociletinib,EGFR INHIBITOR,0.3374139766790705,2.526545384767147,-3.4928259241722017
BRD-K33622447-066-01-9::2.5::HTS,BRD-K33622447-066-01-9,abemaciclib,2.5,HTS,Exp_EIF2D (ENSG00000143486),GE,targeted cancer,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,Launched,0.36781875448140794,0.32415152461,abemaciclib,CDK INHIBITOR,0.3676215181046015,1.6305539838422345,-3.3626926891725697
BRD-K33637378-001-01-7::2.500021224::MTS004,BRD-K33637378-001-01-7,flibanserin,2.500021224,MTS004,Exp_SLC29A2 (ENSG00000174669),GE,noncancer,serotonin receptor agonist,"DRD4, HTR1A, HTR2A",neurology/psychiatry,hypoactive sexual desire disorder,Launched,0.29263333526688,0.241497899145,flibanserin,,,0,0
BRD-K33681278-036-01-2::2.5::HTS,BRD-K33681278-036-01-2,prucalopride,2.5,HTS,METHYL_MIR6886,METHYL,noncancer,serotonin receptor agonist,HTR4,gastroenterology,constipation,Launched,0.306904384160051,0.180642112108,prucalopride,,,0,0
BRD-K33690734-001-01-5::2.5::HTS,BRD-K33690734-001-01-5,5-BDBD,2.5,HTS,MUTpool_BANP (54971),MUTpool,noncancer,purinergic receptor antagonist,P2RX4,,,Preclinical,0.287873894579047,0.0647562683499,5-BDBD,OTHER,0.2862850156763379,-2.2702264987722622,0.6771680150524353
BRD-K33720171-001-01-0::2.5::HTS,BRD-K33720171-001-01-0,difluprednate,2.5,HTS,Exp_POU5F1P5 (ENSG00000236375),GE,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,Launched,0.264145847636023,0.0962332996117,difluprednate,GLUCOCORTICOID RECEPTOR AGONIST,0.2619951428366373,-2.9613686493439424,-3.2646505597912867
BRD-K33732501-004-01-0::2.5::HTS,BRD-K33732501-004-01-0,methylnaltrexone,2.5,HTS,Exp_NKX3-1 (ENSG00000167034),GE,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,constipation,Launched,0.268016793616565,0.134957427469,methylnaltrexone,,,0,0
BRD-K33743361-003-02-6::2.5::HTS,BRD-K33743361-003-02-6,ML133,2.5,HTS,METHYL_MIR4745,METHYL,targeted cancer,potassium channel blocker,,,,Preclinical,0.250861036620221,0.0935050798829,ML133,,,0,0
BRD-K33813875-003-01-8::2.5::HTS,BRD-K33813875-003-01-8,valnemulin,2.5,HTS,Exp_NEURL3 (ENSG00000163121),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",Launched,0.33740718740671194,0.175266623645,valnemulin,OTHER,0.3427979377655529,2.1661536413606486,-2.4317677789027448
BRD-K33814251-001-01-4::2.6::HTS,BRD-K33814251-001-01-4,lubiprostone,2.6,HTS,PROT_Fibronectin,PROT,noncancer,chloride channel activator,CLCN2,gastroenterology,"constipation, irritable bowel syndrome",Launched,0.28969019347577,0.114133324928,lubiprostone,,,0,0
BRD-K33814251-001-02-2::2.5::HTS,BRD-K33814251-001-02-2,lubiprostone,2.5,HTS,PROT_c-Met_pY1235,PROT,noncancer,chloride channel activator,CLCN2,gastroenterology,"constipation, irritable bowel syndrome",Launched,0.28969019347577,0.114133324928,lubiprostone,,,0,0
BRD-K33818169-003-04-6::2.5::HTS,BRD-K33818169-003-04-6,GW-3965,2.5,HTS,CN_DCHS2 (54798),CN,noncancer,LXR agonist,"NR1H2, NR1H3",,,Preclinical,0.292320245856498,0.0310205441106,GW-3965,,,0,0
BRD-K33852358-001-09-9::2.5::HTS,BRD-K33852358-001-09-9,arofylline,2.5,HTS,MIRNA_hsa-miR-653,MIRNA,noncancer,phosphodiesterase inhibitor,PDE4A,,,Phase 3,0.3297852911198,0.0845473113225,arofylline,,,0,0
BRD-K33864865-001-02-5::2.5::HTS,BRD-K33864865-001-02-5,LY225910,2.5,HTS,PROT_INPP4B,PROT,noncancer,CCK receptor antagonist,CCKBR,,,Preclinical,0.266384232410617,0.055706563151,LY225910,,,0,0
BRD-K33882852-003-02-8::2.5::HTS,BRD-K33882852-003-02-8,ZK-93423,2.5,HTS,DEM2_NDUFB5 (4711),DEMETER2_COM,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",,,Phase 3,0.324120846320254,0.272559417144,ZK-93423,OTHER,0.3162880336707199,1.8996710969363089,-2.7243158457640293
BRD-K33892651-001-02-4::2.5::HTS,BRD-K33892651-001-02-4,ML347,2.5,HTS,CRISPR_SLC38A1 (81539),AVANA_PUBLIC_18Q2,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ACVR1, ACVRL1, BMPR1A",,,Preclinical,0.24503865645470702,-0.0438324470281,ML347,,,0,0
BRD-K34022604-001-06-6::2.5::HTS,BRD-K34022604-001-06-6,clofarabine,2.5,HTS,CRISPR_FGFR4 (2264),AVANA_PUBLIC_18Q2,chemo,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.435746238918393,0.233034113607,clofarabine,OTHER,0.4029961712688279,4.363674545928056,-1.8106176080015253
BRD-K34032314-001-04-1::2.5::HTS,BRD-K34032314-001-04-1,betamethasone-valerate,2.5,HTS,PROT_TIGAR,PROT,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.24335719816211,0.113466046437,betamethasone-valerate,GLUCOCORTICOID RECEPTOR AGONIST,0.2543800083714637,-3.6472679479487407,-3.160297565555987
BRD-K34058848-304-03-1::2.5::HTS,BRD-K34058848-304-03-1,cefonicid,2.5,HTS,DEM2_GNL1 (2794),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,Launched,0.283438020902718,0.128237146964,cefonicid,,,0,0
BRD-K34068325-066-03-7::2.499970684::MTS004,BRD-K34068325-066-03-7,delavirdine,2.499970684,MTS004,PROT_RSK1-2-3_Caution,PROT,noncancer,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.24629831191218898,0.112891442383,delavirdine,,,0,0
BRD-K34073885-001-09-3::2.54::HTS,BRD-K34073885-001-09-3,tanshinone-i,2.54,HTS,CRISPR_EFCAB1 (79645),AVANA_PUBLIC_18Q2,targeted cancer,AP inhibitor,IFNG,,,Phase 2,0.308180633298188,0.151950821135,tanshinone-i,OTHER,0.32108258152276525,2.1809160982724403,-2.3425870964565285
BRD-K34122555-057-11-5::2.5::HTS,BRD-K34122555-057-11-5,denatonium-benzoate,2.5,HTS,PROT_Smac_Caution,PROT,noncancer,,,,,Preclinical,0.298901471891562,0.05167191584,denatonium-benzoate,,,0,0
BRD-K34154330-003-06-4::2.5::HTS,BRD-K34154330-003-06-4,tracazolate,2.5,HTS,Exp_RNA5SP216 (ENSG00000251920),GE,noncancer,GABA receptor modulator,GABRA1,,,Phase 2,0.304425696072636,-0.00699064624096,tracazolate,,,0,0
BRD-K34157611-001-16-0::2.5::HTS,BRD-K34157611-001-16-0,cimetidine,2.5,HTS,METHYL_CCL24,METHYL,targeted cancer,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma",Launched,0.21828219181585098,0.169616928414,cimetidine,,,0,0
BRD-K34185671-001-02-8::2.5::HTS,BRD-K34185671-001-02-8,AMG-517,2.5,HTS,METHYL_ZUFSP,METHYL,noncancer,TRPV antagonist,TRPV1,,,Phase 1,0.305585522577453,0.0633452999643,AMG-517,,,0,0
BRD-K34251960-036-01-6::2.459743274::MTS004,BRD-K34251960-036-01-6,cibenzoline,2.459743274,MTS004,PROT_beta Actin_Caution,PROT,noncancer,sodium channel blocker,,,,Launched,0.313897955722551,0.0860423914376,cibenzoline,,,0,0
BRD-K34277641-001-01-2::2.569027627::MTS004,BRD-K34277641-001-01-2,L-365260,2.569027627,MTS004,CRISPR_FZD5 (7855),AVANA_PUBLIC_18Q2,noncancer,CCK receptor antagonist,"CCKAR, CCKBR, KCNQ1",,,Phase 2,0.329675361821388,0.0621395251108,L-365260,,,0,0
BRD-K34313798-001-01-6::2.5::HTS,BRD-K34313798-001-01-6,LY215490,2.5,HTS,PROT_Annexin_VII,PROT,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1",,,Phase 1,0.28004438554807304,0.0531690089502,LY215490,,,0,0
BRD-K34321528-003-01-2::2.5::HTS,BRD-K34321528-003-01-2,CGP-71683,2.5,HTS,DEM2_TM4SF19-TCTEX1D2 (100534611),DEMETER2_COM,noncancer,neuropeptide receptor antagonist,NPY5R,,,Preclinical,0.29270963601500394,0.0599854481768,CGP-71683,,,0,0
BRD-K34328244-001-01-4::2.5::HTS,BRD-K34328244-001-01-4,MF-101,2.5,HTS,METABOL_adenine,METABOL,targeted cancer,estrogen receptor agonist,"CYP19A1, XDH",,,Phase 3,0.26585071423715395,0.113979892321,MF-101,,,0,0
BRD-K34332569-001-01-3::2.5::HTS,BRD-K34332569-001-01-3,imidapril,2.5,HTS,Exp_P2RY6 (ENSG00000171631),GE,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",Launched,0.21661305786950896,0.0709474254366,imidapril,,,0,0
BRD-K34341643-001-01-4::2.5::HTS,BRD-K34341643-001-01-4,glasdegib,2.5,HTS,METHYL_CDK2AP2,METHYL,targeted cancer,hedgehog pathway inhibitor,SMO,,,Phase 2,0.267994842721248,0.1120435047,glasdegib,,,0,0
BRD-K34388247-236-08-2::2.5::HTS,BRD-K34388247-236-08-2,methicillin,2.5,HTS,Exp_MAP3K14-AS1 (ENSG00000267278),GE,noncancer,bacterial cell wall synthesis inhibitor,,,,Launched,0.303212959622529,0.0464748050905,methicillin,,,0,0
BRD-K34411947-001-12-5::2.5::HTS,BRD-K34411947-001-12-5,streptozotocin,2.5,HTS,Exp_MGMT (ENSG00000170430),GE,chemo,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,Launched,0.253367849539533,0.307658567405,streptozotocin,,,0,0
BRD-K34415467-003-13-0::2.5::HTS,BRD-K34415467-003-13-0,trimethobenzamide,2.5,HTS,METABOL_alpha-ketoglutarate,METABOL,noncancer,histamine receptor antagonist,DRD2,gastroenterology,"vomiting, nausea, gastroenteritis",Launched,0.205956754286734,0.0419894407268,trimethobenzamide,,,0,0
BRD-K34441861-003-07-0::2.47::HTS,BRD-K34441861-003-07-0,moexipril,2.47,HTS,Exp_DDX26B-AS1 (ENSG00000225235),GE,noncancer,angiotensin converting enzyme inhibitor,"ACE, ACE2",cardiology,hypertension,Launched,0.30352414315592696,0.0714010314213,moexipril,,,0,0
BRD-K34469523-003-03-0::2.5::HTS,BRD-K34469523-003-03-0,levalbuterol,2.5,HTS,METABOL_cis/trans-hydroxyproline,METABOL,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm,Launched,0.30770301147901596,0.0646078579992,levalbuterol,,,0,0
BRD-K34508702-001-02-4::2.499975465::MTS004,BRD-K34508702-001-02-4,CHF5074,2.499975465,MTS004,Exp_SULT2B1 (ENSG00000088002),GE,noncancer,gamma secretase modulator,PSEN1,,,Phase 2,0.27076307646341297,0.108418592244,CHF5074,,,0,0
BRD-K34533029-001-08-5::2.5::HTS,BRD-K34533029-001-08-5,tyrphostin-AG-494,2.5,HTS,Exp_SLC35D1 (ENSG00000116704),GE,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.312627039527143,0.200575502696,tyrphostin-AG-494,,,0,0
BRD-K34568562-001-04-3::2.5::HTS,BRD-K34568562-001-04-3,tilorone,2.5,HTS,Exp_RNF170 (ENSG00000120925),GE,noncancer,interferon inducer,,"infectious disease, gastroenterology, neurology/psychiatry","influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C",Launched,0.30288802076746696,0.0940052026302,tilorone,,,0,0
BRD-K34591242-001-04-3::2.5::HTS,BRD-K34591242-001-04-3,methoprene-(s),2.5,HTS,METABOL_pipecolic acid,METABOL,noncancer,,,,,Preclinical,0.27026483796484196,0.0480830743155,methoprene-(s),,,0,0
BRD-K34608650-001-02-4::2.5::HTS,BRD-K34608650-001-02-4,GP2a,2.5,HTS,METABOL_urate,METABOL,noncancer,cannabinoid receptor agonist,CNR2,,,Preclinical,0.280774364822145,-0.0232327595449,GP2a,,,0,0
BRD-K34663752-001-09-1::2.5::HTS,BRD-K34663752-001-09-1,6-chloromelatonin,2.5,HTS,DEM2_PROK2 (60675),DEMETER2_COM,noncancer,melatonin receptor agonist,"MTNR1A, MTNR1B",,,Preclinical,0.25898935740612694,-0.0000558671816938,6-chloromelatonin,,,0,0
BRD-K34672903-001-01-7::2.5::HTS,BRD-K34672903-001-01-7,HEMADO,2.5,HTS,Exp_RALYL (ENSG00000184672),GE,noncancer,,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.24732204285666298,0.119460129658,HEMADO,,,0,0
BRD-K34713073-001-01-3::2.5::HTS,BRD-K34713073-001-01-3,PD-123319,2.5,HTS,RMUTmis_PROM2 (150696),MUT,noncancer,angiotensin antagonist,AGTR2,,,Phase 1,0.30341818008578003,0.158519862735,PD-123319,,,0,0
BRD-K34730807-001-17-6::2.5::HTS,BRD-K34730807-001-17-6,levodopa,2.5,HTS,PROT_PI3K-p85,PROT,noncancer,dopamine precursor,"DRD1, DRD2, DRD3, DRD4, DRD5, GPR143",neurology/psychiatry,Parkinson's Disease,Launched,0.30821028986497195,0.00963904238433,levodopa,,,0,0
BRD-K34776109-001-16-6::2.5::HTS,BRD-K34776109-001-16-6,glimepiride,2.5,HTS,METHYL_BCAP29,METHYL,noncancer,insulin secretagogue,"ABCC8, KCNJ1, KCNJ11",endocrinology,diabetes mellitus,Launched,0.31423859940258303,0.040890634106,glimepiride,,,0,0
BRD-K34801930-001-01-9::2.5::HTS,BRD-K34801930-001-01-9,AZD5069,2.5,HTS,PROT_PRAS40_pT246,PROT,targeted cancer,CC chemokine receptor antagonist,CXCR2,,,Phase 2,0.228496600447511,0.110806157365,AZD5069,,,0,0
BRD-K34851558-001-02-3::2.5::HTS,BRD-K34851558-001-02-3,parthenolide-(-),2.5,HTS,CRISPR_RREB1 (6239),AVANA_PUBLIC_18Q2,targeted cancer,NFkB pathway inhibitor,HDAC1,,,Preclinical,0.398603600014711,0.0949879812362,parthenolide-(-),NFKB PATHWAY INHIBITOR,0.3609504765925669,0.4937497437960312,-3.875002472607105
BRD-K34870043-001-01-8::2.5::HTS,BRD-K34870043-001-01-8,adoprazine,2.5,HTS,METHYL_OSER1,METHYL,noncancer,"dopamine receptor antagonist, serotonin receptor agonist","DRD2, HTR1A",,,Phase 2,0.27728170372982597,0.0623463540145,adoprazine,,,0,0
BRD-K34888156-213-01-4::2.5::HTS,BRD-K34888156-213-01-4,theobromine,2.5,HTS,METABOL_adenine,METABOL,noncancer,phosphodiesterase inhibitor,"ADORA1, ADORA2A, PDE4B",,,Launched,0.27729967466543604,0.0386340056467,theobromine,,,0,0
BRD-K35007173-001-07-5::2.5::HTS,BRD-K35007173-001-07-5,enprofylline,2.5,HTS,DEM2_SLC12A5 (57468),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B",,,Phase 3,0.257187225611116,0.142531434173,enprofylline,,,0,0
BRD-K35034482-001-01-8::2.5::HTS,BRD-K35034482-001-01-8,bunazosin,2.5,HTS,METHYL_MIR185,METHYL,noncancer,adrenergic receptor antagonist,ADRA1A,ophthalmology,"glaucoma, intraocular pressure",Launched,0.323879512279649,0.033093562468,bunazosin,,,0,0
BRD-K35079116-001-02-5::2.71::HTS,BRD-K35079116-001-02-5,asiatic-acid,2.71,HTS,CRISPR_FGF19 (9965),AVANA_PUBLIC_18Q2,targeted cancer,apoptosis stimulant,PYGM,,,Preclinical,0.29382505516956897,0.139123629311,asiatic-acid,,,0,0
BRD-K35079116-001-03-3::2.5::HTS,BRD-K35079116-001-03-3,asiatic-acid,2.5,HTS,CRISPR_PTPN14 (5784),AVANA_PUBLIC_18Q2,targeted cancer,apoptosis stimulant,PYGM,,,Preclinical,0.29382505516956897,0.139123629311,asiatic-acid,,,0,0
BRD-K35169477-001-01-9::2.5::HTS,BRD-K35169477-001-01-9,taranabant,2.5,HTS,Exp_CRB2 (ENSG00000148204),GE,noncancer,cannabinoid receptor inverse agonist,CNR1,,,Phase 3,0.284163113660976,0.0427479770101,taranabant,,,0,0
BRD-K35170555-001-09-5::2.5::HTS,BRD-K35170555-001-09-5,caprylic-acid,2.5,HTS,DEM2_ZNF180 (7733),DEMETER2_COM,noncancer,,,,,Launched,0.278114400574999,0.103485510857,caprylic-acid,,,0,0
BRD-K35189033-001-26-1::2.5::HTS,BRD-K35189033-001-26-1,levonorgestrel,2.5,HTS,Exp_AHCYL1 (ENSG00000168710),GE,noncancer,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,Launched,0.20909323398023602,0.066933635139,levonorgestrel,,,0,0
BRD-K35240538-001-26-2::2.5::HTS,BRD-K35240538-001-26-2,methylprednisolone,2.5,HTS,METABOL_thymidine,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis",Launched,0.24585924337658,0.185867098747,methylprednisolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2467615266848221,-0.8129970493601559,-2.461268890260607
BRD-K35245662-001-01-2::2.5::HTS,BRD-K35245662-001-01-2,ciclesonide,2.5,HTS,DEM2_SLC4A7 (9497),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,Launched,0.257108222986245,0.110047069121,ciclesonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2619630841320635,-3.1221481547570287,-3.0827776017215864
BRD-K35304636-001-01-0::2.5::MTS004,BRD-K35304636-001-01-0,examorelin,2.5,MTS004,DEM2_TEAD2 (8463),DEMETER2_COM,noncancer,growth hormone releasing factor agonist,"GHRHR, GHSR",,,Phase 2,0.24227361739893,0.111721300837,examorelin,,,0,0
BRD-K35329391-334-01-7::2.5::HTS,BRD-K35329391-334-01-7,GZD824,2.5,HTS,RMUThot_DNAH5 (1767),MUThot,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,Preclinical,0.327792697290445,0.0435603704343,GZD824,OTHER,0.32676026359550475,3.8115760860280443,-1.1138949547461947
BRD-K35367061-001-01-1::2.5::MTS004,BRD-K35367061-001-01-1,LY223982,2.5,MTS004,METABOL_isoleucine,METABOL,noncancer,leukotriene receptor antagonist,LTB4R,,,Phase 2,0.27504608532235997,0.102635561728,LY223982,,,0,0
BRD-K35430135-003-02-3::2.5::HTS,BRD-K35430135-003-02-3,SR-59230A,2.5,HTS,CN_SIGLEC5 (8778),CN,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,Preclinical,0.243945830523796,-0.0128124672297,SR-59230A,,,0,0
BRD-K35498378-001-06-1::2.5::HTS,BRD-K35498378-001-06-1,alrestatin,2.5,HTS,METABOL_C40:6 PC,METABOL,noncancer,aldose reductase inhibitor,AKR1B1,,,Preclinical,0.29030204550749605,0.0529281191337,alrestatin,,,0,0
BRD-K35520305-001-17-7::2.5::HTS,BRD-K35520305-001-17-7,dacarbazine,2.5,HTS,Exp_SPECC1 (ENSG00000128487),GE,chemo,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma",Launched,0.315123964135552,0.142511068795,dacarbazine,OTHER,0.31367760266759803,3.9015999287364727,-3.3812851531537067
BRD-K35559145-050-08-5::2.5::HTS,BRD-K35559145-050-08-5,levomepromazine,2.5,HTS,CRISPR_PIWIL4 (143689),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C","neurology/psychiatry, gastroenterology","psychosis, schizophrenia, bipolar disorder, nausea, insomnia",Launched,0.27685095178098806,0.0773926010052,levomepromazine,,,0,0
BRD-K35586044-003-15-4::2.5::HTS,BRD-K35586044-003-15-4,yohimbine,2.5,HTS,METHYL_ATP2B4,METHYL,noncancer,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8",cardiology,"cardiac arrythmia, bradycardia",Launched,0.25520435578040895,0.00719569974159,yohimbine,,,0,0
BRD-K35589454-003-01-1::2.5::HTS,BRD-K35589454-003-01-1,danegaptide,2.5,HTS,DEM2_MTCH2 (23788),DEMETER2_COM,noncancer,gap junction modulator,,,,Phase 2,0.208582244675511,0.0316315824389,danegaptide,,,0,0
BRD-K35601925-001-01-9::2.5::HTS,BRD-K35601925-001-01-9,CS-917,2.5,HTS,Exp_GRIN2B (ENSG00000273079),GE,noncancer,fructose biphosphate inhibitor,FBP1,,,Phase 2,0.24493736059913102,0.0659171576385,CS-917,,,0,0
BRD-K35626314-003-01-1::2.499986242::MTS004,BRD-K35626314-003-01-1,TRV130,2.499986242,MTS004,Exp_G3BP2 (ENSG00000138757),GE,noncancer,opioid receptor agonist,OPRM1,,,Phase 3,0.301461404842775,0.0777398089606,TRV130,,,0,0
BRD-K35629949-001-02-0::2.5::HTS,BRD-K35629949-001-02-0,SR-27897,2.5,HTS,LIN_ovary_clear_cell,LIN,targeted cancer,CCK receptor antagonist,CCKAR,,,Phase 2,0.31816682721921197,0.0748401861406,SR-27897,,,0,0
BRD-K35687421-001-02-5::2.5::HTS,BRD-K35687421-001-02-5,gimeracil,2.5,HTS,CRISPR_PRKD2 (25865),AVANA_PUBLIC_18Q2,targeted cancer,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,Launched,0.268661176162578,0.0147769113971,gimeracil,,,0,0
BRD-K35698076-001-01-2::2.5::HTS,BRD-K35698076-001-01-2,laurocapram,2.5,HTS,CRISPR_E2F3 (1871),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 3,0.260513071947491,0.138838705385,laurocapram,,,0,0
BRD-K35719256-001-02-6::2.5::HTS,BRD-K35719256-001-02-6,rotundine,2.5,HTS,DEM2_KCNQ3 (3786),DEMETER2_COM,noncancer,serotonin receptor agonist,"DRD1, DRD2, DRD3, HTR1A",,,Launched,0.34035468954185905,0.0265773070735,rotundine,,,0,0
BRD-K35775715-001-03-1::2.5::HTS,BRD-K35775715-001-03-1,liranaftate,2.5,HTS,RMUTmis_VGLL2 (245806),MUTmis,noncancer,fungal squalene epoxidase inhibitor,,infectious disease,fungal infection,Launched,0.246226884632121,0.0382853097435,liranaftate,,,0,0
BRD-K35781423-001-01-6::2.5::HTS,BRD-K35781423-001-01-6,SANT-2,2.5,HTS,DEM2_MCF2L2 (23101),DEMETER2_COM,targeted cancer,smoothened receptor antagonist,"SHH, SMO",,,Preclinical,0.23422014527475196,0.0239692037989,SANT-2,,,0,0
BRD-K35798650-001-01-4::2.5::MTS004,BRD-K35798650-001-01-4,polidocanol,2.5,MTS004,RMUTmis_SH3PXD2B (285590),MUT,noncancer,local anesthetic,,dermatology,varicose veins,Launched,0.301183781987356,0.0836952656943,polidocanol,,,0,0
BRD-K35882976-001-04-7::2.444346727::MTS004,BRD-K35882976-001-04-7,mitoflaxone,2.444346727,MTS004,MIRNA_hsa-miR-508-5p,MIRNA,targeted cancer,antitumor agent,VWF,,,Phase 2,0.298299252931752,0.073336190157,mitoflaxone,,,0,0
BRD-K35952844-236-01-6::2.5::HTS,BRD-K35952844-236-01-6,sodium-glucoheptonate,2.5,HTS,METHYL_PFKFB3,METHYL,noncancer,,,,,Launched,0.285240589246029,0.0957272629367,sodium-glucoheptonate,,,0,0
BRD-K35952844-238-01-2::2.5::HTS,BRD-K35952844-238-01-2,calcium-gluceptate,2.5,HTS,METHYL_TBK1,METHYL,noncancer,,,,,Launched,0.285240589246029,0.0957272629367,calcium-gluceptate,,,0,0
BRD-K35960502-001-20-0::2.5::HTS,BRD-K35960502-001-20-0,niclosamide,2.5,HTS,Exp_PEX14 (ENSG00000142655),GE,noncancer,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,Launched,0.388881218795811,0.248797200949,niclosamide,OTHER,0.3851430057768858,4.611231488363099,-1.1211294427613303
BRD-K36016295-001-04-5::2.5::HTS,BRD-K36016295-001-04-5,KU-60019,2.5,HTS,METABOL_palmitoylcarnitine,METABOL,noncancer,ATM kinase inhibitor,ATM,,,Preclinical,0.334637003121035,0.153294320367,KU-60019,,,0,0
BRD-K36021395-300-02-4::2.5::HTS,BRD-K36021395-300-02-4,ABT-702,2.5,HTS,Exp_SNTA1 (ENSG00000101400),GE,noncancer,adenosine kinase inhibitor,ADK,,,Preclinical,0.323557767526234,0.0259109205791,ABT-702,,,0,0
BRD-K36040345-001-01-1::2.5::HTS,BRD-K36040345-001-01-1,TXA127,2.5,HTS,CRISPR_OR52R1 (119695),AVANA_PUBLIC_18Q2,targeted cancer,angiotensin receptor agonist,,,,Phase 2,0.25518001126232603,0.0488615157805,TXA127,,,0,0
BRD-K36055864-001-19-2::2.5::HTS,BRD-K36055864-001-19-2,cycloheximide,2.5,HTS,METHYL_MYCNUT,METHYL,targeted cancer,protein synthesis inhibitor,RPL3,,,Preclinical,0.35741585046234997,0.243069162727,cycloheximide,OTHER,0.36105573818549497,4.177539614314853,-0.44761837305330987
BRD-K36116267-001-15-3::2.5::HTS,BRD-K36116267-001-15-3,pyrithyldione,2.5,HTS,MIRNA_hsa-miR-519c-3p,MIRNA,noncancer,psychoactive drug,,,,Withdrawn,0.25408055009813396,0.0376118675276,pyrithyldione,,,0,0
BRD-K36198571-001-02-0::2.5::HTS,BRD-K36198571-001-02-0,WAY-170523,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,metalloproteinase inhibitor,MMP13,,,Preclinical,0.31654567803813105,0.0418241130993,WAY-170523,OTHER,0.31578383221081513,4.300430663923081,-2.3641287187623776
BRD-K36207157-001-07-0::2.52::HTS,BRD-K36207157-001-07-0,chlorprothixene,2.52,HTS,PROT_XBP1_Caution,PROT,noncancer,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.30007926526958,0.156418163085,chlorprothixene,,,0,0
BRD-K36207157-001-09-6::2.5::HTS,BRD-K36207157-001-09-6,chlorprothixene,2.5,HTS,MIRNA_hsa-miR-194,MIRNA,noncancer,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.30007926526958,0.14085260735,chlorprothixene,,,0,0
BRD-K36222532-001-01-8::2.5::HTS,BRD-K36222532-001-01-8,broxaldine,2.5,HTS,Exp_RAB22A (ENSG00000124209),GE,noncancer,,,,,Preclinical,0.27757136198403104,0.220150925911,broxaldine,OTHER,0.27775289700808603,3.9671831964705,-2.786391447784436
BRD-K36234266-001-09-8::2.5::HTS,BRD-K36234266-001-09-8,carmustine,2.5,HTS,Exp_MGMT (ENSG00000170430),GE,chemo,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",Launched,0.310817201748407,0.320040821953,carmustine,OTHER,0.3085330637283746,1.6701602224547334,-3.4727884478104523
BRD-K36258877-001-03-1::2.5::HTS,BRD-K36258877-001-03-1,AZ-10417808,2.5,HTS,CN_HCRTR2 (3062),CN,noncancer,caspase inhibitor,CASP3,,,Preclinical,0.241268640345395,0.0551687526029,AZ-10417808,,,0,0
BRD-K36262466-001-06-3::2.5::HTS,BRD-K36262466-001-06-3,aceneuramic-acid,2.5,HTS,DEM2_DPP10 (57628),DEMETER2_COM,noncancer,,"AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1",,,Phase 3,0.23491265756121102,0.0799578309314,aceneuramic-acid,,,0,0
BRD-K36269323-300-02-6::2.5::HTS,BRD-K36269323-300-02-6,asymmetrical-dimethylarginine,2.5,HTS,PROT_Bad_pS112,PROT,noncancer,nitric oxide synthase inhibitor,"NOS2, NOS3",,,Phase 1,0.28833216085517305,0.0404693292113,asymmetrical-dimethylarginine,,,0,0
BRD-K36270037-001-01-7::2.5::HTS,BRD-K36270037-001-01-7,esculin,2.5,HTS,Exp_FAM111A (ENSG00000166801),GE,targeted cancer,antioxidant,,,,Phase 1,0.28766708042581296,0.0971038449867,esculin,,,0,0
BRD-K36363294-001-04-2::2.5::HTS,BRD-K36363294-001-04-2,I-BET151,2.5,HTS,Exp_U2SURP (ENSG00000163714),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Preclinical,0.301693195600542,0.262173484561,I-BET151,BROMODOMAIN INHIBITOR,0.2714089487903982,-0.263708866687339,3.1181232677562933
BRD-K36379990-001-01-1::2.547414282::MTS004,BRD-K36379990-001-01-1,riodipine,2.547414282,MTS004,METHYL_SNHG22,METHYL,noncancer,calcium channel blocker,,,,Phase 2,0.282267080158346,0.122200982597,riodipine,,,0,0
BRD-K36381762-300-02-7::2.5::HTS,BRD-K36381762-300-02-7,nor-Binaltorphimine-dihydrochloride,2.5,HTS,METHYL_RAD50,METHYL,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.24477484785120002,0.0622395601611,nor-Binaltorphimine-dihydrochloride,,,0,0
BRD-K36386086-001-01-1::2.5::HTS,BRD-K36386086-001-01-1,dolutegravir,2.5,HTS,Exp_ROR1 (ENSG00000185483),GE,noncancer,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.32144957837791605,0.132792111995,dolutegravir,OTHER,0.32500421903548565,1.474696417702492,-3.114887761831084
BRD-K36395411-003-02-2::2.5::HTS,BRD-K36395411-003-02-2,SB-206553,2.5,HTS,MIRNA_hsa-miR-661,MIRNA,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.324682765892119,0.0626955849987,SB-206553,,,0,0
BRD-K36449075-001-01-0::2.5::HTS,BRD-K36449075-001-01-0,copper-histidine,2.5,HTS,PROT_PCNA_Caution,PROT,noncancer,,"HAL, HARS, HDC, SLC15A3, SLC15A4, SLC38A3, SLC38A5",,,Phase 3,0.31420460030302694,0.0807141144158,copper-histidine,,,0,0
BRD-K36461289-001-05-8::2.5::HTS,BRD-K36461289-001-05-8,picrotoxinin,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,GABA receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",,,Preclinical,0.264915466472124,0.106840747067,picrotoxinin,,,0,0
BRD-K36463073-001-03-9::2.499956047::MTS004,BRD-K36463073-001-03-9,OC000459,2.499956047,MTS004,PROT_C-Raf_pS338,PROT,noncancer,CRTH receptor antagonist,PTGDR2,,,Phase 2,0.349272136931305,0.0923563950249,OC000459,,,0,0
BRD-K36467523-001-02-8::2.5::HTS,BRD-K36467523-001-02-8,bindarit,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,noncancer,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",,,Phase 2,0.273646941259672,0.0411777504869,bindarit,,,0,0
BRD-K36524108-065-04-0::2.500001799::MTS004,BRD-K36524108-065-04-0,paromomycin,2.500001799,MTS004,METABOL_sorbitol,METABOL,noncancer,bacterial 30S ribosomal subunit inhibitor,,infectious disease,amebiasis,Launched,0.25551612667772894,0.0845827874084,paromomycin,,,0,0
BRD-K36574127-001-01-3::2.5::MTS004,BRD-K36574127-001-01-3,LOXO-101,2.5,MTS004,DEM2_EEPD1 (80820),DEMETER2_COM,targeted cancer,tropomyosin receptor kinase inhibitor,"NTRK1, NTRK2, NTRK3",,,Phase 2,0.24390048375893106,0.0752646407699,LOXO-101,,,0,0
BRD-K36627727-001-05-4::2.5::HTS,BRD-K36627727-001-05-4,tamibarotene,2.5,HTS,RMUTdmg_TP53 (7157),MUTdmg,targeted cancer,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),Launched,0.316317621107355,-0.0836733391549,tamibarotene,,,0,0
BRD-K36636143-001-01-0::2.518926249::MTS004,BRD-K36636143-001-01-0,nolatrexed,2.518926249,MTS004,Exp_PGBD5 (ENSG00000177614),GE,targeted cancer,thymidylate synthase inhibitor,TYMS,,,Phase 3,0.29485453534710104,0.0847790703083,nolatrexed,,,0,0
BRD-K36660044-001-24-2::2.5::HTS,BRD-K36660044-001-24-2,bufexamac,2.5,HTS,Exp_STX1B (ENSG00000099365),GE,noncancer,cyclooxygenase inhibitor,"HDAC10, HDAC6",,,Withdrawn,0.319107860277473,0.0737278626155,bufexamac,,,0,0
BRD-K36680103-001-01-6::2.5::HTS,BRD-K36680103-001-01-6,omecamtiv-mecarbil,2.5,HTS,Exp_TMEM243 (ENSG00000135185),GE,noncancer,cardiac myosin activator,MYBPC3,,,Phase 2,0.31098379996179903,0.00211695065761,omecamtiv-mecarbil,,,0,0
BRD-K36711084-001-02-0::2.5::HTS,BRD-K36711084-001-02-0,cyromazine,2.5,HTS,RMUTmis_C1orf198 (84886),MUTmis,noncancer,,,,,Launched,0.33335918055140695,0.0715247771205,cyromazine,,,0,0
BRD-K36739687-001-03-0::2.5::HTS,BRD-K36739687-001-03-0,stemregenin-1,2.5,HTS,Exp_EGR2 (ENSG00000122877),GE,noncancer,aryl hydrocarbon receptor antagonist,AHR,,,Preclinical,0.22699149969814603,-0.0130094584789,stemregenin-1,,,0,0
BRD-K36740062-001-06-6::2.5::HTS,BRD-K36740062-001-06-6,GSK1070916,2.5,HTS,PROT_HER3,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",,,Phase 1,0.385414175110141,0.305479473428,GSK1070916,AURORA KINASE INHIBITOR,0.3844879802352341,3.4656409075861663,-3.963869078946286
BRD-K36741660-001-01-1::2.499963039::MTS004,BRD-K36741660-001-01-1,verinurad,2.499963039,MTS004,CRISPR_MIPEP (4285),AVANA_PUBLIC_18Q2,noncancer,urate transporter inhibitor,SLC22A12,,,Phase 2,0.289053613607411,0.146380724929,verinurad,,,0,0
BRD-K36756879-003-08-7::2.5::HTS,BRD-K36756879-003-08-7,ethaverine,2.5,HTS,METHYL_CCDC88C,METHYL,noncancer,calcium channel blocker,,neurology/psychiatry,"muscle relaxant, spasms",Launched,0.30191431312859995,0.128015048805,ethaverine,OTHER,0.2593238474401251,-5.374240846515586,-2.1036242546736403
BRD-K36775483-001-01-4::2.5::HTS,BRD-K36775483-001-01-4,DMeOB,2.5,HTS,PROT_MEK1,PROT,noncancer,,GRM5,,,Preclinical,0.268627833109358,0.0565140195236,DMeOB,,,0,0
BRD-K36788280-001-01-2::2.5::HTS,BRD-K36788280-001-01-2,ribociclib,2.5,HTS,PROT_Cyclin_E1,PROT,targeted cancer,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,Launched,0.3503036643644001,0.249295426228,ribociclib,,,0,0
BRD-K36859431-300-02-3::2.5::HTS,BRD-K36859431-300-02-3,sapropterin,2.5,HTS,METABOL_C22:6 LPE,METABOL,noncancer,phenylalanine 4-hydroxylase stimulant,"NOS3, PAH, TH, TPH1",metabolism,hyperphenylalaninemia (HPA),Launched,0.24355314755771898,0.142316138643,sapropterin,,,0,0
BRD-K36862742-001-25-6::2.5::HTS,BRD-K36862742-001-25-6,hydroflumethiazide,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,sodium/potassium/chloride transporter inhibitor,"ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension",Launched,0.26414780703859103,0.083955858231,hydroflumethiazide,,,0,0
BRD-K36864847-303-02-5::2.5::HTS,BRD-K36864847-303-02-5,BD-1047,2.5,HTS,METHYL_MIR6126,METHYL,noncancer,adrenergic receptor antagonist,SIGMAR1,,,Preclinical,0.271681715742403,0.0467517874766,BD-1047,,,0,0
BRD-K36889451-001-01-1::2.5::HTS,BRD-K36889451-001-01-1,tetramethylthiuram-monosulfide,2.5,HTS,Exp_BMP6 (ENSG00000153162),GE,noncancer,,,,,Preclinical,0.41161257336824797,0.226813253075,tetramethylthiuram-monosulfide,OTHER,0.4097415616643594,4.318483115562087,-0.8982201374832561
BRD-K36927236-001-32-6::2.5::HTS,BRD-K36927236-001-32-6,glyburide,2.5,HTS,METHYL_EBF3,METHYL,noncancer,"ATP channel blocker, insulin secretagogue, sulfonylurea","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1",endocrinology,"diabetes mellitus, hyperglycemia",Launched,0.31013147824090503,0.0609868017441,glyburide,,,0,0
BRD-K36965586-003-08-8::2.5::HTS,BRD-K36965586-003-08-8,m-Chlorophenylbiguanide,2.5,HTS,CRISPR_SOX7 (83595),AVANA_PUBLIC_18Q2,noncancer,,"HTR3A, HTR3B",,,Preclinical,0.300563196032638,0.139461909225,m-Chlorophenylbiguanide,,,0,0
BRD-K36970462-001-01-6::2.5::HTS,BRD-K36970462-001-01-6,tonabersat,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,"gap junction modulator, nitric oxide production inhibitor",,,,Phase 2,0.308170858258046,0.0873566980871,tonabersat,,,0,0
BRD-K36984403-001-02-7::2.5::HTS,BRD-K36984403-001-02-7,go-6983,2.5,HTS,MUTpool_TP53 (7157),MUTpool,targeted cancer,protein kinase inhibitor,"PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ",,,Preclinical,0.34999681617169603,0.135081739458,go-6983,,,0,0
BRD-K37069697-001-01-3::2.5::HTS,BRD-K37069697-001-01-3,fexinidazole,2.5,HTS,Exp_THEM4 (ENSG00000159445),GE,noncancer,,,,,Phase 2/Phase 3,0.28861623177109197,0.102184175756,fexinidazole,,,0,0
BRD-K37083340-001-02-3::2.5::HTS,BRD-K37083340-001-02-3,lycopene,2.5,HTS,MIRNA_hsa-miR-520f,MIRNA,noncancer,free radical scavenger,,,,Phase 3,0.25024593468753403,0.015801725944,lycopene,,,0,0
BRD-K37111771-300-02-6::2.5::HTS,BRD-K37111771-300-02-6,trientine,2.5,HTS,CN_NIPAL4 (348938),CN,noncancer,chelating agent,CA14,metabolism,Wilson's disease,Launched,0.32225170372039,0.0573352398489,trientine,,,0,0
BRD-K37130656-001-04-6::2.5::HTS,BRD-K37130656-001-04-6,rivaroxaban,2.5,HTS,PROT_RAD51,PROT,noncancer,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)",Launched,0.29073946329150396,0.0325682729952,rivaroxaban,,,0,0
BRD-K37203094-001-02-5::2.5::HTS,BRD-K37203094-001-02-5,1-hexadecanol,2.5,HTS,METHYL_PTGER2,METHYL,noncancer,,,dermatology,cosmetic,Launched,0.203058142455365,0.00895929475363,1-hexadecanol,,,0,0
BRD-K37237504-001-02-7::2.5::HTS,BRD-K37237504-001-02-7,CEP-33779,2.5,HTS,METHYL_MIR1257,METHYL,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.287552618663305,0.177233760236,CEP-33779,OTHER,0.31305885688928103,0.5264639387990041,-2.683423481232796
BRD-K37249724-001-25-7::2.5::HTS,BRD-K37249724-001-25-7,astemizole,2.5,HTS,MUTpool_MYH2 (4620),MUTpool,noncancer,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",,,Withdrawn,0.23567784458430602,0.0160392454769,astemizole,,,0,0
BRD-K37270826-001-27-6::2.66::HTS,BRD-K37270826-001-27-6,mifepristone,2.66,HTS,DEM2_AXIN2 (8313),DEMETER2_COM,noncancer,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus",Launched,0.287713484763075,0.181724133484,mifepristone,,,0,0
BRD-K37270826-001-31-8::2.5::HTS,BRD-K37270826-001-31-8,mifepristone,2.5,HTS,DEM2_MMP2 (4313),DEMETER2_COM,noncancer,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus",Launched,0.287713484763075,0.181724133484,mifepristone,,,0,0
BRD-K37289225-001-36-4::2.5::HTS,BRD-K37289225-001-36-4,clozapine,2.5,HTS,Exp_LAMB2 (ENSG00000172037),GE,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7",neurology/psychiatry,schizophrenia,Launched,0.231694684180541,0.0387644209006,clozapine,,,0,0
BRD-K37312348-001-15-0::2.5::HTS,BRD-K37312348-001-15-0,kenpaullone,2.5,HTS,MUTpool_TBC1D32 (221322),MUTpool,targeted cancer,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",,,Preclinical,0.3507938372664411,0.0511107270334,kenpaullone,CDK INHIBITOR,0.3482351808109406,-2.3025104898840363,1.01926451350246
BRD-K37355418-236-01-6::2.5::HTS,BRD-K37355418-236-01-6,efaproxiral,2.5,HTS,RMUTmis_FRG1B (284802),MUT,targeted cancer,haemoglobin oxygen release stimulant,"HBA1, HBB",,,Phase 3,0.258854315967017,-0.0562175826809,efaproxiral,,,0,0
BRD-K37385792-003-02-1::2.5::HTS,BRD-K37385792-003-02-1,conivaptan,2.5,HTS,PROT_Bid_Caution,PROT,noncancer,vasopressin receptor antagonist,"AVPR1A, AVPR2",endocrinology,hyponatremia,Launched,0.23506171032015302,-0.0589487059308,conivaptan,,,0,0
BRD-K37516142-001-10-5::2.5::HTS,BRD-K37516142-001-10-5,idebenone,2.5,HTS,PROT_p70S6K,PROT,noncancer,calcium channel modulator,,"neurology/psychiatry, ophthalmology","Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)",Launched,0.24170417713524597,0.0894198159949,idebenone,,,0,0
BRD-K37543758-001-01-3::2.588829083::MTS004,BRD-K37543758-001-01-3,trepibutone,2.588829083,MTS004,METHYL_HAS1,METHYL,noncancer,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,irritable bowel syndrome,Launched,0.205107226214487,0.154701902185,trepibutone,,,0,0
BRD-K37561857-001-15-5::2.5::HTS,BRD-K37561857-001-15-5,zardaverine,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,phosphodiesterase inhibitor,PDE4D,,,Phase 2,0.540057885739793,0.472773541996,zardaverine,OTHER,0.5494402241893005,2.6382713114733027,-1.9524381727048308
BRD-K37590257-001-02-8::2.5::HTS,BRD-K37590257-001-02-8,GSK256066,2.5,HTS,METABOL_C32:1 PC,METABOL,noncancer,phosphodiesterase inhibitor,PDE4A,,,Phase 2,0.309483090813989,0.173302590093,GSK256066,OTHER,0.31463657214072577,4.041266107468603,0.1462540847003737
BRD-K37618799-001-03-0::2.5::HTS,BRD-K37618799-001-03-0,MRS-1220,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,noncancer,adenosine receptor antagonist,"ADORA2B, ADORA3",,,Preclinical,0.477480436580741,0.455139205566,MRS-1220,OTHER,0.4719566006435558,0.5394165549154464,0.7655614474817354
BRD-K37682401-001-09-3::2.44::HTS,BRD-K37682401-001-09-3,piromidic-acid,2.44,HTS,Exp_FIGN (ENSG00000182263),GE,noncancer,bacterial DNA gyrase inhibitor,,,,Phase 2,0.256103504982445,0.14781143645,piromidic-acid,,,0,0
BRD-K37682401-213-01-1::2.5::HTS,BRD-K37682401-213-01-1,piromidic-acid,2.5,HTS,Exp_THAP1 (ENSG00000131931),GE,noncancer,bacterial DNA gyrase inhibitor,,,,Phase 2,0.256103504982445,0.14781143645,piromidic-acid,,,0,0
BRD-K37687095-001-06-9::2.5::HTS,BRD-K37687095-001-06-9,AZD8330,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,,,,Phase 1,0.4462774557759389,0.563077852398,AZD8330,MEK INHIBITOR,0.4473763830239305,0.3275659812370819,5.046145101693247
BRD-K37687387-237-01-7::2.5::HTS,BRD-K37687387-237-01-7,RU-28318,2.5,HTS,METHYL_IFI44,METHYL,noncancer,cytochrome P450 inhibitor,NR3C2,,,Phase 2,0.222034996658403,0.0428056707352,RU-28318,,,0,0
BRD-K37688416-003-13-1::2.5::HTS,BRD-K37688416-003-13-1,fipexide,2.5,HTS,METHYL_MME,METHYL,noncancer,psychoactive drug,,,,Withdrawn,0.316982235782606,0.140496774256,fipexide,,,0,0
BRD-K37708699-001-01-4::2.530276706::MTS004,BRD-K37708699-001-01-4,exisulind,2.530276706,MTS004,MIRNA_hsa-miR-210,MIRNA,targeted cancer,phosphodiesterase inhibitor,PDE5A,,,Phase 3,0.29624699850887104,0.187587397581,exisulind,,,0,0
BRD-K37714784-305-02-1::2.5::HTS,BRD-K37714784-305-02-1,ABT-724,2.5,HTS,PROT_Cyclin_E1,PROT,noncancer,dopamine receptor agonist,DRD4,,,Phase 2,0.279380991543105,0.131997004179,ABT-724,,,0,0
BRD-K37720887-001-07-8::2.5::HTS,BRD-K37720887-001-07-8,SB-525334,2.5,HTS,PROT_Akt,PROT,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.330748554876072,0.296059674542,SB-525334,OTHER,0.3337548378879567,3.486614887842285,-0.1642463489443058
BRD-K37723606-001-01-5::2.5::HTS,BRD-K37723606-001-01-5,dioscin,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,apoptosis stimulant,CXCR3,,,Preclinical,0.258553879330015,0.0406141377849,dioscin,,,0,0
BRD-K37753391-046-03-2::2.5::HTS,BRD-K37753391-046-03-2,tylosin,2.5,HTS,CN_MIR4436A (100616399),CN,noncancer,protein synthesis inhibitor,,"infectious disease, gastroenterology","gram-positive bacterial infections, colitis",Launched,0.310550669977047,0.0234935968573,tylosin,,,0,0
BRD-K37764012-001-04-1::2.5::HTS,BRD-K37764012-001-04-1,PF-03758309,2.5,HTS,Exp_ARRDC4 (ENSG00000140450),GE,targeted cancer,p21 activated kinase inhibitor,PAK4,,,Phase 1,0.375398153730147,0.280769275417,PF-03758309,OTHER,0.3763635323712125,3.8666167482731466,-1.6008591397374348
BRD-K37793595-003-01-7::2.5::HTS,BRD-K37793595-003-01-7,afobazole,2.5,HTS,CN_SCRN2 (90507),CN,noncancer,anxiolytic,,neurology/psychiatry,anxiety,Launched,0.31300251743886703,0.00838747995552,afobazole,,,0,0
BRD-K37798499-001-27-2::2.5::HTS,BRD-K37798499-001-27-2,etoposide,2.5,HTS,Exp_CCT8 (ENSG00000156261),GE,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),Launched,0.41684997040337196,0.332354068204,etoposide,TOPOISOMERASE INHIBITOR,0.41902399710353866,4.30870396880527,-3.0818266554345297
BRD-K37814297-050-09-6::2.5::HTS,BRD-K37814297-050-09-6,acepromazine,2.5,HTS,METHYL_LOC101927911,METHYL,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,sedative,Launched,0.299759238189234,0.114696553989,acepromazine,,,0,0
BRD-K37846922-001-09-4::0.25::HTS,BRD-K37846922-001-09-4,"3,3'-diindolylmethane",0.25,HTS,Exp_N4BP2L1 (ENSG00000139597),GE,targeted cancer,"CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor","AR, HIF1A, IFNG, PI3",,,Phase 3,0.248146884893772,0.054043414881,"3,3'-diindolylmethane",,,0,0
BRD-K37865504-001-04-1::2.5::HTS,BRD-K37865504-001-04-1,LY2183240,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,noncancer,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,,,Preclinical,0.386617183083383,0.185057469821,LY2183240,OTHER,0.386366470305544,5.834963721858883,-2.0484470402217445
BRD-K37872686-003-01-9::2.5::HTS,BRD-K37872686-003-01-9,tirofiban,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,"platelet aggregation inhibitor, structural glycoprotein antagonist","ITGA2B, ITGB3",cardiology,"myocardial infarction, refactory angina",Launched,0.241983949926932,0.0306775535977,tirofiban,,,0,0
BRD-K37949327-001-06-3::2.5::HTS,BRD-K37949327-001-06-3,etidronic-acid,2.5,HTS,CN_FST (10468),CN,noncancer,bone resorption inhibitor,"ATP6V1A, PTPRS","endocrinology, orthopedics","Paget's disease, heterotopic ossification",Launched,0.27839914764268103,0.0481206470124,etidronic-acid,,,0,0
BRD-K37952347-001-01-4::2.5::HTS,BRD-K37952347-001-01-4,"L-732,138",2.5,HTS,MIRNA_hsa-miR-1259,MIRNA,noncancer,tachykinin antagonist,"TACR1, TACR2",,,Preclinical,0.319303379077445,0.145070625073,"L-732,138",,,0,0
BRD-K37991163-003-13-4::2.5::HTS,BRD-K37991163-003-13-4,paroxetine,2.5,HTS,METHYL_PHACTR2,METHYL,noncancer,selective serotonin reuptake inhibitor (SSRI),"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder",Launched,0.21730050691665304,0.0714426627626,paroxetine,,,0,0
BRD-K38003476-001-09-1::2.5::HTS,BRD-K38003476-001-09-1,clocortolone-pivalate,2.5,HTS,PROT_RBM15,PROT,noncancer,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.24835297813723697,0.159079528316,clocortolone-pivalate,OTHER,0.24747971099906546,-1.7260738987488289,-3.01410864468383
BRD-K38055836-001-21-1::2.5::HTS,BRD-K38055836-001-21-1,ethamivan,2.5,HTS,MIRNA_hsa-miR-577,MIRNA,noncancer,respiratory stimulant,,,,Preclinical,0.291676191994396,0.0757555376486,ethamivan,,,0,0
BRD-K38140108-002-01-2::2.5::HTS,BRD-K38140108-002-01-2,gadodiamide,2.5,HTS,MIRNA_hsa-miR-320d,MIRNA,noncancer,radiopaque medium,,radiology,MRI contrast agent,Launched,0.24235792112049803,0.0910497541808,gadodiamide,,,0,0
BRD-K38158531-001-02-1::2.5::HTS,BRD-K38158531-001-02-1,traxoprodil,2.5,HTS,CRISPR_WWC1 (23286),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,GRIN2B,,,Phase 2,0.300706514144588,0.0488363453869,traxoprodil,,,0,0
BRD-K38168441-001-03-7::2.422985058::MTS004,BRD-K38168441-001-03-7,dabigatran,2.422985058,MTS004,CN_NFIC (4782),CN,noncancer,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)",Launched,0.28323875535209697,0.0955826306167,dabigatran,,,0,0
BRD-K38183498-001-02-0::2.5::HTS,BRD-K38183498-001-02-0,clonazepam,2.5,HTS,Exp_FGD2 (ENSG00000146192),GE,noncancer,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",Launched,0.255321766727451,0.0378721501806,clonazepam,,,0,0
BRD-K38197229-001-29-9::2.5::HTS,BRD-K38197229-001-29-9,bumetanide,2.5,HTS,DEM2_CZ1P-ASNS (107986827),DEMETER2_COM,noncancer,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure",Launched,0.275442264769443,0.064980595983,bumetanide,,,0,0
BRD-K38287497-001-01-2::2.5::HTS,BRD-K38287497-001-01-2,narlaprevir,2.5,HTS,Exp_GPSM3 (ENSG00000213654),GE,noncancer,HCV inhibitor,,,,Phase 2/Phase 3,0.316422181076163,0.0903592143157,narlaprevir,,,0,0
BRD-K38305202-001-17-4::2.5::HTS,BRD-K38305202-001-17-4,domperidone,2.5,HTS,METHYL_DPEP2,METHYL,noncancer,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,Launched,0.31993653611317796,0.114945222143,domperidone,,,0,0
BRD-K38323065-001-19-9::2.5::HTS,BRD-K38323065-001-19-9,phenacetin,2.5,HTS,RMUTmis_RAPGEFL1 (51195),MUTmis,noncancer,cyclooxygenase inhibitor,PTGS1,,,Withdrawn,0.300875801512912,0.121223974629,phenacetin,,,0,0
BRD-K38332599-001-01-3::2.5::HTS,BRD-K38332599-001-01-3,uprosertib,2.5,HTS,METHYL_GLIS3,METHYL,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.395423804811757,0.225551631457,uprosertib,AKT INHIBITOR,0.3958209757764556,5.424787852696356,-2.014003175203122
BRD-K38350380-001-01-8::2.5::HTS,BRD-K38350380-001-01-8,FK-3311,2.5,HTS,PROT_NF-kB-p65_pS536_Caution,PROT,noncancer,cyclooxygenase inhibitor,PTGS2,,,Phase 2,0.252887282622695,0.0281319680645,FK-3311,OTHER,0.254466052508047,2.687803192519704,-0.9286770705946128
BRD-K38370968-050-01-3::2.5::HTS,BRD-K38370968-050-01-3,3-AQC,2.5,HTS,PROT_Syk,PROT,noncancer,serotonin receptor agonist,HTR3A,,,Preclinical,0.21650310377749,0.100020618024,3-AQC,,,0,0
BRD-K38380126-001-01-4::2.5::HTS,BRD-K38380126-001-01-4,thiamet-g,2.5,HTS,Exp_ZNF559 (ENSG00000188321),GE,noncancer,GLCNAC phosphotransferase inhibitor,MGEA5,,,Preclinical,0.246556471642978,0.082403795586,thiamet-g,,,0,0
BRD-K38398115-001-01-9::2.418470509::MTS004,BRD-K38398115-001-01-9,YM-511,2.418470509,MTS004,MIRNA_hsa-miR-146b-5p,MIRNA,targeted cancer,aromatase inhibitor,CYP19A1,,,Phase 2,0.207069305682691,0.151732511249,YM-511,,,0,0
BRD-K38436528-003-26-1::2.5::HTS,BRD-K38436528-003-26-1,imipramine,2.5,HTS,METHYL_STAMBP,METHYL,noncancer,"norepinephrine reputake inhibitor, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry, urology","depression, nocturnal enuresis",Launched,0.246334208123711,0.0535012570651,imipramine,,,0,0
BRD-K38458514-001-01-8::2.5::HTS,BRD-K38458514-001-01-8,diazooxonorleucine,2.5,HTS,CN_CYP2C18 (1562),CN,noncancer,glutamate receptor antagonist,,,,Phase 2,0.23912540342152103,0.0793319589271,diazooxonorleucine,,,0,0
BRD-K38473998-001-02-0::2.5::HTS,BRD-K38473998-001-02-0,cilomilast,2.5,HTS,Exp_GPR19 (ENSG00000183150),GE,noncancer,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4D",,,Phase 3,0.255880276585005,0.0827725028333,cilomilast,,,0,0
BRD-K38477637-001-01-0::2.652726792::MTS004,BRD-K38477637-001-01-0,droloxifene,2.652726792,MTS004,METHYL_ARHGEF3,METHYL,targeted cancer,selective estrogen receptor modulator (SERM),ESR1,,,Phase 3,0.23955105689278403,0.0615306229235,droloxifene,,,0,0
BRD-K38527262-300-01-0::2.300987371::MTS004,BRD-K38527262-300-01-0,atiprimod,2.300987371,MTS004,Exp_ATP10B (ENSG00000118322),GE,targeted cancer,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",,,Phase 2,0.584374770796491,0.472884666441,atiprimod,OTHER,0.5838914914097504,4.6869190394128815,-0.9708674057868598
BRD-K38548312-001-01-0::2.5::HTS,BRD-K38548312-001-01-0,VER-49009,2.5,HTS,Exp_HMGN4 (ENSG00000182952),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Preclinical,0.380311995277962,0.326069459629,VER-49009,HSP INHIBITOR,0.38075177146326294,5.037056900312075,-1.6957083940461717
BRD-K38564664-001-01-1::2.5::MTS004,BRD-K38564664-001-01-1,rolziracetam,2.5,MTS004,PROT_Myosin IIa pS1943,PROT,noncancer,,,,,Phase 2,0.315640133217591,0.100182449517,rolziracetam,,,0,0
BRD-K38580127-003-15-4::2.5::HTS,BRD-K38580127-003-15-4,serotonin,2.5,HTS,METABOL_AMP,METABOL,noncancer,growth factor receptor activator,"DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1",neurology/psychiatry,"anxiety, depression, sleeplessness",Launched,0.301720249259539,0.0708309942399,serotonin,,,0,0
BRD-K38602774-001-03-2::2.5::HTS,BRD-K38602774-001-03-2,sulisobenzone,2.5,HTS,Exp_SLC3A1 (ENSG00000138079),GE,noncancer,,,dermatology,sunscreen lotion,Launched,0.254560059090287,0.164635247516,sulisobenzone,,,0,0
BRD-K38684403-001-05-4::2.5::HTS,BRD-K38684403-001-05-4,roxithromycin,2.5,HTS,Exp_CELF2-AS1 (ENSG00000181800),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,"ABCB1, MLNR",infectious disease,"respiratory tract infections, urinary tract infections, skin infections",Launched,0.24306711182926102,0.00425238659593,roxithromycin,,,0,0
BRD-K38687824-001-02-5::2.5::HTS,BRD-K38687824-001-02-5,beta-amyloid-synthesis-inhibitor,2.5,HTS,METHYL_MRPL45P2,METHYL,noncancer,beta amyloid synthesis inhibitor,APP,,,Preclinical,0.260917594428924,0.0522339703891,beta-amyloid-synthesis-inhibitor,,,0,0
BRD-K38797369-003-01-1::2.46::HTS,BRD-K38797369-003-01-1,PD-128907,2.46,HTS,METABOL_taurocholate,METABOL,noncancer,dopamine receptor agonist,"DRD2, DRD3",,,Preclinical,0.327850454881046,0.0413140331084,PD-128907,,,0,0
BRD-K38852836-001-02-1::2.5::HTS,BRD-K38852836-001-02-1,ganetespib,2.5,HTS,METHYL_IL17RB,METHYL,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 3,0.394284983830923,0.135872898623,ganetespib,HSP INHIBITOR,0.3840379639483542,3.1963890495745284,-0.561879150695944
BRD-K38860038-001-01-2::2.5::HTS,BRD-K38860038-001-01-2,JK-184,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,hedgehog pathway inhibitor,,,,Preclinical,0.402265647652025,0.342124878434,JK-184,OTHER,0.4010641551741281,6.031512202954272,-2.7082346375714423
BRD-K38868394-001-01-3::2.5::HTS,BRD-K38868394-001-01-3,MK-0773,2.5,HTS,METHYL_TRIM31,METHYL,noncancer,androgen receptor modulator,AR,,,Phase 2,0.290791934882825,0.177642841909,MK-0773,,,0,0
BRD-K38903228-001-13-5::2.5::HTS,BRD-K38903228-001-13-5,hesperidin,2.5,HTS,PROT_Di-Ras3_Caution,PROT,noncancer,flavanone glycoside,CACNA1B,,,Launched,0.24727869737944502,0.07632069405,hesperidin,,,0,0
BRD-K38904395-001-02-3::2.5::HTS,BRD-K38904395-001-02-3,SAR131675,2.5,HTS,Exp_FIP1L1 (ENSG00000145216),GE,targeted cancer,VEGFR inhibitor,FLT4,,,Preclinical,0.330548705031415,0.222041058594,SAR131675,,,0,0
BRD-K38911213-003-01-6::2.5::HTS,BRD-K38911213-003-01-6,apraclonidine,2.5,HTS,PROT_Tuberin,PROT,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C",ophthalmology,"glaucoma, intraocular pressure",Launched,0.256878317610486,0.0942877339474,apraclonidine,,,0,0
BRD-K38938675-001-01-4::2.5::HTS,BRD-K38938675-001-01-4,morniflumate,2.5,HTS,METABOL_betaine,METABOL,noncancer,anti-inflammatory agent,,neurology/psychiatry,pain relief,Launched,0.19890548930872698,0.0497283226822,morniflumate,,,0,0
BRD-K39009484-001-01-4::2.5::MTS004,BRD-K39009484-001-01-4,entrectinib,2.5,MTS004,Exp_NHLH2 (ENSG00000177551),GE,targeted cancer,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor","ALK, NTRK1, NTRK2, NTRK3, ROS1",,,Phase 2,0.29935024946216,0.150114815917,entrectinib,OTHER,0.2985686557893001,1.6964920664220378,-2.6898703521283966
BRD-K39023557-001-01-7::2.5::HTS,BRD-K39023557-001-01-7,octocrylene,2.5,HTS,MIRNA_hsa-miR-517a,MIRNA,noncancer,,,dermatology,sunscreen lotion,Launched,0.306522650642531,0.0382099916693,octocrylene,,,0,0
BRD-K39061174-001-01-0::2.62::HTS,BRD-K39061174-001-01-0,beta-glycerophosphoric-acid,2.62,HTS,RMUTmis_ITGA11 (22801),MUTmis,noncancer,,,,,Preclinical,0.254213159363737,0.0307632916004,beta-glycerophosphoric-acid,,,0,0
BRD-K39079086-001-07-6::2.5::HTS,BRD-K39079086-001-07-6,cinchonidine,2.5,HTS,CN_CTBP2 (1488),CN,targeted cancer,P glycoprotein inhibitor,,,,Phase 1,0.285651217490562,0.0605491386646,cinchonidine,,,0,0
BRD-K39120595-304-04-7::2.5::HTS,BRD-K39120595-304-04-7,bithionol,2.5,HTS,PROT_Tuberin,PROT,noncancer,autotaxin inhibitor,"ESR1, ESR2, MCL1",,,Withdrawn,0.27029206464734806,0.0641574089159,bithionol,,,0,0
BRD-K39160765-003-02-9::2.5::HTS,BRD-K39160765-003-02-9,4-chlorophenylguanidine,2.5,HTS,PROT_IRS1,PROT,noncancer,urokinase inhibitor,PLAUR,,,Preclinical,0.290755085893836,0.0674249374751,4-chlorophenylguanidine,,,0,0
BRD-K39166528-001-01-0::2.5::HTS,BRD-K39166528-001-01-0,ID-8,2.5,HTS,Exp_SLC28A3 (ENSG00000197506),GE,noncancer,,,,,Preclinical,0.33562950394913205,0.107094428168,ID-8,,,0,0
BRD-K39252998-003-01-5::2.5::HTS,BRD-K39252998-003-01-5,atipamezole,2.5,HTS,Exp_ZNF750 (ENSG00000141579),GE,noncancer,adrenergic receptor antagonist,,neurology/psychiatry,reverse sedative,Launched,0.38738805570880896,0.270606380507,atipamezole,OTHER,0.3934216520255095,5.0719148687697295,-3.8582436853428437
BRD-K39339537-001-21-0::2.5::HTS,BRD-K39339537-001-21-0,epirizole,2.5,HTS,DEM2_ADAM12 (8038),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Launched,0.2874940017933689,0.0841047448003,epirizole,,,0,0
BRD-K39371216-001-01-3::2.5::HTS,BRD-K39371216-001-01-3,cyacetacide,2.5,HTS,CRISPR_IRG1 (730249),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.24858170250394396,0.0458336472585,cyacetacide,,,0,0
BRD-K39381259-001-01-0::2.5::HTS,BRD-K39381259-001-01-0,DMH1,2.5,HTS,Exp_FAM84A (ENSG00000162981),GE,targeted cancer,ALK tyrosine kinase receptor inhibitor,ACVR1,,,Preclinical,0.290687686012642,0.153489585508,DMH1,,,0,0
BRD-K39462424-050-09-8::2.5::HTS,BRD-K39462424-050-09-8,dexchlorpheniramine,2.5,HTS,METHYL_MIR6126,METHYL,noncancer,histamine receptor antagonist,,"allergy, cardiology","allergic conjunctivitis, allergic rhinitis, urticaria, angioedema",Launched,0.28053195622798804,0.12785236637,dexchlorpheniramine,,,0,0
BRD-K39467894-001-05-9::2.5::HTS,BRD-K39467894-001-05-9,nithiamide,2.5,HTS,METHYL_MIR3180-4,METHYL,noncancer,bacterial DNA inhibitor,,,,Preclinical,0.245428736682012,0.130170043882,nithiamide,,,0,0
BRD-K39467894-001-06-7::2.5::HTS,BRD-K39467894-001-06-7,nithiamide,2.5,HTS,METHYL_DLD,METHYL,noncancer,bacterial DNA inhibitor,,,,Preclinical,0.245428736682012,0.130170043882,nithiamide,,,0,0
BRD-K39495750-001-01-2::2.5::HTS,BRD-K39495750-001-01-2,chlorobutanol,2.5,HTS,METHYL_BDH1,METHYL,noncancer,,,neurology/psychiatry,"anesthetic, sedative",Launched,0.324115421252193,0.0161091723267,chlorobutanol,,,0,0
BRD-K39558284-001-01-2::2.5::HTS,BRD-K39558284-001-01-2,SDZ-WAG-994,2.5,HTS,PROT_Collagen_VI,PROT,noncancer,adenosine receptor agonist,ADORA1,,,Phase 2,0.21602939576918104,0.0683621216448,SDZ-WAG-994,,,0,0
BRD-K39560679-001-01-1::2.500010466::MTS004,BRD-K39560679-001-01-1,eluxadoline,2.500010466,MTS004,METABOL_C34:3 PC,METABOL,noncancer,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,Launched,0.285040134241666,0.146118131052,eluxadoline,,,0,0
BRD-K39624409-003-02-6::2.5::HTS,BRD-K39624409-003-02-6,ADL5859,2.5,HTS,DEM2_STXBP2 (6813),DEMETER2_COM,noncancer,opioid receptor agonist,OPRD1,,,Phase 2,0.287596964804703,0.0495565695255,ADL5859,,,0,0
BRD-K39670393-303-02-1::2.5::HTS,BRD-K39670393-303-02-1,amthamine,2.5,HTS,RMUThot_KRAS (3845),MUThot,noncancer,histamine receptor agonist,HRH2,,,Preclinical,0.282689576204992,0.0379507508634,amthamine,,,0,0
BRD-K39693230-001-01-2::2.5::HTS,BRD-K39693230-001-01-2,N-salicoylaminophenol,2.5,HTS,METHYL_MIR101-2,METHYL,noncancer,ribonucleotide reductase inhibitor,,,,Preclinical,0.283091311151109,0.0762323633605,N-salicoylaminophenol,,,0,0
BRD-K39733634-001-02-6::2.5::HTS,BRD-K39733634-001-02-6,L-161982,2.5,HTS,METHYL_PSMD6,METHYL,noncancer,prostanoid receptor antagonist,PTGER4,,,Preclinical,0.29324868325428305,0.064707727855,L-161982,,,0,0
BRD-K39805756-001-01-6::2.5::HTS,BRD-K39805756-001-01-6,TPPS4,2.5,HTS,PROT_eIF4E,PROT,noncancer,,,,,Phase 1,0.266401974426293,0.105734863016,TPPS4,,,0,0
BRD-K39841531-001-02-1::2.5::HTS,BRD-K39841531-001-02-1,TG-101209,2.5,HTS,MIRNA_hsa-miR-454,MIRNA,noncancer,JAK inhibitor,"JAK2, JAK3",,,Preclinical,0.382276592726442,0.312127531301,TG-101209,OTHER,0.3837266241777307,3.4667573764554267,-2.552382293605973
BRD-K39915878-036-24-4::2.5::HTS,BRD-K39915878-036-24-4,loxapine,2.5,HTS,METHYL_FNIP2,METHYL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,schizophrenia,Launched,0.28033265214200603,0.15043299122,loxapine,,,0,0
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,Exp_PROSER2 (ENSG00000148426),GE,targeted cancer,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,Launched,0.43004202579957107,0.25944445401,lenvatinib,OTHER,0.4476114527668799,0.004902555430529892,-2.0091548212213137
BRD-K39983086-001-06-1::2.45::HTS,BRD-K39983086-001-06-1,loteprednol,2.45,HTS,CRISPR_DYDC1 (143241),AVANA_PUBLIC_18Q2,noncancer,"glucocorticoid receptor agonist, phospholipase inhibitor",NR3C1,ophthalmology,conjunctivitis,Launched,0.300005099220844,0.101307601724,loteprednol,GLUCOCORTICOID RECEPTOR AGONIST,0.31150339013202505,-3.497429019549299,-3.1438115629522634
BRD-K39987650-001-24-1::2.5::HTS,BRD-K39987650-001-24-1,bisacodyl,2.5,HTS,PROT_Fibronectin,PROT,noncancer,laxative,,gastroenterology,constipation,Launched,0.36962550042495207,0.240791579232,bisacodyl,OTHER,0.3704920120491488,-5.144540414727805,-1.6796471986103685
BRD-K40002998-001-01-5::2.5::MTS004,BRD-K40002998-001-01-5,org-26576,2.5,MTS004,PROT_VHL_Caution,PROT,noncancer,glutamate receptor modulator,,,,Phase 2,0.30828708344041494,0.141596699196,org-26576,,,0,0
BRD-K40109029-001-02-9::2.5::HTS,BRD-K40109029-001-02-9,SB-505124,2.5,HTS,Exp_AFAP1-AS1 (ENSG00000272620),GE,noncancer,ALK tyrosine kinase receptor inhibitor,TGFBR1,,,Preclinical,0.445188866841818,0.407900443453,SB-505124,OTHER,0.4495658993483232,2.2939280350528337,-2.4358012058227727
BRD-K40227168-001-12-9::1.7::HTS,BRD-K40227168-001-12-9,vinburnine,1.7,HTS,CRISPR_LRRC10 (376132),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,stroke,Launched,0.268095322417559,0.199179933478,vinburnine,,,0,0
BRD-K40255344-001-17-6::2.5::HTS,BRD-K40255344-001-17-6,tyrphostin-A9,2.5,HTS,Exp_SRRM1 (ENSG00000133226),GE,targeted cancer,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",,,,Preclinical,0.38807770333105995,0.325089147504,tyrphostin-A9,OTHER,0.3888124391974124,4.672645264652464,-3.1296088307256795
BRD-K40269473-001-02-2::2.5::HTS,BRD-K40269473-001-02-2,cathepsin-inhibitor-1,2.5,HTS,CRISPR_FKBP10 (60681),AVANA_PUBLIC_18Q2,noncancer,cathepsin inhibitor,"CTSB, CTSL, CTSV",,,Preclinical,0.27855162497874103,0.11643650105,cathepsin-inhibitor-1,,,0,0
BRD-K40302533-001-02-9::2.5::HTS,BRD-K40302533-001-02-9,PF-5274857,2.5,HTS,CN_SH3RF3 (344558),CN,targeted cancer,smoothened receptor antagonist,SMO,,,Preclinical,0.26461724676451703,0.0985539612361,PF-5274857,,,0,0
BRD-K40308497-001-01-2::2.54::HTS,BRD-K40308497-001-01-2,crizotinib-(S),2.54,HTS,MIRNA_hsa-miR-211,MIRNA,targeted cancer,MTH1 inhibitor,NUDT1,,,Preclinical,0.418444996375318,0.105004277495,crizotinib-(S),OTHER,0.4174059231727606,0.9280788916975974,-2.852522033413398
BRD-K40308497-001-02-0::2.5::HTS,BRD-K40308497-001-02-0,crizotinib-(S),2.5,HTS,METHYL_RPS17,METHYL,targeted cancer,MTH1 inhibitor,NUDT1,,,Preclinical,0.418444996375318,0.0719573143227,crizotinib-(S),,,0,0
BRD-K40438880-305-06-6::2.5::HTS,BRD-K40438880-305-06-6,spermidine,2.5,HTS,DEM2_GZMH (2999),DEMETER2_COM,noncancer,glutamate receptor modulator,"KCNJ4, TXNRD1",,,Preclinical,0.29665513043200703,0.0434039642945,spermidine,,,0,0
BRD-K40496271-396-01-1::2.34::HTS,BRD-K40496271-396-01-1,eltrombopag,2.34,HTS,Exp_PARP1 (ENSG00000143799),GE,noncancer,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia",Launched,0.37435172160709,0.278190679586,eltrombopag,OTHER,0.3744102114062543,3.0042608488751545,-3.2780136370615143
BRD-K40530731-001-11-6::2.5::HTS,BRD-K40530731-001-11-6,hyoscyamine,2.5,HTS,MIRNA_hsa-miR-424,MIRNA,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis",Launched,0.235424899410275,0.0411812399306,hyoscyamine,,,0,0
BRD-K40578143-001-02-6::2.5::HTS,BRD-K40578143-001-02-6,GR-79236,2.5,HTS,DEM2_RRN3P2 (653390),DEMETER2_COM,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A",,,Phase 1,0.304734151721931,0.0441979196403,GR-79236,,,0,0
BRD-K40621224-001-06-7::2.5::HTS,BRD-K40621224-001-06-7,pentetic-acid,2.5,HTS,CN_APTX (54840),CN,noncancer,chelating agent,PGD,,,Phase 2,0.300356254576906,0.0287970275273,pentetic-acid,,,0,0
BRD-K40654626-236-01-5::2.5::HTS,BRD-K40654626-236-01-5,ditiocarb-sodium-trihydrate,2.5,HTS,CRISPR_EFCAB14 (9813),AVANA_PUBLIC_18Q2,noncancer,immunostimulant,"CA1, CA2, CA4",,,Phase 3,0.26998304818225,0.113894468767,ditiocarb-sodium-trihydrate,,,0,0
BRD-K40715924-001-01-1::2.5::HTS,BRD-K40715924-001-01-1,medorinone,2.5,HTS,DEM2_ACTL6B (51412),DEMETER2_COM,noncancer,,,,,Phase 1,0.228252228735329,0.0187917006515,medorinone,,,0,0
BRD-K40718343-001-02-6::2.5::HTS,BRD-K40718343-001-02-6,AEE788,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",,,Phase 1/Phase 2,0.436712051885135,0.500281956291,AEE788,EGFR INHIBITOR,0.4304378492381693,1.1361527127541766,-4.895200267640384
BRD-K40738845-001-05-0::2.5::HTS,BRD-K40738845-001-05-0,BMS-777607,2.5,HTS,CN_LINC01347 (731275),CN,targeted cancer,"AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor","AXL, MERTK, MET, MST1R, TYRO3",,,Phase 1/Phase 2,0.293576687002392,0.0899518389846,BMS-777607,,,0,0
BRD-K40758068-001-08-2::2.5::HTS,BRD-K40758068-001-08-2,efavirenz,2.5,HTS,METHYL_ABRACL,METHYL,noncancer,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.27244057358251,0.107552941926,efavirenz,,,0,0
BRD-K40782193-003-02-9::2.5::HTS,BRD-K40782193-003-02-9,QX-222,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,noncancer,sodium channel blocker,,,,Preclinical,0.327192433579175,0.0607973641072,QX-222,,,0,0
BRD-K40787673-001-02-1::2.5::HTS,BRD-K40787673-001-02-1,lacitol,2.5,HTS,DEM2_SERHL (94009),DEMETER2_COM,noncancer,osmosis stimulant,,gastroenterology,constipation,Launched,0.240773202419072,0.0668342027138,lacitol,,,0,0
BRD-K40797222-001-01-8::2.5::HTS,BRD-K40797222-001-01-8,SC-12267,2.5,HTS,PROT_p21,PROT,noncancer,dihydroorotate dehydrogenase inhibitor,IL17A,,,Phase 2,0.30097153605591404,0.0842680385633,SC-12267,,,0,0
BRD-K40870905-001-01-7::2.5::HTS,BRD-K40870905-001-01-7,CT-7758,2.5,HTS,DEM2_NAPA (8775),DEMETER2_COM,noncancer,integrin antagonist,ITGA4,,,Phase 2,0.23887724228304996,0.0849305279647,CT-7758,,,0,0
BRD-K40887525-001-21-9::2.5::HTS,BRD-K40887525-001-21-9,ritanserin,2.5,HTS,CN_RAPGEF3 (10411),CN,noncancer,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,Phase 3,0.20990284665821698,0.0215984373269,ritanserin,,,0,0
BRD-K40901640-003-01-6::2.5::HTS,BRD-K40901640-003-01-6,cinanserin,2.5,HTS,CRISPR_DAND5 (199699),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,HTR2A,,,Preclinical,0.26672249600563697,0.0586260649974,cinanserin,,,0,0
BRD-K40905133-001-04-9::2.5::HTS,BRD-K40905133-001-04-9,phenacemide,2.5,HTS,RMUTmis_OCSTAMP (128506),MUTmis,noncancer,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, seizures",Launched,0.286299518276992,0.111636622053,phenacemide,,,0,0
BRD-K40992116-001-09-7::2.5::HTS,BRD-K40992116-001-09-7,parachlorophenol,2.5,HTS,CN_SNX5 (27131),CN,noncancer,antiinfective drug,,,,Launched,0.27610986714449,0.106925211824,parachlorophenol,,,0,0
BRD-K41024817-325-01-0::2.5::HTS,BRD-K41024817-325-01-0,4-phenolsulfonic-acid,2.5,HTS,PROT_GSK3_pS9,PROT,noncancer,,,,,Preclinical,0.275889258079569,0.0885346760114,4-phenolsulfonic-acid,,,0,0
BRD-K41104902-001-01-3::2.5::HTS,BRD-K41104902-001-01-3,GSK2656157,2.5,HTS,MUTpool_RBM15B (29890),MUTpool,targeted cancer,PERK inhibitor,,,,Preclinical,0.288537199398664,0.0142365469168,GSK2656157,OTHER,0.2871925723383273,0.6981908421786516,-3.2864294832684724
BRD-K41141507-001-16-2::2.5::HTS,BRD-K41141507-001-16-2,cyproterone-acetate,2.5,HTS,Exp_RAB2B (ENSG00000129472),GE,targeted cancer,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,Launched,0.33835112880136303,0.111758389615,cyproterone-acetate,,,0,0
BRD-K41143549-003-02-4::2.5::HTS,BRD-K41143549-003-02-4,N20C,2.5,HTS,PROT_NF2_Caution,PROT,targeted cancer,glutamate receptor antagonist,,,,Preclinical,0.260176640171256,0.052100219347,N20C,,,0,0
BRD-K41160163-001-06-8::2.5::HTS,BRD-K41160163-001-06-8,fenobam,2.5,HTS,MIRNA_hsa-miR-508-5p,MIRNA,noncancer,glutamate receptor antagonist,GRM5,,,Phase 2,0.28981425721791804,0.0314740838972,fenobam,,,0,0
BRD-K41170226-001-13-8::2.5::HTS,BRD-K41170226-001-13-8,deoxycholic-acid,2.5,HTS,LIN_ovary,LIN,noncancer,"biliverdin reductase A activator, G protein-coupled receptor agonist","EFTUD1, FPR1, GPBAR1",endocrinology,submental fat,Launched,0.26975116820789397,0.0841571721966,deoxycholic-acid,,,0,0
BRD-K41185545-001-02-3::2.5::HTS,BRD-K41185545-001-02-3,ambrisentan,2.5,HTS,PROT_PAI-1,PROT,noncancer,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),Launched,0.221377562030002,0.0894898555859,ambrisentan,,,0,0
BRD-K41213548-001-02-0::2.5::HTS,BRD-K41213548-001-02-0,KW-2478,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,HSP inhibitor,,,,Phase 1/Phase 2,0.42432017373448105,0.548712832275,KW-2478,HSP INHIBITOR,0.4239152243792927,3.79371651887271,-1.6562543978231554
BRD-K41234004-001-03-1::0.03::HTS,BRD-K41234004-001-03-1,icomucret,0.03,HTS,CRISPR_ZSCAN5B (342933),AVANA_PUBLIC_18Q2,noncancer,mucin production enhancer,LTB4R2,,,Phase 3,0.313418969479922,0.108813722376,icomucret,,,0,0
BRD-K41256143-001-12-7::2.5::HTS,BRD-K41256143-001-12-7,dehydroepiandrosterone,2.5,HTS,CN_OPN1MW2 (728458),CN,targeted cancer,protein synthesis stimulant,"ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1",,,Launched,0.273248625141624,0.0213087448086,dehydroepiandrosterone,,,0,0
BRD-K41267922-001-01-4::2.5::MTS004,BRD-K41267922-001-01-4,F351,2.5,MTS004,Exp_LINC00365 (ENSG00000224511),GE,noncancer,TGF beta receptor inhibitor,TGFB1,,,Phase 2,0.282266342964801,0.0970422644872,F351,,,0,0
BRD-K41278234-001-03-0::2.5::HTS,BRD-K41278234-001-03-0,CUDC-101,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.390484116367459,0.253517717723,CUDC-101,EGFR INHIBITOR,0.3890288962131621,5.8738757810806765,-1.3856586174829966
BRD-K41298358-395-03-4::2.46::HTS,BRD-K41298358-395-03-4,tetraethylenepentamine,2.46,HTS,MIRNA_hsa-miR-142-5p,MIRNA,targeted cancer,superoxide dismutase inhibitor,"SOD1, SOD2",,,Phase 2/Phase 3,0.25734319559492896,0.0474669074782,tetraethylenepentamine,,,0,0
BRD-K41304947-001-03-2::2.5::HTS,BRD-K41304947-001-03-2,HA-966-(S)-(-),2.5,HTS,CRISPR_FSTL4 (23105),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,GRIA1,,,Preclinical,0.300794255009158,0.1141151924,HA-966-(S)-(-),,,0,0
BRD-K41312087-001-02-7::2.5::HTS,BRD-K41312087-001-02-7,GW-441756,2.5,HTS,PROT_Bcl-xL,PROT,targeted cancer,growth factor receptor inhibitor,NTRK1,,,Preclinical,0.320594335136316,0.229527803287,GW-441756,OTHER,0.2970755904698879,2.6521536330081616,0.2076753075478286
BRD-K41337261-001-03-0::2.5::HTS,BRD-K41337261-001-03-0,ZM-306416,2.5,HTS,Exp_FAM50A (ENSG00000071859),GE,targeted cancer,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",,,Preclinical,0.382202230870648,0.207700681149,ZM-306416,OTHER,0.38084639780289004,3.0806105658677234,-0.5468262841526923
BRD-K41406082-001-16-2::2.5::HTS,BRD-K41406082-001-16-2,sulfapyridine,2.5,HTS,METHYL_LINC00926,METHYL,noncancer,PABA antagonist,,,,Launched,0.21536863244251,0.131876232004,sulfapyridine,,,0,0
BRD-K41410256-304-02-2::2.5::HTS,BRD-K41410256-304-02-2,balsalazide,2.5,HTS,CRISPR_GNB1L (54584),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"ALOX5, PPARG, PTGS1, PTGS2",gastroenterology,ulcerative colitis,Launched,0.259751617145808,0.0951079900565,balsalazide,,,0,0
BRD-K41434598-003-01-9::2.5::HTS,BRD-K41434598-003-01-9,org-9768,2.5,HTS,CRISPR_NUDCD3 (23386),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,ADRA2A,,,Phase 1,0.315667762225926,0.144798627016,org-9768,,,0,0
BRD-K41438959-001-01-7::2.5::HTS,BRD-K41438959-001-01-7,perampanel,2.5,HTS,Exp_RAMP1 (ENSG00000132329),GE,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",neurology/psychiatry,seizures,Launched,0.269216651373962,0.103471095999,perampanel,,,0,0
BRD-K41445866-001-18-8::2.5::HTS,BRD-K41445866-001-18-8,alfaxalone,2.5,HTS,PROT_PR,PROT,noncancer,"chloride channel agonist, benzodiazepine receptor agonist",GABBR1,neurology/psychiatry,general anaesthetic,Launched,0.298955198093297,0.108389607493,alfaxalone,,,0,0
BRD-K41458421-034-01-6::2.500006592::MTS004,BRD-K41458421-034-01-6,naloxegol,2.500006592,MTS004,PROT_Raptor,PROT,noncancer,opioid receptor antagonist,OPRM1,gastroenterology,constipation,Launched,0.30305024931810903,0.107725095839,naloxegol,,,0,0
BRD-K41524689-001-23-5::2.5::HTS,BRD-K41524689-001-23-5,paracetamol,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,noncancer,cyclooxygenase inhibitor,"FAAH, PTGS1, PTGS2, TRPV1","neurology/psychiatry, endocrinology","pain relief, fever",Launched,0.30190610940964696,0.0978363656362,paracetamol,,,0,0
BRD-K41564320-001-02-0::2.5::HTS,BRD-K41564320-001-02-0,purvalanol-b,2.5,HTS,METHYL_RHOBTB3,METHYL,targeted cancer,tyrosine kinase inhibitor,"CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2",,,Preclinical,0.24031502456673398,0.00587077992148,purvalanol-b,,,0,0
BRD-K41567364-001-04-6::2.5::HTS,BRD-K41567364-001-04-6,SB-334867,2.5,HTS,METHYL_RAB41,METHYL,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Preclinical,0.318033492741789,0.0112654532332,SB-334867,,,0,0
BRD-K41567533-001-08-3::2.5::HTS,BRD-K41567533-001-08-3,coumophos,2.5,HTS,DEM2_BIRC2 (329),DEMETER2_COM,noncancer,cholinesterase inhibitor,,,,Preclinical,0.291610839292141,0.099909272147,coumophos,,,0,0
BRD-K41592905-001-01-6::2.5::MTS004,BRD-K41592905-001-01-6,7-methylxanthine,2.5,MTS004,Exp_HMGB1P19 (ENSG00000253463),GE,noncancer,adenosine receptor antagonist,,,,Phase 2,0.301643683664978,0.161782044086,7-methylxanthine,,,0,0
BRD-K41599323-001-02-3::2.5::HTS,BRD-K41599323-001-02-3,lonafarnib,2.5,HTS,Exp_RCC1 (ENSG00000180198),GE,targeted cancer,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",,,Phase 3,0.371776621185306,0.177979086212,lonafarnib,OTHER,0.3710594244048327,4.309876390916096,-3.0828297324325313
BRD-K41662846-003-01-5::2.517380705::MTS004,BRD-K41662846-003-01-5,tecalcet,2.517380705,MTS004,Exp_RN7SL689P (ENSG00000263432),GE,noncancer,calcium-sensing receptor agonist,CASR,,,Phase 2,0.33045124707433304,0.178242851599,tecalcet,,,0,0
BRD-K41707108-001-05-6::2.5::HTS,BRD-K41707108-001-05-6,ceramide,2.5,HTS,PROT_Smad3,PROT,noncancer,"phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator",,dermatology,cosmetic,Launched,0.228706973363718,0.0416528170791,ceramide,,,0,0
BRD-K41713976-300-02-6::2.5::HTS,BRD-K41713976-300-02-6,E-4031,2.5,HTS,PROT_GSK3-alpha-beta,PROT,noncancer,potassium channel blocker,"KCNH1, KCNH2",,,Phase 1,0.325641441912354,0.0472158372356,E-4031,,,0,0
BRD-K41731458-001-15-1::2.5::HTS,BRD-K41731458-001-15-1,triclosan,2.5,HTS,CN_NUTM2A (728118),CN,noncancer,antibacterial agent,DNMT1,,,Launched,0.28605294738048603,0.130479628554,triclosan,,,0,0
BRD-K41772907-001-01-2::2.5::HTS,BRD-K41772907-001-01-2,tolimidone,2.5,HTS,MIRNA_hsa-miR-1262,MIRNA,noncancer,src activator,"LYN, SRC",,,Phase 2,0.23241991968242198,0.0477492739695,tolimidone,,,0,0
BRD-K41779183-001-01-2::2.5::HTS,BRD-K41779183-001-01-2,CB-03-01,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,androgen receptor antagonist,AR,,,Phase 3,0.28355515914891,0.132429907253,CB-03-01,,,0,0
BRD-K41783120-001-02-8::2.5::HTS,BRD-K41783120-001-02-8,STA-5326,2.5,HTS,METHYL_ZFP3,METHYL,noncancer,interleukin synthesis inhibitor,IL12A,,,Phase 2,0.404202856099281,0.35370898696,STA-5326,OTHER,0.39385343008093293,4.113272806412343,-2.601820438307384
BRD-K41853443-001-02-9::2.5::HTS,BRD-K41853443-001-02-9,"1,3-dipropyl-8-phenylxanthine",2.5,HTS,METABOL_glucuronate,METABOL,noncancer,adenosine receptor antagonist,,,,Preclinical,0.331116101707901,0.106136868269,"1,3-dipropyl-8-phenylxanthine",,,0,0
BRD-K41859756-001-06-8::2.5::HTS,BRD-K41859756-001-06-8,NVP-AUY922,2.5,HTS,METABOL_pipecolic acid,METABOL,targeted cancer,HSP inhibitor,"HSP90AA1, HSP90AB1",,,Phase 2,0.363282126214155,0.261268472918,NVP-AUY922,HSP INHIBITOR,0.3554022140112777,5.1950957176643495,-0.4886742931062758
BRD-K41866823-001-01-3::2.5::HTS,BRD-K41866823-001-01-3,2-hydroxyethyl-salicylate,2.5,HTS,Exp_ANKRD20A11P (ENSG00000215559),GE,noncancer,,,,,Launched,0.322914449015737,0.0775969444899,2-hydroxyethyl-salicylate,,,0,0
BRD-K41869275-001-02-8::2.5::HTS,BRD-K41869275-001-02-8,2-phenylmelatonin,2.5,HTS,METHYL_SDC3,METHYL,noncancer,melatonin receptor agonist,"MTNR1A, MTNR1B",,,Preclinical,0.24496032169689302,0.026097226415,2-phenylmelatonin,,,0,0
BRD-K41876534-001-13-7::2.5::HTS,BRD-K41876534-001-13-7,tioxolone,2.5,HTS,Exp_UGT1A6 (ENSG00000167165),GE,noncancer,carbonic anhydrase inhibitor,CA2,,,Preclinical,0.557303966291342,0.500946714326,tioxolone,OTHER,0.5569602956008161,0.6815688739278282,-4.076616252396843
BRD-K41918892-001-05-9::2.5::HTS,BRD-K41918892-001-05-9,A-769662,2.5,HTS,CN_IMPA2 (3613),CN,noncancer,AMPK activator,,,,Preclinical,0.32748822754434304,0.0701940936018,A-769662,,,0,0
BRD-K42066335-001-01-0::2.499995517::MTS004,BRD-K42066335-001-01-0,lorediplon,2.499995517,MTS004,METABOL_2-deoxyadenosine,METABOL,noncancer,GABA receptor modulator,GABRA1,,,Phase 2,0.242711967653065,0.0573192234248,lorediplon,,,0,0
BRD-K42090719-001-06-5::2.43::HTS,BRD-K42090719-001-06-5,trichloroacetic-acid,2.43,HTS,PROT_Rictor_pT1135,PROT,noncancer,,,dermatology,warts,Launched,0.284316610675275,0.0373274235762,trichloroacetic-acid,,,0,0
BRD-K42095107-001-17-1::2.5::HTS,BRD-K42095107-001-17-1,daidzein,2.5,HTS,METHYL_ZMYND19,METHYL,targeted cancer,estrogen receptor agonist,"ESRRA, ESRRB, ESRRG, TRPC5",,,Phase 2,0.221104783932376,0.0679511816671,daidzein,,,0,0
BRD-K42098891-003-20-5::2.5::HTS,BRD-K42098891-003-20-5,protriptyline,2.5,HTS,LIN_mesothelioma,LIN,noncancer,tricyclic antidepressant,"SLC6A2, SLC6A4",neurology/psychiatry,depression,Launched,0.26632487418029,0.106127225883,protriptyline,,,0,0
BRD-K42140276-402-01-4::2.500009363::MTS004,BRD-K42140276-402-01-4,alarelin,2.500009363,MTS004,Exp_RANBP17 (ENSG00000204764),GE,noncancer,gonadotropin releasing factor hormone receptor antagonist,GNRH1,,,Launched,0.327759263712852,0.0683201790121,alarelin,,,0,0
BRD-K42191735-001-05-3::2.5::HTS,BRD-K42191735-001-05-3,buparlisib,2.5,HTS,METHYL_ANO4,METHYL,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CG",,,Phase 3,0.360500594519615,0.175616687096,buparlisib,PI3K INHIBITOR,0.3617882377248671,4.077432187749252,-1.0861615375764249
BRD-K42205652-001-02-7::2.5::HTS,BRD-K42205652-001-02-7,"MNS-(3,4-Methylenedioxy-nitrostyrene)",2.5,HTS,Exp_TTC13 (ENSG00000143643),GE,noncancer,"src inhibitor, syk inhibitor","SRC, SYK",,,Preclinical,0.354876039729536,0.296397471008,"MNS-(3,4-Methylenedioxy-nitrostyrene)",OTHER,0.35587442931175306,4.761013275456452,-3.25719405309674
BRD-K42221274-003-07-7::2.5::HTS,BRD-K42221274-003-07-7,NNC-711,2.5,HTS,Exp_ADAM12 (ENSG00000148848),GE,noncancer,GABA uptake inhibitor,"SIGMAR1, SLC6A1",,,Preclinical,0.301322302932359,0.0780040504077,NNC-711,,,0,0
BRD-K42260897-001-07-6::2.48::HTS,BRD-K42260897-001-07-6,ezetimibe,2.48,HTS,DEM2_GUK1 (2987),DEMETER2_COM,noncancer,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia",Launched,0.241849965336241,0.0103136292984,ezetimibe,,,0,0
BRD-K42260897-001-09-2::2.5::HTS,BRD-K42260897-001-09-2,ezetimibe,2.5,HTS,CN_MYOM2 (9172),CN,noncancer,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia",Launched,0.25189067241354396,0.00319434672517,ezetimibe,,,0,0
BRD-K42348709-003-13-1::2.5::HTS,BRD-K42348709-003-13-1,cyclobenzaprine,2.5,HTS,PROT_GSK-3-BETA_Caution,PROT,noncancer,"adrenergic receptor agonist, serotonin receptor agonist",HTR2A,neurology/psychiatry,spasms,Launched,0.21672509349147603,0.0538498311517,cyclobenzaprine,,,0,0
BRD-K42352790-001-05-3::2.5::HTS,BRD-K42352790-001-05-3,anandamide,2.5,HTS,PROT_YAP_Caution,PROT,targeted cancer,cannabinoid receptor agonist,"CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1",,,Phase 2,0.273793762062056,0.106175888983,anandamide,,,0,0
BRD-K42417338-045-01-9::2.5::HTS,BRD-K42417338-045-01-9,butorphanol-(+)-tartrate,2.5,HTS,PROT_14-3-3_beta,PROT,noncancer,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1","neurology/psychiatry, gastroenterology","muscle pain, headache, abdominal pain",Launched,0.25922800052588296,0.0247610222135,butorphanol-(+)-tartrate,,,0,0
BRD-K42436189-001-01-2::2.5::HTS,BRD-K42436189-001-01-2,AZ20,2.5,HTS,CN_CASP12 (100506742),CN,targeted cancer,ATR kinase inhibitor,"ATR, MTOR",,,Preclinical,0.37215311851893296,0.202753747465,AZ20,OTHER,0.3875465367647582,4.977518117621576,-1.9625857548298016
BRD-K42452249-001-02-5::2.5::HTS,BRD-K42452249-001-02-5,EO-1428,2.5,HTS,DEM2_AK5 (26289),DEMETER2_COM,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK14",,,Preclinical,0.260123905496087,0.113227307992,EO-1428,,,0,0
BRD-K42495768-001-01-7::2.5::HTS,BRD-K42495768-001-01-7,tasisulam,2.5,HTS,Exp_SYS1 (ENSG00000204070),GE,targeted cancer,apoptosis stimulant,,,,Phase 3,0.4095680885146029,0.340132326546,tasisulam,OTHER,0.4110928600321732,3.815338599228811,-4.196698326747371
BRD-K42497885-001-01-1::2.5::HTS,BRD-K42497885-001-01-1,satraplatin,2.5,HTS,Exp_KDM1A (ENSG00000004487),GE,chemo,DNA alkylating agent,,,,Phase 3,0.415390621335065,0.324865655245,satraplatin,OTHER,0.4132007595956333,4.08665160800064,-2.7814189801563995
BRD-K42500029-001-03-5::2.5::HTS,BRD-K42500029-001-03-5,CGP-57380,2.5,HTS,METHYL_EFNA1,METHYL,targeted cancer,MAP kinase inhibitor,"AURKB, LCK, MKNK1, MKNK2, SGK1",,,Preclinical,0.261839853278864,0.027587417836,CGP-57380,,,0,0
BRD-K42504537-001-01-6::2.500037177::MTS004,BRD-K42504537-001-01-6,norelgestromin,2.500037177,MTS004,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,,PGR,endocrinology,contraceptive,Launched,0.250184511817629,0.11544828412,norelgestromin,,,0,0
BRD-K42563464-001-01-9::2.5::HTS,BRD-K42563464-001-01-9,YM-58483,2.5,HTS,LIN_esophagus,LIN,noncancer,calcium channel blocker,"TRPC3, TRPC5, TRPM4",,,Preclinical,0.31366871891292497,0.053211117514,YM-58483,,,0,0
BRD-K42673188-001-01-1::2.363355746::MTS004,BRD-K42673188-001-01-1,verubulin,2.363355746,MTS004,Exp_TBPL1 (ENSG00000028839),GE,chemo,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.40882496026486004,0.345114447301,verubulin,TUBULIN POLYMERIZATION INHIBITOR,0.413005421978568,5.856832536460214,-3.8061942351239297
BRD-K42679050-001-02-1::2.5::HTS,BRD-K42679050-001-02-1,Y-27152,2.5,HTS,METABOL_C48:2 TAG,METABOL,noncancer,potassium channel activator,KCNJ8,,,Phase 1,0.284693486094761,0.106396027347,Y-27152,,,0,0
BRD-K42748308-300-02-0::2.5::HTS,BRD-K42748308-300-02-0,XE-991,2.5,HTS,METHYL_TRIM26,METHYL,noncancer,potassium channel blocker,"KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",,,Preclinical,0.239410447547286,0.0848839286079,XE-991,,,0,0
BRD-K42756753-001-01-9::2.5::HTS,BRD-K42756753-001-01-9,epiandrosterone,2.5,HTS,MIRNA_hsa-miR-1197,MIRNA,noncancer,steroid,G6PD,,,Preclinical,0.203324373066332,0.0656603196224,epiandrosterone,,,0,0
BRD-K42805893-001-04-9::2.5::HTS,BRD-K42805893-001-04-9,osimertinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.439029743347816,0.53608640338,osimertinib,EGFR INHIBITOR,0.4335821099087843,0.8100716144978829,-4.907425781031169
BRD-K42816473-001-01-0::2.38330586::MTS004,BRD-K42816473-001-01-0,zilpaterol,2.38330586,MTS004,CN_CLPSL1 (340204),CN,noncancer,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid,Launched,0.281173485347672,0.141821980628,zilpaterol,,,0,0
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,OTHER,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K42859542-001-03-3::2.5::HTS,BRD-K42859542-001-03-3,CFM-2,2.5,HTS,CRISPR_PSRC1 (84722),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,,,,Preclinical,0.32703005587912604,0.235477892757,CFM-2,,,0,0
BRD-K42898655-001-01-8::2.5::HTS,BRD-K42898655-001-01-8,temsirolimus,2.5,HTS,Exp_ZEB2 (ENSG00000169554),GE,targeted cancer,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),Launched,0.33475538202637395,0.216965072449,temsirolimus,MTOR INHIBITOR,0.32919032698143924,0.8123165347196505,-1.806225967941708
BRD-K42938903-332-01-1::2.5::HTS,BRD-K42938903-332-01-1,acetophenazine,2.5,HTS,DEM2_WDR78 (79819),DEMETER2_COM,noncancer,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,Launched,0.21657638093306303,0.0998159859666,acetophenazine,,,0,0
BRD-K42948882-305-01-1::2.5::HTS,BRD-K42948882-305-01-1,AMD11070,2.5,HTS,DEM2_CD44 (960),DEMETER2_COM,targeted cancer,CC chemokine receptor antagonist,CXCR4,,,Phase 1/Phase 2,0.307876150413312,0.0773958675557,AMD11070,,,0,0
BRD-K42959922-001-01-5::2.5::HTS,BRD-K42959922-001-01-5,trans-2-Undecenoic-acid,2.5,HTS,DEM2_SERPINA9 (327657),DEMETER2_COM,noncancer,,,,,Preclinical,0.327671239358469,0.0754578907676,trans-2-Undecenoic-acid,,,0,0
BRD-K42973005-001-04-0::2.5::HTS,BRD-K42973005-001-04-0,CHIR-98014,2.5,HTS,Exp_SSR2 (ENSG00000163479),GE,noncancer,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,Preclinical,0.341873985011427,0.234565491712,CHIR-98014,OTHER,0.34255107125849543,5.446137433863611,-2.819622413450236
BRD-K42981054-001-01-9::2.5::HTS,BRD-K42981054-001-01-9,mibampator,2.5,HTS,DEM2_NDUFB5 (4711),DEMETER2_COM,noncancer,glutamate receptor modulator,GRIA1,,,Phase 2,0.299395414519623,0.0620503124514,mibampator,OTHER,0.3146434010281097,0.8251414071528409,-3.3193312123548235
BRD-K42991124-001-03-0::2.5::HTS,BRD-K42991124-001-03-0,creatinol-phosphate,2.5,HTS,MIRNA_hsa-miR-520g,MIRNA,noncancer,,,,,Launched,0.27610466513971504,0.0576007458434,creatinol-phosphate,,,0,0
BRD-K43002771-034-01-6::2.5::HTS,BRD-K43002771-034-01-6,SR-33805,2.5,HTS,CN_MIR3689A (100500846),CN,noncancer,calcium channel blocker,,,,Phase 1,0.370611571636046,0.0401901888926,SR-33805,OTHER,0.3658157813045379,-2.466811337770072,-0.340565919052608
BRD-K43055376-001-01-2::2.5::HTS,BRD-K43055376-001-01-2,ADD-233089,2.5,HTS,METABOL_acetylcholine,METABOL,noncancer,benzodiazepine receptor agonist,,,,Phase 1,0.31510204683110604,0.127861860251,ADD-233089,,,0,0
BRD-K43106192-320-11-8::2.5::HTS,BRD-K43106192-320-11-8,gallamine-triethiodide,2.5,HTS,Exp_PLCB2 (ENSG00000137841),GE,noncancer,acetylcholine receptor antagonist,"ACHE, CHRM2, CHRNA1, CHRNA2",neurology/psychiatry,muscle relaxant,Launched,0.293633398007995,0.0395179864069,gallamine-triethiodide,,,0,0
BRD-K43149758-001-22-7::2.5::HTS,BRD-K43149758-001-22-7,myricetin,2.5,HTS,Exp_RASGRP4 (ENSG00000171777),GE,targeted cancer,"androgen receptor agonist, cytochrome P450 inhibitor",PIK3CG,,,Preclinical,0.318238058209913,0.0850845259043,myricetin,,,0,0
BRD-K43164539-001-11-5::2.5::HTS,BRD-K43164539-001-11-5,cholic-acid,2.5,HTS,MIRNA_hsa-miR-886-3p,MIRNA,noncancer,bile acid,"ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B","gastroenterology, neurology/psychiatry, genetics","bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome",Launched,0.270084160774346,0.0936918297927,cholic-acid,,,0,0
BRD-K43187018-001-03-3::2.52::HTS,BRD-K43187018-001-03-3,GDC-0349,2.52,HTS,Exp_FBXL19-AS1 (ENSG00000260852),GE,targeted cancer,Pim kinase inhibitor,PIK3CA,,,Phase 1,0.308414972567047,0.28839047639,GDC-0349,PIM KINASE INHIBITOR,0.30808689544269985,2.480885384720411,-1.1720900683676407
BRD-K43187796-001-02-3::2.5::HTS,BRD-K43187796-001-02-3,3-indolebutyric-acid,2.5,HTS,PROT_4E-BP1_pT37_T46,PROT,noncancer,,"B2M, HLA-A, TRAC, TRBC1",,,Preclinical,0.28460952563528197,0.0283739527846,3-indolebutyric-acid,,,0,0
BRD-K43192255-048-03-6::2.5::HTS,BRD-K43192255-048-03-6,methyllycaconitine,2.5,HTS,METHYL_TFAP2E,METHYL,noncancer,acetylcholine receptor antagonist,CHRNA7,,,Preclinical,0.291316549302157,0.010100584317,methyllycaconitine,,,0,0
BRD-K43230258-001-01-4::2.50004725::MTS004,BRD-K43230258-001-01-4,crisaborole,2.50004725,MTS004,DEM2_SRPK1 (6732),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,PDE4B,,,Phase 3,0.252757297646343,0.0708872722496,crisaborole,,,0,0
BRD-K43236057-001-07-1::2.6::HTS,BRD-K43236057-001-07-1,polydatin,2.6,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,ICAM1 expression inhibitor,ICAM1,,,Phase 2,0.38503202591057395,0.548940227879,polydatin,OTHER,0.3880928884767401,4.739073732711199,-3.842809021183049
BRD-K43305603-004-02-8::2.5::HTS,BRD-K43305603-004-02-8,rocuronium,2.5,HTS,CRISPR_NME9 (347736),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRM2, CHRNA2, HTR3A",neurology/psychiatry,anesthetic,Launched,0.261740728099074,0.0625737724711,rocuronium,,,0,0
BRD-K43316319-001-01-8::2.356803189::MTS004,BRD-K43316319-001-01-8,MK-2295,2.356803189,MTS004,Exp_LSM3P2 (ENSG00000257847),GE,noncancer,TRPV antagonist,TRPV1,,,Phase 2,0.30828736075671803,0.0932482200278,MK-2295,,,0,0
BRD-K43363084-001-01-3::2.5::HTS,BRD-K43363084-001-01-3,atglistatin,2.5,HTS,CN_TCEAL5 (340543),CN,noncancer,adipose triglyceride lipase inhibitor,,,,Preclinical,0.29416396699502,0.0689745288599,atglistatin,,,0,0
BRD-K43383936-001-05-2::2.5::HTS,BRD-K43383936-001-05-2,flopropione,2.5,HTS,Exp_FAM35A (ENSG00000122376),GE,noncancer,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms,Launched,0.241665434842488,0.0746834731571,flopropione,,,0,0
BRD-K43389698-001-09-9::2.4::HTS,BRD-K43389698-001-09-9,BMS-387032,2.4,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",,,Phase 1,0.34389319060567997,0.0898598329229,BMS-387032,CDK INHIBITOR,0.3468213601011139,5.073693658642744,0.6398439718783115
BRD-K43410529-001-02-3::2.5::HTS,BRD-K43410529-001-02-3,MLN2480,2.5,HTS,DEM2_BRAF (673),DEMETER2_COM,targeted cancer,RAF inhibitor,,,,Phase 1,0.346091590626866,0.307751578014,MLN2480,,,0,0
BRD-K43449605-001-01-0::2.5::HTS,BRD-K43449605-001-01-0,oncrasin-1,2.5,HTS,Exp_SULT1A1 (ENSG00000196502),GE,targeted cancer,apoptosis stimulant,,,,Preclinical,0.617991499365294,0.655962117118,oncrasin-1,OTHER,0.6163011472128322,5.599629506320927,1.5371886838655358
BRD-K43457670-001-27-8::2.5::HTS,BRD-K43457670-001-27-8,acetazolamide,2.5,HTS,PROT_N-Ras,PROT,noncancer,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,Launched,0.262267191808435,-0.042421724039,acetazolamide,,,0,0
BRD-K43471985-001-03-0::2.69::HTS,BRD-K43471985-001-03-0,OTX015,2.69,HTS,Exp_XPO5 (ENSG00000124571),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 1/Phase 2,0.392750751026659,0.257251406466,OTX015,BROMODOMAIN INHIBITOR,0.3878112270886288,-0.41948158015798137,3.298809429462448
BRD-K43471985-001-05-5::2.5::HTS,BRD-K43471985-001-05-5,OTX015,2.5,HTS,Exp_MTG1 (ENSG00000148824),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 1/Phase 2,0.392750751026659,0.257251406466,OTX015,BROMODOMAIN INHIBITOR,0.3358759386996415,-0.439662641400295,3.2842568019784992
BRD-K43578482-001-01-4::2.5::HTS,BRD-K43578482-001-01-4,defactinib,2.5,HTS,Exp_YIPF5 (ENSG00000145817),GE,targeted cancer,focal adhesion kinase inhibitor,PTK2,,,Phase 2,0.30983436459250296,0.234577715369,defactinib,OTHER,0.30833080481636044,1.8682799998758344,-3.6434370249408965
BRD-K43586850-001-02-9::2.5::HTS,BRD-K43586850-001-02-9,lacidipine,2.5,HTS,METHYL_NHLRC1,METHYL,noncancer,calcium channel blocker,CACNA1C,cardiology,hypertension,Launched,0.320952545764652,0.10176499466,lacidipine,,,0,0
BRD-K43621685-001-02-5::2.5::HTS,BRD-K43621685-001-02-5,CP-673451,2.5,HTS,Exp_CTDSPL (ENSG00000144677),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",,,Preclinical,0.31475327470845504,0.261033027649,CP-673451,OTHER,0.3134138133618576,3.878172654955764,-2.808416866478697
BRD-K43639297-001-01-9::2.500038533::MTS004,BRD-K43639297-001-01-9,hemoglobin-modulators-1,2.500038533,MTS004,Exp_CCK (ENSG00000187094),GE,noncancer,hemoglobin modulator,,,,Phase 3,0.323603824641276,0.0838730943877,hemoglobin-modulators-1,,,0,0
BRD-K43647122-001-01-3::2.5::MTS004,BRD-K43647122-001-01-3,nerbacadol,2.5,MTS004,CN_WNK1 (65125),CN,noncancer,cyclooxygenase inhibitor,,,,Phase 3,0.255661782359137,0.0528973595033,nerbacadol,,,0,0
BRD-K43786866-300-02-3::2.5::HTS,BRD-K43786866-300-02-3,opipramol,2.5,HTS,Exp_GJB1 (ENSG00000169562),GE,noncancer,sigma receptor agonist,,neurology/psychiatry,generalized anxiety disorder (GAD),Launched,0.283905806431395,0.0792547183722,opipramol,,,0,0
BRD-K43797669-001-30-4::2.5::HTS,BRD-K43797669-001-30-4,genistein,2.5,HTS,Exp_APOE (ENSG00000130203),GE,targeted cancer,tyrosine kinase inhibitor,"CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5",,,Phase 2/Phase 3,0.337917775679338,0.115566790551,genistein,,,0,0
BRD-K43802723-340-01-9::2.5::HTS,BRD-K43802723-340-01-9,AMG-837,2.5,HTS,CN_ABCA12 (26154),CN,noncancer,free fatty acid receptor agonist,FFAR1,,,Phase 1,0.284488067486856,0.104945576028,AMG-837,,,0,0
BRD-K43837174-003-01-3::2.479237222::MTS004,BRD-K43837174-003-01-3,pruvanserin,2.479237222,MTS004,CN_SLC6A10P (386757),CN,noncancer,serotonin receptor antagonist,"HTR2A, HTR2C",,,Phase 2,0.300895126435124,0.110211864226,pruvanserin,,,0,0
BRD-K43860855-065-11-9::2.5::HTS,BRD-K43860855-065-11-9,iobenguane,2.5,HTS,METABOL_taurocholate,METABOL,targeted cancer,antineoplastic agent,,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma",Launched,0.23724142440249898,0.0227576064524,iobenguane,,,0,0
BRD-K43873574-001-01-8::2.5::HTS,BRD-K43873574-001-01-8,ilepcimide,2.5,HTS,PROT_NDRG1_pT346,PROT,noncancer,anticonvulsant,,,,Phase 3,0.321026556630232,0.090247440985,ilepcimide,,,0,0
BRD-K43880410-001-14-4::2.5::HTS,BRD-K43880410-001-14-4,pregnenolone,2.5,HTS,DEM2_PEX7 (5191),DEMETER2_COM,noncancer,glutamate receptor modulator,"CYP17A1, SULT2B1",,,Launched,0.252481492835804,0.100845847387,pregnenolone,,,0,0
BRD-K43887077-003-26-3::2.5::HTS,BRD-K43887077-003-26-3,dopamine,2.5,HTS,PROT_Smad4,PROT,noncancer,dopamine receptor agonist,"DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4","cardiology, neurology/psychiatry","ventricular arrhythmias, depression, headache, tremors",Launched,0.28490319003569897,0.0485368005506,dopamine,,,0,0
BRD-K43890836-001-01-6::2.5::MTS004,BRD-K43890836-001-01-6,gemcadiol,2.5,MTS004,Exp_KCNMA1 (ENSG00000156113),GE,noncancer,antilipemic,,,,Phase 2,0.32789004310146896,0.240581634505,gemcadiol,,,0,0
BRD-K43905307-001-01-2::2.5::HTS,BRD-K43905307-001-01-2,"L-798,106",2.5,HTS,METHYL_ZNF573,METHYL,noncancer,prostanoid receptor antagonist,PTGER3,,,Preclinical,0.28905133741802397,0.0635078105087,"L-798,106",,,0,0
BRD-K43927145-001-01-2::2.5::HTS,BRD-K43927145-001-01-2,BIBN4096,2.5,HTS,METABOL_C24:1 SM,METABOL,noncancer,calcitonin antagonist,"CALCA, CALCRL, RAMP1",,,Phase 2,0.258511686507577,0.0904067448613,BIBN4096,,,0,0
BRD-K43966364-237-04-8::2.5::HTS,BRD-K43966364-237-04-8,penicillin-v-potassium,2.5,HTS,MIRNA_hsa-miR-367,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever",Launched,0.21198453942918397,0.0756334000458,penicillin-v-potassium,,,0,0
BRD-K43975632-001-01-1::2.499995729::MTS004,BRD-K43975632-001-01-1,terutroban,2.499995729,MTS004,CN_TRG-AS1 (100506776),CN,noncancer,prostanoid receptor antagonist,TBXA2R,,,Phase 3,0.31244690613859805,0.0352333433585,terutroban,,,0,0
BRD-K44009692-001-02-3::2.5::HTS,BRD-K44009692-001-02-3,hyodeoxycholic-acid,2.5,HTS,MUTpool_ERCC4 (2072),MUTpool,noncancer,atherosclerosis formation inhibitor,,,,Phase 1,0.32999342102325396,0.00549015029752,hyodeoxycholic-acid,,,0,0
BRD-K44030614-001-01-6::2.500000065::MTS004,BRD-K44030614-001-01-6,ponesimod,2.500000065,MTS004,MIRNA_hsa-miR-500+hsa-miR-501-5p,MIRNA,noncancer,sphingosine 1 phosphate receptor agonist,S1PR1,,,Phase 3,0.28491716180509896,0.105400851469,ponesimod,,,0,0
BRD-K44067360-001-30-3::2.5::HTS,BRD-K44067360-001-30-3,flufenamic-acid,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",,,Preclinical,0.21170825075461,0.143447489462,flufenamic-acid,OTHER,0.21364220171638465,5.27215601046389,-1.6235982949918728
BRD-K44084986-300-08-4::2.5::HTS,BRD-K44084986-300-08-4,Y-27632,2.5,HTS,Exp_RPL31P11 (ENSG00000213075),GE,targeted cancer,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",,,Preclinical,0.340417201538343,0.19776024642,Y-27632,OTHER,0.33626007255537954,5.965668586101893,-2.5058459950572525
BRD-K44133266-001-10-0::2.5::HTS,BRD-K44133266-001-10-0,sulbactam,2.5,HTS,DEM2_LDHAL6B (92483),DEMETER2_COM,noncancer,beta lactamase inhibitor,,infectious disease,"skin infections, intra-abdominal infections, gynecologic infections",Launched,0.288043213275558,0.0927814005384,sulbactam,,,0,0
BRD-K44164034-003-01-1::2.54181785::MTS004,BRD-K44164034-003-01-1,pumosetrag,2.54181785,MTS004,METABOL_guanosine,METABOL,noncancer,serotonin receptor agonist,"HTR3A, HTR4",,,Phase 2,0.21723186467364602,0.112296805405,pumosetrag,,,0,0
BRD-K44184170-001-01-7::2.5::MTS004,BRD-K44184170-001-01-7,ospemifene,2.5,MTS004,CN_SRP19 (6728),CN,noncancer,selective estrogen receptor modulator (SERM),"ESR1, ESR2","obstetrics/gynecology, endocrinology","vaginal atrophy, dyspareunia, menopause",Launched,0.279279092698992,0.0788063029336,ospemifene,,,0,0
BRD-K44227013-001-06-4::2.5::HTS,BRD-K44227013-001-06-4,ponatinib,2.5,HTS,Exp_DUSP8 (ENSG00000184545),GE,targeted cancer,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.38209937474291705,0.370848795255,ponatinib,OTHER,0.3823279797566612,2.8700431185048743,-0.905867941465862
BRD-K44273375-001-25-0::2.5::HTS,BRD-K44273375-001-25-0,tolnaftate,2.5,HTS,MIRNA_hsa-miR-1244,MIRNA,noncancer,fungal squalene epoxidase inhibitor,,infectious disease,"tinea pedis, tinea corporis",Launched,0.321725060374518,0.0828588402318,tolnaftate,,,0,0
BRD-K44276885-001-07-4::2.5::HTS,BRD-K44276885-001-07-4,acarbose,2.5,HTS,PROT_NDRG1_pT346,PROT,noncancer,glucosidase inhibitor,"AMY2A, GAA, MGAM, SI",endocrinology,diabetes mellitus,Launched,0.269812911583977,0.108651426043,acarbose,,,0,0
BRD-K44309363-003-02-1::2.5::HTS,BRD-K44309363-003-02-1,dexniguldipine,2.5,HTS,METHYL_NETO2,METHYL,targeted cancer,calmodulin antagonist,ADORA3,,,Phase 2,0.326705603482075,0.0649879371328,dexniguldipine,,,0,0
BRD-K44353683-001-08-3::2.5::HTS,BRD-K44353683-001-08-3,nateglinide,2.5,HTS,MIRNA_hsa-miR-620,MIRNA,noncancer,insulin secretagogue,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,diabetes mellitus,Launched,0.349542193788456,0.0159115789901,nateglinide,,,0,0
BRD-K44366189-001-01-9::2.5::HTS,BRD-K44366189-001-01-9,anacetrapib,2.5,HTS,METHYL_LOC285740,METHYL,noncancer,cholesteryl ester transfer protein inhibitor,CETP,,,Phase 3,0.288730356268315,0.0739803384594,anacetrapib,,,0,0
BRD-K44408410-001-17-6::2.5::HTS,BRD-K44408410-001-17-6,2-methoxyestradiol,2.5,HTS,Exp_NCEH1 (ENSG00000144959),GE,targeted cancer,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",,,Phase 2,0.37733724710227295,0.267673454098,2-methoxyestradiol,HIF PROLYL HYDROXYLASE,0.3816974447382275,4.812109146818554,-3.758595116500839
BRD-K44442813-001-12-9::2.5::HTS,BRD-K44442813-001-12-9,pidotimod,2.5,HTS,DEM2_IARS2 (55699),DEMETER2_COM,noncancer,"interferon receptor agonist, interleukin receptor agonist",,infectious disease,immune adjuvant,Launched,0.29333999563523,0.0529261517584,pidotimod,,,0,0
BRD-K44471774-001-01-8::2.670187358::MTS004,BRD-K44471774-001-01-8,bay-w-9798,2.670187358,MTS004,CRISPR_POU5F1B (5462),AVANA_PUBLIC_18Q2,targeted cancer,antioxidant,,,,Phase 2,0.34877827195433,0.0733153000998,bay-w-9798,,,0,0
BRD-K44590731-001-01-7::2.5::HTS,BRD-K44590731-001-01-7,TU-2100,2.5,HTS,DEM2_TRIM24 (8805),DEMETER2_COM,noncancer,,,,,Phase 2,0.24612266353345302,0.076094318011,TU-2100,,,0,0
BRD-K44665581-001-01-8::2.5::HTS,BRD-K44665581-001-01-8,bromosporine,2.5,HTS,PROT_Fibronectin,PROT,noncancer,bromodomain inhibitor,,,,Preclinical,0.3808726639219579,0.325363615459,bromosporine,BROMODOMAIN INHIBITOR,0.3688194486501979,-0.3992974067582145,3.2848667946619776
BRD-K44771174-066-01-0::2.5::HTS,BRD-K44771174-066-01-0,ibutamoren,2.5,HTS,LIN_lung_adenocarcinoma,LIN,noncancer,growth hormone secretagogue receptor agonist,"GHR, GHSR",,,Phase 2,0.309063023023845,0.0692256156272,ibutamoren,,,0,0
BRD-K44777625-001-03-5::2.5::HTS,BRD-K44777625-001-03-5,FH1,2.5,HTS,PROT_PKC-delta_pS664,PROT,noncancer,hepatocyte function enhancer,,,,Preclinical,0.331035644183644,0.127057263041,FH1,,,0,0
BRD-K44824027-001-02-1::2.5::HTS,BRD-K44824027-001-02-1,beclamide,2.5,HTS,DEM2_HDAC1 (3065),DEMETER2_COM,noncancer,anticonvulsant,,neurology/psychiatry,"sedative, seizures",Launched,0.280708620814881,0.00375061549733,beclamide,,,0,0
BRD-K44825564-065-01-4::2.5::HTS,BRD-K44825564-065-01-4,ZAPA,2.5,HTS,CRISPR_RPLP1 (6176),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.321483632550751,0.0379645768182,ZAPA,,,0,0
BRD-K44827188-001-06-0::2.5::HTS,BRD-K44827188-001-06-0,vismodegib,2.5,HTS,MIRNA_hsa-miR-619,MIRNA,targeted cancer,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Launched,0.32751167690525396,0.0314965169327,vismodegib,,,0,0
BRD-K44844162-001-01-6::2.5::HTS,BRD-K44844162-001-01-6,taselisib,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,PIK3CA,,,Phase 3,0.430041046918619,0.502719679653,taselisib,PI3K INHIBITOR,0.4343244753187693,0.6344122627609565,-1.7697257077162272
BRD-K44849676-001-10-5::2.5::HTS,BRD-K44849676-001-10-5,capsazepine,2.5,HTS,CRISPR_C1QTNF7 (114905),AVANA_PUBLIC_18Q2,noncancer,TRPV agonist,"TRPV1, TRPV4",,,Preclinical,0.32950636580877196,0.125014099818,capsazepine,,,0,0
BRD-K44876623-001-03-7::2.5::HTS,BRD-K44876623-001-03-7,zolpidem,2.5,HTS,RMUTdmg_CDKN2A (1029),MUTdmg,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3",neurology/psychiatry,insomnia,Launched,0.24977772510904997,0.0947501230582,zolpidem,,,0,0
BRD-K44942188-001-09-1::2.5::HTS,BRD-K44942188-001-09-1,fomocaine,2.5,HTS,Exp_PI15 (ENSG00000137558),GE,noncancer,voltage-gated sodium channel modulator,,neurology/psychiatry,local anesthetic,Launched,0.24110821441080701,0.0207838716461,fomocaine,,,0,0
BRD-K44942604-346-05-4::2.5::HTS,BRD-K44942604-346-05-4,pentolinium,2.5,HTS,CN_ETS1 (2113),CN,noncancer,cholinergic receptor antagonist,"CHRNA10, CHRNA3, CHRNA4, CHRNB4",cardiology,hypertension,Launched,0.270766757561692,0.04323663588,pentolinium,,,0,0
BRD-K44963273-001-06-9::2.5::HTS,BRD-K44963273-001-06-9,HQK-1001,2.5,HTS,CRISPR_ART5 (116969),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 2,0.20125165831673603,0.0151342190378,HQK-1001,,,0,0
BRD-K44974079-001-01-3::2.5::HTS,BRD-K44974079-001-01-3,ticagrelor,2.5,HTS,DEM2_CNGB1 (1258),DEMETER2_COM,noncancer,purinergic receptor antagonist,P2RY12,cardiology,"acute coronary syndrome (ACS), myocardial infarction",Launched,0.30509634058338103,0.00518505636129,ticagrelor,,,0,0
BRD-K44993696-001-12-3::2.5::HTS,BRD-K44993696-001-12-3,atenolol-(-),2.5,HTS,RMUTdmg_FAT1 (2195),MUTdmg,noncancer,adrenergic receptor antagonist,,,,Phase 2,0.273548744698627,0.0379108136134,atenolol-(-),,,0,0
BRD-K45014108-003-01-8::2.5::HTS,BRD-K45014108-003-01-8,ephedrine,2.5,HTS,METHYL_VTRNA1-2,METHYL,noncancer,adrenergic receptor agonist,"ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity",Launched,0.289566704387643,0.105053328877,ephedrine,,,0,0
BRD-K45033733-001-12-2::2.5::HTS,BRD-K45033733-001-12-2,famciclovir,2.5,HTS,Exp_FOXL2 (ENSG00000183770),GE,noncancer,DNA polymerase inhibitor,,"dental, infectious disease","cold sore, genitial herpes, shingles",Launched,0.27734528030371697,0.178543149449,famciclovir,,,0,0
BRD-K45071273-003-25-6::2.5::HTS,BRD-K45071273-003-25-6,tetracaine,2.5,HTS,MUTpool_NBAS (51594),MUTpool,noncancer,membrane integrity inhibitor,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,anesthetic,Launched,0.279903717606547,0.0334729178279,tetracaine,,,0,0
BRD-K45086103-001-15-5::2.5::HTS,BRD-K45086103-001-15-5,sulfaguanidine,2.5,HTS,PROT_Chk1_pS345_Caution,PROT,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.255433366544121,0.0263488422179,sulfaguanidine,,,0,0
BRD-K45086103-001-16-3::2.5::HTS,BRD-K45086103-001-16-3,sulfaguanidine,2.5,HTS,RMUTmis_GLDN (342035),MUT,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.318010756997025,0.121395216594,sulfaguanidine,,,0,0
BRD-K45114938-236-01-8::2.35::HTS,BRD-K45114938-236-01-8,mezlocillin,2.35,HTS,DEM2_UBXN1 (51035),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections",Launched,0.303889094386888,0.0844831379454,mezlocillin,,,0,0
BRD-K45117373-001-02-9::2.5::HTS,BRD-K45117373-001-02-9,Y-26763,2.5,HTS,CN_RAG2 (5897),CN,noncancer,potassium channel activator,KCNJ8,,,Phase 1,0.293605055653109,0.121340431019,Y-26763,,,0,0
BRD-K45125084-001-01-4::2.5::MTS004,BRD-K45125084-001-01-4,zolimidine,2.5,MTS004,METABOL_alanine,METABOL,noncancer,mucus protecting agent,,,,Launched,0.28403533747479903,0.0372142283658,zolimidine,,,0,0
BRD-K45152786-001-08-4::2.5::HTS,BRD-K45152786-001-08-4,merbarone,2.5,HTS,Exp_TPMTP1 (ENSG00000267156),GE,chemo,topoisomerase inhibitor,TOP2A,,,Phase 2,0.224526400692026,0.0542263339656,merbarone,,,0,0
BRD-K45158365-001-11-4::2.5::HTS,BRD-K45158365-001-11-4,valsartan,2.5,HTS,Exp_GLIPR1L1 (ENSG00000173401),GE,noncancer,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure",Launched,0.30661760256242604,0.105646471127,valsartan,,,0,0
BRD-K45163704-001-01-5::2.5::HTS,BRD-K45163704-001-01-5,midafotel,2.5,HTS,Exp_SPPL3 (ENSG00000157837),GE,noncancer,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Phase 3,0.177628341465302,0.0964131631504,midafotel,,,0,0
BRD-K45168550-001-01-9::2.5::HTS,BRD-K45168550-001-01-9,SB-756050,2.5,HTS,PROT_MIG-6,PROT,noncancer,G protein-coupled receptor agonist,GPBAR1,,,Phase 1,0.22907701505228303,0.115723470248,SB-756050,,,0,0
BRD-K45216060-001-10-0::2.5::HTS,BRD-K45216060-001-10-0,mequinol,2.5,HTS,Exp_PPIAP19 (ENSG00000228169),GE,noncancer,,TYR,dermatology,skin depigmentation,Launched,0.29248833238273303,0.116526766662,mequinol,,,0,0
BRD-K45216060-001-11-8::2.5::HTS,BRD-K45216060-001-11-8,mequinol,2.5,HTS,METHYL_HPS4,METHYL,noncancer,,TYR,dermatology,skin depigmentation,Launched,0.29248833238273303,0.105557606157,mequinol,,,0,0
BRD-K45238818-001-02-6::2.5::HTS,BRD-K45238818-001-02-6,succinic-acid,2.5,HTS,DEM2_DUSP12 (11266),DEMETER2_COM,noncancer,,"ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE",,,Launched,0.329339475733977,0.0655129579232,succinic-acid,,,0,0
BRD-K45245728-335-01-4::2.5::HTS,BRD-K45245728-335-01-4,ursodeoxycholyltaurine,2.5,HTS,Exp_FAR1-IT1 (ENSG00000254791),GE,noncancer,cholesterol inhibitor,,,,Phase 2,0.198640429152625,0.0279813065549,ursodeoxycholyltaurine,,,0,0
BRD-K45252063-001-13-6::2.5::HTS,BRD-K45252063-001-13-6,clofibrate,2.5,HTS,DEM2_P2RY4 (5030),DEMETER2_COM,noncancer,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol",Launched,0.29706494023965,0.0963393217231,clofibrate,,,0,0
BRD-K45275534-001-01-3::2.5::HTS,BRD-K45275534-001-01-3,betrixaban,2.5,HTS,DEM2_HINT3 (135114),DEMETER2_COM,noncancer,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT),Launched,0.27639961314169204,0.047384390224,betrixaban,,,0,0
BRD-K45330754-001-21-7::2.5::HTS,BRD-K45330754-001-21-7,diethylstilbestrol,2.5,HTS,CRISPR_KLKB1 (3818),AVANA_PUBLIC_18Q2,targeted cancer,estrogen receptor agonist,"ESR1, ESR2, ESRRB, ESRRG",,,Withdrawn,0.23100699356761606,0.0380969155271,diethylstilbestrol,,,0,0
BRD-K45385835-001-02-4::2.5::HTS,BRD-K45385835-001-02-4,SX-011,2.5,HTS,PROT_4E-BP1,PROT,noncancer,MAP kinase inhibitor,MAPK14,,,Preclinical,0.276056996767848,0.0515379630547,SX-011,,,0,0
BRD-K45401373-001-20-9::2.5::HTS,BRD-K45401373-001-20-9,betulinic-acid,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,,,Phase 1/Phase 2,0.299733813400325,0.18226666922,betulinic-acid,OTHER,0.2563323520566165,2.2726154308907325,-2.4968564622538274
BRD-K45401373-001-22-5::2.5::HTS,BRD-K45401373-001-22-5,betulinic-acid,2.5,HTS,Exp_SCCPDH (ENSG00000143653),GE,targeted cancer,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,,,Phase 1/Phase 2,0.299733813400325,0.165446550612,betulinic-acid,,,0,0
BRD-K45435259-003-11-1::2.5::HTS,BRD-K45435259-003-11-1,SCH-23390,2.5,HTS,Exp_CCDC178 (ENSG00000166960),GE,noncancer,dopamine receptor antagonist,"DRD1, DRD5, HTR2C, KCNJ4, KCNJ6",,,Preclinical,0.241233319066027,0.151750493907,SCH-23390,,,0,0
BRD-K45437867-005-03-3::2.5::HTS,BRD-K45437867-005-03-3,5-methylfurmethiodide,2.5,HTS,CN_DOCK1 (1793),CN,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,Preclinical,0.214600876883938,0.116470141131,5-methylfurmethiodide,,,0,0
BRD-K45446451-001-05-0::2.5::HTS,BRD-K45446451-001-05-0,JZL-184,2.5,HTS,RMUTmis_PRPF4 (9128),MUT,targeted cancer,monoacylglucerol lipase inhibitor,MGLL,,,Preclinical,0.30685698742084494,0.0310743675025,JZL-184,,,0,0
BRD-K45462423-001-03-7::2.5::HTS,BRD-K45462423-001-03-7,VU0361737,2.5,HTS,MIRNA_hsa-miR-1973,MIRNA,noncancer,glutamate receptor positive allosteric modulator,GRM4,,,Preclinical,0.232791758200307,0.0357093937279,VU0361737,,,0,0
BRD-K45479396-050-01-5::2.5::HTS,BRD-K45479396-050-01-5,BP-554,2.5,HTS,METABOL_C36:3 PC,METABOL,noncancer,serotonin receptor agonist,HTR1A,,,Preclinical,0.308360284093107,0.127796997375,BP-554,,,0,0
BRD-K45503887-001-01-1::2.5::HTS,BRD-K45503887-001-01-1,delivert,2.5,HTS,DEM2_CYP8B1 (1582),DEMETER2_COM,targeted cancer,angiotensin receptor agonist,"AGTR1, AGTR2",,,Launched,0.217190738959274,0.0657628836126,delivert,,,0,0
BRD-K45519571-001-01-8::2.5::HTS,BRD-K45519571-001-01-8,RN-1747,2.5,HTS,Exp_C11orf21 (ENSG00000110665),GE,noncancer,TRPV agonist,TRPV4,,,Preclinical,0.247028666579634,0.0460191653659,RN-1747,,,0,0
BRD-K45528773-001-06-4::2.5::HTS,BRD-K45528773-001-06-4,M-344,2.5,HTS,METABOL_stearoylcarnitine,METABOL,targeted cancer,HDAC inhibitor,,,,Preclinical,0.34936729790061494,0.164620821903,M-344,HDAC INHIBITOR,0.3478350085317576,6.178521390755843,-0.9320619168502629
BRD-K45542189-048-22-1::2.5::HTS,BRD-K45542189-048-22-1,diethylcarbamazine,2.5,HTS,METABOL_pyroglutamic acid,METABOL,noncancer,lipoxygenase inhibitor,"ALOX5, PTGS1",infectious disease,filariasis,Launched,0.24600663461423497,0.0403709427789,diethylcarbamazine,,,0,0
BRD-K45551181-001-02-1::2.49::HTS,BRD-K45551181-001-02-1,MPI-0479605,2.49,HTS,Exp_RCC1 (ENSG00000180198),GE,targeted cancer,mitotic kinase inhibitor,TTK,,,Preclinical,0.36494982854626395,0.229295376133,MPI-0479605,OTHER,0.3639562015740436,3.6687679065594714,-3.4349490041406394
BRD-K45662124-050-01-5::2.5::HTS,BRD-K45662124-050-01-5,3'-fluorobenzylspiperone,2.5,HTS,RMUTmis_TIGD3 (220359),MUTmis,noncancer,dopamine receptor ligand,DRD2,,,Preclinical,0.270038533538118,0.069792908061,3'-fluorobenzylspiperone,,,0,0
BRD-K45664306-001-19-6::2.52::HTS,BRD-K45664306-001-19-6,prednisolone-acetate,2.52,HTS,Exp_PNPLA3 (ENSG00000100344),GE,noncancer,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.26760852455716,0.118210516942,prednisolone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.26651892720603954,-1.207329549323052,-2.737161678431961
BRD-K45746021-003-01-9::2.5::HTS,BRD-K45746021-003-01-9,CC-401,2.5,HTS,Exp_GUCY1A2 (ENSG00000152402),GE,targeted cancer,JNK inhibitor,MAPK8,,,Phase 1,0.280401229152401,0.0859140946168,CC-401,,,0,0
BRD-K45841694-001-11-7::2.65::HTS,BRD-K45841694-001-11-7,IU1,2.65,HTS,MIRNA_hsa-miR-339-5p,MIRNA,noncancer,ubiquitin C-terminal hydrolase inhibitor,USP14,,,Preclinical,0.30050864105691305,0.0637249390063,IU1,,,0,0
BRD-K45861246-001-13-4::2.5::HTS,BRD-K45861246-001-13-4,azaperone,2.5,HTS,MIRNA_hsa-miR-637,MIRNA,noncancer,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,sedative,Launched,0.283576629998885,0.100012507094,azaperone,,,0,0
BRD-K45875383-001-01-2::2.5::HTS,BRD-K45875383-001-01-2,XBD173,2.5,HTS,DEM2_CST9L (128821),DEMETER2_COM,noncancer,benzodiazepine receptor ligand,TSPO,,,Phase 2,0.267415845971515,0.227529511627,XBD173,,,0,0
BRD-K45906612-001-01-8::2.499991411::MTS004,BRD-K45906612-001-01-8,presatovir,2.499991411,MTS004,MIRNA_hsa-miR-548d-5p,MIRNA,noncancer,RSV fusion inhibitor,,,,Phase 2,0.311761188657607,0.149719827217,presatovir,,,0,0
BRD-K45909031-001-01-5::2.5::HTS,BRD-K45909031-001-01-5,WZ4003,2.5,HTS,DEM2_CD36 (948),DEMETER2_COM,noncancer,AMPK inhibitor,"NUAK1, NUAK2",,,Preclinical,0.30314224389720695,0.0624739897548,WZ4003,,,0,0
BRD-K45916615-066-02-5::2.5::HTS,BRD-K45916615-066-02-5,danofloxacin,2.5,HTS,CRISPR_SPPL2A (84888),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA gyrase inhibitor,,pulmonary,bovine respiratory disease (BRD),Launched,0.341682814277037,0.0282766283375,danofloxacin,,,0,0
BRD-K45924332-001-16-8::2.5::HTS,BRD-K45924332-001-16-8,amrinone,2.5,HTS,METHYL_NEO1,METHYL,noncancer,phosphodiesterase inhibitor,"PDE3A, PDE3B, PDE4B, TNF",cardiology,congestive heart failure,Launched,0.205137163876381,0.0519940750745,amrinone,,,0,0
BRD-K46018455-001-27-6::2.5::HTS,BRD-K46018455-001-27-6,bezafibrate,2.5,HTS,CN_SH3RF3 (344558),CN,noncancer,PPAR receptor agonist,"PPARA, PPARD, PPARG",cardiology,cholesterol,Launched,0.199337043597656,0.0462922114909,bezafibrate,,,0,0
BRD-K46061689-001-01-9::2.5::HTS,BRD-K46061689-001-01-9,desogestrel,2.5,HTS,METABOL_xanthosine,METABOL,noncancer,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,Launched,0.293981751196201,0.0687511648596,desogestrel,,,0,0
BRD-K46133855-304-03-8::2.5::HTS,BRD-K46133855-304-03-8,NXY-059,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,free radical scavenger,,,,Phase 3,0.278853011015342,0.049391318263,NXY-059,,,0,0
BRD-K46142322-003-02-4::2.5::HTS,BRD-K46142322-003-02-4,RS-67333,2.5,HTS,Exp_KY (ENSG00000174611),GE,noncancer,serotonin receptor partial agonist,HTR4,,,Preclinical,0.24205193947128198,0.0847460813552,RS-67333,,,0,0
BRD-K46211610-003-26-7::2.5::HTS,BRD-K46211610-003-26-7,tolazoline,2.5,HTS,METHYL_L3MBTL4-AS1,METHYL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2",neurology/psychiatry,reverse sedative,Launched,0.314278851032762,0.0518013484368,tolazoline,,,0,0
BRD-K46290096-001-01-1::2.5::HTS,BRD-K46290096-001-01-1,preladenant,2.5,HTS,MIRNA_hsa-miR-137,MIRNA,targeted cancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Phase 3,0.267490156030485,0.0830929438216,preladenant,,,0,0
BRD-K46317332-003-17-8::2.5::HTS,BRD-K46317332-003-17-8,proadifen,2.5,HTS,METABOL_C34:3 PC,METABOL,noncancer,nitric oxide synthase inhibitor,NOS1,,,Preclinical,0.28430251329553696,0.0964762652593,proadifen,,,0,0
BRD-K46331928-001-05-8::2.5::HTS,BRD-K46331928-001-05-8,ethynodiol-diacetate,2.5,HTS,Exp_TCEAL2 (ENSG00000184905),GE,noncancer,,"ESR1, PGR",endocrinology,contraceptive,Launched,0.291078947808754,0.0277390028989,ethynodiol-diacetate,,,0,0
BRD-K46331928-001-06-6::2.38::HTS,BRD-K46331928-001-06-6,ethynodiol-diacetate,2.38,HTS,CRISPR_ARHGAP1 (392),AVANA_PUBLIC_18Q2,noncancer,,"ESR1, PGR",endocrinology,contraceptive,Launched,0.258664569961856,0.105529860812,ethynodiol-diacetate,,,0,0
BRD-K46384212-001-02-9::2.5::HTS,BRD-K46384212-001-02-9,o-3M3FBS,2.5,HTS,METABOL_C46:0 TAG,METABOL,noncancer,phospholipase activator,,,,Preclinical,0.29710722453370003,0.0174165729291,o-3M3FBS,,,0,0
BRD-K46386702-001-02-1::2.5::HTS,BRD-K46386702-001-02-1,ARRY-334543,2.5,HTS,CRISPR_ITGAV (3685),AVANA_PUBLIC_18Q2,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 2,0.4346574043083,0.484762393669,ARRY-334543,EGFR INHIBITOR,0.4305030672246092,0.3522077241606513,-2.108934988585454
BRD-K46392623-001-02-5::2.5::HTS,BRD-K46392623-001-02-5,TG-100713,2.5,HTS,Exp_SLC43A3 (ENSG00000134802),GE,targeted cancer,PI3K inhibitor,,,,Preclinical,0.31680025109431603,0.208016647323,TG-100713,PI3K INHIBITOR,0.3153062298172066,3.6528921730733885,-0.6416698133922849
BRD-K46424862-001-14-1::2.5::HTS,BRD-K46424862-001-14-1,hymecromone,2.5,HTS,METABOL_C48:0 TAG,METABOL,targeted cancer,monoamine oxidase inhibitor,"MAOA, MAOB",,,Phase 2,0.28931408594378,0.0254338808471,hymecromone,,,0,0
BRD-K46428823-001-02-5::2.5::HTS,BRD-K46428823-001-02-5,liothyronine-(isomer),2.5,HTS,METHYL_ZNF575,METHYL,noncancer,,,,,Preclinical,0.240917928288913,0.0937464463107,liothyronine-(isomer),,,0,0
BRD-K46435528-001-04-4::2.5::HTS,BRD-K46435528-001-04-4,trichloroethylene,2.5,HTS,METHYL_TFCP2L1,METHYL,noncancer,,,,,Preclinical,0.276723133695344,0.0322006219455,trichloroethylene,,,0,0
BRD-K46435977-003-11-1::2.5::HTS,BRD-K46435977-003-11-1,valaciclovir,2.5,HTS,METHYL_C1orf100,METHYL,noncancer,DNA polymerase inhibitor,,infectious disease,"shingles, virus herpes simplex (HSV)",Launched,0.284428699212933,0.00505509985933,valaciclovir,,,0,0
BRD-K46493214-001-06-7::2.5::HTS,BRD-K46493214-001-06-7,saccharin,2.5,HTS,DEM2_CHP2 (63928),DEMETER2_COM,noncancer,DNA polymerase inhibitor,"CA1, CA12, CA2, CA9",,,Launched,0.26809120259879,0.124387368134,saccharin,,,0,0
BRD-K46523383-003-22-9::2.5::HTS,BRD-K46523383-003-22-9,pramoxine,2.5,HTS,CRISPR_CRNKL1 (51340),AVANA_PUBLIC_18Q2,noncancer,topical anesthetic,,dermatology,corticosteroid-responsive dermatoses,Launched,0.299414427822434,0.163381545815,pramoxine,,,0,0
BRD-K46556543-001-01-4::2.5::HTS,BRD-K46556543-001-01-4,potassium-canrenoate,2.5,HTS,CN_GUSBP4 (375513),CN,noncancer,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,Launched,0.25935671308455,0.0887905338961,potassium-canrenoate,,,0,0
BRD-K46556543-237-10-5::2.55::HTS,BRD-K46556543-237-10-5,potassium-canrenoate,2.55,HTS,PROT_Transglutaminase,PROT,noncancer,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,Launched,0.312994540145368,0.0178703242488,potassium-canrenoate,,,0,0
BRD-K46580984-001-03-6::2.584121204::MTS004,BRD-K46580984-001-03-6,phenserine,2.584121204,MTS004,METABOL_GABA,METABOL,noncancer,"acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor","ACHE, BCHE",,,Phase 3,0.24765019800290902,0.0901304655422,phenserine,,,0,0
BRD-K46585355-001-14-3::2.5::HTS,BRD-K46585355-001-14-3,acetylsalicylsalicylic-acid,2.5,HTS,DEM2_CENPH (64946),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,,,,Preclinical,0.262781546475893,0.0772505526225,acetylsalicylsalicylic-acid,,,0,0
BRD-K46625559-001-01-8::2.50003993::MTS004,BRD-K46625559-001-01-8,ozanimod,2.50003993,MTS004,PROT_XRCC1_Caution,PROT,noncancer,sphingosine 1 phosphate receptor agonist,S1PR1,,,Phase 3,0.308427389010799,0.201346012852,ozanimod,,,0,0
BRD-K46654563-238-01-0::2.5::HTS,BRD-K46654563-238-01-0,zofenopril-calcium,2.5,HTS,DEM2_PSMD9 (5715),DEMETER2_COM,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,Launched,0.26698764655918805,0.0644497097636,zofenopril-calcium,,,0,0
BRD-K46690591-001-01-2::2.5::HTS,BRD-K46690591-001-01-2,KP-1212,2.5,HTS,Exp_SIGLEC22P (ENSG00000268849),GE,noncancer,,,,,Phase 2,0.21459588116226397,0.0759361542711,KP-1212,,,0,0
BRD-K46692793-004-01-8::2.5::HTS,BRD-K46692793-004-01-8,umeclidinium,2.5,HTS,Exp_CCR2 (ENSG00000121807),GE,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis, emphysema",Launched,0.227826103222124,0.0818708410156,umeclidinium,,,0,0
BRD-K46731503-050-01-8::2.5::HTS,BRD-K46731503-050-01-8,fesoterodine,2.5,HTS,METABOL_C16:0 CE,METABOL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,Launched,0.339908287219435,0.0702953699686,fesoterodine,,,0,0
BRD-K46741531-001-02-4::1.58::HTS,BRD-K46741531-001-02-4,cafestol,1.58,HTS,CN_MC5R (4161),CN,noncancer,pregnane X receptor agonist,,,,Launched,0.29030664843902004,0.0527084289292,cafestol,,,0,0
BRD-K46742498-003-11-0::2.5::HTS,BRD-K46742498-003-11-0,alosetron,2.5,HTS,METHYL_SNRPB2,METHYL,noncancer,serotonin receptor antagonist,HTR3A,,,Withdrawn,0.31971740052055997,0.114468104029,alosetron,,,0,0
BRD-K46766488-003-02-0::2.5::HTS,BRD-K46766488-003-02-0,S-14506,2.5,HTS,DEM2_SLC8A2 (6543),DEMETER2_COM,noncancer,serotonin receptor agonist,HTR1A,,,Preclinical,0.27421297520822396,0.0882766182738,S-14506,,,0,0
BRD-K46791647-001-01-2::2.5::HTS,BRD-K46791647-001-01-2,stanozolol,2.5,HTS,MIRNA_hsa-miR-596,MIRNA,noncancer,androgen receptor agonist,AR,hematology,anemia,Launched,0.29259988159489597,0.00998129111757,stanozolol,,,0,0
BRD-K46839850-050-04-2::2.5::HTS,BRD-K46839850-050-04-2,cinepazide,2.5,HTS,PROT_beta Actin_Caution,PROT,noncancer,calcium channel activator,,,,Withdrawn,0.258230254731186,0.0854107333201,cinepazide,,,0,0
BRD-K46843573-001-01-9::2.5::MTS004,BRD-K46843573-001-01-9,zotarolimus,2.5,MTS004,DEM2_RPTOR (57521),DEMETER2_COM,noncancer,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,Launched,0.318574528839445,0.185836996417,zotarolimus,MTOR INHIBITOR,0.3204689692779133,0.6097939973990579,-1.6464796296738529
BRD-K46862739-001-14-3::2.499952208::MTS004,BRD-K46862739-001-14-3,metyrapone,2.499952208,MTS004,MIRNA_hsa-miR-628-5p,MIRNA,noncancer,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,Launched,0.350571217153636,0.0623355111317,metyrapone,OTHER,0.35036737789263633,5.765073474567433,-1.4494773272578383
BRD-K46914825-300-01-0::2.5::HTS,BRD-K46914825-300-01-0,zimelidine,2.5,HTS,CN_KIAA0125 (9834),CN,noncancer,selective serotonin reuptake inhibitor (SSRI),"MAOA, MAOB, SLC6A4",,,Withdrawn,0.35370666593590794,0.0778808858586,zimelidine,,,0,0
BRD-K46937689-001-15-0::2.5::HTS,BRD-K46937689-001-15-0,phenazone,2.5,HTS,CRISPR_FGF19 (9965),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Launched,0.24147057382609502,0.0720501435737,phenazone,,,0,0
BRD-K46970505-003-01-9::2.5::HTS,BRD-K46970505-003-01-9,cefozopran,2.5,HTS,DEM2_A4GNT (51146),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,,,Launched,0.324762187592525,0.111066067643,cefozopran,,,0,0
BRD-K46982791-001-09-4::2.5::HTS,BRD-K46982791-001-09-4,cloxyquin,2.5,HTS,Exp_GPR174 (ENSG00000147138),GE,noncancer,potassium channel activator,KCNK18,,,Preclinical,0.258382008411981,0.103874664672,cloxyquin,,,0,0
BRD-K47000838-001-01-6::1.04::HTS,BRD-K47000838-001-01-6,cytochalasin-b,1.04,HTS,Exp_GLIPR1 (ENSG00000139278),GE,noncancer,microtubule inhibitor,ACTB,,,Phase 2,0.21910165211407895,0.222912064821,cytochalasin-b,OTHER,0.22707622856750184,3.9435094436801137,-3.0757986597910483
BRD-K47029922-003-10-9::2.5::HTS,BRD-K47029922-003-10-9,tranylcypromine,2.5,HTS,CRISPR_KLHL25 (64410),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,"KDM1A, MAOA, MAOB",neurology/psychiatry,depression,Launched,0.23664011404090401,0.0902050847623,tranylcypromine,,,0,0
BRD-K47031502-001-01-6::2.5::HTS,BRD-K47031502-001-01-6,eupatilin,2.5,HTS,DEM2_MTHFD2 (10797),DEMETER2_COM,targeted cancer,mucus protecting agent,,,,Launched,0.22064405988332997,0.0983358730602,eupatilin,,,0,0
BRD-K47049295-300-01-5::2.5::HTS,BRD-K47049295-300-01-5,BAN-ORL-24,2.5,HTS,MIRNA_hsa-miR-574-5p,MIRNA,noncancer,nociceptin/orphanin FQ receptor antagonist,OPRL1,,,Preclinical,0.253495553105748,0.14885930025,BAN-ORL-24,,,0,0
BRD-K47079459-004-04-6::2.5::HTS,BRD-K47079459-004-04-6,cetrimonium,2.5,HTS,Exp_SLCO4A1 (ENSG00000101187),GE,noncancer,,,dermatology,cosmetic,Launched,0.37358829534618604,0.32876491708,cetrimonium,OTHER,0.3731880858713729,3.668030882421346,-1.8518855579684972
BRD-K47095176-001-01-6::2.5::HTS,BRD-K47095176-001-01-6,talnetant,2.5,HTS,PROT_Cyclin_E1,PROT,noncancer,tachykinin antagonist,"TACR2, TACR3",,,Phase 2,0.283263222414431,0.0251563699598,talnetant,,,0,0
BRD-K47105409-001-14-5::2.5::HTS,BRD-K47105409-001-14-5,AG-490,2.5,HTS,Exp_CSMD3 (ENSG00000164796),GE,targeted cancer,"EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3",,,Preclinical,0.227263389310602,0.104372147673,AG-490,,,0,0
BRD-K47114202-001-14-6::2.58::HTS,BRD-K47114202-001-14-6,chlorogenic-acid,2.58,HTS,CRISPR_FAM129B (64855),AVANA_PUBLIC_18Q2,noncancer,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis",Launched,0.336498998040699,0.0683735695583,chlorogenic-acid,OTHER,0.3225467258771032,4.910110577621849,0.07559636917965218
BRD-K47150025-001-05-3::2.5::HTS,BRD-K47150025-001-05-3,KI-8751,2.5,HTS,Exp_TGFA (ENSG00000163235),GE,targeted cancer,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,Preclinical,0.37135481267825604,0.26505619223,KI-8751,OTHER,0.37259305966907547,4.724020179158859,-1.2092749597118837
BRD-K47177710-001-03-1::2.5::HTS,BRD-K47177710-001-03-1,DAPT,2.5,HTS,METABOL_C34:4 PC,METABOL,targeted cancer,gamma secretase inhibitor,,,,Preclinical,0.265061612760117,0.0979180351163,DAPT,,,0,0
BRD-K47192521-001-05-4::0.25::HTS,BRD-K47192521-001-05-4,icosapent,0.25,HTS,PROT_HER3,PROT,noncancer,platelet aggregation inhibitor,"ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1",endocrinology,hypertriglyceridemia,Launched,0.253256952510518,0.0992327997892,icosapent,,,0,0
BRD-K47195926-001-06-6::2.5::HTS,BRD-K47195926-001-06-6,acedoben,2.5,HTS,DEM2_MMP9 (4318),DEMETER2_COM,noncancer,,,,,Phase 2,0.23070391732319,0.00363852352586,acedoben,,,0,0
BRD-K47264279-001-08-9::2.5::HTS,BRD-K47264279-001-08-9,psoralen,2.5,HTS,Exp_PRG4 (ENSG00000116690),GE,noncancer,,"MAOA, MAOB",dermatology,"psoriasis, eczema, vitiligo",Launched,0.310886496297707,0.0790178156146,psoralen,,,0,0
BRD-K47278471-003-26-3::2.5::HTS,BRD-K47278471-003-26-3,diphenhydramine,2.5,HTS,METHYL_TENM3,METHYL,noncancer,histamine receptor antagonist,HRH1,neurology/psychiatry,headache,Launched,0.318848992574359,0.123283589857,diphenhydramine,,,0,0
BRD-K47323024-003-24-4::2.5::HTS,BRD-K47323024-003-24-4,methapyrilene,2.5,HTS,RMUTmis_AMMECR1 (9949),MUT,noncancer,histamine receptor antagonist,HRH1,,,Withdrawn,0.24831216401205397,0.124971321767,methapyrilene,,,0,0
BRD-K47337578-034-02-5::2.5::HTS,BRD-K47337578-034-02-5,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,2.5,HTS,RMUTdmg_LSM1 (27257),MUTdmg,noncancer,serotonin receptor antagonist,HTR2A,,,Preclinical,0.28886403660830495,0.0210178761115,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,OTHER,0.28151080799634115,4.073624089759468,1.9053722393275634
BRD-K47371940-001-01-6::2.5::HTS,BRD-K47371940-001-01-6,ecabapide,2.5,HTS,CN_ANKRD20A11P (391267),CN,noncancer,,,,,Phase 3,0.27506446634981896,-0.031425462635,ecabapide,,,0,0
BRD-K47376733-001-08-1::2.5::HTS,BRD-K47376733-001-08-1,JNJ-1661010,2.5,HTS,METABOL_pantothenate,METABOL,noncancer,FAAH inhibitor,FAAH,,,Preclinical,0.32309844060093107,0.0834846128284,JNJ-1661010,,,0,0
BRD-K47407372-001-17-1::2.5::HTS,BRD-K47407372-001-17-1,nifenazone,2.5,HTS,MIRNA_hsa-miR-548m,MIRNA,noncancer,analgesic agent,,neurology/psychiatry,pain relief,Launched,0.285767935705914,0.109962995134,nifenazone,,,0,0
BRD-K47492008-001-02-7::2.5::MTS004,BRD-K47492008-001-02-7,alclofenac,2.5,MTS004,Exp_PKIG (ENSG00000168734),GE,noncancer,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis,Launched,0.308186849179336,0.165655551051,alclofenac,,,0,0
BRD-K47539947-001-03-7::2.5::HTS,BRD-K47539947-001-03-7,tetradecylthioacetic-acid,2.5,HTS,MIRNA_hsa-miR-367,MIRNA,targeted cancer,lipid peroxidase inhibitor,,,,Phase 2,0.199823409260677,0.0615070371341,tetradecylthioacetic-acid,,,0,0
BRD-K47557313-001-02-7::2.5::HTS,BRD-K47557313-001-02-7,LY2109761,2.5,HTS,PROT_AMPK_alpha_Caution,PROT,targeted cancer,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",,,Preclinical,0.282162542755534,0.17918353964,LY2109761,OTHER,0.2847804451635589,4.900358144847859,1.634509356222306
BRD-K47598052-001-15-8::2.5::HTS,BRD-K47598052-001-15-8,PP-1,2.5,HTS,Exp_TAPT1 (ENSG00000169762),GE,targeted cancer,src inhibitor,"HCK, RET",,,Preclinical,0.390602926951334,0.204348409293,PP-1,OTHER,0.3924255052773838,1.930667436728544,-2.5043584732890887
BRD-K47631482-003-06-2::2.5::HTS,BRD-K47631482-003-06-2,bromhexine,2.5,HTS,CRISPR_WDHD1 (11169),AVANA_PUBLIC_18Q2,noncancer,mucolytic agent,,pulmonary,chest congestion,Launched,0.268460753604072,0.0673698420211,bromhexine,,,0,0
BRD-K47635719-001-21-1::2.5::HTS,BRD-K47635719-001-21-1,dexamethasone-acetate,2.5,HTS,Exp_FOXRED2 (ENSG00000100350),GE,noncancer,glucocorticoid receptor agonist,,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.235661002604668,0.0526134071812,dexamethasone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2386834138889365,-1.517745983887402,-2.794380792371617
BRD-K47639036-003-06-6::2.5::HTS,BRD-K47639036-003-06-6,flavoxate,2.5,HTS,METHYL_PCDHB13,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2",urology,"urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis",Launched,0.28453455727111404,0.0609098931639,flavoxate,,,0,0
BRD-K47642186-001-01-3::2.5::HTS,BRD-K47642186-001-01-3,piclamilast,2.5,HTS,DEM2_IGF1R (3480),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",,,Phase 2,0.30432355547406104,0.140859519922,piclamilast,,,0,0
BRD-K47659338-003-02-8::2.5::HTS,BRD-K47659338-003-02-8,EMD-386088,2.5,HTS,PROT_ER-alpha,PROT,noncancer,serotonin receptor agonist,HTR6,,,Preclinical,0.221719665638848,0.0410877406583,EMD-386088,,,0,0
BRD-K47679368-236-01-7::2.5::HTS,BRD-K47679368-236-01-7,bromfenac,2.5,HTS,DEM2_ZBTB6 (10773),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Withdrawn,0.286808870126351,0.00453081007561,bromfenac,,,0,0
BRD-K47690382-001-03-0::2.5::MTS004,BRD-K47690382-001-03-0,bipenamol,2.5,MTS004,Exp_TMEM179B (ENSG00000185475),GE,noncancer,dipeptidyl peptidase inhibitor,CTSC,,,Phase 2,0.32796117767950606,0.131158129879,bipenamol,,,0,0
BRD-K47780086-001-07-9::2.5::HTS,BRD-K47780086-001-07-9,penciclovir,2.5,HTS,LIN_glioma,LIN,noncancer,DNA directed DNA polymerase inhibitor,,dental,cold sore,Launched,0.25826442536713,0.0588429629028,penciclovir,,,0,0
BRD-K47827687-001-02-2::2.5::HTS,BRD-K47827687-001-02-2,amprenavir,2.5,HTS,CRISPR_STK32A (202374),AVANA_PUBLIC_18Q2,noncancer,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.279391675757351,0.0161111353642,amprenavir,,,0,0
BRD-K47832606-001-30-1::2.5::HTS,BRD-K47832606-001-30-1,floxuridine,2.5,HTS,Exp_EIF4A1 (ENSG00000161960),GE,chemo,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,Launched,0.35417732012013003,0.254781062395,floxuridine,OTHER,0.3546857842691573,4.298860710409956,-2.2064931255115896
BRD-K47869605-001-32-0::2.5::HTS,BRD-K47869605-001-32-0,podophyllotoxin,2.5,HTS,METHYL_ZP2,METHYL,noncancer,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,Launched,0.38159068914812794,0.0972764546144,podophyllotoxin,OTHER,0.3908893499579293,5.375247873157506,-0.578917367296206
BRD-K47878171-086-06-0::2.5::HTS,BRD-K47878171-086-06-0,bephenium-hydroxynaphthoate,2.5,HTS,METHYL_MIR5004,METHYL,noncancer,anthelmintic agent,,infectious disease,ascariasis,Launched,0.268721191673566,0.0722256109788,bephenium-hydroxynaphthoate,,,0,0
BRD-K47886988-001-21-4::2.5::HTS,BRD-K47886988-001-21-4,nalidixic-acid,2.5,HTS,DEM2_G3BP1 (10146),DEMETER2_COM,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections,Launched,0.19886747489066395,0.0222010441382,nalidixic-acid,,,0,0
BRD-K47887731-001-01-4::2.5::MTS004,BRD-K47887731-001-01-4,nitenpyram,2.5,MTS004,METABOL_C22:0 SM,METABOL,noncancer,,,infectious disease,flea control,Launched,0.29175851564702804,0.0215165339012,nitenpyram,,,0,0
BRD-K47929404-001-01-0::2.500019706::MTS004,BRD-K47929404-001-01-0,vercirnon,2.500019706,MTS004,Exp_FUT3 (ENSG00000171124),GE,noncancer,CC chemokine receptor antagonist,CCR9,,,Phase 3,0.252760031440275,0.104154163393,vercirnon,,,0,0
BRD-K47936004-003-11-4::2.5::HTS,BRD-K47936004-003-11-4,piribedil,2.5,HTS,CN_MACROD2-AS1 (100379174),CN,noncancer,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B",neurology/psychiatry,"Parkinson's Disease, dizziness",Launched,0.30056611822737,0.0802063685257,piribedil,,,0,0
BRD-K47949423-001-03-1::2.56::HTS,BRD-K47949423-001-03-1,mirabegron,2.56,HTS,METABOL_C56:6 TAG,METABOL,noncancer,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",urology,urinary incontinence,Launched,0.299540322180352,0.0391751584921,mirabegron,,,0,0
BRD-K47976015-001-01-2::2.5::HTS,BRD-K47976015-001-01-2,balapiravir,2.5,HTS,DEM2_DLG5 (9231),DEMETER2_COM,noncancer,RNA polymerase inhibitor,,,,Phase 2,0.291389601438928,0.181375246865,balapiravir,,,0,0
BRD-K47978074-001-02-4::2.5::HTS,BRD-K47978074-001-02-4,trometamol,2.5,HTS,MIRNA_hsa-miR-328,MIRNA,noncancer,,"AMD1, CANT1, DCN, NEIL1, VEGFA",,,Launched,0.290004807186927,0.0182299522552,trometamol,,,0,0
BRD-K48061146-066-01-7::2.5::HTS,BRD-K48061146-066-01-7,benztropine-mesylate,2.5,HTS,METABOL_serotonin,METABOL,noncancer,acetylcholine receptor antagonist,"CHRM1, HRH1, SLC6A3",neurology/psychiatry,"extrapyramidal symptoms (EPS), Parkinson's Disease",Launched,0.31291423939575397,0.0766961770419,benztropine-mesylate,,,0,0
BRD-K48068743-001-01-6::2.5::HTS,BRD-K48068743-001-01-6,teneligliptin,2.5,HTS,METHYL_LRRC74A,METHYL,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.28672671523121396,0.0011612282945,teneligliptin,,,0,0
BRD-K48141473-001-01-7::2.5::HTS,BRD-K48141473-001-01-7,cebranopadol,2.5,HTS,CN_DEFA3 (1668),CN,noncancer,opioid receptor agonist,"OPRL1, OPRM1",,,Phase 3,0.283878960699532,0.0412148190824,cebranopadol,OTHER,0.29332257595495226,-5.055037088414943,-0.7590792659406262
BRD-K48168960-001-19-2::2.5::HTS,BRD-K48168960-001-19-2,propylthiouracil,2.5,HTS,MIRNA_hsa-let-7a,MIRNA,noncancer,thyroid peroxidase inhibitor,"DIO1, TPO",endocrinology,"hyperthyroidism, Grave's disease, goiter",Launched,0.268499765644608,0.00175281613684,propylthiouracil,,,0,0
BRD-K48173020-001-01-8::2.5::HTS,BRD-K48173020-001-01-8,ameltolide,2.5,HTS,CRISPR_MTMR6 (9107),AVANA_PUBLIC_18Q2,noncancer,anticonvulsant,,,,Preclinical,0.28008055241434804,0.00251026747233,ameltolide,,,0,0
BRD-K48195008-001-19-9::2.5::HTS,BRD-K48195008-001-19-9,ethinyl-estradiol,2.5,HTS,Exp_RPS26P31 (ENSG00000235459),GE,noncancer,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,Launched,0.310410595955581,0.0993696564501,ethinyl-estradiol,,,0,0
BRD-K48195801-001-01-6::2.5::HTS,BRD-K48195801-001-01-6,tecastemizole,2.5,HTS,Exp_PRKX (ENSG00000183943),GE,noncancer,histamine receptor antagonist,KCNH2,,,Phase 3,0.3245197329862,0.131129114463,tecastemizole,,,0,0
BRD-K48213016-001-01-8::2.5::HTS,BRD-K48213016-001-01-8,CC-930,2.5,HTS,Exp_IL23R (ENSG00000162594),GE,noncancer,JNK inhibitor,,,,Phase 2,0.25670041910975305,0.0544055596206,CC-930,,,0,0
BRD-K48247567-001-01-9::2.5::HTS,BRD-K48247567-001-01-9,diatrizoic-acid,2.5,HTS,PROT_eEF2_Caution,PROT,noncancer,,,radiology,contrast agent,Launched,0.24874269901689,0.0390550882422,diatrizoic-acid,,,0,0
BRD-K48300629-001-14-5::2.5::HTS,BRD-K48300629-001-14-5,zonisamide,2.5,HTS,METABOL_C38:2 PC,METABOL,noncancer,"sodium channel blocker, T-type calcium channel blocker","CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"seizures, epilepsy",Launched,0.30766406354619297,0.121033013145,zonisamide,,,0,0
BRD-K48329353-001-01-3::2.5::HTS,BRD-K48329353-001-01-3,"6,_7-dehydro-17-acetoxy-progesterone",2.5,HTS,Exp_FRG2B (ENSG00000225899),GE,noncancer,steroidal progestin,,,,Preclinical,0.32613797548687107,0.0751426711603,"6,_7-dehydro-17-acetoxy-progesterone",,,0,0
BRD-K48367671-001-05-9::2.5::HTS,BRD-K48367671-001-05-9,febuxostat,2.5,HTS,CN_LYAR (55646),CN,noncancer,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia,Launched,0.295659711929547,0.0555170267546,febuxostat,,,0,0
BRD-K48429278-001-01-3::2.5::MTS004,BRD-K48429278-001-01-3,pipotiazine-palmitate,2.5,MTS004,CRISPR_NUMA1 (4926),AVANA_PUBLIC_18Q2,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, DRD2, HTR1A, HTR2A",,,Launched,0.23496589087021,0.0933091220743,pipotiazine-palmitate,,,0,0
BRD-K48443249-001-01-0::2.5::HTS,BRD-K48443249-001-01-0,CNX-774,2.5,HTS,Exp_SEMA3G (ENSG00000010319),GE,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,Preclinical,0.31489060123325796,0.239395320665,CNX-774,OTHER,0.31537344992705785,6.581369345372182,-1.6056510922323195
BRD-K48452630-001-01-8::2.5::MTS004,BRD-K48452630-001-01-8,SRT2104,2.5,MTS004,CRISPR_MAPK13 (5603),AVANA_PUBLIC_18Q2,noncancer,SIRT activator,SIRT1,,,Phase 2,0.330332184109443,0.157489212773,SRT2104,,,0,0
BRD-K48488978-001-05-3::2.5::HTS,BRD-K48488978-001-05-3,YM-201636,2.5,HTS,Exp_KCNMB3 (ENSG00000171121),GE,targeted cancer,PI3K inhibitor,,,,Preclinical,0.376206305681492,0.275694669744,YM-201636,PI3K INHIBITOR,0.3757278835781863,1.6128716520222133,-1.97069076959428
BRD-K48535733-003-01-2::2.5::HTS,BRD-K48535733-003-01-2,VU0155069,2.5,HTS,CN_LOC100507194 (100507194),CN,targeted cancer,phospholipase inhibitor,PLD1,,,Preclinical,0.251451844072557,0.0657382102403,VU0155069,,,0,0
BRD-K48578705-001-16-8::2.5::HTS,BRD-K48578705-001-16-8,methyldopa,2.5,HTS,MIRNA_hsa-miR-654-3p,MIRNA,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,Launched,0.288502044956211,0.105143754371,methyldopa,,,0,0
BRD-K48619321-004-16-8::2.54::HTS,BRD-K48619321-004-16-8,methscopolamine,2.54,HTS,METABOL_C34:1 PC,METABOL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.33994147328493396,0.0958320676596,methscopolamine,,,0,0
BRD-K48684885-001-04-2::2.5::HTS,BRD-K48684885-001-04-2,BAY-11-7085,2.5,HTS,MIRNA_hsa-miR-626,MIRNA,targeted cancer,NFkB pathway inhibitor,NFKBIA,,,Preclinical,0.372425255820258,0.152597135562,BAY-11-7085,NFKB PATHWAY INHIBITOR,0.37857568610633385,4.930139054587566,-0.8924838327510272
BRD-K48692744-001-02-0::2.5::HTS,BRD-K48692744-001-02-0,NU-1025,2.5,HTS,Exp_NCAM2 (ENSG00000154654),GE,targeted cancer,PARP inhibitor,PARP1,,,Preclinical,0.28644061715712,0.103695580363,NU-1025,,,0,0
BRD-K48722258-300-10-2::2.5::HTS,BRD-K48722258-300-10-2,dilazep,2.5,HTS,METHYL_ATP5J2-PTCD1,METHYL,noncancer,adenosine reuptake inhibitor,SLC29A1,,,Launched,0.23577318339697398,0.114848259283,dilazep,,,0,0
BRD-K48722833-001-07-6::2.5::HTS,BRD-K48722833-001-07-6,iloperidone,2.5,HTS,METHYL_APOOL,METHYL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,Launched,0.331302222861856,0.0591886650195,iloperidone,,,0,0
BRD-K48826825-001-01-8::2.5::HTS,BRD-K48826825-001-01-8,S26948,2.5,HTS,METHYL_THUMPD1,METHYL,noncancer,PPAR receptor agonist,PPARG,,,Preclinical,0.24526628572240802,0.0468872436209,S26948,,,0,0
BRD-K48830578-001-01-9::2.5::HTS,BRD-K48830578-001-01-9,OMDM-2,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,noncancer,FAAH inhibitor,GPR119,,,Preclinical,0.262297383705078,0.0826700993277,OMDM-2,,,0,0
BRD-K48888725-001-01-9::2.5::HTS,BRD-K48888725-001-01-9,CG-400549,2.5,HTS,Exp_TPMTP1 (ENSG00000267156),GE,noncancer,FABI inhibitor,,,,Phase 2,0.29161861062236,0.10447087545,CG-400549,,,0,0
BRD-K48892307-001-04-1::2.5::HTS,BRD-K48892307-001-04-1,sasapyrine,2.5,HTS,Exp_CXorf49B (ENSG00000215113),GE,noncancer,NFkB pathway inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis",Launched,0.25818105531740804,0.00595789908631,sasapyrine,,,0,0
BRD-K48894757-001-01-8::2.5::HTS,BRD-K48894757-001-01-8,laropiprant,2.5,HTS,Exp_ACTBL2 (ENSG00000169067),GE,noncancer,prostanoid receptor antagonist,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R",cardiology,cholesterol,Launched,0.35911363451358297,0.0343957002803,laropiprant,,,0,0
BRD-K48988407-001-01-2::2.5::HTS,BRD-K48988407-001-01-2,cytochlor,2.5,HTS,LIN_melanoma,LIN,targeted cancer,,,,,Phase 1,0.40192549529195204,0.202128962932,cytochlor,OTHER,0.4017715407518127,4.08918940705392,-2.5403048076615318
BRD-K48996094-001-01-3::2.5::HTS,BRD-K48996094-001-01-3,pentacosanoic-acid,2.5,HTS,PROT_MIG-6,PROT,noncancer,,,,,Preclinical,0.28453060274623604,0.165057342804,pentacosanoic-acid,,,0,0
BRD-K49027941-001-01-1::2.5::HTS,BRD-K49027941-001-01-1,PSB-1115,2.5,HTS,METABOL_pyroglutamic acid,METABOL,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",,,Preclinical,0.22683841389447199,0.0345747383494,PSB-1115,,,0,0
BRD-K49049886-001-08-7::2.5::HTS,BRD-K49049886-001-08-7,CGS-15943,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.51098898727436,0.506958132877,CGS-15943,OTHER,0.5063152460778902,-0.7359579822230791,0.9072330900572876
BRD-K49055432-001-04-2::2.5::HTS,BRD-K49055432-001-04-2,A66,2.5,HTS,DEM2_PIK3CA (5290),DEMETER2_COM,targeted cancer,PI3K inhibitor,PIK3CA,,,Preclinical,0.34120786303993894,0.339314677791,A66,PI3K INHIBITOR,0.31975641345437844,0.5931369765905694,-1.5686908948556044
BRD-K49071277-001-04-7::2.5::HTS,BRD-K49071277-001-04-7,securinine,2.5,HTS,MUTpool_FAM47A (158724),MUTpool,noncancer,"GABA receptor antagonist, TP53 activator",GABRA1,,,Preclinical,0.364721721314761,0.0340211771823,securinine,,,0,0
BRD-K49075727-001-08-5::2.5::HTS,BRD-K49075727-001-08-5,nintedanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),Launched,0.39097148638159795,0.298050541055,nintedanib,OTHER,0.3895847014985172,1.7587321479893276,-2.1205049654860684
BRD-K49111258-003-29-7::2.5::HTS,BRD-K49111258-003-29-7,prazosin,2.5,HTS,CRISPR_IDH3A (3419),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,Launched,0.30534506748594104,0.126047028627,prazosin,,,0,0
BRD-K49119234-003-02-6::2.5::HTS,BRD-K49119234-003-02-6,TMPH,2.5,HTS,Exp_CYSLTR1 (ENSG00000173198),GE,noncancer,,,,,Preclinical,0.23633955266776102,0.0693763331997,TMPH,,,0,0
BRD-K49197823-001-09-8::2.5::HTS,BRD-K49197823-001-09-8,CV-1808,2.5,HTS,PROT_Cyclin_E1,PROT,noncancer,adenosine receptor agonist,ADORA2A,,,Preclinical,0.304357901184601,0.107931008834,CV-1808,,,0,0
BRD-K49215523-001-04-2::2.5::HTS,BRD-K49215523-001-04-2,GSK2636771,2.5,HTS,DEM2_PIK3CB (5291),DEMETER2_COM,targeted cancer,PI3K inhibitor,PIK3CB,,,Phase 2,0.29216139991806106,0.164995974307,GSK2636771,,,0,0
BRD-K49236613-001-02-3::2.5::HTS,BRD-K49236613-001-02-3,6-iodo-nordihydrocapsaicin,2.5,HTS,DEM2_RPAP3 (79657),DEMETER2_COM,noncancer,TRPV antagonist,TRPV1,,,Preclinical,0.234237073053249,0.116461815022,6-iodo-nordihydrocapsaicin,,,0,0
BRD-K49294207-300-03-8::2.5::HTS,BRD-K49294207-300-03-8,BIBU-1361,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.42899030566157603,0.446887572034,BIBU-1361,EGFR INHIBITOR,0.3894995449868105,1.1326069078799952,-5.396724646843059
BRD-K49313711-001-05-4::2.5::HTS,BRD-K49313711-001-05-4,ribitol,2.5,HTS,METABOL_glutamate,METABOL,noncancer,,,,,Preclinical,0.27854354455532104,0.0200472033981,ribitol,,,0,0
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49338325-001-03-4::2.5::HTS,BRD-K49338325-001-03-4,etofibrate,2.5,HTS,CRISPR_FTSJ3 (117246),AVANA_PUBLIC_18Q2,noncancer,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia,Launched,0.28871231331366404,0.138519565397,etofibrate,,,0,0
BRD-K49350383-001-13-7::2.5::HTS,BRD-K49350383-001-13-7,thioguanine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.41142642716361,0.296921861054,thioguanine,OTHER,0.4116419800127768,3.989619554602284,-3.847017954869628
BRD-K49372556-001-04-1::2.5::MTS004,BRD-K49372556-001-04-1,mofezolac,2.5,MTS004,METHYL_IL4I1,METHYL,noncancer,cyclooxygenase inhibitor,PTGS1,"rheumatology, orthopedics","rheumatoid arthritis, osteoporosis",Launched,0.295048035118724,0.113561766614,mofezolac,,,0,0
BRD-K49404994-001-10-9::2.5::HTS,BRD-K49404994-001-10-9,levetiracetam,2.5,HTS,DEM2_BMP2 (650),DEMETER2_COM,noncancer,calcium channel blocker,"CACNA1B, SCN1A, SV2A",neurology/psychiatry,seizures,Launched,0.25867851462041697,0.0459789465474,levetiracetam,,,0,0
BRD-K49456274-001-01-9::2.5::HTS,BRD-K49456274-001-01-9,pilaralisib,2.5,HTS,CRISPR_CCDC77 (84318),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,,,,Phase 2,0.28904711023220003,0.0578625288525,pilaralisib,,,0,0
BRD-K49460120-001-02-5::2.5::HTS,BRD-K49460120-001-02-5,10058-F4,2.5,HTS,PROT_A-Raf_pS299_Caution,PROT,targeted cancer,c-Myc inhibitor,,,,Preclinical,0.26497394595367896,0.0265868288834,10058-F4,,,0,0
BRD-K49481516-004-18-3::2.5::HTS,BRD-K49481516-004-18-3,galantamine,2.5,HTS,DEM2_WRN (7486),DEMETER2_COM,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG",neurology/psychiatry,senile dementia,Launched,0.25904699355821803,0.0683877933479,galantamine,,,0,0
BRD-K49504902-001-01-6::2.5::HTS,BRD-K49504902-001-01-6,SEP-227900,2.5,HTS,MIRNA_hsa-miR-362-5p,MIRNA,noncancer,D-Amino Acid Oxidase Inhibitor,DAO,,,Phase 1,0.289434188007266,0.068955713485,SEP-227900,,,0,0
BRD-K49519144-001-04-6::2.5::HTS,BRD-K49519144-001-04-6,LY2140023,2.5,HTS,CN_RTL1 (388015),CN,noncancer,glutamate receptor agonist,GRM3,,,Phase 3,0.27998113610389,0.067935950676,LY2140023,,,0,0
BRD-K49522529-001-02-9::2.53::HTS,BRD-K49522529-001-02-9,alfacalcidol,2.53,HTS,CRISPR_PTK2 (5747),AVANA_PUBLIC_18Q2,noncancer,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,Launched,0.355442402286188,0.194923523568,alfacalcidol,VITAMIN D RECEPTOR AGONIST,0.3529607649023792,0.37979155019968425,-1.5610122650554032
BRD-K49522529-001-03-7::2.5::HTS,BRD-K49522529-001-03-7,alfacalcidol,2.5,HTS,CRISPR_ESRP1 (54845),AVANA_PUBLIC_18Q2,noncancer,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,Launched,0.355442402286188,0.194923523568,alfacalcidol,VITAMIN D RECEPTOR AGONIST,0.3349120140337989,0.3339534594421137,-1.635520850303715
BRD-K49545903-003-01-4::2.5::HTS,BRD-K49545903-003-01-4,"4,4-pentamethylenepiperidine",2.5,HTS,PROT_VAV1_Caution,PROT,noncancer,M2 channel blocker,,,,Preclinical,0.270748275329693,0.0327950356768,"4,4-pentamethylenepiperidine",,,0,0
BRD-K49555808-001-03-9::2.5::HTS,BRD-K49555808-001-03-9,BMS-707035,2.5,HTS,METHYL_USP7,METHYL,noncancer,HIV integrase inhibitor,,,,Phase 2,0.327519162055404,0.244929489117,BMS-707035,OTHER,0.3270366029268765,3.9197764583373065,-2.7021500706844908
BRD-K49657628-001-14-8::2.5::HTS,BRD-K49657628-001-14-8,tyrphostin-AG-18,2.5,HTS,PROT_SETD2_Caution,PROT,targeted cancer,"EGFR inhibitor, tyrosine kinase inhibitor",EGFR,,,Preclinical,0.26359751417974797,0.0645506329579,tyrphostin-AG-18,,,0,0
BRD-K49659468-436-01-2::2.500002467::MTS004,BRD-K49659468-436-01-2,TMC647055,2.500002467,MTS004,PROT_RSK1-2-3_Caution,PROT,noncancer,RNA polymerase inhibitor,,,,Phase 2,0.260561327380796,0.186604694271,TMC647055,,,0,0
BRD-K49668410-001-18-8::2.5::HTS,BRD-K49668410-001-18-8,clarithromycin,2.5,HTS,METABOL_asparagine,METABOL,noncancer,bacterial 50S ribosomal subunit inhibitor,CYP3A4,"otolaryngology, pulmonary, infectious disease","pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis",Launched,0.268799074730536,0.134662638393,clarithromycin,,,0,0
BRD-K49669041-001-08-4::2.5::HTS,BRD-K49669041-001-08-4,BX-912,2.5,HTS,Exp_NKX2-5 (ENSG00000183072),GE,targeted cancer,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",,,Preclinical,0.421753437277252,0.267854450466,BX-912,OTHER,0.4225601523009587,3.509298423056168,-4.246950323404442
BRD-K49671696-045-08-5::2.5::HTS,BRD-K49671696-045-08-5,ketanserin,2.5,HTS,METABOL_anthranilic acid,METABOL,noncancer,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2",cardiology,hypertension,Launched,0.263018356737937,0.013938010557,ketanserin,,,0,0
BRD-K49685476-001-15-9::2.5::HTS,BRD-K49685476-001-15-9,TTNPB,2.5,HTS,CRISPR_C21orf2 (755),AVANA_PUBLIC_18Q2,noncancer,retinoid receptor agonist,"RARA, RARB, RARG",,,Phase 1,0.296602823975759,0.0891208714737,TTNPB,,,0,0
BRD-K49702221-003-01-6::2.5::HTS,BRD-K49702221-003-01-6,SNAP-94847,2.5,HTS,METABOL_C50:1 TAG,METABOL,noncancer,,"ADRA1A, DRD2",,,Preclinical,0.30241739126175105,0.0179221682724,SNAP-94847,,,0,0
BRD-K49738308-065-04-9::2.5::HTS,BRD-K49738308-065-04-9,agmatine,2.5,HTS,MIRNA_hsa-miR-556-3p,MIRNA,noncancer,nitric oxide synthase inhibitor,"ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH",,,Phase 3,0.297857222925499,0.113969727173,agmatine,,,0,0
BRD-K49759007-001-11-9::2.5::HTS,BRD-K49759007-001-11-9,4-hydroxy-phenazone,2.5,HTS,CRISPR_FGF19 (9965),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.284932791054456,0.0982179895201,4-hydroxy-phenazone,,,0,0
BRD-K49783248-303-08-4::2.5::HTS,BRD-K49783248-303-08-4,decamethonium,2.5,HTS,CRISPR_UBAP2 (55833),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor agonist,"ACHE, CHRNA2",neurology/psychiatry,muscle relaxant,Launched,0.25194745154653003,0.151515264635,decamethonium,,,0,0
BRD-K49793107-402-02-6::2.5::MTS004,BRD-K49793107-402-02-6,caspofungin-acetate,2.5,MTS004,Exp_ATP11B (ENSG00000058063),GE,noncancer,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,"candidemia, esophageal candidiasis, aspergillosis, peritonitis",Launched,0.251607517719713,0.074948610975,caspofungin-acetate,,,0,0
BRD-K49807096-003-15-5::2.5::HTS,BRD-K49807096-003-15-5,benazepril,2.5,HTS,PROT_PEA15_pS116,PROT,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,Launched,0.22971086652344197,0.0366949458812,benazepril,,,0,0
BRD-K49811169-004-06-6::2.5::HTS,BRD-K49811169-004-06-6,NSC-9965,2.5,HTS,METHYL_HIST1H3E,METHYL,noncancer,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",,,Preclinical,0.255451959281201,0.166754710875,NSC-9965,,,0,0
BRD-K49840922-001-05-1::2.5::HTS,BRD-K49840922-001-05-1,etofylline-clofibrate,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,platelet aggregation inhibitor,PPARA,,,Launched,0.229623831879133,0.03223768637,etofylline-clofibrate,,,0,0
BRD-K49841478-001-01-6::2.690488579::MTS004,BRD-K49841478-001-01-6,rosoxacin,2.690488579,MTS004,CRISPR_JUND (3727),AVANA_PUBLIC_18Q2,noncancer,topoisomerase inhibitor,,infectious disease,urinary tract infections,Launched,0.290623277216122,0.0641562577672,rosoxacin,,,0,0
BRD-K49865102-001-08-4::2.5::HTS,BRD-K49865102-001-08-4,PD-0325901,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 2,0.470274705728401,0.557783767375,PD-0325901,MEK INHIBITOR,0.4691728190396805,0.2977417707587833,4.9766014558326575
BRD-K49880111-236-09-2::2.5::HTS,BRD-K49880111-236-09-2,cephapirin,2.5,HTS,CRISPR_SP8 (221833),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis,Launched,0.251010534449356,0.12709707457,cephapirin,,,0,0
BRD-K49945136-001-10-0::2.5::HTS,BRD-K49945136-001-10-0,GR-113808,2.5,HTS,CRISPR_RBFOX1 (54715),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,HTR4,,,Preclinical,0.240981232495249,0.0447181013145,GR-113808,,,0,0
BRD-K49954789-001-02-9::2.5::HTS,BRD-K49954789-001-02-9,mesna,2.5,HTS,CRISPR_FBF1 (85302),AVANA_PUBLIC_18Q2,noncancer,antioxidant,,urology,hemorrhagic cystitis,Launched,0.2787728660258039,0.0475625323946,mesna,,,0,0
BRD-K49962337-001-02-9::2.56::HTS,BRD-K49962337-001-02-9,baicalin,2.56,HTS,LIN_kidney,LIN,noncancer,beta glucuronidase inhibitor,PREP,,,Launched,0.376042441835276,0.24381914816,baicalin,OTHER,0.2946623682526589,4.298907490676382,-0.8545082785922165
BRD-K50000283-001-04-4::2.5::HTS,BRD-K50000283-001-04-4,PHA-767491,2.5,HTS,Exp_ABCC4 (ENSG00000125257),GE,targeted cancer,CDC inhibitor,"CDK1, RPS6KB1",,,Preclinical,0.452883751398934,0.206652915145,PHA-767491,OTHER,0.4530697668818965,5.044879683019358,-1.8934164456754123
BRD-K50010139-001-02-3::2.5::MTS004,BRD-K50010139-001-02-3,poziotinib,2.5,MTS004,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 2,0.46440552719184897,0.524461296828,poziotinib,EGFR INHIBITOR,0.4621716473168822,1.235026426907074,-4.903157800496
BRD-K50018155-003-02-1::2.5::HTS,BRD-K50018155-003-02-1,RS-67506,2.5,HTS,Exp_LNP1 (ENSG00000206535),GE,noncancer,serotonin receptor partial agonist,HTR4,,,Preclinical,0.298446548723648,0.0303336805917,RS-67506,,,0,0
BRD-K50031829-001-01-6::2.5::HTS,BRD-K50031829-001-01-6,PF-04447943,2.5,HTS,METHYL_CCDC81,METHYL,noncancer,phosphodiesterase inhibitor,PDE9A,,,Phase 2,0.299792609469306,0.0444472796925,PF-04447943,,,0,0
BRD-K50050533-001-02-1::2.5::HTS,BRD-K50050533-001-02-1,docosanol,2.5,HTS,MIRNA_hsa-miR-148a,MIRNA,noncancer,lipase clearing factor inhibitor,TLR7,dental,cold sore,Launched,0.271389401534409,0.0776422394915,docosanol,,,0,0
BRD-K50055394-001-03-6::2.701086832::MTS004,BRD-K50055394-001-03-6,halopemide,2.701086832,MTS004,CN_HNF1B (6928),CN,noncancer,phospholipase inhibitor,"PLD1, PLD2",,,Phase 2,0.31771136561912106,0.111891286265,halopemide,,,0,0
BRD-K50071428-001-03-3::2.5::HTS,BRD-K50071428-001-03-3,abiraterone,2.5,HTS,MUTpool_PLEKHG1 (57480),MUTpool,targeted cancer,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,Launched,0.308931335250722,0.0511237332306,abiraterone,,,0,0
BRD-K50122911-001-01-2::2.5::MTS004,BRD-K50122911-001-01-2,boronophenylalanine,2.5,MTS004,METABOL_serine,METABOL,targeted cancer,,,,,Phase 2,0.248543709656214,0.107901147843,boronophenylalanine,,,0,0
BRD-K50133271-001-18-7::2.5::HTS,BRD-K50133271-001-18-7,tolfenamic-acid,2.5,HTS,CRISPR_PTRHD1 (391356),AVANA_PUBLIC_18Q2,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist",,neurology/psychiatry,migraine headache,Launched,0.27779604776410305,0.00449476469453,tolfenamic-acid,,,0,0
BRD-K50135270-300-02-3::2.5::HTS,BRD-K50135270-300-02-3,GBR-12935,2.5,HTS,METABOL_2-deoxyadenosine,METABOL,noncancer,dopamine uptake inhibitor,"AGTR1, SLC6A3",,,Preclinical,0.303839974467139,0.0944566199732,GBR-12935,,,0,0
BRD-K50140147-001-10-1::2.5::HTS,BRD-K50140147-001-10-1,NVP-TAE684,2.5,HTS,PROT_Chk2_pT68_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",,,Preclinical,0.36336131042184205,0.192690226374,NVP-TAE684,OTHER,0.36949757612169815,4.994435374674978,-1.7441942226531042
BRD-K50163129-001-01-4::2.5::HTS,BRD-K50163129-001-01-4,acrivastine,2.5,HTS,DEM2_IVNS1ABP (10625),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.27275095980112196,0.137269973571,acrivastine,,,0,0
BRD-K50168500-001-07-9::2.5::HTS,BRD-K50168500-001-07-9,canertinib,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",,,Phase 3,0.44782039099235205,0.412117532412,canertinib,EGFR INHIBITOR,0.42055014321500855,0.9758855022491768,-5.06070546381342
BRD-K50325075-001-02-1::2.5::HTS,BRD-K50325075-001-02-1,UCL-2077,2.5,HTS,METHYL_PPL,METHYL,noncancer,slow afterhyperpolarization channel blocker,,,,Preclinical,0.351657561001046,0.0842131375424,UCL-2077,,,0,0
BRD-K50388907-001-30-4::2.5::HTS,BRD-K50388907-001-30-4,fenofibrate,2.5,HTS,MIRNA_hsa-miR-200c,MIRNA,noncancer,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia",Launched,0.28633465836709493,0.25554209482,fenofibrate,OTHER,0.261926899992387,1.5519576514439792,-4.621798098099784
BRD-K50398167-236-22-7::2.5::HTS,BRD-K50398167-236-22-7,meclofenamic-acid,2.5,HTS,DEM2_FLI1 (2313),DEMETER2_COM,noncancer,"cyclooxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2","rheumatology, neurology/psychiatry, endocrinology","joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)",Launched,0.23623009941884196,0.0445677997822,meclofenamic-acid,,,0,0
BRD-K50406511-001-26-0::2.5::HTS,BRD-K50406511-001-26-0,hycanthone,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,RNA synthesis inhibitor,,infectious disease,schistosomiasis,Launched,0.31654320128665697,0.132079633387,hycanthone,OTHER,0.3155144370927789,-4.804959674892009,-0.6071949156566325
BRD-K50417881-003-17-4::2.5::HTS,BRD-K50417881-003-17-4,eticlopride,2.5,HTS,CN_C5orf45 (51149),CN,noncancer,dopamine receptor antagonist,"DRD2, DRD3, DRD4",,,Preclinical,0.299362845971274,0.0437148863843,eticlopride,,,0,0
BRD-K50422030-001-05-3::2.5::HTS,BRD-K50422030-001-05-3,clomethiazole,2.5,HTS,PROT_4E-BP1,PROT,noncancer,"GABA receptor antagonist, GABA receptor modulator",GABRA1,neurology/psychiatry,"Parkinson's Disease, sedative, muscle relaxant",Launched,0.255925935229607,0.139501518724,clomethiazole,,,0,0
BRD-K50489389-001-01-8::2.500007911::MTS004,BRD-K50489389-001-01-8,ranirestat,2.500007911,MTS004,METHYL_CD46,METHYL,noncancer,aldose reductase inhibitor,AKR1B1,,,Phase 3,0.27176574132062903,0.168487902109,ranirestat,,,0,0
BRD-K50495309-001-02-0::2.5::HTS,BRD-K50495309-001-02-0,SRC-kinase-inhibitor-I,2.5,HTS,Exp_GAST (ENSG00000184502),GE,noncancer,src inhibitor,"CSK, LCK, RIPK2",,,Preclinical,0.308926364024793,0.307860290613,SRC-kinase-inhibitor-I,,,0,0
BRD-K50498985-001-03-3::2.5::HTS,BRD-K50498985-001-03-3,taladegib,2.5,HTS,DEM2_IFNA6 (3443),DEMETER2_COM,targeted cancer,smoothened receptor antagonist,"DHH, IHH, SMO",,,Phase 2,0.24850255305090396,0.0863330335517,taladegib,,,0,0
BRD-K50564936-001-01-6::2.5::HTS,BRD-K50564936-001-01-6,E-2012,2.5,HTS,METABOL_proline,METABOL,noncancer,gamma secretase modulator,"APH1A, APH1B, PSENEN",,,Phase 1,0.27258574595989604,-0.00897816054887,E-2012,,,0,0
BRD-K50590187-001-19-9::2.5::HTS,BRD-K50590187-001-19-9,capsaicin,2.5,HTS,METABOL_C54:6 TAG,METABOL,noncancer,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis",Launched,0.23481496741604999,0.0273852103143,capsaicin,,,0,0
BRD-K50631926-001-02-3::2.5::HTS,BRD-K50631926-001-02-3,PIK-294,2.5,HTS,CRISPR_LYRM7 (90624),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",,,Preclinical,0.27177148511206894,0.083541130135,PIK-294,,,0,0
BRD-K50660797-001-05-1::2.499989832::MTS004,BRD-K50660797-001-05-1,epicatechin-gallate-(-),2.499989832,MTS004,PROT_STAT3_pY705,PROT,targeted cancer,bacterial DNA gyrase inhibitor,"BACE1, FASN",,,Phase 2,0.253825632325138,0.0764211394878,epicatechin-gallate-(-),,,0,0
BRD-K50677762-001-01-5::2.5::HTS,BRD-K50677762-001-01-5,oxiracetam,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,acetylcholine receptor agonist,,,,Launched,0.380545419537415,0.202038383781,oxiracetam,OTHER,0.38252237856725385,5.795958343035821,-2.4281326827892817
BRD-K50785021-001-02-1::2.5::HTS,BRD-K50785021-001-02-1,cyclamic-acid,2.5,HTS,CRISPR_ARL14EP (120534),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.291823214288882,0.0528290897509,cyclamic-acid,,,0,0
BRD-K50813454-001-01-9::2.592830582::MTS004,BRD-K50813454-001-01-9,amflutizole,2.592830582,MTS004,Exp_ANKRD20A7P (ENSG00000236816),GE,noncancer,xanthine oxidase inhibitor,XDH,,,Phase 2,0.31282868510647,0.0650655194755,amflutizole,,,0,0
BRD-K50817623-303-05-7::2.5::HTS,BRD-K50817623-303-05-7,pancuronium,2.5,HTS,METHYL_GPER1,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM2, CHRM3, CHRNA1, CHRNA2","critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant",Launched,0.301949265206003,0.162182345769,pancuronium,,,0,0
BRD-K50836978-001-02-5::2.5::HTS,BRD-K50836978-001-02-5,purvalanol-a,2.5,HTS,CN_LOC400655 (400655),CN,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC",,,Preclinical,0.299219775184722,0.074430794831,purvalanol-a,,,0,0
BRD-K50850824-237-04-8::2.5::HTS,BRD-K50850824-237-04-8,acesulfame-potassium,2.5,HTS,DEM2_SPPL2A (84888),DEMETER2_COM,noncancer,,,,,Phase 3,0.327384240844748,0.092374842996,acesulfame-potassium,OTHER,0.3396300463253857,3.364945264029811,-0.02831244536858435
BRD-K50853363-001-02-3::2.5::HTS,BRD-K50853363-001-02-3,dienogest,2.5,HTS,CRISPR_CSTF1 (1477),AVANA_PUBLIC_18Q2,noncancer,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",Launched,0.35721723368512104,0.230373978889,dienogest,OTHER,0.3406141914478054,4.692505540343271,-1.2675490124632631
BRD-K50859149-001-19-5::2.5::HTS,BRD-K50859149-001-19-5,sulfafurazole,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,bacterial antifolate,,infectious disease,urinary tract infections,Launched,0.275477142196456,0.0700162725776,sulfafurazole,,,0,0
BRD-K50866992-003-09-5::2.5::HTS,BRD-K50866992-003-09-5,tropisetron,2.5,HTS,CRISPR_CCDC37 (348807),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting",Launched,0.262304434419851,0.136800114564,tropisetron,,,0,0
BRD-K50866992-003-10-3::2.5::HTS,BRD-K50866992-003-10-3,tropisetron,2.5,HTS,Exp_NAALADL1 (ENSG00000168060),GE,noncancer,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting",Launched,0.262304434419851,0.163807683599,tropisetron,,,0,0
BRD-K50891186-001-04-4::2.5::HTS,BRD-K50891186-001-04-4,GR-103691,2.5,HTS,CRISPR_DYNC1H1 (1778),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor antagonist,DRD3,,,Preclinical,0.25748028659263505,0.109078649202,GR-103691,,,0,0
BRD-K50938287-036-13-8::2.5::HTS,BRD-K50938287-036-13-8,sumatriptan,2.5,HTS,PROT_CDK1,PROT,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7",neurology/psychiatry,migraine headache,Launched,0.24418862006830303,0.0399067842563,sumatriptan,,,0,0
BRD-K50938786-003-11-8::2.5::HTS,BRD-K50938786-003-11-8,ropivacaine,2.5,HTS,Exp_RNPEPL1 (ENSG00000142327),GE,noncancer,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic,Launched,0.256036831734536,0.0845070908821,ropivacaine,,,0,0
BRD-K51033547-003-02-6::2.5::HTS,BRD-K51033547-003-02-6,tramadol,2.5,HTS,CRISPR_PEX6 (5190),AVANA_PUBLIC_18Q2,noncancer,"norepinephrine reputake inhibitor, opioid receptor agonist, serotonin reuptake inhibitor","CHRFAM7A, CHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4",neurology/psychiatry,"acute pain, chronic pain",Launched,0.26185333738648897,0.0812847358236,tramadol,,,0,0
BRD-K51040301-001-02-1::2.5::HTS,BRD-K51040301-001-02-1,cobicistat,2.5,HTS,CRISPR_MZT1 (440145),AVANA_PUBLIC_18Q2,noncancer,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.308498829065484,0.0676512282355,cobicistat,,,0,0
BRD-K51087630-001-01-6::2.5::HTS,BRD-K51087630-001-01-6,tirasemtiv,2.5,HTS,METABOL_C16:0 LPC,METABOL,noncancer,troponin activator,,,,Phase 2,0.172444967542493,0.120495256801,tirasemtiv,,,0,0
BRD-K51143828-003-03-1::2.5::HTS,BRD-K51143828-003-03-1,lurasidone,2.5,HTS,Exp_CNGA1 (ENSG00000198515),GE,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,Launched,0.283063865628769,0.057816151954,lurasidone,,,0,0
BRD-K51199656-003-01-4::2.5::HTS,BRD-K51199656-003-01-4,fluoromethylcholine,2.5,HTS,METHYL_MGST3,METHYL,noncancer,,,,,Launched,0.23444934126430605,0.0499818290975,fluoromethylcholine,,,0,0
BRD-K51207550-001-23-0::2.5::HTS,BRD-K51207550-001-23-0,ethionamide,2.5,HTS,METHYL_TICAM1,METHYL,noncancer,mycolic synthesis inhibitor,,infectious disease,tuberculosis,Launched,0.230771677840993,0.0590152775255,ethionamide,,,0,0
BRD-K51247865-001-01-2::2.5::HTS,BRD-K51247865-001-01-2,ipragliflozin-l-proline,2.5,HTS,Exp_HSPB7 (ENSG00000173641),GE,noncancer,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,Launched,0.209293578814006,-0.0249958465238,ipragliflozin-l-proline,,,0,0
BRD-K51263939-001-08-6::2.5::HTS,BRD-K51263939-001-08-6,sarcosine,2.5,HTS,METABOL_myristoylcarnitine,METABOL,noncancer,Glycine transporter 1 inhibitor,SLC6A9,,,Phase 2,0.31426541823075393,0.0602665401394,sarcosine,,,0,0
BRD-K51313569-003-03-3::2.5::HTS,BRD-K51313569-003-03-3,palbociclib,2.5,HTS,CRISPR_ZC3H14 (79882),AVANA_PUBLIC_18Q2,targeted cancer,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,Launched,0.326245891243462,0.222903527872,palbociclib,CDK INHIBITOR,0.32505404172120184,-4.206599789524887,-1.5953204300445805
BRD-K51318897-001-15-3::2.5::HTS,BRD-K51318897-001-15-3,fenbendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms",Launched,0.282070159701193,0.251112160526,fenbendazole,TUBULIN POLYMERIZATION INHIBITOR,0.2819550333364852,6.165813244475388,-2.1757213243172746
BRD-K51324732-001-01-0::2.5::HTS,BRD-K51324732-001-01-0,meglitinide,2.5,HTS,MIRNA_hsa-miR-582-5p,MIRNA,noncancer,potassium channel blocker,CCR2,,,Phase 2,0.34640786549616703,0.0671476546516,meglitinide,,,0,0
BRD-K51333959-003-01-3::2.5::HTS,BRD-K51333959-003-01-3,siramesine,2.5,HTS,METABOL_C38:2 PC,METABOL,targeted cancer,sigma receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",,,Phase 2,0.300576663969013,0.0764481643001,siramesine,,,0,0
BRD-K51431759-001-02-9::2.5::HTS,BRD-K51431759-001-02-9,dextrose,2.5,HTS,METHYL_PSIP1,METHYL,noncancer,,,endocrinology,hypoglycemia,Launched,0.26647852671583605,0.0739669506238,dextrose,,,0,0
BRD-K51471001-303-04-7::2.5::HTS,BRD-K51471001-303-04-7,demecarium,2.5,HTS,MIRNA_hsa-miR-29b,MIRNA,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",Launched,0.302601707483402,0.10740813096,demecarium,,,0,0
BRD-K51474575-001-10-4::2.5::HTS,BRD-K51474575-001-10-4,taurine,2.5,HTS,Exp_IKZF3 (ENSG00000161405),GE,noncancer,antioxidant,,neurology/psychiatry,"anxiety, irritability, sleeplessness",Launched,0.261876198028112,0.041062915879,taurine,,,0,0
BRD-K51485625-001-08-4::2.5::HTS,BRD-K51485625-001-08-4,ritonavir,2.5,HTS,CRISPR_NFATC4 (4776),AVANA_PUBLIC_18Q2,noncancer,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.27436866392719,0.0866721238838,ritonavir,,,0,0
BRD-K51486818-003-02-8::2.5::HTS,BRD-K51486818-003-02-8,lazabemide,2.5,HTS,CRISPR_ARL9 (132946),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,MAOB,,,Phase 3,0.239673479764078,0.0699833268025,lazabemide,,,0,0
BRD-K51541829-050-01-0::2.5::HTS,BRD-K51541829-050-01-0,Ro-25-6981,2.5,HTS,Exp_HIGD1AP1 (ENSG00000258016),GE,noncancer,,GRIN2B,,,Preclinical,0.323632705826243,0.0957972232944,Ro-25-6981,,,0,0
BRD-K51544265-001-04-2::2.5::HTS,BRD-K51544265-001-04-2,cabozantinib,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),Launched,0.372061453816323,0.234655735689,cabozantinib,RET TYROSINE KINASE INHIBITOR,0.382836261777951,0.7054930113445562,-2.2952267007309715
BRD-K51575138-001-13-2::2.5::HTS,BRD-K51575138-001-13-2,TPCA-1,2.5,HTS,Exp_ARTN (ENSG00000117407),GE,targeted cancer,IKK inhibitor,IKBKB,,,Preclinical,0.405789034039964,0.191379182207,TPCA-1,OTHER,0.4030147301164052,0.5458301673292362,-2.818086684365208
BRD-K51579475-003-02-4::2.5::HTS,BRD-K51579475-003-02-4,dapoxetine,2.5,HTS,CRISPR_MS4A7 (58475),AVANA_PUBLIC_18Q2,noncancer,selective serotonin reuptake inhibitor (SSRI),"HTR1A, HTR1B, HTR2C, SLC6A4",urology,premature ejaculation (PE),Launched,0.26397284570958895,0.125516007529,dapoxetine,,,0,0
BRD-K51662849-001-05-4::2.5::HTS,BRD-K51662849-001-05-4,ilomastat,2.5,HTS,PROT_Annexin 1,PROT,noncancer,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",,,Phase 3,0.350250377525032,0.0610859281597,ilomastat,,,0,0
BRD-K51662849-001-08-8::2.61::HTS,BRD-K51662849-001-08-8,ilomastat,2.61,HTS,Exp_SCGB2B2 (ENSG00000205209),GE,noncancer,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",,,Phase 3,0.350250377525032,0.0667165609207,ilomastat,,,0,0
BRD-K51671335-001-10-6::2.5::HTS,BRD-K51671335-001-10-6,levosulpiride,2.5,HTS,Exp_CACNA1C (ENSG00000151067),GE,noncancer,dopamine receptor antagonist,"CA1, CA12, CA7, DRD2, DRD3","neurology/psychiatry, gastroenterology, urology","schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)",Launched,0.306386412024693,0.129853722613,levosulpiride,,,0,0
BRD-K51677086-001-12-0::2.5::HTS,BRD-K51677086-001-12-0,erythromycin-ethylsuccinate,2.5,HTS,MUTpool_TGM7 (116179),MUTpool,noncancer,"cytochrome P450 inhibitor, protein synthesis inhibitor","ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1",infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma",Launched,0.21885669032399,0.0501160059308,erythromycin-ethylsuccinate,,,0,0
BRD-K51730347-001-06-4::2.5::MTS004,BRD-K51730347-001-06-4,diphencyprone,2.5,MTS004,CN_SAMSN1-AS1 (100874190),CN,targeted cancer,immunostimulant,,,,Phase 2,0.279782442910299,0.073238872133,diphencyprone,,,0,0
BRD-K51747290-001-12-3::2.5::HTS,BRD-K51747290-001-12-3,hydroxyurea,2.5,HTS,DEM2_PRCP (5547),DEMETER2_COM,chemo,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)",Launched,0.279001965854072,0.0286231223287,hydroxyurea,,,0,0
BRD-K51747290-001-13-1::2.5::HTS,BRD-K51747290-001-13-1,hydroxyurea,2.5,HTS,METABOL_serotonin,METABOL,chemo,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)",Launched,0.24005712927608103,0.0155837232714,hydroxyurea,,,0,0
BRD-K51751936-001-09-1::2.5::HTS,BRD-K51751936-001-09-1,alfadolone-acetate,2.5,HTS,PROT_XBP1_Caution,PROT,noncancer,benzodiazepine receptor agonist,,,,Phase 2,0.27566744155920003,0.0648983327692,alfadolone-acetate,,,0,0
BRD-K51770398-001-01-9::2.5::HTS,BRD-K51770398-001-01-9,JNJ-17203212,2.5,HTS,METHYL_PVALB,METHYL,noncancer,TRPV antagonist,TRPV1,,,Preclinical,0.28398219380093603,0.131992755385,JNJ-17203212,,,0,0
BRD-K51885093-001-11-2::2.5::HTS,BRD-K51885093-001-11-2,quinolinic-acid,2.5,HTS,METHYL_C1orf186,METHYL,noncancer,glutamate receptor agonist,,,,Preclinical,0.301889157428883,0.00397606090333,quinolinic-acid,,,0,0
BRD-K51899933-001-02-6::2.500004375::MTS004,BRD-K51899933-001-02-6,azeliragon,2.500004375,MTS004,PROT_Src,PROT,noncancer,RAGE receptor antagonist,AGER,,,Phase 3,0.28570700461517307,0.127115671994,azeliragon,,,0,0
BRD-K51918615-303-02-9::2.5::HTS,BRD-K51918615-303-02-9,iodophenpropit,2.5,HTS,MIRNA_hsv2-miR-H4-3p,MIRNA,noncancer,histamine receptor antagonist,"HRH3, HRH4",,,Preclinical,0.279206838316889,0.057281931369,iodophenpropit,,,0,0
BRD-K51937257-001-01-4::2.5::HTS,BRD-K51937257-001-01-4,bilastine,2.5,HTS,RMUTdmg_CSPP1 (79848),MUTdmg,noncancer,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,Launched,0.307600305289482,0.0644889095282,bilastine,,,0,0
BRD-K51956333-001-03-8::2.52122192::MTS004,BRD-K51956333-001-03-8,iopodic-acid,2.52122192,MTS004,Exp_LRIG3 (ENSG00000139263),GE,noncancer,,,radiology,contrast agent,Launched,0.20680091460181502,0.0831882820993,iopodic-acid,,,0,0
BRD-K52020312-001-26-8::2.5::HTS,BRD-K52020312-001-26-8,metronidazole,2.5,HTS,MIRNA_hsa-miR-149,MIRNA,noncancer,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,Launched,0.30933684525716404,0.0657738623139,metronidazole,,,0,0
BRD-K52075040-001-09-7::5.6::HTS,BRD-K52075040-001-09-7,cerulenin,5.6,HTS,PROT_Caveolin-1,PROT,noncancer,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,Launched,0.344534722467324,0.0721924224789,cerulenin,OTHER,0.3269709475368083,-4.0442855685022225,-1.5130190444269729
BRD-K52075715-001-06-7::2.5::HTS,BRD-K52075715-001-06-7,oxibendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,Launched,0.40407579064530796,0.27807389918,oxibendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4030711029375416,5.504008717394713,-2.8618212868220048
BRD-K52080565-001-09-2::2.5::HTS,BRD-K52080565-001-09-2,nandrolone,2.5,HTS,Exp_ZNF536 (ENSG00000198597),GE,noncancer,imidazoline receptor agonist,"AR, CYP19A1, MAOA, MAOB",hematology,anemia,Launched,0.28498182688863694,0.0611853564435,nandrolone,,,0,0
BRD-K52113681-003-02-1::2.5::HTS,BRD-K52113681-003-02-1,CP-339818,2.5,HTS,MIRNA_hsa-miR-1973,MIRNA,noncancer,potassium channel blocker,KCNA3,,,Preclinical,0.36089503211153706,0.0298662660357,CP-339818,,,0,0
BRD-K52172416-001-11-4::2.5::HTS,BRD-K52172416-001-11-4,anastrozole,2.5,HTS,METHYL_MAATS1,METHYL,targeted cancer,aromatase inhibitor,CYP19A1,oncology,breast cancer,Launched,0.241473669944698,0.104379972264,anastrozole,,,0,0
BRD-K52219182-001-02-4::2.5::HTS,BRD-K52219182-001-02-4,ICI-63197,2.5,HTS,DEM2_RRAGC (64121),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,,,,Preclinical,0.27400794937517603,0.039876587696,ICI-63197,,,0,0
BRD-K52256627-300-06-6::2.5::HTS,BRD-K52256627-300-06-6,chlorhexidine,2.5,HTS,Exp_EREG (ENSG00000124882),GE,noncancer,membrane integrity inhibitor,,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Launched,0.472692332609723,0.380570370155,chlorhexidine,OTHER,0.4739362413930641,1.54037772056328,-3.8421685355984088
BRD-K52284881-236-02-4::2.5::HTS,BRD-K52284881-236-02-4,chiniofon,2.5,HTS,DEM2_KLK15 (55554),DEMETER2_COM,noncancer,antiprotozoal agent,,infectious disease,amebiasis,Launched,0.267045055552673,0.129235800113,chiniofon,,,0,0
BRD-K52313696-001-12-3::2.5::HTS,BRD-K52313696-001-12-3,tacedinaline,2.5,HTS,CRISPR_PPIL1 (51645),AVANA_PUBLIC_18Q2,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 3,0.335289356780877,0.222571851133,tacedinaline,HDAC INHIBITOR,0.31732385523826184,6.967467912447919,-1.9239692423266923
BRD-K52394958-001-02-7::2.5::HTS,BRD-K52394958-001-02-7,GR-159897,2.5,HTS,CN_LOC100129520 (100129520),CN,noncancer,tachykinin antagonist,"TAC1, TACR2",,,Preclinical,0.23289935462409,0.0355737796841,GR-159897,,,0,0
BRD-K52396582-001-06-7::2.5::HTS,BRD-K52396582-001-06-7,CF102,2.5,HTS,Exp_MT1F (ENSG00000198417),GE,targeted cancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Phase 2,0.249154398691087,0.0698705131,CF102,,,0,0
BRD-K52397688-003-06-4::2.5::HTS,BRD-K52397688-003-06-4,amperozide,2.5,HTS,MIRNA_hcmv-miR-US5-1,MIRNA,noncancer,dopamine receptor antagonist,"FAAH, HTR2A",neurology/psychiatry,psychosis,Launched,0.291961246560737,0.0326877285573,amperozide,,,0,0
BRD-K52408781-001-02-8::2.5::HTS,BRD-K52408781-001-02-8,clobazam,2.5,HTS,Exp_SNTB2 (ENSG00000168807),GE,noncancer,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,seizures,Launched,0.2846839253497,0.0561014303179,clobazam,,,0,0
BRD-K52459018-001-09-1::2.5::HTS,BRD-K52459018-001-09-1,kainic-acid,2.5,HTS,Exp_IL23R (ENSG00000162594),GE,noncancer,kainate receptor agonist,"GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5",,,Preclinical,0.255531438230799,0.0245894418866,kainic-acid,,,0,0
BRD-K52459643-001-17-7::2.5::HTS,BRD-K52459643-001-17-7,alprostadil,2.5,HTS,METABOL_beta-alanine,METABOL,noncancer,prostanoid receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR",cardiology,congenital heart defects,Launched,0.28103673268508805,0.0767665643538,alprostadil,,,0,0
BRD-K52487250-003-01-2::2.5::HTS,BRD-K52487250-003-01-2,"ICI-215,001",2.5,HTS,MIRNA_hsa-miR-127-3p,MIRNA,noncancer,adrenergic receptor agonist,ADRB3,,,Preclinical,0.273385677358017,0.117077740397,"ICI-215,001",,,0,0
BRD-K52512893-001-08-9::2.5::HTS,BRD-K52512893-001-08-9,SC-19220,2.5,HTS,METABOL_C16:0 LPE,METABOL,noncancer,prostanoid receptor antagonist,PTGER1,,,Preclinical,0.26692851982345606,0.0994998455124,SC-19220,,,0,0
BRD-K52523550-001-01-5::2.5::HTS,BRD-K52523550-001-01-5,N-acetylcarnosine,2.5,HTS,METABOL_proline,METABOL,noncancer,,,,,Phase 2,0.271679954772172,0.0366145272596,N-acetylcarnosine,,,0,0
BRD-K52559566-001-02-9::2.5::HTS,BRD-K52559566-001-02-9,monosodium-alpha-luminol,2.5,HTS,Exp_MTAPP2 (ENSG00000230077),GE,noncancer,,,,,Launched,0.21163714328364602,0.0304150409775,monosodium-alpha-luminol,,,0,0
BRD-K52579889-001-01-9::2.499985811::MTS004,BRD-K52579889-001-01-9,TGR-1202,2.499985811,MTS004,PROT_PKC-alpha_pS657_Caution,PROT,targeted cancer,PI3K inhibitor,,,,Phase 3,0.286681580751279,0.161713359912,TGR-1202,,,0,0
BRD-K52618540-001-09-9::2.5::HTS,BRD-K52618540-001-09-9,inositol,2.5,HTS,DEM2_NRF1 (4899),DEMETER2_COM,noncancer,insulin sensitizer,"CDIPT, GBA",,,Launched,0.26673553256750604,0.0758855213165,inositol,,,0,0
BRD-K52662033-003-21-2::2.5::HTS,BRD-K52662033-003-21-2,lidocaine,2.5,HTS,CRISPR_STAMBP (10617),AVANA_PUBLIC_18Q2,noncancer,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage",Launched,0.250172764334285,0.0201636399912,lidocaine,,,0,0
BRD-K52681925-050-01-6::2.472084005::MTS004,BRD-K52681925-050-01-6,altinicline,2.472084005,MTS004,CRISPR_TM7SF3 (51768),AVANA_PUBLIC_18Q2,noncancer,nicotinic receptor agonist,"CHRNA4, CHRNB2",,,Phase 2,0.291128227842031,0.0658825989977,altinicline,,,0,0
BRD-K52751261-001-06-1::2.5::HTS,BRD-K52751261-001-06-1,TAK-715,2.5,HTS,Exp_ARCN1 (ENSG00000095139),GE,noncancer,p38 MAPK inhibitor,MAPK14,,,Phase 2,0.270335174150866,0.0707032070112,TAK-715,,,0,0
BRD-K52756523-001-24-7::2.5::HTS,BRD-K52756523-001-24-7,dirithromycin,2.5,HTS,CRISPR_ATOX1 (475),AVANA_PUBLIC_18Q2,noncancer,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis,Launched,0.285905250691161,0.0701928888522,dirithromycin,,,0,0
BRD-K52762805-001-01-2::2.5::HTS,BRD-K52762805-001-01-2,epothilone-d,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 2,0.392511332852066,0.232180931769,epothilone-d,OTHER,0.3894586355892942,6.116193740396273,-1.8932784437615575
BRD-K52911425-001-09-8::2.5::HTS,BRD-K52911425-001-09-8,GDC-0941,2.5,HTS,CRISPR_PNN (5411),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 2,0.344252502838951,0.367778243192,GDC-0941,PI3K INHIBITOR,0.3420933284019244,0.680298498810724,-1.4459033534674923
BRD-K52914072-001-01-5::2.5::MTS004,BRD-K52914072-001-01-5,LTA,2.5,MTS004,Exp_CBX1P1 (ENSG00000230823),GE,noncancer,,,,,Phase 2,0.32191140856539896,0.140274589446,LTA,,,0,0
BRD-K52959329-238-01-9::2.5::HTS,BRD-K52959329-238-01-9,mitiglinide,2.5,HTS,METHYL_XK,METHYL,noncancer,insulin secretagogue,"ABCC8, KCNJ10, PPARG",endocrinology,diabetes mellitus,Launched,0.30607806626675704,0.122554222643,mitiglinide,,,0,0
BRD-K52960356-001-15-5::2.499955314::MTS004,BRD-K52960356-001-15-5,acetohexamide,2.499955314,MTS004,METABOL_GABA,METABOL,noncancer,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,Launched,0.313869287509953,0.0729808114098,acetohexamide,,,0,0
BRD-K52989797-003-26-4::2.5::HTS,BRD-K52989797-003-26-4,clomipramine,2.5,HTS,CRISPR_FZD5 (7855),AVANA_PUBLIC_18Q2,noncancer,serotonin transporter (SERT) inhibitor,"GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,obsessive compulsive disorder (OCD),Launched,0.24498579250108302,0.0590194405701,clomipramine,,,0,0
BRD-K53061490-003-13-9::2.5::HTS,BRD-K53061490-003-13-9,ozagrel,2.5,HTS,METABOL_cAMP,METABOL,noncancer,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke,Launched,0.24908921134852802,0.100277638738,ozagrel,,,0,0
BRD-K53083666-001-01-0::2.5::HTS,BRD-K53083666-001-01-0,"1,5-dicaffeoylquinic-acid",2.5,HTS,Exp_PRKAB1 (ENSG00000111725),GE,noncancer,,,,,Phase 1,0.255526609318321,0.11125317208,"1,5-dicaffeoylquinic-acid",,,0,0
BRD-K53097745-001-01-5::2.5::HTS,BRD-K53097745-001-01-5,pterostilbene,2.5,HTS,Exp_GFRA2 (ENSG00000168546),GE,targeted cancer,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,,,Phase 2/Phase 3,0.272271673275025,0.209727820814,pterostilbene,,,0,0
BRD-K53123955-001-10-5::2.5::HTS,BRD-K53123955-001-10-5,niridazole,2.5,HTS,CRISPR_FGF3 (2248),AVANA_PUBLIC_18Q2,noncancer,phosphofructokinase inhibitor,,infectious disease,schistosomiasis,Launched,0.23646977642053002,0.0276315875173,niridazole,,,0,0
BRD-K53124401-001-03-8::0.03::HTS,BRD-K53124401-001-03-8,LTB4,0.03,HTS,DEM2_RSPO2 (340419),DEMETER2_COM,targeted cancer,leukocyte activator,"LTB4R, LTB4R2",,,Phase 2,0.26585907255291497,0.0782425898747,LTB4,,,0,0
BRD-K53153417-001-10-4::2.5::HTS,BRD-K53153417-001-10-4,butylated-hydroxytoluene,2.5,HTS,METHYL_ZNF718,METHYL,noncancer,carbonic anhydrase inhibitor,CA2,,,Phase 1,0.292146074967797,0.0643562228323,butylated-hydroxytoluene,,,0,0
BRD-K53156626-001-01-3::2.5::MTS004,BRD-K53156626-001-01-3,7-methoxytacrine,2.5,MTS004,PROT_GSK-3-BETA_Caution,PROT,noncancer,acetylcholinesterase inhibitor,ACHE,,,Phase 2,0.31418992844531396,0.163042326219,7-methoxytacrine,,,0,0
BRD-K53195974-001-01-9::2.298572309::MTS004,BRD-K53195974-001-01-9,sipatrigine,2.298572309,MTS004,Exp_SAA4 (ENSG00000148965),GE,noncancer,voltage-gated sodium channel blocker,"CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A",,,Phase 2,0.303505977858051,0.09410904524,sipatrigine,,,0,0
BRD-K53205568-001-02-6::2.5::HTS,BRD-K53205568-001-02-6,afalanine,2.5,HTS,METHYL_LMAN2,METHYL,noncancer,dopamine receptor agonist,DRD2,,,Phase 3,0.23435777152985202,0.117574649287,afalanine,,,0,0
BRD-K53220666-001-02-6::2.5::HTS,BRD-K53220666-001-02-6,trimetozine,2.5,HTS,MUTpool_SLC4A2 (6522),MUTpool,noncancer,sedative,,neurology/psychiatry,sedative,Launched,0.269823458351466,0.0355241892546,trimetozine,,,0,0
BRD-K53234107-001-01-6::2.5::HTS,BRD-K53234107-001-01-6,IWP-L6,2.5,HTS,MIRNA_hsa-miR-1248,MIRNA,targeted cancer,porcupine inhibitor,PORCN,,,Preclinical,0.280417066359872,0.0732818199754,IWP-L6,,,0,0
BRD-K53236343-003-03-7::2.625172304::MTS004,BRD-K53236343-003-03-7,aprindine,2.625172304,MTS004,Exp_CAMTA1 (ENSG00000171735),GE,noncancer,voltage-gated sodium channel blocker,"CALM1, SCN5A",cardiology,cardiac arrythmia,Launched,0.24559529788355303,0.138307585068,aprindine,,,0,0
BRD-K53263234-001-05-2::2.5::HTS,BRD-K53263234-001-05-2,CITCO,2.5,HTS,Exp_C8orf44-SGK3 (ENSG00000270024),GE,noncancer,constitutive androstane receptor (CAR) agonist,NR1I3,,,Preclinical,0.260439034117855,0.074253618019,CITCO,,,0,0
BRD-K53318339-001-24-9::2.5::HTS,BRD-K53318339-001-24-9,vinpocetine,2.5,HTS,CRISPR_C12orf73 (728568),AVANA_PUBLIC_18Q2,noncancer,"phosphodiesterase inhibitor, sodium channel blocker","PDE1A, PDE1C",,,Launched,0.295929345343479,0.0692827378162,vinpocetine,,,0,0
BRD-K53319039-001-01-8::2.5::MTS004,BRD-K53319039-001-01-8,estradiol-acetate,2.5,MTS004,METHYL_TPM2,METHYL,noncancer,estrogen receptor agonist,ESR1,"endocrinology, obstetrics/gynecology","menopause, vaginal atrophy",Launched,0.27480067233613503,0.0948724093653,estradiol-acetate,,,0,0
BRD-K53397409-001-12-3::2.5::HTS,BRD-K53397409-001-12-3,benzoic-acid,2.5,HTS,DEM2_FLOT1 (10211),DEMETER2_COM,noncancer,food preservative,"DAO, HRSP12, PRDX5, RAB9A",infectious disease,tinea pedis,Launched,0.23679084020788602,0.0534479882777,benzoic-acid,,,0,0
BRD-K53414658-001-08-2::2.5::HTS,BRD-K53414658-001-08-2,tivozanib,2.5,HTS,MIRNA_hsa-miR-216a,MIRNA,targeted cancer,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.291306935341937,0.126809937532,tivozanib,VEGFR INHIBITOR,0.2720105359014036,4.597206134584806,-1.8160616187633492
BRD-K53448858-001-07-0::2.5::HTS,BRD-K53448858-001-07-0,acadesine,2.5,HTS,CN_KRT17P5 (339240),CN,targeted cancer,AMPK activator,,,,Phase 3,0.26034247792306603,0.114006222066,acadesine,,,0,0
BRD-K53508936-001-01-0::2.5::HTS,BRD-K53508936-001-01-0,CTS-1027,2.5,HTS,METABOL_cAMP,METABOL,noncancer,metalloproteinase inhibitor,"MMP1, MMP13, MMP2, MMP3, MMP9",,,Phase 2,0.275259825990942,0.0541139375901,CTS-1027,,,0,0
BRD-K53517854-051-01-4::2.5::HTS,BRD-K53517854-051-01-4,fluvoxamine,2.5,HTS,PROT_PREX1,PROT,noncancer,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),Launched,0.24108256819684604,-0.00537858041748,fluvoxamine,,,0,0
BRD-K53523901-001-04-4::2.5::HTS,BRD-K53523901-001-04-4,arctigenin,2.5,HTS,CRISPR_CHCHD7 (79145),AVANA_PUBLIC_18Q2,targeted cancer,MEK inhibitor,"CHUK, MAP2K1",,,Preclinical,0.286041868449262,0.14964140894,arctigenin,MEK INHIBITOR,0.27485585672482793,0.6232641218423822,-3.4552997198370563
BRD-K53532120-003-09-5::2.5::HTS,BRD-K53532120-003-09-5,U-50488-(-),2.5,HTS,PROT_c-Kit,PROT,noncancer,opioid receptor agonist,OPRK1,,,Preclinical,0.280486695148162,0.046040748523,U-50488-(-),,,0,0
BRD-K53532120-003-11-1::2.5::HTS,BRD-K53532120-003-11-1,U-50488-(-),2.5,HTS,CRISPR_AVPI1 (60370),AVANA_PUBLIC_18Q2,noncancer,opioid receptor agonist,OPRK1,,,Preclinical,0.289121225311208,0.0224554097085,U-50488-(-),,,0,0
BRD-K53561341-001-07-5::2.5::HTS,BRD-K53561341-001-07-5,aurora-a-inhibitor-i,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Preclinical,0.397554766874425,0.259366297332,aurora-a-inhibitor-i,AURORA KINASE INHIBITOR,0.385171362168646,5.45253093793096,-2.768414133420274
BRD-K53581288-001-02-9::2.5::HTS,BRD-K53581288-001-02-9,baricitinib,2.5,HTS,DEM2_MTUS1 (57509),DEMETER2_COM,noncancer,JAK inhibitor,"JAK1, JAK2",,,Phase 3,0.329376314583212,0.124422164499,baricitinib,,,0,0
BRD-K53665955-001-03-0::2.5::HTS,BRD-K53665955-001-03-0,MK-5108,2.5,HTS,Exp_NUP88 (ENSG00000108559),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.3789933941977629,0.223262609599,MK-5108,AURORA KINASE INHIBITOR,0.381235641951481,5.035420815587724,-3.0614947916630646
BRD-K53720352-001-03-2::2.5::HTS,BRD-K53720352-001-03-2,cinalukast,2.5,HTS,CRISPR_FBXO24 (26261),AVANA_PUBLIC_18Q2,noncancer,leukotriene receptor antagonist,CYSLTR1,,,Phase 2,0.240022357258792,0.064453971183,cinalukast,,,0,0
BRD-K53734668-003-02-0::2.66::HTS,BRD-K53734668-003-02-0,PRT062607,2.66,HTS,METHYL_ITGA2,METHYL,targeted cancer,syk inhibitor,"FGR, MAP3K9, SYK",,,Phase 2,0.18760410798131696,0.0932606568457,PRT062607,OTHER,0.20662616010609725,1.2928690548848047,-3.1983435286881168
BRD-K53734668-003-04-6::2.5::HTS,BRD-K53734668-003-04-6,PRT062607,2.5,HTS,METHYL_OMP,METHYL,targeted cancer,syk inhibitor,"FGR, MAP3K9, SYK",,,Phase 2,0.18760410798131696,0.0932606568457,PRT062607,,,0,0
BRD-K53737926-003-27-8::2.5::HTS,BRD-K53737926-003-27-8,amitriptyline,2.5,HTS,METHYL_FXN,METHYL,noncancer,"norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin-norepinephrine reuptake inhibitor (SNRI)","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,Launched,0.25808185854364,0.17927095941,amitriptyline,,,0,0
BRD-K53765467-001-02-1::2.5::HTS,BRD-K53765467-001-02-1,empagliflozin,2.5,HTS,RMUTmis_TTLL12 (23170),MUT,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,Launched,0.24333736746541798,0.0490170584015,empagliflozin,,,0,0
BRD-K53809807-304-02-4::2.7277447::MTS004,BRD-K53809807-304-02-4,fosphenytoin,2.7277447,MTS004,CN_RGPD4 (285190),CN,noncancer,sodium channel blocker,SCN5A,neurology/psychiatry,"epilepsy, seizures",Launched,0.295165599667745,0.0770264396165,fosphenytoin,,,0,0
BRD-K53814070-310-01-3::2.5::HTS,BRD-K53814070-310-01-3,ripasudil,2.5,HTS,Exp_CTNNBIP1 (ENSG00000178585),GE,noncancer,rho associated kinase inhibitor,"ROCK1, ROCK2",ophthalmology,"glaucoma, ocular hypertension",Launched,0.28136289351194893,0.19807271052,ripasudil,,,0,0
BRD-K53852914-001-01-8::2.5::HTS,BRD-K53852914-001-01-8,menbutone,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,,,gastroenterology,bile stimulation,Launched,0.28057103571916,0.0703210966773,menbutone,,,0,0
BRD-K53857191-001-22-7::2.5::HTS,BRD-K53857191-001-22-7,risperidone,2.5,HTS,CRISPR_TYK2 (7297),AVANA_PUBLIC_18Q2,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder, irritability",Launched,0.326777747672177,0.0923039139701,risperidone,,,0,0
BRD-K53913732-001-05-9::2.5::HTS,BRD-K53913732-001-05-9,SB-408124,2.5,HTS,RMUTmis_ADAMTS13 (11093),MUTmis,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Preclinical,0.266660147408002,0.026109484885,SB-408124,,,0,0
BRD-K53963539-004-02-0::2.5::HTS,BRD-K53963539-004-02-0,vortioxetine,2.5,HTS,CN_CDKN2B (1030),CN,noncancer,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4",neurology/psychiatry,depression,Launched,0.24255722935851,0.0514173643967,vortioxetine,,,0,0
BRD-K53972329-001-07-0::2.5::HTS,BRD-K53972329-001-07-0,ruxolitinib,2.5,HTS,CN_CD247 (919),CN,targeted cancer,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",Launched,0.305620972962544,0.132608199736,ruxolitinib,OTHER,0.3185908605641721,4.6977733588717765,-0.7952983862115892
BRD-K53979406-003-02-8::2.5::HTS,BRD-K53979406-003-02-8,ALX-5407,2.5,HTS,MIRNA_kshv-miR-K12-4-3p,MIRNA,noncancer,Glycine transporter 1 inhibitor,SLC6A9,,,Phase 1,0.217798322948796,0.057663834668,ALX-5407,,,0,0
BRD-K54006094-051-01-7::2.5::HTS,BRD-K54006094-051-01-7,formoterol,2.5,HTS,Exp_APLN (ENSG00000171388),GE,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,"asthma, chronic obstructive pulmonary disease (COPD), bronchospasm",Launched,0.2699196524258,0.150307080939,formoterol,,,0,0
BRD-K54028654-001-02-6::2.5::HTS,BRD-K54028654-001-02-6,cabaletta,2.5,HTS,PROT_Bid_Caution,PROT,noncancer,pharmacological chaperone,,,,Phase 2,0.271114235088251,0.078267200473,cabaletta,,,0,0
BRD-K54057105-001-01-2::2.5::HTS,BRD-K54057105-001-01-2,isobutyramide,2.5,HTS,RMUTmis_AL627309.1 (0),MUTmis,noncancer,gene expression stimulant,"HBE1, HBG1",,,Phase 2,0.28664169899729103,0.103545014964,isobutyramide,,,0,0
BRD-K54094468-003-11-1::2.5::HTS,BRD-K54094468-003-11-1,remoxipride,2.5,HTS,CN_NUGGC (389643),CN,noncancer,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",,,Withdrawn,0.27464366380043104,0.0440640360373,remoxipride,,,0,0
BRD-K54095730-001-03-1::2.5::HTS,BRD-K54095730-001-03-1,CMPD-1,2.5,HTS,CRISPR_TTF2 (8458),AVANA_PUBLIC_18Q2,noncancer,p38 MAPK inhibitor,"GNRHR, MAPK14",,,Preclinical,0.38022512742390796,0.26999750056,CMPD-1,OTHER,0.3803695303592985,5.201670570479791,-2.6500993600649467
BRD-K54142781-003-11-8::2.5::HTS,BRD-K54142781-003-11-8,cirazoline,2.5,HTS,MIRNA_hsa-miR-644,MIRNA,noncancer,adrenergic receptor agonist,ADRA1A,,,Preclinical,0.27666921184251697,0.0347528198483,cirazoline,,,0,0
BRD-K54187111-001-08-4::2.51::HTS,BRD-K54187111-001-08-4,dichlorisone-acetate,2.51,HTS,PROT_14-3-3_zeta,PROT,noncancer,,,,,Phase 2,0.28639230975521096,0.12835676549,dichlorisone-acetate,OTHER,0.2842511163656329,-3.6007123720821888,-3.2654680392509503
BRD-K54187111-001-09-2::2.5::HTS,BRD-K54187111-001-09-2,dichlorisone-acetate,2.5,HTS,Exp_LOH12CR2 (ENSG00000205791),GE,noncancer,,,,,Phase 2,0.298636035870415,0.0787752918308,dichlorisone-acetate,OTHER,0.2954401662777057,-1.7731104359028045,-2.8267855124659103
BRD-K54262262-001-09-0::2.5::HTS,BRD-K54262262-001-09-0,monobenzone,2.5,HTS,METHYL_MIR4297,METHYL,noncancer,melanin inhibitor,TYR,dermatology,skin depigmentation,Launched,0.38261480307079904,0.235188182685,monobenzone,OTHER,0.3916407375866244,-3.0281059463046374,-0.4559666264213482
BRD-K54314721-001-10-2::2.5::HTS,BRD-K54314721-001-10-2,zolmitriptan,2.5,HTS,MIRNA_hsa-miR-633,MIRNA,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,Launched,0.25715008296192,0.0330257709569,zolmitriptan,,,0,0
BRD-K54316499-046-04-5::2.5::HTS,BRD-K54316499-046-04-5,tolterodine,2.5,HTS,METHYL_MGST3,METHYL,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency",Launched,0.307063055007043,0.0660846331808,tolterodine,,,0,0
BRD-K54330070-001-15-4::2.5::HTS,BRD-K54330070-001-15-4,SB-202190,2.5,HTS,CRISPR_LRRC57 (255252),AVANA_PUBLIC_18Q2,targeted cancer,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.26949883821842996,0.116318573556,SB-202190,OTHER,0.2631687225743732,1.0076169563609292,-5.283829230411394
BRD-K54339150-001-01-8::2.5::MTS004,BRD-K54339150-001-01-8,proquazone,2.5,MTS004,METABOL_sorbitol,METABOL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,Launched,0.29064113353689,0.0998249612041,proquazone,,,0,0
BRD-K54395039-001-01-7::2.5::HTS,BRD-K54395039-001-01-7,PR-619,2.5,HTS,Exp_GCLC (ENSG00000001084),GE,noncancer,DUB inhibitor,,,,Preclinical,0.491908191869293,0.32479671892,PR-619,OTHER,0.4913986832340397,1.7507822933276689,-3.5895064330915307
BRD-K54416256-001-19-9::2.5::HTS,BRD-K54416256-001-19-9,methimazole,2.5,HTS,DEM2_CBSL&CBS (102724560&875),DEMETER2_COM,noncancer,antithyroid agent,TPO,endocrinology,hyperthyroidism,Launched,0.264155128529037,0.117505146179,methimazole,,,0,0
BRD-K54472332-001-03-4::2.5::HTS,BRD-K54472332-001-03-4,elvitegravir,2.5,HTS,CRISPR_PLAC8L1 (153770),AVANA_PUBLIC_18Q2,noncancer,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.287495044098572,0.0395909962959,elvitegravir,,,0,0
BRD-K54496168-003-01-2::2.5::HTS,BRD-K54496168-003-01-2,propacetamol,2.5,HTS,METABOL_urate,METABOL,noncancer,cyclooxygenase inhibitor,PTGS2,"endocrinology, neurology/psychiatry","fever, pain relief",Launched,0.279034096425285,0.0242884856627,propacetamol,,,0,0
BRD-K54519451-001-02-9::2.499971332::MTS004,BRD-K54519451-001-02-9,pexidartinib,2.499971332,MTS004,MIRNA_hsa-miR-214,MIRNA,targeted cancer,tyrosine kinase inhibitor,"CSF1R, FLT3, KIT",,,Phase 3,0.310371423224763,0.0844027084214,pexidartinib,,,0,0
BRD-K54520417-001-01-2::2.5::HTS,BRD-K54520417-001-01-2,LXR-623,2.5,HTS,MIRNA_hsa-miR-601,MIRNA,noncancer,LXR agonist,"AR, NR1H2, NR1H3, NR1I2, NR3C1",,,Phase 1,0.270098799119321,-0.00549022750508,LXR-623,,,0,0
BRD-K54521836-001-02-1::2.5::HTS,BRD-K54521836-001-02-1,thiodiglycol,2.5,HTS,MIRNA_hcmv-miR-US33-5p,MIRNA,noncancer,,,,,Preclinical,0.253546128262495,0.0447350993763,thiodiglycol,,,0,0
BRD-K54529596-001-26-3::2.5::HTS,BRD-K54529596-001-26-3,captopril,2.5,HTS,CRISPR_FGFR1 (2260),AVANA_PUBLIC_18Q2,noncancer,angiotensin converting enzyme inhibitor,"ACE, LTA4H, MMP2, MMP9","cardiology, endocrinology, nephrology","hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy",Launched,0.29912850311054495,0.0418242520052,captopril,,,0,0
BRD-K54606188-001-13-1::2.5::HTS,BRD-K54606188-001-13-1,JQ1-(+),2.5,HTS,Exp_U2SURP (ENSG00000163714),GE,targeted cancer,bromodomain inhibitor,"BRD4, BRDT",,,Preclinical,0.355873287611933,0.31432776468,JQ1-(+),BROMODOMAIN INHIBITOR,0.3556495729149801,-0.5205566131923942,3.2001038404350184
BRD-K54634444-001-05-9::2.5::HTS,BRD-K54634444-001-05-9,artesunate,2.5,HTS,Exp_ALDH3B1 (ENSG00000006534),GE,noncancer,DNA synthesis inhibitor,,infectious disease,malaria,Launched,0.36702947709593603,0.302265169101,artesunate,OTHER,0.34354413686861784,1.4873235784925476,-3.436563937524004
BRD-K54640016-001-04-7::2.5::HTS,BRD-K54640016-001-04-7,WAY-362450,2.5,HTS,CN_MIR4436A (100616399),CN,noncancer,FXR agonist,NR1H4,,,Phase 1,0.24005747599503197,0.0281880019847,WAY-362450,,,0,0
BRD-K54665485-001-07-9::2.5::HTS,BRD-K54665485-001-07-9,R-59022,2.5,HTS,Exp_CEP57L1 (ENSG00000183137),GE,targeted cancer,"diacylglycerol kinase inhibitor, protein kinase inhibitor",DGKA,,,Preclinical,0.27570279192677194,0.125047427913,R-59022,,,0,0
BRD-K54708045-001-02-1::2.5::HTS,BRD-K54708045-001-02-1,nTZDpa,2.5,HTS,MIRNA_hsa-miR-512-5p,MIRNA,noncancer,PPAR receptor agonist,PPARG,,,Preclinical,0.29512433683334005,0.0143088060721,nTZDpa,,,0,0
BRD-K54759182-003-08-0::2.5::HTS,BRD-K54759182-003-08-0,dosulepin,2.5,HTS,MIRNA_hsa-miR-1973,MIRNA,noncancer,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4",neurology/psychiatry,depression,Launched,0.28907873492438896,0.0555980355119,dosulepin,,,0,0
BRD-K54770957-001-04-3::2.5::HTS,BRD-K54770957-001-04-3,etoricoxib,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,cyclooxygenase inhibitor,PTGS2,rheumatology,"rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis",Launched,0.27908410562256897,0.0423666501123,etoricoxib,,,0,0
BRD-K54790157-001-15-5::2.5::HTS,BRD-K54790157-001-15-5,trioxsalen,2.5,HTS,CN_WNT3 (7473),CN,noncancer,DNA synthesis inhibitor,,dermatology,"vitiligo, eczema",Launched,0.247361809515916,0.111970692667,trioxsalen,,,0,0
BRD-K54824716-001-04-0::2.5::HTS,BRD-K54824716-001-04-0,procodazole,2.5,HTS,DEM2_CYB5D2 (124936),DEMETER2_COM,noncancer,immunostimulant,,,,Preclinical,0.248479474371869,0.0871863131307,procodazole,,,0,0
BRD-K54838207-001-02-0::2.5::HTS,BRD-K54838207-001-02-0,fudosteine,2.5,HTS,Exp_RN7SL749P (ENSG00000242853),GE,noncancer,mucolytic agent,,pulmonary,chest congestion,Launched,0.23186176105895298,0.00800779367793,fudosteine,,,0,0
BRD-K54838207-001-03-8::2.5::HTS,BRD-K54838207-001-03-8,fudosteine,2.5,HTS,MUTpool_CCDC129 (223075),MUTpool,noncancer,mucolytic agent,,pulmonary,chest congestion,Launched,0.23186176105895298,0.0571903158295,fudosteine,,,0,0
BRD-K54847683-001-03-2::2.5::HTS,BRD-K54847683-001-03-2,equol,2.5,HTS,Exp_HS6ST3 (ENSG00000185352),GE,noncancer,estrogen receptor agonist,"ESR1, ESR2",,,Launched,0.287702821942175,0.0383676692346,equol,,,0,0
BRD-K54847683-001-04-0::2.5::HTS,BRD-K54847683-001-04-0,equol,2.5,HTS,Exp_RHOT1P2 (ENSG00000203616),GE,noncancer,estrogen receptor agonist,"ESR1, ESR2",,,Launched,0.287702821942175,0.0383676692346,equol,,,0,0
BRD-K54863166-001-01-9::2.693644572::MTS004,BRD-K54863166-001-01-9,darusentan,2.693644572,MTS004,CRISPR_LIG3 (3980),AVANA_PUBLIC_18Q2,noncancer,endothelin receptor antagonist,EDNRA,,,Phase 3,0.301486166946488,0.213028509492,darusentan,,,0,0
BRD-K54907283-001-01-2::2.4999956::MTS004,BRD-K54907283-001-01-2,AKBA,2.4999956,MTS004,MIRNA_hsa-miR-26b,MIRNA,targeted cancer,lipoxygenase inhibitor,ALOX5,,,Phase 3,0.266097019618315,0.0854354487143,AKBA,,,0,0
BRD-K54955827-001-02-2::2.49997945::MTS004,BRD-K54955827-001-02-2,niraparib,2.49997945,MTS004,Exp_TCF3 (ENSG00000071564),GE,targeted cancer,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),Launched,0.41437852569753403,0.309180857293,niraparib,OTHER,0.4151824653298735,3.4539016679660026,-3.7683739486231267
BRD-K54997624-001-06-0::2.5::HTS,BRD-K54997624-001-06-0,alpelisib,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 3,0.42583744790027606,0.452714774665,alpelisib,PI3K INHIBITOR,0.4260672503281087,0.6496688237187089,-1.7253785706650475
BRD-K55013654-003-02-3::2.5::HTS,BRD-K55013654-003-02-3,lorcaserin,2.5,HTS,PROT_Src,PROT,noncancer,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",endocrinology,obesity,Launched,0.24053566574191898,0.0813235129973,lorcaserin,,,0,0
BRD-K55029398-001-01-6::2.499962393::MTS004,BRD-K55029398-001-01-6,JNJ-40411813,2.499962393,MTS004,Exp_HR (ENSG00000168453),GE,noncancer,glutamate receptor positive allosteric modulator,GRM2,,,Phase 2,0.27781559616469803,0.0872038456146,JNJ-40411813,,,0,0
BRD-K55034111-066-17-1::2.5::HTS,BRD-K55034111-066-17-1,pefloxacin,2.5,HTS,PROT_53BP1,PROT,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","gastrointestinal infections, urethritis, gonorrhea, urinary tract infections",Launched,0.249568447824675,0.0704301924726,pefloxacin,,,0,0
BRD-K55044200-001-14-6::2.5::HTS,BRD-K55044200-001-14-6,amoxicillin,2.5,HTS,METHYL_SP2-AS1,METHYL,noncancer,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections",Launched,0.33207096694633503,0.123541255577,amoxicillin,,,0,0
BRD-K55044200-001-15-3::2.5::HTS,BRD-K55044200-001-15-3,amoxicillin,2.5,HTS,METHYL_SNORD45B,METHYL,noncancer,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections",Launched,0.33207096694633503,0.123541255577,amoxicillin,,,0,0
BRD-K55055802-001-10-2::2.5::HTS,BRD-K55055802-001-10-2,etomidate,2.5,HTS,METHYL_UEVLD,METHYL,noncancer,GABA receptor modulator,"ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,general anaesthetic,Launched,0.294312591903903,0.0775891583883,etomidate,,,0,0
BRD-K55127134-300-11-2::2.5::HTS,BRD-K55127134-300-11-2,fluphenazine,2.5,HTS,CN_XPOT (11260),CN,noncancer,dopamine receptor antagonist,"CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,Launched,0.264434804407871,-0.00214299414092,fluphenazine,,,0,0
BRD-K55160477-001-04-7::2.5::HTS,BRD-K55160477-001-04-7,benzo[d]thiazole-2(3h)-thione,2.5,HTS,RMUTmis_CSMD1 (64478),MUTmis,noncancer,,,,,Phase 1,0.275535057629239,0.0604521346166,benzo[d]thiazole-2(3h)-thione,,,0,0
BRD-K55166090-001-09-0::2.5::HTS,BRD-K55166090-001-09-0,efloxate,2.5,HTS,MIRNA_hsa-miR-139-5p,MIRNA,noncancer,vasodilator,,,,Preclinical,0.32163118317614503,0.0587212911323,efloxate,,,0,0
BRD-K55172746-001-01-3::2.5::MTS004,BRD-K55172746-001-01-3,apricitabine,2.5,MTS004,Exp_BLK (ENSG00000136573),GE,noncancer,nucleoside reverse transcriptase inhibitor,,,,Phase 3,0.31105962799696996,0.133936028305,apricitabine,,,0,0
BRD-K55187425-236-05-2::2.5::HTS,BRD-K55187425-236-05-2,rigosertib,2.5,HTS,METHYL_CNNM4,METHYL,targeted cancer,"cell cycle inhibitor, PLK inhibitor",PLK1,,,Phase 3,0.373076461455072,0.129190126737,rigosertib,OTHER,0.3690454991645071,5.512029782903807,-1.070784467256404
BRD-K55191674-237-18-3::2.5::HTS,BRD-K55191674-237-18-3,benzylpenicillin,2.5,HTS,Exp_ITM2BP1 (ENSG00000266853),GE,noncancer,penicillin binding protein inhibitor,,infectious disease,"celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia",Launched,0.254608259329817,0.0337710636609,benzylpenicillin,,,0,0
BRD-K55250441-001-13-0::2.5::HTS,BRD-K55250441-001-13-0,sulfadoxine,2.5,HTS,PROT_MEK1,PROT,noncancer,dihydropteroate synthase inhibitor,,infectious disease,malaria,Launched,0.264457658028795,0.0467868835589,sulfadoxine,,,0,0
BRD-K55305701-001-01-2::2.5::HTS,BRD-K55305701-001-01-2,SC-144,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,P glycoprotein inhibitor,,,,Preclinical,0.39880938884809003,0.319068497165,SC-144,OTHER,0.4050485349193489,4.137803973815686,-2.098746069854724
BRD-K55344148-003-02-6::2.5::HTS,BRD-K55344148-003-02-6,BU-224,2.5,HTS,METHYL_TRAM2,METHYL,noncancer,imidazoline receptor ligand,"MAOA, MAOB",,,Preclinical,0.272929835898146,0.0901048648931,BU-224,,,0,0
BRD-K55424922-003-02-8::2.5::HTS,BRD-K55424922-003-02-8,anpirtoline,2.5,HTS,DEM2_SUSD6 (9766),DEMETER2_COM,noncancer,serotonin receptor agonist,HTR1B,,,Phase 1,0.304297811451334,0.083817941339,anpirtoline,,,0,0
BRD-K55462201-001-07-3::2.5::HTS,BRD-K55462201-001-07-3,AM-404,2.5,HTS,Exp_CD44 (ENSG00000026508),GE,noncancer,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",,,Preclinical,0.34359095241021903,0.249844369823,AM-404,OTHER,0.3425342064610264,-5.246861966321298,-1.5545291733815048
BRD-K55468218-001-26-1::2.5::HTS,BRD-K55468218-001-26-1,spiperone,2.5,HTS,METABOL_C18:1 LPC,METABOL,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7",neurology/psychiatry,schizophrenia,Launched,0.287652309576399,0.00979253853014,spiperone,,,0,0
BRD-K55512740-001-01-6::2.5::HTS,BRD-K55512740-001-01-6,MK-8033,2.5,HTS,DEM2_MET (4233),DEMETER2_COM,targeted cancer,c-Met inhibitor,MET,,,Phase 1,0.254942150352367,0.12412765047,MK-8033,,,0,0
BRD-K55567017-001-12-3::2.5::HTS,BRD-K55567017-001-12-3,formononetin,2.5,HTS,MIRNA_hsa-miR-1978,MIRNA,targeted cancer,alcohol dehydrogenase inhibitor,"ADH1C, SLC5A2",,,Preclinical,0.22146451984878196,0.0802818618952,formononetin,,,0,0
BRD-K55675242-001-03-0::2.5::HTS,BRD-K55675242-001-03-0,torcetrapib,2.5,HTS,METHYL_WWC3,METHYL,noncancer,cholesteryl ester transfer protein inhibitor,CETP,,,Phase 3,0.267294279268679,0.110184198773,torcetrapib,,,0,0
BRD-K55677650-003-02-9::2.5::HTS,BRD-K55677650-003-02-9,CO-101244,2.5,HTS,METABOL_anthranilic acid,METABOL,noncancer,glutamate receptor antagonist,GRIN2B,,,Preclinical,0.26868169869271596,0.147839694676,CO-101244,,,0,0
BRD-K55696337-003-24-4::2.50001813::MTS004,BRD-K55696337-003-24-4,topotecan,2.50001813,MTS004,Exp_TOP1 (ENSG00000198900),GE,chemo,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer",Launched,0.39256436408624107,0.360834559306,topotecan,TOPOISOMERASE INHIBITOR,0.3913563604184497,2.0641157340344463,-0.3743863435140065
BRD-K55703048-001-07-7::2.5::HTS,BRD-K55703048-001-07-7,latrepirdine,2.5,HTS,Exp_SDF2 (ENSG00000132581),GE,noncancer,glutamate receptor antagonist,"HRH1, HTR6",,,Phase 3,0.32712223207318003,0.0494157310535,latrepirdine,,,0,0
BRD-K55705469-065-01-0::2.5::HTS,BRD-K55705469-065-01-0,penbutolol,2.5,HTS,MIRNA_hsa-miR-555,MIRNA,noncancer,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B",cardiology,hypertension,Launched,0.315867765136292,0.140053027804,penbutolol,,,0,0
BRD-K55748775-001-02-2::2.5::HTS,BRD-K55748775-001-02-2,SCH-28080,2.5,HTS,METHYL_JARID2,METHYL,noncancer,ATPase inhibitor,ATP4A,,,Phase 1,0.261140525702656,0.0503163338096,SCH-28080,,,0,0
BRD-K55773932-001-02-0::2.5::HTS,BRD-K55773932-001-02-0,BMS-806,2.5,HTS,DEM2_TYMS (7298),DEMETER2_COM,noncancer,HIV attachment inhibitor,,,,Phase 1,0.304569337989847,0.14823138568,BMS-806,,,0,0
BRD-K55847762-304-01-7::2.5::HTS,BRD-K55847762-304-01-7,lobenzarit,2.5,HTS,CN_NECAP2 (55707),CN,noncancer,immunosuppressant,,rheumatology,rheumatoid arthritis,Launched,0.27405680118666703,0.0581401576036,lobenzarit,,,0,0
BRD-K55892330-001-01-8::2.5::HTS,BRD-K55892330-001-01-8,sorbic-acid,2.5,HTS,METHYL_PHLDB2,METHYL,noncancer,,,,,Preclinical,0.30892850275445694,0.110149160907,sorbic-acid,,,0,0
BRD-K55930204-236-24-3::2.5::HTS,BRD-K55930204-236-24-3,phenytoin,2.5,HTS,DEM2_MAMDC2 (256691),DEMETER2_COM,noncancer,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.237280117664526,-0.0159602195366,phenytoin,,,0,0
BRD-K55966568-001-05-4::2.5::HTS,BRD-K55966568-001-05-4,orantinib,2.5,HTS,MIRNA_hsa-miR-188-3p,MIRNA,targeted cancer,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",,,Phase 3,0.28015768296737203,0.0751294060041,orantinib,,,0,0
BRD-K55991142-001-01-6::2.5::MTS004,BRD-K55991142-001-01-6,alcaftadine,2.5,MTS004,PROT_eEF2K,PROT,noncancer,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis,Launched,0.306395808452422,0.0797710192368,alcaftadine,,,0,0
BRD-K56032964-001-02-1::2.5::HTS,BRD-K56032964-001-02-1,AP26113,2.5,HTS,PROT_CD49b,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",,,Phase 2,0.35334075825424394,0.352713410275,AP26113,OTHER,0.35022051157164513,2.4560142083241883,-2.519333247639709
BRD-K56033645-001-07-5::2.5::HTS,BRD-K56033645-001-07-5,5-methylhydantoin-(L),2.5,HTS,CN_LOC100288814 (100288814),CN,noncancer,,,,,Preclinical,0.25447452597175096,0.0362684433151,5-methylhydantoin-(L),,,0,0
BRD-K56047318-001-06-3::2.5::HTS,BRD-K56047318-001-06-3,RHC-80267,2.5,HTS,CRISPR_NR5A2 (2494),AVANA_PUBLIC_18Q2,noncancer,triacylglycerol lipase inhibitor,"DAGLA, DAGLB",,,Preclinical,0.32483180332575,0.126655172882,RHC-80267,,,0,0
BRD-K56077740-001-09-2::2.5::HTS,BRD-K56077740-001-09-2,MMPX,2.5,HTS,MUTpool_SLC4A9 (83697),MUTpool,noncancer,phosphodiesterase inhibitor,,,,Preclinical,0.27771696035093396,0.0593507017205,MMPX,,,0,0
BRD-K56104152-008-04-1::2.5::HTS,BRD-K56104152-008-04-1,oxiconazole,2.5,HTS,CN_UGT2B17 (7367),CN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.26936687730508396,0.0334945495289,oxiconazole,,,0,0
BRD-K56107812-001-01-7::2.499996486::MTS004,BRD-K56107812-001-01-7,carbetocin,2.499996486,MTS004,METABOL_myristoylcarnitine,METABOL,noncancer,oxytocin receptor agonist,OXTR,hematology,hemorrhage,Launched,0.287245396618083,0.0566703510153,carbetocin,,,0,0
BRD-K56115039-003-02-1::2.5::HTS,BRD-K56115039-003-02-1,BU226,2.5,HTS,CN_USP18 (11274),CN,noncancer,imidazoline receptor ligand,,,,Preclinical,0.252023663155968,0.137421100159,BU226,,,0,0
BRD-K56155962-001-12-1::2.355251659::MTS004,BRD-K56155962-001-12-1,ergocalciferol,2.355251659,MTS004,DEM2_RAMP3 (10268),DEMETER2_COM,noncancer,vitamin analog,VDR,"endocrinology, orthopedics","hypoparathyroidism, rickets, hypophosphatemia",Launched,0.331566888833069,0.111645741955,ergocalciferol,,,0,0
BRD-K56156805-001-09-6::2.5::HTS,BRD-K56156805-001-09-6,benznidazole,2.5,HTS,DEM2_BMPR1A (657),DEMETER2_COM,noncancer,DNA synthesis inhibitor,,infectious disease,Chagas disease,Launched,0.301559304538986,0.112619239351,benznidazole,,,0,0
BRD-K56195681-001-01-0::2.5::HTS,BRD-K56195681-001-01-0,losmapimod,2.5,HTS,MIRNA_hsa-miR-200b,MIRNA,noncancer,p38 MAPK inhibitor,MAPK14,,,Phase 3,0.298186151467289,0.0748203944569,losmapimod,,,0,0
BRD-K56277358-001-07-5::2.5::HTS,BRD-K56277358-001-07-5,MGCD-265,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,"AXL, MET",,,Preclinical,0.333056385596755,0.297762576594,MGCD-265,VEGFR INHIBITOR,0.3358867673577928,-3.0605927207947428,-0.18164926195621775
BRD-K56291712-001-01-0::2.5::HTS,BRD-K56291712-001-01-0,voxtalisib,2.5,HTS,Exp_MCOLN3 (ENSG00000055732),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",,,Phase 2,0.33936887593476506,0.0937165653991,voxtalisib,MTOR INHIBITOR,0.327449755965424,0.8075320851236577,-1.382729904285524
BRD-K56301217-001-07-4::2.5::HTS,BRD-K56301217-001-07-4,ABT-737,2.5,HTS,Exp_LYPD1 (ENSG00000150551),GE,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,Phase 1/Phase 2,0.43464344713799996,0.160642679536,ABT-737,OTHER,0.43471690273104496,-2.598117266596161,-0.1639332915520173
BRD-K56334280-001-05-1::2.5::HTS,BRD-K56334280-001-05-1,amonafide,2.5,HTS,Exp_HNRNPC (ENSG00000092199),GE,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",,,Phase 3,0.36810773029055605,0.394345338724,amonafide,TOPOISOMERASE INHIBITOR,0.3673980213445154,3.579854499475587,-3.549695922024724
BRD-K56343971-001-10-6::2.5::HTS,BRD-K56343971-001-10-6,vemurafenib,2.5,HTS,RMUThot_BRAF (673),MUThot,targeted cancer,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,Launched,0.43011531895809,0.472175129846,vemurafenib,RAF INHIBITOR,0.4263214951724831,1.286412776964137,3.250078831360125
BRD-K56405753-001-02-4::2.5::HTS,BRD-K56405753-001-02-4,MK-2461,2.5,HTS,PROT_HER3,PROT,targeted cancer,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",,,Phase 1/Phase 2,0.4683058496110529,0.346705398448,MK-2461,OTHER,0.48428806940021396,1.0770514990723847,-2.355992299816582
BRD-K56429665-001-09-6::2.500032186::MTS004,BRD-K56429665-001-09-6,calcipotriol,2.500032186,MTS004,CN_CTSZ (1522),CN,noncancer,vitamin D receptor agonist,VDR,dermatology,psoriasis,Launched,0.34250802459466495,0.134156141009,calcipotriol,VITAMIN D RECEPTOR AGONIST,0.355756149897004,0.9864217453921176,-0.5590870422587653
BRD-K56483981-342-06-4::2.5::HTS,BRD-K56483981-342-06-4,chicago-sky-blue-6b,2.5,HTS,PROT_Shc_pY317,PROT,noncancer,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,,,Preclinical,0.29145784773950895,0.1076109018,chicago-sky-blue-6b,,,0,0
BRD-K56515112-001-21-6::2.5::HTS,BRD-K56515112-001-21-6,medrysone,2.5,HTS,MIRNA_hsa-miR-211,MIRNA,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,"conjunctivitis, episcleritis",Launched,0.249758943607807,0.0549190599748,medrysone,GLUCOCORTICOID RECEPTOR AGONIST,0.2408098691009926,-4.360166580399431,-2.6683071794773143
BRD-K56542719-065-01-4::2.5::HTS,BRD-K56542719-065-01-4,cefpirome,2.5,HTS,MIRNA_kshv-miR-K12-4-3p,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.26018370422803,0.0500741602785,cefpirome,,,0,0
BRD-K56543881-001-02-7::2.5::HTS,BRD-K56543881-001-02-7,ADX-47273,2.5,HTS,CN_MIR4263 (100422965),CN,noncancer,glutamate receptor modulator,GRM5,,,Preclinical,0.291038495579291,0.15003735186,ADX-47273,,,0,0
BRD-K56558538-003-11-9::2.5::HTS,BRD-K56558538-003-11-9,ambroxol,2.5,HTS,METABOL_thiamine,METABOL,noncancer,sodium channel blocker,CYP3A4,pulmonary,bronchitis,Launched,0.328418680739525,0.161041294635,ambroxol,,,0,0
BRD-K56596464-004-10-7::2.5::HTS,BRD-K56596464-004-10-7,QX-314,2.5,HTS,CRISPR_CD36 (948),AVANA_PUBLIC_18Q2,noncancer,sodium channel blocker,"MAPK14, TGFBR1",,,Preclinical,0.26573185036089897,0.0751721640465,QX-314,,,0,0
BRD-K56614220-001-19-0::2.5::HTS,BRD-K56614220-001-19-0,clofazimine,2.5,HTS,CRISPR_GNG5 (2787),AVANA_PUBLIC_18Q2,noncancer,GK0582 inhibitor,,infectious disease,leprosy,Launched,0.33706256713694605,0.126667135166,clofazimine,OTHER,0.33703748007682205,0.8377462691742034,-3.5464142360117705
BRD-K56691760-001-01-2::2.5::HTS,BRD-K56691760-001-01-2,pikamilone,2.5,HTS,CRISPR_TRAF3IP1 (26146),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 1,0.303222344641448,0.0716815309473,pikamilone,,,0,0
BRD-K56707426-001-02-0::2.5::HTS,BRD-K56707426-001-02-0,nitarsone,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,,,dermatology,blackhead disease,Launched,0.226619547344555,0.0690310396585,nitarsone,,,0,0
BRD-K56735750-001-06-8::2.5::HTS,BRD-K56735750-001-06-8,carbadox,2.5,HTS,METABOL_3-methyladipate/pimelate,METABOL,noncancer,other antibiotic,,"infectious disease, gastroenterology","dysentry, enteritis",Launched,0.342401095233958,0.0254103070985,carbadox,,,0,0
BRD-K56740996-001-01-3::2.601527794::MTS004,BRD-K56740996-001-01-3,flindokalner,2.601527794,MTS004,METHYL_TNRC6B,METHYL,noncancer,potassium channel agonist,"KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5",,,Phase 3,0.23319428216669802,0.138410301999,flindokalner,,,0,0
BRD-K56751279-300-01-4::2.5::HTS,BRD-K56751279-300-01-4,Y-39983,2.5,HTS,PROT_Myosin IIa pS1943,PROT,noncancer,rho associated kinase inhibitor,"ROCK1, ROCK2",,,Phase 2,0.23484367617362198,0.150400998843,Y-39983,OTHER,0.2329938323457509,3.256665161462553,-3.19598375439336
BRD-K56807945-001-01-2::2.500001454::MTS004,BRD-K56807945-001-01-2,FG-2216,2.500001454,MTS004,CRISPR_FBLN1 (2192),AVANA_PUBLIC_18Q2,noncancer,hypoxia inducible factor prolyl hydroxylase inhibitor,"EGLN1, EGLN2, HIF1A",,,Phase 2,0.245089114902452,0.0548204945657,FG-2216,,,0,0
BRD-K56810756-001-03-0::2.5::HTS,BRD-K56810756-001-03-0,fomepizole,2.5,HTS,METHYL_RFX3-AS1,METHYL,noncancer,alcohol dehydrogenase inhibitor,"ADH1A, ADH1B, ADH1C, AKR1A1, CAT",critical care,poison antidote,Launched,0.288113587371869,0.144402522187,fomepizole,,,0,0
BRD-K56851771-001-06-8::2.5::HTS,BRD-K56851771-001-06-8,enzalutamide,2.5,HTS,METABOL_C16:1 CE,METABOL,targeted cancer,androgen receptor antagonist,AR,oncology,prostate cancer,Launched,0.335799029925385,0.0353453242615,enzalutamide,,,0,0
BRD-K56908511-001-01-2::2.5::HTS,BRD-K56908511-001-01-2,fluroxene,2.5,HTS,Exp_M1AP (ENSG00000159374),GE,noncancer,local anesthetic,,,,Preclinical,0.348338111712422,0.0479280686301,fluroxene,OTHER,0.3482828207966577,-3.9686702346642,-2.8335445045288834
BRD-K56912469-003-02-0::2.499992214::MTS004,BRD-K56912469-003-02-0,SAR407899,2.499992214,MTS004,PROT_Bid_Caution,PROT,noncancer,rho associated kinase inhibitor,ROCK1,,,Phase 2,0.28268824404337,0.202706348303,SAR407899,,,0,0
BRD-K56940463-001-13-8::2.5::HTS,BRD-K56940463-001-13-8,oxethazaine,2.5,HTS,MUTpool_MYOM3 (127294),MUTpool,noncancer,local anesthetic,,neurology/psychiatry,local anesthetic,Launched,0.224216596355142,0.0465437555257,oxethazaine,,,0,0
BRD-K56940914-001-04-2::2.5::HTS,BRD-K56940914-001-04-2,cresol,2.5,HTS,DEM2_FGD5 (152273),DEMETER2_COM,noncancer,,,,,Launched,0.255012268944524,0.0742870876776,cresol,,,0,0
BRD-K56981171-001-01-0::2.500008954::MTS004,BRD-K56981171-001-01-0,brigatinib,2.500008954,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),Launched,0.367757423930709,0.274119975957,brigatinib,OTHER,0.3656658992773486,2.4624851837319883,-2.283017707249601
BRD-K57033106-003-19-7::2.5::HTS,BRD-K57033106-003-19-7,tripelennamine,2.5,HTS,PROT_Notch1,PROT,noncancer,histamine receptor antagonist,HRH1,"pulmonary, allergy","asthma, allergic rhinitis, urticaria",Launched,0.264560769820438,0.0599048278566,tripelennamine,,,0,0
BRD-K57041787-001-02-6::2.5::HTS,BRD-K57041787-001-02-6,dabigatran-etexilate,2.5,HTS,CRISPR_PIM1 (5292),AVANA_PUBLIC_18Q2,noncancer,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)",Launched,0.26716455988123605,0.0787406526786,dabigatran-etexilate,,,0,0
BRD-K57080016-001-15-9::2.5::HTS,BRD-K57080016-001-15-9,selumetinib,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 3,0.497730143542748,0.516927703605,selumetinib,MEK INHIBITOR,0.4948112080917145,0.4759093286349534,4.683015584079701
BRD-K57136142-001-02-4::2.5::HTS,BRD-K57136142-001-02-4,CCT129202,2.5,HTS,PROT_HER3,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.34981165355433,0.294175846607,CCT129202,AURORA KINASE INHIBITOR,0.3495272271778743,3.8541204196620544,-2.9992936389079303
BRD-K57155378-001-01-1::2.499996307::MTS004,BRD-K57155378-001-01-1,TAK-063,2.499996307,MTS004,DEM2_SUB1 (10923),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,PDE10A,,,Phase 2,0.33247729945028304,0.189171652794,TAK-063,,,0,0
BRD-K57169635-001-04-5::2.5::HTS,BRD-K57169635-001-04-5,dacomitinib,2.5,HTS,PROT_Shc_pY317,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 3,0.43415864020504996,0.442606811944,dacomitinib,EGFR INHIBITOR,0.4182885382373995,0.8866766979862327,-4.951795808184809
BRD-K57179821-001-15-4::2.5::HTS,BRD-K57179821-001-15-4,crotamiton,2.5,HTS,MIRNA_hsa-miR-875-5p,MIRNA,noncancer,antipruritic,,infectious disease,scabies,Launched,0.27008745420117003,0.0762047396999,crotamiton,,,0,0
BRD-K57222227-001-30-1::2.5::HTS,BRD-K57222227-001-30-1,indomethacin,2.5,HTS,METABOL_C34:2 DAG,METABOL,noncancer,cyclooxygenase inhibitor,"GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1","rheumatology, orthopedics","rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis",Launched,0.27680958213626,0.101668856466,indomethacin,,,0,0
BRD-K57252450-001-02-5::2.5::HTS,BRD-K57252450-001-02-5,cilengitide,2.5,HTS,Exp_HOXA10 (ENSG00000253293),GE,targeted cancer,integrin antagonist,"ITGAV, ITGB3",,,Phase 3,0.31727964409604303,0.0678626336215,cilengitide,,,0,0
BRD-K57275767-001-02-4::2.61::HTS,BRD-K57275767-001-02-4,geniposide,2.61,HTS,DEM2_HPGD (3248),DEMETER2_COM,targeted cancer,GLP receptor agonist,GLP1R,,,Preclinical,0.271643179966457,0.0404194462096,geniposide,,,0,0
BRD-K57275767-001-03-2::2.5::HTS,BRD-K57275767-001-03-2,geniposide,2.5,HTS,CRISPR_FGFR3 (2261),AVANA_PUBLIC_18Q2,targeted cancer,GLP receptor agonist,GLP1R,,,Preclinical,0.311441108664004,0.0448195522396,geniposide,,,0,0
BRD-K57284066-001-01-6::2.5::HTS,BRD-K57284066-001-01-6,Ro-9187,2.5,HTS,MUTpool_MTCH2 (23788),MUTpool,noncancer,HCV inhibitor,,,,Preclinical,0.30619184469909994,0.129161501225,Ro-9187,,,0,0
BRD-K57291914-003-09-4::2.5::HTS,BRD-K57291914-003-09-4,moroxydine,2.5,HTS,DEM2_CAMK4 (814),DEMETER2_COM,noncancer,antiviral,,infectious disease,influenza A virus infection,Launched,0.24996139323563396,0.0625585246138,moroxydine,,,0,0
BRD-K57304726-003-06-9::2.5::HTS,BRD-K57304726-003-06-9,PRE-084,2.5,HTS,METABOL_inosine,METABOL,noncancer,sigma receptor agonist,SIGMAR1,,,Preclinical,0.294905105857028,0.0742765343262,PRE-084,,,0,0
BRD-K57313110-001-06-8::2.5::HTS,BRD-K57313110-001-06-8,pidolic-acid,2.5,HTS,DEM2_LAMB1 (3912),DEMETER2_COM,noncancer,,"ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA",dermatology,xerosis cutis,Launched,0.27525639973057503,0.162155980533,pidolic-acid,,,0,0
BRD-K57371763-001-01-7::2.5::HTS,BRD-K57371763-001-01-7,fidaxomicin,2.5,HTS,CRISPR_SNCG (6623),AVANA_PUBLIC_18Q2,noncancer,RNA polymerase inhibitor,,gastroenterology,diarrhea,Launched,0.317663474281908,0.12929121343,fidaxomicin,,,0,0
BRD-K57427145-001-01-6::2.5::MTS004,BRD-K57427145-001-01-6,ripazepam,2.5,MTS004,MIRNA_hsa-miR-1201,MIRNA,noncancer,benzodiazepine receptor agonist,GABRA1,,,Phase 2,0.339083197575427,0.1288965212,ripazepam,,,0,0
BRD-K57432881-003-21-8::2.5::HTS,BRD-K57432881-003-21-8,tiapride,2.5,HTS,RMUTmis_MTRR (4552),MUT,noncancer,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,"dyskinesia, abstinence from alcohol, psychosis",Launched,0.332531796702736,0.0965330660082,tiapride,,,0,0
BRD-K57545991-050-23-1::2.5::HTS,BRD-K57545991-050-23-1,enalapril,2.5,HTS,CN_TSLP (85480),CN,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)",Launched,0.266167081534277,0.0896642520529,enalapril,,,0,0
BRD-K57569181-001-27-5::2.5::HTS,BRD-K57569181-001-27-5,pentoxifylline,2.5,HTS,DEM2_ERICH6 (131831),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF",cardiology,claudication,Launched,0.273294523988317,0.0505747777736,pentoxifylline,,,0,0
BRD-K57597776-001-01-2::2.5::HTS,BRD-K57597776-001-01-2,org-27569,2.5,HTS,CRISPR_D2HGDH (728294),AVANA_PUBLIC_18Q2,noncancer,cannabinoid receptor modulator,CNR1,,,Preclinical,0.26234782833285,0.0269240966393,org-27569,,,0,0
BRD-K57631554-003-06-2::2.5::HTS,BRD-K57631554-003-06-2,5-aminolevulinic-acid,2.5,HTS,METABOL_asparagine,METABOL,targeted cancer,oxidizing agent,ALAD,,,Launched,0.25035806754980805,0.027793191594,5-aminolevulinic-acid,,,0,0
BRD-K57718010-001-11-9::2.5::HTS,BRD-K57718010-001-11-9,pentylenetetrazol,2.5,HTS,Exp_BEST2 (ENSG00000039987),GE,noncancer,GABA receptor antagonist,,,,Withdrawn,0.267712315880501,0.0734202096079,pentylenetetrazol,,,0,0
BRD-K57754230-001-02-7::2.5::HTS,BRD-K57754230-001-02-7,EPZ005687,2.5,HTS,PROT_PR,PROT,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.295830878167782,0.0407494222134,EPZ005687,,,0,0
BRD-K57764956-001-02-8::2.5::HTS,BRD-K57764956-001-02-8,cariprazine,2.5,HTS,METHYL_LMAN2,METHYL,noncancer,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,schizophrenia,Launched,0.269784340083838,0.0705221105841,cariprazine,,,0,0
BRD-K57774929-001-01-3::2.643351543::MTS004,BRD-K57774929-001-01-3,foropafant,2.643351543,MTS004,DEM2_PRKACA (5566),DEMETER2_COM,noncancer,platelet activating factor receptor antagonist,PTAFR,,,Phase 3,0.22156891609204102,0.0903079892355,foropafant,,,0,0
BRD-K57853941-304-02-5::2.5::HTS,BRD-K57853941-304-02-5,olsalazine,2.5,HTS,CRISPR_ERCC8 (1161),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"IFNG, TPMT",gastroenterology,ulcerative colitis,Launched,0.277891836011688,0.0833125634996,olsalazine,,,0,0
BRD-K57886322-001-16-6::2.5::MTS004,BRD-K57886322-001-16-6,fluocinonide,2.5,MTS004,Exp_TDP1 (ENSG00000042088),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6, SMO",dermatology,"seborrheic dermatitis, eczema",Launched,0.35664863586487106,0.106693210088,fluocinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.3375919592674048,2.44385331858705,4.603922258585384
BRD-K57927309-001-01-7::2.5::HTS,BRD-K57927309-001-01-7,BW-180C,2.5,HTS,CN_ZNF468 (90333),CN,noncancer,opioid receptor agonist,"OPRD1, OPRM1",,,Phase 2,0.19081563840379998,0.044010946643,BW-180C,,,0,0
BRD-K58010567-003-02-2::2.5::HTS,BRD-K58010567-003-02-2,vilazodone,2.5,HTS,PROT_Annexin 1,PROT,noncancer,serotonin reuptake inhibitor,"DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4",neurology/psychiatry,depression,Launched,0.27161243133415197,-0.0072970197565,vilazodone,,,0,0
BRD-K58046914-001-03-8::2.5::HTS,BRD-K58046914-001-03-8,HA-966-(R)-(+),2.5,HTS,Exp_OSCAR (ENSG00000170909),GE,noncancer,glutamate receptor agonist,GRIA1,,,Preclinical,0.248186835923011,0.0315849400785,HA-966-(R)-(+),,,0,0
BRD-K58049875-001-04-7::2.5::HTS,BRD-K58049875-001-04-7,thiostrepton,2.5,HTS,Exp_ANXA4 (ENSG00000196975),GE,noncancer,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,Launched,0.438400583472128,0.436223920492,thiostrepton,OTHER,0.4371872187105839,4.798335223109503,-1.9371095930235835
BRD-K58114536-001-01-6::2.5::HTS,BRD-K58114536-001-01-6,rasagiline,2.5,HTS,METABOL_pipecolic acid,METABOL,noncancer,monoamine oxidase inhibitor,"BCL2, MAOB",neurology/psychiatry,Parkinson's Disease,Launched,0.305530494036643,0.0241589347807,rasagiline,,,0,0
BRD-K58148589-001-03-6::2.5::HTS,BRD-K58148589-001-03-6,betamethasone-dipropionate,2.5,HTS,Exp_CCNE1 (ENSG00000105173),GE,noncancer,anti-inflammatory agent,,dermatology,corticosteroid-responsive dermatoses,Launched,0.301421366702493,0.207182588018,betamethasone-dipropionate,OTHER,0.29886378564261845,-1.0350335919017977,-2.57517379678008
BRD-K58160573-001-05-4::2.5::HTS,BRD-K58160573-001-05-4,dapagliflozin,2.5,HTS,DEM2_OLIG1 (116448),DEMETER2_COM,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,Launched,0.246211204907705,0.0868192963364,dapagliflozin,,,0,0
BRD-K58262659-001-09-7::2.5::HTS,BRD-K58262659-001-09-7,doxifluridine,2.5,HTS,Exp_AIFM3 (ENSG00000183773),GE,targeted cancer,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,Launched,0.329888993883274,0.159017632508,doxifluridine,OTHER,0.3297848967855579,5.582766252938072,0.5299807560112486
BRD-K58265391-001-12-7::2.5::HTS,BRD-K58265391-001-12-7,meticrane,2.5,HTS,DEM2_ADAMTS10 (81794),DEMETER2_COM,noncancer,diuretic,,cardiology,edema,Launched,0.294156517833007,0.0672636290185,meticrane,,,0,0
BRD-K58277159-001-01-7::2.5::MTS004,BRD-K58277159-001-01-7,NPC-01,2.5,MTS004,METHYL_ATP8B3,METHYL,noncancer,steroid,,,,Phase 3,0.29494711461281103,0.0351018058131,NPC-01,,,0,0
BRD-K58299615-001-03-5::2.5::HTS,BRD-K58299615-001-03-5,Ro-90-7501,2.5,HTS,Exp_PRDM13 (ENSG00000112238),GE,noncancer,,APP,,,Preclinical,0.262772148966588,0.107365787967,Ro-90-7501,OTHER,0.2620844478167294,-5.5983514420604585,1.938493962019113
BRD-K58343622-001-01-6::2.5::HTS,BRD-K58343622-001-01-6,DY131,2.5,HTS,CN_MIR4280 (100422887),CN,noncancer,estrogen-related receptor agonist,"ESRRB, ESRRG",,,Preclinical,0.213284418211734,0.105375170701,DY131,,,0,0
BRD-K58466253-003-14-0::2.5::HTS,BRD-K58466253-003-14-0,palmatine-chloride,2.5,HTS,METABOL_C34:1 DAG,METABOL,noncancer,dopamine synthesis inhibitor,CYP3A4,,,Preclinical,0.30517739646715997,0.110454796293,palmatine-chloride,OTHER,0.3166675458372319,0.5798162826699537,-3.488456545169263
BRD-K58486055-001-02-7::2.5::HTS,BRD-K58486055-001-02-7,reparixin,2.5,HTS,PROT_Smad3,PROT,targeted cancer,CC chemokine receptor antagonist,"CXCR1, CXCR2",,,Phase 3,0.24239545302012,0.0671541848897,reparixin,,,0,0
BRD-K58497451-237-10-7::2.5::HTS,BRD-K58497451-237-10-7,potassium-p-aminobenzoate,2.5,HTS,Exp_CYP2C9 (ENSG00000138109),GE,noncancer,,,"rheumatology, urology","scleroderma, dermatomyositis, Peyronie's disease",Launched,0.256959186148223,0.0416003047059,potassium-p-aminobenzoate,,,0,0
BRD-K58501140-002-01-0::2.5::HTS,BRD-K58501140-002-01-0,TAK-875,2.5,HTS,MUTpool_ARMC12 (221481),MUTpool,noncancer,insulin secretagogue,FFAR1,,,Phase 3,0.298558032033028,0.0504917497612,TAK-875,,,0,0
BRD-K58513245-304-02-7::2.5::HTS,BRD-K58513245-304-02-7,pamidronate,2.5,HTS,CRISPR_MLF2 (8079),AVANA_PUBLIC_18Q2,targeted cancer,bone resorption inhibitor,FDPS,"endocrinology, oncology, hematologic malignancy","hypercalcemia, Paget's disease, breast cancer, multiple myeloma",Launched,0.269109140621921,0.10040667868,pamidronate,,,0,0
BRD-K58529924-001-01-5::2.648577938::MTS004,BRD-K58529924-001-01-5,ONC201,2.648577938,MTS004,Exp_CLPP (ENSG00000125656),GE,targeted cancer,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,,,Phase 2,0.407521886838256,0.299797365554,ONC201,AKT INHIBITOR,0.4074141992397822,5.843474302636162,-3.4015639829355413
BRD-K58550667-001-08-7::2.5::HTS,BRD-K58550667-001-08-7,FK-866,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,,Phase 2,0.31507375847978397,0.200609440087,FK-866,OTHER,0.32155625285169304,4.020140660177213,-0.8031531359173371
BRD-K58568447-001-01-1::2.5::HTS,BRD-K58568447-001-01-1,K02288,2.5,HTS,RMUTdmg_ANK3 (288),MUTdmg,targeted cancer,bone morphogenic protein inhibitor,BMP1,,,Preclinical,0.30608718455975104,0.0783385278435,K02288,,,0,0
BRD-K58626373-003-07-8::2.5::HTS,BRD-K58626373-003-07-8,dexfenfluramine,2.5,HTS,Exp_WTIP (ENSG00000142279),GE,noncancer,serotonin receptor agonist,"HTR2C, SLC6A4",,,Withdrawn,0.23662553875391604,0.0128438908983,dexfenfluramine,,,0,0
BRD-K58648841-001-04-7::2.5::HTS,BRD-K58648841-001-04-7,cresopirine,2.5,HTS,CRISPR_SLC2A2 (6514),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.238662909402228,0.0494230321224,cresopirine,,,0,0
BRD-K58685305-001-20-4::2.5::HTS,BRD-K58685305-001-20-4,emodin,2.5,HTS,RMUTdmg_SCRIB (23513),MUTdmg,targeted cancer,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,,,Preclinical,0.229330587311658,0.0458326825077,emodin,,,0,0
BRD-K58736316-001-09-5::2.5::HTS,BRD-K58736316-001-09-5,cianidanol,2.5,HTS,Exp_SLC2A5 (ENSG00000142583),GE,noncancer,fatty acid synthase inhibitor,PTGS1,,,Withdrawn,0.20765008820508604,0.0823183491619,cianidanol,,,0,0
BRD-K58770988-001-01-8::2.5::HTS,BRD-K58770988-001-01-8,NMS-E973,2.5,HTS,METHYL_RAB34,METHYL,targeted cancer,HSP inhibitor,,,,Preclinical,0.364367493325447,0.403327291802,NMS-E973,HSP INHIBITOR,0.3609718944850287,5.204390823926793,-0.515050671549528
BRD-K58772419-001-07-0::2.5::HTS,BRD-K58772419-001-07-0,AZD6482,2.5,HTS,CRISPR_SHB (6461),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.34097612690002194,0.079912332754,AZD6482,PI3K INHIBITOR,0.3367992100683447,2.1952598781028305,-1.0231041302454535
BRD-K58810291-001-16-2::2.564588683::MTS004,BRD-K58810291-001-16-2,clobetasone-butyrate,2.564588683,MTS004,CRISPR_FZD5 (7855),AVANA_PUBLIC_18Q2,noncancer,corticosteroid agonist,NR3C1,dermatology,"eczema, psoriasis, dermatitis",Launched,0.30649038779530796,0.155925582134,clobetasone-butyrate,GLUCOCORTICOID RECEPTOR AGONIST,0.3056420143933197,2.452025814682421,4.304377260351949
BRD-K58819470-001-05-9::2.5::HTS,BRD-K58819470-001-05-9,2-thiouracil,2.5,HTS,Exp_AGTR1 (ENSG00000144891),GE,noncancer,,,,,Preclinical,0.302485613355713,0.0912587308114,2-thiouracil,,,0,0
BRD-K58930050-050-15-8::2.5::HTS,BRD-K58930050-050-15-8,dizocilpine-(+),2.5,HTS,METABOL_sarcosine,METABOL,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Preclinical,0.27153538678017297,0.0708667884532,dizocilpine-(+),,,0,0
BRD-K58937086-001-01-4::2.5::HTS,BRD-K58937086-001-01-4,glutathione-monoisopropyl-ester,2.5,HTS,MIRNA_hsa-miR-210,MIRNA,noncancer,lipid peroxidase inhibitor,,,,Phase 2,0.29377830280997497,-0.0115313751935,glutathione-monoisopropyl-ester,,,0,0
BRD-K58968598-001-03-6::2.5::HTS,BRD-K58968598-001-03-6,sucralose,2.5,HTS,CRISPR_SLC22A15 (55356),AVANA_PUBLIC_18Q2,noncancer,,,,,Launched,0.30814083891831295,0.123677269242,sucralose,,,0,0
BRD-K59013864-001-01-1::2.5::HTS,BRD-K59013864-001-01-1,AM-24,2.5,HTS,DEM2_NDUFA5 (4698),DEMETER2_COM,noncancer,lipoxygenase inhibitor,ALOX5,,,Phase 2,0.156058723989272,0.0218359240695,AM-24,,,0,0
BRD-K59036917-001-16-7::2.5::HTS,BRD-K59036917-001-16-7,ML161,2.5,HTS,Exp_CCBL1 (ENSG00000171097),GE,noncancer,protease-activated receptor inhibitor,,,,Preclinical,0.28798013005395695,0.0592969858115,ML161,,,0,0
BRD-K59037100-001-14-7::2.5::HTS,BRD-K59037100-001-14-7,oxybenzone,2.5,HTS,MIRNA_hsa-miR-1288,MIRNA,noncancer,lipase inhibitor,LIPE,dermatology,sunscreen lotion,Launched,0.288856056465123,0.0441042748561,oxybenzone,,,0,0
BRD-K59045783-001-01-1::2.5::HTS,BRD-K59045783-001-01-1,faropenem-medoxomil,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,lactamase inhibitor,,"otolaryngology, infectious disease, pulmonary","sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections",Launched,0.29681162958103696,0.0702578226984,faropenem-medoxomil,,,0,0
BRD-K59058747-001-18-3::2.5::HTS,BRD-K59058747-001-18-3,acetylcysteine,2.5,HTS,MUTpool_ISLR (3671),MUTpool,noncancer,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury",Launched,0.33246571712127504,0.161176411332,acetylcysteine,OTHER,0.33823524754145473,4.939578743277925,0.4990213848080442
BRD-K59058747-001-20-9::2.5::HTS,BRD-K59058747-001-20-9,acetylcysteine,2.5,HTS,PROT_P-Cadherin_Caution,PROT,noncancer,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury",Launched,0.33246571712127504,0.0942890246943,acetylcysteine,,,0,0
BRD-K59110290-238-01-7::2.5::HTS,BRD-K59110290-238-01-7,fosamprenavir,2.5,HTS,METABOL_C22:0 SM,METABOL,noncancer,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.235417694589394,0.0801464200652,fosamprenavir,,,0,0
BRD-K59146805-001-03-7::2.5::HTS,BRD-K59146805-001-03-7,AZ3146,2.5,HTS,Exp_SLC2A4 (ENSG00000181856),GE,noncancer,monopolar spindle 1 kinase inhibitor,,,,Preclinical,0.437334619421318,0.296758287176,AZ3146,OTHER,0.4367646458227093,3.0806045298927907,-3.5558640980468565
BRD-K59184148-001-21-6::2.5::HTS,BRD-K59184148-001-21-6,SB-216763,2.5,HTS,Exp_SPINK4 (ENSG00000122711),GE,noncancer,glycogen synthase kinase inhibitor,"CCNA2, CDK2, GSK3A, GSK3B",,,Preclinical,0.289318183902733,0.0773450094892,SB-216763,,,0,0
BRD-K59197931-001-04-5::2.5::HTS,BRD-K59197931-001-04-5,naproxen,2.5,HTS,DEM2_ABT1 (29777),DEMETER2_COM,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever",Launched,0.271159439025614,0.0452065631539,naproxen,,,0,0
BRD-K59204667-001-03-1::2.5::HTS,BRD-K59204667-001-03-1,DBeQ,2.5,HTS,Exp_C22orf34 (ENSG00000188511),GE,targeted cancer,ATPase inhibitor,CASP3,,,Preclinical,0.305482272814371,0.13302005386,DBeQ,,,0,0
BRD-K59227464-334-02-4::2.5::HTS,BRD-K59227464-334-02-4,LY2228820,2.5,HTS,Exp_CC2D2A (ENSG00000048342),GE,noncancer,p38 MAPK inhibitor,MAPK14,,,Phase 2,0.293804135663236,0.149375079185,LY2228820,OTHER,0.2937655662513713,1.0966295889031097,-5.274967118920554
BRD-K59256312-066-15-7::2.431061328::MTS004,BRD-K59256312-066-15-7,gabexate,2.431061328,MTS004,PROT_cIAP_Caution,PROT,noncancer,serine protease inhibitor,"PRSS1, TPSAB1",gastroenterology,pancreatitis,Launched,0.276274580309047,0.105188850228,gabexate,,,0,0
BRD-K59273480-001-10-6::2.5::HTS,BRD-K59273480-001-10-6,propentofylline,2.5,HTS,CRISPR_HYKK (123688),AVANA_PUBLIC_18Q2,noncancer,"adenosine reuptake inhibitor, phosphodiesterase inhibitor",PDE1A,neurology/psychiatry,stroke,Launched,0.245160237471993,0.0432604363237,propentofylline,,,0,0
BRD-K59284035-001-07-9::2.5::HTS,BRD-K59284035-001-07-9,chrysophanic-acid,2.5,HTS,METABOL_5-adenosylhomocysteine,METABOL,targeted cancer,EGFR inhibitor,"EGFR, MTOR",,,Preclinical,0.25437439964507697,0.0263873905402,chrysophanic-acid,,,0,0
BRD-K59317601-001-05-5::2.5::HTS,BRD-K59317601-001-05-5,MLN0128,2.5,HTS,PROT_4E-BP1_pT70,PROT,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.359877322290091,0.205500103831,MLN0128,MTOR INHIBITOR,0.3620365101906841,2.286182434776358,-0.8569604707898506
BRD-K59332007-300-02-7::2.5::HTS,BRD-K59332007-300-02-7,linopirdine,2.5,HTS,METABOL_C24:0 SM,METABOL,noncancer,potassium channel blocker,"KCNQ2, KCNQ3, KCNQ4, KCNQ5",,,Phase 3,0.30886522076455103,0.128433156728,linopirdine,,,0,0
BRD-K59333713-003-02-0::2.5::HTS,BRD-K59333713-003-02-0,niguldipine-(S)-(+),2.5,HTS,METHYL_MAS1,METHYL,noncancer,adrenergic receptor antagonist,ADRA1A,,,Preclinical,0.240168556210368,0.115441902279,niguldipine-(S)-(+),,,0,0
BRD-K59339270-001-02-6::2.5::HTS,BRD-K59339270-001-02-6,AH6809,2.5,HTS,METABOL_C58:8 TAG,METABOL,noncancer,prostanoid receptor antagonist,"PTGDR, PTGER1, PTGER2, PTGER3",,,Preclinical,0.262539510525649,0.074341641116,AH6809,,,0,0
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",,,Phase 2,0.428469836257435,0.276321736551,tozasertib,AURORA KINASE INHIBITOR,0.428818440470585,3.6397995088752855,-4.1885734977152715
BRD-K59390331-045-01-5::2.5::HTS,BRD-K59390331-045-01-5,tarafenacin,2.5,HTS,DEM2_POU5F1B (5462),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CHRM3,,,Phase 2,0.315995922388405,0.0592265618323,tarafenacin,,,0,0
BRD-K59391348-001-01-7::2.5::MTS004,BRD-K59391348-001-01-7,lixivaptan,2.5,MTS004,MIRNA_hsa-miR-339-5p,MIRNA,noncancer,vasopressin receptor antagonist,AVPR2,,,Phase 3,0.264474598486113,0.0656549980748,lixivaptan,,,0,0
BRD-K59419204-001-02-7::2.5::HTS,BRD-K59419204-001-02-7,AM-281,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,cannabinoid receptor antagonist,"CNR1, CNR2, GPR55",,,Preclinical,0.29020304329264196,0.0867178938895,AM-281,,,0,0
BRD-K59424860-001-01-4::2.5::HTS,BRD-K59424860-001-01-4,val,2.5,HTS,CRISPR_LPAR6 (10161),AVANA_PUBLIC_18Q2,noncancer,,"BCAT1, PCCB, VARS",,,Phase 2,0.3005334879426311,0.138391310408,val,,,0,0
BRD-K59436580-001-01-7::2.5::HTS,BRD-K59436580-001-01-7,tedizolid,2.5,HTS,Exp_NABP1 (ENSG00000173559),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,skin infections,Launched,0.344769645761844,0.25581856529,tedizolid,OTHER,0.34437851065108555,1.983518279256021,-2.7964147752301347
BRD-K59456551-001-22-6::2.51::HTS,BRD-K59456551-001-22-6,methotrexate,2.51,HTS,Exp_RAN (ENSG00000132341),GE,chemo,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis",Launched,0.323518903240038,0.269635867595,methotrexate,OTHER,0.3233668926106857,3.6497395929465175,-3.107763739427796
BRD-K59469039-001-08-0::2.5::HTS,BRD-K59469039-001-08-0,tyrphostin-AG-879,2.5,HTS,Exp_ABI3 (ENSG00000108798),GE,targeted cancer,tyrosine kinase inhibitor,"ERBB2, KDR, NTRK1",,,Preclinical,0.28954411155118104,0.0456542533759,tyrphostin-AG-879,,,0,0
BRD-K59506194-015-04-9::2.5::HTS,BRD-K59506194-015-04-9,targinine,2.5,HTS,METHYL_RANBP3L,METHYL,noncancer,nitric oxide synthase inhibitor,NOS3,,,Phase 3,0.29167647534963,0.105005236878,targinine,,,0,0
BRD-K59522102-001-15-3::2.46::HTS,BRD-K59522102-001-15-3,piperine,2.46,HTS,CN_FOCAD (54914),CN,targeted cancer,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",,,Phase 1,0.269144943570848,0.0310332338097,piperine,,,0,0
BRD-K59524082-001-01-3::2.5::HTS,BRD-K59524082-001-01-3,maribavir,2.5,HTS,Exp_DPEP2 (ENSG00000167261),GE,noncancer,"cytomegalovirus inhibitor, protein kinase inhibitor",PYGM,,,Phase 3,0.26521073551123703,0.0480855587781,maribavir,,,0,0
BRD-K59527975-236-01-8::2.5::HTS,BRD-K59527975-236-01-8,S-Sulfo-L-cysteine-sodium-salt,2.5,HTS,PROT_NDRG1_pT346,PROT,noncancer,glutamate receptor agonist,,,,Preclinical,0.241687600374795,0.080608452098,S-Sulfo-L-cysteine-sodium-salt,,,0,0
BRD-K59574735-001-11-8::2.5::HTS,BRD-K59574735-001-11-8,ubenimex,2.5,HTS,Exp_ANKRD23 (ENSG00000163126),GE,targeted cancer,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.314934057780488,0.0617214000639,ubenimex,,,0,0
BRD-K59597909-001-17-6::2.5::HTS,BRD-K59597909-001-17-6,phenothiazine,2.5,HTS,RMUTmis_MUC19 (283463),MUTmis,noncancer,dopamine receptor antagonist,,,,Preclinical,0.24264962162720102,0.0890549655056,phenothiazine,,,0,0
BRD-K59632282-052-03-1::2.5::HTS,BRD-K59632282-052-03-1,quinidine,2.5,HTS,METABOL_C16:0 LPC,METABOL,noncancer,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",Launched,0.292302742579011,0.134640089634,quinidine,,,0,0
BRD-K59647213-001-10-5::2.5::HTS,BRD-K59647213-001-10-5,levocarnitine,2.5,HTS,METABOL_C36:4 PC-A,METABOL,noncancer,,,endocrinology,carnitine deficiency,Launched,0.28877222132177505,0.0773130805498,levocarnitine,,,0,0
BRD-K59715032-362-01-4::2.5::HTS,BRD-K59715032-362-01-4,pasireotide,2.5,HTS,DEM2_SLC35E1 (79939),DEMETER2_COM,noncancer,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5",endocrinology,"Cushing's syndrome, acromegaly",Launched,0.320672107171266,0.0135596182363,pasireotide,,,0,0
BRD-K59745944-001-02-0::2.5::HTS,BRD-K59745944-001-02-0,PHT-427,2.5,HTS,Exp_MCF2 (ENSG00000101977),GE,targeted cancer,"AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1",,,Preclinical,0.250515385302236,-0.0246030576974,PHT-427,,,0,0
BRD-K59753975-001-02-6::2.5::MTS004,BRD-K59753975-001-02-6,vindesine,2.5,MTS004,Exp_TTC39A (ENSG00000085831),GE,chemo,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",Launched,0.3893839264965229,0.400229746201,vindesine,TUBULIN POLYMERIZATION INHIBITOR,0.3916119505494929,5.7602081771732765,-3.7960716601618474
BRD-K59831625-001-01-6::2.5::HTS,BRD-K59831625-001-01-6,LDN-212854,2.5,HTS,Exp_SGSM1 (ENSG00000167037),GE,noncancer,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",,,Preclinical,0.373557032798389,0.289747272572,LDN-212854,OTHER,0.3735853304059543,4.178600750676427,-0.3935871336243313
BRD-K59866480-001-07-3::2.379655165::MTS004,BRD-K59866480-001-07-3,cyclovalone,2.379655165,MTS004,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,Launched,0.46543332969564,0.425051402789,cyclovalone,OTHER,0.4660241302366827,5.567516816428096,-3.2321370771069966
BRD-K59875992-001-01-8::2.5::HTS,BRD-K59875992-001-01-8,FPL-62064,2.5,HTS,PROT_Shc_pY317,PROT,noncancer,"cyclooxygenase inhibitor, lipoxygenase inhibitor",,,,Phase 2,0.30326423434598804,0.114220510689,FPL-62064,,,0,0
BRD-K59895502-001-01-9::2.591975371::MTS004,BRD-K59895502-001-01-9,caramiphen,2.591975371,MTS004,MIRNA_hsa-miR-523,MIRNA,noncancer,cholinergic receptor antagonist,"CHRM1, CHRM2",neurology/psychiatry,Parkinson's Disease,Launched,0.24322020794208102,0.0701512454384,caramiphen,,,0,0
BRD-K59929863-001-01-9::2.5::HTS,BRD-K59929863-001-01-9,CB-10-277,2.5,HTS,METHYL_TUBA3C,METHYL,chemo,DNA synthesis inhibitor,,,,Phase 1,0.265615814659597,0.0886372349396,CB-10-277,,,0,0
BRD-K59983611-001-21-9::2.5::HTS,BRD-K59983611-001-21-9,sulfabenzamide,2.5,HTS,PROT_INPP4B,PROT,noncancer,bacterial antifolate,,,,Launched,0.253562168813544,0.0770217485445,sulfabenzamide,,,0,0
BRD-K59998349-003-01-4::2.5::HTS,BRD-K59998349-003-01-4,aminolevulinic-acid-benzyl-ester,2.5,HTS,DEM2_CREB3L2 (64764),DEMETER2_COM,targeted cancer,,,,,Phase 1,0.28330071334799894,0.0542649063163,aminolevulinic-acid-benzyl-ester,,,0,0
BRD-K60005752-001-01-9::2.5::HTS,BRD-K60005752-001-01-9,S-111,2.5,HTS,DEM2_ZNF594 (84622),DEMETER2_COM,targeted cancer,PARP inhibitor,PARP1,,,Phase 2,0.239815446419469,0.0792678169537,S-111,,,0,0
BRD-K60036103-003-01-6::2.5::HTS,BRD-K60036103-003-01-6,L-NIL,2.5,HTS,METHYL_STOM,METHYL,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,Preclinical,0.26355214043932396,0.0704746405407,L-NIL,,,0,0
BRD-K60038276-001-09-0::2.5::HTS,BRD-K60038276-001-09-0,irbesartan,2.5,HTS,PROT_EGFR,PROT,noncancer,angiotensin receptor antagonist,"AGTR1, JUN, SLC10A1","cardiology, nephrology","hypertension, diabetic nephropathy",Launched,0.272559963116374,0.117411817351,irbesartan,,,0,0
BRD-K60060639-005-02-2::2.5::HTS,BRD-K60060639-005-02-2,N-methyllidocaine-iodide,2.5,HTS,METHYL_ANXA2R,METHYL,noncancer,antiarrhythmic medication,,,,Preclinical,0.22308904837339902,0.0645490886722,N-methyllidocaine-iodide,,,0,0
BRD-K60102752-001-02-2::2.5::HTS,BRD-K60102752-001-02-2,alibendol,2.5,HTS,DEM2_ARHGAP1 (392),DEMETER2_COM,noncancer,antispasmodic,,gastroenterology,bile stimulation,Launched,0.18912727154660602,0.00265376142745,alibendol,,,0,0
BRD-K60130390-001-02-1::2.5::MTS004,BRD-K60130390-001-02-1,UNC0642,2.5,MTS004,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.36594866898893796,0.134120449624,UNC0642,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.33992176814781805,5.520213841464126,-1.1916647105201503
BRD-K60160658-003-11-2::2.5::HTS,BRD-K60160658-003-11-2,tiagabine,2.5,HTS,METHYL_B9D1,METHYL,noncancer,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,Launched,0.278693251888154,0.0744004143013,tiagabine,,,0,0
BRD-K60184833-001-05-6::2.5::HTS,BRD-K60184833-001-05-6,tyrphostin-AG-99,2.5,HTS,DEM2_MED26 (9441),DEMETER2_COM,targeted cancer,tyrosine kinase inhibitor,EGFR,,,Preclinical,0.18795976095806197,0.0526134953712,tyrphostin-AG-99,,,0,0
BRD-K60212747-236-01-1::2.5::HTS,BRD-K60212747-236-01-1,neridronic-acid,2.5,HTS,RMUTmis_ZC3H12D (340152),MUTmis,noncancer,bone resorption inhibitor,FDPS,endocrinology,"brittle bone disease, Paget's disease",Launched,0.297637448782565,0.0550301206664,neridronic-acid,,,0,0
BRD-K60237333-001-27-1::2.5::HTS,BRD-K60237333-001-27-1,niacin,2.5,HTS,PROT_PRAS40_pT246,PROT,noncancer,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,Launched,0.291006850529295,0.112243825379,niacin,,,0,0
BRD-K60240222-001-01-4::2.5::HTS,BRD-K60240222-001-01-4,carglumic-acid,2.5,HTS,CN_ARHGAP35 (2909),CN,noncancer,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia,Launched,0.263862617062268,0.00478938091697,carglumic-acid,,,0,0
BRD-K60241851-001-11-9::2.5::MTS004,BRD-K60241851-001-11-9,isodibut,2.5,MTS004,Exp_RASGEF1B (ENSG00000138670),GE,noncancer,aldehyde reductase inhibitor,,,,Phase 2,0.298164792897122,0.116868095458,isodibut,,,0,0
BRD-K60284353-001-01-3::2.5::MTS004,BRD-K60284353-001-01-3,titanocene-dichloride,2.5,MTS004,MIRNA_hsa-miR-503,MIRNA,targeted cancer,apoptosis stimulant,,,,Phase 2,0.266199779552369,0.0927026850865,titanocene-dichloride,,,0,0
BRD-K60287130-001-05-7::2.5::HTS,BRD-K60287130-001-05-7,"5,7-dichlorokynurenic-acid",2.5,HTS,MIRNA_hsa-miR-548h,MIRNA,noncancer,glutamate receptor antagonist,"GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Preclinical,0.290166491414456,0.0789133812835,"5,7-dichlorokynurenic-acid",,,0,0
BRD-K60341624-001-02-2::2.5::HTS,BRD-K60341624-001-02-2,GSK1292263,2.5,HTS,DEM2_PSG11 (5680),DEMETER2_COM,noncancer,glucose dependent insulinotropic receptor agonist,GRPR,,,Phase 2,0.27673137280789895,0.0940849029765,GSK1292263,OTHER,0.2998764415698681,1.9058035168509928,-2.6234587603774155
BRD-K60369935-001-18-3::2.5::HTS,BRD-K60369935-001-18-3,ribavirin,2.5,HTS,MIRNA_hsa-miR-593,MIRNA,noncancer,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,Launched,0.37272781068114796,0.125514068622,ribavirin,,,0,0
BRD-K60421517-001-01-4::2.499975038::MTS004,BRD-K60421517-001-01-4,olmutinib,2.499975038,MTS004,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,"EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor","BTK, EGFR",,,Launched,0.285950837429763,0.19212203124,olmutinib,EGFR INHIBITOR,0.28719374387290925,1.0389407753759945,-4.7472756211085425
BRD-K60441002-001-04-8::2.5::HTS,BRD-K60441002-001-04-8,muscimol,2.5,HTS,CRISPR_FGFR1 (2260),AVANA_PUBLIC_18Q2,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",,,Phase 1,0.22055654322339396,0.163510479991,muscimol,,,0,0
BRD-K60443845-001-08-6::2.5::HTS,BRD-K60443845-001-08-6,chlormidazole,2.5,HTS,Exp_TGFBI (ENSG00000120708),GE,noncancer,fungal lanosterol demethylase inhibitor,,infectious disease,fungal infection,Launched,0.3543451188660429,0.359555737398,chlormidazole,OTHER,0.34216905531629616,2.2613846841443723,-2.563899790526074
BRD-K60511616-236-08-9::2.5::HTS,BRD-K60511616-236-08-9,pravastatin,2.5,HTS,METABOL_C46:2 TAG,METABOL,noncancer,HMGCR inhibitor,"HMGCR, SLCO1B1","endocrinology, cardiology","hypercholesterolemia, myocardial infarction, hyperlipidemia",Launched,0.326980987047193,0.263182818203,pravastatin,,,0,0
BRD-K60567437-001-10-2::2.5::HTS,BRD-K60567437-001-10-2,dimpylate,2.5,HTS,METHYL_SLC25A29,METHYL,noncancer,acetylcholinesterase inhibitor,ACHE,,,Launched,0.273728248352715,0.121970037417,dimpylate,,,0,0
BRD-K60585088-001-01-5::2.5::HTS,BRD-K60585088-001-01-5,paricalcitol,2.5,HTS,Exp_CBX6 (ENSG00000183741),GE,noncancer,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",Launched,0.3225654270215,0.27106132852,paricalcitol,VITAMIN D RECEPTOR AGONIST,0.3209006281759064,1.0394318044118345,-0.5054086526142156
BRD-K60640630-001-11-0::2.5::HTS,BRD-K60640630-001-11-0,mometasone-furoate,2.5,HTS,CRISPR_ANP32A (8125),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.25072477840007,0.0309639323224,mometasone-furoate,GLUCOCORTICOID RECEPTOR AGONIST,0.2430744620255936,-2.6988315476757827,-3.1816036526482034
BRD-K60690191-001-03-3::2.5::HTS,BRD-K60690191-001-03-3,MPEP,2.5,HTS,DEM2_OR14A16 (284532),DEMETER2_COM,noncancer,glutamate receptor antagonist,"GRM1, GRM4, GRM5",,,Preclinical,0.32997354611935,0.163057567573,MPEP,,,0,0
BRD-K60762818-003-26-0::2.467864576::MTS004,BRD-K60762818-003-26-0,desipramine,2.467864576,MTS004,PROT_GATA3,PROT,noncancer,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1",neurology/psychiatry,depression,Launched,0.337653082578118,0.158741681039,desipramine,,,0,0
BRD-K60770992-066-25-0::2.47::HTS,BRD-K60770992-066-25-0,pergolide,2.47,HTS,Exp_RNF157 (ENSG00000141576),GE,noncancer,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,Withdrawn,0.28644086422375703,0.113975894244,pergolide,,,0,0
BRD-K60798049-001-03-8::2.665505334::MTS004,BRD-K60798049-001-03-8,fanetizole,2.665505334,MTS004,DEM2_RRM2 (6241),DEMETER2_COM,noncancer,neutrophil superoxide production,,,,Phase 3,0.32138949535362,0.0863307906767,fanetizole,,,0,0
BRD-K60866521-001-07-1::2.5::HTS,BRD-K60866521-001-07-1,idelalisib,2.5,HTS,CRISPR_MECOM (2122),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),Launched,0.296655194834181,0.00466002639996,idelalisib,,,0,0
BRD-K60907894-003-23-5::2.5::HTS,BRD-K60907894-003-23-5,adiphenine,2.5,HTS,PROT_Dvl3,PROT,noncancer,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms,Launched,0.23933790467296898,0.0732528066215,adiphenine,,,0,0
BRD-K60914966-001-01-4::2.5::HTS,BRD-K60914966-001-01-4,etosalamide,2.5,HTS,DEM2_SORCS1 (114815),DEMETER2_COM,noncancer,anti-inflammatory agent,,,,Preclinical,0.252365802886993,0.0918834456036,etosalamide,,,0,0
BRD-K60918217-001-03-8::2.56::HTS,BRD-K60918217-001-03-8,laquinimod,2.56,HTS,PROT_c-Jun_pS73,PROT,noncancer,immunosuppressant,CXCL2,,,Phase 3,0.327478237859211,0.111130525004,laquinimod,,,0,0
BRD-K60984070-001-01-0::2.5::HTS,BRD-K60984070-001-01-0,PD-166793,2.5,HTS,METABOL_C36:1 DAG,METABOL,targeted cancer,"collagenase inhibitor, metalloproteinase inhibitor","MMP13, MMP2, MMP3",,,Preclinical,0.27944912366942304,0.121850747979,PD-166793,,,0,0
BRD-K60997853-001-02-3::2.5::HTS,BRD-K60997853-001-02-3,PHA-848125,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",,,Phase 2,0.383647133525259,0.246675312923,PHA-848125,CDK INHIBITOR,0.3816800686915989,4.600710803837272,-0.3425969732370153
BRD-K61032563-001-02-9::2.5::HTS,BRD-K61032563-001-02-9,neohesperidin-dihydrochalcone,2.5,HTS,METABOL_C22:0 SM,METABOL,noncancer,,,,,Preclinical,0.248247768222939,0.113350313705,neohesperidin-dihydrochalcone,,,0,0
BRD-K61036791-001-01-6::2.5::HTS,BRD-K61036791-001-01-6,rucinol,2.5,HTS,METHYL_CELA3B,METHYL,noncancer,tyrosinase inhibitor,TYR,,,Phase 1,0.307305470180463,0.150512469057,rucinol,,,0,0
BRD-K61097567-001-08-5::2.5::HTS,BRD-K61097567-001-08-5,SB-218795,2.5,HTS,PROT_MDM2_pS166,PROT,noncancer,tachykinin antagonist,TACR3,,,Preclinical,0.256022049971926,0.118429718203,SB-218795,,,0,0
BRD-K61177364-003-02-9::2.5::HTS,BRD-K61177364-003-02-9,NBI-27914,2.5,HTS,DEM2_RFXANK (8625),DEMETER2_COM,noncancer,corticosteroid releasing factor receptor antagonist,CRHR1,,,Preclinical,0.263047496474823,0.0947696328722,NBI-27914,,,0,0
BRD-K61192372-001-05-5::2.54::HTS,BRD-K61192372-001-05-5,capecitabine,2.54,HTS,CRISPR_METRNL (284207),AVANA_PUBLIC_18Q2,chemo,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer",Launched,0.284884653827592,0.160758240531,capecitabine,,,0,0
BRD-K61195623-001-01-4::2.5::HTS,BRD-K61195623-001-01-4,combretastatin-A-4,2.5,HTS,Exp_SCO1 (ENSG00000133028),GE,chemo,tubulin polymerization inhibitor,,,,Phase 2,0.42890765175224604,0.225694345621,combretastatin-A-4,TUBULIN POLYMERIZATION INHIBITOR,0.4309839758514848,4.08692192940776,-1.3186032820850184
BRD-K61228301-001-01-2::2.5::HTS,BRD-K61228301-001-01-2,SGI-1027,2.5,HTS,Exp_ZEB1 (ENSG00000148516),GE,targeted cancer,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",,,Preclinical,0.433014605865255,0.409782147821,SGI-1027,OTHER,0.4304754076375288,5.0783511766521645,-1.7899167122874378
BRD-K61236135-001-08-2::2.5::HTS,BRD-K61236135-001-08-2,tiratricol,2.5,HTS,CRISPR_CD36 (948),AVANA_PUBLIC_18Q2,noncancer,thyroid hormone stimulant,"THRA, THRB",endocrinology,Refetoff syndrome,Launched,0.262274392091143,0.152626040654,tiratricol,,,0,0
BRD-K61237927-001-01-7::2.5::HTS,BRD-K61237927-001-01-7,eslicarbazepine-acetate,2.5,HTS,METHYL_ZBTB20,METHYL,noncancer,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.22384061430590899,0.0326581506019,eslicarbazepine-acetate,,,0,0
BRD-K61250484-001-02-3::2.5::HTS,BRD-K61250484-001-02-3,FPH1-(BRD-6125),2.5,HTS,METHYL_CRNDE,METHYL,noncancer,hepatocyte function enhancer,,,,Preclinical,0.301048631456184,0.118539071081,FPH1-(BRD-6125),,,0,0
BRD-K61250553-003-32-2::2.5::HTS,BRD-K61250553-003-32-2,loperamide,2.5,HTS,MUTpool_ZDHHC8 (29801),MUTpool,noncancer,opioid receptor agonist,"CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC",gastroenterology,diarrhea,Launched,0.222489571711922,0.0670672147657,loperamide,,,0,0
BRD-K61269089-001-05-5::2.5::HTS,BRD-K61269089-001-05-5,daphnetin,2.5,HTS,Exp_CGB (ENSG00000104827),GE,targeted cancer,protein kinase inhibitor,,,,Preclinical,0.21415123803965602,0.0803612601697,daphnetin,,,0,0
BRD-K61279411-001-02-0::2.5::HTS,BRD-K61279411-001-02-0,oxaloacetate,2.5,HTS,Exp_STAG3 (ENSG00000066923),GE,targeted cancer,glutamate release inhibitor,"CS, SPR",,,Phase 2/Phase 3,0.20936498984396104,0.0804598987158,oxaloacetate,,,0,0
BRD-K61295575-001-03-6::2.5::HTS,BRD-K61295575-001-03-6,blebbistatin-(-),2.5,HTS,CN_SORCS1 (114815),CN,noncancer,ATPase inhibitor,,,,Preclinical,0.270357386678846,0.0900196417287,blebbistatin-(-),,,0,0
BRD-K61314889-001-04-4::2.5::HTS,BRD-K61314889-001-04-4,endo-IWR-1,2.5,HTS,Exp_BAX (ENSG00000087088),GE,targeted cancer,PARP inhibitor,"TNKS, TNKS2",,,Preclinical,0.32119923294479696,0.246458949744,endo-IWR-1,,,0,0
BRD-K61314889-001-05-1::2.5::HTS,BRD-K61314889-001-05-1,endo-IWR-1,2.5,HTS,Exp_ADAMTS9 (ENSG00000163638),GE,targeted cancer,PARP inhibitor,"TNKS, TNKS2",,,Preclinical,0.32119923294479696,0.246458949744,endo-IWR-1,OTHER,0.3272762077265803,-4.654040648177415,-0.30390077927996906
BRD-K61323504-001-04-0::2.5::HTS,BRD-K61323504-001-04-0,SB-225002,2.5,HTS,Exp_ANXA4 (ENSG00000196975),GE,noncancer,CC chemokine receptor antagonist,CXCR2,,,Preclinical,0.397135622457574,0.324414195354,SB-225002,OTHER,0.3969775252454045,5.2713606412634935,-3.4530302796581864
BRD-K61337602-003-02-1::2.5::HTS,BRD-K61337602-003-02-1,naratriptan,2.5,HTS,METABOL_dCMP,METABOL,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,Launched,0.27741638349990005,0.0747881091423,naratriptan,,,0,0
BRD-K61443506-239-01-6::2.5::HTS,BRD-K61443506-239-01-6,esomeprazole,2.5,HTS,METABOL_C16:0 LPC,METABOL,noncancer,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)",Launched,0.31638213869277504,0.0428521466725,esomeprazole,,,0,0
BRD-K61443650-236-13-1::2.5::HTS,BRD-K61443650-236-13-1,thiomersal,2.5,HTS,Exp_TMEM45B (ENSG00000151715),GE,noncancer,other antibiotic,OXCT1,,,Launched,0.38405723066562103,0.386717111546,thiomersal,OTHER,0.387033069393356,4.649908090558196,-1.3032725085614052
BRD-K61452026-001-04-6::2.5::HTS,BRD-K61452026-001-04-6,emtricitabine,2.5,HTS,LIN_glioma,LIN,noncancer,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.265407555034505,0.0855070240993,emtricitabine,,,0,0
BRD-K61496577-001-19-4::2.5::MTS004,BRD-K61496577-001-19-4,flumethasone,2.5,MTS004,PROT_MYH11,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.33283653325485496,0.190862676397,flumethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.33813293558064034,2.501259705015786,4.8313800517428565
BRD-K61496577-001-20-2::2.5::HTS,BRD-K61496577-001-20-2,flumethasone,2.5,HTS,PROT_STAT3_Caution,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.33283653325485496,0.190862676397,flumethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.28048612641106685,-2.7628696586381927,-3.2195220978873462
BRD-K61536264-001-01-3::2.499924728::MTS004,BRD-K61536264-001-01-3,fagomine,2.499924728,MTS004,METHYL_SLC14A2-AS1,METHYL,noncancer,glucosidase inhibitor,GLB1,,,Phase 2,0.276755556645252,0.092904740167,fagomine,,,0,0
BRD-K61536336-001-01-7::2.5::HTS,BRD-K61536336-001-01-7,SB-366791,2.5,HTS,Exp_DCDC2 (ENSG00000146038),GE,noncancer,TRPV antagonist,TRPV1,,,Preclinical,0.321025620209663,0.119251529767,SB-366791,,,0,0
BRD-K61567297-001-01-9::2.5::HTS,BRD-K61567297-001-01-9,resatorvid,2.5,HTS,RMUTdmg_EYS (346007),MUTdmg,noncancer,toll-like receptor antagonist,TLR4,,,Phase 3,0.295027811071576,0.0538585424353,resatorvid,,,0,0
BRD-K61585876-001-01-0::2.5::HTS,BRD-K61585876-001-01-0,3-carboxy-4-hydroxyphenylglycine-(S),2.5,HTS,PROT_BRCA2_Caution,PROT,noncancer,glutamate receptor antagonist,"GRM1, GRM5",,,Preclinical,0.226122594074579,0.0682796165725,3-carboxy-4-hydroxyphenylglycine-(S),,,0,0
BRD-K61642990-001-01-0::2.5::HTS,BRD-K61642990-001-01-0,FERb-033,2.5,HTS,METABOL_C56:4 TAG,METABOL,targeted cancer,EGFR inhibitor,ERBB2,,,Preclinical,0.29428887903078305,0.074766584532,FERb-033,,,0,0
BRD-K61665160-001-01-5::2.5::HTS,BRD-K61665160-001-01-5,BYK-204165,2.5,HTS,CRISPR_KCNB2 (9312),AVANA_PUBLIC_18Q2,noncancer,PARP inhibitor,PARP1,,,Preclinical,0.279273322877431,0.0834401155949,BYK-204165,,,0,0
BRD-K61688984-001-02-9::2.5::HTS,BRD-K61688984-001-02-9,RGFP966,2.5,HTS,Exp_HACE1 (ENSG00000085382),GE,targeted cancer,HDAC inhibitor,HDAC3,,,Preclinical,0.35530978564853005,0.322431730745,RGFP966,HDAC INHIBITOR,0.3570267335603505,2.833962153048484,-4.331447986787284
BRD-K61691541-001-01-1::2.5::HTS,BRD-K61691541-001-01-1,PF-03084014,2.5,HTS,Exp_REN (ENSG00000143839),GE,targeted cancer,gamma secretase inhibitor,,,,Phase 2,0.27899238818561,0.185813686005,PF-03084014,,,0,0
BRD-K61693562-300-01-7::2.5::HTS,BRD-K61693562-300-01-7,pyrazinoylguanidine,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,diuretic,,,,Phase 1,0.26797348902928697,0.128807218142,pyrazinoylguanidine,,,0,0
BRD-K61717546-001-04-3::2.5::HTS,BRD-K61717546-001-04-3,fleroxacin,2.5,HTS,PROT_c-Kit,PROT,noncancer,topoisomerase inhibitor,,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections",Launched,0.256320715268082,0.0592840533384,fleroxacin,,,0,0
BRD-K61717546-001-05-0::2.47::HTS,BRD-K61717546-001-05-0,fleroxacin,2.47,HTS,PROT_Stathmin,PROT,noncancer,topoisomerase inhibitor,,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections",Launched,0.256320715268082,0.0592840533384,fleroxacin,,,0,0
BRD-K61734568-003-02-1::2.5::HTS,BRD-K61734568-003-02-1,"2,3-DCPE",2.5,HTS,Exp_C2CD5 (ENSG00000111731),GE,targeted cancer,Bcl-XL downregulator,BCL2L1,,,Preclinical,0.48875772902993503,0.451767037458,"2,3-DCPE",OTHER,0.4914802927320253,4.340651679856122,-3.7444656541224153
BRD-K61802864-001-08-8::2.5::HTS,BRD-K61802864-001-08-8,chlorindione,2.5,HTS,METABOL_C34:3 PC,METABOL,noncancer,,,,,Preclinical,0.266448275191863,0.118775623139,chlorindione,,,0,0
BRD-K61868322-050-01-7::2.5::HTS,BRD-K61868322-050-01-7,tenofovir-disoproxil,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B",Launched,0.28878647223654497,0.12332855958,tenofovir-disoproxil,,,0,0
BRD-K61923022-001-02-4::2.499990535::MTS004,BRD-K61923022-001-02-4,GDC-0810,2.499990535,MTS004,DEM2_GCSAM (257144),DEMETER2_COM,targeted cancer,selective estrogen receptor destabilizer,ESR1,,,Phase 2,0.30958380619987497,0.168075567243,GDC-0810,,,0,0
BRD-K61936403-001-01-7::2.5::HTS,BRD-K61936403-001-01-7,AS-1949490,2.5,HTS,METABOL_C18:0 LPE,METABOL,noncancer,SHIP2 phosphatase inhibitor,INPP5D,,,Preclinical,0.26055294943021,0.0397899593479,AS-1949490,,,0,0
BRD-K61937613-001-01-1::2.5::HTS,BRD-K61937613-001-01-1,doconexent-ethyl-ester,2.5,HTS,CRISPR_ELMSAN1 (91748),AVANA_PUBLIC_18Q2,noncancer,omega 3 fatty acid stimulant,,,,Launched,0.29851970987196996,0.129477522989,doconexent-ethyl-ester,,,0,0
BRD-K61951118-001-07-9::2.5::HTS,BRD-K61951118-001-07-9,FG-7142,2.5,HTS,MIRNA_hsa-miR-611,MIRNA,noncancer,GABA benzodiazepine site receptor inverse agonist,,,,Preclinical,0.30171292096617,0.0788860653019,FG-7142,,,0,0
BRD-K62008436-001-22-1::2.5::HTS,BRD-K62008436-001-22-1,paclitaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)",Launched,0.40504734544188703,0.23955984227,paclitaxel,TUBULIN POLYMERIZATION INHIBITOR,0.4035264766491036,5.831260866817032,-1.6777908822268337
BRD-K62012036-001-14-4::2.44::HTS,BRD-K62012036-001-14-4,acitretin,2.44,HTS,MIRNA_hsa-miR-211,MIRNA,noncancer,retinoid receptor agonist,"RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3",dermatology,psoriasis,Launched,0.36504261017902595,0.167748338142,acitretin,,,0,0
BRD-K62040061-001-01-0::2.500015381::MTS004,BRD-K62040061-001-01-0,toceranib,2.500015381,MTS004,Exp_MAP3K9 (ENSG00000006432),GE,targeted cancer,protein tyrosine kinase inhibitor,"FLT1, FLT3, KDR, PDGFRA, PDGFRB",oncology,"cutaneous mast cell tumors, cutaneous mast cell tumors",Launched,0.29200640191496197,0.231428624627,toceranib,,,0,0
BRD-K62050508-001-01-0::2.499980818::MTS004,BRD-K62050508-001-01-0,grapiprant,2.499980818,MTS004,CN_MIR3659 (100500801),CN,noncancer,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis,Launched,0.27196246604198804,0.0120952359257,grapiprant,,,0,0
BRD-K62056274-332-01-8::2.5::HTS,BRD-K62056274-332-01-8,N-methylquipazine,2.5,HTS,PROT_CDK1,PROT,noncancer,serotonin receptor agonist,"HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4",,,Preclinical,0.23032157664706499,0.156153901551,N-methylquipazine,,,0,0
BRD-K62186992-334-02-8::2.5::HTS,BRD-K62186992-334-02-8,hydroxystilbamidine,2.5,HTS,DEM2_EIF2AK1 (27102),DEMETER2_COM,noncancer,,,,,Launched,0.289646078583527,0.0476586793626,hydroxystilbamidine,,,0,0
BRD-K62196610-001-01-6::2.5::HTS,BRD-K62196610-001-01-6,AVN-944,2.5,HTS,CRISPR_FCGR3B (2215),AVANA_PUBLIC_18Q2,targeted cancer,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",,,Phase 2,0.33545396490744606,0.267587172058,AVN-944,OTHER,0.3459612635142289,2.6737878388123417,-3.4226481951148644
BRD-K62200014-003-10-5::2.5::HTS,BRD-K62200014-003-10-5,anagrelide,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,targeted cancer,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms",Launched,0.41186644278968,0.312634136757,anagrelide,OTHER,0.4233657394898525,2.748733660439179,-2.3553403464243594
BRD-K62213621-001-01-6::2.5::HTS,BRD-K62213621-001-01-6,dihydroartemisinin,2.5,HTS,Exp_CDC25A (ENSG00000164045),GE,noncancer,antimalarial agent,,infectious disease,malaria,Launched,0.393545965161635,0.28756275407,dihydroartemisinin,OTHER,0.3943210923204053,1.1166820431795779,-3.494864206819159
BRD-K62240499-001-05-9::2.500058444::MTS004,BRD-K62240499-001-05-9,huperzine-a,2.500058444,MTS004,METABOL_alpha-glycerophosphate,METABOL,noncancer,acetylcholinesterase inhibitor,ACHE,,,Phase 2,0.306382121622751,0.142810183027,huperzine-a,,,0,0
BRD-K62277907-001-01-6::1.2::HTS,BRD-K62277907-001-01-6,PYM50028,1.2,HTS,CRISPR_GLI2 (2736),AVANA_PUBLIC_18Q2,noncancer,neurotrophic agent,,,,Phase 2,0.276863541818181,0.0420350527051,PYM50028,,,0,0
BRD-K62304154-001-04-2::2.5::HTS,BRD-K62304154-001-04-2,deforolimus,2.5,HTS,Exp_TDG (ENSG00000139372),GE,targeted cancer,mTOR inhibitor,MTOR,,,Phase 3,0.305180115742803,0.30108841319,deforolimus,MTOR INHIBITOR,0.2971084038457764,0.9355458663148464,-1.7613058547361282
BRD-K62309135-001-05-2::3.119534994::MTS004,BRD-K62309135-001-05-2,L-glutamic-acid,3.119534994,MTS004,CRISPR_TMEM199 (147007),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor agonist,"AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT",,,Launched,0.28034477968368,0.102472698776,L-glutamic-acid,,,0,0
BRD-K62310379-001-10-5::2.5::HTS,BRD-K62310379-001-10-5,fluticasone-propionate,2.5,HTS,Exp_SUN2 (ENSG00000100242),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,Launched,0.329241347790672,0.128315499002,fluticasone-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.32612320679824675,-2.2699305581259392,-3.315863320006116
BRD-K62326629-001-19-0::2.5::HTS,BRD-K62326629-001-19-0,dichlorophen,2.5,HTS,PROT_Tuberin_pT1462,PROT,noncancer,anticestodal agent,,,,Launched,0.32522217841087103,0.0947269961781,dichlorophen,,,0,0
BRD-K62353271-001-04-7::2.5::HTS,BRD-K62353271-001-04-7,baclofen-(R),2.5,HTS,CRISPR_CTC1 (80169),AVANA_PUBLIC_18Q2,noncancer,benzodiazepine receptor agonist,"GABBR1, GABBR2",,,Preclinical,0.24770519210506498,0.0185994638399,baclofen-(R),,,0,0
BRD-K62363391-001-24-9::2.5::HTS,BRD-K62363391-001-24-9,dapsone,2.5,HTS,DEM2_PRIM1 (5557),DEMETER2_COM,noncancer,bacterial antifolate,DHFR,"dermatology, infectious disease","dermatitis herpetiformis (DH), leprosy",Launched,0.249574150908663,0.113002260983,dapsone,,,0,0
BRD-K62374002-001-01-5::2.499972663::MTS004,BRD-K62374002-001-01-5,PI3K-IN-2,2.499972663,MTS004,DEM2_PIK3CA (5290),DEMETER2_COM,targeted cancer,PI3K inhibitor,,,,Phase 2,0.38551696743457603,0.260826767472,PI3K-IN-2,PI3K INHIBITOR,0.3851570891702296,1.6867546151267885,-1.0605978150250783
BRD-K62374253-001-07-8::2.5::HTS,BRD-K62374253-001-07-8,rufloxacin,2.5,HTS,CRISPR_CATSPER3 (347732),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.22641050484680203,0.070498319987,rufloxacin,,,0,0
BRD-K62384160-001-02-0::2.499970983::MTS004,BRD-K62384160-001-02-0,siponimod,2.499970983,MTS004,MIRNA_hcmv-miR-UL22A,MIRNA,noncancer,sphingosine phosphate receptor modulator,S1PR1,,,Phase 3,0.23885732378779798,0.119053060713,siponimod,,,0,0
BRD-K62387885-001-01-9::2.5::HTS,BRD-K62387885-001-01-9,basimglurant,2.5,HTS,CRISPR_FRRS1 (391059),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,GRM5,,,Phase 2,0.28894680547046003,0.141531676063,basimglurant,,,0,0
BRD-K62391742-001-03-0::2.5::HTS,BRD-K62391742-001-03-0,venetoclax,2.5,HTS,PROT_p27_pT157_Caution,PROT,targeted cancer,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),Launched,0.270519686300544,0.0169122356271,venetoclax,,,0,0
BRD-K62398570-300-01-2::2.5::HTS,BRD-K62398570-300-01-2,lerisetron,2.5,HTS,CN_LRRC37BP1 (147172),CN,noncancer,serotonin receptor antagonist,HTR3A,,,Phase 3,0.250896411862245,0.0848936713017,lerisetron,,,0,0
BRD-K62412084-001-07-1::2.5::HTS,BRD-K62412084-001-07-1,para-toluenesulfonamide,2.5,HTS,CN_DEFA1 (1667),CN,targeted cancer,,"CA12, CA2, CA6, CA9",,,Phase 3,0.26188867929303306,0.0670563619406,para-toluenesulfonamide,,,0,0
BRD-K62414032-001-12-0::2.5::HTS,BRD-K62414032-001-12-0,NMDA,2.5,HTS,Exp_TWISTNB (ENSG00000105849),GE,noncancer,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Preclinical,0.259325643567598,-0.0137804677516,NMDA,,,0,0
BRD-K62427771-001-01-0::2.5::HTS,BRD-K62427771-001-01-0,AS-77,2.5,HTS,PROT_p27_pT157_Caution,PROT,noncancer,potassium channel blocker,"KCNA3, KCNA5, KCNN4",,,Preclinical,0.26947404165594,0.0494024930953,AS-77,,,0,0
BRD-K62456038-003-07-1::2.5::HTS,BRD-K62456038-003-07-1,PD-128907,2.5,HTS,MIRNA_hsa-miR-146a,MIRNA,noncancer,dopamine receptor agonist,"DRD2, DRD3",,,Preclinical,0.258826267297166,0.104140397979,PD-128907,,,0,0
BRD-K62490786-001-01-1::2.495325825::MTS004,BRD-K62490786-001-01-1,ibrolipim,2.495325825,MTS004,METHYL_NTN5,METHYL,noncancer,lipoprotein lipase activator,LPL,,,Phase 2,0.28422779966564,0.0550171060503,ibrolipim,,,0,0
BRD-K62537556-001-02-5::2.5::HTS,BRD-K62537556-001-02-5,4-IBP,2.5,HTS,PROT_G6PD,PROT,targeted cancer,sigma receptor agonist,SIGMAR1,,,Preclinical,0.28760885356574,0.128096698855,4-IBP,,,0,0
BRD-K62562723-003-02-7::2.5::HTS,BRD-K62562723-003-02-7,SR-2640,2.5,HTS,Exp_TESPA1 (ENSG00000135426),GE,noncancer,leukotriene receptor antagonist,CYSLTR1,,,Phase 2,0.263231668797045,0.0198087280002,SR-2640,,,0,0
BRD-K62581435-001-03-8::2.5::HTS,BRD-K62581435-001-03-8,3-MPPI,2.5,HTS,DEM2_SLC4A11 (83959),DEMETER2_COM,noncancer,adrenergic receptor ligand,ADRA1A,,,Preclinical,0.29141323924456103,0.0824796166321,3-MPPI,,,0,0
BRD-K62594868-082-08-6::2.5::HTS,BRD-K62594868-082-08-6,GR125487,2.5,HTS,CRISPR_FBXO5 (26271),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,HTR4,,,Preclinical,0.31131757322511894,0.0474324033633,GR125487,,,0,0
BRD-K62607865-001-09-7::2.62::HTS,BRD-K62607865-001-09-7,aztreonam,2.62,HTS,MIRNA_hsa-miR-574-5p,MIRNA,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections",Launched,0.18930476039494,0.0961839744729,aztreonam,,,0,0
BRD-K62621335-001-01-7::2.5::HTS,BRD-K62621335-001-01-7,SRPIN340,2.5,HTS,CRISPR_TAX1BP3 (30851),AVANA_PUBLIC_18Q2,targeted cancer,serine arginine protein kinase inhibitor,"SRPK1, SRPK2",,,Preclinical,0.28462988148845697,0.0766846991694,SRPIN340,,,0,0
BRD-K62627508-001-01-5::2.5::HTS,BRD-K62627508-001-01-5,idasanutlin,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,"MDM2, TP53",,,Phase 3,0.6983561657843621,0.814597591505,idasanutlin,MDM INHIBITOR,0.6858689077520054,2.9745854318703713,-1.907911881189107
BRD-K62676709-065-05-5::2.5::HTS,BRD-K62676709-065-05-5,guanethidine,2.5,HTS,MUTpool_PTPRJ (5795),MUTpool,noncancer,adrenergic inhibitor,SLC6A2,cardiology,hypertension,Launched,0.285805258930052,0.0340550671528,guanethidine,,,0,0
BRD-K62685538-001-01-7::2.5::HTS,BRD-K62685538-001-01-7,triptorelin,2.5,HTS,MIRNA_hsa-miR-196a,MIRNA,targeted cancer,gonadotropin releasing factor hormone receptor agonist,GNRHR,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria",Launched,0.26040883434249396,0.0393148408658,triptorelin,,,0,0
BRD-K62696033-001-01-4::2.5::HTS,BRD-K62696033-001-01-4,G-1,2.5,HTS,DEM2_UGT1A3 (54659),DEMETER2_COM,targeted cancer,G protein-coupled receptor agonist,GPER1,,,Preclinical,0.409392791745646,0.295980867148,G-1,OTHER,0.4094539851467381,5.1620830047298165,-3.2185814952975704
BRD-K62734952-001-01-0::2.5::HTS,BRD-K62734952-001-01-0,arglabin,2.5,HTS,RMUTmis_NBPF10 (100132406),MUTmis,targeted cancer,farnesyltransferase inhibitor,"FNTA, NFKB1",,,Launched,0.27971235222201196,0.0801139460994,arglabin,,,0,0
BRD-K62736196-015-11-0::2.41::HTS,BRD-K62736196-015-11-0,guanaben-acetate,2.41,HTS,PROT_GSK-3-BETA_Caution,PROT,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,Launched,0.198929559706717,0.119116807189,guanaben-acetate,,,0,0
BRD-K62736196-015-13-6::2.5::HTS,BRD-K62736196-015-13-6,guanaben-acetate,2.5,HTS,MIRNA_hsa-miR-608,MIRNA,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,Launched,0.295637888060861,0.0495452137061,guanaben-acetate,,,0,0
BRD-K62737565-003-02-6::2.5::HTS,BRD-K62737565-003-02-6,gabapentin,2.5,HTS,CN_SMARCB1 (6598),CN,noncancer,calcium channel blocker,"ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","infectious disease, neurology/psychiatry","virus herpes simplex (HSV), shingles, seizures, restless leg syndrome",Launched,0.20382904567715998,0.0761266623196,gabapentin,,,0,0
BRD-K62762455-001-01-3::2.5::HTS,BRD-K62762455-001-01-3,RU-58841,2.5,HTS,DEM2_ARHGEF3 (50650),DEMETER2_COM,noncancer,androgen receptor antagonist,AR,,,Phase 2,0.221604851318311,0.125977536212,RU-58841,,,0,0
BRD-K62779383-001-05-5::2.38::HTS,BRD-K62779383-001-05-5,cholecalciferol,2.38,HTS,MIRNA_hsa-miR-548p,MIRNA,noncancer,,VDR,endocrinology,vitamin D deficiency,Launched,0.29226489250980897,0.15534884631,cholecalciferol,,,0,0
BRD-K62810658-001-12-2::2.5::HTS,BRD-K62810658-001-12-2,PD-98059,2.5,HTS,Exp_RPS6 (ENSG00000137154),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.308873577661648,0.0554908596212,PD-98059,MEK INHIBITOR,0.3021297579331715,4.272375336123259,-2.6961656592962604
BRD-K62814476-001-03-3::2.5::HTS,BRD-K62814476-001-03-3,BMS-265246,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2",,,Preclinical,0.342226881496436,0.294443153103,BMS-265246,CDK INHIBITOR,0.34375900191339154,4.856631389444134,-2.290075881634753
BRD-K62858456-001-01-8::2.5::HTS,BRD-K62858456-001-01-8,lomerizine,2.5,HTS,MIRNA_hsa-miR-576-5p,MIRNA,noncancer,calcium channel blocker,"CACNA1B, SCN5A",neurology/psychiatry,migraine headache,Launched,0.256454124700384,0.0692607105451,lomerizine,,,0,0
BRD-K62929068-001-16-5::2.5::HTS,BRD-K62929068-001-16-5,6-benzylaminopurine,2.5,HTS,METABOL_C54:7 TAG,METABOL,noncancer,purinergic receptor activator,,,,Preclinical,0.251406942438936,0.109207460738,6-benzylaminopurine,,,0,0
BRD-K62965247-001-04-9::2.5::HTS,BRD-K62965247-001-04-9,tipifarnib,2.5,HTS,Exp_CAD (ENSG00000084774),GE,targeted cancer,farnesyltransferase inhibitor,"FNTA, FNTB",,,Phase 3,0.34741296868028304,0.2509227196,tipifarnib,OTHER,0.3457636080373148,2.676672098137527,-3.628988175787144
BRD-K62971431-001-01-9::2.5::MTS004,BRD-K62971431-001-01-9,tasimelteon,2.5,MTS004,METHYL_RNF126,METHYL,noncancer,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder,Launched,0.300244602706341,0.145541816569,tasimelteon,,,0,0
BRD-K62996583-001-10-3::2.5::HTS,BRD-K62996583-001-10-3,lidoflazine,2.5,HTS,CN_RBBP8NL (140893),CN,noncancer,calcium channel blocker,"SCN1A, SCN3A, SLC29A1",,,Launched,0.298250918658638,0.0705302997788,lidoflazine,,,0,0
BRD-K63001556-001-08-8::2.5::HTS,BRD-K63001556-001-08-8,orbifloxacin,2.5,HTS,METABOL_2-deoxycytidine,METABOL,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections,Launched,0.254389286162996,0.101441026864,orbifloxacin,,,0,0
BRD-K63001556-001-09-6::2.57::HTS,BRD-K63001556-001-09-6,orbifloxacin,2.57,HTS,MIRNA_hsa-miR-92b,MIRNA,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections,Launched,0.202267826815161,0.0537112817692,orbifloxacin,,,0,0
BRD-K63018010-001-01-7::2.500011413::MTS004,BRD-K63018010-001-01-7,relebactam,2.500011413,MTS004,DEM2_FAM86B3P (286042),DEMETER2_COM,noncancer,beta lactamase inhibitor,,,,Phase 3,0.29047718729512,0.21550101958,relebactam,,,0,0
BRD-K63068307-001-08-9::2.5::HTS,BRD-K63068307-001-08-9,ZSTK-474,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",,,Phase 1/Phase 2,0.371911181512344,0.353805473262,ZSTK-474,PI3K INHIBITOR,0.35382442310918283,1.9538269207929144,-1.3109245350936891
BRD-K63123526-001-01-2::2.5::HTS,BRD-K63123526-001-01-2,S-methylcysteine,2.5,HTS,METHYL_ALG13,METHYL,noncancer,,"CTSD, MGMT",,,Phase 1,0.215039252545835,0.0796951928204,S-methylcysteine,,,0,0
BRD-K63126190-003-01-6::2.5::HTS,BRD-K63126190-003-01-6,epinephrine,2.5,HTS,METABOL_cystathionine,METABOL,noncancer,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma",Launched,0.31488251112073806,0.0805468301634,epinephrine,,,0,0
BRD-K63150726-001-02-1::2.5::HTS,BRD-K63150726-001-02-1,JTE-907,2.5,HTS,METABOL_isocitrate,METABOL,noncancer,cannabinoid receptor inverse agonist,CNR2,,,Phase 1,0.328906421466448,0.105696089387,JTE-907,,,0,0
BRD-K63151507-001-02-4::2.5::HTS,BRD-K63151507-001-02-4,MNITMT,2.5,HTS,CRISPR_PDK1 (5163),AVANA_PUBLIC_18Q2,noncancer,lymphocyte inhibitor,,,,Preclinical,0.333007005109761,0.0467648697421,MNITMT,,,0,0
BRD-K63165456-001-10-8::2.5::HTS,BRD-K63165456-001-10-8,norcyclobenzaprine,2.5,HTS,CN_PID1 (55022),CN,noncancer,"adrenergic receptor agonist, serotonin receptor antagonist",,,,Preclinical,0.26905681440511303,0.0783321439726,norcyclobenzaprine,,,0,0
BRD-K63169195-001-01-5::2.5::HTS,BRD-K63169195-001-01-5,U-0124,2.5,HTS,PROT_CD20 _Caution,PROT,noncancer,MEK inhibitor,,,,Preclinical,0.253422366594293,0.00754937094965,U-0124,,,0,0
BRD-K63177377-001-01-8::2.499971604::MTS004,BRD-K63177377-001-01-8,ETC-1002,2.499971604,MTS004,Exp_TBC1D26 (ENSG00000214946),GE,noncancer,AMPK inhibitor,ACLY,,,Phase 3,0.28448827914747804,0.0407564698606,ETC-1002,,,0,0
BRD-K63178091-001-01-1::2.5::HTS,BRD-K63178091-001-01-1,telotristat,2.5,HTS,PROT_TSC1_Caution,PROT,noncancer,tryptophan hydroxylase inhibitor,TPH1,,,Launched,0.26074882810610606,0.0767363742601,telotristat,,,0,0
BRD-K63343048-001-12-2::2.5::HTS,BRD-K63343048-001-12-2,orlistat,2.5,HTS,MUTpool_MADD (8567),MUTpool,noncancer,lipase inhibitor,"CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP",endocrinology,weight-loss aid,Launched,0.30347165560724604,0.033988613787,orlistat,,,0,0
BRD-K63430059-001-17-2::2.5::HTS,BRD-K63430059-001-17-2,methoxsalen,2.5,HTS,METHYL_DUSP5P1,METHYL,noncancer,DNA synthesis inhibitor,"CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4",dermatology,psoriasis,Launched,0.30369064485088004,-0.0492549772639,methoxsalen,,,0,0
BRD-K63504947-001-15-4::2.5::HTS,BRD-K63504947-001-15-4,semaxanib,2.5,HTS,Exp_FSCN1 (ENSG00000075618),GE,targeted cancer,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,Phase 3,0.396477804561616,0.222736275212,semaxanib,,,0,0
BRD-K63516691-003-02-0::2.5::HTS,BRD-K63516691-003-02-0,T-0156,2.5,HTS,LIN_liver,LIN,noncancer,phosphodiesterase inhibitor,PDE5A,,,Preclinical,0.255265916124737,0.10182342209,T-0156,,,0,0
BRD-K63533170-001-02-9::2.5::HTS,BRD-K63533170-001-02-9,AM-630,2.5,HTS,CRISPR_ODF2 (4957),AVANA_PUBLIC_18Q2,noncancer,cannabinoid receptor antagonist,"CNR1, CNR2",,,Preclinical,0.312069673460861,0.0581877591738,AM-630,,,0,0
BRD-K63550407-001-12-7::2.5::HTS,BRD-K63550407-001-12-7,erythromycin,2.5,HTS,METHYL_RBM19,METHYL,noncancer,NFkB pathway inhibitor,MLNR,infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma",Launched,0.234182528938679,0.0776355493927,erythromycin,,,0,0
BRD-K63550407-001-13-5::2.5::HTS,BRD-K63550407-001-13-5,erythromycin,2.5,HTS,METHYL_C8orf33,METHYL,noncancer,NFkB pathway inhibitor,MLNR,infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma",Launched,0.234182528938679,0.0776355493927,erythromycin,,,0,0
BRD-K63630713-001-25-8::2.5::HTS,BRD-K63630713-001-25-8,etacrynic-acid,2.5,HTS,Exp_GSTP1 (ENSG00000084207),GE,noncancer,sodium/potassium/chloride transporter inhibitor,"ATP1A1, SLC12A1","cardiology, gastroenterology, nephrology, rheumatology","hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome",Launched,0.228494151578132,0.1552904696,etacrynic-acid,,,0,0
BRD-K63675182-003-23-6::2.5::HTS,BRD-K63675182-003-23-6,triflupromazine,2.5,HTS,DEM2_MIA-RAB4B (100529262),DEMETER2_COM,noncancer,dopamine receptor antagonist,"CHRM1, CHRM2, DRD1, DRD2, HTR2B","neurology/psychiatry, gastroenterology","psychosis, nausea, vomiting",Launched,0.289837533729763,0.161473511646,triflupromazine,,,0,0
BRD-K63712959-001-01-8::2.5::HTS,BRD-K63712959-001-01-8,temoporfin,2.5,HTS,PROT_p21,PROT,targeted cancer,radical formation stimulant,,oncology,head and neck squamous cell carcinoma (HNSCC),Launched,0.301776353273343,0.0606572694205,temoporfin,,,0,0
BRD-K63736853-001-04-8::2.5::HTS,BRD-K63736853-001-04-8,acipimox,2.5,HTS,PROT_VEGFR2,PROT,noncancer,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,Launched,0.276443376808846,0.0719116196019,acipimox,,,0,0
BRD-K63750851-001-20-7::2.5::HTS,BRD-K63750851-001-20-7,mycophenolic-acid,2.5,HTS,Exp_CREBRF (ENSG00000164463),GE,noncancer,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.36066723084308705,0.306898397264,mycophenolic-acid,OTHER,0.3598391378625777,2.807586907292055,-3.3326240347035467
BRD-K63772874-001-02-2::2.499989061::MTS004,BRD-K63772874-001-02-2,icatibant-acetate,2.499989061,MTS004,Exp_SNORA55 (ENSG00000201457),GE,noncancer,bradykinin receptor antagonist,"ANPEP, BDKRB2",cardiology,angioedema,Launched,0.281101425351,0.110234041781,icatibant-acetate,,,0,0
BRD-K63792901-075-02-1::2.5::HTS,BRD-K63792901-075-02-1,arecaidine-but-2-ynyl-ester,2.5,HTS,METHYL_GPD1L,METHYL,noncancer,acetylcholine receptor agonist,CHRM2,,,Preclinical,0.255984109895086,0.0620927055697,arecaidine-but-2-ynyl-ester,,,0,0
BRD-K63806092-236-02-6::2.5::HTS,BRD-K63806092-236-02-6,sitaxentan,2.5,HTS,METHYL_MIR6738,METHYL,noncancer,endothelin receptor antagonist,EDNRA,,,Withdrawn,0.261130676881682,0.125277036301,sitaxentan,,,0,0
BRD-K63828191-003-32-1::2.5::HTS,BRD-K63828191-003-32-1,raloxifene,2.5,HTS,DEM2_CTSV (1515),DEMETER2_COM,targeted cancer,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer",Launched,0.313774810323129,0.0401122464341,raloxifene,,,0,0
BRD-K63861289-001-19-6::2.5::HTS,BRD-K63861289-001-19-6,molsidomine,2.5,HTS,Exp_KY (ENSG00000174611),GE,noncancer,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD),Launched,0.268023731452526,0.0782888996718,molsidomine,,,0,0
BRD-K63874012-001-02-9::2.5::HTS,BRD-K63874012-001-02-9,thioperamide,2.5,HTS,METABOL_C38:2 PC,METABOL,noncancer,histamine receptor antagonist,"HRH3, HRH4",,,Preclinical,0.278384925378983,0.0265538535207,thioperamide,,,0,0
BRD-K63915849-001-03-7::2.5::HTS,BRD-K63915849-001-03-7,AS-604850,2.5,HTS,PROT_p90RSK_pT573_Caution,PROT,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CG",,,Preclinical,0.29567731868721603,0.0235199143422,AS-604850,,,0,0
BRD-K63923597-001-10-0::2.5::HTS,BRD-K63923597-001-10-0,barasertib-HQPA,2.5,HTS,Exp_RFPL3S (ENSG00000205853),GE,targeted cancer,Aurora kinase inhibitor,AURKB,,,Phase 2/Phase 3,0.374960394906877,0.234206641957,barasertib-HQPA,AURORA KINASE INHIBITOR,0.3736579260356863,4.16244257655484,-3.2882191407460173
BRD-K63932022-001-01-5::2.5::HTS,BRD-K63932022-001-01-5,2'-MeCCPA,2.5,HTS,MIRNA_hsa-miR-873,MIRNA,noncancer,adenosine receptor agonist,ADORA1,,,Preclinical,0.23448707327772897,0.149450456751,2'-MeCCPA,,,0,0
BRD-K64034691-001-01-9::2.499981916::MTS004,BRD-K64034691-001-01-9,acalabrutinib,2.499981916,MTS004,PROT_ETS-1,PROT,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,Phase 3,0.3394353175791501,0.14875814572,acalabrutinib,,,0,0
BRD-K64052750-001-17-5::2.5::HTS,BRD-K64052750-001-17-5,gefitinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.44363296686048903,0.476164958373,gefitinib,EGFR INHIBITOR,0.4348208672152679,0.9950024248165648,-5.169844837759602
BRD-K64054020-001-03-5::0.25::HTS,BRD-K64054020-001-03-5,epoprostenol,0.25,HTS,CN_BEX4 (56271),CN,noncancer,prostacyclin analog,"P2RY12, PTGER1, PTGER4, PTGIR, PTGIS",cardiology,hypertension,Launched,0.245769182396397,0.12889986646,epoprostenol,,,0,0
BRD-K64120610-001-01-4::2.5::MTS004,BRD-K64120610-001-01-4,vinflunine,2.5,MTS004,Exp_BCL2L1 (ENSG00000171552),GE,chemo,microtubule inhibitor,,oncology,bladder cancer,Launched,0.3528620272956429,0.29667900876,vinflunine,OTHER,0.3559878823179365,5.600436462417027,-3.6679086223822304
BRD-K64137799-003-02-5::2.5::HTS,BRD-K64137799-003-02-5,2-methyl-5-hydroxytryptamine,2.5,HTS,DEM2_DGUOK (1716),DEMETER2_COM,noncancer,serotonin receptor agonist,"HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6",,,Preclinical,0.312598354412562,0.114996112834,2-methyl-5-hydroxytryptamine,,,0,0
BRD-K64157027-003-02-7::2.5::HTS,BRD-K64157027-003-02-7,ZD-2079,2.5,HTS,Exp_RSL24D1P1 (ENSG00000218069),GE,noncancer,adrenergic receptor agonist,ADRB3,,,Phase 2,0.256032808988295,0.0687081388381,ZD-2079,,,0,0
BRD-K64178227-001-09-0::2.5::HTS,BRD-K64178227-001-09-0,BTS,2.5,HTS,METABOL_6-phosphogluconate,METABOL,noncancer,,,,,Preclinical,0.256318726642998,0.0434230681587,BTS,,,0,0
BRD-K64191834-001-03-1::2.5::HTS,BRD-K64191834-001-03-1,"CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide",2.5,HTS,METHYL_MAB21L2,METHYL,noncancer,,,,,Preclinical,0.29359933987456,0.0865754863823,"CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide",,,0,0
BRD-K64338723-001-01-6::2.5::HTS,BRD-K64338723-001-01-6,milacemide,2.5,HTS,DEM2_SLC36A3 (285641),DEMETER2_COM,noncancer,monoamine oxidase inhibitor,MAOB,,,Phase 3,0.25122197730814105,0.0233732541733,milacemide,,,0,0
BRD-K64341947-003-02-4::2.5::HTS,BRD-K64341947-003-02-4,CFM-1571,2.5,HTS,LIN_colorectal_MSI,LIN,noncancer,guanylate cyclase activator,,,,Preclinical,0.28454906173537203,0.0629325477761,CFM-1571,,,0,0
BRD-K64381438-001-03-8::2.5::HTS,BRD-K64381438-001-03-8,ulipristal,2.5,HTS,METHYL_CAPN15,METHYL,noncancer,progesterone receptor antagonist,PGR,endocrinology,contraceptive,Launched,0.25860094932649297,0.186248541156,ulipristal,,,0,0
BRD-K64400208-001-08-3::2.5::HTS,BRD-K64400208-001-08-3,DNQX,2.5,HTS,PROT_CDK1,PROT,noncancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B",,,Preclinical,0.274608119573228,0.0366598358268,DNQX,,,0,0
BRD-K64422603-300-02-7::2.5::HTS,BRD-K64422603-300-02-7,N-alpha-Methylhistamine-dihydrochloride,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,histamine receptor agonist,HRH4,,,Phase 3,0.278026455273712,0.024703539984,N-alpha-Methylhistamine-dihydrochloride,,,0,0
BRD-K64514229-001-05-2::2.5::HTS,BRD-K64514229-001-05-2,toltrazuril,2.5,HTS,Exp_IL4 (ENSG00000113520),GE,noncancer,antiprotozoal agent,,infectious disease,coccidiosis,Launched,0.22510571711870603,0.0591403946881,toltrazuril,,,0,0
BRD-K64538373-001-01-4::2.5::HTS,BRD-K64538373-001-01-4,Ro-4987655,2.5,HTS,Exp_PHLDA1 (ENSG00000139289),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 1,0.45657456396773294,0.519670104753,Ro-4987655,MEK INHIBITOR,0.4555045112843197,0.3194791367773261,4.950820675009756
BRD-K64557645-001-02-4::2.5::HTS,BRD-K64557645-001-02-4,zotepine,2.5,HTS,Exp_HTR1F (ENSG00000179097),GE,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4",neurology/psychiatry,schizophrenia,Launched,0.25313569039065,0.0270184080877,zotepine,,,0,0
BRD-K64614248-001-12-3::2.5::HTS,BRD-K64614248-001-12-3,salicin,2.5,HTS,MUTpool_GLTSCR1L (23506),MUTpool,noncancer,anti-inflammatory agent,,,,Phase 1,0.27959968217042896,0.0785523467894,salicin,,,0,0
BRD-K64636206-001-02-7::2.5::HTS,BRD-K64636206-001-02-7,D-alpha-tocopheryl-succinate,2.5,HTS,CRISPR_PSRC1 (84722),AVANA_PUBLIC_18Q2,targeted cancer,,,,,Launched,0.20943495471280899,0.0956909913921,D-alpha-tocopheryl-succinate,,,0,0
BRD-K64659768-001-12-8::2.5::HTS,BRD-K64659768-001-12-8,phthalylsulfathiazole,2.5,HTS,RMUTmis_PDE9A (5152),MUT,noncancer,dihydropteroate synthetase inhibitor,,"infectious disease, gastroenterology","dysentry, colitis",Launched,0.259719072030252,0.00397669736237,phthalylsulfathiazole,,,0,0
BRD-K64716392-001-01-3::2.5::HTS,BRD-K64716392-001-01-3,nedocromil,2.5,HTS,CN_PPP1R2P3 (153743),CN,noncancer,histamine receptor antagonist,"CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR","neurology/psychiatry, ophthalmology","itching, conjunctivitis",Launched,0.29654730601754903,0.133914681725,nedocromil,,,0,0
BRD-K64755930-003-03-2::2.5::HTS,BRD-K64755930-003-03-2,etazolate,2.5,HTS,MUTpool_LRRN2 (10446),MUTpool,targeted cancer,phosphodiesterase inhibitor,"GABRB3, PDE4A",,,Phase 2,0.27521434292887,0.0376469924049,etazolate,,,0,0
BRD-K64785675-001-04-0::2.5::HTS,BRD-K64785675-001-04-0,TG100-115,2.5,HTS,CN_ALPL (249),CN,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1/Phase 2,0.3715888635139529,0.0523321624605,TG100-115,,,0,0
BRD-K64800655-001-07-4::2.5::HTS,BRD-K64800655-001-07-4,PHA-793887,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",,,Phase 1,0.394962718433861,0.316592431343,PHA-793887,CDK INHIBITOR,0.39579194086055103,4.080084083237193,-1.7996860455600254
BRD-K64835161-001-02-8::2.5::HTS,BRD-K64835161-001-02-8,ML167,2.5,HTS,CN_ALPPL2 (251),CN,targeted cancer,"CLK inhibitor, DYRK inhibitor","CLK4, DYRK1B",,,Preclinical,0.263766106823054,-0.00211326023801,ML167,,,0,0
BRD-K64838454-001-01-0::2.5::HTS,BRD-K64838454-001-01-0,dipraglurant,2.5,HTS,DEM2_STARD6 (147323),DEMETER2_COM,noncancer,glutamate receptor negative allosteric modulator,GRM5,,,Phase 2,0.229133253948332,0.0517013325943,dipraglurant,,,0,0
BRD-K64866502-001-03-9::2.5::HTS,BRD-K64866502-001-03-9,CYC116,2.5,HTS,Exp_SERBP1 (ENSG00000142864),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, KDR",,,Phase 1,0.330310638012,0.287297045131,CYC116,AURORA KINASE INHIBITOR,0.331545946472744,3.930136617386044,-3.1208262921896215
BRD-K64874225-001-04-7::1.13::HTS,BRD-K64874225-001-04-7,NSC-4644,1.13,HTS,MIRNA_hsa-miR-151-3p,MIRNA,noncancer,"ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor",PYGM,,,Phase 2,0.28024118931069003,0.0769420304485,NSC-4644,,,0,0
BRD-K64881305-001-03-7::2.5::HTS,BRD-K64881305-001-03-7,ispinesib,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,kinesin inhibitor,KIF11,,,Phase 2,0.38238087176218205,0.252655357663,ispinesib,OTHER,0.3830314395636396,5.559164752796629,-2.1816479401400706
BRD-K64888243-001-03-7::2.5::HTS,BRD-K64888243-001-03-7,AZ960,2.5,HTS,Exp_KAT2B (ENSG00000114166),GE,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.38573365367690704,0.368571353278,AZ960,OTHER,0.3847858434489003,3.8419466746314495,-3.354439424075609
BRD-K64890080-001-13-8::2.5::HTS,BRD-K64890080-001-13-8,BI-2536,2.5,HTS,Exp_ANAPC1 (ENSG00000153107),GE,targeted cancer,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",,,Phase 2,0.41067411913265994,0.327747244945,BI-2536,OTHER,0.4114876937097006,4.464282520347017,-1.3962876095246837
BRD-K64925568-001-01-8::2.5::HTS,BRD-K64925568-001-01-8,AMG-232,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,MDM2,,,Phase 1/Phase 2,0.6383310197241769,0.774941076314,AMG-232,MDM INHIBITOR,0.6496494663589717,3.219380286530073,-1.6275777368750637
BRD-K64931368-003-01-4::2.5::HTS,BRD-K64931368-003-01-4,aminocaproic-acid,2.5,HTS,CN_MIR3944 (100500911),CN,noncancer,plasminogen activator inhibitor,"LPA, PLAT, PLG",hematology,fibrinolytic bleeding,Launched,0.296190851608123,0.0479886103236,aminocaproic-acid,,,0,0
BRD-K64990126-004-01-1::2.5::HTS,BRD-K64990126-004-01-1,scopolamine,2.5,HTS,METHYL_F11R,METHYL,noncancer,acetylcholine receptor antagonist,,"neurology/psychiatry, gastroenterology","motion sickness, vomiting, nausea",Launched,0.306146102745482,0.1034128526,scopolamine,,,0,0
BRD-K64990520-001-08-4::2.5::HTS,BRD-K64990520-001-08-4,apocynin,2.5,HTS,DEM2_SLC24A2 (25769),DEMETER2_COM,noncancer,NADPH oxidase inhibitor,NOX4,,,Phase 1,0.27496456506250605,0.0354105398311,apocynin,,,0,0
BRD-K64994968-001-32-5::2.5::HTS,BRD-K64994968-001-32-5,progesterone,2.5,HTS,MIRNA_hsa-miR-514,MIRNA,noncancer,progesterone receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5","obstetrics/gynecology, endocrinology","infertility, amenorrhea",Launched,0.263042961563908,0.0635822059107,progesterone,,,0,0
BRD-K65146499-001-27-9::2.5::HTS,BRD-K65146499-001-27-9,nabumetone,2.5,HTS,RMUTmis_C16orf86 (388284),MUTmis,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.287265813889184,0.0931418602346,nabumetone,OTHER,0.28723485717224395,3.9268514699009742,1.2625214628129509
BRD-K65170927-001-01-6::2.5::HTS,BRD-K65170927-001-01-6,aprepitant,2.5,HTS,MIRNA_hsa-miR-1915,MIRNA,noncancer,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",Launched,0.303192133759662,0.0293371838727,aprepitant,,,0,0
BRD-K65275554-001-04-7::2.5::HTS,BRD-K65275554-001-04-7,NPC-15199,2.5,HTS,CN_ACER2 (340485),CN,noncancer,ICAM1 antagonist,PPARG,,,Phase 2,0.266939662584391,0.0711278438049,NPC-15199,,,0,0
BRD-K65285700-001-02-3::2.5::HTS,BRD-K65285700-001-02-3,GP1a,2.5,HTS,CN_WNK1 (65125),CN,noncancer,cannabinoid receptor agonist,CNR2,,,Preclinical,0.221675467231647,-0.035219937918,GP1a,,,0,0
BRD-K65359424-001-01-3::2.5::HTS,BRD-K65359424-001-01-3,eglumetad,2.5,HTS,Exp_RN7SL364P (ENSG00000243560),GE,noncancer,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM8",,,Phase 2,0.21606871697699104,0.00331826235229,eglumetad,,,0,0
BRD-K65377893-001-07-4::2.58::HTS,BRD-K65377893-001-07-4,7-aminocephalosporanic-acid,2.58,HTS,METHYL_PMEL,METHYL,noncancer,beta lactamase inhibitor,,,,Preclinical,0.290474381547383,0.0971129845396,7-aminocephalosporanic-acid,,,0,0
BRD-K65417056-003-10-1::2.5::HTS,BRD-K65417056-003-10-1,meprylcaine,2.5,HTS,CN_TPTE2P3 (220115),CN,noncancer,local anesthetic,,,,Preclinical,0.237944437048936,0.0551234499408,meprylcaine,,,0,0
BRD-K65428967-001-08-4::2.5::HTS,BRD-K65428967-001-08-4,cordycepin,2.5,HTS,METHYL_KU-MEL-3,METHYL,chemo,DNA inhibitor,,,,Phase 1/Phase 2,0.266788361544921,-0.0199402218508,cordycepin,,,0,0
BRD-K65498798-001-01-7::2.5::MTS004,BRD-K65498798-001-01-7,abametapir,2.5,MTS004,METABOL_1-methylnicotinamide,METABOL,noncancer,metalloproteinase inhibitor,MMP9,,,Phase 3,0.30226465317117895,0.188795154702,abametapir,,,0,0
BRD-K65503129-001-06-3::2.5::HTS,BRD-K65503129-001-06-3,CCT018159,2.5,HTS,CRISPR_EIF2AK3 (9451),AVANA_PUBLIC_18Q2,targeted cancer,HSP inhibitor,"HSP90AA1, HSP90AB1",,,Preclinical,0.304205722638121,0.0186568824859,CCT018159,,,0,0
BRD-K65518078-002-01-1::2.5::HTS,BRD-K65518078-002-01-1,cilazapril,2.5,HTS,DEM2_TRIM14 (9830),DEMETER2_COM,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",Launched,0.268879564953186,0.118347178628,cilazapril,,,0,0
BRD-K65639003-001-09-0::2.5::HTS,BRD-K65639003-001-09-0,icariin,2.5,HTS,RMUTmis_C9orf84 (158401),MUTmis,targeted cancer,phosphodiesterase inhibitor,PDE5A,,,Phase 3,0.263848702849061,0.0449357495706,icariin,,,0,0
BRD-K65667145-001-14-0::2.5::HTS,BRD-K65667145-001-14-0,kinetin,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,cell division inducer,,dermatology,sunburn,Launched,0.280856996582039,0.150226783187,kinetin,,,0,0
BRD-K65678996-001-05-5::2.5::HTS,BRD-K65678996-001-05-5,nefiracetam,2.5,HTS,PROT_eEF2_Caution,PROT,noncancer,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,,,Phase 3,0.257503678554046,0.0338264982068,nefiracetam,,,0,0
BRD-K65716359-001-02-1::2.5::HTS,BRD-K65716359-001-02-1,exifone,2.5,HTS,DEM2_AMBP (259),DEMETER2_COM,noncancer,nootropic agent,TYR,,,Withdrawn,0.289184127183023,0.171992711246,exifone,,,0,0
BRD-K65781196-001-03-0::2.5::HTS,BRD-K65781196-001-03-0,avanafil,2.5,HTS,Exp_FGD5-AS1 (ENSG00000225733),GE,noncancer,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,Launched,0.26847078321435996,0.154707396796,avanafil,,,0,0
BRD-K65786282-001-07-5::2.5::HTS,BRD-K65786282-001-07-5,CGP-7930,2.5,HTS,CN_ENOSF1 (55556),CN,noncancer,GABA receptor modulator,GABBR1,,,Preclinical,0.26542456876516396,0.0535381385116,CGP-7930,,,0,0
BRD-K65814004-003-02-9::2.5::HTS,BRD-K65814004-003-02-9,diphenyleneiodonium,2.5,HTS,DEM2_DDX27 (55661),DEMETER2_COM,targeted cancer,nitric oxide synthase inhibitor,"NOS2, NOS3",,,Preclinical,0.378745028643943,0.276776327948,diphenyleneiodonium,OTHER,0.40027741991380794,4.191204066321145,-1.9990388665176315
BRD-K65820248-001-01-8::2.5::HTS,BRD-K65820248-001-01-8,SDZ-NKT-343,2.5,HTS,METHYL_FAM72B,METHYL,noncancer,tachykinin antagonist,TACR1,,,Phase 1,0.268942320417624,0.109239129367,SDZ-NKT-343,,,0,0
BRD-K65856711-001-04-4::2.5::HTS,BRD-K65856711-001-04-4,rolipram-S(+),2.5,HTS,Exp_IL23R (ENSG00000162594),GE,noncancer,phosphodiesterase inhibitor,,,,Preclinical,0.263824401981068,0.156071648475,rolipram-S(+),,,0,0
BRD-K65877271-001-01-8::2.5::HTS,BRD-K65877271-001-01-8,halobetasol-propionate,2.5,HTS,Exp_CREG2 (ENSG00000175874),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.31445196402483805,0.164634760277,halobetasol-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.31410792023188144,-1.7550351357870475,-3.0017774749502144
BRD-K65890018-236-01-1::2.5::HTS,BRD-K65890018-236-01-1,SSR128129E,2.5,HTS,DEM2_MAGEB5 (347541),DEMETER2_COM,noncancer,,,,,Preclinical,0.309244649717097,0.0830899923263,SSR128129E,,,0,0
BRD-K65900713-003-01-0::2.686421113::MTS004,BRD-K65900713-003-01-0,caroverine,2.686421113,MTS004,CN_AQR (9716),CN,noncancer,"glutamate receptor antagonist, calcium channel blocker",,neurology/psychiatry,tinnitus,Launched,0.31571653881104605,0.10704828284,caroverine,,,0,0
BRD-K65904673-001-01-4::2.5::HTS,BRD-K65904673-001-01-4,tandospirone,2.5,HTS,DEM2_USE1 (55850),DEMETER2_COM,noncancer,serotonin receptor agonist,HTR1A,neurology/psychiatry,"generalized anxiety disorder (GAD), dysthymic disorder",Launched,0.295408342467167,0.104166714722,tandospirone,,,0,0
BRD-K65924316-001-03-1::2.5::HTS,BRD-K65924316-001-03-1,serdemetan,2.5,HTS,PROT_JAK2,PROT,targeted cancer,MDM inhibitor,MDM2,,,Phase 1,0.34691055409244204,0.250737423555,serdemetan,MDM INHIBITOR,0.3528615824998228,4.030608072902047,-2.4682558965530412
BRD-K65928735-001-04-3::2.5::HTS,BRD-K65928735-001-04-3,AZD1480,2.5,HTS,PROT_Gab2,PROT,targeted cancer,JAK inhibitor,"JAK1, JAK2, JAK3",,,Phase 1,0.337266602679702,0.115222949365,AZD1480,OTHER,0.30981413263113844,5.644047433589159,-2.750766387991246
BRD-K65991129-001-02-9::2.5::HTS,BRD-K65991129-001-02-9,SB-705498,2.5,HTS,METHYL_VHL,METHYL,noncancer,TRPV antagonist,TRPV1,,,Phase 2,0.270917649341014,0.0521826987248,SB-705498,,,0,0
BRD-K65992024-001-01-5::2.5::HTS,BRD-K65992024-001-01-5,pirenoxine,2.5,HTS,DEM2_TYR (7299),DEMETER2_COM,noncancer,AGE inhibitor,,ophthalmology,cataracts,Launched,0.23703186120043698,0.0611349389161,pirenoxine,,,0,0
BRD-K66030860-001-03-6::2.5::HTS,BRD-K66030860-001-03-6,salidroside,2.5,HTS,MUTpool_CXCR1 (3577),MUTpool,noncancer,beta amyloid protein neurotoxicity inhibitor,APP,,,Preclinical,0.26555820230772303,0.0507315902819,salidroside,,,0,0
BRD-K66035042-001-10-1::2.5::HTS,BRD-K66035042-001-10-1,sorbitol,2.5,HTS,METABOL_C56:2 TAG,METABOL,noncancer,mucolytic agent,,,,Launched,0.24196337116174502,0.0486786581294,sorbitol,,,0,0
BRD-K66093087-001-03-1::2.5::HTS,BRD-K66093087-001-03-1,FGIN-1-43,2.5,HTS,CRISPR_TUBB4B (10383),AVANA_PUBLIC_18Q2,noncancer,benzodiazepine receptor agonist,TSPO,,,Preclinical,0.301286897071305,0.0797567196917,FGIN-1-43,,,0,0
BRD-K66094457-001-01-5::2.5::HTS,BRD-K66094457-001-01-5,CPP,2.5,HTS,METHYL_VMO1,METHYL,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,Phase 2,0.284884902967763,0.172140179864,CPP,,,0,0
BRD-K66097663-001-01-8::2.5::HTS,BRD-K66097663-001-01-8,TMC-353121,2.5,HTS,MUTpool_ALPK3 (57538),MUTpool,noncancer,RSV fusion inhibitor,,,,Phase 2,0.308209133487318,0.0721753515966,TMC-353121,,,0,0
BRD-K66175015-001-09-0::2.5::HTS,BRD-K66175015-001-09-0,afatinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),Launched,0.41291335219417796,0.432148978648,afatinib,EGFR INHIBITOR,0.4084109933478121,0.8777716957362737,-4.9255965114273295
BRD-K66192203-001-02-2::2.50001534::MTS004,BRD-K66192203-001-02-2,opicapone,2.50001534,MTS004,CRISPR_FBXL22 (283807),AVANA_PUBLIC_18Q2,noncancer,catechol O methyltransferase inhibitor,COMT,,,Phase 3,0.33924799351678403,0.0496296984324,opicapone,,,0,0
BRD-K66241279-001-01-8::2.5::HTS,BRD-K66241279-001-01-8,cinromide,2.5,HTS,METHYL_SBSPON,METHYL,noncancer,,,,,Phase 3,0.32124935307616403,0.0544066468025,cinromide,,,0,0
BRD-K66295376-001-13-1::2.5::MTS004,BRD-K66295376-001-13-1,ferulic-acid,2.5,MTS004,CRISPR_WDR73 (84942),AVANA_PUBLIC_18Q2,noncancer,antioxidant,"CA1, CA12, CA14, CA2, CA4, CA6, CA9",,,Phase 2,0.282666937857954,0.0767019954732,ferulic-acid,,,0,0
BRD-K66296774-236-11-3::2.63::HTS,BRD-K66296774-236-11-3,fluvastatin,2.63,HTS,Exp_GPX8 (ENSG00000164294),GE,noncancer,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects",Launched,0.43742974010697605,0.370941456644,fluvastatin,HMGCR INHIBITOR,0.4351019801369141,5.0325914531551845,-0.2668109211576333
BRD-K66353228-001-14-6::2.5::HTS,BRD-K66353228-001-14-6,zoxazolamine,2.5,HTS,CN_NXF3 (56000),CN,noncancer,myorelaxant,,,,Phase 2,0.23824095284371202,0.0569466837496,zoxazolamine,,,0,0
BRD-K66404838-310-01-1::2.5::HTS,BRD-K66404838-310-01-1,nalbuphine,2.5,HTS,CRISPR_PRELID1 (27166),AVANA_PUBLIC_18Q2,noncancer,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1",neurology/psychiatry,pain relief,Launched,0.28678724881697404,0.0389679576095,nalbuphine,,,0,0
BRD-K66412701-066-01-6::2.5::HTS,BRD-K66412701-066-01-6,pazufloxacin,2.5,HTS,MIRNA_hsa-miR-934,MIRNA,noncancer,topoisomerase inhibitor,,infectious disease,"pneumonia, peritonitis, bacterial septicemia",Launched,0.308064952051716,0.0446037229009,pazufloxacin,,,0,0
BRD-K66437909-001-01-0::2.49636183::MTS004,BRD-K66437909-001-01-0,KT-433,2.49636183,MTS004,METABOL_C56:7 TAG,METABOL,noncancer,uricosuric agent,,,,Phase 2,0.24852818254600198,0.0482372907159,KT-433,,,0,0
BRD-K66465025-001-05-1::2.5::HTS,BRD-K66465025-001-05-1,ACPC,2.5,HTS,CRISPR_NBEA (26960),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,,,,Phase 1,0.360446401208441,0.148503141617,ACPC,,,0,0
BRD-K66480997-003-10-0::2.5::HTS,BRD-K66480997-003-10-0,isoguvacine,2.5,HTS,MIRNA_hsa-miR-143,MIRNA,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",,,Preclinical,0.210057438312192,0.0785373289997,isoguvacine,,,0,0
BRD-K66527818-001-02-6::2.5::HTS,BRD-K66527818-001-02-6,VU0364770,2.5,HTS,METHYL_LOC101929441,METHYL,noncancer,glutamate receptor positive allosteric modulator,GRM4,,,Preclinical,0.285414159073132,0.0552249591161,VU0364770,,,0,0
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor","KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,OTHER,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K66615216-003-14-8::2.5::HTS,BRD-K66615216-003-14-8,moxifloxacin,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,bacterial DNA gyrase inhibitor,TOP2A,"otolaryngology, pulmonary, infectious disease","sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections",Launched,0.287164218523917,0.128006672877,moxifloxacin,,,0,0
BRD-K66715657-050-01-0::2.5::HTS,BRD-K66715657-050-01-0,UH-232-(+),2.5,HTS,PROT_MDM2_pS166,PROT,noncancer,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",,,Preclinical,0.19710444805268001,0.039730010027,UH-232-(+),,,0,0
BRD-K66766661-001-19-2::2.5::HTS,BRD-K66766661-001-19-2,estradiol-valerate,2.5,HTS,CRISPR_ARHGAP1 (392),AVANA_PUBLIC_18Q2,targeted cancer,estrogen receptor agonist,ESR1,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, hypoestrogenism, menopause, vaginal atrophy",Launched,0.238819705293733,0.0345350355201,estradiol-valerate,,,0,0
BRD-K66786476-001-01-3::2.500037331::MTS004,BRD-K66786476-001-01-3,pregabalin,2.500037331,MTS004,CN_MIR603 (693188),CN,noncancer,voltage-gated calcium channel ligand,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8","neurology/psychiatry, rheumatology","peripheral neuropathy, seizures, fibromyalgia, postherpetic neuralgia",Launched,0.28385224536305,0.03268085551,pregabalin,,,0,0
BRD-K66788707-001-14-3::2.5::HTS,BRD-K66788707-001-14-3,fludarabine,2.5,HTS,RMUTmis_ATP2B3 (492),MUTmis,chemo,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),Launched,0.309814223001386,0.113014142078,fludarabine,,,0,0
BRD-K66808046-065-03-7::2.5::HTS,BRD-K66808046-065-03-7,oxyquinoline,2.5,HTS,Exp_AMPD3 (ENSG00000133805),GE,noncancer,chelating agent,METAP2,dermatology,cosmetic,Launched,0.413222447891725,0.282244023188,oxyquinoline,OTHER,0.4026195366087261,3.4441989301531275,-1.8687283737824412
BRD-K66845263-001-03-0::2.5::MTS004,BRD-K66845263-001-03-0,sophocarpine,2.5,MTS004,Exp_ZFP36L2 (ENSG00000152518),GE,targeted cancer,,,,,Phase 3,0.276028422096714,0.0935226362639,sophocarpine,,,0,0
BRD-K66850609-001-07-4::2.5::HTS,BRD-K66850609-001-07-4,voglibose,2.5,HTS,Exp_MOV10L1 (ENSG00000073146),GE,noncancer,glucosidase inhibitor,MGAM,endocrinology,"diabetes mellitus, hyperglycemia",Launched,0.302753058597326,0.106262112624,voglibose,,,0,0
BRD-K66876909-001-12-6::2.5::HTS,BRD-K66876909-001-12-6,linezolid,2.5,HTS,MIRNA_hsa-miR-24,MIRNA,noncancer,bacterial 50S ribosomal subunit inhibitor,"MAOA, MAOB",infectious disease,"pneumonia, skin infections",Launched,0.279983047262216,0.118861325676,linezolid,,,0,0
BRD-K66896231-001-08-1::2.5::HTS,BRD-K66896231-001-08-1,ipidacrine,2.5,HTS,Exp_FIBIN (ENSG00000176971),GE,noncancer,acetylcholinesterase inhibitor,ACHE,,,Phase 3,0.29060053619760995,0.0898920192287,ipidacrine,,,0,0
BRD-K66911501-003-01-2::2.5::HTS,BRD-K66911501-003-01-2,MK-3207,2.5,HTS,MIRNA_hsa-miR-526a+hsa-miR-518d-5p+hsa-miR-520c-5p,MIRNA,noncancer,calcitonin antagonist,CALCA,,,Phase 2,0.283049565807283,0.0182145531758,MK-3207,,,0,0
BRD-K66937583-001-01-2::2.5::HTS,BRD-K66937583-001-01-2,lodoxamide,2.5,HTS,DEM2_ARHGAP1 (392),DEMETER2_COM,noncancer,histamine receptor antagonist,,ophthalmology,vernal keratoconjunctivitis (VKC),Launched,0.253117995156779,0.112321127909,lodoxamide,,,0,0
BRD-K66956375-001-11-3::2.5::HTS,BRD-K66956375-001-11-3,oleoylethanolamide,2.5,HTS,DEM2_ZNF322 (79692),DEMETER2_COM,noncancer,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",,,Preclinical,0.22214269550121804,0.0774100479727,oleoylethanolamide,,,0,0
BRD-K67043667-001-26-4::2.5::HTS,BRD-K67043667-001-26-4,altretamine,2.5,HTS,DEM2_CDKL5 (6792),DEMETER2_COM,chemo,DNA synthesis inhibitor,,oncology,ovarian cancer,Launched,0.30800110967745503,0.154423645199,altretamine,,,0,0
BRD-K67068943-001-01-0::2.5::HTS,BRD-K67068943-001-01-0,ORE1001,2.5,HTS,CRISPR_DYSF (8291),AVANA_PUBLIC_18Q2,noncancer,angiotensin converting enzyme inhibitor,ACE2,,,Phase 1/Phase 2,0.23538641997044002,0.102624390853,ORE1001,,,0,0
BRD-K67080878-001-15-4::2.5::HTS,BRD-K67080878-001-15-4,milrinone,2.5,HTS,Exp_NEDD8 (ENSG00000129559),GE,noncancer,phosphodiesterase inhibitor,"PDE2A, PDE3A, PDE3B, PDE5A",cardiology,congestive heart failure,Launched,0.25544484108588,0.0635065813894,milrinone,,,0,0
BRD-K67100011-003-06-3::2.5::HTS,BRD-K67100011-003-06-3,pivmecillinam,2.5,HTS,Exp_TGOLN2 (ENSG00000152291),GE,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, gram-negative bacterial infections",Launched,0.29342880921642894,0.0806121548456,pivmecillinam,,,0,0
BRD-K67102207-236-07-7::2.5::HTS,BRD-K67102207-236-07-7,phenylbutyrate,2.5,HTS,METABOL_inositol,METABOL,noncancer,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders,Launched,0.298075240725097,0.0860811950526,phenylbutyrate,,,0,0
BRD-K67117832-001-01-9::2.5::MTS004,BRD-K67117832-001-01-9,dextran,2.5,MTS004,MIRNA_hsa-miR-187,MIRNA,noncancer,,,"hematology, critical care","thrombosis, hypovolemia",Launched,0.2806828290237561,0.115538601012,dextran,,,0,0
BRD-K67121414-001-03-3::2.5::HTS,BRD-K67121414-001-03-3,apixaban,2.5,HTS,PROT_Dvl3,PROT,noncancer,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)",Launched,0.18829477856264604,0.0392920315422,apixaban,,,0,0
BRD-K67173685-001-06-9::2.39::HTS,BRD-K67173685-001-06-9,4E1RCat,2.39,HTS,Exp_GLT8D2 (ENSG00000120820),GE,noncancer,protein synthesis inhibitor,"EIF4E, EIF4G1",,,Preclinical,0.35157676195670196,0.149539291446,4E1RCat,OTHER,0.3418339415601519,1.4553555999176329,-3.2234907350974087
BRD-K67186445-001-02-1::2.500004874::MTS004,BRD-K67186445-001-02-1,dehydrocorydaline,2.500004874,MTS004,Exp_AREG (ENSG00000109321),GE,noncancer,acetylcholinesterase inhibitor,ACHE,,,Phase 3,0.300506180709943,0.129219268194,dehydrocorydaline,,,0,0
BRD-K67217586-001-08-0::2.5::HTS,BRD-K67217586-001-08-0,fenthion,2.5,HTS,Exp_ATP5J2-PTCD1 (ENSG00000248919),GE,noncancer,cholinesterase inhibitor,,,,Launched,0.298330772809079,0.0416961280475,fenthion,,,0,0
BRD-K67261995-001-11-7::2.5::HTS,BRD-K67261995-001-11-7,iodipamide,2.5,HTS,METHYL_MKS1,METHYL,noncancer,radiopaque medium,ALB,radiology,contrast agent,Launched,0.208644434475935,0.0930706489441,iodipamide,,,0,0
BRD-K67277431-002-10-5::2.5::HTS,BRD-K67277431-002-10-5,picotamide,2.5,HTS,METHYL_PLEKHB1,METHYL,noncancer,"thromboxane receptor antagonist, thromboxane synthase inhibitor",TBXA2R,hematology,thrombosis,Launched,0.24550502685430703,0.0401078183275,picotamide,,,0,0
BRD-K67298865-001-09-0::2.5::HTS,BRD-K67298865-001-09-0,SB-431542,2.5,HTS,PROT_PAI-1,PROT,targeted cancer,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",,,Preclinical,0.300370013269853,0.0657908332393,SB-431542,OTHER,0.3001957140637233,2.860167267930517,-0.5766815724554433
BRD-K67304264-001-08-5::2.5::HTS,BRD-K67304264-001-08-5,SKA-31,2.5,HTS,METHYL_RNF4,METHYL,noncancer,potassium channel activator,KCNN4,,,Preclinical,0.321690902092572,0.16765907361,SKA-31,,,0,0
BRD-K67482377-001-01-8::2.500004112::MTS004,BRD-K67482377-001-01-8,itacitinib,2.500004112,MTS004,DEM2_GNG7 (2788),DEMETER2_COM,targeted cancer,JAK inhibitor,JAK1,,,Phase 2,0.27547641532345296,0.119987766053,itacitinib,,,0,0
BRD-K67511046-001-02-3::2.5::HTS,BRD-K67511046-001-02-3,naloxone,2.5,HTS,METHYL_HOXA7,METHYL,noncancer,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,Launched,0.19903258227704898,0.0513477845931,naloxone,,,0,0
BRD-K67525671-001-02-5::2.5::HTS,BRD-K67525671-001-02-5,ZK-200775,2.5,HTS,MIRNA_hsa-miR-491-3p,MIRNA,noncancer,kainate receptor antagonist,,,,Phase 2,0.253596959446793,0.108807486644,ZK-200775,,,0,0
BRD-K67536197-003-11-4::2.5::HTS,BRD-K67536197-003-11-4,cyclocytidine,2.5,HTS,PROT_Bcl-xL,PROT,chemo,"DNA synthesis inhibitor, RNA synthesis inhibitor",,,,Preclinical,0.39804866844924,0.186706475954,cyclocytidine,OTHER,0.3873088401768582,4.441358632413109,-1.7215216335107728
BRD-K67537649-001-04-5::2.5::HTS,BRD-K67537649-001-04-5,PQ-401,2.5,HTS,Exp_PLD2 (ENSG00000129219),GE,targeted cancer,IGF-1 inhibitor,IGF1R,,,Preclinical,0.22495402329440303,0.166487780244,PQ-401,,,0,0
BRD-K67563174-001-17-6::2.5::HTS,BRD-K67563174-001-17-6,acemetacin,2.5,HTS,CRISPR_LRP10 (26020),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,osteoarthritis,Launched,0.29342817985892305,0.0799363503578,acemetacin,,,0,0
BRD-K67566344-001-07-5::2.5::HTS,BRD-K67566344-001-07-5,ku-0063794,2.5,HTS,Exp_THAP9-AS1 (ENSG00000251022),GE,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.342070676179628,0.267559737063,ku-0063794,MTOR INHIBITOR,0.3427989549492713,1.1176418054321382,-1.6408025177670058
BRD-K67578145-001-09-7::2.38::HTS,BRD-K67578145-001-09-7,GDC-0879,2.38,HTS,Exp_RXRG (ENSG00000143171),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.41980457527485704,0.453712527295,GDC-0879,RAF INHIBITOR,0.3959570253412782,1.0990038562797009,3.923203904155877
BRD-K67578145-001-12-1::2.5::HTS,BRD-K67578145-001-12-1,GDC-0879,2.5,HTS,Exp_UCN2 (ENSG00000145040),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.41980457527485704,0.453712527295,GDC-0879,RAF INHIBITOR,0.3337577711309578,1.285491762840318,3.686672506852124
BRD-K67601717-037-02-4::2.5::HTS,BRD-K67601717-037-02-4,almotriptan,2.5,HTS,CRISPR_EIF2AK3 (9451),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor agonist,"HTR1B, HTR1D",neurology/psychiatry,migraine headache,Launched,0.23060317284189,0.0565960934191,almotriptan,,,0,0
BRD-K67628093-001-01-9::2.500004949::MTS004,BRD-K67628093-001-01-9,INCB-3284,2.500004949,MTS004,Exp_GUCY2C (ENSG00000070019),GE,noncancer,CC chemokine receptor antagonist,CCR2,,,Phase 2,0.241146558548514,0.157100353843,INCB-3284,,,0,0
BRD-K67637637-003-12-6::2.5::HTS,BRD-K67637637-003-12-6,olopatadine,2.5,HTS,DEM2_AP4M1 (9179),DEMETER2_COM,noncancer,histamine receptor antagonist,"HRH1, S100A1, S100A12, S100A13, S100A2, S100B",ophthalmology,conjunctivitis,Launched,0.22005929247175898,0.0610361148944,olopatadine,,,0,0
BRD-K67680372-003-02-6::2.5::HTS,BRD-K67680372-003-02-6,CI-966,2.5,HTS,CRISPR_CLINT1 (9685),AVANA_PUBLIC_18Q2,noncancer,GAT inhibitor,SLC6A1,,,Phase 1,0.333880094736816,0.16555555922,CI-966,,,0,0
BRD-K67772619-001-05-1::2.5::HTS,BRD-K67772619-001-05-1,rheochrysidin,2.5,HTS,DEM2_ZBTB20 (26137),DEMETER2_COM,targeted cancer,protein tyrosine kinase inhibitor,PTPN1,,,Preclinical,0.261461227314457,0.136493938061,rheochrysidin,,,0,0
BRD-K67783091-001-26-1::2.5::HTS,BRD-K67783091-001-26-1,haloperidol,2.5,HTS,Exp_C19orf48 (ENSG00000167747),GE,noncancer,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1",neurology/psychiatry,"schizophrenia, Tourette's disorder",Launched,0.24726240960281898,0.13094489983,haloperidol,,,0,0
BRD-K67789209-001-01-0::2.5::HTS,BRD-K67789209-001-01-0,adatanserin,2.5,HTS,DEM2_CHD1 (1105),DEMETER2_COM,noncancer,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR2A",,,Phase 2,0.299556308873758,0.117572771922,adatanserin,,,0,0
BRD-K67831364-003-03-3::2.5::HTS,BRD-K67831364-003-03-3,ZM-323881,2.5,HTS,CN_CEBPA (1050),CN,targeted cancer,VEGFR inhibitor,KDR,,,Preclinical,0.246229506705815,0.0527774085563,ZM-323881,,,0,0
BRD-K67844266-003-01-9::2.5::HTS,BRD-K67844266-003-01-9,pevonedistat,2.5,HTS,Exp_PGM2 (ENSG00000169299),GE,targeted cancer,nedd activating enzyme inhibitor,"NAE1, UBA3",,,Phase 2,0.379891253916675,0.290614553968,pevonedistat,OTHER,0.3801360231187552,4.504968723751986,-1.9045517644570715
BRD-K67860401-001-05-6::2.5::HTS,BRD-K67860401-001-05-6,AR-A014418,2.5,HTS,CRISPR_DPRX (503834),AVANA_PUBLIC_18Q2,targeted cancer,glycogen synthase kinase inhibitor,GSK3B,,,Preclinical,0.21679207490089897,0.0731611181091,AR-A014418,,,0,0
BRD-K67868012-001-07-6::2.5::HTS,BRD-K67868012-001-07-6,PI-103,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,Preclinical,0.29464258959735307,0.279593750407,PI-103,MTOR INHIBITOR,0.2940556044411721,2.0191468011182483,-1.4470930158010782
BRD-K67901620-001-02-0::2.5::HTS,BRD-K67901620-001-02-0,avasimibe,2.5,HTS,DEM2_SREBF2 (6721),DEMETER2_COM,targeted cancer,ACAT inhibitor,CES1,,,Phase 3,0.23439893978878698,0.059381125062,avasimibe,,,0,0
BRD-K67943528-050-01-4::2.5::HTS,BRD-K67943528-050-01-4,lisuride,2.5,HTS,CN_CTHRC1 (115908),CN,noncancer,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6",neurology/psychiatry,Parkinson's Disease,Launched,0.31484518677125106,0.0521676714667,lisuride,,,0,0
BRD-K67966701-001-11-6::2.5::HTS,BRD-K67966701-001-11-6,lisinopril,2.5,HTS,Exp_TFDP1 (ENSG00000198176),GE,noncancer,angiotensin converting enzyme inhibitor,"ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus",Launched,0.26341116708826395,0.0866991853104,lisinopril,,,0,0
BRD-K67966701-001-12-4::2.5::HTS,BRD-K67966701-001-12-4,lisinopril,2.5,HTS,METABOL_2-aminoadipate,METABOL,noncancer,angiotensin converting enzyme inhibitor,"ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus",Launched,0.32648369391441995,0.053353927926,lisinopril,,,0,0
BRD-K67977190-066-02-3::2.5::HTS,BRD-K67977190-066-02-3,eprosartan,2.5,HTS,METHYL_LINC00880,METHYL,noncancer,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,Launched,0.293409924204841,0.20750050888,eprosartan,,,0,0
BRD-K68065987-300-09-1::2.5::HTS,BRD-K68065987-300-09-1,MK-2206,2.5,HTS,Exp_AKT3 (ENSG00000117020),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.36915618032698,0.322756972577,MK-2206,AKT INHIBITOR,0.366484040922232,0.6015008429743662,-1.9447001702962456
BRD-K68095457-001-10-1::2.5::HTS,BRD-K68095457-001-10-1,palmitoylethanolamide,2.5,HTS,MIRNA_hsa-miR-1280,MIRNA,noncancer,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",,,Launched,0.21743995613309397,0.103348884266,palmitoylethanolamide,,,0,0
BRD-K68103045-001-02-9::2.5::HTS,BRD-K68103045-001-02-9,CGS-20625,2.5,HTS,METABOL_4-pyridoxate,METABOL,noncancer,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",,,Phase 1,0.264635033185417,0.0702817196673,CGS-20625,,,0,0
BRD-K68132782-003-13-8::2.5::HTS,BRD-K68132782-003-13-8,terbinafine,2.5,HTS,DEM2_NDUFB6 (4712),DEMETER2_COM,noncancer,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.24367480564678895,0.0281663164092,terbinafine,,,0,0
BRD-K68164687-001-01-6::2.5::HTS,BRD-K68164687-001-01-6,epothilone-b,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 3,0.417752218533801,0.273207755121,epothilone-b,OTHER,0.4151753887802863,5.175861298526113,-2.5120452124136032
BRD-K68185022-001-14-8::2.5::HTS,BRD-K68185022-001-14-8,ursolic-acid,2.5,HTS,METABOL_C54:7 TAG,METABOL,targeted cancer,"ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor","HSD11B1, PLA2G1B, PTPN1, PYGM",,,Phase 1,0.279823116745844,0.0880575273458,ursolic-acid,,,0,0
BRD-K68188368-001-09-4::2.5::HTS,BRD-K68188368-001-09-4,nifuroxazide,2.5,HTS,Exp_THBS1 (ENSG00000137801),GE,noncancer,bacterial DNA inhibitor,,gastroenterology,"colitis, diarrhea",Launched,0.30885476387691496,0.210049409357,nifuroxazide,OTHER,0.31354130003239866,-4.673706841905124,-0.705761648366602
BRD-K68232413-001-01-2::2.5::HTS,BRD-K68232413-001-01-2,etizolam,2.5,HTS,CRISPR_RPP25 (54913),AVANA_PUBLIC_18Q2,noncancer,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,"insomnia, anxiety",Launched,0.291564662892657,0.0897662332429,etizolam,,,0,0
BRD-K68232650-001-02-2::2.5::HTS,BRD-K68232650-001-02-2,lacosamide,2.5,HTS,CN_FAM157A (728262),CN,noncancer,"collapsin response mediator protein inhibitor, collapsin response mediator protein stimulant, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.28633653108331397,0.102017328437,lacosamide,,,0,0
BRD-K68264559-045-02-4::2.5::HTS,BRD-K68264559-045-02-4,brimonidine,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.25215994919963397,0.0633844445101,brimonidine,,,0,0
BRD-K68264559-045-04-0::2.58::HTS,BRD-K68264559-045-04-0,brimonidine,2.58,HTS,CRISPR_HSPA9 (3313),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.19709616260693,0.0738941074704,brimonidine,,,0,0
BRD-K68336408-001-10-9::2.5::HTS,BRD-K68336408-001-10-9,tyrphostin-AG-1478,2.5,HTS,Exp_EPHA1 (ENSG00000146904),GE,targeted cancer,EGFR inhibitor,"EGFR, MAPK14",,,Preclinical,0.39688808181573,0.497379472739,tyrphostin-AG-1478,EGFR INHIBITOR,0.41458063905171183,0.9167179771637928,-5.199247396765233
BRD-K68346641-001-01-4::2.5::HTS,BRD-K68346641-001-01-4,amsacrine,2.5,HTS,Exp_GEMIN4 (ENSG00000179409),GE,chemo,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",Launched,0.382644312489669,0.251936618255,amsacrine,TOPOISOMERASE INHIBITOR,0.3710298158744496,4.80260665128697,-1.9248547044015
BRD-K68346641-001-02-2::2.5::HTS,BRD-K68346641-001-02-2,amsacrine,2.5,HTS,Exp_PTCHD4 (ENSG00000244694),GE,chemo,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",Launched,0.382644312489669,0.251936618255,amsacrine,TOPOISOMERASE INHIBITOR,0.38307453109075057,4.240215934211228,-2.3297709181198902
BRD-K68392338-003-02-0::2.5::HTS,BRD-K68392338-003-02-0,ZK-93426,2.5,HTS,MUTpool_GTF3C1 (2975),MUTpool,noncancer,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,Phase 1,0.264414679357199,0.125094423777,ZK-93426,,,0,0
BRD-K68395654-001-03-1::2.5::HTS,BRD-K68395654-001-03-1,EVP4593,2.5,HTS,Exp_KRT80 (ENSG00000167767),GE,noncancer,NFkB pathway inhibitor,,,,Preclinical,0.359822948085759,0.353335947881,EVP4593,NFKB PATHWAY INHIBITOR,0.3311559429995433,1.896315694764936,-2.7097955077935363
BRD-K68402494-003-03-5::2.5::HTS,BRD-K68402494-003-03-5,ML-9,2.5,HTS,MIRNA_hsa-miR-1268,MIRNA,noncancer,myosin light chain kinase inhibitor,TRPC6,,,Preclinical,0.257013681254758,0.0439294486907,ML-9,,,0,0
BRD-K68405354-001-06-4::2.5::HTS,BRD-K68405354-001-06-4,spaglumic-acid,2.5,HTS,METHYL_PGRMC2,METHYL,noncancer,glutamate receptor antagonist,GRM3,allergy,"allergic conjunctivitis, allergic rhinitis",Launched,0.23543018662206897,-0.0113604746105,spaglumic-acid,,,0,0
BRD-K68405354-001-07-2::2.5::HTS,BRD-K68405354-001-07-2,spaglumic-acid,2.5,HTS,CONF_P935,PR500_Confounders,noncancer,glutamate receptor antagonist,GRM3,allergy,"allergic conjunctivitis, allergic rhinitis",Launched,0.296263010202917,0.121135401577,spaglumic-acid,,,0,0
BRD-K68408467-065-01-8::2.5::HTS,BRD-K68408467-065-01-8,proflavine-hemisulfate,2.5,HTS,Exp_USP27X-AS1 (ENSG00000234390),GE,noncancer,topical anesthetic,F2,,,Phase 2,0.342344077384886,0.241562703096,proflavine-hemisulfate,OTHER,0.3423436623263326,3.908571468907057,-2.409232056792102
BRD-K68408772-001-05-4::2.420640995::MTS004,BRD-K68408772-001-05-4,carboxyamidotriazole,2.420640995,MTS004,METABOL_C34:1 DAG,METABOL,targeted cancer,calcium channel blocker,CXCL8,,,Phase 3,0.37239988836758897,0.190707062723,carboxyamidotriazole,OTHER,0.3407150472023993,1.5674827152854052,-2.9829192604210113
BRD-K68432770-236-23-1::2.500029469::MTS004,BRD-K68432770-236-23-1,ampicillin,2.500029469,MTS004,METABOL_C52:5 TAG,METABOL,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections",Launched,0.27321484559410797,0.113737680579,ampicillin,,,0,0
BRD-K68474068-001-01-8::2.5::HTS,BRD-K68474068-001-01-8,MM-102,2.5,HTS,METHYL_MIR2355,METHYL,noncancer,WDR5/MLL interaction inhibitor,,,,Preclinical,0.31124916811208797,0.118382447254,MM-102,,,0,0
BRD-K68488863-001-04-9::2.5::HTS,BRD-K68488863-001-04-9,ENMD-2076,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",,,Phase 2,0.419573999076324,0.330685283464,ENMD-2076,AURORA KINASE INHIBITOR,0.4160230237769837,3.3497626168475745,-3.5323933776314216
BRD-K68502831-001-01-2::2.5::HTS,BRD-K68502831-001-01-2,dianhydrogalactitol,2.5,HTS,CRISPR_C15orf41 (84529),AVANA_PUBLIC_18Q2,chemo,DNA alkylating agent,,,,Phase 1,0.431389614618363,0.328179574013,dianhydrogalactitol,OTHER,0.4149677082419415,2.5835397035463035,-4.067893498026116
BRD-K68507560-003-24-6::2.5::HTS,BRD-K68507560-003-24-6,dicycloverine,2.5,HTS,PROT_Bax,PROT,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,Launched,0.257036990672307,0.102557904716,dicycloverine,,,0,0
BRD-K68532323-003-02-8::2.5::HTS,BRD-K68532323-003-02-8,SB-743921,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Phase 1/Phase 2,0.39726442940778295,0.350864161658,SB-743921,OTHER,0.3994934654873061,5.299922154928587,-2.391479683405234
BRD-K68538666-001-12-3::2.5::HTS,BRD-K68538666-001-12-3,aceclofenac,2.5,HTS,CN_OR4P4 (81300),CN,noncancer,prostanoid receptor antagonist,PTGS2,rheumatology,"rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia",Launched,0.275417863032915,0.116946759349,aceclofenac,,,0,0
BRD-K68544925-001-01-1::2.500014712::MTS004,BRD-K68544925-001-01-1,avatrombopag,2.500014712,MTS004,Exp_MAP3K5 (ENSG00000197442),GE,noncancer,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia,Launched,0.30740936878564,0.129574457845,avatrombopag,,,0,0
BRD-K68552125-001-05-3::2.03::HTS,BRD-K68552125-001-05-3,12-O-tetradecanoylphorbol-13-acetate,2.03,HTS,Exp_ABI2 (ENSG00000138443),GE,targeted cancer,PKC activator,"KCNT2, TRPV4",,,Phase 2,0.365045579915165,0.0751432568722,12-O-tetradecanoylphorbol-13-acetate,OTHER,0.3580324659557653,-0.2376587155003416,-3.2952089257067376
BRD-K68553471-003-12-3::2.5::HTS,BRD-K68553471-003-12-3,todralazine,2.5,HTS,Exp_TMEM138 (ENSG00000149483),GE,noncancer,antihypertensive agent,,,,Launched,0.214966837142567,0.0849454839937,todralazine,,,0,0
BRD-K68558722-001-04-0::2.5::HTS,BRD-K68558722-001-04-0,deracoxib,2.5,HTS,CRISPR_ZKSCAN1 (7586),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,Launched,0.30874359561181003,0.0671084363459,deracoxib,,,0,0
BRD-K68567222-001-01-2::2.5::HTS,BRD-K68567222-001-01-2,BVT-948,2.5,HTS,PROT_ATM,PROT,noncancer,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",,,Preclinical,0.309269901566963,0.108387439346,BVT-948,OTHER,0.30868491167540185,3.2443460765404604,-2.1948490465326818
BRD-K68620903-001-11-4::2.5::HTS,BRD-K68620903-001-11-4,dydrogesterone,2.5,HTS,Exp_P2RY8 (ENSG00000182162),GE,noncancer,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility,Launched,0.22445523930637198,0.0556063952716,dydrogesterone,,,0,0
BRD-K68633617-003-02-9::2.5::HTS,BRD-K68633617-003-02-9,ACDPP,2.5,HTS,Exp_PTMAP3 (ENSG00000218902),GE,noncancer,glutamate receptor antagonist,GRM5,,,Preclinical,0.305568914246038,0.183516319587,ACDPP,OTHER,0.3127729826452361,-1.7365933492412535,0.8820810644682082
BRD-K68653965-001-01-1::2.5::HTS,BRD-K68653965-001-01-1,picolamine,2.5,HTS,Exp_SLMO1 (ENSG00000141391),GE,noncancer,,,,,Preclinical,0.21071638010151503,0.140059486002,picolamine,,,0,0
BRD-K68693535-001-03-4::2.5::HTS,BRD-K68693535-001-03-4,lidamidine,2.5,HTS,CN_DCBLD1 (285761),CN,noncancer,adrenergic receptor agonist,,gastroenterology,diarrhea,Launched,0.31559279715397803,0.00653566561069,lidamidine,,,0,0
BRD-K68747584-001-02-0::2.5::HTS,BRD-K68747584-001-02-0,PF-03814735,2.5,HTS,Exp_KHDRBS1 (ENSG00000121774),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Phase 1,0.37727972312694297,0.335455581443,PF-03814735,AURORA KINASE INHIBITOR,0.3760133868679617,3.672954661375975,-3.5664150234124223
BRD-K68756823-001-07-1::2.5::HTS,BRD-K68756823-001-07-1,FR-180204,2.5,HTS,MIRNA_hsa-miR-1203,MIRNA,targeted cancer,MAP kinase inhibitor,"MAPK1, MAPK3",,,Preclinical,0.28341254502198,0.0504068137119,FR-180204,,,0,0
BRD-K68764924-001-03-2::2.5::MTS004,BRD-K68764924-001-03-2,pantethine,2.5,MTS004,CRISPR_FZD5 (7855),AVANA_PUBLIC_18Q2,noncancer,coenzyme A precursor,,,,Launched,0.24436132693062199,-0.0168832202226,pantethine,,,0,0
BRD-K68770713-001-01-8::2.5::HTS,BRD-K68770713-001-01-8,azosemide,2.5,HTS,METHYL_MGST2,METHYL,noncancer,electrolyte reabsorption inhibitor,"SLC12A1, SLC12A2",cardiology,edema,Launched,0.26230697189296304,0.0570413438077,azosemide,,,0,0
BRD-K68805147-001-01-8::2.5::HTS,BRD-K68805147-001-01-8,pafuramidine,2.5,HTS,CN_MIR650 (723778),CN,targeted cancer,DNA synthesis inhibitor,,,,Phase 3,0.268634819425416,0.0777042546205,pafuramidine,,,0,0
BRD-K68810443-001-01-9::2.5::HTS,BRD-K68810443-001-01-9,adiporon,2.5,HTS,DEM2_MYO3B (140469),DEMETER2_COM,targeted cancer,adiponectin receptor agonist,"ADIPOR1, ADIPOR2",,,Preclinical,0.281990193592172,0.0773664982808,adiporon,,,0,0
BRD-K68867920-051-11-5::2.5::HTS,BRD-K68867920-051-11-5,quetiapine,2.5,HTS,PROT_RAD51,PROT,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.339360952714471,0.0749882422513,quetiapine,,,0,0
BRD-K68870568-066-01-5::2.5::HTS,BRD-K68870568-066-01-5,flumatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",,,Phase 3,0.28830478043145097,0.29316189043,flumatinib,OTHER,0.2877824254396794,2.1689786421404595,-1.3756394993715837
BRD-K68938568-001-01-7::2.5::HTS,BRD-K68938568-001-01-7,GDC-0152,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",,,Phase 1,0.37425576116136894,0.361515465101,GDC-0152,XIAP INHIBITOR,0.3731202193725408,4.848086845438114,-2.3577378059152383
BRD-K68997413-001-05-1::2.5::HTS,BRD-K68997413-001-05-1,PF-3845,2.5,HTS,PROT_p70S6K,PROT,noncancer,FAAH inhibitor,FAAH,,,Preclinical,0.32457098364591697,0.167267091074,PF-3845,,,0,0
BRD-K69001009-001-02-8::2.5::HTS,BRD-K69001009-001-02-8,golvatinib,2.5,HTS,PROT_c-Met_pY1235,PROT,targeted cancer,VEGFR inhibitor,"KDR, MET",,,Phase 2,0.3796007029549389,0.168488621749,golvatinib,VEGFR INHIBITOR,0.3867258062867393,0.6095660460543921,-2.5448261992784724
BRD-K69035426-001-01-3::2.5::HTS,BRD-K69035426-001-01-3,omeprazole-sulfide,2.5,HTS,DEM2_VPREB3 (29802),DEMETER2_COM,noncancer,ATPase inhibitor,,,,Phase 1,0.271515564594969,0.0812199773953,omeprazole-sulfide,,,0,0
BRD-K69070623-003-01-7::2.5::HTS,BRD-K69070623-003-01-7,EPZ004777,2.5,HTS,Exp_CCDC82 (ENSG00000149231),GE,targeted cancer,histone lysine methyltransferase inhibitor,DOT1L,,,Preclinical,0.259639563176394,-0.000809635762202,EPZ004777,,,0,0
BRD-K69116396-001-04-1::2.5::HTS,BRD-K69116396-001-04-1,sertindole,2.5,HTS,METABOL_C56:5 TAG,METABOL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",,,Withdrawn,0.28561256792573103,0.117770504799,sertindole,,,0,0
BRD-K69122748-001-10-1::2.5::HTS,BRD-K69122748-001-10-1,diacerein,2.5,HTS,CRISPR_SPRY2 (10253),AVANA_PUBLIC_18Q2,noncancer,interleukin inhibitor,IL1B,rheumatology,osteoarthritis,Launched,0.25467845179883997,0.100912956656,diacerein,,,0,0
BRD-K69172251-001-08-9::2.5::HTS,BRD-K69172251-001-08-9,cisplatin,2.5,HTS,METHYL_TYROBP,METHYL,chemo,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer",Launched,0.31010855975388396,0.0766657217246,cisplatin,,,0,0
BRD-K69195780-004-08-4::2.5::HTS,BRD-K69195780-004-08-4,NAN-190,2.5,HTS,MIRNA_hsa-miR-601,MIRNA,noncancer,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",,,Preclinical,0.227078943439022,0.0966843649342,NAN-190,,,0,0
BRD-K69216798-001-01-9::2.5::HTS,BRD-K69216798-001-01-9,iodoantipyrine,2.5,HTS,MIRNA_hsa-miR-499-3p,MIRNA,noncancer,,,,,Preclinical,0.290289766979831,0.0557707357546,iodoantipyrine,,,0,0
BRD-K69231085-003-05-7::2.86::HTS,BRD-K69231085-003-05-7,trigonelline,2.86,HTS,CRISPR_ATG14 (22863),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 1,0.3623275325312179,0.080247131944,trigonelline,,,0,0
BRD-K69236721-001-02-7::2.5::HTS,BRD-K69236721-001-02-7,lumacaftor,2.5,HTS,DEM2_SLC9A9 (285195),DEMETER2_COM,noncancer,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis,Launched,0.292465582384443,0.1132381327,lumacaftor,,,0,0
BRD-K69247067-001-01-8::2.5::HTS,BRD-K69247067-001-01-8,afloqualone,2.5,HTS,PROT_STAT3_Caution,PROT,noncancer,acetylcholine receptor antagonist,,neurology/psychiatry,sedative,Launched,0.287063541839297,0.0491733952598,afloqualone,,,0,0
BRD-K69253806-001-02-0::2.5::HTS,BRD-K69253806-001-02-0,hexestrol,2.5,HTS,CN_DNASE2 (1777),CN,noncancer,synthetic estrogen,"AKR1C1, ESR1, ESR2",,,Launched,0.246129283897542,0.0350217973246,hexestrol,,,0,0
BRD-K69280563-001-01-8::2.5::HTS,BRD-K69280563-001-01-8,vinorelbine,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),Launched,0.4378090314031579,0.296580062206,vinorelbine,TUBULIN POLYMERIZATION INHIBITOR,0.4361107121887789,6.065643779588902,-2.1402350324814394
BRD-K69346723-001-04-8::2.5::HTS,BRD-K69346723-001-04-8,glutathione,2.5,HTS,METABOL_arachidonyl_carnitine,METABOL,noncancer,antioxidant,"ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12",,,Phase 3,0.23113612464241198,0.0281427210687,glutathione,,,0,0
BRD-K69469734-003-02-5::2.5::HTS,BRD-K69469734-003-02-5,trospium,2.5,HTS,METHYL_OSGIN1,METHYL,noncancer,acetylcholine receptor antagonist,CHRM1,urology,"urinary incontinence, urinary frequency",Launched,0.22657963817645602,0.0903550808096,trospium,,,0,0
BRD-K69470111-236-08-9::2.5::HTS,BRD-K69470111-236-08-9,montelukast,2.5,HTS,CRISPR_RCE1 (9986),AVANA_PUBLIC_18Q2,noncancer,leukotriene receptor antagonist,"ALOX5, CYSLTR1","pulmonary, allergy","asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)",Launched,0.23444312329793804,-0.00117027240235,montelukast,,,0,0
BRD-K69577666-001-01-3::2.5::HTS,BRD-K69577666-001-01-3,SGC-0946,2.5,HTS,METHYL_ADCYAP1,METHYL,noncancer,histone lysine methyltransferase inhibitor,,,,Preclinical,0.356152155067406,0.0555221029811,SGC-0946,,,0,0
BRD-K69600043-328-05-5::2.5::HTS,BRD-K69600043-328-05-5,thiethylperazine,2.5,HTS,PROT_Acetyl-a-Tubulin (Lys40)_Caution,PROT,noncancer,dopamine receptor antagonist,"DRD1, DRD2, DRD4",gastroenterology,nausea,Launched,0.32751922031422,0.0584791626452,thiethylperazine,,,0,0
BRD-K69608737-001-10-2::2.5::HTS,BRD-K69608737-001-10-2,tacrolimus,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,noncancer,calcineurin inhibitor,FKBP1A,transplant,organ rejection,Launched,0.29575634407448703,0.0754705212435,tacrolimus,,,0,0
BRD-K69636617-001-01-7::2.49998713::MTS004,BRD-K69636617-001-01-7,testolactone,2.49998713,MTS004,Exp_C1orf35 (ENSG00000143793),GE,targeted cancer,aromatase inhibitor,CYP19A1,oncology,breast cancer,Launched,0.22531783501745298,0.10482089192,testolactone,,,0,0
BRD-K69669039-001-01-8::2.499979212::MTS004,BRD-K69669039-001-01-8,GSK163090,2.499979212,MTS004,CRISPR_SPPL3 (121665),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D",,,Phase 2,0.28570841640936,0.0896041197767,GSK163090,,,0,0
BRD-K69688083-004-23-1::2.5::HTS,BRD-K69688083-004-23-1,mestinon,2.5,HTS,PROT_TIGAR,PROT,noncancer,cholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,Launched,0.259445172485159,0.205590096258,mestinon,OTHER,0.27879760389537833,-4.184096611198482,-3.2050387449556528
BRD-K69726342-238-02-4::2.5::HTS,BRD-K69726342-238-02-4,atorvastatin,2.5,HTS,Exp_PAFAH1B1 (ENSG00000007168),GE,noncancer,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack",Launched,0.47794424792584905,0.382217144493,atorvastatin,HMGCR INHIBITOR,0.4911522235568417,1.75300590070493,5.3044665328758365
BRD-K69726595-001-01-2::2.5::HTS,BRD-K69726595-001-01-2,mericitabine,2.5,HTS,CN_LINC00266-1 (140849),CN,noncancer,HCV inhibitor,,,,Phase 2,0.39885937637813107,0.174256186353,mericitabine,OTHER,0.3601680902621154,2.1080827879612314,-2.871410318557917
BRD-K69776681-001-03-8::2.5::HTS,BRD-K69776681-001-03-8,volasertib,2.5,HTS,Exp_SYNCRIP (ENSG00000135316),GE,targeted cancer,PLK inhibitor,PLK1,,,Phase 3,0.412494959073185,0.353806616584,volasertib,OTHER,0.4153937775783579,4.677176340758108,-1.5938765577898426
BRD-K69812556-305-02-0::2.5::HTS,BRD-K69812556-305-02-0,WAY-100635,2.5,HTS,Exp_KLHL30 (ENSG00000168427),GE,noncancer,serotonin receptor antagonist,HTR1A,,,Phase 1,0.23931982594861198,0.0413434301303,WAY-100635,,,0,0
BRD-K69837166-003-02-0::2.5::HTS,BRD-K69837166-003-02-0,trap-101,2.5,HTS,METHYL_OAZ3,METHYL,noncancer,"nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist",OPRL1,,,Preclinical,0.292095631217433,0.0310297085294,trap-101,,,0,0
BRD-K69907333-001-10-6::2.5::HTS,BRD-K69907333-001-10-6,flurbiprofen-(S)-(+),2.5,HTS,MUTpool_ZP1 (22917),MUTpool,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.252021503625292,0.0447877834744,flurbiprofen-(S)-(+),,,0,0
BRD-K70053378-001-01-1::2.5::HTS,BRD-K70053378-001-01-1,SM-108,2.5,HTS,RMUTmis_POM121C (100101267),MUTmis,targeted cancer,,,,,Phase 2,0.221767627502447,0.0760493916157,SM-108,,,0,0
BRD-K70088346-001-01-6::2.5::HTS,BRD-K70088346-001-01-6,2-chloro-N6-cyclopentyladenosine,2.5,HTS,METABOL_C46:0 TAG,METABOL,noncancer,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.315617121129653,0.0918248549391,2-chloro-N6-cyclopentyladenosine,,,0,0
BRD-K70159787-001-01-1::2.5::HTS,BRD-K70159787-001-01-1,SMI-4a,2.5,HTS,CRISPR_TAX1BP3 (30851),AVANA_PUBLIC_18Q2,targeted cancer,Pim kinase inhibitor,PIM1,,,Preclinical,0.318138971702144,0.078498453766,SMI-4a,,,0,0
BRD-K70163715-300-05-7::2.42::HTS,BRD-K70163715-300-05-7,vatalanib,2.42,HTS,PROT_p27,PROT,targeted cancer,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",,,Phase 3,0.178622313820966,0.130842592411,vatalanib,,,0,0
BRD-K70177501-003-01-4::2.5::HTS,BRD-K70177501-003-01-4,INH1,2.5,HTS,CRISPR_C18orf8 (29919),AVANA_PUBLIC_18Q2,targeted cancer,Hec1 inhibitor,NDC80,,,Preclinical,0.330206002204763,-0.0439184510682,INH1,,,0,0
BRD-K70246307-001-04-1::2.5::HTS,BRD-K70246307-001-04-1,riboflavin,2.5,HTS,METABOL_pyroglutamic acid,METABOL,noncancer,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,Launched,0.269439632859875,0.016791566643,riboflavin,,,0,0
BRD-K70262971-001-01-9::2.499966077::MTS004,BRD-K70262971-001-01-9,AGN-194310,2.499966077,MTS004,PROT_Stathmin,PROT,noncancer,retinoid receptor antagonist,"RXRA, RXRB, RXRG",,,Phase 3,0.34007076920655394,0.106757771189,AGN-194310,,,0,0
BRD-K70281171-050-08-9::2.5::HTS,BRD-K70281171-050-08-9,U-99194,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,dopamine receptor antagonist,DRD3,,,Preclinical,0.188648835456732,0.0762803316272,U-99194,,,0,0
BRD-K70301465-001-02-6::2.5::HTS,BRD-K70301465-001-02-6,ibrutinib,2.5,HTS,Exp_EPHA1 (ENSG00000146904),GE,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)",Launched,0.460161825324805,0.544113055586,ibrutinib,OTHER,0.4483161795645612,1.1720934931622151,-4.983575100511873
BRD-K70301876-034-13-7::2.5::HTS,BRD-K70301876-034-13-7,escitalopram,2.5,HTS,METHYL_DLL4,METHYL,noncancer,selective serotonin reuptake inhibitor (SSRI),"ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD)",Launched,0.274787022387583,0.118413297462,escitalopram,,,0,0
BRD-K70327167-348-13-4::2.5::HTS,BRD-K70327167-348-13-4,suramin,2.5,HTS,DEM2_CCDC171 (203238),DEMETER2_COM,noncancer,DNA synthesis inhibitor,"F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5",infectious disease,"African trypanosomiasis, onchocerciasis",Launched,0.227656298935875,0.109261610653,suramin,,,0,0
BRD-K70327191-001-02-2::2.5::HTS,BRD-K70327191-001-02-2,benzoxiquine,2.5,HTS,METABOL_2-deoxycytidine,METABOL,noncancer,antiinfective drug,,,,Preclinical,0.259160472294713,0.0686176104768,benzoxiquine,,,0,0
BRD-K70330032-001-01-1::2.50000853::MTS004,BRD-K70330032-001-01-1,JNJ-42165279,2.50000853,MTS004,DEM2_NDUFB9 (4715),DEMETER2_COM,noncancer,FAAH inhibitor,FAAH,,,Phase 2,0.280373143385045,0.0129026869706,JNJ-42165279,,,0,0
BRD-K70330367-003-07-9::2.5::HTS,BRD-K70330367-003-07-9,amantadine,2.5,HTS,DEM2_ZFP28 (140612),DEMETER2_COM,noncancer,glutamate receptor antagonist,"DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A","infectious disease, neurology/psychiatry","influenza A virus infection, Parkinson's Disease",Launched,0.33561920243854604,0.00962693623601,amantadine,,,0,0
BRD-K70358946-001-15-7::2.5::HTS,BRD-K70358946-001-15-7,aripiprazole,2.5,HTS,DEM2_ADSL (158),DEMETER2_COM,noncancer,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder",Launched,0.308035514598172,0.146393525284,aripiprazole,OTHER,0.3028137096745728,4.326480274021579,-2.5936863675551445
BRD-K70401845-003-09-6::2.5::HTS,BRD-K70401845-003-09-6,erlotinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer",Launched,0.40630030561703295,0.38610926851,erlotinib,EGFR INHIBITOR,0.4089099286754243,1.0057298203224287,-4.351595381829201
BRD-K70402238-001-02-8::2.5::HTS,BRD-K70402238-001-02-8,nexturastat-a,2.5,HTS,Exp_ZMYND8 (ENSG00000101040),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC6",,,Preclinical,0.32508977063728006,0.182159926624,nexturastat-a,HDAC INHIBITOR,0.31026071494637825,6.995235218795272,-2.034355746759502
BRD-K70463136-001-01-5::2.5::HTS,BRD-K70463136-001-01-5,BAY-87-2243,2.5,HTS,Exp_SLC2A1 (ENSG00000117394),GE,targeted cancer,hypoxia inducible factor inhibitor,HIF1A,,,Phase 1,0.364096532552087,0.360377250409,BAY-87-2243,HIF PROLYL HYDROXYLASE,0.3613064996461231,1.8081622063123013,-2.8656641532985647
BRD-K70487031-001-02-8::2.5::HTS,BRD-K70487031-001-02-8,flupentixol,2.5,HTS,METABOL_2-deoxycytidine,METABOL,noncancer,dopamine receptor antagonist,"ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A",neurology/psychiatry,"schizophrenia, depression",Launched,0.29167718322598,0.0455745747294,flupentixol,,,0,0
BRD-K70490179-300-01-2::2.5::HTS,BRD-K70490179-300-01-2,rimcazole,2.5,HTS,CN_DUSP2 (1844),CN,targeted cancer,sigma receptor antagonist,SIGMAR1,,,Phase 1,0.262031397694912,0.0729433415742,rimcazole,,,0,0
BRD-K70504253-001-01-3::2.500017504::MTS004,BRD-K70504253-001-01-3,fruquintinib,2.500017504,MTS004,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,KDR,,,Phase 3,0.271047590083081,0.166867953304,fruquintinib,,,0,0
BRD-K70505054-003-12-4::2.5::HTS,BRD-K70505054-003-12-4,ranitidine,2.5,HTS,RMUTmis_RBMXL3 (139804),MUT,noncancer,histamine receptor antagonist,HRH2,gastroenterology,heartburn,Launched,0.250390480059462,0.0700541510549,ranitidine,,,0,0
BRD-K70507123-001-09-7::2.5::HTS,BRD-K70507123-001-09-7,doxofylline,2.5,HTS,METHYL_FAM20C,METHYL,noncancer,adenosine receptor antagonist,"ADORA1, PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,asthma,Launched,0.268120183089811,0.13361646693,doxofylline,,,0,0
BRD-K70557564-305-03-6::2.5::HTS,BRD-K70557564-305-03-6,zosuquidar,2.5,HTS,Exp_RHBDL1 (ENSG00000103269),GE,targeted cancer,P glycoprotein inhibitor,"ABCB1, ABCB4",,,Phase 3,0.25226435596334196,0.0187752326372,zosuquidar,,,0,0
BRD-K70586315-001-02-4::2.5::HTS,BRD-K70586315-001-02-4,1-EBIO,2.5,HTS,Exp_STAU2-AS1 (ENSG00000253302),GE,noncancer,potassium channel activator,"KCNN1, KCNN2, KCNN3, KCNN4",,,Preclinical,0.31156124765966,0.00499251122912,1-EBIO,,,0,0
BRD-K70592483-001-01-0::2.5::HTS,BRD-K70592483-001-01-0,phenylacetylglutamine,2.5,HTS,DEM2_TFAM (7019),DEMETER2_COM,noncancer,"DNA methylase inhibitor, protein synthesis inhibitor",,,,Phase 2,0.294391714967602,0.150008440995,phenylacetylglutamine,,,0,0
BRD-K70592963-001-31-6::2.5::MTS004,BRD-K70592963-001-31-6,phenindione,2.5,MTS004,Exp_AUP1 (ENSG00000115307),GE,noncancer,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),Launched,0.326799750292417,0.18689181003,phenindione,,,0,0
BRD-K70601687-001-01-3::2.500008826::MTS004,BRD-K70601687-001-01-3,enasidenib,2.500008826,MTS004,METABOL_inositol,METABOL,targeted cancer,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),Launched,0.230534214192248,0.088712755539,enasidenib,,,0,0
BRD-K70610771-001-02-9::2.5::HTS,BRD-K70610771-001-02-9,VX-222,2.5,HTS,METHYL_ETV3,METHYL,noncancer,HCV inhibitor,,,,Phase 2,0.25259297198024305,0.0369079321161,VX-222,,,0,0
BRD-K70650177-001-01-7::2.500008535::MTS004,BRD-K70650177-001-01-7,testosterone-undecanoate,2.500008535,MTS004,Exp_MRPL14 (ENSG00000180992),GE,noncancer,androgen receptor agonist,AR,endocrinology,hypogonadism,Launched,0.27982024126301,0.0738817247096,testosterone-undecanoate,,,0,0
BRD-K70778732-003-26-7::2.5::HTS,BRD-K70778732-003-26-7,trazodone,2.5,HTS,CRISPR_RPP25 (54913),AVANA_PUBLIC_18Q2,noncancer,"adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4",neurology/psychiatry,depression,Launched,0.265664234622196,0.040123079449,trazodone,,,0,0
BRD-K70792160-003-04-6::2.5::HTS,BRD-K70792160-003-04-6,10-DEBC,2.5,HTS,CRISPR_COPS8 (10920),AVANA_PUBLIC_18Q2,targeted cancer,AKT inhibitor,PIM1,,,Preclinical,0.28588162119127003,0.0794714969422,10-DEBC,,,0,0
BRD-K70821460-300-02-4::2.5::HTS,BRD-K70821460-300-02-4,4-methylhistamine,2.5,HTS,DEM2_HMGB4 (127540),DEMETER2_COM,noncancer,histamine receptor agonist,HRH4,,,Preclinical,0.241808300126673,0.084780360922,4-methylhistamine,,,0,0
BRD-K70898774-001-03-5::2.5::HTS,BRD-K70898774-001-03-5,naloxone-benzoylhydrazone,2.5,HTS,CRISPR_NEDD4L (23327),AVANA_PUBLIC_18Q2,noncancer,opioid receptor antagonist,"OPRK1, OPRM1",,,Preclinical,0.219173423608094,0.0619842858503,naloxone-benzoylhydrazone,,,0,0
BRD-K70912147-001-01-8::2.5::HTS,BRD-K70912147-001-01-8,co-102862,2.5,HTS,METABOL_C48:2 TAG,METABOL,noncancer,,"SCN4A, SCN9A",,,Phase 1,0.283482057796915,0.150883500953,co-102862,,,0,0
BRD-K70914287-300-02-8::2.5::HTS,BRD-K70914287-300-02-8,BIBX-1382,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.403801716843192,0.463004979652,BIBX-1382,EGFR INHIBITOR,0.4040055637319845,1.0690363733856905,-5.400798738935901
BRD-K70924353-001-01-2::2.5::HTS,BRD-K70924353-001-01-2,amtolmetin-guacil,2.5,HTS,METABOL_isoleucine,METABOL,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.25730540640357996,0.10252919628,amtolmetin-guacil,,,0,0
BRD-K71026158-304-01-0::2.397404387::MTS004,BRD-K71026158-304-01-0,carumonam,2.397404387,MTS004,CRISPR_KMT2A (4297),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, gram-negative bacterial infections",Launched,0.25337759733658,0.132919076171,carumonam,,,0,0
BRD-K71035033-001-07-1::2.5::HTS,BRD-K71035033-001-07-1,masitinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,noncancer,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,Launched,0.257065825663453,0.28991826598,masitinib,,,0,0
BRD-K71055333-224-05-8::2.5::HTS,BRD-K71055333-224-05-8,etamsylate,2.5,HTS,CRISPR_SNX8 (29886),AVANA_PUBLIC_18Q2,noncancer,haemostatic agent,,hematology,hemorrhage,Launched,0.274124547266749,0.0526078492831,etamsylate,,,0,0
BRD-K71058253-001-01-9::2.5::HTS,BRD-K71058253-001-01-9,luliconazole,2.5,HTS,CN_CCL7 (6354),CN,noncancer,sterol demethylase inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.29014256541007394,0.0838883558344,luliconazole,,,0,0
BRD-K71059170-001-11-6::2.5::HTS,BRD-K71059170-001-11-6,cefixime,2.5,HTS,METABOL_inositol,METABOL,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, pulmonary","urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis",Launched,0.282272723315773,0.0222805156077,cefixime,,,0,0
BRD-K71075609-003-01-0::2.5::HTS,BRD-K71075609-003-01-0,dorzolamide,2.5,HTS,PROT_beta-Catenin,PROT,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",Launched,0.27220239811045,0.10787074606,dorzolamide,OTHER,0.2807751485853074,4.532269585738664,-1.3583140333048962
BRD-K71103788-003-12-0::2.5::HTS,BRD-K71103788-003-12-0,duloxetine,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)","HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy",Launched,0.279989025340145,0.136367495849,duloxetine,,,0,0
BRD-K71106091-001-06-1::2.5::HTS,BRD-K71106091-001-06-1,fludarabine-phosphate,2.5,HTS,PROT_MEK1_pS217_S221,PROT,chemo,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),Launched,0.37666253050504706,0.107465224313,fludarabine-phosphate,OTHER,0.3710802899991829,3.80373087146532,-2.0735362308109897
BRD-K71125014-001-27-1::2.5::HTS,BRD-K71125014-001-27-1,sulphadimethoxine,2.5,HTS,MIRNA_hsa-miR-512-3p,MIRNA,noncancer,dihydropteroate synthetase inhibitor,,,,Launched,0.283995217274076,0.0598897769553,sulphadimethoxine,,,0,0
BRD-K71164191-001-01-0::2.5::HTS,BRD-K71164191-001-01-0,KD-023,2.5,HTS,Exp_DUSP4 (ENSG00000120875),GE,noncancer,ACAT inhibitor,"ACACA, ACACB",,,Phase 2,0.376988146295634,0.217467960773,KD-023,OTHER,0.3800870135902778,0.17057094067218145,-4.14161885003924
BRD-K71221037-001-01-6::2.5::HTS,BRD-K71221037-001-01-6,birinapant,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, XIAP",,,Phase 2,0.513663229248262,0.460161756399,birinapant,XIAP INHIBITOR,0.5133703505319652,4.76486395628375,-2.083826417737124
BRD-K71266197-236-02-7::2.5::HTS,BRD-K71266197-236-02-7,PSB-06126,2.5,HTS,Exp_CD6 (ENSG00000013725),GE,noncancer,NTPDase inhibitor,ENTPD3,,,Preclinical,0.272133609039125,0.0590808548159,PSB-06126,,,0,0
BRD-K71289571-001-11-4::2.5::HTS,BRD-K71289571-001-11-4,zafirlukast,2.5,HTS,Exp_MARC2 (ENSG00000117791),GE,noncancer,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2",pulmonary,asthma,Launched,0.27728853631421396,0.0960737781049,zafirlukast,,,0,0
BRD-K71350836-001-02-4::2.5::HTS,BRD-K71350836-001-02-4,butalbital,2.5,HTS,METHYL_RASGRF2,METHYL,noncancer,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,"headache, muscle relaxant",Launched,0.27339309545327695,0.0823210546036,butalbital,,,0,0
BRD-K71430621-303-02-3::2.5::HTS,BRD-K71430621-303-02-3,clobenpropit,2.5,HTS,MIRNA_kshv-miR-K12-8,MIRNA,noncancer,histamine receptor antagonist,"HRH1, HRH2, HRH3, HRH4",,,Preclinical,0.347722004816636,-0.0158276858247,clobenpropit,,,0,0
BRD-K71480163-001-01-4::2.5::HTS,BRD-K71480163-001-01-4,GDC-0068,2.5,HTS,PROT_Akt_pS473,PROT,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",,,Phase 2,0.414832600260785,0.456791290483,GDC-0068,AKT INHIBITOR,0.4114147508756591,0.41947834447798,-2.188279906572796
BRD-K71499074-001-12-9::2.5::HTS,BRD-K71499074-001-12-9,diclofenamide,2.5,HTS,CRISPR_ZNF224 (7767),AVANA_PUBLIC_18Q2,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA4, CA7","ophthalmology, neurology/psychiatry","glaucoma, epilepsy",Launched,0.29643934453613,0.139934427782,diclofenamide,,,0,0
BRD-K71512533-066-02-8::2.5::HTS,BRD-K71512533-066-02-8,SNS-314,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.332236870985276,0.301854492234,SNS-314,AURORA KINASE INHIBITOR,0.33351078375907417,4.2165874946212885,-3.089086406716161
BRD-K71534238-001-10-0::2.5::HTS,BRD-K71534238-001-10-0,GW-9508,2.5,HTS,CRISPR_C17orf58 (284018),AVANA_PUBLIC_18Q2,noncancer,"free fatty acid receptor agonist, G protein-coupled receptor agonist","FFAR1, FFAR4",,,Preclinical,0.23830608469934603,0.0404961531343,GW-9508,,,0,0
BRD-K71603915-003-01-8::2.5::HTS,BRD-K71603915-003-01-8,EVP-6124,2.5,HTS,CRISPR_TRIM43 (129868),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor agonist,CHRNA7,,,Phase 3,0.29435466833987,0.0867767240987,EVP-6124,,,0,0
BRD-K71698503-003-01-6::2.5::HTS,BRD-K71698503-003-01-6,I-BZA2,2.5,HTS,CRISPR_EPHB1 (2047),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 3,0.35114940622901797,0.124923216528,I-BZA2,,,0,0
BRD-K71731651-001-04-3::2.5::HTS,BRD-K71731651-001-04-3,PNU-120596,2.5,HTS,PROT_p90RSK_Caution,PROT,noncancer,acetylcholine receptor agonist,CHRNA7,,,Preclinical,0.327367468328662,0.094944638256,PNU-120596,,,0,0
BRD-K71799949-001-36-4::2.5::HTS,BRD-K71799949-001-36-4,carbamazepine,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,carboxamide antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,Launched,0.30025978130797804,0.0447472229393,carbamazepine,,,0,0
BRD-K71822263-001-03-2::2.5::HTS,BRD-K71822263-001-03-2,D-Serine,2.5,HTS,DEM2_RRAS2 (22800),DEMETER2_COM,noncancer,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",,,Launched,0.27157973135138197,0.0273745092281,D-Serine,,,0,0
BRD-K71823332-001-03-7::2.5::HTS,BRD-K71823332-001-03-7,epothilone-a,2.5,HTS,Exp_TP53INP1 (ENSG00000164938),GE,chemo,microtubule stabilizing agent,,,,Preclinical,0.40867938337677395,0.204401581311,epothilone-a,OTHER,0.4075783057456101,6.166653726361832,-1.752809426720857
BRD-K71847383-001-12-5::2.5::HTS,BRD-K71847383-001-12-5,cytarabine,2.5,HTS,METHYL_HNRNPA3P1,METHYL,chemo,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)",Launched,0.33607415171186106,0.102598229946,cytarabine,,,0,0
BRD-K71926323-001-13-8::2.5::HTS,BRD-K71926323-001-13-8,marbofloxacin,2.5,HTS,MIRNA_hcmv-miR-UL148D,MIRNA,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.282422685600176,0.12415123954,marbofloxacin,,,0,0
BRD-K71926323-001-14-6::2.52::HTS,BRD-K71926323-001-14-6,marbofloxacin,2.52,HTS,MIRNA_hsa-miR-197,MIRNA,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.282422685600176,0.12415123954,marbofloxacin,,,0,0
BRD-K71977764-001-01-2::2.5::MTS004,BRD-K71977764-001-01-2,piroximone,2.5,MTS004,DEM2_LIMS3-LOC440895 (100271835),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,PDE3A,,,Phase 2,0.284261060192779,0.128256313162,piroximone,,,0,0
BRD-K72004355-001-01-9::2.5::HTS,BRD-K72004355-001-01-9,CFTRinh-172,2.5,HTS,METABOL_valerylcarnitine/isovalerylcarnitine/2-methylbutyroylcarnitine,METABOL,noncancer,chloride channel blocker,CFTR,,,Preclinical,0.26819937388169396,0.0745330898526,CFTRinh-172,,,0,0
BRD-K72005722-001-01-2::2.5::HTS,BRD-K72005722-001-01-2,VT-464,2.5,HTS,MIRNA_hsa-miR-640,MIRNA,targeted cancer,cytochrome P450 inhibitor,CYP17A1,,,Phase 2,0.318443949122794,0.0808070549963,VT-464,,,0,0
BRD-K72029282-001-22-0::2.5::HTS,BRD-K72029282-001-22-0,probucol,2.5,HTS,DEM2_ZNF738 (148203),DEMETER2_COM,noncancer,atherogenesis inhibitor,"ABCA1, ABCB11, CES1",cardiology,coronary artery disease (CAD),Launched,0.285093574540208,-0.0180470925452,probucol,,,0,0
BRD-K72093121-001-16-3::2.5::HTS,BRD-K72093121-001-16-3,vidarabine,2.5,HTS,MUTpool_SLC5A3 (6526),MUTpool,noncancer,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)",Launched,0.288828427011611,0.0936837228047,vidarabine,,,0,0
BRD-K72093555-001-01-0::2.5::HTS,BRD-K72093555-001-01-0,procyanidin-b-2,2.5,HTS,CN_CSTF2T (23283),CN,noncancer,,,,,Phase 2,0.273472975204478,0.109347494098,procyanidin-b-2,,,0,0
BRD-K72106461-001-02-1::2.5::HTS,BRD-K72106461-001-02-1,SYM-2081,2.5,HTS,METHYL_RGS6,METHYL,noncancer,kainate receptor antagonist,"GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2",,,Preclinical,0.2374762411096,0.116624861116,SYM-2081,,,0,0
BRD-K72166146-066-05-4::2.5::HTS,BRD-K72166146-066-05-4,dihydroergotamine,2.5,HTS,MIRNA_hsa-miR-302e,MIRNA,noncancer,serotonin receptor agonist,"ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,Launched,0.277476765962272,0.056112256746,dihydroergotamine,,,0,0
BRD-K72167406-001-02-1::2.5::HTS,BRD-K72167406-001-02-1,cefditoren-pivoxil,2.5,HTS,PROT_4E-BP1,PROT,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis",Launched,0.351524390550308,0.209214527402,cefditoren-pivoxil,OTHER,0.35104612359819376,5.920965767190702,-2.077805804477647
BRD-K72167406-001-03-9::2.5::HTS,BRD-K72167406-001-03-9,cefditoren-pivoxil,2.5,HTS,Exp_C1orf100 (ENSG00000173728),GE,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis",Launched,0.351524390550308,0.172706661639,cefditoren-pivoxil,,,0,0
BRD-K72215350-001-06-5::2.5::HTS,BRD-K72215350-001-06-5,acexamic-acid,2.5,HTS,CRISPR_RELB (5971),AVANA_PUBLIC_18Q2,noncancer,5 alpha reductase inhibitor,GAST,dermatology,wound healing,Launched,0.317309981843036,0.0785772801426,acexamic-acid,,,0,0
BRD-K72222507-003-16-8::2.5::HTS,BRD-K72222507-003-16-8,quinapril,2.5,HTS,LIN_glioma,LIN,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, angioedema",Launched,0.28557843978782,0.0483328710701,quinapril,,,0,0
BRD-K72231366-001-02-3::2.5::HTS,BRD-K72231366-001-02-3,TAME,2.5,HTS,METHYL_MIR5708,METHYL,noncancer,,,,,Preclinical,0.226523146999726,0.0885326475132,TAME,,,0,0
BRD-K72259270-003-25-6::2.444857586::MTS004,BRD-K72259270-003-25-6,dyclonine,2.444857586,MTS004,Exp_ETV4 (ENSG00000175832),GE,noncancer,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,local anesthetic,Launched,0.319455093809365,0.121674056606,dyclonine,,,0,0
BRD-K72264770-001-03-2::2.5::MTS004,BRD-K72264770-001-03-2,BRD4770,2.5,MTS004,Exp_IL31RA (ENSG00000164509),GE,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.347942356677956,0.239362342001,BRD4770,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3489644759273051,3.037409906523727,-3.588044457600738
BRD-K72280606-001-01-2::2.499993939::MTS004,BRD-K72280606-001-01-2,gilteritinib,2.499993939,MTS004,CN_KLK1 (3816),CN,targeted cancer,FLT3 inhibitor,FLT3,,,Phase 3,0.35626074979837796,0.0935729420253,gilteritinib,OTHER,0.3591658410126348,1.6538711566906423,-2.378962043736041
BRD-K72327355-001-14-7::2.5::HTS,BRD-K72327355-001-14-7,baicalein,2.5,HTS,METHYL_HNRNPA3P1,METHYL,targeted cancer,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",,,Preclinical,0.382081033146156,0.215479518197,baicalein,OTHER,0.3895300992039917,-3.45343489104397,0.22187840784613003
BRD-K72339976-065-02-1::2.5::HTS,BRD-K72339976-065-02-1,cefoselis,2.5,HTS,CRISPR_C6orf223 (221416),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,,,Launched,0.281831836346081,0.11838661782,cefoselis,,,0,0
BRD-K72339976-065-03-9::2.5::HTS,BRD-K72339976-065-03-9,cefoselis,2.5,HTS,CRISPR_KRTAP16-1 (100505753),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,,,Launched,0.281831836346081,0.11838661782,cefoselis,,,0,0
BRD-K72339976-065-04-7::2.5::HTS,BRD-K72339976-065-04-7,cefoselis,2.5,HTS,CRISPR_NOTCH1 (4851),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,,,Launched,0.281831836346081,0.11838661782,cefoselis,,,0,0
BRD-K72369578-001-04-1::2.5::HTS,BRD-K72369578-001-04-1,AZD4282,2.5,HTS,CRISPR_ECHDC3 (79746),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,"AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9",,,Phase 1,0.294793213432752,0.117600221073,AZD4282,,,0,0
BRD-K72384124-001-08-0::2.5::HTS,BRD-K72384124-001-08-0,sulbentine,2.5,HTS,METABOL_glutamine,METABOL,noncancer,other antifungal,,,,Preclinical,0.26238777218885,0.0817493928361,sulbentine,,,0,0
BRD-K72420232-001-12-3::2.5::HTS,BRD-K72420232-001-12-3,WZ-4002,2.5,HTS,CRISPR_WDR4 (10785),AVANA_PUBLIC_18Q2,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Preclinical,0.35196991166989294,0.28536734718,WZ-4002,EGFR INHIBITOR,0.33629188381800884,1.0668439441837938,-5.024952406324467
BRD-K72462751-001-02-7::2.5::HTS,BRD-K72462751-001-02-7,C-1,2.5,HTS,METABOL_glutamine,METABOL,noncancer,protein kinase inhibitor,PRKCA,,,Preclinical,0.264880308105594,0.055837396652,C-1,,,0,0
BRD-K72533376-001-01-2::2.5::MTS004,BRD-K72533376-001-01-2,etoposide-phosphate,2.5,MTS004,CRISPR_SUB1 (10923),AVANA_PUBLIC_18Q2,chemo,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",Launched,0.32830811110799296,0.243229613095,etoposide-phosphate,TOPOISOMERASE INHIBITOR,0.339534517699433,3.8159071045744337,-3.4806934604995035
BRD-K72542090-304-02-4::2.5::HTS,BRD-K72542090-304-02-4,clodronic-acid,2.5,HTS,MIRNA_hsa-miR-944,MIRNA,targeted cancer,bone resorption inhibitor,"SLC25A4, SLC25A5, SLC25A6","orthopedics, endocrinology, hematologic malignancy","osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma",Launched,0.278809463151293,0.1593541796,clodronic-acid,,,0,0
BRD-K72687424-001-02-6::2.5::HTS,BRD-K72687424-001-02-6,VU0364439,2.5,HTS,CRISPR_C1QTNF8 (390664),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor positive allosteric modulator,GRM4,,,Preclinical,0.215935150893217,0.0471900392717,VU0364439,,,0,0
BRD-K72703948-001-10-1::2.5::HTS,BRD-K72703948-001-10-1,ZM-447439,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Preclinical,0.37759411906597296,0.199537391082,ZM-447439,AURORA KINASE INHIBITOR,0.3795252580322136,4.382685544288516,-3.0397495078272687
BRD-K72723676-003-17-8::2.5::HTS,BRD-K72723676-003-17-8,benzethonium,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,Launched,0.399975896816741,0.487864972805,benzethonium,OTHER,0.40288718739637824,3.5046876978354913,-1.8513523645158452
BRD-K72726508-001-02-1::2.5::HTS,BRD-K72726508-001-02-1,arcyriaflavin-a,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,targeted cancer,CDK inhibitor,"CCND1, CDK4",,,Preclinical,0.41405131687230395,0.312339348209,arcyriaflavin-a,CDK INHIBITOR,0.4114360399208638,-0.2490111444072336,0.9337664608567248
BRD-K72728560-001-01-4::2.5::HTS,BRD-K72728560-001-01-4,dimetridazole,2.5,HTS,Exp_GPC5 (ENSG00000179399),GE,noncancer,bacterial DNA inhibitor,,,,Launched,0.279430260767781,0.0921356032023,dimetridazole,,,0,0
BRD-K72815923-034-01-2::2.5::HTS,BRD-K72815923-034-01-2,xanomeline,2.5,HTS,Exp_TCTEX1D4 (ENSG00000188396),GE,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",,,Phase 3,0.352562459806253,0.30540485412,xanomeline,OTHER,0.3531823979496405,5.354969698005793,-2.974644142345512
BRD-K72827473-001-01-0::2.5::HTS,BRD-K72827473-001-01-0,CEP-37440,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,ALK,,,Phase 1,0.32774569644235396,0.0904197070595,CEP-37440,OTHER,0.3321357090110255,1.1698176902265185,-2.9423659292655584
BRD-K72904818-001-01-1::2.5::HTS,BRD-K72904818-001-01-1,NNC-63-0532,2.5,HTS,Exp_ERMN (ENSG00000136541),GE,noncancer,opioid receptor agonist,OPRL1,,,Preclinical,0.287856786862035,0.0604341464962,NNC-63-0532,,,0,0
BRD-K72912098-001-02-3::2.5::HTS,BRD-K72912098-001-02-3,telaprevir,2.5,HTS,METHYL_SIX4,METHYL,noncancer,HCV inhibitor,"CTSA, PGR",infectious disease,hepatitis C,Launched,0.29556367545176,0.0265483329628,telaprevir,OTHER,0.3004689196482322,0.8452478798380322,-3.4104311364372717
BRD-K72915123-001-18-1::2.5::HTS,BRD-K72915123-001-18-1,cinchophen,2.5,HTS,METABOL_glutathione oxidized,METABOL,noncancer,analgesic agent,,rheumatology,gout,Launched,0.266140047540769,0.0303546533447,cinchophen,,,0,0
BRD-K72925150-001-11-1::2.5::HTS,BRD-K72925150-001-11-1,sclareolide,2.5,HTS,MIRNA_hsa-miR-223,MIRNA,noncancer,other antifungal,,,,Launched,0.27173486997457297,0.0200558270501,sclareolide,,,0,0
BRD-K72951360-001-01-4::2.5::HTS,BRD-K72951360-001-01-4,valrubicin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,chemo,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,Launched,0.39401892317501,0.223806057429,valrubicin,OTHER,0.3953000624723401,4.289489230790103,-1.6377493918822807
BRD-K73027814-003-01-0::2.693425643::MTS004,BRD-K73027814-003-01-0,oxyfedrine,2.693425643,MTS004,METHYL_PNPLA7,METHYL,noncancer,adrenergic receptor agonist,,cardiology,angina pectoris,Launched,0.29395218234689197,0.112377813978,oxyfedrine,,,0,0
BRD-K73028949-001-02-8::2.5::MTS004,BRD-K73028949-001-02-8,vasopressin,2.5,MTS004,MIRNA_hsa-miR-523,MIRNA,noncancer,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",gastroenterology,abdominal distension,Launched,0.270555442115682,0.0540320202062,vasopressin,,,0,0
BRD-K73073971-001-01-7::2.5::HTS,BRD-K73073971-001-01-7,ZLN005,2.5,HTS,PROT_Bap1 c-4,PROT,noncancer,,,,,Preclinical,0.29285941361489193,0.0414571611338,ZLN005,OTHER,0.2804439286711608,-4.399982315034057,-2.5678772507701426
BRD-K73107279-003-12-5::2.5::HTS,BRD-K73107279-003-12-5,levamisole,2.5,HTS,MIRNA_hsa-miR-106a+hsa-miR-17,MIRNA,targeted cancer,acetylcholine receptor agonist,"ALPL, ALPPL2, CHRNA3",,,Withdrawn,0.2946520154996681,0.070072946234,levamisole,,,0,0
BRD-K73109821-001-20-1::2.5::HTS,BRD-K73109821-001-20-1,diazoxide,2.5,HTS,Exp_LRIF1 (ENSG00000121931),GE,noncancer,potassium channel activator,"ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3",endocrinology,hypoglycemia,Launched,0.24043043626609698,0.0761313776139,diazoxide,,,0,0
BRD-K73132780-001-01-2::2.5::MTS004,BRD-K73132780-001-01-2,pyronaridine,2.5,MTS004,CRISPR_DCLK1 (9201),AVANA_PUBLIC_18Q2,noncancer,antimalarial agent,,,,Phase 3,0.30623718843259395,0.224775488809,pyronaridine,OTHER,0.3114240415709824,4.035050122554559,-2.288617293855534
BRD-K73157543-001-04-1::2.5::HTS,BRD-K73157543-001-04-1,phenyl-aminosalicylate,2.5,HTS,PROT_Fibronectin,PROT,noncancer,,,infectious disease,tuberculosis,Launched,0.260607327465524,0.0838286279871,phenyl-aminosalicylate,,,0,0
BRD-K73191876-001-11-2::2.5::HTS,BRD-K73191876-001-11-2,alizarin,2.5,HTS,CN_SPINT4 (391253),CN,noncancer,,,,,Preclinical,0.271688917427015,0.00525196089901,alizarin,,,0,0
BRD-K73196317-003-14-8::2.5::HTS,BRD-K73196317-003-14-8,urapidil,2.5,HTS,MIRNA_hsa-miR-130a,MIRNA,noncancer,adrenergic receptor antagonist,HTR1A,cardiology,hypertension,Launched,0.26965358247738896,0.0911847857119,urapidil,,,0,0
BRD-K73234506-235-02-1::2.5::HTS,BRD-K73234506-235-02-1,lithium-acetoacetate,2.5,HTS,PROT_cIAP_Caution,PROT,noncancer,,,,,Preclinical,0.283992294294607,0.0908907070547,lithium-acetoacetate,,,0,0
BRD-K73237276-001-01-0::2.5::HTS,BRD-K73237276-001-01-0,tacalcitol,2.5,HTS,Exp_CBX6 (ENSG00000183741),GE,noncancer,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",Launched,0.317052301760802,0.164100685805,tacalcitol,VITAMIN D RECEPTOR AGONIST,0.3167727195810381,0.7235614370359925,-0.7678308298395082
BRD-K73290745-003-02-6::2.5::HTS,BRD-K73290745-003-02-6,ICI-199441,2.5,HTS,RMUTmis_ELFN2 (114794),MUT,noncancer,opioid receptor agonist,"CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R",,,Preclinical,0.26629478716042704,0.0879311541669,ICI-199441,,,0,0
BRD-K73293050-001-03-1::2.5::HTS,BRD-K73293050-001-03-1,WZ-3146,2.5,HTS,PROT_Annexin 1,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.357436791682455,0.301513105205,WZ-3146,EGFR INHIBITOR,0.36674171904919295,4.609658662141582,-1.2387756047800345
BRD-K73303757-001-21-6::2.5::HTS,BRD-K73303757-001-21-6,4-methylgenistein,2.5,HTS,PROT_p38_pT180_Y182,PROT,targeted cancer,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",,,Preclinical,0.286289438418053,0.0509126845219,4-methylgenistein,,,0,0
BRD-K73309154-003-02-8::2.5::HTS,BRD-K73309154-003-02-8,OSI-420,2.5,HTS,PROT_Shc_pY317,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.498378189722727,0.501159691586,OSI-420,EGFR INHIBITOR,0.4934040148112999,1.1035948997745575,-4.969230814816026
BRD-K73319509-001-08-0::2.5::HTS,BRD-K73319509-001-08-0,PF-04217903,2.5,HTS,METHYL_SFTPC,METHYL,targeted cancer,c-Met inhibitor,MET,,,Phase 1,0.35602650006678904,0.0671965156864,PF-04217903,,,0,0
BRD-K73323637-003-10-9::2.5::HTS,BRD-K73323637-003-10-9,levobunolol-(+),2.5,HTS,METABOL_inositol,METABOL,noncancer,adrenergic receptor antagonist,,,,Preclinical,0.23941168684657899,0.0831332919887,levobunolol-(+),,,0,0
BRD-K73368362-001-07-5::2.5::HTS,BRD-K73368362-001-07-5,BIX-02189,2.5,HTS,METHYL_CTXN1,METHYL,targeted cancer,MEK inhibitor,"MAP2K5, MAPK7",,,Preclinical,0.281167031193462,0.103945536849,BIX-02189,,,0,0
BRD-K73381198-001-01-1::2.5::HTS,BRD-K73381198-001-01-1,5-fluoro-3-pyridyl-methanol,2.5,HTS,Exp_MAMLD1 (ENSG00000013619),GE,noncancer,,,,,Preclinical,0.296515977962419,0.0920574314056,5-fluoro-3-pyridyl-methanol,,,0,0
BRD-K73381542-003-23-4::2.5::HTS,BRD-K73381542-003-23-4,phenylephrine,2.5,HTS,METHYL_LINC01355,METHYL,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D","otolaryngology, gastroenterology, cardiology","nasal congestion, hemorrhoids, hypotension",Launched,0.28452782289042,0.108752664761,phenylephrine,,,0,0
BRD-K73383190-001-02-3::2.56::HTS,BRD-K73383190-001-02-3,C646,2.56,HTS,METHYL_LRRN4,METHYL,targeted cancer,histone acetyltransferase inhibitor,EP300,,,Preclinical,0.32328175231017,0.171957151883,C646,OTHER,0.3434601805321126,4.729383900676836,-2.2020744456356938
BRD-K73383190-001-03-1::2.5::HTS,BRD-K73383190-001-03-1,C646,2.5,HTS,METHYL_PJA1,METHYL,targeted cancer,histone acetyltransferase inhibitor,EP300,,,Preclinical,0.32328175231017,0.171957151883,C646,,,0,0
BRD-K73391359-003-10-2::2.5::HTS,BRD-K73391359-003-10-2,dimethisoquin,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,local anesthetic,,neurology/psychiatry,local anesthetic,Launched,0.27783280773602503,0.0824445447356,dimethisoquin,,,0,0
BRD-K73394555-237-01-1::2.5::HTS,BRD-K73394555-237-01-1,oxolinic-acid,2.5,HTS,CRISPR_RCE1 (9986),AVANA_PUBLIC_18Q2,noncancer,bacterial DNA gyrase inhibitor,,,,Preclinical,0.315843537245193,0.0361112468677,oxolinic-acid,,,0,0
BRD-K73397362-001-06-6::2.5::HTS,BRD-K73397362-001-06-6,purmorphamine,2.5,HTS,CN_P2RY2 (5029),CN,noncancer,smoothened receptor agonist,SMO,,,Preclinical,0.311641342992375,0.0553774841643,purmorphamine,,,0,0
BRD-K73425385-065-04-8::2.5::HTS,BRD-K73425385-065-04-8,bekanamycin,2.5,HTS,METABOL_sucrose,METABOL,noncancer,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.235664558506977,0.0782078258665,bekanamycin,,,0,0
BRD-K73440166-001-01-3::2.5::HTS,BRD-K73440166-001-01-3,cinaciguat,2.5,HTS,RMUTdmg_BAZ2B (29994),MUTdmg,noncancer,guanylate cyclase activator,"GUCY1A3, GUCY1B3",,,Phase 2,0.22114884031904702,0.0216405561679,cinaciguat,,,0,0
BRD-K73451719-001-01-2::2.5::MTS004,BRD-K73451719-001-01-2,terlipressin,2.5,MTS004,CRISPR_TTLL6 (284076),AVANA_PUBLIC_18Q2,noncancer,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2",cardiology,hypotension,Launched,0.2800133722205,0.123751831276,terlipressin,,,0,0
BRD-K73469236-001-01-8::2.5::HTS,BRD-K73469236-001-01-8,nedaplatin,2.5,HTS,CN_TP63 (8626),CN,chemo,DNA inhibitor,,,,Launched,0.283709012002703,-0.054967597922,nedaplatin,,,0,0
BRD-K73477617-001-08-5::2.5::HTS,BRD-K73477617-001-08-5,dibutyl-phthalate,2.5,HTS,MIRNA_hsa-miR-520d-5p+hsa-miR-527+hsa-miR-518a-5p,MIRNA,noncancer,,TRPA1,,,Preclinical,0.29191625635198803,0.0776638130854,dibutyl-phthalate,,,0,0
BRD-K73504359-001-01-3::2.5::MTS004,BRD-K73504359-001-01-3,bivalirudin,2.5,MTS004,METHYL_TNFRSF19,METHYL,noncancer,thrombin inhibitor,F2,cardiology,angina pectoris,Launched,0.277984364263056,0.1917509324,bivalirudin,,,0,0
BRD-K73524797-001-01-1::2.5::HTS,BRD-K73524797-001-01-1,ST-1859,2.5,HTS,Exp_KATNA1 (ENSG00000186625),GE,noncancer,antiamyloidogenic agent,,,,Phase 1,0.252200132535037,0.0949849117723,ST-1859,,,0,0
BRD-K73529671-001-02-9::2.5::HTS,BRD-K73529671-001-02-9,troxerutin,2.5,HTS,METHYL_SMIM22,METHYL,noncancer,antioxidant,,,,Launched,0.271582700581713,0.0733358345977,troxerutin,,,0,0
BRD-K73529671-001-04-5::2.5::HTS,BRD-K73529671-001-04-5,troxerutin,2.5,HTS,DEM2_RING1 (6015),DEMETER2_COM,noncancer,antioxidant,,,,Launched,0.271582700581713,0.0590904349556,troxerutin,,,0,0
BRD-K73541271-001-03-6::2.5::HTS,BRD-K73541271-001-03-6,etofenamate,2.5,HTS,Exp_EPHA5 (ENSG00000145242),GE,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",Launched,0.22127919915332,0.0245672637376,etofenamate,,,0,0
BRD-K73585091-001-02-3::2.499988098::MTS004,BRD-K73585091-001-02-3,GS-9620,2.499988098,MTS004,MIRNA_hsa-miR-135b,MIRNA,noncancer,toll-like receptor agonist,TLR7,,,Phase 2,0.215479705603536,0.0734901906115,GS-9620,,,0,0
BRD-K73589401-001-23-6::2.5::HTS,BRD-K73589401-001-23-6,corticosterone,2.5,HTS,MIRNA_hsa-miR-153,MIRNA,noncancer,mineralocorticoid receptor agonist,"HSD11B1, NCOA1, NR3C2",,,Preclinical,0.267425789491328,0.109759865771,corticosterone,OTHER,0.2680238073401909,-4.382041803566448,-2.4680194819580734
BRD-K73589491-001-11-2::2.5::HTS,BRD-K73589491-001-11-2,nizatidine,2.5,HTS,CRISPR_ANKRD13D (338692),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)",Launched,0.23367687691234199,0.0321746582981,nizatidine,,,0,0
BRD-K73642618-001-13-3::2.5::HTS,BRD-K73642618-001-13-3,bromopride,2.5,HTS,CN_MAP4K5 (11183),CN,noncancer,dopamine receptor antagonist,DRD2,gastroenterology,"nausea, vomiting, gastroesophageal reflux disease (GERD)",Launched,0.23081912175900102,0.0573806017085,bromopride,,,0,0
BRD-K73700643-001-11-2::2.5::HTS,BRD-K73700643-001-11-2,N-acetyltryptamine,2.5,HTS,CRISPR_ARHGAP25 (9938),AVANA_PUBLIC_18Q2,noncancer,melatonin receptor agonist,,,,Preclinical,0.329844682290348,0.0494554027265,N-acetyltryptamine,,,0,0
BRD-K73753850-003-01-6::2.499957259::MTS004,BRD-K73753850-003-01-6,hexaminolevulinate,2.499957259,MTS004,MIRNA_hsa-miR-23b,MIRNA,noncancer,,,radiology,diagnostic agent,Launched,0.441446465470363,0.136649855534,hexaminolevulinate,OTHER,0.4319704613340083,3.460978002226237,-3.065251975385868
BRD-K73771095-001-02-5::2.44::HTS,BRD-K73771095-001-02-5,geniposidic-acid,2.44,HTS,METHYL_FAM53A,METHYL,noncancer,cyclooxygenase inhibitor,,,,Preclinical,0.24795911002460896,0.0123092463066,geniposidic-acid,,,0,0
BRD-K73771095-001-03-3::2.5::HTS,BRD-K73771095-001-03-3,geniposidic-acid,2.5,HTS,PROT_p21,PROT,noncancer,cyclooxygenase inhibitor,,,,Preclinical,0.35047448175065005,0.0928887329552,geniposidic-acid,,,0,0
BRD-K73789395-001-10-7::2.5::HTS,BRD-K73789395-001-10-7,ZM-336372,2.5,HTS,DEM2_NDUFC2-KCTD14 (100532726),DEMETER2_COM,targeted cancer,RAF inhibitor,"BRAF, LCK, MAPK14, RAF1",,,Preclinical,0.272441413464613,0.124458207256,ZM-336372,,,0,0
BRD-K73815512-001-02-5::2.5::HTS,BRD-K73815512-001-02-5,HC-030031,2.5,HTS,MIRNA_hsa-miR-518b,MIRNA,noncancer,TRPA1 channel blocker,TRPA1,,,Phase 1,0.22595427235089802,0.0491177180336,HC-030031,,,0,0
BRD-K73881242-003-04-6::2.500023768::MTS004,BRD-K73881242-003-04-6,arbidol,2.500023768,MTS004,MIRNA_hsa-miR-603,MIRNA,noncancer,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection,Launched,0.271027784757693,0.10895620867,arbidol,,,0,0
BRD-K73923631-003-02-9::2.5::HTS,BRD-K73923631-003-02-9,difloxacin,2.5,HTS,METABOL_lactose,METABOL,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,"skin infections, urinary tract infections",Launched,0.305483362785628,0.11097064073,difloxacin,,,0,0
BRD-K73982490-001-02-9::2.5::HTS,BRD-K73982490-001-02-9,BI-78D3,2.5,HTS,Exp_FOPNL (ENSG00000133393),GE,noncancer,JNK inhibitor,MAPK8,,,Preclinical,0.373472134569755,0.261153520931,BI-78D3,OTHER,0.3747349193102292,4.268234662849748,-1.4063713358685712
BRD-K73999723-001-11-3::2.5::HTS,BRD-K73999723-001-11-3,telmisartan,2.5,HTS,METHYL_KRT27,METHYL,noncancer,angiotensin receptor antagonist,"AGTR1, PPARG",cardiology,hypertension,Launched,0.266201746684401,0.103465757577,telmisartan,,,0,0
BRD-K74057757-001-01-9::2.5::HTS,BRD-K74057757-001-01-9,indibulin,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,tubulin polymerization inhibitor,,,,Phase 1/Phase 2,0.380745566726054,0.30481776312,indibulin,TUBULIN POLYMERIZATION INHIBITOR,0.379766055927822,5.4940067014415925,-3.001937312625638
BRD-K74065929-001-07-2::2.5::HTS,BRD-K74065929-001-07-2,doramapimod,2.5,HTS,CN_NSF (4905),CN,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK13, MAPK14",,,Phase 2,0.32715287075040506,0.103869246435,doramapimod,,,0,0
BRD-K74117820-066-10-8::2.5::HTS,BRD-K74117820-066-10-8,nelfinavir,2.5,HTS,DEM2_KRT4 (3851),DEMETER2_COM,noncancer,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.29990471131638796,0.0480711855439,nelfinavir,,,0,0
BRD-K74141488-003-11-2::2.5::HTS,BRD-K74141488-003-11-2,naftifine,2.5,HTS,RMUThot_NRAS (4893),MUThot,noncancer,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.27656132147506607,0.0977700153892,naftifine,,,0,0
BRD-K74186897-001-12-4::2.5::HTS,BRD-K74186897-001-12-4,cytisine,2.5,HTS,PROT_Collagen_VI,PROT,noncancer,acetylcholine receptor agonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4",neurology/psychiatry,nicotinism,Launched,0.24597071651990696,0.0994209979424,cytisine,,,0,0
BRD-K74190368-001-04-3::2.5::HTS,BRD-K74190368-001-04-3,resorcinol,2.5,HTS,CN_LRRIQ3 (127255),CN,noncancer,phosphodiesterase inhibitor,"CA12, CA14, CA2, PTGS1",dermatology,"acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis",Launched,0.228232200609751,0.0867989931916,resorcinol,,,0,0
BRD-K74195153-050-12-1::2.5::HTS,BRD-K74195153-050-12-1,irsogladine,2.5,HTS,PROT_MIG-6,PROT,noncancer,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD),Launched,0.26310603587111997,0.0722272923779,irsogladine,,,0,0
BRD-K74227499-001-01-1::2.5::HTS,BRD-K74227499-001-01-1,se-methylselenocysteine,2.5,HTS,MUTpool_PHIP (55023),MUTpool,targeted cancer,,,,,Phase 2,0.0925911309377555,0.106988103918,se-methylselenocysteine,,,0,0
BRD-K74236984-001-04-8::2.5::MTS004,BRD-K74236984-001-04-8,UNC0321,2.5,MTS004,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.44295631285260706,0.271298971017,UNC0321,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4083356588590553,5.8632179975804135,-1.3225108817662052
BRD-K74305673-001-06-2::2.5::HTS,BRD-K74305673-001-06-2,IKK-2-inhibitor-V,2.5,HTS,Exp_PDK1 (ENSG00000152256),GE,targeted cancer,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,,,Phase 1,0.3693223990864679,0.284117600093,IKK-2-inhibitor-V,OTHER,0.3699498297759085,3.9517341243558346,-1.6614229780439596
BRD-K74339692-001-01-9::2.5::HTS,BRD-K74339692-001-01-9,tamsulosin,2.5,HTS,MIRNA_hsa-miR-106a+hsa-miR-17,MIRNA,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),Launched,0.334813687667645,0.150080584506,tamsulosin,,,0,0
BRD-K74363950-004-01-0::2.5::HTS,BRD-K74363950-004-01-0,aclidinium,2.5,HTS,Exp_IFI16 (ENSG00000163565),GE,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)",Launched,0.24580001527713102,0.132061580733,aclidinium,,,0,0
BRD-K74371986-001-01-7::2.5::HTS,BRD-K74371986-001-01-7,NSI-189,2.5,HTS,METHYL_FGD4,METHYL,noncancer,neurotrophic agent,,,,Phase 2,0.266138928453439,0.127206278505,NSI-189,,,0,0
BRD-K74501079-001-18-1::2.5::HTS,BRD-K74501079-001-18-1,azithromycin,2.5,HTS,CRISPR_PRR23D2 (100133251),AVANA_PUBLIC_18Q2,noncancer,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia",Launched,0.224587804884305,-0.083275098319,azithromycin,,,0,0
BRD-K74514084-001-03-9::2.5::HTS,BRD-K74514084-001-03-9,pazopanib,2.5,HTS,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)",Launched,0.368346445231315,0.207058645193,pazopanib,OTHER,0.3750745618453133,0.8877095529391413,-2.216170319595117
BRD-K74603273-003-01-1::2.5::HTS,BRD-K74603273-003-01-1,"ICI-118,551",2.5,HTS,METHYL_PMS2P5,METHYL,noncancer,adrenergic receptor antagonist,"ADRB2, ADRB3",,,Phase 2,0.266302517386633,0.0667627100908,"ICI-118,551",,,0,0
BRD-K74664543-213-01-2::2.5::HTS,BRD-K74664543-213-01-2,selenomethionine,2.5,HTS,CRISPR_FAXDC2 (10826),AVANA_PUBLIC_18Q2,targeted cancer,,,,,Launched,0.320455054123312,0.156219001373,selenomethionine,,,0,0
BRD-K74671368-001-01-8::2.5::MTS004,BRD-K74671368-001-01-8,idronoxil,2.5,MTS004,Exp_NAALAD2 (ENSG00000077616),GE,targeted cancer,XIAP inhibitor,"ENOX2, SPHK1",,,Phase 3,0.40205972717322996,0.214343479422,idronoxil,XIAP INHIBITOR,0.3986319019790872,3.2279785564069567,-4.109913970465246
BRD-K74717603-001-02-2::2.5::HTS,BRD-K74717603-001-02-2,etravirine,2.5,HTS,CN_ACSM4 (341392),CN,noncancer,non-nucleoside reverse transcriptase inhibitor,"CYP2C19, CYP2C9, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.292635645045282,0.159013383635,etravirine,,,0,0
BRD-K74759733-065-01-4::2.5::MTS004,BRD-K74759733-065-01-4,isepamicin,2.5,MTS004,PROT_PKC-pan_BetaII_pS660,PROT,noncancer,protein synthesis inhibitor,,infectious disease,"pneumonia, peritonitis",Launched,0.314939494660678,0.107064119866,isepamicin,,,0,0
BRD-K74763371-002-04-0::2.5::HTS,BRD-K74763371-002-04-0,bosentan,2.5,HTS,METHYL_TRDMT1,METHYL,noncancer,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),Launched,0.18847576722545198,0.047462537718,bosentan,,,0,0
BRD-K74765201-001-16-7::0.25::HTS,BRD-K74765201-001-16-7,tomelukast,0.25,HTS,Exp_KLKB1 (ENSG00000164344),GE,noncancer,leukotriene receptor antagonist,CYSLTR1,,,Phase 3,0.273671835958,-0.0187410571107,tomelukast,,,0,0
BRD-K74913225-001-12-4::2.5::HTS,BRD-K74913225-001-12-4,brinzolamide,2.5,HTS,METHYL_CWF19L2,METHYL,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA5A, CA7",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",Launched,0.267172531798159,0.0310311007124,brinzolamide,,,0,0
BRD-K74990253-001-02-8::2.5::HTS,BRD-K74990253-001-02-8,BW-373U86,2.5,HTS,METHYL_CA8,METHYL,noncancer,opioid receptor agonist,OPRD1,,,Preclinical,0.26985520064044605,0.116981953615,BW-373U86,,,0,0
BRD-K75009076-001-02-1::2.43::HTS,BRD-K75009076-001-02-1,SCH-900776,2.43,HTS,Exp_PRKD3 (ENSG00000115825),GE,targeted cancer,CHK inhibitor,"CDK2, CHEK1",,,Phase 2,0.42185948950345004,0.216424262193,SCH-900776,OTHER,0.4205282807654488,3.0814688080980184,-3.3114744772725624
BRD-K75024268-001-01-0::2.5::HTS,BRD-K75024268-001-01-0,lesinurad,2.5,HTS,METHYL_PRUNE,METHYL,noncancer,uric acid diuretic,SLC22A12,rheumatology,gout,Launched,0.311859174387011,0.0289157187708,lesinurad,,,0,0
BRD-K75037734-003-13-9::2.5::HTS,BRD-K75037734-003-13-9,carbachol,2.5,HTS,Exp_SPTLC1P1 (ENSG00000230397),GE,noncancer,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,Launched,0.28164349824164897,0.0576530740885,carbachol,,,0,0
BRD-K75080769-001-01-6::2.5::HTS,BRD-K75080769-001-01-6,"trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",2.5,HTS,CRISPR_ADCY9 (115),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.29622201571851803,0.0948078157187,"trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",,,0,0
BRD-K75089421-003-24-5::2.5::HTS,BRD-K75089421-003-24-5,procainamide,2.5,HTS,RMUTmis_CHL1 (10752),MUTmis,noncancer,sodium channel blocker,"DNMT1, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)",Launched,0.21533858471589498,0.0338592791805,procainamide,,,0,0
BRD-K75250001-001-01-3::2.5::HTS,BRD-K75250001-001-01-3,tiracizine,2.5,HTS,RMUTmis_KPNA4 (3840),MUT,noncancer,sodium channel blocker,SCN5A,,,Withdrawn,0.262299040136177,0.078338015909,tiracizine,,,0,0
BRD-K75282704-001-02-4::2.5::HTS,BRD-K75282704-001-02-4,BL-5583,2.5,HTS,DEM2_GPER1 (2852),DEMETER2_COM,noncancer,hypercalcaemic agent,,,,Preclinical,0.268553577930669,0.0966111752134,BL-5583,,,0,0
BRD-K75295174-001-05-0::2.5::HTS,BRD-K75295174-001-05-0,alisertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Phase 3,0.38575343325704603,0.269986299385,alisertib,AURORA KINASE INHIBITOR,0.38946205930071937,3.385814165394237,-4.1007378305518065
BRD-K75308783-001-07-0::2.5::HTS,BRD-K75308783-001-07-0,SAR-245409,2.5,HTS,CRISPR_DNLZ (728489),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"MTOR, PIK3CG",,,Phase 1/Phase 2,0.21466195848199301,0.119185384399,SAR-245409,,,0,0
BRD-K75352575-001-01-3::2.5::HTS,BRD-K75352575-001-01-3,KPT-276,2.5,HTS,Exp_DDX19B (ENSG00000157349),GE,targeted cancer,exportin antagonist,XPO1,,,Preclinical,0.35385999330843604,0.278640317854,KPT-276,OTHER,0.3547195934577096,4.9870774755903,-0.6295462681594706
BRD-K75360161-001-18-0::2.5::HTS,BRD-K75360161-001-18-0,protionamide,2.5,HTS,METABOL_C54:7 TAG,METABOL,noncancer,,,infectious disease,tuberculosis,Launched,0.224595531157766,0.00733098041108,protionamide,,,0,0
BRD-K75385383-001-01-5::2.548558667::MTS004,BRD-K75385383-001-01-5,DIPT,2.548558667,MTS004,PROT_Chk2,PROT,noncancer,"dopamine reuptake inhibitor, serotonin reuptake inhibitor","HTR1A, HTR2A, HTR2C",,,Launched,0.279719470497527,0.082876246729,DIPT,,,0,0
BRD-K75445017-001-01-1::2.5::MTS004,BRD-K75445017-001-01-1,estetrol,2.5,MTS004,Exp_CYP4F2 (ENSG00000186115),GE,targeted cancer,selective estrogen receptor modulator (SERM),ESR1,,,Phase 3,0.254529969621891,0.038233646954,estetrol,,,0,0
BRD-K75466013-001-14-4::2.5::HTS,BRD-K75466013-001-14-4,benzocaine,2.5,HTS,METHYL_MIR6859-2,METHYL,noncancer,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,Launched,0.27650051394992603,0.110529040557,benzocaine,,,0,0
BRD-K75478907-001-02-3::2.5::HTS,BRD-K75478907-001-02-3,GS-39783,2.5,HTS,METHYL_CXorf36,METHYL,noncancer,GABA receptor modulator,GABBR1,,,Preclinical,0.226904585928507,0.0711939097848,GS-39783,,,0,0
BRD-K75506300-001-01-6::2.5::HTS,BRD-K75506300-001-01-6,NPS-2143,2.5,HTS,CN_DKK4 (27121),CN,noncancer,calcium receptor antagonist,CASR,,,Preclinical,0.259323879071861,0.0174984335523,NPS-2143,,,0,0
BRD-K75516118-001-03-3::2.5::HTS,BRD-K75516118-001-03-3,rolipram-R(-),2.5,HTS,CRISPR_CDH10 (1008),AVANA_PUBLIC_18Q2,noncancer,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D, PDE5A",,,Preclinical,0.20908087255557803,0.107567529532,rolipram-R(-),,,0,0
BRD-K75527158-360-04-9::2.5::HTS,BRD-K75527158-360-04-9,alendronate,2.5,HTS,CN_COLEC12 (81035),CN,noncancer,bone resorption inhibitor,"ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS",orthopedics,osteoporosis,Launched,0.300236186980536,0.0883590806723,alendronate,,,0,0
BRD-K75608666-001-08-3::2.5::HTS,BRD-K75608666-001-08-3,hydroxytoluic-acid,2.5,HTS,DEM2_KCNN1 (3780),DEMETER2_COM,noncancer,,,,,Preclinical,0.24253186812096,0.0537818094065,hydroxytoluic-acid,,,0,0
BRD-K75615183-300-03-9::2.5::HTS,BRD-K75615183-300-03-9,talipexole,2.5,HTS,DEM2_ZNF563 (147837),DEMETER2_COM,noncancer,"adrenergic receptor agonist, dopamine receptor agonist","ADRA2A, DRD2, HTR3A",infectious disease,genitial herpes,Launched,0.314476800780347,0.00680363461481,talipexole,OTHER,0.2872542075446177,-4.322859524831006,-2.4888734146992673
BRD-K75641298-003-25-0::2.5::HTS,BRD-K75641298-003-25-0,metoclopramide,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","CHRM1, DRD2, HTR3A, HTR3B, HTR4",gastroenterology,"gastroparesis, nausea, vomiting",Launched,0.250257914804893,0.0962223781184,metoclopramide,,,0,0
BRD-K75649340-001-13-1::2.5::HTS,BRD-K75649340-001-13-1,tioguanine,2.5,HTS,METHYL_SLC43A3,METHYL,targeted cancer,purine antagonist,,,,Phase 2,0.404745198943381,0.31852120818,tioguanine,OTHER,0.396241943576411,4.018819101350218,-3.8959521894174927
BRD-K75699339-057-08-1::2.5::HTS,BRD-K75699339-057-08-1,rizatriptan,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,Launched,0.27786264914954,0.0966033875497,rizatriptan,,,0,0
BRD-K75844781-003-08-0::2.5::HTS,BRD-K75844781-003-08-0,mCPP,2.5,HTS,METHYL_MGST3,METHYL,noncancer,serotonin receptor agonist,"HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6",,,Phase 2,0.253418217226433,0.14943272305,mCPP,,,0,0
BRD-K75855670-001-14-2::2.5::HTS,BRD-K75855670-001-14-2,iodoquinol,2.5,HTS,MIRNA_hsa-miR-141,MIRNA,noncancer,antiseptic,,infectious disease,amebiasis,Launched,0.294696380877715,0.0997358130124,iodoquinol,,,0,0
BRD-K75868704-001-05-3::2.5::HTS,BRD-K75868704-001-05-3,iopamidol,2.5,HTS,DEM2_ZNF320 (162967),DEMETER2_COM,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.32073607637986606,0.113346414644,iopamidol,,,0,0
BRD-K75911534-001-01-6::2.5::HTS,BRD-K75911534-001-01-6,SU014813,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,Phase 2,0.28002547514731607,0.270261834357,SU014813,OTHER,0.3111302693401125,-0.11698942133317446,-2.46618881723885
BRD-K75923785-003-02-1::2.5::HTS,BRD-K75923785-003-02-1,scopine,2.5,HTS,PROT_p38_pT180_Y182,PROT,noncancer,,,,,Launched,0.24608119461208702,0.0501263713249,scopine,,,0,0
BRD-K75956464-237-01-5::2.5::HTS,BRD-K75956464-237-01-5,VCH-916,2.5,HTS,Exp_LRP2BP (ENSG00000109771),GE,noncancer,HCV inhibitor,,,,Phase 1,0.25219108107314603,0.0645020322334,VCH-916,,,0,0
BRD-K75958195-037-09-4::2.5::HTS,BRD-K75958195-037-09-4,pizotifen,2.5,HTS,RMUTdmg_ZNF616 (90317),MUTdmg,noncancer,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C",neurology/psychiatry,migraine headache,Launched,0.32959070287375,-0.0154116005341,pizotifen,,,0,0
BRD-K75958547-238-01-0::2.5::HTS,BRD-K75958547-238-01-0,pitavastatin,2.5,HTS,Exp_GPX2 (ENSG00000176153),GE,noncancer,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,Launched,0.4809389037573929,0.43929497599,pitavastatin,HMGCR INHIBITOR,0.4812966784487095,1.8486395467600676,4.833342295739994
BRD-K76011241-001-01-8::2.5::HTS,BRD-K76011241-001-01-8,oseltamivir-phosphate,2.5,HTS,METHYL_PINK1-AS,METHYL,noncancer,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,Launched,0.298530680269033,0.0756670116471,oseltamivir-phosphate,,,0,0
BRD-K76022557-003-02-7::2.5::HTS,BRD-K76022557-003-02-7,r(-)-apomorphine,2.5,HTS,CRISPR_TMEM259 (91304),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor agonist,"DRD2, HTR5A",neurology/psychiatry,Parkinson's Disease,Launched,0.21285137119528896,0.112093094334,r(-)-apomorphine,,,0,0
BRD-K76037122-001-02-5::2.5::HTS,BRD-K76037122-001-02-5,guanidine,2.5,HTS,MUTpool_DNAH9 (1770),MUTpool,noncancer,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),Launched,0.277243203946741,0.103414303643,guanidine,,,0,0
BRD-K76064317-001-07-3::2.5::HTS,BRD-K76064317-001-07-3,tyrphostin-AG-1296,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,targeted cancer,FLT3 inhibitor,FLT3,,,Preclinical,0.3639403159978929,0.224941758706,tyrphostin-AG-1296,OTHER,0.3768735058480663,-4.6085972578599765,-1.258682615934262
BRD-K76180386-001-01-6::2.5::HTS,BRD-K76180386-001-01-6,JIB04,2.5,HTS,Exp_IFI16 (ENSG00000163565),GE,noncancer,histone lysine demethylase inhibitor,KDM4E,,,Preclinical,0.46665026659609704,0.273735707306,JIB04,OTHER,0.4665582677575932,2.0392523675706555,-2.530550600913002
BRD-K76204040-001-03-8::2.5::MTS004,BRD-K76204040-001-03-8,pyridoxal,2.5,MTS004,Exp_TDGF1P5 (ENSG00000254274),GE,noncancer,,PDXK,neurology/psychiatry,epilepsy,Launched,0.23488206958748697,0.116116367088,pyridoxal,,,0,0
BRD-K76205745-237-16-5::2.5::HTS,BRD-K76205745-237-16-5,losartan,2.5,HTS,Exp_OR2I1P (ENSG00000237988),GE,noncancer,angiotensin receptor antagonist,AGTR1,"cardiology, nephrology","hypertension, diabetic nephropathy",Launched,0.23763986301815498,0.0998567738474,losartan,,,0,0
BRD-K76210423-001-01-6::2.5::HTS,BRD-K76210423-001-01-6,resiquimod,2.5,HTS,PROT_Rictor_pT1135,PROT,targeted cancer,toll-like receptor agonist,"TLR7, TLR8",,,Phase 3,0.34768506488870005,0.0859248673139,resiquimod,OTHER,0.3409986988937729,4.637021470535684,-1.1901816247037589
BRD-K76239644-001-01-8::2.5::HTS,BRD-K76239644-001-01-8,BMS-690514,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,targeted cancer,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",,,Phase 2,0.441821971624813,0.522720299356,BMS-690514,EGFR INHIBITOR,0.44202865570474464,1.4657815232256688,-4.6620873601305215
BRD-K76304753-003-20-3::2.5::HTS,BRD-K76304753-003-20-3,phenazopyridine,2.5,HTS,METHYL_TMEM201,METHYL,noncancer,local anesthetic,SCN1A,infectious disease,urinary tract infections,Launched,0.297269502006779,0.0829022524875,phenazopyridine,,,0,0
BRD-K76304753-003-21-1::2.5::HTS,BRD-K76304753-003-21-1,phenazopyridine,2.5,HTS,CRISPR_CA10 (56934),AVANA_PUBLIC_18Q2,noncancer,local anesthetic,SCN1A,infectious disease,urinary tract infections,Launched,0.297269502006779,0.0856175791148,phenazopyridine,,,0,0
BRD-K76315403-015-02-5::2.5::MTS004,BRD-K76315403-015-02-5,cetrorelix,2.5,MTS004,METHYL_LOC221122,METHYL,noncancer,gonadotropin releasing factor hormone receptor antagonist,"GNRHR, LHCGR",endocrinology,premature luteinizing hormone surges,Launched,0.313813362838712,0.19426140567,cetrorelix,,,0,0
BRD-K76381435-001-08-6::2.5::HTS,BRD-K76381435-001-08-6,nitromide,2.5,HTS,MUTpool_TRIML2 (205860),MUTpool,noncancer,,,,,Launched,0.324841560578226,0.112357075039,nitromide,,,0,0
BRD-K76406695-001-02-9::2.5::HTS,BRD-K76406695-001-02-9,CCT128930,2.5,HTS,RMUTdmg_ARID1A (8289),MUTdmg,targeted cancer,AKT inhibitor,"PKIA, PRKACA",,,Preclinical,0.35859515594513797,0.197446953645,CCT128930,AKT INHIBITOR,0.3233740980224972,0.33778552053998834,-2.0943094275959
BRD-K76452401-001-03-6::2.5::HTS,BRD-K76452401-001-03-6,piperonyl-butoxide,2.5,HTS,PROT_Rad50,PROT,noncancer,cytochrome P450 inhibitor,,infectious disease,lice,Launched,0.306979111473479,-0.000159278786664,piperonyl-butoxide,,,0,0
BRD-K76534306-001-22-7::2.5::HTS,BRD-K76534306-001-22-7,enrofloxacin,2.5,HTS,METHYL_NPLOC4,METHYL,noncancer,bacterial DNA gyrase inhibitor,,infectious disease,"gram-negative bacterial infections, gram-negative bacterial infections",Launched,0.286128064530901,0.0954394820175,enrofloxacin,,,0,0
BRD-K76568384-001-02-2::2.5::HTS,BRD-K76568384-001-02-2,PHTPP,2.5,HTS,Exp_SCARNA7 (ENSG00000238741),GE,noncancer,estrogen receptor antagonist,ESR2,,,Preclinical,0.287140494003718,0.0840073368405,PHTPP,,,0,0
BRD-K76592088-001-02-1::2.5::HTS,BRD-K76592088-001-02-1,3-carboxy-4-hydroxyphenylglycine-(R),2.5,HTS,CRISPR_NFIX (4784),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",,,Preclinical,0.201499886699204,0.0570444343406,3-carboxy-4-hydroxyphenylglycine-(R),,,0,0
BRD-K76594255-001-01-6::2.5000235::MTS004,BRD-K76594255-001-01-6,maropitant,2.5000235,MTS004,CN_XIRP2 (129446),CN,noncancer,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting,Launched,0.308103138356617,0.0890001383175,maropitant,,,0,0
BRD-K76600340-045-04-9::2.5::HTS,BRD-K76600340-045-04-9,nicotinyl-alcohol-tartrate,2.5,HTS,METHYL_ZNF749,METHYL,noncancer,,,,,Launched,0.290689213606325,0.0940494124685,nicotinyl-alcohol-tartrate,,,0,0
BRD-K76606751-001-01-7::2.5::HTS,BRD-K76606751-001-01-7,mebicar,2.5,HTS,MIRNA_ebv-miR-BART15,MIRNA,noncancer,anxiolytic,,neurology/psychiatry,anxiety,Launched,0.293429487021858,0.144241757702,mebicar,,,0,0
BRD-K76609936-001-08-4::2.5::HTS,BRD-K76609936-001-08-4,imidacloprid,2.5,HTS,CRISPR_WWOX (51741),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,CHRFAM7A,,,Launched,0.35993033901972793,0.0840303541571,imidacloprid,,,0,0
BRD-K76614248-001-01-2::2.707477898::MTS004,BRD-K76614248-001-01-2,atizoram,2.707477898,MTS004,Exp_BEST3 (ENSG00000127325),GE,noncancer,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",,,Phase 2,0.268272308789279,0.148797974724,atizoram,,,0,0
BRD-K76617868-003-11-9::2.5::HTS,BRD-K76617868-003-11-9,fasudil,2.5,HTS,METABOL_2-deoxycytidine,METABOL,noncancer,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1, ROCK2",neurology/psychiatry,cerebral vasospasm,Launched,0.227749136990816,0.112746833431,fasudil,,,0,0
BRD-K76634210-001-12-1::2.5::MTS004,BRD-K76634210-001-12-1,idoxuridine,2.5,MTS004,Exp_IGLV4-69 (ENSG00000211637),GE,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),Launched,0.313007250211217,0.310257589061,idoxuridine,OTHER,0.32122421399836193,4.220286863648485,-3.034938973151519
BRD-K76634210-001-14-7::2.5::HTS,BRD-K76634210-001-14-7,idoxuridine,2.5,HTS,Exp_CYR61 (ENSG00000142871),GE,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),Launched,0.313007250211217,0.310257589061,idoxuridine,OTHER,0.3155599337288328,3.861140058102556,-1.5157787793352604
BRD-K76677554-003-02-1::2.5::HTS,BRD-K76677554-003-02-1,AJ76-(+),2.5,HTS,PROT_MIG-6,PROT,noncancer,dopamine receptor antagonist,"DRD2, DRD3, DRD4",,,Preclinical,0.28523267870400393,0.0783240762819,AJ76-(+),,,0,0
BRD-K76719364-001-02-5::2.466617435::MTS004,BRD-K76719364-001-02-5,GS-9973,2.466617435,MTS004,CRISPR_ESR2 (2100),AVANA_PUBLIC_18Q2,noncancer,syk inhibitor,SYK,,,Phase 2,0.338430719853152,0.0979067957153,GS-9973,OTHER,0.33946238352422153,2.152663377548216,-1.1783193450742506
BRD-K76775527-001-30-2::2.5::HTS,BRD-K76775527-001-30-2,nimesulide,2.5,HTS,Exp_PYHIN1 (ENSG00000163564),GE,noncancer,cyclooxygenase inhibitor,"LTF, PLA2G2E, PTGS1, PTGS2","rheumatology, obstetrics/gynecology","osteoarthritis, menstrual pain",Launched,0.299313530187731,0.0589838694057,nimesulide,,,0,0
BRD-K76805682-001-15-9::2.5::HTS,BRD-K76805682-001-15-9,SB-415286,2.5,HTS,METHYL_METTL20,METHYL,noncancer,glycogen synthase kinase inhibitor,"GSK3A, GSK3B, RPS6KB1",,,Preclinical,0.323991055041438,0.00581759058554,SB-415286,,,0,0
BRD-K76810206-001-07-3::2.5::HTS,BRD-K76810206-001-07-3,nicergoline,2.5,HTS,CRISPR_PVR (5817),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,ADRA1A,"rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis",Launched,0.32324661131892,0.134083656401,nicergoline,,,0,0
BRD-K76810206-001-08-1::2.5::HTS,BRD-K76810206-001-08-1,nicergoline,2.5,HTS,MIRNA_hsa-miR-361-5p,MIRNA,noncancer,adrenergic receptor antagonist,ADRA1A,"rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis",Launched,0.266945453895677,0.0591565783294,nicergoline,,,0,0
BRD-K76811153-003-01-3::2.5::HTS,BRD-K76811153-003-01-3,L-Arginine,2.5,HTS,CN_RNLS (55328),CN,noncancer,nitric oxide precursor,"ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4","cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology","congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold",Launched,0.23259187122017802,0.103945247839,L-Arginine,,,0,0
BRD-K76812510-236-14-8::2.5::HTS,BRD-K76812510-236-14-8,metamizole,2.5,HTS,DEM2_G3BP1 (10146),DEMETER2_COM,noncancer,"cyclooxygenase inhibitor, opioid receptor agonist",PTGS1,,,Withdrawn,0.24872323256868203,0.0700065454095,metamizole,,,0,0
BRD-K76840893-003-02-5::2.5::HTS,BRD-K76840893-003-02-5,RS-17053,2.5,HTS,METHYL_SNORA26,METHYL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1D",,,Preclinical,0.29630667619094203,0.016324801868,RS-17053,OTHER,0.2896535490337056,2.104369094656282,-3.9917191582563936
BRD-K76841105-001-04-7::2.5::HTS,BRD-K76841105-001-04-7,tazarotene,2.5,HTS,CN_LARP1B (55132),CN,noncancer,retinoid receptor agonist,"RARA, RARB, RARG, RXRB",dermatology,"cosmetic, sunscreen lotion",Launched,0.350910378045106,0.14055480873,tazarotene,,,0,0
BRD-K76845197-001-05-4::2.5::HTS,BRD-K76845197-001-05-4,sulfanitran,2.5,HTS,PROT_Gab2,PROT,noncancer,,,,,Launched,0.25667593591862303,0.0719468796154,sulfanitran,,,0,0
BRD-K76890464-001-02-3::2.5::HTS,BRD-K76890464-001-02-3,triazolam,2.5,HTS,CN_P4HB (5034),CN,noncancer,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",,,Withdrawn,0.232371626481191,0.0762501108599,triazolam,,,0,0
BRD-K76908866-001-07-6::2.5::HTS,BRD-K76908866-001-07-6,CP-724714,2.5,HTS,PROT_S6_pS235_S236,PROT,targeted cancer,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,,,Phase 2,0.315297226304699,0.209454587058,CP-724714,,,0,0
BRD-K76927775-001-11-8::2.500019441::MTS004,BRD-K76927775-001-11-8,nitrofurantoin,2.500019441,MTS004,DEM2_ANK1 (286),DEMETER2_COM,noncancer,DNA inhibitor,,infectious disease,"urinary tract infections, pyelonephritis",Launched,0.28408059746050396,0.0779817224131,nitrofurantoin,,,0,0
BRD-K76953762-001-08-5::2.5::HTS,BRD-K76953762-001-08-5,indoramin,2.5,HTS,CN_WNK1 (65125),CN,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension",Launched,0.227193890955417,0.0518636017471,indoramin,,,0,0
BRD-K76973696-001-12-6::2.01::HTS,BRD-K76973696-001-12-6,tryptanthrin,2.01,HTS,Exp_MGST1 (ENSG00000008394),GE,targeted cancer,cyclooxygenase inhibitor,IDO1,,,Preclinical,0.387762714561363,0.169615243653,tryptanthrin,OTHER,0.38716731371818186,1.9917856758413623,-3.1933912802391
BRD-K77008974-001-03-2::2.5::HTS,BRD-K77008974-001-03-2,WYE-354,2.5,HTS,METHYL_SLC39A13,METHYL,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.32835703645003994,0.147994312358,WYE-354,MTOR INHIBITOR,0.3317610436516548,1.0376881663961623,-1.3438041707197628
BRD-K77012840-300-01-6::2.5::HTS,BRD-K77012840-300-01-6,AY-9944,2.5,HTS,DEM2_CENPE (1062),DEMETER2_COM,targeted cancer,hedgehog pathway modulator,,,,Preclinical,0.296797387936887,0.0451565306814,AY-9944,,,0,0
BRD-K77038618-356-01-3::2.500022896::MTS004,BRD-K77038618-356-01-3,garenoxacin,2.500022896,MTS004,DEM2_HIGD1A (25994),DEMETER2_COM,noncancer,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections,Launched,0.286916258753277,0.0842549671428,garenoxacin,,,0,0
BRD-K77060810-001-01-5::2.5::HTS,BRD-K77060810-001-01-5,AZD1283,2.5,HTS,METHYL_MIS12,METHYL,noncancer,purinergic receptor antagonist,P2RY12,,,Preclinical,0.280510928322841,0.0547693997355,AZD1283,,,0,0
BRD-K77073709-435-01-2::2.5::MTS004,BRD-K77073709-435-01-2,cefminox,2.5,MTS004,CN_ANKRD32 (84250),CN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.28842040931074603,0.0957739208125,cefminox,,,0,0
BRD-K77115421-001-02-6::2.5::HTS,BRD-K77115421-001-02-6,phthalylsulfacetamide,2.5,HTS,METABOL_glutamate,METABOL,noncancer,,,,,Preclinical,0.281944569211033,0.0357535457677,phthalylsulfacetamide,,,0,0
BRD-K77171813-034-01-8::2.5::HTS,BRD-K77171813-034-01-8,proxyfan,2.5,HTS,DEM2_SSX1 (6756),DEMETER2_COM,noncancer,histamine receptor modulator,HRH3,,,Preclinical,0.277995911043753,0.172703095101,proxyfan,,,0,0
BRD-K77175907-001-08-0::2.555048691::MTS004,BRD-K77175907-001-08-0,calcifediol,2.555048691,MTS004,METABOL_C18:1 LPC,METABOL,noncancer,vitamin D receptor agonist,VDR,,,Launched,0.41385251509397797,0.0814624717617,calcifediol,VITAMIN D RECEPTOR AGONIST,0.41085611373649855,1.0604068022038642,-0.6423104336989507
BRD-K77245796-003-01-6::2.5::HTS,BRD-K77245796-003-01-6,gamma-aminobutyric-acid,2.5,HTS,MIRNA_hsa-miR-499-3p,MIRNA,noncancer,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",,,Preclinical,0.251297010352872,0.0688036447052,gamma-aminobutyric-acid,,,0,0
BRD-K77251551-304-02-9::2.5::HTS,BRD-K77251551-304-02-9,sodium-picosulfate,2.5,HTS,Exp_PDE7B (ENSG00000171408),GE,noncancer,,,gastroenterology,constipation,Launched,0.274019399976484,0.104842028814,sodium-picosulfate,,,0,0
BRD-K77258318-001-04-6::2.5::HTS,BRD-K77258318-001-04-6,lactulose,2.5,HTS,METABOL_alpha-glycerophosphocholine,METABOL,noncancer,laxative,,gastroenterology,portal-systemic encephalopathy (PSE),Launched,0.279533461429694,0.0770940241407,lactulose,,,0,0
BRD-K77300776-001-02-5::2.5::HTS,BRD-K77300776-001-02-5,choline,2.5,HTS,Exp_PLAA (ENSG00000137055),GE,noncancer,acetylcholine precursor,"ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2",,,Phase 3,0.335193864287331,0.0857869864756,choline,,,0,0
BRD-K77320845-001-01-2::2.29566066::MTS004,BRD-K77320845-001-01-2,secoisolariciresinol-diglucoside,2.29566066,MTS004,CRISPR_HIF1AN (55662),AVANA_PUBLIC_18Q2,noncancer,antioxidant,,,,Phase 2,0.31936080619201196,0.12304967079,secoisolariciresinol-diglucoside,,,0,0
BRD-K77345217-001-05-0::2.5::HTS,BRD-K77345217-001-05-0,gallic-acid,2.5,HTS,MIRNA_hsa-miR-491-5p,MIRNA,targeted cancer,"beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP",,,Preclinical,0.293865863511466,0.0318895021573,gallic-acid,,,0,0
BRD-K77396579-300-01-0::2.5::HTS,BRD-K77396579-300-01-0,NVP-DPP728,2.5,HTS,MUTpool_CEP128 (145508),MUTpool,noncancer,dipeptidyl peptidase inhibitor,DPP4,,,Phase 2,0.266911876829573,0.0347441425293,NVP-DPP728,,,0,0
BRD-K77428767-001-01-7::2.5::MTS004,BRD-K77428767-001-01-7,UNC0224,2.5,MTS004,METABOL_C52:4 TAG,METABOL,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.334230227577135,0.0488645928152,UNC0224,,,0,0
BRD-K77432251-001-01-2::2.715966218::MTS004,BRD-K77432251-001-01-2,abafungin,2.715966218,MTS004,DEM2_MCL1 (4170),DEMETER2_COM,noncancer,sterol methyltransferase inhibitor,,,,Phase 3,0.306455091172822,0.114870225721,abafungin,,,0,0
BRD-K77484724-001-02-0::2.5::HTS,BRD-K77484724-001-02-0,adefovir,2.5,HTS,CN_DUX4L4 (441056),CN,noncancer,DNA polymerase inhibitor,,infectious disease,hepatitis B,Launched,0.305491275973771,0.0869151157768,adefovir,,,0,0
BRD-K77552740-004-01-0::2.5::HTS,BRD-K77552740-004-01-0,tiquizium,2.5,HTS,CRISPR_OR4D5 (219875),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,,neurology/psychiatry,spasms,Launched,0.31813032823022197,0.025326790196,tiquizium,,,0,0
BRD-K77554836-001-11-6::2.57::HTS,BRD-K77554836-001-11-6,triamcinolone,2.57,HTS,PROT_14-3-3_zeta,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.271628967442343,0.151095762145,triamcinolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2860553232756325,-1.2963504347586166,-2.6822110029516093
BRD-K77554836-001-14-0::2.5::HTS,BRD-K77554836-001-14-0,triamcinolone,2.5,HTS,METABOL_C36:4 PC-A,METABOL,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.271628967442343,0.132168844179,triamcinolone,GLUCOCORTICOID RECEPTOR AGONIST,0.28887639166579704,-2.2110217452817453,-3.261524715618741
BRD-K77561571-001-01-1::2.5::HTS,BRD-K77561571-001-01-1,topiroxostat,2.5,HTS,METABOL_phosphocreatine,METABOL,noncancer,xanthine oxidase inhibitor,XDH,"rheumatology, nephrology","gout, hyperuricemia",Launched,0.258765813270829,0.0832776577679,topiroxostat,,,0,0
BRD-K77564118-001-03-1::2.67296817::MTS004,BRD-K77564118-001-03-1,fenoverine,2.67296817,MTS004,CRISPR_SAMD4B (55095),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,,neurology/psychiatry,spasms,Launched,0.287822820048618,0.14464740977,fenoverine,,,0,0
BRD-K77597856-003-02-5::2.5::HTS,BRD-K77597856-003-02-5,detomidine,2.5,HTS,CRISPR_SFT2D2 (375035),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative,Launched,0.226795560817755,0.146672118293,detomidine,,,0,0
BRD-K77625799-001-07-7::2.5::HTS,BRD-K77625799-001-07-7,vandetanib,2.5,HTS,Exp_FGFR2 (ENSG00000066468),GE,targeted cancer,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),Launched,0.37330229889289707,0.402053233963,vandetanib,EGFR INHIBITOR,0.3673003579456741,1.4716504090361735,-4.637272982724372
BRD-K77627880-001-04-0::2.5::HTS,BRD-K77627880-001-04-0,A205804,2.5,HTS,PROT_Syk,PROT,noncancer,ICAM1 expression inhibitor,"ICAM1, SELE",,,Preclinical,0.316681386326056,0.0607800503754,A205804,OTHER,0.3155739741056414,1.4074977667406556,-3.7092793272732316
BRD-K77634909-001-03-5::2.5::HTS,BRD-K77634909-001-03-5,AEG3482,2.5,HTS,METABOL_C16:1 CE,METABOL,targeted cancer,HSP inducer,,,,Preclinical,0.314054514021135,0.0985349019428,AEG3482,,,0,0
BRD-K77641333-003-27-1::2.5::HTS,BRD-K77641333-003-27-1,naphazoline,2.5,HTS,MIRNA_hsa-miR-409-3p,MIRNA,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA2A",ophthalmology,eye irritation,Launched,0.29517347985515097,0.0846057399455,naphazoline,,,0,0
BRD-K77677632-003-02-6::2.5::HTS,BRD-K77677632-003-02-6,SB-200646,2.5,HTS,MUTpool_FNDC1 (84624),MUTpool,noncancer,serotonin receptor antagonist,"HTR2B, HTR2C",,,Preclinical,0.255442818113363,0.0838403893827,SB-200646,,,0,0
BRD-K77685957-300-09-1::2.5::HTS,BRD-K77685957-300-09-1,dequalinium,2.5,HTS,Exp_DNASE2 (ENSG00000105612),GE,targeted cancer,PKC inhibitor,"KCNN1, KCNN3",,,Launched,0.40836752333442894,0.275318282886,dequalinium,OTHER,0.4080119118181262,2.622641884680261,-1.6573586235155968
BRD-K77695569-001-30-0::2.5::HTS,BRD-K77695569-001-30-0,tiabendazole,2.5,HTS,CN_OR4C46 (119749),CN,noncancer,angiogenesis inhibitor,,infectious disease,"gastrointestinal roundworms, hookworm",Launched,0.272458042480227,0.109216698726,tiabendazole,,,0,0
BRD-K77771411-003-10-7::2.5::HTS,BRD-K77771411-003-10-7,moxonidine,2.5,HTS,Exp_NCF1C (ENSG00000165178),GE,noncancer,imidazoline receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,Launched,0.244780486156988,0.0891047720658,moxonidine,,,0,0
BRD-K77791657-001-01-1::2.5::HTS,BRD-K77791657-001-01-1,3-deazaneplanocin-A,2.5,HTS,Exp_LAMP2 (ENSG00000005893),GE,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.3880833573317129,0.330864216137,3-deazaneplanocin-A,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4041992374418002,2.145703800839535,-3.953870045271581
BRD-K77791657-003-01-7::2.67::HTS,BRD-K77791657-003-01-7,3-deazaneplanocin-A,2.67,HTS,Exp_C8orf46 (ENSG00000169085),GE,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.3880833573317129,0.330864216137,3-deazaneplanocin-A,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3857539323632793,2.484244980598477,-3.8318497698838954
BRD-K77793136-003-03-0::2.5::HTS,BRD-K77793136-003-03-0,hydroxyfasudil,2.5,HTS,METHYL_XRCC6,METHYL,noncancer,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1",,,Preclinical,0.289735472655322,0.00386574694469,hydroxyfasudil,,,0,0
BRD-K77821588-364-01-2::2.5::HTS,BRD-K77821588-364-01-2,azatadine,2.5,HTS,METHYL_CRNDE,METHYL,noncancer,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Launched,0.300111425573641,0.0673883377725,azatadine,,,0,0
BRD-K77867004-001-02-7::2.5::HTS,BRD-K77867004-001-02-7,U-104,2.5,HTS,DEM2_AICDA (57379),DEMETER2_COM,targeted cancer,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA9",,,Preclinical,0.267039109921117,0.0476728187319,U-104,,,0,0
BRD-K77908580-001-09-6::2.5::HTS,BRD-K77908580-001-09-6,entinostat,2.5,HTS,Exp_ANKS1A (ENSG00000064999),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",,,Phase 3,0.368808518902544,0.377082610272,entinostat,HDAC INHIBITOR,0.3698708581653991,6.232230927554808,-1.2499069518022572
BRD-K77925998-050-14-3::2.5::HTS,BRD-K77925998-050-14-3,quipazine,2.5,HTS,MIRNA_ebv-miR-BART15,MIRNA,noncancer,serotonin receptor agonist,,,,Preclinical,0.214856914510541,0.0380378389244,quipazine,,,0,0
BRD-K77943374-001-02-8::2.5::HTS,BRD-K77943374-001-02-8,NVP-BVU972,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,targeted cancer,MET inhibitor,MET,,,Preclinical,0.47644902229912495,0.304670800858,NVP-BVU972,OTHER,0.4717925748525042,-0.2433912717274569,0.9601337316072164
BRD-K77947974-001-16-3::2.5::HTS,BRD-K77947974-001-16-3,fluspirilene,2.5,HTS,MUTpool_DSC1 (1823),MUTpool,noncancer,dopamine receptor antagonist,"CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.298218329299304,0.0558517825014,fluspirilene,,,0,0
BRD-K77950083-001-03-3::2.5::HTS,BRD-K77950083-001-03-3,UPF-1069,2.5,HTS,CRISPR_PSMD4 (5710),AVANA_PUBLIC_18Q2,noncancer,PARP inhibitor,PARP2,,,Preclinical,0.23676461605958998,0.0636210149589,UPF-1069,,,0,0
BRD-K77987382-001-13-2::2.5::HTS,BRD-K77987382-001-13-2,mebendazole,2.5,HTS,DEM2_BATF (10538),DEMETER2_COM,noncancer,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",Launched,0.41950175475708096,0.285210484251,mebendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4226685136013294,5.109001014540107,-3.134684598427373
BRD-K78010432-001-21-5::2.5::HTS,BRD-K78010432-001-21-5,furosemide,2.5,HTS,CRISPR_CHRNA1 (1134),AVANA_PUBLIC_18Q2,noncancer,diuretic,"CA2, GPR35, SLC12A1, SLC12A2","cardiology, rheumatology","edema, hypertension, congestive heart failure, nephrotic syndrome",Launched,0.22268029014660298,0.0898646580236,furosemide,,,0,0
BRD-K78055238-001-01-8::2.5::HTS,BRD-K78055238-001-01-8,LY2090314,2.5,HTS,Exp_SUN3 (ENSG00000164744),GE,targeted cancer,glycogen synthase kinase inhibitor,GSK3B,,,Phase 2,0.446208441457377,0.300638475277,LY2090314,OTHER,0.44790210237622896,3.766985883459067,-3.3482240610009297
BRD-K78061844-050-01-9::2.5::HTS,BRD-K78061844-050-01-9,4-PPBP,2.5,HTS,MIRNA_hcmv-miR-US5-2,MIRNA,noncancer,sigma receptor ligand,SIGMAR1,,,Preclinical,0.313796240668395,0.117744260609,4-PPBP,,,0,0
BRD-K78086729-001-02-7::2.5::HTS,BRD-K78086729-001-02-7,GW-788388,2.5,HTS,CRISPR_TXNDC12 (51060),AVANA_PUBLIC_18Q2,noncancer,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",,,Preclinical,0.253330450805357,0.0964810843365,GW-788388,,,0,0
BRD-K78096648-001-05-7::2.5::HTS,BRD-K78096648-001-05-7,oxiperomide,2.5,HTS,Exp_KHSRP (ENSG00000088247),GE,noncancer,dopamine receptor antagonist,,,,Phase 2,0.340934565698027,0.270979051035,oxiperomide,OTHER,0.3487018568860133,1.9391441414834607,-2.6457165605017163
BRD-K78113049-001-16-2::2.5::HTS,BRD-K78113049-001-16-2,enoxacin,2.5,HTS,PROT_N-Cadherin,PROT,noncancer,topoisomerase inhibitor,TOP2A,infectious disease,"urinary tract infections, gonorrhea",Launched,0.301528874770716,0.0519953599365,enoxacin,,,0,0
BRD-K78118466-001-03-3::2.5::HTS,BRD-K78118466-001-03-3,LY2157299,2.5,HTS,PROT_eIF4G_Caution,PROT,targeted cancer,TGF beta receptor inhibitor,TGFBR1,,,Phase 2/Phase 3,0.28863888470646004,0.118729646623,LY2157299,,,0,0
BRD-K78126613-001-28-5::2.5::HTS,BRD-K78126613-001-28-5,menadione,2.5,HTS,Exp_TXN (ENSG00000136810),GE,noncancer,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis",Launched,0.365982463689741,0.380122543604,menadione,OTHER,0.3700695881239856,1.7539488721595011,-3.3246065750312384
BRD-K78294846-001-12-4::2.5::HTS,BRD-K78294846-001-12-4,osthol,2.5,HTS,METHYL_TUBA3D,METHYL,noncancer,calcium channel blocker,,,,Preclinical,0.28602319214690003,0.0314690087497,osthol,,,0,0
BRD-K78299798-001-02-2::2.5::HTS,BRD-K78299798-001-02-2,mepiroxol,2.5,HTS,CRISPR_ADAM33 (80332),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.24685781760013603,0.139028093877,mepiroxol,,,0,0
BRD-K78303961-001-02-3::2.5::HTS,BRD-K78303961-001-02-3,glycitein,2.5,HTS,METABOL_uracil,METABOL,noncancer,tumor necrosis factor release inhibitor,TNF,,,Phase 3,0.26557002485256004,0.0759948309807,glycitein,,,0,0
BRD-K78318619-001-02-7::2.5::HTS,BRD-K78318619-001-02-7,PF-4981517,2.5,HTS,RMUTmis_CYP4B1 (1580),MUTmis,noncancer,cytochrome P450 inhibitor,CYP3A4,,,Preclinical,0.300240208550338,0.119249541959,PF-4981517,OTHER,0.30077158309063595,5.334363606389894,-1.9459976872460416
BRD-K78342372-001-02-4::2.5::HTS,BRD-K78342372-001-02-4,hematoxylin,2.5,HTS,MIRNA_hsa-miR-611,MIRNA,noncancer,,,,,Preclinical,0.31877651157099796,0.0444292716265,hematoxylin,,,0,0
BRD-K78431006-001-10-2::2.5::HTS,BRD-K78431006-001-10-2,crizotinib,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),Launched,0.38024066812541096,0.249735158069,crizotinib,OTHER,0.3748514187931927,3.115312036685613,-3.844793409437172
BRD-K78455053-001-01-2::2.5::HTS,BRD-K78455053-001-01-2,wnt-c59,2.5,HTS,Exp_ETNPPL (ENSG00000164089),GE,targeted cancer,porcupine inhibitor,PORCN,,,Preclinical,0.28489719593421003,-0.0681888293294,wnt-c59,,,0,0
BRD-K78496197-001-03-9::2.5::HTS,BRD-K78496197-001-03-9,SCS,2.5,HTS,Exp_BEND4 (ENSG00000188848),GE,noncancer,,,,,Preclinical,0.38169480380929,0.160849659318,SCS,OTHER,0.38038215777829343,3.281279818801855,-2.8540579483545723
BRD-K78513633-001-15-7::2.5::HTS,BRD-K78513633-001-15-7,lonidamine,2.5,HTS,METHYL_FOXH1,METHYL,targeted cancer,glucokinase inhibitor,GCK,,,Launched,0.252685952896799,0.125706317252,lonidamine,,,0,0
BRD-K78567475-001-01-4::2.5::HTS,BRD-K78567475-001-01-4,dolastatin-10,2.5,HTS,Exp_PDK1 (ENSG00000152256),GE,targeted cancer,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.403003978016177,0.248807375166,dolastatin-10,TUBULIN POLYMERIZATION INHIBITOR,0.4003324389846388,5.80765754140126,-2.0513319585842016
BRD-K78633253-001-10-3::2.5::HTS,BRD-K78633253-001-10-3,EXO-1,2.5,HTS,METHYL_MGST3,METHYL,noncancer,ARF inhibitor,,,,Preclinical,0.29033879416438696,0.124056233608,EXO-1,,,0,0
BRD-K78637815-001-02-2::2.5::HTS,BRD-K78637815-001-02-2,LY320135,2.5,HTS,PROT_RBM15,PROT,noncancer,cannabinoid receptor antagonist,CNR1,,,Preclinical,0.23093503801452397,0.0692260903832,LY320135,,,0,0
BRD-K78643075-001-11-6::2.5::HTS,BRD-K78643075-001-11-6,bromperidol,2.5,HTS,METABOL_pipecolic acid,METABOL,noncancer,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,Launched,0.305852246592354,0.0775371847504,bromperidol,,,0,0
BRD-K78666663-001-01-6::2.499978008::MTS004,BRD-K78666663-001-01-6,lemborexant,2.499978008,MTS004,CRISPR_ADHFE1 (137872),AVANA_PUBLIC_18Q2,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Phase 3,0.262599068550795,0.117756448423,lemborexant,,,0,0
BRD-K78666826-003-01-6::2.5::HTS,BRD-K78666826-003-01-6,procaterol,2.5,HTS,Exp_PTGFR (ENSG00000122420),GE,noncancer,adrenergic receptor agonist,ADRB2,pulmonary,asthma,Launched,0.280789383266166,0.15615365445,procaterol,,,0,0
BRD-K78692225-001-24-5::2.5::HTS,BRD-K78692225-001-24-5,leflunomide,2.5,HTS,DEM2_SYS1-DBNDD2 (767557),DEMETER2_COM,noncancer,"dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor","AHR, DHODH, PTK2B",rheumatology,rheumatoid arthritis,Launched,0.344143324972709,0.0812344399886,leflunomide,,,0,0
BRD-K78720403-001-01-6::2.5::HTS,BRD-K78720403-001-01-6,SB-328437,2.5,HTS,CN_ZNF106 (64397),CN,noncancer,CCR antagonist,,,,Preclinical,0.25494895113851995,0.0410796963184,SB-328437,,,0,0
BRD-K78781788-003-01-9::2.5::HTS,BRD-K78781788-003-01-9,barnidipine,2.5,HTS,Exp_ASB13 (ENSG00000196372),GE,noncancer,calcium channel blocker,,cardiology,hypertension,Launched,0.27557213181657003,0.00767573865693,barnidipine,,,0,0
BRD-K78789465-001-01-6::2.5::HTS,BRD-K78789465-001-01-6,pentagastrin,2.5,HTS,CRISPR_GJA1 (2697),AVANA_PUBLIC_18Q2,noncancer,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic",Launched,0.302901556259704,0.0932337980339,pentagastrin,,,0,0
BRD-K78789465-001-02-4::2.5::HTS,BRD-K78789465-001-02-4,pentagastrin,2.5,HTS,RMUTmis_PCSK1N (27344),MUT,noncancer,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic",Launched,0.27809989856906897,0.0541821033662,pentagastrin,OTHER,0.27860354607787,-1.6614959619110412,-2.629157314057798
BRD-K78809024-001-05-7::2.5::HTS,BRD-K78809024-001-05-7,SB-590885,2.5,HTS,RMUThot_BRAF (673),MUT,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.39463602531535796,0.397684532349,SB-590885,RAF INHIBITOR,0.3934480280758277,1.1400561491374668,3.6944562174215587
BRD-K78815826-001-14-6::2.5::HTS,BRD-K78815826-001-14-6,suxibuzone,2.5,HTS,Exp_FAM153B (ENSG00000182230),GE,noncancer,cyclooxygenase inhibitor,,"rheumatology, neurology/psychiatry","joint pain, muscle pain",Launched,0.28116297757057,0.0414090518749,suxibuzone,,,0,0
BRD-K78841970-001-13-8::2.388586862::MTS004,BRD-K78841970-001-13-8,aspartame,2.388586862,MTS004,PROT_p90RSK_pT573_Caution,PROT,noncancer,,"TAS1R2, TRPV1",,,Launched,0.276771011042851,0.032427657537,aspartame,,,0,0
BRD-K78844995-001-02-6::2.5::HTS,BRD-K78844995-001-02-6,N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide,2.5,HTS,MIRNA_hsa-miR-1185,MIRNA,noncancer,sigma receptor ligand,,,,Preclinical,0.25910859757467397,0.0503959973869,N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide,,,0,0
BRD-K78941306-001-02-4::2.5::HTS,BRD-K78941306-001-02-4,SB-742457,2.5,HTS,METABOL_C56:3 TAG,METABOL,noncancer,serotonin receptor antagonist,HTR6,,,Phase 3,0.27140251769551,0.0528598943839,SB-742457,,,0,0
BRD-K78959463-001-13-2::2.5::HTS,BRD-K78959463-001-13-2,FPL-64176,2.5,HTS,RMUTmis_ZNF184 (7738),MUT,noncancer,calcium channel activator,"CACNA1C, CACNA1S",,,Preclinical,0.30537878559164,0.00205843211632,FPL-64176,,,0,0
BRD-K78960041-001-03-2::2.5::HTS,BRD-K78960041-001-03-2,oxaliplatin,2.5,HTS,Exp_FDXR (ENSG00000161513),GE,chemo,DNA inhibitor,,oncology,colorectal cancer,Launched,0.4044682120540529,0.387962702632,oxaliplatin,OTHER,0.4047515072848979,3.1344480275365543,-1.5933306320948653
BRD-K78960041-001-05-7::2.54::HTS,BRD-K78960041-001-05-7,oxaliplatin,2.54,HTS,Exp_DHX33 (ENSG00000005100),GE,chemo,DNA inhibitor,,oncology,colorectal cancer,Launched,0.4044682120540529,0.387962702632,oxaliplatin,OTHER,0.3596616732132571,3.406969133209727,-3.335131826965561
BRD-K79092138-001-11-0::2.5::HTS,BRD-K79092138-001-11-0,nitrofurazone,2.5,HTS,RMUThot_TP53 (7157),MUThot,noncancer,bacterial DNA inhibitor,,infectious disease,first-aid antibiotic,Launched,0.293528322881242,0.0454296189673,nitrofurazone,,,0,0
BRD-K79095980-001-09-6::2.5::HTS,BRD-K79095980-001-09-6,broxuridine,2.5,HTS,Exp_RXRG (ENSG00000143171),GE,targeted cancer,antimetabolite,,,,Phase 2,0.34543696045795597,0.328477621188,broxuridine,OTHER,0.34813895780463977,3.844027494838621,-3.300230507742933
BRD-K79102359-003-01-6::2.5::HTS,BRD-K79102359-003-01-6,idalopirdine,2.5,HTS,METABOL_phosphocreatine,METABOL,noncancer,serotonin receptor antagonist,HTR6,,,Phase 3,0.277393116378075,0.173354445634,idalopirdine,,,0,0
BRD-K79116891-003-15-1::2.5::HTS,BRD-K79116891-003-15-1,proxymetacaine,2.5,HTS,DEM2_SMARCC1 (6599),DEMETER2_COM,noncancer,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,anesthetic,Launched,0.248376663978552,0.0689903333307,proxymetacaine,,,0,0
BRD-K79124250-001-08-9::2.5::HTS,BRD-K79124250-001-08-9,ioxaglic-acid,2.5,HTS,CN_PCDH15 (65217),CN,noncancer,radiopaque medium,,radiology,contrast agent,Launched,0.30208787511332696,0.00883231005992,ioxaglic-acid,,,0,0
BRD-K79131256-001-17-9::2.5::HTS,BRD-K79131256-001-17-9,albendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis",Launched,0.41505908516553497,0.255394712189,albendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4186299775609527,5.566051144924168,-2.733373283702817
BRD-K79132813-001-09-0::2.5::HTS,BRD-K79132813-001-09-0,pibenzimol,2.5,HTS,CN_ANGEL2 (90806),CN,targeted cancer,DNA inhibitor,,,,Phase 2,0.24676331977732302,0.0417127021569,pibenzimol,,,0,0
BRD-K79145628-001-05-5::2.5::HTS,BRD-K79145628-001-05-5,nimorazole,2.5,HTS,METHYL_XAGE5,METHYL,targeted cancer,bacterial DNA inhibitor,,oncology,head and neck squamous cell carcinoma (HNSCC),Launched,0.328956091449034,0.07445907009,nimorazole,,,0,0
BRD-K79145749-003-02-2::2.5::HTS,BRD-K79145749-003-02-2,dibenzepine,2.5,HTS,MIRNA_hsa-miR-297,MIRNA,noncancer,norepinephrine reputake inhibitor,,,,Preclinical,0.24072368395457897,0.140498997178,dibenzepine,,,0,0
BRD-K79239947-001-06-8::2.5::HTS,BRD-K79239947-001-06-8,PF-573228,2.5,HTS,Exp_DLX6 (ENSG00000006377),GE,targeted cancer,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",,,Preclinical,0.32695185723203807,0.278311044114,PF-573228,OTHER,0.3247653954996983,1.3854161418481232,-3.527444112663108
BRD-K79254416-001-22-6::2.5::HTS,BRD-K79254416-001-22-6,decitabine,2.5,HTS,PROT_Caveolin-1,PROT,targeted cancer,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)",Launched,0.336811773305953,0.266408416379,decitabine,OTHER,0.3463481423982133,4.4383794885183985,-1.89879964184089
BRD-K79259477-001-04-9::2.5::HTS,BRD-K79259477-001-04-9,NVP-BHG712,2.5,HTS,Exp_ARMCX1 (ENSG00000126947),GE,targeted cancer,ephrin inhibitor,EPHB4,,,Preclinical,0.35973486766030605,0.390925476486,NVP-BHG712,OTHER,0.3615210064538831,1.5179018271092413,-2.3778750301123885
BRD-K79277568-003-04-7::2.5::HTS,BRD-K79277568-003-04-7,methoxyamine,2.5,HTS,METHYL_KLF4,METHYL,targeted cancer,DNA repair enzyme inhibitor,APEX1,,,Phase 2,0.31579767721928004,0.0753878125462,methoxyamine,,,0,0
BRD-K79315489-001-07-8::2.5::HTS,BRD-K79315489-001-07-8,erythritol,2.5,HTS,METHYL_MIR331,METHYL,noncancer,,,,,Launched,0.25887379071995703,0.0773272970576,erythritol,,,0,0
BRD-K79404599-001-09-3::2.5::HTS,BRD-K79404599-001-09-3,enzastaurin,2.5,HTS,MUTpool_SDK1 (221935),MUTpool,targeted cancer,PKC inhibitor,"AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG",,,Phase 3,0.31064662029693896,0.127226905977,enzastaurin,,,0,0
BRD-K79425933-001-09-3::2.5::HTS,BRD-K79425933-001-09-3,benperidol,2.5,HTS,DEM2_DHX57 (90957),DEMETER2_COM,noncancer,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,Launched,0.268817247355021,0.0865648230613,benperidol,,,0,0
BRD-K79437791-001-05-7::2.5::HTS,BRD-K79437791-001-05-7,acetyl-farnesyl-cysteine,2.5,HTS,METABOL_C36:3 PC,METABOL,noncancer,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV),Launched,0.279399019168498,0.0680322764193,acetyl-farnesyl-cysteine,,,0,0
BRD-K79450420-001-01-8::2.499997604::MTS004,BRD-K79450420-001-01-8,INCB-024360,2.499997604,MTS004,METHYL_TMEM123,METHYL,targeted cancer,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,Phase 2,0.31000248735128494,0.103819995272,INCB-024360,,,0,0
BRD-K79450420-001-02-6::2.5::MTS004,BRD-K79450420-001-02-6,epacadostat,2.5,MTS004,Exp_C10orf95 (ENSG00000120055),GE,targeted cancer,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,Phase 3,0.31000248735128494,0.201515366931,epacadostat,,,0,0
BRD-K79501723-001-04-6::2.5::HTS,BRD-K79501723-001-04-6,cyclizine,2.5,HTS,METABOL_glycine,METABOL,noncancer,histamine receptor modulator,"HRH1, SULT1E1","gastroenterology, neurology/psychiatry","nausea, vomiting, vertigo, motion sickness",Launched,0.263989063131337,0.0436229233042,cyclizine,,,0,0
BRD-K79555887-001-01-0::2.5::HTS,BRD-K79555887-001-01-0,RI-1,2.5,HTS,MIRNA_hsa-miR-606,MIRNA,targeted cancer,,RAD51,,,Preclinical,0.23985644171526802,0.118604103231,RI-1,,,0,0
BRD-K79584249-001-01-3::2.5::HTS,BRD-K79584249-001-01-3,CGM097,2.5,HTS,DEM2_MDM2 (4193),DEMETER2_COM,targeted cancer,MDM inhibitor,MDM2,,,Phase 1,0.674455226700119,0.804112007016,CGM097,MDM INHIBITOR,0.6610313540698002,3.262711245983482,-1.8614594785057068
BRD-K79595931-312-01-3::2.5::HTS,BRD-K79595931-312-01-3,bavisant,2.5,HTS,CN_LINC00477 (144360),CN,noncancer,histamine receptor antagonist,HRH3,,,Phase 2,0.273015566656464,0.0488348150924,bavisant,,,0,0
BRD-K79602928-003-19-9::2.5::HTS,BRD-K79602928-003-19-9,metformin,2.5,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,insulin sensitizer,"ACACB, PRKAB1",endocrinology,diabetes mellitus,Launched,0.23628224287869898,0.0562691407206,metformin,,,0,0
BRD-K79612754-001-19-1::2.62::HTS,BRD-K79612754-001-19-1,inosine,2.62,HTS,CN_MIR874 (100126343),CN,noncancer,neurotrophic agent,"PARP1, PNP",,,Launched,0.40672121439395204,0.267490748226,inosine,OTHER,0.40590431439553787,2.870361200647163,-4.111501920094681
BRD-K79612754-001-21-7::2.5::HTS,BRD-K79612754-001-21-7,inosine,2.5,HTS,DEM2_PAG1 (55824),DEMETER2_COM,noncancer,neurotrophic agent,"PARP1, PNP",,,Launched,0.40672121439395204,0.0442004282747,inosine,,,0,0
BRD-K79633074-001-01-8::2.5::HTS,BRD-K79633074-001-01-8,xilobam,2.5,HTS,CRISPR_FAM161B (145483),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 1,0.31657665430160997,0.0790984970633,xilobam,,,0,0
BRD-K79684402-300-02-8::2.5::HTS,BRD-K79684402-300-02-8,Ro-10-5824,2.5,HTS,Exp_S100A12 (ENSG00000163221),GE,noncancer,dopamine receptor agonist,DRD4,,,Preclinical,0.281390876341949,0.107392505722,Ro-10-5824,,,0,0
BRD-K79710622-001-02-9::2.5::MTS004,BRD-K79710622-001-02-9,GKT137831,2.5,MTS004,Exp_VSNL1 (ENSG00000163032),GE,noncancer,NADPH oxidase inhibitor,"NOX1, NOX4",,,Phase 2,0.33357001540423803,0.157846302589,GKT137831,,,0,0
BRD-K79711234-001-18-3::2.5::HTS,BRD-K79711234-001-18-3,thiamphenicol,2.5,HTS,Exp_SKOR1 (ENSG00000188779),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,pelvic inflammatory disease,Launched,0.279377266087428,0.0937339128968,thiamphenicol,OTHER,0.28185266821000843,0.4898464952087144,-3.4097120090143083
BRD-K79753741-001-01-7::2.5::HTS,BRD-K79753741-001-01-7,UBP-302,2.5,HTS,METHYL_GATSL3,METHYL,noncancer,glutamate receptor antagonist,GRIK1,,,Preclinical,0.272721897978837,0.0699929793912,UBP-302,,,0,0
BRD-K79759585-048-04-8::2.5::HTS,BRD-K79759585-048-04-8,sildenafil,2.5,HTS,MIRNA_hsa-miR-638,MIRNA,noncancer,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3",cardiology,hypertension,Launched,0.32197172906358196,0.0757938942985,sildenafil,,,0,0
BRD-K79803033-300-01-3::2.5::MTS004,BRD-K79803033-300-01-3,pozanicline,2.5,MTS004,CRISPR_CCDC185 (164127),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",,,Phase 2,0.280562049009282,0.153203158453,pozanicline,,,0,0
BRD-K79821389-001-03-5::2.562009205::MTS004,BRD-K79821389-001-03-5,rubitecan,2.562009205,MTS004,Exp_ERO1L (ENSG00000197930),GE,chemo,topoisomerase inhibitor,TOP1,,,Phase 3,0.42919069047454794,0.285634087647,rubitecan,TOPOISOMERASE INHIBITOR,0.4266283242659185,2.382929836349001,-0.5002000758756053
BRD-K79884267-001-01-4::2.5::HTS,BRD-K79884267-001-01-4,retinaldehyde,2.5,HTS,CN_MINK1 (50488),CN,noncancer,,,dermatology,cosmetic,Launched,0.238920687988564,0.0529561193974,retinaldehyde,,,0,0
BRD-K79892937-001-02-5::2.5::HTS,BRD-K79892937-001-02-5,phenolsulfonphthalein,2.5,HTS,CN_SPINT4 (391253),CN,noncancer,,,,,Launched,0.24558127397096102,0.0571243779111,phenolsulfonphthalein,,,0,0
BRD-K79905821-004-03-6::2.5::HTS,BRD-K79905821-004-03-6,gabazine,2.5,HTS,DEM2_OR2T12 (127064),DEMETER2_COM,noncancer,GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2",,,Preclinical,0.29935727421187197,0.0488444949809,gabazine,,,0,0
BRD-K79930101-300-03-7::2.5::HTS,BRD-K79930101-300-03-7,GW-583340,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Preclinical,0.46952131060494295,0.511894893675,GW-583340,EGFR INHIBITOR,0.4678735966826801,0.7361439981172478,-5.0426647898441885
BRD-K79966802-034-01-2::2.5::HTS,BRD-K79966802-034-01-2,rivanicline,2.5,HTS,CRISPR_PTPRA (5786),AVANA_PUBLIC_18Q2,noncancer,acetylcholine receptor agonist,"CHRNA4, CHRNB2, CXCL8",,,Phase 2,0.304783027736107,0.075818983296,rivanicline,,,0,0
BRD-K79989959-001-01-4::2.5::HTS,BRD-K79989959-001-01-4,nesbuvir,2.5,HTS,DEM2_RDH11 (51109),DEMETER2_COM,noncancer,RNA polymerase inhibitor,,,,Phase 2,0.251250597813085,0.100070508062,nesbuvir,,,0,0
BRD-K80025777-001-01-4::2.5::HTS,BRD-K80025777-001-01-4,"cis-9,trans-11-Conjugated-linoleic-acid",2.5,HTS,CRISPR_ZNF287 (57336),AVANA_PUBLIC_18Q2,noncancer,,,,,Launched,0.337396413178529,0.142008333616,"cis-9,trans-11-Conjugated-linoleic-acid",,,0,0
BRD-K80028314-303-02-6::2.5::HTS,BRD-K80028314-303-02-6,alpha-methylhistamine-dihydrobromide-(R)-(-),2.5,HTS,METHYL_LOC101929516,METHYL,noncancer,histamine receptor agonist,HRH3,,,Preclinical,0.306159088016724,0.144581991722,alpha-methylhistamine-dihydrobromide-(R)-(-),,,0,0
BRD-K80036624-001-04-0::2.5::HTS,BRD-K80036624-001-04-0,clopidol,2.5,HTS,Exp_EOMES (ENSG00000163508),GE,noncancer,,,infectious disease,coccidiosis,Launched,0.31495965458714503,0.0732120741107,clopidol,,,0,0
BRD-K80043866-236-01-1::2.5::HTS,BRD-K80043866-236-01-1,sodium-gualenate,2.5,HTS,DEM2_ANKRD13B (124930),DEMETER2_COM,noncancer,antacid,,,,Launched,0.255290927884065,0.0958969449552,sodium-gualenate,,,0,0
BRD-K80060353-303-03-9::2.46::HTS,BRD-K80060353-303-03-9,IEM1754,2.46,HTS,RMUTmis_PPFIBP2 (8495),MUTmis,noncancer,glutamate receptor antagonist,GRIA1,,,Preclinical,0.343361162889318,0.0199592610976,IEM1754,,,0,0
BRD-K80076813-001-08-8::2.356620242::MTS004,BRD-K80076813-001-08-8,diftalone,2.356620242,MTS004,METABOL_C50:1 TAG,METABOL,noncancer,cyclooxygenase inhibitor,,endocrinology,thyroiditis,Launched,0.167676912059667,0.0153106282781,diftalone,,,0,0
BRD-K80082640-001-01-0::2.5::HTS,BRD-K80082640-001-01-0,otamixaban,2.5,HTS,CN_CTDSPL (10217),CN,noncancer,coagulation factor inhibitor,F10,,,Phase 3,0.27130621513928,0.102961633664,otamixaban,,,0,0
BRD-K80129304-001-08-1::2.5::HTS,BRD-K80129304-001-08-1,uracil,2.5,HTS,MIRNA_hsa-miR-581,MIRNA,targeted cancer,,"DPYD, UCKL1",,,Launched,0.28934104034935304,0.0371680315736,uracil,,,0,0
BRD-K80262108-001-07-0::2.5::HTS,BRD-K80262108-001-07-0,amifampridine,2.5,HTS,DEM2_ZNF649 (65251),DEMETER2_COM,noncancer,potassium channel blocker,,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),Launched,0.232402988528254,0.103432996406,amifampridine,,,0,0
BRD-K80267133-001-17-7::2.5::HTS,BRD-K80267133-001-17-7,aminosalicylate,2.5,HTS,MIRNA_hsa-miR-302f,MIRNA,noncancer,cyclooxygenase inhibitor,"ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2",gastroenterology,"inflammatory bowel disease, ulcerative colitis",Launched,0.29304074926322,0.0227248092504,aminosalicylate,,,0,0
BRD-K80267133-001-19-3::2.5::HTS,BRD-K80267133-001-19-3,aminosalicylate,2.5,HTS,METABOL_NADP,METABOL,noncancer,cyclooxygenase inhibitor,"ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2",gastroenterology,"inflammatory bowel disease, ulcerative colitis",Launched,0.254083447056157,0.080335814974,aminosalicylate,,,0,0
BRD-K80343549-001-02-6::2.5::HTS,BRD-K80343549-001-02-6,TAK-285,2.5,HTS,METHYL_LOC102723927,METHYL,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 1,0.24543202699260602,0.343913882571,TAK-285,EGFR INHIBITOR,0.25534460737687953,4.918257047972253,1.3254911800490672
BRD-K80353138-001-12-1::2.5::HTS,BRD-K80353138-001-12-1,silibinin,2.5,HTS,METHYL_IL13RA2,METHYL,noncancer,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis,Launched,0.271339696668027,0.0387550653569,silibinin,,,0,0
BRD-K80353807-001-25-3::2.5::MTS004,BRD-K80353807-001-25-3,khellin,2.5,MTS004,Exp_AGTR1 (ENSG00000144891),GE,noncancer,vasodilator,,,,Phase 2,0.305346008719158,0.201136133406,khellin,,,0,0
BRD-K80359953-001-01-3::2.500041136::MTS004,BRD-K80359953-001-01-3,talampanel,2.500041136,MTS004,METABOL_alpha-ketoglutarate,METABOL,targeted cancer,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,Phase 2,0.31190345518493795,0.160511955032,talampanel,,,0,0
BRD-K80396088-001-12-0::2.5::HTS,BRD-K80396088-001-12-0,gliquidone,2.5,HTS,PROT_Tuberin,PROT,noncancer,sulfonylurea,"ABCC8, KCNJ10, KCNJ8",endocrinology,diabetes mellitus,Launched,0.19709443638222304,0.0397420125003,gliquidone,,,0,0
BRD-K80419150-001-02-4::2.5::MTS004,BRD-K80419150-001-02-4,debrisoquin,2.5,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,adrenergic neuron blocker,SLC6A2,cardiology,hypertension,Launched,0.248370931128315,0.185486748851,debrisoquin,,,0,0
BRD-K80431395-001-07-3::2.49::HTS,BRD-K80431395-001-07-3,triciribine,2.49,HTS,Exp_ADK (ENSG00000156110),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 1/Phase 2,0.357973694137944,0.302242289976,triciribine,AKT INHIBITOR,0.3774242245902242,2.2627121402774284,-3.943794978919106
BRD-K80431395-001-09-9::2.5::HTS,BRD-K80431395-001-09-9,triciribine,2.5,HTS,Exp_DHRSX (ENSG00000169084),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 1/Phase 2,0.357973694137944,0.302242289976,triciribine,AKT INHIBITOR,0.35615359343862635,2.0729645182631664,-3.857397009482625
BRD-K80451230-051-02-6::2.5::HTS,BRD-K80451230-051-02-6,zamifenacin,2.5,HTS,METHYL_B3GALNT1,METHYL,noncancer,acetylcholine receptor antagonist,CHRM3,,,Phase 3,0.267771583103619,0.129582440804,zamifenacin,,,0,0
BRD-K80480517-001-02-4::2.5::HTS,BRD-K80480517-001-02-4,repsox,2.5,HTS,Exp_ARF4P2 (ENSG00000236527),GE,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.34950684101813106,0.152285303946,repsox,OTHER,0.33376854087477503,4.363456978051813,-0.9219238271746466
BRD-K80607346-001-01-1::2.5::MTS004,BRD-K80607346-001-01-1,FK-962,2.5,MTS004,Exp_SLC5A11 (ENSG00000158865),GE,noncancer,somatostatin receptor agonist,,,,Phase 2,0.301972377474205,0.06461814367,FK-962,,,0,0
BRD-K80608265-001-01-6::2.5::HTS,BRD-K80608265-001-01-6,erteberel,2.5,HTS,CN_HCAR2 (338442),CN,noncancer,estrogen receptor agonist,"ESR1, ESR2",,,Phase 2,0.22756427591869702,0.0732071381366,erteberel,,,0,0
BRD-K80639402-003-02-9::2.5::HTS,BRD-K80639402-003-02-9,SB-258585,2.5,HTS,PROT_B-Raf_pS445,PROT,noncancer,serotonin receptor antagonist,HTR6,,,Preclinical,0.32733010594802503,0.0301084622886,SB-258585,,,0,0
BRD-K80653534-001-01-7::2.5::HTS,BRD-K80653534-001-01-7,N-acetyl-D-glucosamine,2.5,HTS,PROT_NF2_Caution,PROT,noncancer,,"B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP",,,Phase 2/Phase 3,0.242582112653231,0.0122792744278,N-acetyl-D-glucosamine,,,0,0
BRD-K80700417-001-04-2::2.5::HTS,BRD-K80700417-001-04-2,SGI-1776,2.5,HTS,Exp_ATP10A (ENSG00000206190),GE,targeted cancer,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",,,Phase 1,0.32682258200826697,0.112022125203,SGI-1776,PIM KINASE INHIBITOR,0.33582774431341955,2.3933309735103903,-1.2718981117068435
BRD-K80725821-300-02-9::2.5::HTS,BRD-K80725821-300-02-9,RS-16566,2.5,HTS,Exp_NCOR1P1 (ENSG00000240108),GE,noncancer,serotonin receptor antagonist,,,,Preclinical,0.29944900331567104,0.135450205286,RS-16566,,,0,0
BRD-K80738081-001-46-8::2.500037854::MTS004,BRD-K80738081-001-46-8,resveratrol,2.500037854,MTS004,METABOL_2-hydroxyglutarate,METABOL,targeted cancer,"cytochrome P450 inhibitor, SIRT activator","CSNK2A1, NQO2, PTGS1, PTGS2",,,Launched,0.26460821514474603,0.108929706775,resveratrol,,,0,0
BRD-K80762071-236-02-5::2.5::MTS004,BRD-K80762071-236-02-5,indocyanine-green,2.5,MTS004,METHYL_HBEGF,METHYL,noncancer,contrast agent,SLCO1B1,,,Launched,0.29191848762927003,0.12234263641,indocyanine-green,,,0,0
BRD-K80778372-001-02-5::2.5::HTS,BRD-K80778372-001-02-5,Ro-19-4605,2.5,HTS,CRISPR_OCM2 (4951),AVANA_PUBLIC_18Q2,noncancer,,"GABRA1, GABRA2, GABRA3, GABRA5",,,Preclinical,0.335481939145029,0.140471569284,Ro-19-4605,,,0,0
BRD-K80859331-001-01-5::2.5::MTS004,BRD-K80859331-001-01-5,haloperidol-decanoate,2.5,MTS004,Exp_ERGIC1 (ENSG00000113719),GE,noncancer,psychoactive drug,"DRD2, DRD3, DRD4, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.293601202371452,0.0337882026538,haloperidol-decanoate,,,0,0
BRD-K80935598-001-01-1::2.5::HTS,BRD-K80935598-001-01-1,AZ191,2.5,HTS,METHYL_MARCH7,METHYL,targeted cancer,DYRK inhibitor,DYRK1B,,,Preclinical,0.268737038564054,0.00743622561152,AZ191,,,0,0
BRD-K81016934-001-02-0::2.5::HTS,BRD-K81016934-001-02-0,INC-280,2.5,HTS,MIRNA_hsa-miR-374b,MIRNA,targeted cancer,c-Met inhibitor,MET,,,Phase 2,0.20398757664504996,0.142894695263,INC-280,,,0,0
BRD-K81062487-001-05-8::2.5::HTS,BRD-K81062487-001-05-8,taurocholate,2.5,HTS,DEM2_AOC3 (8639),DEMETER2_COM,noncancer,G protein-coupled receptor agonist,"CEL, FABP6, SLCO1C1",,,Phase 1,0.24983294757970703,0.0451309540589,taurocholate,,,0,0
BRD-K81074237-001-02-3::2.5::HTS,BRD-K81074237-001-02-3,azilsartan,2.5,HTS,MUTpool_COL6A3 (1293),MUTpool,noncancer,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,Launched,0.292472362166799,0.0897100139754,azilsartan,,,0,0
BRD-K81092066-311-01-6::2.5::HTS,BRD-K81092066-311-01-6,phenacaine,2.5,HTS,MIRNA_hsa-miR-1277,MIRNA,noncancer,local anesthetic,,neurology/psychiatry,local anesthetic,Launched,0.24833801453129803,0.0959057333531,phenacaine,,,0,0
BRD-K81101512-234-01-9::2.5::HTS,BRD-K81101512-234-01-9,fosfomycin,2.5,HTS,CRISPR_GMDS (2762),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections,Launched,0.269480871510132,0.0793543403985,fosfomycin,,,0,0
BRD-K81128206-003-24-4::2.5::HTS,BRD-K81128206-003-24-4,edrophonium,2.5,HTS,METHYL_PNCK,METHYL,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,Launched,0.314848600532967,0.0155560738233,edrophonium,,,0,0
BRD-K81130846-001-17-4::2.5::HTS,BRD-K81130846-001-17-4,salicylamide,2.5,HTS,METHYL_RBM26,METHYL,noncancer,analgesic agent,,"neurology/psychiatry, endocrinology","pain relief, fever",Launched,0.283881471027412,0.0362542533161,salicylamide,,,0,0
BRD-K81136890-003-01-6::2.5::HTS,BRD-K81136890-003-01-6,leucylleucine-methyl-ester,2.5,HTS,Exp_BAP1 (ENSG00000163930),GE,noncancer,,,,,Phase 2,0.259542871423563,0.136638785914,leucylleucine-methyl-ester,,,0,0
BRD-K81144366-003-19-7::2.5::HTS,BRD-K81144366-003-19-7,moxisylyte,2.5,HTS,CRISPR_SRMS (6725),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor antagonist,,,,Withdrawn,0.28848668591721804,0.100398546028,moxisylyte,,,0,0
BRD-K81197548-003-01-4::2.5::HTS,BRD-K81197548-003-01-4,NSC-632839,2.5,HTS,Exp_CHST7 (ENSG00000147119),GE,targeted cancer,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",,,Preclinical,0.402727462266002,0.0795232152145,NSC-632839,OTHER,0.36683176739760615,4.750055996966776,0.2207688097198268
BRD-K81225797-001-02-3::2.5::HTS,BRD-K81225797-001-02-3,SCH-58261,2.5,HTS,Exp_FOXA1 (ENSG00000129514),GE,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.359200931608214,0.231970347432,SCH-58261,OTHER,0.35566165813325845,-1.2725544404406128,0.8689867709463788
BRD-K81272440-236-13-5::2.5::HTS,BRD-K81272440-236-13-5,dantrolene,2.5,HTS,METABOL_C56:8 TAG,METABOL,noncancer,calcium channel blocker,"RYR1, RYR3","neurology/psychiatry, endocrinology","spasms, malignant hyperthermia (MH)",Launched,0.23925684493934804,0.000224930639404,dantrolene,,,0,0
BRD-K81316007-001-01-8::2.5::HTS,BRD-K81316007-001-01-8,4-mu-8C,2.5,HTS,METABOL_glycodeoxycholate/glycochenodeoxycholate,METABOL,noncancer,IRE1 inhibitor,ERN1,,,Preclinical,0.298526486880318,0.0642751504286,4-mu-8C,,,0,0
BRD-K81326768-001-04-0::2.5::HTS,BRD-K81326768-001-04-0,zomepirac,2.5,HTS,CRISPR_RPRD1B (58490),AVANA_PUBLIC_18Q2,noncancer,prostaglandin synthesis inhibitor,PTGDR2,,,Withdrawn,0.299675757150271,0.168637591615,zomepirac,,,0,0
BRD-K81330143-001-04-8::2.38::HTS,BRD-K81330143-001-04-8,tideglusib,2.38,HTS,METHYL_MIR548K,METHYL,noncancer,glycogen synthase kinase inhibitor,GSK3B,,,Phase 2,0.299424661516407,0.132357130066,tideglusib,,,0,0
BRD-K81332461-001-01-4::2.5::HTS,BRD-K81332461-001-01-4,maxacalcitol,2.5,HTS,Exp_SMIM22 (ENSG00000267795),GE,noncancer,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,Launched,0.25501131714971803,0.234661129239,maxacalcitol,VITAMIN D RECEPTOR AGONIST,0.2621822665111273,0.5222134547568827,-1.1981262510131452
BRD-K81376179-001-04-8::2.5::HTS,BRD-K81376179-001-04-8,TCS-359,2.5,HTS,CRISPR_ZNF410 (57862),AVANA_PUBLIC_18Q2,targeted cancer,FLT3 inhibitor,FLT3,,,Preclinical,0.29928260460311,0.0706743266197,TCS-359,,,0,0
BRD-K81405859-300-01-4::2.5::MTS004,BRD-K81405859-300-01-4,JTE-607,2.5,MTS004,Exp_HES7 (ENSG00000179111),GE,noncancer,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",,,Phase 2,0.400334315512565,0.230225595269,JTE-607,OTHER,0.4059820641055381,4.941886706029576,-3.206662039205689
BRD-K81418486-001-47-5::2.5::HTS,BRD-K81418486-001-47-5,vorinostat,2.5,HTS,Exp_PARS2 (ENSG00000162396),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Launched,0.39084154394416704,0.218249965138,vorinostat,HDAC INHIBITOR,0.3904897959308937,6.40861490716446,-1.1284321521037834
BRD-K81447180-003-21-4::2.58::HTS,BRD-K81447180-003-21-4,lincomycin,2.58,HTS,METHYL_ACTR10,METHYL,noncancer,bacterial 30S ribosomal subunit inhibitor,,gastroenterology,enteritis,Launched,0.274173723977305,0.00516862229389,lincomycin,,,0,0
BRD-K81458380-001-04-9::2.5::HTS,BRD-K81458380-001-04-9,CX-4945,2.5,HTS,Exp_C10orf35 (ENSG00000171224),GE,targeted cancer,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",,,Phase 1/Phase 2,0.289062186893456,0.12029831628,CX-4945,OTHER,0.2907713577276801,3.3269333427067296,-2.4507810405259893
BRD-K81473043-001-14-6::2.5::HTS,BRD-K81473043-001-14-6,tanespimycin,2.5,HTS,PROT_Gab2,PROT,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 3,0.35965515243038604,0.216321367862,tanespimycin,HSP INHIBITOR,0.34990239940121576,4.855349286646348,-0.7221369840770042
BRD-K81473089-003-26-1::2.5::HTS,BRD-K81473089-003-26-1,tacrine,2.5,HTS,METABOL_C18:1 SM,METABOL,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,Alzheimer's disease,Launched,0.23107314105779897,0.070597291725,tacrine,,,0,0
BRD-K81528515-001-13-8::2.5::HTS,BRD-K81528515-001-13-8,nilotinib,2.5,HTS,Exp_ELFN1 (ENSG00000225968),GE,targeted cancer,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.238626865283068,0.122763394996,nilotinib,OTHER,0.2388433404560248,3.0255011572375072,-0.4119071484158163
BRD-K81548480-001-01-2::2.5::HTS,BRD-K81548480-001-01-2,AC-264613,2.5,HTS,CN_ASXL1 (171023),CN,noncancer,PAR agonist,F2RL1,,,Preclinical,0.267076655156306,-0.0258338241236,AC-264613,,,0,0
BRD-K81572616-001-01-9::2.5::HTS,BRD-K81572616-001-01-9,CK-636,2.5,HTS,MIRNA_hsa-miR-523,MIRNA,noncancer,actin related protein inhibitor,"ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5",,,Preclinical,0.21400115382686202,0.111647282235,CK-636,,,0,0
BRD-K81613478-001-01-8::2.5::HTS,BRD-K81613478-001-01-8,gastrodin,2.5,HTS,CN_DNAH11 (8701),CN,noncancer,,,,,Phase 2,0.30170246124506106,0.0735005291992,gastrodin,OTHER,0.2883684179315796,4.471863360954513,-0.7539845218718888
BRD-K81616657-001-01-4::2.665005855::MTS004,BRD-K81616657-001-01-4,PNU-142633,2.665005855,MTS004,CN_GPR37L1 (9283),CN,noncancer,serotonin receptor agonist,HTR1D,,,Phase 2,0.29992730825034997,0.0568878061187,PNU-142633,,,0,0
BRD-K81623406-004-08-3::2.5::HTS,BRD-K81623406-004-08-3,EIT-hydrobromide,2.5,HTS,MIRNA_hsa-miR-886-3p,MIRNA,noncancer,nitric oxide synthase inhibitor,"NOS2, NOS3",,,Preclinical,0.26727646276432504,0.0718254206099,EIT-hydrobromide,,,0,0
BRD-K81645297-236-01-1::2.5::HTS,BRD-K81645297-236-01-1,NKP-1339,2.5,HTS,PROT_Akt_pS473,PROT,noncancer,HSP inhibitor,,,,Phase 1,0.286187500369417,0.0809165313671,NKP-1339,,,0,0
BRD-K81645907-001-01-1::2.5::HTS,BRD-K81645907-001-01-1,captamine,2.5,HTS,CN_HLA-DPB2 (3116),CN,noncancer,,,,,Preclinical,0.282283849621206,0.0862767637721,captamine,,,0,0
BRD-K81647657-001-04-3::2.5::HTS,BRD-K81647657-001-04-3,3-methyladenine,2.5,HTS,CRISPR_CCDC101 (112869),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,PI3,,,Preclinical,0.262685745430649,0.116654819242,3-methyladenine,,,0,0
BRD-K81672972-001-03-1::2.5::HTS,BRD-K81672972-001-03-1,dinoprost,2.5,HTS,CN_MAGEB1 (4112),CN,noncancer,prostacyclin analog,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R",obstetrics/gynecology,labor induction,Launched,0.24293428437439699,0.0625088354742,dinoprost,,,0,0
BRD-K81694556-003-01-9::2.5::HTS,BRD-K81694556-003-01-9,VTP-27999,2.5,HTS,METABOL_C36:2 PC,METABOL,noncancer,renin inhibitor,REN,,,Phase 1,0.221706407487645,0.201083191624,VTP-27999,,,0,0
BRD-K81728688-001-04-4::2.5::HTS,BRD-K81728688-001-04-4,WZ8040,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.288637857177547,0.363431175608,WZ8040,EGFR INHIBITOR,0.30655161321349705,1.0135591652707934,-4.867557064025284
BRD-K81729199-001-02-8::2.5::HTS,BRD-K81729199-001-02-8,AQ-RA741,2.5,HTS,DEM2_PSMD10 (5716),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CHRM2,,,Preclinical,0.186844229786722,0.0883990550992,AQ-RA741,,,0,0
BRD-K81795818-019-01-4::2.5::HTS,BRD-K81795818-019-01-4,exherin,2.5,HTS,CN_FAM155A (728215),CN,targeted cancer,cadherin antagonist,CDH2,,,Phase 2,0.28453019792465506,0.0516450539215,exherin,,,0,0
BRD-K81801188-001-02-8::2.5::HTS,BRD-K81801188-001-02-8,PP-121,2.5,HTS,Exp_IL6 (ENSG00000136244),GE,noncancer,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",,,Preclinical,0.37385281808028104,0.22174037605,PP-121,OTHER,0.38033188975138205,2.4265603972509604,-0.6959009454990102
BRD-K81807412-001-10-6::2.5::HTS,BRD-K81807412-001-10-6,N6-methyladenosine,2.5,HTS,METABOL_C56:8 TAG,METABOL,noncancer,,,,,Preclinical,0.258180399332985,-0.0331111253934,N6-methyladenosine,,,0,0
BRD-K81839095-001-25-1::2.6::HTS,BRD-K81839095-001-25-1,estrone,2.6,HTS,PROT_Bim(EP1036),PROT,noncancer,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",,,Launched,0.24956788754751702,0.0156434634919,estrone,,,0,0
BRD-K81839095-001-30-1::2.5::HTS,BRD-K81839095-001-30-1,estrone,2.5,HTS,METHYL_CGB2,METHYL,noncancer,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",,,Launched,0.29141694745159497,0.113770352376,estrone,,,0,0
BRD-K81855038-003-13-9::2.5::HTS,BRD-K81855038-003-13-9,roxatidine-acetate,2.5,HTS,DEM2_SLC4A10 (57282),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH2,gastroenterology,"Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis",Launched,0.307920900746389,0.0476716538009,roxatidine-acetate,,,0,0
BRD-K81876028-300-02-0::2.5::HTS,BRD-K81876028-300-02-0,CP-93129,2.5,HTS,Exp_RAP1GAP (ENSG00000076864),GE,noncancer,serotonin receptor agonist,HTR1A,,,Preclinical,0.282983603649524,0.0713690166869,CP-93129,,,0,0
BRD-K81916719-001-13-9::2.5::HTS,BRD-K81916719-001-13-9,triclabendazole,2.5,HTS,PROT_B-Raf_Caution,PROT,noncancer,microtubule inhibitor,DNMT1,infectious disease,tapeworm,Launched,0.226869711014337,0.0594241679928,triclabendazole,,,0,0
BRD-K81957469-001-01-0::2.5::HTS,BRD-K81957469-001-01-0,semagacestat,2.5,HTS,PROT_SETD2_Caution,PROT,noncancer,gamma secretase inhibitor,PSEN1,,,Phase 3,0.315415400312355,0.129978902048,semagacestat,,,0,0
BRD-K81981783-236-02-9::2.570718613::MTS004,BRD-K81981783-236-02-9,gavestinel,2.570718613,MTS004,Exp_BLK (ENSG00000136573),GE,noncancer,glutamate receptor antagonist,GLRB,,,Phase 3,0.269914574303547,0.14373553092,gavestinel,,,0,0
BRD-K82002057-001-01-2::2.5::HTS,BRD-K82002057-001-01-2,DFB,2.5,HTS,PROT_PRDX1,PROT,noncancer,glutamate receptor agonist,GRM5,,,Preclinical,0.23302559496136602,0.138205882383,DFB,,,0,0
BRD-K82027074-001-07-5::2.5::HTS,BRD-K82027074-001-07-5,2-hydroxyflutamide,2.5,HTS,DEM2_CTAG1B&CTAG1A (1485&246100),DEMETER2_COM,targeted cancer,androgen receptor antagonist,AR,,,Phase 1/Phase 2,0.308796594022079,0.0908712930979,2-hydroxyflutamide,,,0,0
BRD-K82028950-300-02-9::2.5::HTS,BRD-K82028950-300-02-9,CGH2466,2.5,HTS,RMUTmis_ZFHX3 (463),MUT,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",,,Preclinical,0.30211275238456203,0.110866865355,CGH2466,,,0,0
BRD-K82036761-003-20-3::2.5::HTS,BRD-K82036761-003-20-3,sertraline,2.5,HTS,DEM2_CD302 (9936),DEMETER2_COM,noncancer,selective serotonin reuptake inhibitor (SSRI),"SLC6A3, SLC6A4","neurology/psychiatry, obstetrics/gynecology","depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder",Launched,0.307682816091589,0.0171541283141,sertraline,,,0,0
BRD-K82091397-001-03-0::2.5::HTS,BRD-K82091397-001-03-0,SB-239063,2.5,HTS,MIRNA_hsa-miR-100,MIRNA,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",,,Preclinical,0.276903573686189,0.263477635264,SB-239063,OTHER,0.2747344067979472,4.086575687972753,-0.247044836031562
BRD-K82103381-003-09-4::2.500073689::MTS004,BRD-K82103381-003-09-4,hydralazine,2.500073689,MTS004,MIRNA_hsa-miR-98,MIRNA,noncancer,vasodilator,"AOC3, P4HA1",cardiology,hypertension,Launched,0.24922774577822498,0.0592835226139,hydralazine,,,0,0
BRD-K82104468-001-05-0::2.5::HTS,BRD-K82104468-001-05-0,ethyl-vanillin,2.5,HTS,CN_TIMM23 (100287932),CN,noncancer,,,,,Preclinical,0.297902929984945,0.1438849381,ethyl-vanillin,,,0,0
BRD-K82118441-001-03-7::2.646883368::MTS004,BRD-K82118441-001-03-7,pyrantel,2.646883368,MTS004,Exp_RNF185 (ENSG00000138942),GE,noncancer,nicotinic receptor agonist,,infectious disease,"gastrointestinal roundworms, gastrointestinal roundworms",Launched,0.27757622046028196,0.106028621158,pyrantel,,,0,0
BRD-K82122102-323-01-1::2.5::HTS,BRD-K82122102-323-01-1,amfenac,2.5,HTS,MIRNA_hsv1-miR-H4-5p,MIRNA,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Launched,0.244700215253934,0.0639537681816,amfenac,,,0,0
BRD-K82135108-001-04-3::2.5::HTS,BRD-K82135108-001-04-3,elesclomol,2.5,HTS,Exp_CCT5 (ENSG00000150753),GE,targeted cancer,oxidative stress inducer,HSPA1A,,,Phase 3,0.35460271790087106,0.24419373054,elesclomol,OTHER,0.353275713205187,3.9028976926442263,-1.0939050656294933
BRD-K82142815-001-19-1::2.5::HTS,BRD-K82142815-001-19-1,betamipron,2.5,HTS,METABOL_alpha-glycerophosphate,METABOL,noncancer,panipenem uptake inhibitor,,nephrology,renal toxicity,Launched,0.26777346028308896,0.0912884820965,betamipron,,,0,0
BRD-K82143716-001-19-9::2.5::HTS,BRD-K82143716-001-19-9,flucytosine,2.5,HTS,Exp_LINC00211 (ENSG00000237803),GE,noncancer,other antifungal,DNMT1,infectious disease,"bacterial septicemia, endocarditis, urinary tract infections, meningitis",Launched,0.252602099047685,0.126955734252,flucytosine,,,0,0
BRD-K82164249-001-03-5::2.5::HTS,BRD-K82164249-001-03-5,andarine,2.5,HTS,CN_MAGEB1 (4112),CN,noncancer,androgen receptor modulator,AR,,,Phase 1,0.267786423226013,0.116904537948,andarine,,,0,0
BRD-K82181219-001-04-3::2.5::HTS,BRD-K82181219-001-04-3,pyritinol,2.5,HTS,METHYL_LINC00693,METHYL,noncancer,,,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Launched,0.274268656832475,0.112845415515,pyritinol,,,0,0
BRD-K82225283-001-03-1::2.5::HTS,BRD-K82225283-001-03-1,isosorbide-mononitrate,2.5,HTS,MIRNA_hsa-miR-886-5p,MIRNA,noncancer,nitric oxide stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,"angina pectoris, coronary artery disease (CAD)",Launched,0.169223849851036,0.0494840717368,isosorbide-mononitrate,,,0,0
BRD-K82234479-001-09-4::2.5::HTS,BRD-K82234479-001-09-4,tramiprosate,2.5,HTS,METHYL_CD81-AS1,METHYL,noncancer,beta amyloid protein neurotoxicity inhibitor,APP,,,Phase 3,0.180667304070803,0.0263182861633,tramiprosate,,,0,0
BRD-K82236108-001-04-9::2.5::HTS,BRD-K82236108-001-04-9,"N-methyl-(-)ephedrine-[1r,2s]",2.5,HTS,MIRNA_hsa-miR-610,MIRNA,noncancer,,,,,Preclinical,0.26532275980361,0.0284827778033,"N-methyl-(-)ephedrine-[1r,2s]",,,0,0
BRD-K82236179-213-01-0::2.5::HTS,BRD-K82236179-213-01-0,dicoumarol,2.5,HTS,CN_CTAGE15 (441294),CN,noncancer,NADPH inhibitor,"CRYZ, NQO1, VKORC1",hematology,deep vein thrombosis (DVT),Launched,0.284982235810074,-0.0907084475233,dicoumarol,,,0,0
BRD-K82244583-001-01-3::2.5::HTS,BRD-K82244583-001-01-3,MEK162,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 3,0.42288478493428205,0.521343691633,MEK162,MEK INHIBITOR,0.42179372453150094,0.40596626860011975,4.813111352303714
BRD-K82255054-001-15-9::2.5::HTS,BRD-K82255054-001-15-9,propofol,2.5,HTS,METHYL_ZNF519,METHYL,noncancer,benzodiazepine receptor agonist,"FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A",neurology/psychiatry,anesthetic,Launched,0.257450963391875,0.10173676015,propofol,,,0,0
BRD-K82343404-003-02-4::2.5::HTS,BRD-K82343404-003-02-4,adrenalone,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,noncancer,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage,Launched,0.252886439730558,0.108793670492,adrenalone,,,0,0
BRD-K82357231-001-17-5::2.5::HTS,BRD-K82357231-001-17-5,desloratadine,2.5,HTS,METHYL_SLC25A33,METHYL,noncancer,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",Launched,0.204662599197814,0.112187168346,desloratadine,,,0,0
BRD-K82381502-003-23-1::2.5::HTS,BRD-K82381502-003-23-1,acetylcholine,2.5,HTS,DEM2_LYNX1 (66004),DEMETER2_COM,noncancer,acetylcholine receptor agonist,"ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","neurology/psychiatry, gastroenterology, pulmonary","drowsiness, fatigue, headache, indigestion, chest congestion",Launched,0.27057990556241895,0.146376675838,acetylcholine,,,0,0
BRD-K82421491-001-02-6::2.5::HTS,BRD-K82421491-001-02-6,IPAG,2.5,HTS,RMUTmis_HECTD1 (25831),MUTmis,noncancer,,,,,Preclinical,0.267123926021947,0.0999446019205,IPAG,,,0,0
BRD-K82467063-001-02-7::2.5::HTS,BRD-K82467063-001-02-7,SB-271046,2.5,HTS,METHYL_RPS6KB1,METHYL,noncancer,serotonin receptor antagonist,HTR6,,,Phase 1,0.30172468160370103,0.0691890581355,SB-271046,,,0,0
BRD-K82484965-003-03-5::2.5::HTS,BRD-K82484965-003-03-5,carmoxirole,2.5,HTS,PROT_S6_pS235_S236,PROT,noncancer,dopamine receptor agonist,DRD2,,,Phase 2,0.304590713681521,0.0711085725912,carmoxirole,,,0,0
BRD-K82522873-001-01-1::2.5::HTS,BRD-K82522873-001-01-1,N6022,2.5,HTS,PROT_BRCA2_Caution,PROT,noncancer,alcohol dehydrogenase inhibitor,ADH5,,,Phase 1/Phase 2,0.281302011526402,0.103974609523,N6022,,,0,0
BRD-K82562631-236-04-6::2.5::HTS,BRD-K82562631-236-04-6,tolmetin,2.5,HTS,Exp_GPHN (ENSG00000171723),GE,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.316073445025377,0.145441968928,tolmetin,,,0,0
BRD-K82603084-408-01-1::2.5::HTS,BRD-K82603084-408-01-1,ethylenediaminetetraacetic-acid,2.5,HTS,Exp_LYPD2 (ENSG00000197353),GE,noncancer,PKC inhibitor,,neurology/psychiatry,metal toxicity,Launched,0.29290301723904805,0.0726463636767,ethylenediaminetetraacetic-acid,,,0,0
BRD-K82677201-001-01-6::2.5::HTS,BRD-K82677201-001-01-6,almitrine,2.5,HTS,Exp_SUGT1P2 (ENSG00000213842),GE,noncancer,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD),Launched,0.315822550454111,0.088638773212,almitrine,,,0,0
BRD-K82687598-001-01-6::2.5::MTS004,BRD-K82687598-001-01-6,tolonidine,2.5,MTS004,Exp_OCA2 (ENSG00000104044),GE,noncancer,adrenergic receptor antagonist,ADRA2A,,,Launched,0.248997315080987,0.0802411640242,tolonidine,,,0,0
BRD-K82731415-001-07-0::2.5::HTS,BRD-K82731415-001-07-0,olomoucine,2.5,HTS,Exp_AQP4 (ENSG00000171885),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK5, MAPK1",,,Preclinical,0.258983518401158,0.0584559384025,olomoucine,,,0,0
BRD-K82746043-001-15-1::2.5::HTS,BRD-K82746043-001-15-1,navitoclax,2.5,HTS,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,Phase 2,0.380985702948247,0.430368100161,navitoclax,OTHER,0.4386407978459547,5.881185812047794,-0.3621917871480361
BRD-K82767007-001-01-1::2.5::HTS,BRD-K82767007-001-01-1,dazoxiben,2.5,HTS,Exp_PIM1 (ENSG00000137193),GE,noncancer,thromboxane synthase inhibitor,TBXAS1,,,Phase 2,0.28906547448105796,0.120284458513,dazoxiben,,,0,0
BRD-K82795137-001-26-2::2.5::HTS,BRD-K82795137-001-26-2,loratadine,2.5,HTS,DEM2_DIABLO (56616),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,"allergy, neurology/psychiatry","allergic rhinitis, itching",Launched,0.18247760827259601,-0.00351705780987,loratadine,,,0,0
BRD-K82800842-001-01-9::2.5::HTS,BRD-K82800842-001-01-9,inositol-hexanicotinate,2.5,HTS,METHYL_LOC100507639,METHYL,noncancer,,,"dermatology, cardiology, rheumatology, neurology/psychiatry","statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)",Launched,0.27075818061308,0.00943012285448,inositol-hexanicotinate,,,0,0
BRD-K82818427-001-02-2::2.39::HTS,BRD-K82818427-001-02-2,batimastat,2.39,HTS,Exp_KBTBD11 (ENSG00000176595),GE,targeted cancer,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",,,Phase 3,0.35895189590023907,0.243640391837,batimastat,OTHER,0.35696236264247105,4.0289344703994665,-2.10034423700451
BRD-K82818427-001-04-8::2.5::HTS,BRD-K82818427-001-04-8,batimastat,2.5,HTS,Exp_TBC1D10A (ENSG00000099992),GE,targeted cancer,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",,,Phase 3,0.35895189590023907,0.243640391837,batimastat,OTHER,0.3595998566286925,3.806071447645016,-1.754767057652737
BRD-K82823076-001-02-6::2.5::HTS,BRD-K82823076-001-02-6,Ro-15-4513,2.5,HTS,METHYL_FMO5,METHYL,noncancer,,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",,,Preclinical,0.258618614763402,0.0918829233044,Ro-15-4513,,,0,0
BRD-K82823804-001-04-1::2.5::HTS,BRD-K82823804-001-04-1,PD-407824,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,PKC inhibitor,WEE1,,,Preclinical,0.42400055090235206,0.300496230364,PD-407824,OTHER,0.4223325308807216,3.1653627727019544,-3.0048152445819314
BRD-K82846253-001-15-4::2.5::HTS,BRD-K82846253-001-15-4,repaglinide,2.5,HTS,LIN_glioma,LIN,noncancer,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,Launched,0.21971357810799,0.0397330059091,repaglinide,,,0,0
BRD-K82850175-001-01-1::2.5::HTS,BRD-K82850175-001-01-1,navarixin,2.5,HTS,CRISPR_TRA2B (6434),AVANA_PUBLIC_18Q2,targeted cancer,CC chemokine receptor antagonist,"CXCR1, CXCR2",,,Phase 2,0.281428270409677,0.12285981804,navarixin,,,0,0
BRD-K82861010-001-02-5::2.5::HTS,BRD-K82861010-001-02-5,daclatasvir,2.5,HTS,MIRNA_bkv-miR-B1-5p,MIRNA,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.284281652189708,0.105621087255,daclatasvir,,,0,0
BRD-K82903013-001-01-4::2.5::HTS,BRD-K82903013-001-01-4,"3,3'-dichlorobenzaldazine",2.5,HTS,PROT_PR,PROT,noncancer,glutamate receptor allosteric ligand,GRM5,,,Preclinical,0.28431856196502,0.0285694684022,"3,3'-dichlorobenzaldazine",,,0,0
BRD-K82908348-001-01-9::2.434467427::MTS004,BRD-K82908348-001-01-9,darglitazone,2.434467427,MTS004,CN_CARD8 (22900),CN,noncancer,PPAR receptor antagonist,PPARG,,,Phase 2,0.291006355357554,0.0756896021825,darglitazone,,,0,0
BRD-K82928847-001-04-7::2.5::HTS,BRD-K82928847-001-04-7,ACY-1215,2.5,HTS,Exp_IFI35 (ENSG00000068079),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",,,Phase 1/Phase 2,0.348217183658667,0.291092137822,ACY-1215,HDAC INHIBITOR,0.34322078750986906,7.1059038567342965,-1.988685644511067
BRD-K82928892-001-02-5::2.46::HTS,BRD-K82928892-001-02-5,doxercalciferol,2.46,HTS,Exp_ITGB3 (ENSG00000259207),GE,noncancer,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism",Launched,0.32634299949601503,0.240459617821,doxercalciferol,VITAMIN D RECEPTOR AGONIST,0.32495281605296217,1.4149192255072331,-0.14154940530994375
BRD-K82941592-238-04-5::2.5::HTS,BRD-K82941592-238-04-5,rosuvastatin,2.5,HTS,DEM2_RAB17 (64284),DEMETER2_COM,noncancer,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis",Launched,0.186233888432853,0.104891957832,rosuvastatin,,,0,0
BRD-K82960980-003-01-9::2.5::HTS,BRD-K82960980-003-01-9,ceftiofur,2.5,HTS,CN_FANCC (2176),CN,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, respiratory tract infections",Launched,0.33979179429242307,0.118818163011,ceftiofur,,,0,0
BRD-K82967180-001-01-6::2.500024493::MTS004,BRD-K82967180-001-01-6,LY3023414,2.500024493,MTS004,Exp_PFKFB3 (ENSG00000170525),GE,targeted cancer,"PI3K inhibitor, mTOR inhibitor",MTOR,,,Phase 2,0.37864104722169606,0.273963456701,LY3023414,PI3K INHIBITOR,0.3823782223416795,1.8457137705834223,-0.2465944601256313
BRD-K82967685-300-01-2::2.5::HTS,BRD-K82967685-300-01-2,mirodenafil,2.5,HTS,METHYL_NR4A2,METHYL,noncancer,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,Launched,0.31179936885974796,0.0335350205059,mirodenafil,,,0,0
BRD-K82983861-001-04-3::2.5::HTS,BRD-K82983861-001-04-3,GW-0742,2.5,HTS,CRISPR_CTNNB1 (1499),AVANA_PUBLIC_18Q2,noncancer,PPAR receptor agonist,PPARD,,,Preclinical,0.31553385144756896,0.0587300709861,GW-0742,,,0,0
BRD-K83003151-057-02-4::2.35::HTS,BRD-K83003151-057-02-4,alogliptin,2.35,HTS,CRISPR_GANAB (23193),AVANA_PUBLIC_18Q2,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.33641598365960396,0.0994418636108,alogliptin,OTHER,0.3175522383853337,3.1300467595479415,-3.877217182377156
BRD-K83022601-001-01-0::2.5::HTS,BRD-K83022601-001-01-0,CI-844,2.5,HTS,Exp_TMEM9 (ENSG00000116857),GE,noncancer,,,,,Phase 2,0.24577462156112198,0.153005821014,CI-844,,,0,0
BRD-K83023055-001-02-7::2.5::HTS,BRD-K83023055-001-02-7,GR-135531,2.5,HTS,METHYL_KIAA0226L,METHYL,noncancer,melatonin receptor agonist,,,,Preclinical,0.316044655531807,0.0513657951831,GR-135531,,,0,0
BRD-K83029223-001-01-3::2.500025378::MTS004,BRD-K83029223-001-01-3,litronesib,2.500025378,MTS004,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Phase 2,0.38426421445314796,0.305522530592,litronesib,OTHER,0.3875993133860684,5.477335081056327,-3.3935873028302064
BRD-K83063356-003-02-5::2.5::HTS,BRD-K83063356-003-02-5,RS-102895,2.5,HTS,METABOL_C18:2 LPC,METABOL,noncancer,CCR antagonist,CCR2,,,Preclinical,0.17180332726472697,0.0285091429458,RS-102895,,,0,0
BRD-K83064458-001-23-0::2.5::HTS,BRD-K83064458-001-23-0,etofylline,2.5,HTS,MIRNA_hsa-miR-548i,MIRNA,noncancer,adenosine receptor antagonist,ADORA1,pulmonary,"asthma, bronchitis",Launched,0.258958534630843,0.108107908058,etofylline,,,0,0
BRD-K83144676-001-09-5::2.5::MTS004,BRD-K83144676-001-09-5,olmesartan,2.5,MTS004,CRISPR_LRRC8D (55144),AVANA_PUBLIC_18Q2,noncancer,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,Launched,0.27561251770056205,0.117767598204,olmesartan,,,0,0
BRD-K83186168-001-01-8::2.5::HTS,BRD-K83186168-001-01-8,AZD1981,2.5,HTS,METHYL_P2RX4,METHYL,noncancer,CRTH receptor antagonist,PTGDR2,,,Phase 2,0.248554195340751,0.0780477292126,AZD1981,,,0,0
BRD-K83192048-050-02-7::2.5::HTS,BRD-K83192048-050-02-7,dimethindene-(S)-(+),2.5,HTS,METABOL_CMP,METABOL,noncancer,acetylcholine receptor antagonist,HRH1,,,Preclinical,0.22695773142361,0.0731767475944,dimethindene-(S)-(+),,,0,0
BRD-K83245588-001-01-4::2.5::HTS,BRD-K83245588-001-01-4,pilsicainide,2.5,HTS,MIRNA_hsa-miR-16,MIRNA,noncancer,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,Launched,0.287857879825285,0.0783474716625,pilsicainide,,,0,0
BRD-K83257731-003-23-5::2.5::HTS,BRD-K83257731-003-23-5,chloropyramine,2.5,HTS,Exp_RAB34 (ENSG00000109113),GE,noncancer,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",Launched,0.313162470353634,0.247487543947,chloropyramine,OTHER,0.31502797262844623,3.98536643742415,-1.7104362422101662
BRD-K83322645-050-01-9::2.5::HTS,BRD-K83322645-050-01-9,L-693403,2.5,HTS,DEM2_EHHADH (1962),DEMETER2_COM,noncancer,"sigma receptor agonist, sigma receptor antagonist","DRD2, SIGMAR1",,,Preclinical,0.24382750556601399,0.0357313313275,L-693403,,,0,0
BRD-K83335125-001-07-0::2.5::HTS,BRD-K83335125-001-07-0,chloroxoquinoline,2.5,HTS,DEM2_WDR63 (126820),DEMETER2_COM,noncancer,,,,,Launched,0.238279194628607,0.0956278902168,chloroxoquinoline,,,0,0
BRD-K83359602-001-02-3::2.5::HTS,BRD-K83359602-001-02-3,barbital,2.5,HTS,CN_FAM45A (404636),CN,noncancer,sedative,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2",neurology/psychiatry,"sedative, seizures",Launched,0.31682213643241997,0.072733023165,barbital,,,0,0
BRD-K83405785-001-01-5::2.5::HTS,BRD-K83405785-001-01-5,pimavanserin,2.5,HTS,DEM2_PDCD2L (84306),DEMETER2_COM,noncancer,serotonin receptor inverse agonist,"DRD2, HTR2A",,,Launched,0.282881972720036,0.0278453627585,pimavanserin,,,0,0
BRD-K83508485-001-02-7::2.5::HTS,BRD-K83508485-001-02-7,FK-888,2.5,HTS,CN_SPINT4 (391253),CN,noncancer,tachykinin antagonist,"TACR1, TACR2",,,Phase 2,0.284216398606338,0.143324440932,FK-888,OTHER,0.28227317683814745,4.17376711301122,-3.2228501384169848
BRD-K83551379-001-01-8::2.5::HTS,BRD-K83551379-001-01-8,levodropropizine,2.5,HTS,MUTpool_CBX8 (57332),MUTpool,noncancer,antitussive,,pulmonary,cough suppressant,Launched,0.298172647639437,0.037591428036,levodropropizine,,,0,0
BRD-K83551379-001-02-6::2.5::HTS,BRD-K83551379-001-02-6,levodropropizine,2.5,HTS,DEM2_LRRC8C (84230),DEMETER2_COM,noncancer,antitussive,,pulmonary,cough suppressant,Launched,0.285512845168949,0.0659018656988,levodropropizine,,,0,0
BRD-K83597974-003-22-2::2.5::HTS,BRD-K83597974-003-22-2,pargyline,2.5,HTS,CRISPR_LRRC14B (389257),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",cardiology,hypertension,Launched,0.232243133922473,0.0430652868631,pargyline,,,0,0
BRD-K83607951-001-02-2::2.5::HTS,BRD-K83607951-001-02-2,skepinone-l,2.5,HTS,Exp_CPZ (ENSG00000109625),GE,noncancer,p38 MAPK inhibitor,MAPK14,,,Preclinical,0.240650801551928,0.129145704861,skepinone-l,,,0,0
BRD-K83636919-001-04-8::2.5::HTS,BRD-K83636919-001-04-8,entacapone,2.5,HTS,CN_CSF3R (1441),CN,noncancer,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease,Launched,0.256383112380757,0.0909908192912,entacapone,,,0,0
BRD-K83720053-001-03-8::2.5::HTS,BRD-K83720053-001-03-8,avagacestat,2.5,HTS,CN_ZMAT1 (84460),CN,noncancer,gamma secretase inhibitor,PSEN1,,,Phase 2,0.20190643845121697,0.0482649181045,avagacestat,,,0,0
BRD-K83766205-001-03-8::2.5::HTS,BRD-K83766205-001-03-8,metirosine,2.5,HTS,DEM2_SLC4A1 (6521),DEMETER2_COM,noncancer,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension,Launched,0.313844202613156,0.0170349871391,metirosine,,,0,0
BRD-K83776863-001-08-9::2.5::MTS004,BRD-K83776863-001-08-9,tryptophan,2.5,MTS004,Exp_BAG1 (ENSG00000107262),GE,noncancer,serotonin receptor partial agonist,"CASR, IDO1, SLC36A1, WARS, WARS2","neurology/psychiatry, gastroenterology","anxiety, bloating, constipation, fatigue, sleeplessness",Launched,0.36080736459847296,0.183438148619,tryptophan,,,0,0
BRD-K83794243-001-01-8::2.5::HTS,BRD-K83794243-001-01-8,palovarotene,2.5,HTS,METHYL_LRIT2,METHYL,noncancer,retinoid receptor agonist,RARG,,,Phase 2,0.30885603624853303,0.0964108076477,palovarotene,,,0,0
BRD-K83834509-001-01-1::2.5::HTS,BRD-K83834509-001-01-1,PTC-209,2.5,HTS,Exp_SRA1 (ENSG00000213523),GE,targeted cancer,BMI-1 inhibitor,,,,Preclinical,0.34289320243982596,0.354844625407,PTC-209,OTHER,0.3442804101593254,2.429606111247127,-3.4971130999843982
BRD-K83896451-001-06-7::2.5::HTS,BRD-K83896451-001-06-7,glutamine-(l),2.5,HTS,DEM2_DIRAS1 (148252),DEMETER2_COM,noncancer,,"CTPS1, GLUL, GPRC6A, PPAT","gastroenterology, dental, neurology/psychiatry, rheumatology","diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia",Launched,0.31014093986034,0.0196848828243,glutamine-(l),,,0,0
BRD-K83963101-001-06-9::2.5::HTS,BRD-K83963101-001-06-9,MLN-8054,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Phase 1,0.34639080210870504,0.285901518553,MLN-8054,AURORA KINASE INHIBITOR,0.34541003435266515,4.093711268233679,-3.2688817014325755
BRD-K83988098-001-02-0::2.5::HTS,BRD-K83988098-001-02-0,alvespimycin,2.5,HTS,Exp_GJC1 (ENSG00000182963),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 2,0.40768180341461896,0.136458012236,alvespimycin,HSP INHIBITOR,0.3998062952827556,4.9375587977411435,-0.5467238525385505
BRD-K83988098-003-03-4::2.5::HTS,BRD-K83988098-003-03-4,alvespimycin,2.5,HTS,Exp_SMAD7 (ENSG00000101665),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 2,0.40768180341461896,0.136458012236,alvespimycin,HSP INHIBITOR,0.370358845576073,5.326623664637968,0.1392914829033769
BRD-K84011460-051-01-7::2.5::HTS,BRD-K84011460-051-01-7,nizofenone,2.5,HTS,DEM2_TSIX (9383),DEMETER2_COM,noncancer,ion channel antagonist,,neurology/psychiatry,stroke,Launched,0.230228056737475,0.0666746901865,nizofenone,,,0,0
BRD-K84036904-001-08-8::2.500018826::MTS004,BRD-K84036904-001-08-8,17-alpha-methyltestosterone,2.500018826,MTS004,PROT_ERK2_Caution,PROT,targeted cancer,aromatase inhibitor,AR,,,Launched,0.2919990761052019,0.0867913719478,17-alpha-methyltestosterone,,,0,0
BRD-K84075000-001-05-5::2.5::HTS,BRD-K84075000-001-05-5,2-Chloropyrazine,2.5,HTS,METHYL_RAB4A,METHYL,noncancer,,,,,Preclinical,0.304051563164543,0.157222786915,2-Chloropyrazine,,,0,0
BRD-K84091759-001-07-1::2.5::HTS,BRD-K84091759-001-07-1,candesartan,2.5,HTS,RMUTmis_RP11-410N8.4 (0),MUT,noncancer,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure",Launched,0.24140943045325,0.0892362878726,candesartan,,,0,0
BRD-K84163249-001-01-9::2.5::HTS,BRD-K84163249-001-01-9,ercalcitriol,2.5,HTS,PROT_Syk,PROT,noncancer,vitamin D receptor agonist,VDR,,,Phase 1,0.267181010459849,0.180180498307,ercalcitriol,VITAMIN D RECEPTOR AGONIST,0.2516914154913968,1.3619274890733233,0.07315620564036962
BRD-K84173274-001-01-6::2.5::MTS004,BRD-K84173274-001-01-6,ufenamate,2.5,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",dermatology,"eczema, dermatitis",Launched,0.27875409936659007,0.154017643925,ufenamate,,,0,0
BRD-K84214706-001-05-7::2.5::HTS,BRD-K84214706-001-05-7,7-chlorokynurenic-acid,2.5,HTS,METHYL_RPS6KB1,METHYL,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",,,Preclinical,0.20009358075768602,0.149906855001,7-chlorokynurenic-acid,,,0,0
BRD-K84266862-001-03-2::2.5::HTS,BRD-K84266862-001-03-2,BRL-50481,2.5,HTS,DEM2_HELZ2 (85441),DEMETER2_COM,noncancer,phosphodiesterase inhibitor,"PDE7A, PDE7B",,,Preclinical,0.267212271768724,0.0417990954879,BRL-50481,,,0,0
BRD-K84281997-003-08-4::2.500011105::MTS004,BRD-K84281997-003-08-4,pralidoxime,2.500011105,MTS004,CRISPR_TADA2B (93624),AVANA_PUBLIC_18Q2,noncancer,acetylcholinesterase inhibitor,"ACHE, BCHE",critical care,organophosphate poisoning,Launched,0.26686555104188897,0.134115784402,pralidoxime,,,0,0
BRD-K84459715-001-01-6::2.403005639::MTS004,BRD-K84459715-001-01-6,zopolrestat,2.403005639,MTS004,PROT_GSK3_pS9,PROT,noncancer,,,,,Phase 2,0.28039832828628103,0.0828816564919,zopolrestat,,,0,0
BRD-K84466663-001-05-4::2.5::HTS,BRD-K84466663-001-05-4,nelarabine,2.5,HTS,MIRNA_hsa-miR-127-3p,MIRNA,chemo,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",Launched,0.274710290417503,0.123579534947,nelarabine,,,0,0
BRD-K84544951-236-01-0::2.5::HTS,BRD-K84544951-236-01-0,sodium-tetradecyl-sulfate,2.5,HTS,METABOL_taurocholate,METABOL,noncancer,,"PROC, PROS1",dermatology,"varicose veins, varicose veins",Launched,0.306660402010765,0.0230634975018,sodium-tetradecyl-sulfate,,,0,0
BRD-K84564571-001-02-4::2.5::HTS,BRD-K84564571-001-02-4,telatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,Phase 2,0.32797773378045103,0.224507479283,telatinib,OTHER,0.3241875064136507,-3.6786908742942703,0.052515351755042065
BRD-K84663978-003-02-9::2.5::HTS,BRD-K84663978-003-02-9,trequinsin,2.5,HTS,CRISPR_C10orf76 (79591),AVANA_PUBLIC_18Q2,noncancer,phosphodiesterase inhibitor,PDE5A,,,Phase 1,0.27220281905178195,0.0959741549343,trequinsin,,,0,0
BRD-K84683831-001-01-0::2.5::HTS,BRD-K84683831-001-01-0,radezolid,2.5,HTS,MIRNA_hsa-miR-181a,MIRNA,noncancer,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",,,,Phase 2,0.340990793441792,0.148978728913,radezolid,OTHER,0.3538387646155585,2.0910125442185152,-2.597648334044032
BRD-K84698278-001-03-4::2.5::HTS,BRD-K84698278-001-03-4,agomelatine,2.5,HTS,METHYL_EPS15L1,METHYL,noncancer,"melatonin receptor agonist, serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B",neurology/psychiatry,depression,Launched,0.28439208616865697,0.0168827169334,agomelatine,,,0,0
BRD-K84748119-050-01-1::2.5::HTS,BRD-K84748119-050-01-1,vicriviroc,2.5,HTS,DEM2_GPER1 (2852),DEMETER2_COM,targeted cancer,CC chemokine receptor antagonist,CCR5,,,Phase 3,0.23630088726019896,0.0672678412701,vicriviroc,,,0,0
BRD-K84783599-001-01-0::2.5::HTS,BRD-K84783599-001-01-0,riociguat,2.5,HTS,CN_DEFA10P (449493),CN,noncancer,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,Launched,0.16299592056107,0.0431252446526,riociguat,,,0,0
BRD-K84794093-001-07-5::2.5::HTS,BRD-K84794093-001-07-5,dideoxyadenosine,2.5,HTS,METHYL_MIR4536-1,METHYL,noncancer,nucleoside reverse transcriptase inhibitor,,,,Phase 1,0.24150290163627103,0.101278387481,dideoxyadenosine,,,0,0
BRD-K84798689-236-02-9::2.5::HTS,BRD-K84798689-236-02-9,sodium-tanshinone-ii-a-sulfonate,2.5,HTS,MIRNA_hsa-miR-548b-3p,MIRNA,noncancer,potassium channel activator,,,,Phase 2,0.176387143833377,-0.00337700828717,sodium-tanshinone-ii-a-sulfonate,,,0,0
BRD-K84810405-003-01-1::2.5::HTS,BRD-K84810405-003-01-1,almorexant,2.5,HTS,CRISPR_MCUR1 (63933),AVANA_PUBLIC_18Q2,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Phase 3,0.242256298048061,0.114534956119,almorexant,OTHER,0.25814064180873936,5.759187456935918,2.9094857795421936
BRD-K84868168-001-01-0::2.500006364::MTS004,BRD-K84868168-001-01-0,erdafitinib,2.500006364,MTS004,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",,,Phase 2,0.35618456281008704,0.280717900924,erdafitinib,OTHER,0.3748345278686712,1.061811425825637,-2.4102213412973725
BRD-K84892605-001-01-1::2.5::HTS,BRD-K84892605-001-01-1,IOWH032,2.5,HTS,Exp_EPSTI1 (ENSG00000133106),GE,noncancer,CFTR channel antagonist,CFTR,,,Phase 2,0.24111990884333603,0.0475032811063,IOWH032,,,0,0
BRD-K84895041-001-02-4::2.5::HTS,BRD-K84895041-001-02-4,BMY-45778,2.5,HTS,CRISPR_TRA2A (29896),AVANA_PUBLIC_18Q2,noncancer,IP1 prostacyclin receptor agonist,PTGIR,,,Preclinical,0.266234178750564,0.0507672986533,BMY-45778,,,0,0
BRD-K84925803-001-01-9::2.5::HTS,BRD-K84925803-001-01-9,T-5224,2.5,HTS,MIRNA_hsv1-miR-H2-3p,MIRNA,noncancer,AP inhibitor,JUN,,,Phase 2,0.241604430723969,0.0944281050467,T-5224,,,0,0
BRD-K84937637-001-09-9::2.5::HTS,BRD-K84937637-001-09-9,sirolimus,2.5,HTS,Exp_HAGHL (ENSG00000103253),GE,noncancer,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis",Launched,0.32433840192078994,0.259921459956,sirolimus,MTOR INHIBITOR,0.3259635482160741,3.8170893080536934,-1.9333352048270225
BRD-K84971356-001-01-4::2.632189712::MTS004,BRD-K84971356-001-01-4,etafenone,2.632189712,MTS004,MIRNA_hsa-miR-130a,MIRNA,noncancer,calcium channel blocker,,,,Launched,0.296686407630287,0.0774779302249,etafenone,,,0,0
BRD-K84986517-001-01-8::2.5::HTS,BRD-K84986517-001-01-8,darunavir,2.5,HTS,Exp_TTC5 (ENSG00000136319),GE,noncancer,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.268936475074913,0.0433325241565,darunavir,,,0,0
BRD-K84996356-001-01-1::2.5::HTS,BRD-K84996356-001-01-1,AZD3514,2.5,HTS,Exp_CPT2 (ENSG00000157184),GE,targeted cancer,androgen receptor modulator,AR,,,Phase 1,0.333998568535456,0.283912920711,AZD3514,OTHER,0.3313313418264485,-3.848967027707739,-0.626452104990264
BRD-K85014146-001-02-5::2.5::HTS,BRD-K85014146-001-02-5,AZD2461,2.5,HTS,METHYL_AGAP2-AS1,METHYL,targeted cancer,PARP inhibitor,,,,Phase 1,0.41023448464251505,0.153222854469,AZD2461,OTHER,0.4058927587358672,2.248180405957924,-4.219396343538353
BRD-K85046107-003-01-2::2.5::HTS,BRD-K85046107-003-01-2,ramosetron,2.5,HTS,CN_FAM118A (55007),CN,noncancer,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting, irritable bowel syndrome",Launched,0.28566419113946195,0.165169943523,ramosetron,,,0,0
BRD-K85066592-001-01-6::2.5::HTS,BRD-K85066592-001-01-6,gly-gln,2.5,HTS,DEM2_GBE1 (2632),DEMETER2_COM,noncancer,,,,,Phase 2,0.299337686278979,0.0969676532868,gly-gln,,,0,0
BRD-K85090592-008-22-7::2.5::HTS,BRD-K85090592-008-22-7,pilocarpine,2.5,HTS,RMUTmis_CC2D1A (54862),MUT,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension",Launched,0.263737642171477,0.0136399795613,pilocarpine,OTHER,0.2640411697503265,-0.5699049468445659,-2.2052238347816573
BRD-K85119730-001-28-9::2.5::HTS,BRD-K85119730-001-28-9,tolbutamide,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,ATP channel blocker,"ABCC8, KCNJ1, KCNJ11, KCNJ8",endocrinology,diabetes mellitus,Launched,0.316041633816013,0.0265271941003,tolbutamide,,,0,0
BRD-K85146014-314-05-4::2.5::HTS,BRD-K85146014-314-05-4,foscarnet,2.5,HTS,METHYL_MEX3B,METHYL,noncancer,DNA polymerase inhibitor,,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)",Launched,0.31008075642326194,0.0698450119583,foscarnet,,,0,0
BRD-K85178109-001-02-3::2.5::HTS,BRD-K85178109-001-02-3,fostamatinib,2.5,HTS,PROT_HER3,PROT,noncancer,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),Launched,0.38155948676445,0.31458132088,fostamatinib,OTHER,0.37707791398114576,1.6700633072138251,-2.4331470630547427
BRD-K85307935-236-09-5::2.5::HTS,BRD-K85307935-236-09-5,novobiocin,2.5,HTS,Exp_IGFL3 (ENSG00000188624),GE,noncancer,bacterial DNA gyrase inhibitor,,obstetrics/gynecology,mastitis,Launched,0.12425462280859301,0.0437127940449,novobiocin,,,0,0
BRD-K85333151-003-13-4::2.5::HTS,BRD-K85333151-003-13-4,ramifenazone,2.5,HTS,Exp_IL23R (ENSG00000162594),GE,noncancer,cyclooxygenase inhibitor,,"neurology/psychiatry, endocrinology","pain relief, fever",Launched,0.213973466493473,0.041318495094,ramifenazone,,,0,0
BRD-K85337334-004-02-6::2.5::HTS,BRD-K85337334-004-02-6,otilonium,2.5,HTS,DEM2_SHOC2 (8036),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome,Launched,0.16674674848968699,0.11430645162,otilonium,,,0,0
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,EGFR INHIBITOR,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,EGFR INHIBITOR,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K85406984-001-01-0::2.5::HTS,BRD-K85406984-001-01-0,sobetirome,2.5,HTS,DEM2_RPP14 (11102),DEMETER2_COM,noncancer,thyroid hormone receptor agonist,"THRA, THRB",,,Phase 1,0.28286910776590196,0.0711420229925,sobetirome,,,0,0
BRD-K85479953-001-11-3::2.5::HTS,BRD-K85479953-001-11-3,STF-62247,2.5,HTS,CRISPR_RNF111 (54778),AVANA_PUBLIC_18Q2,targeted cancer,autophagy inducer,,,,Preclinical,0.305934813134565,0.149062672362,STF-62247,OTHER,0.2972332998965821,5.623682050259154,-0.19539105364522769
BRD-K85503079-001-02-8::2.5::HTS,BRD-K85503079-001-02-8,perospirone,2.5,HTS,CRISPR_UBE2E1 (7324),AVANA_PUBLIC_18Q2,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, DRD3, DRD4",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.24345261001051602,0.125041381895,perospirone,,,0,0
BRD-K85554912-001-06-3::2.5::HTS,BRD-K85554912-001-06-3,ivermectin,2.5,HTS,Exp_ISG20 (ENSG00000172183),GE,noncancer,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies",Launched,0.370169298262183,0.116024036019,ivermectin,OTHER,0.3648514988817351,0.6813950567477994,-3.3425514806418146
BRD-K85554912-001-08-9::2.5::HTS,BRD-K85554912-001-08-9,ivermectin,2.5,HTS,DEM2_PNPT1 (87178),DEMETER2_COM,noncancer,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies",Launched,0.33124383641481603,0.189703156785,ivermectin,OTHER,0.31150066928995085,0.3475973877112224,-3.4034219515804214
BRD-K85606544-001-09-1::2.5::HTS,BRD-K85606544-001-09-1,neratinib,2.5,HTS,Exp_FAM83B (ENSG00000168143),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, KDR",,,Phase 3,0.363259191356945,0.454553104957,neratinib,EGFR INHIBITOR,0.36519727466838897,0.937268709121678,-4.973267676447599
BRD-K85751432-001-03-3::2.5::HTS,BRD-K85751432-001-03-3,refametinib,2.5,HTS,RMUThot_BRAF (673),MUThot,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 2,0.5320757822836889,0.471774715852,refametinib,MEK INHIBITOR,0.5136224061734835,0.5490112316325853,4.766147019695176
BRD-K85757157-001-01-7::2.5::HTS,BRD-K85757157-001-01-7,nifursol,2.5,HTS,PROT_TSC1_Caution,PROT,noncancer,bacterial DNA inhibitor,,,,Launched,0.297415614685558,0.0830861635201,nifursol,,,0,0
BRD-K85849709-001-01-5::2.5::HTS,BRD-K85849709-001-01-5,AZD2858,2.5,HTS,Exp_PTGES3P1 (ENSG00000234518),GE,noncancer,glycogen synthase kinase inhibitor,GSK3B,,,Preclinical,0.41480975302834994,0.306682300541,AZD2858,OTHER,0.4124094374711516,5.642496409256357,-0.5365443297230663
BRD-K85872723-001-15-9::2.5::HTS,BRD-K85872723-001-15-9,kynurenic-acid,2.5,HTS,MUTpool_PCDHB4 (56131),MUTpool,noncancer,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",,,Preclinical,0.263190917432311,0.0680461540525,kynurenic-acid,,,0,0
BRD-K85882401-323-01-5::2.500009065::MTS004,BRD-K85882401-323-01-5,avibactam,2.500009065,MTS004,METABOL_glutamine,METABOL,noncancer,beta lactamase inhibitor,,infectious disease,"intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis",Launched,0.26324821027468104,0.142784808971,avibactam,,,0,0
BRD-K85883481-001-25-7::2.5::HTS,BRD-K85883481-001-25-7,prednisone,2.5,HTS,METHYL_HLA-B,METHYL,noncancer,glucocorticoid receptor agonist,"HSD11B1, NR3C1","endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry","congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis",Launched,0.25702525473422,0.0171301775602,prednisone,,,0,0
BRD-K85920262-001-02-1::2.5::HTS,BRD-K85920262-001-02-1,WAY-600,2.5,HTS,Exp_UGT1A6 (ENSG00000167165),GE,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.388277336833294,0.298947439163,WAY-600,MTOR INHIBITOR,0.38910620332058704,1.824910256981565,-1.583965508957851
BRD-K85925969-001-17-4::2.5::HTS,BRD-K85925969-001-17-4,zalcitabine,2.5,HTS,METHYL_WBP2NL,METHYL,noncancer,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.321669784421724,0.028196602374,zalcitabine,,,0,0
BRD-K86003836-001-10-5::2.5::HTS,BRD-K86003836-001-10-5,flubendazole,2.5,HTS,Exp_SIAH2 (ENSG00000181788),GE,noncancer,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,Launched,0.38047518259999497,0.238069832741,flubendazole,TUBULIN POLYMERIZATION INHIBITOR,0.3853317091552823,5.589393228798657,-2.9386120972252616
BRD-K86109159-001-02-6::2.5::HTS,BRD-K86109159-001-02-6,VU0357121,2.5,HTS,Exp_DTNA (ENSG00000134769),GE,noncancer,glutamate receptor positive allosteric modulator,GRM5,,,Preclinical,0.27895779762150896,0.104972093385,VU0357121,,,0,0
BRD-K86118762-001-01-8::2.5::HTS,BRD-K86118762-001-01-8,linsitinib,2.5,HTS,DEM2_AP5M1 (55745),DEMETER2_COM,targeted cancer,IGF-1 inhibitor,"IGF1R, INSR, INSRR",,,Phase 3,0.318858197384646,0.0975038239925,linsitinib,OTHER,0.31744150782898745,-3.8241818156442258,-0.5143709395407905
BRD-K86161929-001-11-7::2.52::HTS,BRD-K86161929-001-11-7,cortisone-acetate,2.52,HTS,DEM2_ACTR5 (79913),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,NR3C1,"pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis",Launched,0.26566216281855,0.0452373785731,cortisone-acetate,,,0,0
BRD-K86161929-001-13-3::2.5::HTS,BRD-K86161929-001-13-3,cortisone-acetate,2.5,HTS,CRISPR_ZBTB2 (57621),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,"pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis",Launched,0.32260984122320396,0.103121753174,cortisone-acetate,,,0,0
BRD-K86171477-001-01-3::2.5::MTS004,BRD-K86171477-001-01-3,eltoprazine,2.5,MTS004,CRISPR_FAM35A (54537),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor agonist,"HTR1A, HTR1B",,,Phase 2,0.29056977482653,0.0686905271884,eltoprazine,,,0,0
BRD-K86204871-001-16-2::2.5::HTS,BRD-K86204871-001-16-2,terconazole,2.5,HTS,RMUTmis_ITGAV (3685),MUT,noncancer,sterol demethylase inhibitor,,infectious disease,vulvovaginal candidiasis,Launched,0.26227459351228,0.0839803778305,terconazole,,,0,0
BRD-K86294588-001-01-9::2.5::HTS,BRD-K86294588-001-01-9,schisandrin-b,2.5,HTS,MIRNA_hsa-miR-143,MIRNA,noncancer,antioxidant,ATR,,,Preclinical,0.2849474741573039,0.0284897245666,schisandrin-b,,,0,0
BRD-K86301799-001-34-8::2.5::HTS,BRD-K86301799-001-34-8,dipyridamole,2.5,HTS,METHYL_RPRD2,METHYL,noncancer,phosphodiesterase inhibitor,"ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1",cardiology,"coronary artery disease (CAD), peripheral artery disease (PAD), hypertension",Launched,0.328691832822539,0.218155664325,dipyridamole,,,0,0
BRD-K86307448-001-17-5::2.5::HTS,BRD-K86307448-001-17-5,allopurinol,2.5,HTS,MIRNA_hsa-miR-520f,MIRNA,noncancer,xanthine oxidase inhibitor,XDH,"rheumatology, urology","gout, kidney stones",Launched,0.26042777626758395,0.0550238406288,allopurinol,,,0,0
BRD-K86307448-001-19-1::2.5::HTS,BRD-K86307448-001-19-1,allopurinol,2.5,HTS,DEM2_PLXNA3 (55558),DEMETER2_COM,noncancer,xanthine oxidase inhibitor,XDH,"rheumatology, urology","gout, kidney stones",Launched,0.26363607808345196,0.116989681855,allopurinol,,,0,0
BRD-K86344238-003-04-6::2.5::HTS,BRD-K86344238-003-04-6,linsidomine,2.5,HTS,CRISPR_ITM2C (81618),AVANA_PUBLIC_18Q2,noncancer,nitric oxide donor,,urology,erectile dysfunction,Launched,0.285986796160049,0.0996258956188,linsidomine,,,0,0
BRD-K86358349-001-02-0::2.440473496::MTS004,BRD-K86358349-001-02-0,bromantan,2.440473496,MTS004,METABOL_glycine,METABOL,noncancer,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",,neurology/psychiatry,neurasthenia,Launched,0.32573066136378104,0.0755140589121,bromantan,,,0,0
BRD-K86410485-046-01-0::2.499987354::MTS004,BRD-K86410485-046-01-0,eliglustat,2.499987354,MTS004,PROT_Rab25,PROT,noncancer,Glycosyl transferase inhibitor,UGCG,hematology,"Gaucher disease, Gaucher disease",Launched,0.24854436998672302,0.117265158857,eliglustat,,,0,0
BRD-K86435560-001-01-0::2.5::HTS,BRD-K86435560-001-01-0,perchlozone,2.5,HTS,DEM2_GPR35 (2859),DEMETER2_COM,noncancer,,,infectious disease,tuberculosis,Launched,0.29849125335596804,0.111024185896,perchlozone,,,0,0
BRD-K86436199-003-01-3::2.5::HTS,BRD-K86436199-003-01-3,landiolol,2.5,HTS,METHYL_PDE12,METHYL,noncancer,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia,Launched,0.274851215708221,0.0947251537329,landiolol,,,0,0
BRD-K86525559-001-04-5::2.5::HTS,BRD-K86525559-001-04-5,AZD7762,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.35136719954104806,0.248498546072,AZD7762,OTHER,0.35412861966729103,6.0106948753098814,0.5535268766932826
BRD-K86600316-003-02-0::2.5::HTS,BRD-K86600316-003-02-0,RS-79948,2.5,HTS,Exp_FDPSP8 (ENSG00000224763),GE,noncancer,adrenergic receptor antagonist,ADRA2A,,,Preclinical,0.270215035564203,0.0619116764787,RS-79948,,,0,0
BRD-K86670086-001-02-5::2.500040519::MTS004,BRD-K86670086-001-02-5,sutezolid,2.500040519,MTS004,MIRNA_hsa-miR-558,MIRNA,noncancer,protein synthesis inhibitor,,,,Phase 2,0.290885445363948,0.0369365507987,sutezolid,,,0,0
BRD-K86727142-001-12-4::2.5::HTS,BRD-K86727142-001-12-4,embelin,2.5,HTS,Exp_RBM34 (ENSG00000188739),GE,targeted cancer,"HCV inhibitor, XIAP inhibitor",XIAP,,,Preclinical,0.264982791229534,0.091157894164,embelin,,,0,0
BRD-K86797399-001-04-4::2.5::HTS,BRD-K86797399-001-04-4,SB-939,2.5,HTS,METHYL_ELAVL4,METHYL,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",,,Phase 2,0.360136784621431,0.103537727731,SB-939,HDAC INHIBITOR,0.3585646982502147,6.31374705692155,-0.4975747040522149
BRD-K86799112-001-02-0::2.5::HTS,BRD-K86799112-001-02-0,5-HMF,2.5,HTS,CRISPR_MNAT1 (4331),AVANA_PUBLIC_18Q2,noncancer,,,,,Phase 2,0.29301289820272997,0.134947101729,5-HMF,,,0,0
BRD-K86816506-001-01-8::2.5::HTS,BRD-K86816506-001-01-8,PF-04457845,2.5,HTS,RMUTmis_SAMD9 (54809),MUT,noncancer,FAAH inhibitor,FAAH,,,Phase 2,0.238315681591008,0.0306329733475,PF-04457845,,,0,0
BRD-K86856088-001-06-9::2.5::MTS004,BRD-K86856088-001-06-9,UNC0638,2.5,MTS004,Exp_HSPA13 (ENSG00000155304),GE,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.276146780406279,0.101444160973,UNC0638,,,0,0
BRD-K86864073-001-01-1::2.5::MTS004,BRD-K86864073-001-01-1,chloroprocaine,2.5,MTS004,DEM2_PTAFR (5724),DEMETER2_COM,noncancer,sodium channel blocker,"ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3",neurology/psychiatry,local anesthetic,Launched,0.291732738759154,0.0852930227808,chloroprocaine,,,0,0
BRD-K86873305-236-14-7::2.448463554::MTS004,BRD-K86873305-236-14-7,piperacillin,2.448463554,MTS004,DEM2_CDC7 (8317),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia",Launched,0.31570725375969,0.022167880029,piperacillin,,,0,0
BRD-K86882815-001-03-2::2.5::HTS,BRD-K86882815-001-03-2,cabergoline,2.5,HTS,CRISPR_HSPA9 (3313),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7",endocrinology,hyperprolactinemia,Launched,0.28085662090144003,0.0480454478921,cabergoline,,,0,0
BRD-K86887724-001-10-6::2.59::HTS,BRD-K86887724-001-10-6,dofetilide,2.59,HTS,PROT_PAI-1,PROT,noncancer,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",,,Withdrawn,0.22605157386664398,0.103720022553,dofetilide,,,0,0
BRD-K86892782-001-17-0::2.5::HTS,BRD-K86892782-001-17-0,edoxudine,2.5,HTS,Exp_POU3F1 (ENSG00000185668),GE,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),Launched,0.291160878975984,0.199428603045,edoxudine,,,0,0
BRD-K86930074-001-05-0::2.5::HTS,BRD-K86930074-001-05-0,cediranib,2.5,HTS,Exp_MICU3 (ENSG00000155970),GE,targeted cancer,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.418711644201704,0.356042510685,cediranib,OTHER,0.4197369795690476,1.358577123496744,-2.2751079959301537
BRD-K86972824-001-01-4::2.5::HTS,BRD-K86972824-001-01-4,oltipraz,2.5,HTS,PROT_Bap1 c-4,PROT,targeted cancer,"nuclear factor erythroid derived, like (NRF2) activator",ANG,,,Phase 3,0.218471274940966,0.0210196636363,oltipraz,,,0,0
BRD-K86972824-001-02-2::2.5::HTS,BRD-K86972824-001-02-2,oltipraz,2.5,HTS,Exp_BNIP3 (ENSG00000176171),GE,targeted cancer,"nuclear factor erythroid derived, like (NRF2) activator",ANG,,,Phase 3,0.269225245014577,0.0780897294833,oltipraz,,,0,0
BRD-K87024524-065-17-7::2.5::HTS,BRD-K87024524-065-17-7,phenelzine,2.5,HTS,CRISPR_LRRTM3 (347731),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,Launched,0.263548557564158,0.0879789624219,phenelzine,,,0,0
BRD-K87028197-001-01-3::2.5::HTS,BRD-K87028197-001-01-3,asunaprevir,2.5,HTS,MIRNA_hsa-miR-122,MIRNA,noncancer,HCV inhibitor,,,,Phase 3,0.26635608275037503,0.170893224728,asunaprevir,,,0,0
BRD-K87036601-001-01-6::2.5::HTS,BRD-K87036601-001-01-6,azodicarbonamide,2.5,HTS,CRISPR_TUBGCP3 (10426),AVANA_PUBLIC_18Q2,noncancer,DNA synthesis inhibitor,,,,Phase 2,0.105694275524545,0.0948878055769,azodicarbonamide,,,0,0
BRD-K87048468-003-02-7::2.5::HTS,BRD-K87048468-003-02-7,RS-102221,2.5,HTS,DEM2_CRTAM (56253),DEMETER2_COM,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.321240179866433,0.104178086612,RS-102221,,,0,0
BRD-K87112191-001-04-5::2.5::HTS,BRD-K87112191-001-04-5,PP242,2.5,HTS,Exp_ZNF506 (ENSG00000081665),GE,targeted cancer,mTOR inhibitor,"MTOR, PASK",,,Preclinical,0.36448344541703903,0.293809275034,PP242,MTOR INHIBITOR,0.36559684371254986,2.1035952858539235,-1.099700686970083
BRD-K87124298-001-03-4::2.5::HTS,BRD-K87124298-001-03-4,OSI-027,2.5,HTS,Exp_AOC1 (ENSG00000002726),GE,targeted cancer,mTOR inhibitor,MTOR,,,Phase 1,0.40666010427002797,0.238929267564,OSI-027,MTOR INHIBITOR,0.4090784082976193,1.527573685311825,-1.3511501139048696
BRD-K87156652-001-12-7::2.5::HTS,BRD-K87156652-001-12-7,carbimazole,2.5,HTS,PROT_Gab2,PROT,noncancer,antithyroid agent,TPO,endocrinology,hyperthyroidism,Launched,0.261127499793545,0.0205130626448,carbimazole,,,0,0
BRD-K87158025-001-01-6::2.5::HTS,BRD-K87158025-001-01-6,benzamil,2.5,HTS,METHYL_CAV2,METHYL,noncancer,sodium channel blocker,"ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1",,,Phase 2,0.303344005946349,0.0977927359604,benzamil,OTHER,0.3044558003549349,-2.248272612852336,0.7266974673168329
BRD-K87202646-001-32-6::2.5::HTS,BRD-K87202646-001-32-6,isoniazid,2.5,HTS,MIRNA_hsa-miR-92b,MIRNA,noncancer,FABI inhibitor,"CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4",infectious disease,tuberculosis,Launched,0.31812682793804303,0.074079741193,isoniazid,,,0,0
BRD-K87202646-061-04-9::2.5::HTS,BRD-K87202646-061-04-9,pasiniazid,2.5,HTS,METHYL_DPY30,METHYL,noncancer,cyclooxygenase inhibitor,,infectious disease,tuberculosis,Launched,0.25936654739960197,0.0453131081963,pasiniazid,,,0,0
BRD-K87278688-001-01-0::2.5::HTS,BRD-K87278688-001-01-0,armodafinil,2.5,HTS,DEM2_ANG (283),DEMETER2_COM,noncancer,adrenergic receptor agonist,SLC6A3,"pulmonary, neurology/psychiatry","obstructive sleep apnea, narcolepsy, shift work disorder (SWD)",Launched,0.193988769133055,0.0583752177676,armodafinil,,,0,0
BRD-K87316765-001-01-4::2.499975056::MTS004,BRD-K87316765-001-01-4,prinaberel,2.499975056,MTS004,Exp_CTDSP1 (ENSG00000144579),GE,noncancer,estrogen receptor agonist,"ESR2, NCOA1",,,Phase 2,0.248866022097533,0.133878457979,prinaberel,,,0,0
BRD-K87349602-001-03-8::2.5::HTS,BRD-K87349602-001-03-8,beta-CCB,2.5,HTS,CRISPR_GSTM1 (2944),AVANA_PUBLIC_18Q2,noncancer,benzodiazepine receptor ligand,"GABRA1, GABRG2",,,Launched,0.294178156411446,0.0794496708741,beta-CCB,,,0,0
BRD-K87349682-347-03-8::2.36::HTS,BRD-K87349682-347-03-8,norepinephrine,2.36,HTS,Exp_ROBO4 (ENSG00000154133),GE,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder",Launched,0.31284051097172605,0.186107055542,norepinephrine,,,0,0
BRD-K87386013-001-01-7::2.5::MTS004,BRD-K87386013-001-01-7,diroximel-fumarate,2.5,MTS004,Exp_ANGPTL3 (ENSG00000132855),GE,noncancer,anti-inflammatory agent,,,,Phase 3,0.315836914721607,0.0710398692735,diroximel-fumarate,,,0,0
BRD-K87465484-001-02-7::2.5::MTS004,BRD-K87465484-001-02-7,UNC0646,2.5,MTS004,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.34518640228802694,0.222073781217,UNC0646,,,0,0
BRD-K87510569-001-02-8::2.5::HTS,BRD-K87510569-001-02-8,RS-504393,2.5,HTS,DEM2_HSFY2&HSFY1 (159119&86614),DEMETER2_COM,noncancer,CC chemokine receptor antagonist,"CCL2, CCR2",,,Preclinical,0.298723542869321,0.0546650434332,RS-504393,,,0,0
BRD-K87512222-019-01-7::2.5::HTS,BRD-K87512222-019-01-7,taltobulin,2.5,HTS,Exp_PTPRA (ENSG00000132670),GE,chemo,tubulin polymerization inhibitor,,,,Phase 1,0.392475911860582,0.177041992513,taltobulin,TUBULIN POLYMERIZATION INHIBITOR,0.3862923441870058,4.471114542704604,-0.8395511348992915
BRD-K87535339-001-01-6::2.53::HTS,BRD-K87535339-001-01-6,"5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",2.53,HTS,CRISPR_STMN1 (3925),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.256295133722161,-0.00591534467376,"5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",,,0,0
BRD-K87573013-001-01-0::2.5::MTS004,BRD-K87573013-001-01-0,CL-225385,2.5,MTS004,PROT_TSC1_Caution,PROT,noncancer,,,,,Phase 2,0.282796420992796,0.0975684869342,CL-225385,,,0,0
BRD-K87696786-003-04-4::2.5::HTS,BRD-K87696786-003-04-4,LY456236,2.5,HTS,PROT_EGFR,PROT,noncancer,glutamate receptor antagonist,GRM1,,,Preclinical,0.26429420313753305,0.134154272157,LY456236,,,0,0
BRD-K87700323-003-05-1::2.5::HTS,BRD-K87700323-003-05-1,cetylpyridinium,2.5,HTS,Exp_SLCO4A1 (ENSG00000101187),GE,noncancer,,,dental,"gingivitis, mouth inflammation",Launched,0.30970984213034997,0.278212419512,cetylpyridinium,OTHER,0.3076788761089378,3.6270031809942798,-2.003252625859776
BRD-K87737963-001-06-0::2.5::HTS,BRD-K87737963-001-06-0,cyt387,2.5,HTS,MIRNA_hsa-miR-548a-3p,MIRNA,targeted cancer,,"JAK1, JAK2, JAK3",,,Phase 3,0.338859434417612,0.25160427523,cyt387,OTHER,0.34048629400513897,1.6996075579543537,-3.5102428461429684
BRD-K87774949-001-03-9::2.5::HTS,BRD-K87774949-001-03-9,istradefylline,2.5,HTS,DEM2_SLC35E1 (79939),DEMETER2_COM,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia",Launched,0.274461311373427,0.0751963447009,istradefylline,,,0,0
BRD-K87777313-001-02-2::2.5::MTS004,BRD-K87777313-001-02-2,irosustat,2.5,MTS004,PROT_TAZ,PROT,targeted cancer,steroid sulfatase inhibitor,"CA2, STS",,,Phase 2,0.297990038744674,0.0828987479609,irosustat,,,0,0
BRD-K87782578-001-01-4::2.5::HTS,BRD-K87782578-001-01-4,AVL-292,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",,,Phase 2,0.40420987317887896,0.180136921482,AVL-292,OTHER,0.4023052957646589,1.6969124184007174,-3.1243143593329616
BRD-K87827419-001-16-8::2.5::HTS,BRD-K87827419-001-16-8,melphalan,2.5,HTS,Exp_NCEH1 (ENSG00000144959),GE,chemo,"DNA alkylating agent, DNA inhibitor",,hematologic malignancy,multiple myeloma,Launched,0.4540207928752629,0.350466535022,melphalan,OTHER,0.4533685687301758,3.4365541210206163,-3.0485786035282567
BRD-K87932577-001-02-4::2.5::HTS,BRD-K87932577-001-02-4,CDK1-5-inhibitor,2.5,HTS,CRISPR_FBXO40 (51725),AVANA_PUBLIC_18Q2,targeted cancer,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3B",,,Preclinical,0.271939273979382,0.115909952044,CDK1-5-inhibitor,,,0,0
BRD-K87948281-001-01-9::2.499985333::MTS004,BRD-K87948281-001-01-9,F-11440,2.499985333,MTS004,METHYL_DAPK3,METHYL,noncancer,serotonin receptor agonist,HTR1A,,,Phase 2,0.308511080133451,0.140676423604,F-11440,,,0,0
BRD-K87990216-001-10-2::2.5::HTS,BRD-K87990216-001-10-2,piretanide,2.5,HTS,LIN_glioblastoma,LIN,noncancer,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",Launched,0.16894225672450502,0.130890266176,piretanide,,,0,0
BRD-K88025533-003-03-3::2.5::HTS,BRD-K88025533-003-03-3,fingolimod,2.5,HTS,DEM2_CYP3A7 (1551),DEMETER2_COM,noncancer,"immunosuppressant, sphingosine phosphate receptor agonist","S1PR1, S1PR5",neurology/psychiatry,multiple sclerosis,Launched,0.314325090719982,0.0166013330481,fingolimod,,,0,0
BRD-K88052444-001-08-8::2.5::HTS,BRD-K88052444-001-08-8,urea,2.5,HTS,MIRNA_hsa-miR-516b,MIRNA,noncancer,hydroxy radical formation stimulant,"ARG1, CA2, CTNNB1",dermatology,"psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis",Launched,0.26837114807966,0.0948115713839,urea,,,0,0
BRD-K88061624-001-21-4::2.5::HTS,BRD-K88061624-001-21-4,mizoribine,2.5,HTS,CRISPR_CD14 (929),AVANA_PUBLIC_18Q2,noncancer,"immunosuppressant, inosine monophosphate dehydrogenase inhibitor",IMPDH1,,,Launched,0.330851815959236,0.111558605236,mizoribine,,,0,0
BRD-K88090157-050-10-8::2.5::HTS,BRD-K88090157-050-10-8,pimethixene,2.5,HTS,PROT_Chk2,PROT,noncancer,antihistamine,,"neurology/psychiatry, allergy","attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis",Launched,0.281080509290365,0.11775945529,pimethixene,,,0,0
BRD-K88143662-001-01-5::2.5::MTS004,BRD-K88143662-001-01-5,metharbital,2.5,MTS004,CN_SERHL (94009),CN,noncancer,GABA receptor modulator,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,epilepsy,Launched,0.297990145922192,0.0789911740958,metharbital,,,0,0
BRD-K88172511-003-20-3::2.42::HTS,BRD-K88172511-003-20-3,naltrexone,2.42,HTS,CRISPR_SP110 (3431),AVANA_PUBLIC_18Q2,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,Launched,0.35483555220746005,0.0839872439416,naltrexone,,,0,0
BRD-K88172511-003-21-1::2.5::HTS,BRD-K88172511-003-21-1,naltrexone,2.5,HTS,LIN_gastric_adenocarcinoma,LIN,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,Launched,0.254263519618678,0.0944110739423,naltrexone,,,0,0
BRD-K88186167-001-04-8::2.5::HTS,BRD-K88186167-001-04-8,GW-4064,2.5,HTS,CRISPR_AHSA2 (130872),AVANA_PUBLIC_18Q2,noncancer,FXR agonist,NR1H4,,,Preclinical,0.262536698431937,0.129562288446,GW-4064,,,0,0
BRD-K88219015-001-10-8::2.5::HTS,BRD-K88219015-001-10-8,asaraldehyde,2.5,HTS,MIRNA_hsa-miR-573,MIRNA,noncancer,cyclooxygenase inhibitor,PTGS2,,,Preclinical,0.288938038615182,0.086311655889,asaraldehyde,,,0,0
BRD-K88308881-001-06-8::2.5::HTS,BRD-K88308881-001-06-8,ethenzamide,2.5,HTS,PROT_Bid_Caution,PROT,noncancer,analgesic agent,,"neurology/psychiatry, endocrinology, otolaryngology","headache, fever, common cold",Launched,0.207233297866624,0.119789470904,ethenzamide,,,0,0
BRD-K88358234-003-04-8::2.5::HTS,BRD-K88358234-003-04-8,xaliproden,2.5,HTS,METABOL_2-hydroxyglutarate,METABOL,targeted cancer,serotonin receptor agonist,HTR1A,,,Phase 3,0.280124731747768,0.110350541816,xaliproden,,,0,0
BRD-K88366685-300-06-0::2.5::HTS,BRD-K88366685-300-06-0,trimetazidine,2.5,HTS,METABOL_C58:7 TAG,METABOL,noncancer,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris,Launched,0.212358019363667,0.0634716855553,trimetazidine,,,0,0
BRD-K88405679-003-03-1::2.5::HTS,BRD-K88405679-003-03-1,thonzylamine,2.5,HTS,MIRNA_hsa-miR-204,MIRNA,noncancer,antihistamine,,neurology/psychiatry,itching,Launched,0.250865367541596,0.0634541066908,thonzylamine,,,0,0
BRD-K88429204-001-35-1::2.5::HTS,BRD-K88429204-001-35-1,pyrimethamine,2.5,HTS,Exp_C11orf68 (ENSG00000175573),GE,noncancer,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,Launched,0.38918721171350396,0.369375643654,pyrimethamine,OTHER,0.3898910857162395,2.222802564529449,-3.5910356740876
BRD-K88506063-001-01-8::2.5::HTS,BRD-K88506063-001-01-8,KD025,2.5,HTS,Exp_PSG11 (ENSG00000243130),GE,targeted cancer,rho associated kinase inhibitor,ROCK2,,,Phase 2,0.279789749392662,0.141075613065,KD025,OTHER,0.2705523238592695,0.6089107304001253,-3.2586765019707977
BRD-K88544581-001-06-1::2.5::HTS,BRD-K88544581-001-06-1,CI-976,2.5,HTS,METHYL_PGRMC2,METHYL,noncancer,ACAT inhibitor,"ACAT1, CES1",,,Phase 1,0.289815656334829,0.09456156252,CI-976,,,0,0
BRD-K88553858-001-02-7::2.5::HTS,BRD-K88553858-001-02-7,benurestat,2.5,HTS,CN_GMDS (2762),CN,noncancer,urease inhibitor,,,,Phase 1,0.254468138580644,0.0871612412907,benurestat,,,0,0
BRD-K88560311-011-06-3::2.5::HTS,BRD-K88560311-011-06-3,rucaparib,2.5,HTS,MIRNA_hsa-miR-95,MIRNA,targeted cancer,PARP inhibitor,"PARP1, PARP2",,,Phase 3,0.295106665735382,0.0869822406921,rucaparib,,,0,0
BRD-K88568253-011-19-9::2.5::HTS,BRD-K88568253-011-19-9,iproniazid,2.5,HTS,Exp_NR1H4 (ENSG00000012504),GE,noncancer,monoamine oxidase inhibitor,"MAOA, MAOB",,,Withdrawn,0.276087485983573,0.0792463428013,iproniazid,,,0,0
BRD-K88611939-001-22-4::2.5::HTS,BRD-K88611939-001-22-4,aniracetam,2.5,HTS,CRISPR_FAM134A (79137),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor agonist,"DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A",,,Launched,0.24680217750308497,0.0699684416787,aniracetam,,,0,0
BRD-K88625236-001-04-2::2.5::HTS,BRD-K88625236-001-04-2,nonoxynol-9,2.5,HTS,METHYL_LOC101927100,METHYL,noncancer,membrane integrity inhibitor,,endocrinology,contraceptive,Launched,0.37210924529232203,0.225807816729,nonoxynol-9,OTHER,0.3682872130451125,2.2140697950524126,-2.351063785058277
BRD-K88646909-004-16-2::2.5::HTS,BRD-K88646909-004-16-2,arecoline,2.5,HTS,METABOL_C34:4 PC,METABOL,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,Phase 1,0.306421801638719,0.0996241859087,arecoline,,,0,0
BRD-K88677950-001-03-9::2.5::HTS,BRD-K88677950-001-03-9,PD-198306,2.5,HTS,Exp_FMN1 (ENSG00000248905),GE,targeted cancer,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",,,Preclinical,0.45965829503979794,0.425544990723,PD-198306,OTHER,0.4547396266675545,0.450190287910457,4.858630073130459
BRD-K88682005-001-15-8::2.5::HTS,BRD-K88682005-001-15-8,chlorothiazide,2.5,HTS,PROT_4E-BP1_pS65,PROT,noncancer,diuretic,"CA1, CA2, CA4, SLC12A3",cardiology,hypertension,Launched,0.257918451153573,0.0631416539799,chlorothiazide,,,0,0
BRD-K88701661-001-02-9::2.5::HTS,BRD-K88701661-001-02-9,dimercaptosuccinic-acid,2.5,HTS,PROT_PEA15_pS116,PROT,noncancer,chelating agent,DNMT1,neurology/psychiatry,metal toxicity,Launched,0.299565849830348,0.118052324457,dimercaptosuccinic-acid,,,0,0
BRD-K88742110-001-07-9::2.5::HTS,BRD-K88742110-001-07-9,PCI-34051,2.5,HTS,PROT_PRDX1,PROT,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC6, HDAC8",,,Preclinical,0.292485898710101,0.149331123796,PCI-34051,,,0,0
BRD-K88759641-003-02-8::2.5::HTS,BRD-K88759641-003-02-8,EMD-66684,2.5,HTS,Exp_GABPB1 (ENSG00000104064),GE,noncancer,angiotensin receptor antagonist,AGTR1,,,Preclinical,0.35440739145434996,0.113016715561,EMD-66684,,,0,0
BRD-K88789588-001-14-9::2.5::HTS,BRD-K88789588-001-14-9,letrozole,2.5,HTS,Exp_BLID (ENSG00000259571),GE,targeted cancer,aromatase inhibitor,CYP19A1,oncology,breast cancer,Launched,0.303210250125666,0.148301939534,letrozole,,,0,0
BRD-K88807631-001-01-3::2.5::HTS,BRD-K88807631-001-01-3,elacridar,2.5,HTS,MIRNA_hsa-miR-519d,MIRNA,targeted cancer,P glycoprotein inhibitor,ABCB1,,,Phase 1,0.30159420163355,0.104251437341,elacridar,,,0,0
BRD-K88854110-001-01-5::2.499975441::MTS004,BRD-K88854110-001-01-5,taprenepag,2.499975441,MTS004,PROT_p70S6K,PROT,noncancer,prostaglandin receptor agonist,PTGER2,,,Phase 2,0.266368076668774,0.197542208437,taprenepag,,,0,0
BRD-K88956297-003-01-9::2.5::HTS,BRD-K88956297-003-01-9,"1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",2.5,HTS,METHYL_MIR3918,METHYL,noncancer,,,,,Preclinical,0.33097688462028496,0.0468526213094,"1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",,,0,0
BRD-K89014967-001-04-3::2.5::HTS,BRD-K89014967-001-04-3,AS-703026,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 2,0.44644425998157894,0.524775525953,AS-703026,MEK INHIBITOR,0.4460171735748528,0.453188102608736,4.776749515680903
BRD-K89015388-001-01-7::2.5::HTS,BRD-K89015388-001-01-7,GSK923295,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,centromere associated protein inhibitor,CENPE,,,Phase 1,0.384311805724046,0.422525804999,GSK923295,OTHER,0.3883427030359593,4.961148890022101,-3.637148465115285
BRD-K89048337-001-06-9::2.5::HTS,BRD-K89048337-001-06-9,puerarin,2.5,HTS,METHYL_GLI1,METHYL,noncancer,serotonin receptor antagonist,,,,Phase 2,0.246774697944082,0.0772122508607,puerarin,,,0,0
BRD-K89053832-001-01-0::2.5::HTS,BRD-K89053832-001-01-0,VLX600,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,ubiquitin C-terminal hydrolase inhibitor,USP14,,,Phase 1,0.41527454538904895,0.262248311228,VLX600,OTHER,0.3945977324013584,4.10929345518541,-1.7196108418914662
BRD-K89055274-048-22-7::2.5::HTS,BRD-K89055274-048-22-7,alverine,2.5,HTS,METABOL_C16:0 CE,METABOL,noncancer,muscle relaxant,HTR1A,gastroenterology,"irritable bowel syndrome, diverticular disease",Launched,0.26433894456949103,0.043797421127,alverine,,,0,0
BRD-K89056082-001-07-7::2.5::HTS,BRD-K89056082-001-07-7,chlorocresol,2.5,HTS,CN_CARD8 (22900),CN,noncancer,ryanodine receptor activator,,infectious disease,first-aid antiseptic,Launched,0.25693160902082296,0.034712236936,chlorocresol,,,0,0
BRD-K89071957-001-01-1::0.25::HTS,BRD-K89071957-001-01-1,CTS21166,0.25,HTS,METABOL_serotonin,METABOL,noncancer,beta-secretase inhibitor,BACE1,,,Phase 1,0.31015639166445397,0.0574499819907,CTS21166,,,0,0
BRD-K89072800-001-01-8::2.5::HTS,BRD-K89072800-001-01-8,2-TEDC,2.5,HTS,METABOL_C22:6 CE,METABOL,noncancer,lipoxygenase inhibitor,ALOX12,,,Preclinical,0.19344094402933298,0.0755144247088,2-TEDC,,,0,0
BRD-K89085489-001-23-2::2.499967871::MTS004,BRD-K89085489-001-23-2,fenretinide,2.499967871,MTS004,Exp_CASKIN1 (ENSG00000167971),GE,targeted cancer,"apoptosis stimulant, retinoid receptor agonist",RARA,,,Phase 3,0.380905916585394,0.301715458699,fenretinide,OTHER,0.3522846467187311,3.1277377841074867,-4.092922830077573
BRD-K89104321-003-14-8::2.5::HTS,BRD-K89104321-003-14-8,gaboxadol,2.5,HTS,DEM2_FRK (2444),DEMETER2_COM,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3",,,Phase 3,0.22911380429418202,0.164060436676,gaboxadol,,,0,0
BRD-K89121095-001-01-7::2.499999138::MTS004,BRD-K89121095-001-01-7,tedizolid-phosphate,2.499999138,MTS004,Exp_TP63 (ENSG00000073282),GE,noncancer,protein synthesis inhibitor,,infectious disease,skin infections,Launched,0.42411527280933,0.312003056807,tedizolid-phosphate,OTHER,0.4215759731766988,5.302212658886606,-4.046252481301118
BRD-K89125793-001-26-0::2.5::HTS,BRD-K89125793-001-26-0,tinidazole,2.5,HTS,MIRNA_hsa-miR-490-5p,MIRNA,noncancer,antiprotozoal agent,,"infectious disease, obstetrics/gynecology","giardiasis, amebiasis, bacterial vaginosis, trichomoniasis",Launched,0.27722063172973,0.00344313194772,tinidazole,,,0,0
BRD-K89162000-001-06-4::2.5::HTS,BRD-K89162000-001-06-4,tandutinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",,,Phase 2,0.295319619025588,0.284967322438,tandutinib,,,0,0
BRD-K89210380-001-13-7::2.5::HTS,BRD-K89210380-001-13-7,biotin,2.5,HTS,DEM2_RREB1 (6239),DEMETER2_COM,noncancer,vitamin B,"ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6",,,Launched,0.2770563597643039,0.0789087167286,biotin,,,0,0
BRD-K89272762-001-12-7::2.5::HTS,BRD-K89272762-001-12-7,NPPB,2.5,HTS,MIRNA_hsa-miR-132,MIRNA,targeted cancer,chloride channel blocker,"ANO1, CLCN2, CLCN7, TRPA1",,,Preclinical,0.263532768385369,0.0554148523432,NPPB,,,0,0
BRD-K89272869-003-01-8::2.499996082::MTS004,BRD-K89272869-003-01-8,nalfurafine,2.499996082,MTS004,Exp_RN7SL181P (ENSG00000243738),GE,noncancer,opioid receptor agonist,"OPRK1, OPRM1",nephrology,uremic pruritus,Launched,0.298826653823208,0.0522352988182,nalfurafine,,,0,0
BRD-K89274813-001-02-3::2.5::HTS,BRD-K89274813-001-02-3,DMP-543,2.5,HTS,CRISPR_TAF9 (6880),AVANA_PUBLIC_18Q2,noncancer,acetylcholine release enhancer,,,,Phase 2,0.266172065289395,0.0845621516313,DMP-543,,,0,0
BRD-K89299012-001-06-0::2.5::HTS,BRD-K89299012-001-06-0,DCEBIO,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,potassium channel activator,"KCNN2, KCNN3, KCNN4",,,Preclinical,0.48478252176321707,0.426929556856,DCEBIO,OTHER,0.4929783525293603,2.7649510800279584,-1.8314626281042328
BRD-K89306950-001-12-5::2.5::HTS,BRD-K89306950-001-12-5,ML130,2.5,HTS,MIRNA_hsa-miR-566,MIRNA,noncancer,NOD1 inhibitor,,,,Preclinical,0.289813728738227,0.0756462519974,ML130,,,0,0
BRD-K89375097-300-08-8::2.5::HTS,BRD-K89375097-300-08-8,pirenzepine,2.5,HTS,PROT_Di-Ras3_Caution,PROT,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),Launched,0.29596182414195,0.0153948485038,pirenzepine,,,0,0
BRD-K89391146-001-08-0::2.5::HTS,BRD-K89391146-001-08-0,RG108,2.5,HTS,METABOL_uracil,METABOL,targeted cancer,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",,,Preclinical,0.22139366953108103,0.0964719812516,RG108,,,0,0
BRD-K89402695-001-02-3::2.5::HTS,BRD-K89402695-001-02-3,L-655240,2.5,HTS,PROT_YAP_Caution,PROT,noncancer,thromboxane receptor antagonist,PTGES,,,Phase 1,0.271414758506973,0.0299173324715,L-655240,,,0,0
BRD-K89413285-074-01-5::2.500023482::MTS004,BRD-K89413285-074-01-5,remimazolam,2.500023482,MTS004,METHYL_AIM1L,METHYL,noncancer,benzodiazepine receptor agonist,GABBR1,,,Phase 3,0.228254424464806,0.213539435297,remimazolam,,,0,0
BRD-K89490285-001-08-1::2.521612095::MTS004,BRD-K89490285-001-08-1,bentazepam,2.521612095,MTS004,METABOL_C22:1 SM,METABOL,noncancer,benzodiazepine receptor agonist,,neurology/psychiatry,"anxiety, sedative, muscle relaxant",Launched,0.356188573653408,0.104605367456,bentazepam,OTHER,0.35216353017090896,4.9915779260111215,-3.886656044257372
BRD-K89588135-001-01-9::2.5::HTS,BRD-K89588135-001-01-9,tagatose,2.5,HTS,MIRNA_hsa-miR-886-5p,MIRNA,noncancer,phosphorylase inhibitor,PYGL,,,Phase 3,0.294641978399431,0.0406414138098,tagatose,,,0,0
BRD-K89634775-001-09-9::2.5::HTS,BRD-K89634775-001-09-9,allylthiourea,2.5,HTS,CN_ABCA13 (154664),CN,noncancer,nitrification inhibitor,,,,Preclinical,0.304402128663364,0.0557576165261,allylthiourea,,,0,0
BRD-K89657519-001-01-8::2.5::HTS,BRD-K89657519-001-01-8,testosterone-enanthate,2.5,HTS,CRISPR_C15orf57 (90416),AVANA_PUBLIC_18Q2,noncancer,androgen receptor agonist,AR,endocrinology,hypogonadism,Launched,0.25216840728684603,0.115527594152,testosterone-enanthate,,,0,0
BRD-K89665618-003-02-5::2.5::HTS,BRD-K89665618-003-02-5,1-deoxymannojirimycin,2.5,HTS,METABOL_carnosine,METABOL,noncancer,alpha mannosidase inhibitor,MAN2A1,,,Preclinical,0.21988980357788399,0.0585464698472,1-deoxymannojirimycin,,,0,0
BRD-K89704198-001-12-3::2.5::HTS,BRD-K89704198-001-12-3,vincamine,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,noncancer,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,Withdrawn,0.249589248355092,0.045978954967,vincamine,,,0,0
BRD-K89712525-001-02-1::2.57::HTS,BRD-K89712525-001-02-1,2-oxoglutaric-acid,2.57,HTS,CRISPR_S100A6 (6277),AVANA_PUBLIC_18Q2,noncancer,,OXGR1,,,Preclinical,0.338315155333191,0.062187765846,2-oxoglutaric-acid,,,0,0
BRD-K89714990-001-01-5::2.5::HTS,BRD-K89714990-001-01-5,tepoxalin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia",Launched,0.400335224639358,0.340309304664,tepoxalin,OTHER,0.3977027237336369,5.968924853301365,-0.5735700779753583
BRD-K89732114-300-14-7::2.5::HTS,BRD-K89732114-300-14-7,trifluoperazine,2.5,HTS,MIRNA_hsa-miR-890,MIRNA,noncancer,dopamine receptor antagonist,"ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1",neurology/psychiatry,schizophrenia,Launched,0.300018197356432,0.0358110545221,trifluoperazine,,,0,0
BRD-K89839824-001-05-3::2.5::HTS,BRD-K89839824-001-05-3,raltitrexed,2.5,HTS,DEM2_CDK14 (5218),DEMETER2_COM,targeted cancer,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,Launched,0.378478011536352,0.113819164428,raltitrexed,OTHER,0.3618011656839857,3.9157755539003514,-3.2094139059946567
BRD-K89917372-001-01-2::2.5::HTS,BRD-K89917372-001-01-2,retigabine,2.5,HTS,MIRNA_hsa-miR-26a,MIRNA,noncancer,potassium channel activator,"KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",neurology/psychiatry,epilepsy,Launched,0.291266746380647,0.0717741440606,retigabine,,,0,0
BRD-K89920762-001-01-4::2.500013597::MTS004,BRD-K89920762-001-01-4,paritaprevir,2.500013597,MTS004,CRISPR_PPAPDC3 (84814),AVANA_PUBLIC_18Q2,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.309036367417795,0.000180165322159,paritaprevir,,,0,0
BRD-K89997465-003-43-0::2.5::HTS,BRD-K89997465-003-43-0,chlorpromazine,2.5,HTS,CN_FLOT1 (10211),CN,noncancer,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5","neurology/psychiatry, gastroenterology, hematology, infectious disease","schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus",Launched,0.269846119047075,0.0624465596063,chlorpromazine,,,0,0
BRD-K90027121-003-01-7::2.5::HTS,BRD-K90027121-003-01-7,amprolium,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,thiamine uptake blocker,,infectious disease,coccidiosis,Launched,0.296766866643563,0.123628777192,amprolium,,,0,0
BRD-K90027355-001-13-3::2.44::HTS,BRD-K90027355-001-13-3,spironolactone,2.44,HTS,Exp_FBLN7 (ENSG00000144152),GE,noncancer,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia",Launched,0.42290579182496296,0.30624307613,spironolactone,OTHER,0.4224969194755288,1.4507043021999606,-4.585880288996154
BRD-K90027355-001-19-0::2.5::HTS,BRD-K90027355-001-19-0,spironolactone,2.5,HTS,Exp_FGF8 (ENSG00000107831),GE,noncancer,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia",Launched,0.42290579182496296,0.30624307613,spironolactone,,,0,0
BRD-K90065682-300-02-6::2.5::HTS,BRD-K90065682-300-02-6,5-iodo-A-85380,2.5,HTS,PROT_HER3,PROT,noncancer,acetylcholine receptor agonist,,,,Phase 2,0.326446788003584,0.144506714731,5-iodo-A-85380,,,0,0
BRD-K90069354-001-03-7::2.5::MTS004,BRD-K90069354-001-03-7,isovaleramide,2.5,MTS004,METHYL_C9orf92,METHYL,noncancer,alcohol dehydrogenase inhibitor,,,,Phase 2,0.32194112289103805,0.0334812157299,isovaleramide,,,0,0
BRD-K90171280-001-01-4::2.328630918::MTS004,BRD-K90171280-001-01-4,LY2452473,2.328630918,MTS004,DEM2_ANO6 (196527),DEMETER2_COM,targeted cancer,androgen receptor modulator,AR,,,Phase 2,0.293912617545083,0.0991823406918,LY2452473,,,0,0
BRD-K90195324-003-02-5::2.5::HTS,BRD-K90195324-003-02-5,bazedoxifene,2.5,HTS,METHYL_PCDHGB8P,METHYL,noncancer,selective estrogen receptor modulator (SERM),"ESR1, ESR2","orthopedics, endocrinology","osteoporosis, menopause",Launched,0.27476812071713,0.12448591821,bazedoxifene,,,0,0
BRD-K90239174-001-01-8::2.5::HTS,BRD-K90239174-001-01-8,AMG-487,2.5,HTS,METABOL_palmitoylcarnitine,METABOL,noncancer,CC chemokine receptor antagonist,,,,Phase 2,0.253237913816379,0.0762480001491,AMG-487,,,0,0
BRD-K90333595-003-21-4::2.5::HTS,BRD-K90333595-003-21-4,phentolamine,2.5,HTS,RMUTmis_HOXB3 (3213),MUT,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","endocrinology, cardiology","pheochromocytoma, hypertension",Launched,0.252350817448648,0.0432681079418,phentolamine,,,0,0
BRD-K90374350-001-09-2::2.5::HTS,BRD-K90374350-001-09-2,chlorquinaldol,2.5,HTS,Exp_C11orf1 (ENSG00000137720),GE,noncancer,other antibiotic,,infectious disease,fungal infection,Launched,0.33984031873217097,0.179888328292,chlorquinaldol,OTHER,0.33705452381483825,3.106946688799004,-2.931626385845867
BRD-K90382497-001-10-7::2.5::HTS,BRD-K90382497-001-10-7,GW-843682X,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,PLK inhibitor,"PLK1, PLK3",,,Preclinical,0.3720912013758089,0.296025042573,GW-843682X,OTHER,0.3706841745710716,5.944760061744058,-2.78690416530387
BRD-K90497590-001-04-2::2.5::HTS,BRD-K90497590-001-04-2,AR-12,2.5,HTS,CN_CLEC18B (497190),CN,targeted cancer,phosphoinositide dependent kinase inhibitor,PDPK1,,,Phase 1,0.374224572595668,0.125810028193,AR-12,OTHER,0.3716895784122992,3.198977530798645,-3.058812817472975
BRD-K90524085-001-07-8::2.5::HTS,BRD-K90524085-001-07-8,MY-5445,2.5,HTS,Exp_ALKBH6 (ENSG00000239382),GE,noncancer,"phosphodiesterase inhibitor, platelet aggregation inhibitor",PDE5A,,,Preclinical,0.320677199668822,0.115643288326,MY-5445,,,0,0
BRD-K90563805-001-02-6::2.5::MTS004,BRD-K90563805-001-02-6,natamycin,2.5,MTS004,METABOL_anthranilic acid,METABOL,noncancer,fungal ergosterol inhibitor,,"ophthalmology, infectious disease","conjunctivitis, fungal keratosis, blepharitis",Launched,0.252297257693301,0.0379113755769,natamycin,,,0,0
BRD-K90574421-001-03-5::2.5::HTS,BRD-K90574421-001-03-5,ipsapirone,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,serotonin receptor agonist,HTR1A,,,Phase 3,0.242410328001091,0.0606732004392,ipsapirone,,,0,0
BRD-K90629600-001-01-4::2.5::MTS004,BRD-K90629600-001-01-4,emorfazone,2.5,MTS004,CRISPR_FBRSL1 (57666),AVANA_PUBLIC_18Q2,noncancer,"antiinflammatory agent, cyclooxygenase inhibitor",,dental,mouth inflammation,Launched,0.304289926149096,0.098913850672,emorfazone,,,0,0
BRD-K90630139-003-05-9::2.5::HTS,BRD-K90630139-003-05-9,butenafine,2.5,HTS,METHYL_SNX14,METHYL,noncancer,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Launched,0.289148176075948,0.0588152848073,butenafine,,,0,0
BRD-K90647725-001-06-5::2.5::HTS,BRD-K90647725-001-06-5,oleanolic-acid,2.5,HTS,METHYL_ZNF541,METHYL,noncancer,G protein-coupled receptor agonist,GPBAR1,,,Preclinical,0.303647354895017,0.11488491629,oleanolic-acid,,,0,0
BRD-K90647725-001-07-3::2.5::HTS,BRD-K90647725-001-07-3,oleanolic-acid,2.5,HTS,Exp_LPCAT2 (ENSG00000087253),GE,noncancer,G protein-coupled receptor agonist,GPBAR1,,,Preclinical,0.303647354895017,0.179306788834,oleanolic-acid,OTHER,0.3043663102778372,4.58238493374753,-0.4978991546759164
BRD-K90777969-300-01-2::2.5::HTS,BRD-K90777969-300-01-2,cutamesine,2.5,HTS,Exp_RPS20P31 (ENSG00000240925),GE,noncancer,sigma receptor agonist,SIGMAR1,,,Phase 2,0.25892724877012396,0.0792826776714,cutamesine,,,0,0
BRD-K90789829-001-07-8::2.5::HTS,BRD-K90789829-001-07-8,nefazodone,2.5,HTS,Exp_RNF141 (ENSG00000110315),GE,noncancer,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4",,,Withdrawn,0.290660392546216,0.0771575924502,nefazodone,,,0,0
BRD-K90817094-001-02-6::2.5::HTS,BRD-K90817094-001-02-6,bedaquiline,2.5,HTS,PROT_GAPDH_Caution,PROT,noncancer,ATPase inhibitor,,infectious disease,tuberculosis,Launched,0.302690408123572,0.0589947752427,bedaquiline,,,0,0
BRD-K90825648-001-02-0::2.5::HTS,BRD-K90825648-001-02-0,RS-127445,2.5,HTS,CRISPR_DOC2A (8448),AVANA_PUBLIC_18Q2,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Phase 1,0.285839654964406,0.00374080997569,RS-127445,,,0,0
BRD-K90868879-001-03-8::2.5::HTS,BRD-K90868879-001-03-8,canagliflozin,2.5,HTS,CRISPR_WWC1 (23286),AVANA_PUBLIC_18Q2,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,Launched,0.261967533221353,-0.0243224127173,canagliflozin,,,0,0
BRD-K90885812-004-24-2::2.5::HTS,BRD-K90885812-004-24-2,propantheline,2.5,HTS,MIRNA_hsa-miR-1973,MIRNA,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,peptic ulcer disease (PUD),Launched,0.246021640108895,0.0343785994931,propantheline,,,0,0
BRD-K90947825-001-02-7::2.5::HTS,BRD-K90947825-001-02-7,carboplatin,2.5,HTS,METHYL_MESP1,METHYL,chemo,"DNA alkylating agent, DNA inhibitor",,oncology,ovarian cancer,Launched,0.29320480362027695,0.0741786632629,carboplatin,,,0,0
BRD-K90948141-001-01-4::2.5::HTS,BRD-K90948141-001-01-4,indiplon,2.5,HTS,METABOL_asparagine,METABOL,noncancer,benzodiazepine receptor agonist,GABRA1,,,Phase 3,0.299327624592919,0.0568976225555,indiplon,,,0,0
BRD-K90982969-001-01-2::2.5::MTS004,BRD-K90982969-001-01-2,etilevodopa,2.5,MTS004,PROT_G6PD,PROT,noncancer,dopamine receptor agonist,DRD3,,,Phase 3,0.28073278446422806,0.149582027637,etilevodopa,,,0,0
BRD-K90993449-001-02-7::2.5::HTS,BRD-K90993449-001-02-7,KRN-633,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,"FLT1, FLT4, KDR",,,Preclinical,0.375175737692224,0.295754848332,KRN-633,,,0,0
BRD-K91065602-003-05-5::2.5::HTS,BRD-K91065602-003-05-5,vancomycin,2.5,HTS,DEM2_CSNK2A3 (283106),DEMETER2_COM,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,endocarditis,Launched,0.286458017448991,0.145951240638,vancomycin,,,0,0
BRD-K91111634-001-01-2::2.5::HTS,BRD-K91111634-001-01-2,rotigotine,2.5,HTS,CN_TBX5-AS1 (255480),CN,noncancer,dopamine receptor agonist,"ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome",Launched,0.273158662282888,0.131684211071,rotigotine,,,0,0
BRD-K91147684-001-01-5::2.5::HTS,BRD-K91147684-001-01-5,m-THP,2.5,HTS,CN_CHKB-AS1 (100144603),CN,noncancer,,,,,Phase 1,0.25681774372864397,0.0589028710342,m-THP,,,0,0
BRD-K91159026-001-01-7::2.5::HTS,BRD-K91159026-001-01-7,telcagepant,2.5,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,calcitonin antagonist,"CALCRL, RAMP1",,,Phase 3,0.26011900394440496,0.0875503811591,telcagepant,,,0,0
BRD-K91188791-001-18-3::2.5::HTS,BRD-K91188791-001-18-3,aloxistatin,2.5,HTS,PROT_Rictor_Caution,PROT,noncancer,protease inhibitor,CTSG,,,Phase 3,0.230574539738694,0.042831091873,aloxistatin,,,0,0
BRD-K91244729-003-01-3::2.316613157::MTS004,BRD-K91244729-003-01-3,propiverine,2.316613157,MTS004,DEM2_ACO1 (48),DEMETER2_COM,noncancer,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence,Launched,0.29446747183272903,0.134267571883,propiverine,,,0,0
BRD-K91263825-003-21-4::2.5::HTS,BRD-K91263825-003-21-4,nortriptyline,2.5,HTS,DEM2_RAB6A (5870),DEMETER2_COM,noncancer,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,Launched,0.283543768616116,0.109644442262,nortriptyline,,,0,0
BRD-K91301684-003-05-5::2.5::HTS,BRD-K91301684-003-05-5,noscapine,2.5,HTS,METABOL_lysine,METABOL,noncancer,"bradykinin receptor antagonist, tubulin polymerization inhibitor",SIGMAR1,pulmonary,cough suppressant,Launched,0.334131969113688,0.0940045159109,noscapine,,,0,0
BRD-K91308639-001-02-7::2.5::HTS,BRD-K91308639-001-02-7,apalutamide,2.5,HTS,DEM2_NUDT19 (390916),DEMETER2_COM,targeted cancer,androgen receptor antagonist,,oncology,prostate cancer,Launched,0.317434106381673,0.0828781209115,apalutamide,,,0,0
BRD-K91315211-300-05-7::2.5::HTS,BRD-K91315211-300-05-7,betahistine,2.5,HTS,Exp_KIAA0825 (ENSG00000185261),GE,noncancer,"histamine receptor agonist, histamine receptor antagonist","HRH1, HRH3",neurology/psychiatry,Meniere's disease,Launched,0.22612774757497,0.0560838523474,betahistine,,,0,0
BRD-K91336023-003-01-0::2.5::HTS,BRD-K91336023-003-01-0,mesulergine,2.5,HTS,PROT_Rictor_pT1135,PROT,noncancer,dopamine receptor agonist,"HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7",,,Phase 2,0.247549635064506,0.0375801946018,mesulergine,,,0,0
BRD-K91370081-001-25-1::2.5::HTS,BRD-K91370081-001-25-1,anisomycin,2.5,HTS,CRISPR_MYC (4609),AVANA_PUBLIC_18Q2,noncancer,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,Preclinical,0.40008690701782795,0.0992420297861,anisomycin,OTHER,0.3743549632526414,5.079599198909311,-0.8446409716274159
BRD-K91405252-001-01-9::2.500076093::MTS004,BRD-K91405252-001-01-9,MK-0354,2.500076093,MTS004,PROT_N-Cadherin,PROT,noncancer,niacin receptor agonist,"HCAR2, HCAR3",,,Phase 2,0.2413624499281,0.112870090108,MK-0354,,,0,0
BRD-K91422571-001-01-8::2.5::HTS,BRD-K91422571-001-01-8,tromaril,2.5,HTS,PROT_N-Cadherin,PROT,noncancer,prostanoid receptor antagonist,,,,Launched,0.29380545552940696,0.0754502939379,tromaril,,,0,0
BRD-K91456750-238-01-7::2.5::HTS,BRD-K91456750-238-01-7,sacubitril,2.5,HTS,Exp_MTX1P1 (ENSG00000236675),GE,noncancer,neprilysin inhibitor,MME,cardiology,congestive heart failure,Launched,0.302147895315833,0.040708801891,sacubitril,,,0,0
BRD-K91495480-001-02-2::2.5::HTS,BRD-K91495480-001-02-2,AGP-103,2.5,HTS,Exp_ACAD11 (ENSG00000240303),GE,noncancer,membrane permeability inhibitor,,,,Launched,0.35256750383634394,0.0887369486064,AGP-103,,,0,0
BRD-K91509126-001-23-6::2.5::HTS,BRD-K91509126-001-23-6,piceatannol,2.5,HTS,Exp_PCDHB19P (ENSG00000262096),GE,noncancer,SYK inhibitor,"ATP5A1, ATP5B, ATP5C1, IRF3",,,Preclinical,0.253311577028611,0.0530853652656,piceatannol,,,0,0
BRD-K91543828-001-02-0::2.500044381::MTS004,BRD-K91543828-001-02-0,pentostatin,2.500044381,MTS004,Exp_ANXA10 (ENSG00000109511),GE,chemo,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,Launched,0.266642232906593,0.0969082099615,pentostatin,,,0,0
BRD-K91544578-001-03-8::2.5::HTS,BRD-K91544578-001-03-8,nikethamide,2.5,HTS,MIRNA_hsa-miR-767-3p,MIRNA,noncancer,immunostimulant,,,,Withdrawn,0.295419426993213,0.0870382058487,nikethamide,,,0,0
BRD-K91601245-001-12-0::2.5::HTS,BRD-K91601245-001-12-0,mercaptopurine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.357806372894776,0.278849917866,mercaptopurine,OTHER,0.3593176407853801,3.7889997435007836,-3.758793341785228
BRD-K91614056-001-02-2::2.5::HTS,BRD-K91614056-001-02-2,trans-4-Hydroxycrotonic-acid,2.5,HTS,CN_STKLD1 (169436),CN,noncancer,gamma hydroxybutyric acid ligand,,,,Preclinical,0.24929676005439103,0.0383187277071,trans-4-Hydroxycrotonic-acid,,,0,0
BRD-K91623615-001-05-0::2.46::HTS,BRD-K91623615-001-05-0,ABT-751,2.46,HTS,Exp_COQ3 (ENSG00000132423),GE,chemo,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.413037323107545,0.346103026501,ABT-751,TUBULIN POLYMERIZATION INHIBITOR,0.4141087594605762,6.245009994681617,-2.735499490389284
BRD-K91699951-001-10-2::2.5::HTS,BRD-K91699951-001-10-2,benzonatate,2.5,HTS,CRISPR_COX6B1 (1340),AVANA_PUBLIC_18Q2,noncancer,local anesthetic,SCN5A,pulmonary,cough suppressant,Launched,0.288698721268257,0.130944111636,benzonatate,,,0,0
BRD-K91701654-001-03-1::2.38::HTS,BRD-K91701654-001-03-1,U-0126,2.38,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.395071124529589,0.365509090001,U-0126,MEK INHIBITOR,0.3900976174070792,0.5409891418466737,4.6813457537330985
BRD-K91740057-001-19-8::2.5::HTS,BRD-K91740057-001-19-8,felbinac,2.5,HTS,MIRNA_hsa-miR-380,MIRNA,noncancer,cyclooxygenase inhibitor,CTSL,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain",Launched,0.2604714683155,0.0684977802573,felbinac,,,0,0
BRD-K91758890-001-10-0::2.5::HTS,BRD-K91758890-001-10-0,4-HQN,2.5,HTS,Exp_PLRG1 (ENSG00000171566),GE,targeted cancer,PARP inhibitor,PARP1,,,Preclinical,0.309899451563859,0.0439255059622,4-HQN,,,0,0
BRD-K91822704-003-07-2::2.5::HTS,BRD-K91822704-003-07-2,torcitabine,2.5,HTS,CRISPR_OR51E2 (81285),AVANA_PUBLIC_18Q2,noncancer,DNA polymerase inhibitor,"DCK, TK2",,,Phase 2,0.273206858781545,0.00288712397846,torcitabine,,,0,0
BRD-K91825936-001-01-2::2.5::HTS,BRD-K91825936-001-01-2,ZK811752,2.5,HTS,PROT_p70S6K,PROT,targeted cancer,CC chemokine receptor antagonist,CCR1,,,Phase 2,0.312100236232693,0.140189099047,ZK811752,OTHER,0.3133845509706849,1.0986046691387492,-3.2144842425908458
BRD-K91868854-001-03-6::2.5::HTS,BRD-K91868854-001-03-6,2-[1-(4-piperonyl)piperazinyl]benzothiazole,2.5,HTS,DEM2_KCNA3 (3738),DEMETER2_COM,noncancer,serotonin receptor agonist,HTR4,,,Preclinical,0.23237844385077397,-0.00730698830871,2-[1-(4-piperonyl)piperazinyl]benzothiazole,,,0,0
BRD-K91900765-001-07-6::2.500030257::MTS004,BRD-K91900765-001-07-6,VX-745,2.500030257,MTS004,PROT_Fibronectin,PROT,targeted cancer,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",,,Phase 2,0.32837219792565303,0.17505433468,VX-745,OTHER,0.3256803111566912,-0.285238458944026,-1.8877749430792379
BRD-K91904471-001-02-4::2.5::HTS,BRD-K91904471-001-02-4,SD-169,2.5,HTS,METHYL_KIFAP3,METHYL,noncancer,p38 MAPK inhibitor,MAPK14,,,Preclinical,0.288186558830945,0.0687714160035,SD-169,,,0,0
BRD-K92000912-001-12-6::2.5::HTS,BRD-K92000912-001-12-6,AM-251,2.5,HTS,CRISPR_C9orf85 (138241),AVANA_PUBLIC_18Q2,targeted cancer,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",,,Preclinical,0.295291481279222,0.11626853375,AM-251,,,0,0
BRD-K92015269-300-01-2::2.5::HTS,BRD-K92015269-300-01-2,GBR-12783,2.5,HTS,PROT_4E-BP1_pS65,PROT,noncancer,dopamine uptake inhibitor,,,,Preclinical,0.268903779254602,0.0284783836896,GBR-12783,,,0,0
BRD-K92041145-001-09-5::2.5::HTS,BRD-K92041145-001-09-5,O6-Benzylguanine,2.5,HTS,PROT_PEA15,PROT,chemo,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,Phase 3,0.305782934320104,0.0600868407526,O6-Benzylguanine,,,0,0
BRD-K92049597-001-20-8::2.5::HTS,BRD-K92049597-001-20-8,triamterene,2.5,HTS,MIRNA_hsa-miR-346,MIRNA,noncancer,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema",Launched,0.324019694479683,0.164063756344,triamterene,OTHER,0.32143048760212456,-2.9273262198673358,0.4584560167330021
BRD-K92073408-001-15-7::2.5::MTS004,BRD-K92073408-001-15-7,norethindrone,2.5,MTS004,PROT_NF2_Caution,PROT,noncancer,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,Launched,0.266857178175244,0.0966181296303,norethindrone,,,0,0
BRD-K92073408-001-16-5::2.5::HTS,BRD-K92073408-001-16-5,norethindrone,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,Launched,0.316645243242322,0.23761290563,norethindrone,,,0,0
BRD-K92107055-001-01-9::2.5::HTS,BRD-K92107055-001-01-9,pimecrolimus,2.5,HTS,CRISPR_KRTAP17-1 (83902),AVANA_PUBLIC_18Q2,noncancer,calcineurin inhibitor,"FKBP1A, MTOR",dermatology,eczema,Launched,0.29561887489341304,0.13347804336,pimecrolimus,,,0,0
BRD-K92116564-001-01-4::2.5::HTS,BRD-K92116564-001-01-4,isoxepac,2.5,HTS,MIRNA_hsa-miR-1915,MIRNA,noncancer,anti-inflammatory agent,,,,Phase 2,0.261796719382214,0.0242439071826,isoxepac,,,0,0
BRD-K92213669-001-01-3::2.5::HTS,BRD-K92213669-001-01-3,lomitapide,2.5,HTS,PROT_YB-1,PROT,noncancer,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,Launched,0.280562589087276,-0.00639880048578,lomitapide,,,0,0
BRD-K92241597-001-06-0::2.5::HTS,BRD-K92241597-001-06-0,tosedostat,2.5,HTS,Exp_FMN1 (ENSG00000248905),GE,targeted cancer,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",,,Phase 2,0.37445984426334905,0.268478464041,tosedostat,OTHER,0.3716976424853837,4.644227552219071,-2.282116146083233
BRD-K92301463-001-05-5::0.25::HTS,BRD-K92301463-001-05-5,"16,16-dimethylprostaglandin-e2",0.25,HTS,Exp_HSD17B6 (ENSG00000025423),GE,targeted cancer,prostanoid receptor agonist,HPGD,,,Phase 2,0.319085473059705,0.108271174,"16,16-dimethylprostaglandin-e2",,,0,0
BRD-K92303087-001-01-6::2.5::HTS,BRD-K92303087-001-01-6,oglemilast,2.5,HTS,PROT_MIG-6,PROT,noncancer,phosphodiesterase inhibitor,,,,Phase 2,0.312368437366348,0.074011056352,oglemilast,,,0,0
BRD-K92382976-050-01-1::2.5::HTS,BRD-K92382976-050-01-1,5-carboxamidotryptamine,2.5,HTS,DEM2_U2AF1L4 (199746),DEMETER2_COM,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,Preclinical,0.277009775976833,0.0462356299603,5-carboxamidotryptamine,,,0,0
BRD-K92404805-001-07-0::2.5::HTS,BRD-K92404805-001-07-0,L-Quisqualic-acid,2.5,HTS,CRISPR_SLC6A3 (6531),AVANA_PUBLIC_18Q2,noncancer,glutamate receptor agonist,"FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8",,,Preclinical,0.285214216201115,0.147469169627,L-Quisqualic-acid,,,0,0
BRD-K92413528-001-06-9::2.5::MTS004,BRD-K92413528-001-06-9,procysteine,2.5,MTS004,METHYL_MIR4289,METHYL,noncancer,glutathione synthase stimulant,,,,Phase 3,0.25914606200627,0.0984744363139,procysteine,,,0,0
BRD-K92426617-001-06-3::2.5::MTS004,BRD-K92426617-001-06-3,esaprazole,2.5,MTS004,PROT_PKC-delta_pS664,PROT,noncancer,,,,,Phase 2,0.31539687142273604,0.059352801209,esaprazole,,,0,0
BRD-K92428153-001-04-4::2.5::HTS,BRD-K92428153-001-04-4,mycophenolate-mofetil,2.5,HTS,Exp_TCTA (ENSG00000145022),GE,noncancer,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.37285325141756104,0.253347268789,mycophenolate-mofetil,OTHER,0.3695616035480502,3.4492559036449983,-2.5088368919424884
BRD-K92428232-001-10-6::2.5::HTS,BRD-K92428232-001-10-6,GSK461364,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,PLK inhibitor,PLK1,,,Phase 1,0.377140029471395,0.308423858274,GSK461364,OTHER,0.375804521821895,4.55435145847577,-1.320208522167534
BRD-K92441787-001-04-1::2.5::HTS,BRD-K92441787-001-04-1,bexarotene,2.5,HTS,METHYL_PGBD2,METHYL,targeted cancer,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Launched,0.27721415123629806,0.127802281612,bexarotene,,,0,0
BRD-K92446736-003-02-2::2.5::HTS,BRD-K92446736-003-02-2,zatebradine,2.5,HTS,METHYL_SYN2,METHYL,noncancer,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",,,Phase 3,0.28152322524650103,0.0939394764757,zatebradine,,,0,0
BRD-K92467929-001-01-1::2.5::HTS,BRD-K92467929-001-01-1,oxandrolone,2.5,HTS,METHYL_WWC2,METHYL,noncancer,androgen receptor agonist,AR,endocrinology,weight-gain aid,Launched,0.24652993805312198,0.150248760427,oxandrolone,,,0,0
BRD-K92490248-001-06-6::2.500037393::MTS004,BRD-K92490248-001-06-6,anethole-trithione,2.500037393,MTS004,CN_PLCZ1 (89869),CN,noncancer,glutathione transferase stimulant,,,,Launched,0.2842879094685061,0.0444426701422,anethole-trithione,,,0,0
BRD-K92492521-001-02-9::2.5::HTS,BRD-K92492521-001-02-9,LY255283,2.5,HTS,Exp_SPDYE3 (ENSG00000214300),GE,noncancer,leukotriene receptor antagonist,"LTB4R, LTB4R2",,,Preclinical,0.281533254060466,0.0340512308233,LY255283,,,0,0
BRD-K92493880-001-03-0::2.5::HTS,BRD-K92493880-001-03-0,AMPA-(S),2.5,HTS,Exp_ACSM1 (ENSG00000166743),GE,noncancer,glutamate receptor agonist,GRIN1,,,Preclinical,0.310429533969584,0.0333481129173,AMPA-(S),,,0,0
BRD-K92577649-300-01-2::2.5::HTS,BRD-K92577649-300-01-2,GBR-13069,2.5,HTS,CRISPR_KLHL38 (340359),AVANA_PUBLIC_18Q2,noncancer,dopamine uptake inhibitor,SLC6A3,,,Preclinical,0.329844538320728,0.095666172569,GBR-13069,,,0,0
BRD-K92581468-001-01-6::2.389082227::MTS004,BRD-K92581468-001-01-6,ocinaplon,2.389082227,MTS004,MIRNA_hsa-miR-1911,MIRNA,noncancer,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA5",,,Phase 3,0.31577477373634005,0.0850808802918,ocinaplon,,,0,0
BRD-K92588747-051-02-7::2.5::HTS,BRD-K92588747-051-02-7,2-CMDO,2.5,HTS,CRISPR_GATAD2A (54815),AVANA_PUBLIC_18Q2,noncancer,dopamine receptor antagonist,"DRD2, DRD4",,,Preclinical,0.288105444882915,0.112446752229,2-CMDO,,,0,0
BRD-K92613113-066-02-7::2.5::HTS,BRD-K92613113-066-02-7,safinamide,2.5,HTS,METABOL_C18:2 SM,METABOL,noncancer,"dopamine uptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",MAOB,neurology/psychiatry,Parkinson's Disease,Launched,0.285514312125266,0.0860653735832,safinamide,,,0,0
BRD-K92657060-001-05-7::2.5::HTS,BRD-K92657060-001-05-7,zaleplon,2.5,HTS,Exp_EMC6 (ENSG00000127774),GE,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,Launched,0.319293952852984,0.172315428951,zaleplon,,,0,0
BRD-K92723993-001-06-7::2.5::HTS,BRD-K92723993-001-06-7,imatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)",Launched,0.244462394768401,0.255147250895,imatinib,,,0,0
BRD-K92731339-227-04-9::2.5::HTS,BRD-K92731339-227-04-9,perindopril,2.5,HTS,Exp_HOXA11 (ENSG00000005073),GE,noncancer,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction, coronary artery disease (CAD)",Launched,0.265184415085785,0.10026115192,perindopril,,,0,0
BRD-K92758126-001-18-8::1.44::HTS,BRD-K92758126-001-18-8,MD-920,1.44,HTS,METHYL_PISD,METHYL,targeted cancer,NFkB pathway inhibitor,AADACL2,,,Phase 1,0.28653437837713,0.0511117566142,MD-920,,,0,0
BRD-K92760278-001-07-3::2.43::HTS,BRD-K92760278-001-07-3,riboflavin,2.43,HTS,METABOL_PEP,METABOL,noncancer,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,Launched,0.278982263642078,0.0909588310397,riboflavin,,,0,0
BRD-K92778217-001-32-7::2.5::HTS,BRD-K92778217-001-32-7,mefenamic-acid,2.5,HTS,CRISPR_TPCN2 (219931),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,"KCNQ1, PTGS1, PTGS2, TRPM3",endocrinology,primary dysmenorrhea (PD),Launched,0.221349566819092,0.0410114469376,mefenamic-acid,,,0,0
BRD-K92830582-003-10-5::2.5::HTS,BRD-K92830582-003-10-5,propranolol-(R),2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,targeted cancer,adrenergic receptor antagonist,"ADRB2, ADRB3",,,Preclinical,0.28596455205565,-0.00661698923712,propranolol-(R),,,0,0
BRD-K92838188-001-01-9::2.5::HTS,BRD-K92838188-001-01-9,rifaximin,2.5,HTS,PROT_JAK2,PROT,noncancer,RNA synthesis inhibitor,NR1I2,gastroenterology,"diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)",Launched,0.287316769158728,0.141733602684,rifaximin,,,0,0
BRD-K92844263-001-09-8::2.5::HTS,BRD-K92844263-001-09-8,triacetin,2.5,HTS,CN_CCNK (8812),CN,noncancer,,,,,Launched,0.300661376760233,0.128177632132,triacetin,,,0,0
BRD-K92848252-001-01-9::2.5::HTS,BRD-K92848252-001-01-9,diminazene-aceturate,2.5,HTS,METHYL_CTAGE11P,METHYL,noncancer,angiotensin converting enzyme activator,"AOC1, PRDX5, PRSS1",,,Phase 3,0.301807362196522,0.0736823532966,diminazene-aceturate,,,0,0
BRD-K92872987-001-02-9::2.5::HTS,BRD-K92872987-001-02-9,cefpiramide,2.5,HTS,CRISPR_ALDH1A2 (8854),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,Launched,0.275520200534143,0.121077205411,cefpiramide,,,0,0
BRD-K92902018-001-01-9::2.507952536::MTS004,BRD-K92902018-001-01-9,hydroxyprogesterone-acetate,2.507952536,MTS004,DEM2_AGTPBP1 (23287),DEMETER2_COM,noncancer,progesterone receptor agonist,PGR,,,Launched,0.293520207713796,0.117410515666,hydroxyprogesterone-acetate,,,0,0
BRD-K92908289-001-01-8::2.501017998::MTS004,BRD-K92908289-001-01-8,medica-16,2.501017998,MTS004,METHYL_LINC00926,METHYL,noncancer,ATP citrase lyase inhibitor,FFAR1,,,Phase 2,0.234700226551332,0.1974070281,medica-16,,,0,0
BRD-K92968657-001-01-6::2.5::HTS,BRD-K92968657-001-01-6,tirapazamine,2.5,HTS,DEM2_IMPDH2 (3615),DEMETER2_COM,chemo,DNA inhibitor,,,,Phase 3,0.30069271223167604,0.0629922525991,tirapazamine,,,0,0
BRD-K92976206-001-01-5::2.5::HTS,BRD-K92976206-001-01-5,guanosine,2.5,HTS,METHYL_LOC100128770,METHYL,noncancer,,PNP,,,Preclinical,0.27263698347174997,0.132035297674,guanosine,,,0,0
BRD-K92980438-001-03-3::2.5::HTS,BRD-K92980438-001-03-3,3-bromopyruvate,2.5,HTS,MIRNA_hsa-miR-590-5p,MIRNA,targeted cancer,hexokinase inhibitor,HK2,,,Preclinical,0.275316358319293,0.0735129666907,3-bromopyruvate,,,0,0
BRD-K92984783-003-05-7::2.5::HTS,BRD-K92984783-003-05-7,melperone,2.5,HTS,Exp_MYO18B (ENSG00000133454),GE,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,psychosis,Launched,0.282019305360597,0.0749605669964,melperone,,,0,0
BRD-K92988025-001-01-9::2.5::HTS,BRD-K92988025-001-01-9,perflubron,2.5,HTS,DEM2_BLOC1S5-TXNDC5 (100526836),DEMETER2_COM,noncancer,contrast agent,,radiology,contrast agent,Launched,0.263820316203642,0.118636950019,perflubron,,,0,0
BRD-K92991072-001-04-9::2.5::HTS,BRD-K92991072-001-04-9,PAC-1,2.5,HTS,Exp_C22orf24 (ENSG00000128254),GE,targeted cancer,caspase activator,CASP3,,,Phase 1,0.255335870925484,0.139964432376,PAC-1,OTHER,0.2541909577932584,2.9622694588956135,-3.032555355759753
BRD-K93034159-001-25-8::2.5::HTS,BRD-K93034159-001-25-8,cladribine,2.5,HTS,METHYL_LOC100134391,METHYL,chemo,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Launched,0.36560620848838704,0.0859270534083,cladribine,OTHER,0.3705754486953171,4.209458045307586,-1.92954211115173
BRD-K93045741-001-01-0::2.5::HTS,BRD-K93045741-001-01-0,tozadenant,2.5,HTS,METABOL_5-HIAA,METABOL,noncancer,adenosine receptor antagonist,ADORA2A,,,Phase 3,0.308685356100956,0.125018775177,tozadenant,,,0,0
BRD-K93123848-001-04-1::2.5::HTS,BRD-K93123848-001-04-1,RAF265,2.5,HTS,Exp_PLEKHA6 (ENSG00000143850),GE,targeted cancer,"RAF inhibitor, VEGFR inhibitor",BRAF,,,Phase 2,0.410228004642371,0.318815125393,RAF265,RAF INHIBITOR,0.40331883615929054,3.6888583227367615,-2.482930255468452
BRD-K93176058-001-03-6::2.5::HTS,BRD-K93176058-001-03-6,AC-55649,2.5,HTS,METHYL_LOC101927066,METHYL,targeted cancer,retinoid receptor agonist,"RARA, RARB",,,Preclinical,0.30162997060130997,0.0537720313648,AC-55649,,,0,0
BRD-K93188295-300-02-2::2.5::HTS,BRD-K93188295-300-02-2,ARC-239,2.5,HTS,CN_UPP2 (151531),CN,noncancer,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C",,,Preclinical,0.262615336012692,0.0198090599227,ARC-239,,,0,0
BRD-K93231391-300-05-6::2.5::HTS,BRD-K93231391-300-05-6,ethambutol,2.5,HTS,Exp_RFPL1S (ENSG00000225465),GE,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis,Launched,0.24436611946820003,0.11223921571,ethambutol,,,0,0
BRD-K93240442-001-08-4::2.5::HTS,BRD-K93240442-001-08-4,dinitolmide,2.5,HTS,PROT_Src_pY527,PROT,noncancer,,,infectious disease,coccidiosis,Launched,0.27443334262108104,0.0997415196625,dinitolmide,,,0,0
BRD-K93255255-001-02-1::2.5::HTS,BRD-K93255255-001-02-1,indoximod,2.5,HTS,DEM2_RABGGTA (5875),DEMETER2_COM,targeted cancer,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,Phase 2,0.25458119148716896,0.0890408934511,indoximod,,,0,0
BRD-K93258693-001-17-3::2.5::HTS,BRD-K93258693-001-17-3,GW-9662,2.5,HTS,PROT_GSK3_pS9,PROT,noncancer,PPAR receptor antagonist,"NCOA2, PPARG, RXRA",,,Preclinical,0.303428535709418,0.0889401453486,GW-9662,,,0,0
BRD-K93441486-067-12-8::2.5::HTS,BRD-K93441486-067-12-8,diphemanil,2.5,HTS,MUTpool_NCOA2 (10499),MUTpool,noncancer,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,Launched,0.31529104813361797,0.0349722267623,diphemanil,,,0,0
BRD-K93442924-001-03-4::2.5::MTS004,BRD-K93442924-001-03-4,vorapaxar,2.5,MTS004,PROT_Lck,PROT,noncancer,thrombin receptor antagonist,F2R,cardiology,"myocardial infarction, peripheral artery disease (PAD)",Launched,0.244291752989035,0.11868458334,vorapaxar,,,0,0
BRD-K93460210-001-23-7::2.5::HTS,BRD-K93460210-001-23-7,lamotrigine,2.5,HTS,MIRNA_hsa-miR-526b,MIRNA,noncancer,"serotonin receptor antagonist, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, bipolar disorder",Launched,0.238824525009465,0.0900888247995,lamotrigine,,,0,0
BRD-K93468883-001-02-0::2.5::HTS,BRD-K93468883-001-02-0,IPI-145,2.5,HTS,DEM2_HSPA4 (3308),DEMETER2_COM,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 3,0.329902585566009,0.134928752357,IPI-145,PI3K INHIBITOR,0.3363087143545117,1.6859055506235796,-2.224646057915584
BRD-K93502141-001-01-6::2.5::HTS,BRD-K93502141-001-01-6,amylene-hydrate,2.5,HTS,DEM2_ATP5A1 (498),DEMETER2_COM,noncancer,local anesthetic,,,,Preclinical,0.25959790934301996,0.0598305431307,amylene-hydrate,,,0,0
BRD-K93568044-001-32-0::2.5::HTS,BRD-K93568044-001-32-0,hydrocortisone,2.5,HTS,CRISPR_PIGM (93183),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching",Launched,0.321027711367711,0.208101693583,hydrocortisone,GLUCOCORTICOID RECEPTOR AGONIST,0.3002482023954378,-4.076856524948506,-3.1062959562766483
BRD-K93611241-001-02-2::2.5::HTS,BRD-K93611241-001-02-2,diacetamate,2.5,HTS,Exp_LPO (ENSG00000167419),GE,noncancer,,,,,Preclinical,0.29622101601130396,0.0995007220559,diacetamate,,,0,0
BRD-K93618743-001-21-0::2.5::HTS,BRD-K93618743-001-21-0,ipriflavone,2.5,HTS,Exp_ALKBH6 (ENSG00000239382),GE,noncancer,bone resorption inhibitor,,orthopedics,osteoporosis,Launched,0.308940328412424,0.145635292328,ipriflavone,,,0,0
BRD-K93631643-001-02-4::2.5::HTS,BRD-K93631643-001-02-4,hordenine,2.5,HTS,METABOL_cAMP,METABOL,noncancer,,,,,Preclinical,0.256769848429488,0.0842872759577,hordenine,,,0,0
BRD-K93632104-001-17-2::2.5::HTS,BRD-K93632104-001-17-2,salicylic-acid,2.5,HTS,METABOL_propionylcarnitine,METABOL,noncancer,cyclooxygenase inhibitor,"AKR1C1, PTGS1, PTGS2",dermatology,acne vulgaris (AV),Launched,0.24442913680009,0.0621601995634,salicylic-acid,,,0,0
BRD-K93632104-001-18-0::2.5::HTS,BRD-K93632104-001-18-0,sodium-salicylate,2.5,HTS,METABOL_C36:1 DAG,METABOL,noncancer,prostanoid receptor antagonist,"ASIC3, PTGS1, PTGS2","endocrinology, neurology/psychiatry","fever, pain relief",Launched,0.24442913680009,0.0621601995634,sodium-salicylate,,,0,0
BRD-K93645900-001-11-3::2.5::HTS,BRD-K93645900-001-11-3,tadalafil,2.5,HTS,PROT_Src_pY527,PROT,noncancer,phosphodiesterase inhibitor,"PDE11A, PDE5A",cardiology,hypertension,Launched,0.259281096976279,0.0266766401457,tadalafil,,,0,0
BRD-K93754473-048-20-2::2.5::HTS,BRD-K93754473-048-20-2,tamoxifen,2.5,HTS,METHYL_HIST1H4B,METHYL,targeted cancer,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,Launched,0.24872177984510002,0.05211938895,tamoxifen,,,0,0
BRD-K93767137-001-01-1::2.5::HTS,BRD-K93767137-001-01-1,oseltamivir-carboxylate,2.5,HTS,METABOL_C24:1 SM,METABOL,noncancer,neuraminidase inhibitor,,infectious disease,influenza A virus infection,Launched,0.306227632195634,-0.00411594327419,oseltamivir-carboxylate,,,0,0
BRD-K93779381-001-01-9::2.5::HTS,BRD-K93779381-001-01-9,ingenol-mebutate,2.5,HTS,Exp_UBE2Q1 (ENSG00000160714),GE,noncancer,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),Launched,0.328234328552526,0.103488732787,ingenol-mebutate,,,0,0
BRD-K93806173-003-01-8::2.5::HTS,BRD-K93806173-003-01-8,N-MPPP,2.5,HTS,METABOL_urate,METABOL,noncancer,opioid receptor agonist,,,,Preclinical,0.27834943667225,0.0296883720375,N-MPPP,,,0,0
BRD-K93869735-001-01-1::2.5::HTS,BRD-K93869735-001-01-1,taltirelin,2.5,HTS,DEM2_CAPN9 (10753),DEMETER2_COM,noncancer,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,Launched,0.309237919272778,0.136236329357,taltirelin,,,0,0
BRD-K93880783-001-26-6::2.5::HTS,BRD-K93880783-001-26-6,stavudine,2.5,HTS,PROT_p90RSK_Caution,PROT,noncancer,"DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.280959164307411,0.0454924957132,stavudine,,,0,0
BRD-K93900986-001-15-0::2.613957824::MTS004,BRD-K93900986-001-15-0,stetaderm,2.613957824,MTS004,Exp_KANSL1-AS1 (ENSG00000214401),GE,targeted cancer,,,,,Launched,0.29601865133593996,0.0219302110722,stetaderm,,,0,0
BRD-K93918653-001-08-9::2.5::HTS,BRD-K93918653-001-08-9,quizartinib,2.5,HTS,METHYL_CXorf21,METHYL,targeted cancer,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",,,Phase 3,0.382219210356292,0.0960249204476,quizartinib,OTHER,0.38325683574115854,0.599357911606306,-3.1043466318201247
BRD-K93944989-001-08-0::0.25::HTS,BRD-K93944989-001-08-0,safingol,0.25,HTS,CN_CHN1 (1123),CN,targeted cancer,PKC inhibitor,TRPM3,,,Phase 1,0.312370815052169,0.00309169888432,safingol,,,0,0
BRD-K94072573-001-09-9::2.5::MTS004,BRD-K94072573-001-09-9,medronic-acid,2.5,MTS004,METHYL_AQP6,METHYL,noncancer,bone resorption inhibitor,,radiology,skeletal imaging agent,Launched,0.31358450271502303,0.13503167071,medronic-acid,,,0,0
BRD-K94080537-001-09-7::2.5::HTS,BRD-K94080537-001-09-7,diethyltoluamide,2.5,HTS,MIRNA_hsa-miR-1291,MIRNA,noncancer,ionotropic receptor IR40a activator,,dermatology,sunscreen lotion,Launched,0.25300348442049997,-0.0604272953096,diethyltoluamide,,,0,0
BRD-K94144010-001-13-9::2.5::HTS,BRD-K94144010-001-13-9,cotinine,2.5,HTS,MIRNA_hsa-miR-655,MIRNA,noncancer,nicotine metabolite,,,,Phase 2,0.313902469634674,0.12809755426,cotinine,,,0,0
BRD-K94146583-001-01-6::2.500085506::MTS004,BRD-K94146583-001-01-6,didox,2.500085506,MTS004,DEM2_SMG1P2 (440354),DEMETER2_COM,chemo,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer,Launched,0.287818012678002,0.111937087029,didox,,,0,0
BRD-K94176593-001-09-4::2.5::HTS,BRD-K94176593-001-09-4,TWS-119,2.5,HTS,Exp_TFPT (ENSG00000105619),GE,noncancer,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",,,Preclinical,0.33197013126115804,0.157041529062,TWS-119,OTHER,0.32997087258182256,1.4788597427421464,-4.564286532258556
BRD-K94239562-001-05-5::2.5::HTS,BRD-K94239562-001-05-5,paeonol,2.5,HTS,METHYL_KCNE1L,METHYL,noncancer,anti-inflammatory agent,,,,Preclinical,0.24470448602159803,0.0713184629027,paeonol,,,0,0
BRD-K94266545-001-24-1::2.5::HTS,BRD-K94266545-001-24-1,ronidazole,2.5,HTS,MIRNA_hsa-miR-196b,MIRNA,noncancer,antiprotozoal agent,,infectious disease,"histomoniasis, dysentry",Launched,0.275016093596525,0.0682377077439,ronidazole,,,0,0
BRD-K94288301-001-01-7::2.5::HTS,BRD-K94288301-001-01-7,letermovir,2.5,HTS,Exp_DBNDD1 (ENSG00000003249),GE,noncancer,CMV terminase inhibitor,,,,Phase 3,0.269396738896832,0.0844604088835,letermovir,,,0,0
BRD-K94293891-001-01-3::2.5::HTS,BRD-K94293891-001-01-3,suvorexant,2.5,HTS,METHYL_C11orf70,METHYL,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",neurology/psychiatry,insomnia,Launched,0.203618391660022,0.0501053813391,suvorexant,,,0,0
BRD-K94353609-001-21-6::2.5::HTS,BRD-K94353609-001-21-6,fluocinolone-acetonide,2.5,HTS,CRISPR_KIAA0586 (9786),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,Launched,0.268175867719735,0.0931202401299,fluocinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2630742906734965,-2.1093571738678274,-3.0835597038073743
BRD-K94358652-001-02-1::2.5::HTS,BRD-K94358652-001-02-1,daptomycin,2.5,HTS,PROT_SETD2_Caution,PROT,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, endocarditis",Launched,0.27854333021733196,0.124782454166,daptomycin,,,0,0
BRD-K94379058-001-06-8::2.5::HTS,BRD-K94379058-001-06-8,BML-190,2.5,HTS,CN_BCL2 (596),CN,noncancer,cannabinoid receptor inverse agonist,CNR2,,,Preclinical,0.276660664058117,0.0400953105418,BML-190,,,0,0
BRD-K94420399-001-01-9::2.5::HTS,BRD-K94420399-001-01-9,PF-04136309,2.5,HTS,CRISPR_NXN (64359),AVANA_PUBLIC_18Q2,targeted cancer,CC chemokine receptor antagonist,,,,Phase 2,0.267351841731067,0.105754520826,PF-04136309,,,0,0
BRD-K94436377-001-10-2::2.5::HTS,BRD-K94436377-001-10-2,diosmin,2.5,HTS,MIRNA_hsa-miR-922,MIRNA,noncancer,"aryl hydrocarbon receptor agonist, capillary stabilizing agent",AHR,"cardiology, hematology, dermatology","chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome",Launched,0.288517208995499,-0.0153700064781,diosmin,,,0,0
BRD-K94441233-001-13-0::2.6::HTS,BRD-K94441233-001-13-0,mevastatin,2.6,HTS,PROT_Paxillin_Caution,PROT,noncancer,HMGCR inhibitor,HMGCR,,,Preclinical,0.48809771899430604,0.38945069269,mevastatin,HMGCR INHIBITOR,0.4739397865621333,1.7595255719579952,5.0075305606717775
BRD-K94441233-001-17-1::2.5::HTS,BRD-K94441233-001-17-1,mevastatin,2.5,HTS,PROT_E-Cadherin,PROT,noncancer,HMGCR inhibitor,HMGCR,,,Preclinical,0.48809771899430604,0.38945069269,mevastatin,HMGCR INHIBITOR,0.4836388775413653,1.763828137985529,5.238064174438363
BRD-K94455792-001-01-8::2.5::HTS,BRD-K94455792-001-01-8,ICG-001,2.5,HTS,Exp_CD83 (ENSG00000112149),GE,targeted cancer,beta-catenin inhibitor,CTNNB1,,,Preclinical,0.35152659585230894,0.352329780801,ICG-001,OTHER,0.3539202530003946,2.606761968480133,-2.7936463337596216
BRD-K94485812-001-02-9::2.55::HTS,BRD-K94485812-001-02-9,LDN-57444,2.55,HTS,MIRNA_hsa-miR-934,MIRNA,noncancer,ubiquitin C-terminal hydrolase inhibitor,,,,Preclinical,0.276405855026229,0.150003853081,LDN-57444,OTHER,0.2898042178313945,-0.8065263115379607,-2.672493392117623
BRD-K94534639-001-02-5::2.5::HTS,BRD-K94534639-001-02-5,LY2811376,2.5,HTS,METHYL_ELL,METHYL,noncancer,beta-secretase inhibitor,BACE1,,,Phase 1,0.285178585854766,0.0292988535575,LY2811376,,,0,0
BRD-K94559059-091-01-6::2.5::HTS,BRD-K94559059-091-01-6,telotristat-ethyl,2.5,HTS,PROT_p21,PROT,noncancer,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,Launched,0.258905544068969,0.0144432805313,telotristat-ethyl,,,0,0
BRD-K94649603-001-10-6::2.5::HTS,BRD-K94649603-001-10-6,taxifolin,2.5,HTS,Exp_KRT16P2 (ENSG00000227300),GE,noncancer,opioid receptor antagonist,ADIPOR2,,,Phase 2,0.196841312405447,0.0550435826147,taxifolin,,,0,0
BRD-K94689771-001-09-0::1.95::HTS,BRD-K94689771-001-09-0,pinocembrin,1.95,HTS,METABOL_palmitoylcarnitine,METABOL,targeted cancer,cytochrome P450 inhibitor,CYP1B1,,,Phase 2,0.183000910228186,0.0608230278006,pinocembrin,,,0,0
BRD-K94720315-001-10-4::2.5::HTS,BRD-K94720315-001-10-4,chromocarb,2.5,HTS,METABOL_hexanoylcarnitine,METABOL,noncancer,antispasmodic,,,,Launched,0.239112020385768,0.124684149703,chromocarb,,,0,0
BRD-K94723713-001-10-6::2.5::HTS,BRD-K94723713-001-10-6,rutaecarpine,2.5,HTS,CRISPR_TICAM1 (148022),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,PTGS2,,,Preclinical,0.40900521701498405,0.174108964098,rutaecarpine,OTHER,0.3701827759933256,-1.9313333222712368,0.7308296552675566
BRD-K94780074-001-06-7::2.5::HTS,BRD-K94780074-001-06-7,S-Nitrosoglutathione,2.5,HTS,PROT_ATM,PROT,noncancer,nitric oxide stimulant,PTPN1,,,Phase 1,0.28451165445344107,0.0244387894573,S-Nitrosoglutathione,,,0,0
BRD-K94830213-001-01-3::2.635005669::MTS004,BRD-K94830213-001-01-3,tofisopam,2.635005669,MTS004,DEM2_FST (10468),DEMETER2_COM,noncancer,"phosphodiesterase inhibitor, cytochrome P450 inhibitor","CYP3A4, PDE10A, PDE2A, PDE3A, PDE4A",neurology/psychiatry,"anxiety, abstinence from alcohol",Launched,0.21754875453626502,0.1591527212,tofisopam,,,0,0
BRD-K94830329-001-03-0::2.5::HTS,BRD-K94830329-001-03-0,ataluren,2.5,HTS,Exp_NOTCH4 (ENSG00000204301),GE,noncancer,"CFTR channel agonist, dystrophin stimulant",DMD,"genetics, pulmonary","duchenne muscular dystrophy (DMD), cystic fibrosis",Launched,0.27885028340328494,0.059190645325,ataluren,,,0,0
BRD-K94832621-001-02-3::2.5::HTS,BRD-K94832621-001-02-3,Y-134,2.5,HTS,LIN_urinary_tract,LIN,targeted cancer,estrogen receptor antagonist,"ESR1, ESR2",,,Preclinical,0.285746260863794,0.08973121644,Y-134,,,0,0
BRD-K95015809-001-02-8::5::HTS,BRD-K95015809-001-02-8,2-cyanopyrimidine,5,HTS,Exp_IBSP (ENSG00000029559),GE,noncancer,cathepsin inhibitor,,,,Preclinical,0.263288097779008,0.0760770231794,2-cyanopyrimidine,,,0,0
BRD-K95053546-001-01-9::2.5::HTS,BRD-K95053546-001-01-9,tempol,2.5,HTS,CN_UBAC2-AS1 (100289373),CN,targeted cancer,free radical scavenger,,,,Phase 2,0.3560727788341429,0.156014923399,tempol,,,0,0
BRD-K95053546-001-02-7::2.5::HTS,BRD-K95053546-001-02-7,tempol,2.5,HTS,MIRNA_ebv-miR-BART7,MIRNA,targeted cancer,free radical scavenger,,,,Phase 2,0.25136596414472895,0.0566967013735,tempol,,,0,0
BRD-K95053546-001-03-5::2.5::HTS,BRD-K95053546-001-03-5,tempol,2.5,HTS,CRISPR_ADARB1 (104),AVANA_PUBLIC_18Q2,targeted cancer,free radical scavenger,,,,Phase 2,0.3560727788341429,0.142646552749,tempol,,,0,0
BRD-K95110148-003-01-5::2.5::HTS,BRD-K95110148-003-01-5,beta-funaltrexamine,2.5,HTS,Exp_RPS14P4 (ENSG00000226928),GE,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.24628061993821398,0.036065809889,beta-funaltrexamine,,,0,0
BRD-K95142244-001-01-5::2.5::HTS,BRD-K95142244-001-01-5,talazoparib,2.5,HTS,Exp_HNRNPC (ENSG00000092199),GE,targeted cancer,PARP inhibitor,PARP2,,,Phase 3,0.39706645269454205,0.347232919642,talazoparib,OTHER,0.3954384831904734,3.906241368568661,-3.3788598544732285
BRD-K95161686-001-02-8::2.5::HTS,BRD-K95161686-001-02-8,octisalate,2.5,HTS,METHYL_C1D,METHYL,noncancer,,,dermatology,sunscreen lotion,Launched,0.29947910335058303,0.042057653386,octisalate,,,0,0
BRD-K95237249-001-26-5::2.5::HTS,BRD-K95237249-001-26-5,probenecid,2.5,HTS,MIRNA_hsa-miR-622,MIRNA,noncancer,uricosuric blocker,"PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1","nephrology, rheumatology","hyperuricemia, gout",Launched,0.30622158862184806,0.070760802822,probenecid,,,0,0
BRD-K95260951-050-03-1::2.5::HTS,BRD-K95260951-050-03-1,asenapine,2.5,HTS,METABOL_anthranilic acid,METABOL,noncancer,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, HRH1, HRH2, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder",Launched,0.23119703252609397,0.105362382244,asenapine,,,0,0
BRD-K95292280-001-01-3::2.5::HTS,BRD-K95292280-001-01-3,SB-657510,2.5,HTS,METABOL_beta-alanine,METABOL,noncancer,urotensin receptor antagonist,UTS2R,,,Preclinical,0.27766070541769894,0.128314581916,SB-657510,,,0,0
BRD-K95309561-001-24-7::2.5::HTS,BRD-K95309561-001-24-7,dienestrol,2.5,HTS,Exp_SP8 (ENSG00000164651),GE,noncancer,estrogen receptor agonist,ESR1,endocrinology,menopause,Launched,0.27037358201554296,0.12788297389,dienestrol,,,0,0
BRD-K95362002-001-01-1::2.354783058::MTS004,BRD-K95362002-001-01-1,cipemastat,2.354783058,MTS004,METHYL_PDCD6IP,METHYL,noncancer,metalloproteinase inhibitor,"ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9",,,Phase 3,0.333337803639391,0.102138515217,cipemastat,,,0,0
BRD-K95412502-003-01-5::2.5::HTS,BRD-K95412502-003-01-5,istaroxime,2.5,HTS,METABOL_C36:2 DAG,METABOL,noncancer,ATPase inhibitor,ATP1A1,,,Phase 2,0.224874988103648,0.0456160433778,istaroxime,,,0,0
BRD-K95435023-001-10-1::2.5::HTS,BRD-K95435023-001-10-1,PHA-665752,2.5,HTS,PROT_VHL_Caution,PROT,targeted cancer,c-Met inhibitor,MET,,,Preclinical,0.38635460030431107,0.163467999571,PHA-665752,OTHER,0.3862645463920513,-6.775438290220227,1.6731693465479194
BRD-K95523387-001-09-6::2.5::HTS,BRD-K95523387-001-09-6,OLDA,2.5,HTS,Exp_CARD10 (ENSG00000100065),GE,noncancer,TRPV agonist,GPR119,,,Preclinical,0.4393146101698,0.340694623954,OLDA,OTHER,0.4411634355301423,3.3659279671588465,-3.916438838981284
BRD-K95573441-001-01-2::2.5::HTS,BRD-K95573441-001-01-2,PFK-015,2.5,HTS,PROT_HSP70_Caution,PROT,targeted cancer,phosphofructokinase inhibitor,PFKFB3,,,Phase 1,0.353394251913723,0.297257150931,PFK-015,OTHER,0.3596345759448296,5.0988187099203035,-1.4441940370653592
BRD-K95581532-001-01-5::2.5::HTS,BRD-K95581532-001-01-5,RN-1734,2.5,HTS,MIRNA_ebv-miR-BHRF1-2,MIRNA,noncancer,TRPV antagonist,TRPV4,,,Preclinical,0.282430173841609,0.0152540749597,RN-1734,,,0,0
BRD-K95600043-001-01-5::2.5::HTS,BRD-K95600043-001-01-5,NPY-5RA972,2.5,HTS,DEM2_RACGAP1 (29127),DEMETER2_COM,noncancer,neuropeptide receptor antagonist,NPY5R,,,Preclinical,0.25840778344827803,0.0985151934079,NPY-5RA972,,,0,0
BRD-K95609758-001-03-7::2.5::HTS,BRD-K95609758-001-03-7,BMS-191011,2.5,HTS,METHYL_CAPN7,METHYL,noncancer,potassium channel activator,KCNMA1,,,Preclinical,0.2817142560958039,0.0901839435073,BMS-191011,,,0,0
BRD-K95739795-001-03-7::2.5::HTS,BRD-K95739795-001-03-7,tetrabenazine,2.5,HTS,PROT_mTOR,PROT,noncancer,vesicular monoamine transporter inhibitor,"DRD2, SLC18A1, SLC18A2","infectious disease, neurology/psychiatry","cholera, Huntington's disease",Launched,0.289183938249695,0.0981903100523,tetrabenazine,,,0,0
BRD-K95763993-001-19-3::2.5::HTS,BRD-K95763993-001-19-3,trapidil,2.5,HTS,PROT_TSC1_Caution,PROT,noncancer,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),Launched,0.229959637731784,0.0668770031966,trapidil,,,0,0
BRD-K95773607-004-03-8::2.5::HTS,BRD-K95773607-004-03-8,darifenacin,2.5,HTS,MUTpool_VPS51 (738),MUTpool,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,Launched,0.3506408683027539,0.139785472271,darifenacin,,,0,0
BRD-K95785345-300-14-8::2.5::HTS,BRD-K95785345-300-14-8,thiamine,2.5,HTS,METABOL_pipecolic acid,METABOL,noncancer,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,Launched,0.24440198967335802,0.0488653369903,thiamine,,,0,0
BRD-K95785537-001-23-1::2.5::HTS,BRD-K95785537-001-23-1,PP-2,2.5,HTS,Exp_GYG2 (ENSG00000056998),GE,targeted cancer,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",,,Preclinical,0.324435726032246,0.164629178995,PP-2,OTHER,0.32192073855545233,1.6465578294906529,-2.8403816051113857
BRD-K95828359-001-01-0::2.5::HTS,BRD-K95828359-001-01-0,MK-3697,2.5,HTS,PROT_GSK3-alpha-beta_pS21_S9,PROT,noncancer,orexin receptor antagonist,HCRTR2,,,Phase 2,0.22139304828656897,0.116623055542,MK-3697,,,0,0
BRD-K95837862-300-01-7::2.5::HTS,BRD-K95837862-300-01-7,JDTic,2.5,HTS,DEM2_SYNRG (11276),DEMETER2_COM,noncancer,opioid receptor antagonist,OPRK1,,,Phase 1,0.30275075896868603,0.151360380786,JDTic,,,0,0
BRD-K95851186-001-07-8::2.5::HTS,BRD-K95851186-001-07-8,CGP-13501,2.5,HTS,METABOL_asparagine,METABOL,noncancer,GABA receptor modulator,GABBR1,,,Preclinical,0.296138098592232,0.0577143730585,CGP-13501,,,0,0
BRD-K95880107-001-02-4::2.5::HTS,BRD-K95880107-001-02-4,PH-797804,2.5,HTS,MUTpool_SLFN13 (146857),MUTpool,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK14",,,Phase 2,0.27528971337312896,0.0461774266878,PH-797804,,,0,0
BRD-K95899059-003-02-8::2.5::HTS,BRD-K95899059-003-02-8,LY344864,2.5,HTS,CN_TRDN (10345),CN,noncancer,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7",,,Preclinical,0.19688659664623603,0.0690178842575,LY344864,,,0,0
BRD-K95901403-001-04-5::2.5::HTS,BRD-K95901403-001-04-5,XL-147,2.5,HTS,Exp_CHST1 (ENSG00000175264),GE,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.31206070632039895,0.188998770154,XL-147,,,0,0
BRD-K95921201-001-14-6::2.5::HTS,BRD-K95921201-001-14-6,reserpine,2.5,HTS,CN_AQP7 (364),CN,noncancer,vesicular monoamine transporter inhibitor,"SLC18A1, SLC18A2",cardiology,hypertension,Launched,0.28445088179732303,0.0657608798932,reserpine,,,0,0
BRD-K95926480-003-03-6::2.5::HTS,BRD-K95926480-003-03-6,SRT1720,2.5,HTS,DEM2_BAAT (570),DEMETER2_COM,noncancer,SIRT activator,SIRT1,,,Preclinical,0.426226326037235,0.20029072347,SRT1720,OTHER,0.3999713186665028,0.3492427716909763,-2.7264524531644403
BRD-K95941975-001-01-5::2.5::MTS004,BRD-K95941975-001-01-5,piperazinedione,2.5,MTS004,CN_ANKRD32 (84250),CN,noncancer,DNA synthesis inhibitor,,,,Phase 2,0.22517052819185998,0.134935441405,piperazinedione,,,0,0
BRD-K95957366-001-02-6::2.5::HTS,BRD-K95957366-001-02-6,isaxonine,2.5,HTS,Exp_PHF5CP (ENSG00000267178),GE,noncancer,nerve growth factor agonist,,,,Withdrawn,0.272922653559747,0.119772372714,isaxonine,,,0,0
BRD-K96006502-001-02-6::2.5::HTS,BRD-K96006502-001-02-6,deflazacort,2.5,HTS,CN_PITRM1-AS1 (100507034),CN,noncancer,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,Launched,0.30413678278781703,0.0670076072107,deflazacort,GLUCOCORTICOID RECEPTOR AGONIST,0.3019696146349685,-1.4830526595601583,-2.768537059667172
BRD-K96029467-003-01-9::2.5::HTS,BRD-K96029467-003-01-9,alagebrium,2.5,HTS,PROT_4E-BP1_pS65,PROT,noncancer,glycosylation inhibitor,,,,Phase 2/Phase 3,0.251392124180514,0.0926140775167,alagebrium,,,0,0
BRD-K96042922-001-09-8::2.5::HTS,BRD-K96042922-001-09-8,etanidazole,2.5,HTS,CRISPR_HSPA9 (3313),AVANA_PUBLIC_18Q2,targeted cancer,bacterial cell wall synthesis inhibitor,,,,Phase 3,0.266138725374264,-0.0228832487111,etanidazole,,,0,0
BRD-K96055017-003-02-7::2.5::HTS,BRD-K96055017-003-02-7,1-acetyl-4-methylpiperazine,2.5,HTS,Exp_UTS2B (ENSG00000188958),GE,noncancer,acetylcholine receptor agonist,,,,Preclinical,0.242268915754109,0.0619057078015,1-acetyl-4-methylpiperazine,,,0,0
BRD-K96123349-236-02-8::2.5::HTS,BRD-K96123349-236-02-8,brequinar,2.5,HTS,Exp_SUPT16H (ENSG00000092201),GE,targeted cancer,dihydroorotate dehydrogenase inhibitor,DHODH,,,Phase 2,0.29512470705029803,0.220552021476,brequinar,OTHER,0.29410005685906243,3.086595486692464,-3.2806981288319124
BRD-K96153583-001-05-1::2.52::HTS,BRD-K96153583-001-05-1,cidofovir,2.52,HTS,METHYL_C10orf113,METHYL,noncancer,DNA polymerase inhibitor,,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis",Launched,0.283234152015305,0.0744271966444,cidofovir,,,0,0
BRD-K96159438-001-06-3::2.5::HTS,BRD-K96159438-001-06-3,adefovir-dipivoxil,2.5,HTS,METHYL_HSD17B1,METHYL,noncancer,DNA polymerase inhibitor,,infectious disease,hepatitis B,Launched,0.386354170994915,0.235122328164,adefovir-dipivoxil,OTHER,0.3950918226364605,3.73939093990152,-3.341743923241885
BRD-K96188950-001-16-9::2.5::HTS,BRD-K96188950-001-16-9,caffeic-acid-phenethyl-ester,2.5,HTS,METHYL_LOC647323,METHYL,targeted cancer,HIV integrase inhibitor,RELA,,,Preclinical,0.283727811687926,0.187667910255,caffeic-acid-phenethyl-ester,OTHER,0.2806804024090337,-3.614994751386871,-0.9389902263178111
BRD-K96194081-001-10-2::2.5::HTS,BRD-K96194081-001-10-2,cepharanthine,2.5,HTS,PROT_Akt,PROT,targeted cancer,NFkB pathway inhibitor,,,,Phase 2,0.307994427654144,0.138198252123,cepharanthine,,,0,0
BRD-K96206066-001-07-9::2.591957442::MTS004,BRD-K96206066-001-07-9,difenpiramide,2.591957442,MTS004,Exp_GMFG (ENSG00000130755),GE,noncancer,"cyclooxygenase inhibitor, prostaglandin inhibitor",,,,Launched,0.24707161557708698,0.111880740643,difenpiramide,,,0,0
BRD-K96233303-001-01-9::2.5::HTS,BRD-K96233303-001-01-9,TMS,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,,,,,Preclinical,0.41683894328688703,0.294438440136,TMS,OTHER,0.4177950692877515,5.029461040266439,-2.3186732123077785
BRD-K96253961-046-03-1::2.5::HTS,BRD-K96253961-046-03-1,metaraminol,2.5,HTS,CRISPR_ALG3 (10195),AVANA_PUBLIC_18Q2,noncancer,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,Launched,0.31131746291180395,0.15716245638,metaraminol,,,0,0
BRD-K96259238-001-01-4::2.5::HTS,BRD-K96259238-001-01-4,Y-320,2.5,HTS,Exp_LINC00337 (ENSG00000225077),GE,noncancer,interleukin inhibitor,IL17A,,,Preclinical,0.42001917429193103,0.323039703723,Y-320,OTHER,0.420901600786454,5.003582802492342,-0.7220534041491202
BRD-K96263742-001-14-8::2.5::HTS,BRD-K96263742-001-14-8,GW-7647,2.5,HTS,MUTpool_CLPB (81570),MUTpool,noncancer,PPAR receptor agonist,PPARA,,,Preclinical,0.274507770028694,0.033045719229,GW-7647,,,0,0
BRD-K96299080-001-02-7::2.5::HTS,BRD-K96299080-001-02-7,neohesperidin,2.5,HTS,RMUTmis_PIKFYVE (200576),MUT,noncancer,,,,,Preclinical,0.24226020240494398,0.0711765345193,neohesperidin,,,0,0
BRD-K96319534-003-03-9::2.5::HTS,BRD-K96319534-003-03-9,phentermine,2.5,HTS,DEM2_SERTM1 (400120),DEMETER2_COM,noncancer,"dopamine uptake inhibitor, serotonin reuptake inhibitor","MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",endocrinology,weight-loss aid,Launched,0.286224073997527,0.0555816499448,phentermine,,,0,0
BRD-K96344439-002-02-7::2.500011072::MTS004,BRD-K96344439-002-02-7,tofogliflozin,2.500011072,MTS004,CRISPR_VWA9 (81556),AVANA_PUBLIC_18Q2,noncancer,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus",Launched,0.44790221650083795,0.152135149649,tofogliflozin,OTHER,0.4591623499330409,4.527136121478663,-1.9740149474771629
BRD-K96391852-001-02-8::2.5::HTS,BRD-K96391852-001-02-8,aloperine,2.5,HTS,CRISPR_CHCHD5 (84269),AVANA_PUBLIC_18Q2,noncancer,,,,,Preclinical,0.301915529849068,0.106643430592,aloperine,,,0,0
BRD-K96424892-001-02-9::2.5::HTS,BRD-K96424892-001-02-9,chloramphenicol-palmitate,2.5,HTS,PROT_CD49b,PROT,noncancer,protein synthesis inhibitor,,"infectious disease, endocrinology","meningitis, fever, cholera",Launched,0.24870647783275102,0.0633037219112,chloramphenicol-palmitate,,,0,0
BRD-K96436774-001-01-8::2.5::HTS,BRD-K96436774-001-01-8,pelanserin,2.5,HTS,METABOL_C36:1 DAG,METABOL,noncancer,serotonin receptor antagonist,HTR2A,,,Phase 2,0.31268176943147197,0.11892405242,pelanserin,,,0,0
BRD-K96471533-001-09-0::2.592774962::MTS004,BRD-K96471533-001-09-0,nitazoxanide,2.592774962,MTS004,DEM2_UBXN1 (51035),DEMETER2_COM,noncancer,pyruvate ferredoxin oxidoreductase inhibitor,,gastroenterology,diarrhea,Launched,0.309088791469724,0.048153965252,nitazoxanide,,,0,0
BRD-K96550715-001-02-6::2.5::HTS,BRD-K96550715-001-02-6,linagliptin,2.5,HTS,Exp_HMGCL (ENSG00000117305),GE,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.28936638485334804,0.0976691133414,linagliptin,,,0,0
BRD-K96615647-001-01-2::2.5::HTS,BRD-K96615647-001-01-2,AV-608,2.5,HTS,PROT_p53_Caution,PROT,noncancer,tachykinin antagonist,TACR1,,,Phase 2,0.267975757553793,0.0771768445056,AV-608,,,0,0
BRD-K96631475-001-02-4::2.43::HTS,BRD-K96631475-001-02-4,10-deacetylbaccatin,2.43,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,antitumor agent,,,,Preclinical,0.403664124544914,0.560032043653,10-deacetylbaccatin,OTHER,0.40551943566990944,4.738151385341589,-3.7156911555064687
BRD-K96631475-001-04-0::2.5::HTS,BRD-K96631475-001-04-0,10-deacetylbaccatin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,antitumor agent,,,,Preclinical,0.403664124544914,0.560032043653,10-deacetylbaccatin,OTHER,0.36181193489145613,3.799105524062029,-1.6572124282240788
BRD-K96669468-300-01-1::2.5::MTS004,BRD-K96669468-300-01-1,pyridoxamine,2.5,MTS004,Exp_IBA57 (ENSG00000181873),GE,noncancer,AGE inhibitor,,,,Phase 3,0.260199035599333,0.192534668528,pyridoxamine,,,0,0
BRD-K96671969-001-03-1::2.5::HTS,BRD-K96671969-001-03-1,PA-824,2.5,HTS,PROT_GSK3-alpha-beta,PROT,noncancer,nitric oxide donor,FASN,,,Phase 3,0.311080358135028,0.0184361437309,PA-824,,,0,0
BRD-K96691275-001-01-2::2.5::MTS004,BRD-K96691275-001-01-2,mebrofenin,2.5,MTS004,PROT_Paxillin_Caution,PROT,noncancer,,,radiology,diagnostic agent,Launched,0.283712317025582,0.113007490664,mebrofenin,,,0,0
BRD-K96714749-001-01-0::2.5::HTS,BRD-K96714749-001-01-0,isobutamben,2.5,HTS,PROT_Stathmin,PROT,noncancer,local anesthetic,,,,Preclinical,0.239119449192262,0.0437846801292,isobutamben,,,0,0
BRD-K96720755-001-02-6::2.5::HTS,BRD-K96720755-001-02-6,relcovaptan,2.5,HTS,CRISPR_MAT2A (4144),AVANA_PUBLIC_18Q2,targeted cancer,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2, OXTR",,,Phase 2,0.271725160429745,0.0722446601123,relcovaptan,,,0,0
BRD-K96734425-304-01-7::2.500007729::MTS004,BRD-K96734425-304-01-7,ceftriaxone,2.500007729,MTS004,CRISPR_POU4F1 (5457),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis",Launched,0.28367731167918103,0.0820964632191,ceftriaxone,,,0,0
BRD-K96740444-001-02-1::2.5::HTS,BRD-K96740444-001-02-1,itopride,2.5,HTS,METHYL_EVPLL,METHYL,noncancer,dopamine receptor antagonist,"CHRM3, DRD2","gastroenterology, neurology/psychiatry","dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia",Launched,0.300647871267747,0.113450853621,itopride,,,0,0
BRD-K96758128-001-01-8::2.5::HTS,BRD-K96758128-001-01-8,WAY-213613,2.5,HTS,PROT_PKC-delta_pS664,PROT,noncancer,glutamate inhibitor,SLC1A2,,,Preclinical,0.292795674438957,0.0124047047279,WAY-213613,,,0,0
BRD-K96786677-236-02-4::2.5::HTS,BRD-K96786677-236-02-4,oxacillin,2.5,HTS,MUTpool_PAPOLG (64895),MUTpool,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,staphylococcal infections,Launched,0.250618592704354,0.0610423038017,oxacillin,,,0,0
BRD-K96786677-323-02-0::2.58::HTS,BRD-K96786677-323-02-0,oxacillin,2.58,HTS,CRISPR_HOXC9 (3225),AVANA_PUBLIC_18Q2,noncancer,bacterial cell wall synthesis inhibitor,,infectious disease,staphylococcal infections,Launched,0.250951900002654,0.112280402374,oxacillin,,,0,0
BRD-K96799727-001-06-6::2.5::HTS,BRD-K96799727-001-06-6,pifithrin-mu,2.5,HTS,METHYL_LOC102724000,METHYL,targeted cancer,HSP inhibitor,"HSPA1A, TP53",,,Preclinical,0.353466783003121,0.0849244606474,pifithrin-mu,,,0,0
BRD-K96809896-300-02-3::2.5::HTS,BRD-K96809896-300-02-3,SKF-86002,2.5,HTS,Exp_CASP16 (ENSG00000228146),GE,noncancer,p38 MAPK inhibitor,"ALOX5, MAPK14",,,Preclinical,0.30011562356718996,0.212946127965,SKF-86002,OTHER,0.2967516639613572,-4.1659044367660085,-2.938779710117675
BRD-K96862998-001-15-5::2.5::HTS,BRD-K96862998-001-15-5,pirfenidone,2.5,HTS,Exp_PIGUP1 (ENSG00000224437),GE,noncancer,TGF beta receptor inhibitor,"FURIN, TNF",pulmonary,idiopathic pulmonary fibrosis (IPF),Launched,0.259732107097382,0.0625855536559,pirfenidone,,,0,0
BRD-K96874295-015-01-0::2.500009134::MTS004,BRD-K96874295-015-01-0,gonadorelin,2.500009134,MTS004,Exp_SGTB (ENSG00000197860),GE,noncancer,gonadotropin releasing factor hormone receptor agonist,"GNRHR, GNRHR2",obstetrics/gynecology,"cystic ovaries, reproductive synchrony",Launched,0.292657283155567,0.161524945048,gonadorelin,,,0,0
BRD-K97009491-238-03-8::2.58::HTS,BRD-K97009491-238-03-8,calcium-levofolinate,2.58,HTS,METHYL_TMEM168,METHYL,targeted cancer,,,,,Launched,0.239604672813318,0.0628258325386,calcium-levofolinate,,,0,0
BRD-K97010173-001-04-1::2.5::HTS,BRD-K97010173-001-04-1,deferasirox,2.5,HTS,Exp_HMGA1P4 (ENSG00000234705),GE,noncancer,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",Launched,0.348215352206856,0.284282932373,deferasirox,OTHER,0.3489760681427184,2.827165965792285,-3.4166899105517214
BRD-K97019106-005-02-9::2.5::HTS,BRD-K97019106-005-02-9,"4-acetyl-1,1-dimethylpiperazinium",2.5,HTS,LIN_colorectal,LIN,noncancer,acetylcholine receptor agonist,,,,Preclinical,0.237422035072773,0.00895122241672,"4-acetyl-1,1-dimethylpiperazinium",,,0,0
BRD-K97025174-001-01-4::2.5::HTS,BRD-K97025174-001-01-4,capadenoson,2.5,HTS,CN_ST6GALNAC2 (10610),CN,noncancer,adenosine receptor agonist,ADORA1,,,Phase 2,0.256166607948041,0.0569202179733,capadenoson,,,0,0
BRD-K97028990-001-04-4::2.5::HTS,BRD-K97028990-001-04-4,quinine-ethyl-carbonate,2.5,HTS,PROT_IGFBP2,PROT,noncancer,,,infectious disease,malaria,Launched,0.217394475029208,0.0488720834937,quinine-ethyl-carbonate,,,0,0
BRD-K97045029-001-02-7::2.5::HTS,BRD-K97045029-001-02-7,pranlukast,2.5,HTS,METABOL_adipate,METABOL,noncancer,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF",pulmonary,"bronchospasm, asthma, bronchospasm, asthma",Launched,0.21155741744182396,0.0975531272644,pranlukast,,,0,0
BRD-K97045029-001-04-3::2.5::HTS,BRD-K97045029-001-04-3,pranlukast,2.5,HTS,DEM2_ZNF157 (7712),DEMETER2_COM,noncancer,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF",pulmonary,"bronchospasm, asthma, bronchospasm, asthma",Launched,0.21155741744182396,0.063657606962,pranlukast,,,0,0
BRD-K97056771-001-13-1::2.5::HTS,BRD-K97056771-001-13-1,GNF-2,2.5,HTS,CN_NFIA (4774),CN,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,Preclinical,0.24348223739757602,0.00558855838137,GNF-2,,,0,0
BRD-K97061094-001-21-4::2.63::HTS,BRD-K97061094-001-21-4,azacyclonol,2.63,HTS,CRISPR_MFSD9 (84804),AVANA_PUBLIC_18Q2,noncancer,histamine receptor antagonist,HRH1,,,Preclinical,0.26711819135777304,0.118481443745,azacyclonol,,,0,0
BRD-K97072811-001-11-4::2.5::HTS,BRD-K97072811-001-11-4,TG-003,2.5,HTS,Exp_PODNL1 (ENSG00000132000),GE,targeted cancer,CLK inhibitor,"CLK1, CLK4, DYRK1A, DYRK1B",,,Preclinical,0.241146328373959,0.111089858427,TG-003,,,0,0
BRD-K97101532-001-02-8::2.5::HTS,BRD-K97101532-001-02-8,tezacaftor,2.5,HTS,MUTpool_RABL2B (11158),MUTpool,noncancer,CFTR channel agonist,,pulmonary,cystic fibrosis,Launched,0.266798827149756,0.0107394119029,tezacaftor,,,0,0
BRD-K97118047-001-03-8::2.5::HTS,BRD-K97118047-001-03-8,"4,5,6,7-tetrabromobenzotriazole",2.5,HTS,DEM2_CRLF3 (51379),DEMETER2_COM,targeted cancer,casein kinase inhibitor,"AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.266567681814258,0.0886750864887,"4,5,6,7-tetrabromobenzotriazole",,,0,0
BRD-K97158071-001-18-1::2.5::HTS,BRD-K97158071-001-18-1,droperidol,2.5,HTS,DEM2_CDK20 (23552),DEMETER2_COM,noncancer,dopamine receptor antagonist,"ADRA1A, DRD2, DRD3, DRD4, HTR2A",gastroenterology,"nausea, vomiting",Launched,0.22101150417691,0.0427246857226,droperidol,,,0,0
BRD-K97163964-001-03-3::2.5::HTS,BRD-K97163964-001-03-3,L-Aspartic-Acid,2.5,HTS,CRISPR_ZBTB2 (57621),AVANA_PUBLIC_18Q2,noncancer,metallic radical formation stimulant,"ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13",,,Launched,0.30758305680847103,0.0897502833423,L-Aspartic-Acid,,,0,0
BRD-K97181089-003-24-7::2.5::HTS,BRD-K97181089-003-24-7,amiloride,2.5,HTS,DEM2_RHOH (399),DEMETER2_COM,noncancer,sodium channel blocker,"AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2",cardiology,"hypertension, congestive heart failure",Launched,0.251275151476074,0.0596815156234,amiloride,,,0,0
BRD-K97181463-003-01-1::2.5::HTS,BRD-K97181463-003-01-1,benidipine,2.5,HTS,MIRNA_hsa-miR-1250,MIRNA,noncancer,calcium channel blocker,"CACNA1C, CACNA1G",cardiology,hypertension,Launched,0.30108331656445897,0.0618699921989,benidipine,,,0,0
BRD-K97197005-001-03-2::2.5::HTS,BRD-K97197005-001-03-2,gestodene,2.5,HTS,PROT_VHL_Caution,PROT,noncancer,contraceptive agent,,endocrinology,contraceptive,Launched,0.24810932653159498,0.0465761461999,gestodene,,,0,0
BRD-K97309399-001-09-4::2.5::HTS,BRD-K97309399-001-09-4,thiothixene,2.5,HTS,MIRNA_hsa-miR-365,MIRNA,noncancer,dopamine receptor antagonist,"DRD1, DRD2, HRH1, HTR2A",neurology/psychiatry,schizophrenia,Launched,0.255430809474222,0.0536819564342,thiothixene,,,0,0
BRD-K97365803-001-02-1::2.5::HTS,BRD-K97365803-001-02-1,PI-828,2.5,HTS,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,PI3K inhibitor,,,,Preclinical,0.327760477676259,0.3583420816,PI-828,PI3K INHIBITOR,0.3270719363267902,1.0201200071596577,-1.0853515270108582
BRD-K97399794-001-15-3::2.5::HTS,BRD-K97399794-001-15-3,quercetin,2.5,HTS,Exp_CYSLTR1 (ENSG00000173198),GE,noncancer,polar auxin transport inhibitor,"ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1","neurology/psychiatry, allergy","fatigue, allergic rhinitis, drowsiness",Launched,0.297853758643435,0.107782228642,quercetin,,,0,0
BRD-K97417064-001-02-4::2.5::HTS,BRD-K97417064-001-02-4,acedapsone,2.5,HTS,Exp_CNTN6 (ENSG00000134115),GE,noncancer,,,infectious disease,leprosy,Launched,0.300013527121552,0.0986171959234,acedapsone,,,0,0
BRD-K97428065-001-01-2::2.5::HTS,BRD-K97428065-001-01-2,netupitant,2.5,HTS,DEM2_PYROXD2 (84795),DEMETER2_COM,noncancer,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",Launched,0.22930965122521,0.0582048975187,netupitant,,,0,0
BRD-K97440753-066-18-1::2.5::HTS,BRD-K97440753-066-18-1,dihydroergocristine,2.5,HTS,RMUTmis_MUC4 (4585),MUTmis,noncancer,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",,,Launched,0.308722008954612,0.0836389098772,dihydroergocristine,,,0,0
BRD-K97464279-001-03-5::2.5::HTS,BRD-K97464279-001-03-5,diaveridine,2.5,HTS,Exp_ARSG (ENSG00000141337),GE,noncancer,dihydrofolate reductase inhibitor,,,,Launched,0.35540026855648293,0.0913749302444,diaveridine,,,0,0
BRD-K97472745-001-01-8::2.5::HTS,BRD-K97472745-001-01-8,gestrinone,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,Launched,0.40080535874868495,0.172266878124,gestrinone,OTHER,0.4081288009520477,2.655695925595088,-1.740301322154453
BRD-K97521363-001-16-1::2.5::HTS,BRD-K97521363-001-16-1,clorsulon,2.5,HTS,METABOL_histidine,METABOL,noncancer,glycolysis inhibitor,,infectious disease,"gastrointestinal roundworms, lungworms, liver flukes, lice, mites",Launched,0.305121407258192,0.0241207010754,clorsulon,,,0,0
BRD-K97530723-001-20-9::2.5::HTS,BRD-K97530723-001-20-9,melatonin,2.5,HTS,CRISPR_ZNF652 (22834),AVANA_PUBLIC_18Q2,noncancer,"melatonin receptor agonist, nitric oxide synthase inhibitor","ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB",neurology/psychiatry,sleep cycle support,Launched,0.29260868099690995,0.0693444941063,melatonin,,,0,0
BRD-K97564742-050-32-7::2.5::HTS,BRD-K97564742-050-32-7,mepyramine,2.5,HTS,DEM2_KRT6C (286887),DEMETER2_COM,noncancer,histamine receptor antagonist,HRH1,"otolaryngology, obstetrics/gynecology","common cold, menstrual pain",Launched,0.30831066411537894,0.0989502157462,mepyramine,,,0,0
BRD-K97643133-003-09-3::2.5::HTS,BRD-K97643133-003-09-3,amiprilose,2.5,HTS,PROT_RAD51,PROT,noncancer,CD antagonist,,,,Phase 3,0.33967848836825804,0.119971622354,amiprilose,,,0,0
BRD-K97714174-001-01-3::2.5::HTS,BRD-K97714174-001-01-3,P22077,2.5,HTS,Exp_GSTA2 (ENSG00000244067),GE,noncancer,ubiquitin specific protease inhibitor,USP7,,,Preclinical,0.44851284022508203,0.330328404482,P22077,OTHER,0.4468387747414604,-0.5988986151819229,0.6481435755295273
BRD-K97746869-001-27-0::2.5::HTS,BRD-K97746869-001-27-0,chlorpropamide,2.5,HTS,Exp_KIAA1841 (ENSG00000162929),GE,noncancer,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,Launched,0.312413095336839,0.11369537839,chlorpropamide,,,0,0
BRD-K97752965-001-16-4::2.5::HTS,BRD-K97752965-001-16-4,nicorandil,2.5,HTS,DEM2_ACTL6A (86),DEMETER2_COM,noncancer,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,Launched,0.303076662976012,0.0287022811236,nicorandil,,,0,0
BRD-K97764662-001-17-3::2.5::HTS,BRD-K97764662-001-17-3,PD-173074,2.5,HTS,CRISPR_RELB (5971),AVANA_PUBLIC_18Q2,targeted cancer,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",,,Preclinical,0.362749258239907,0.151819476088,PD-173074,OTHER,0.365906831220606,0.3087459488449005,-2.4099803204810284
BRD-K97799481-001-16-0::2.5::HTS,BRD-K97799481-001-16-0,theophylline,2.5,HTS,MIRNA_hsa-miR-548m,MIRNA,noncancer,adenosine receptor antagonist,,pulmonary,"asthma, emphysema, bronchitis",Launched,0.32533906746884195,0.0733208519719,theophylline,,,0,0
BRD-K97799481-230-01-7::2.5::HTS,BRD-K97799481-230-01-7,aminophylline,2.5,HTS,MIRNA_ebv-miR-BART11-3p,MIRNA,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,"asthma, bronchitis, emphysema",Launched,0.32533906746884195,0.0733208519719,aminophylline,,,0,0
BRD-K97808269-001-02-7::2.5::HTS,BRD-K97808269-001-02-7,2-deoxyglucose,2.5,HTS,DEM2_ABCA11P (79963),DEMETER2_COM,targeted cancer,glycolysis inhibitor,"SLC2A1, SLC2A2, SLC2A3, SLC2A4",,,Phase 2,0.27313766999137,0.134425868822,2-deoxyglucose,,,0,0
BRD-K97810537-001-12-8::2.54::HTS,BRD-K97810537-001-12-8,beclomethasone-dipropionate,2.54,HTS,DEM2_C1orf74 (148304),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,Launched,0.292280849085579,0.107821240269,beclomethasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2912757818618376,-2.0696969209726563,-3.1957492101685228
BRD-K97810537-001-13-6::2.5::HTS,BRD-K97810537-001-13-6,beclomethasone-dipropionate,2.5,HTS,DEM2_WNT4 (54361),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,Launched,0.292280849085579,0.107821240269,beclomethasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2879234180035132,-2.4244479811229915,-3.1756520569631914
BRD-K97883416-001-01-4::2.5::HTS,BRD-K97883416-001-01-4,BMS-626529,2.5,HTS,DEM2_ADRA1A (148),DEMETER2_COM,noncancer,HIV attachment inhibitor,,,,Phase 3,0.32908124407743106,0.066484597582,BMS-626529,,,0,0
BRD-K97884852-001-05-4::2.5::HTS,BRD-K97884852-001-05-4,malotilate,2.5,HTS,CRISPR_BEND6 (221336),AVANA_PUBLIC_18Q2,noncancer,protein synthesis stimulant,,gastroenterology,hepatic cirrhosis,Launched,0.272261670838019,-0.004246391757,malotilate,,,0,0
BRD-K97939847-001-12-0::2.5::MTS004,BRD-K97939847-001-12-0,cridanimod,2.5,MTS004,Exp_CDH6 (ENSG00000113361),GE,targeted cancer,progesterone receptor agonist,PGR,,,Launched,0.30320346700046596,0.084360123201,cridanimod,,,0,0
BRD-K97963946-001-01-3::2.5::HTS,BRD-K97963946-001-01-3,EMD-1214063,2.5,HTS,PROT_c-Met_pY1235,PROT,targeted cancer,hepatocyte growth factor receptor inhibitor,MET,,,Phase 1,0.21074492090549105,0.10006840535,EMD-1214063,,,0,0
BRD-K98004573-051-02-8::2.5::HTS,BRD-K98004573-051-02-8,rupatadine,2.5,HTS,CN_LOC285762 (285762),CN,noncancer,"histamine receptor antagonist, platelet activating factor receptor antagonist","HRH1, PTAFR",allergy,"allergic rhinitis, urticaria",Launched,0.233600938808446,0.0553076332836,rupatadine,,,0,0
BRD-K98054437-001-09-9::2.494413182::MTS004,BRD-K98054437-001-09-9,epalrestat,2.494413182,MTS004,METHYL_SORBS2,METHYL,noncancer,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy,Launched,0.23164106078404104,0.0402036036473,epalrestat,,,0,0
BRD-K98143539-001-02-2::2.5::HTS,BRD-K98143539-001-02-2,compound-w,2.5,HTS,METHYL_RPS18P9,METHYL,noncancer,beta-secretase inhibitor,BACE1,,,Preclinical,0.24397578689615101,0.0324090140169,compound-w,,,0,0
BRD-K98155362-001-07-7::2.5::HTS,BRD-K98155362-001-07-7,GR46611,2.5,HTS,MIRNA_hsa-miR-200a,MIRNA,noncancer,serotonin receptor agonist,HTR1D,,,Preclinical,0.287313514664235,0.0363883543279,GR46611,,,0,0
BRD-K98157055-001-10-9::2.5::HTS,BRD-K98157055-001-10-9,SIB-1757,2.5,HTS,DEM2_TNFRSF10A (8797),DEMETER2_COM,noncancer,glutamate receptor antagonist,GRM5,,,Preclinical,0.284073920155899,0.112634329982,SIB-1757,,,0,0
BRD-K98174813-001-18-0::2.5::HTS,BRD-K98174813-001-18-0,chlorzoxazone,2.5,HTS,CRISPR_ENPEP (2028),AVANA_PUBLIC_18Q2,noncancer,bacterial 30S ribosomal subunit inhibitor,"KCNMA1, KCNN4",neurology/psychiatry,muscle relaxant,Launched,0.26809746983878,0.0475978245456,chlorzoxazone,,,0,0
BRD-K98203492-003-04-1::2.5::HTS,BRD-K98203492-003-04-1,GSK-J4,2.5,HTS,Exp_IFI44 (ENSG00000137965),GE,targeted cancer,histone lysine demethylase inhibitor,"KDM6A, KDM6B",,,Preclinical,0.384826978710271,0.224262557079,GSK-J4,OTHER,0.38388712805977104,3.0601400636803744,-3.130178923213866
BRD-K98251413-001-04-0::2.5::HTS,BRD-K98251413-001-04-0,IOX2,2.5,HTS,Exp_SLC1A1 (ENSG00000106688),GE,noncancer,hypoxia inducible factor inhibitor,"EGLN1, KDM2A, KDM5C",,,Preclinical,0.28733685914357504,0.102113997348,IOX2,,,0,0
BRD-K98372770-001-08-2::2.5::HTS,BRD-K98372770-001-08-2,L-165041,2.5,HTS,CRISPR_WISP3 (8838),AVANA_PUBLIC_18Q2,noncancer,PPAR receptor agonist,PPARD,,,Preclinical,0.340790712952732,0.17032538695,L-165041,,,0,0
BRD-K98384930-003-01-5::2.5::HTS,BRD-K98384930-003-01-5,finafloxacin,2.5,HTS,METHYL_ELMO1-AS1,METHYL,noncancer,bacterial DNA gyrase inhibitor,,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",Launched,0.277780769948355,0.164332221673,finafloxacin,,,0,0
BRD-K98453471-001-01-7::2.5::HTS,BRD-K98453471-001-01-7,salirasib,2.5,HTS,PROT_Akt,PROT,targeted cancer,mTOR inhibitor,TRPA1,,,Phase 2,0.298616245721907,0.0451020920531,salirasib,,,0,0
BRD-K98493452-001-14-9::2.5::HTS,BRD-K98493452-001-14-9,honokiol,2.5,HTS,Exp_RN7SL370P (ENSG00000243437),GE,targeted cancer,AKT inhibitor,"ALOX5, PTGS1, PTGS2",,,Phase 3,0.225754512815749,-0.00652368432608,honokiol,,,0,0
BRD-K98521173-001-19-4::2.5::HTS,BRD-K98521173-001-19-4,desoxycortone,2.5,HTS,LIN_melanoma,LIN,noncancer,mineralocorticoid receptor agonist,"NR3C1, NR3C2",,,Preclinical,0.325345766592195,0.0732438037411,desoxycortone,,,0,0
BRD-K98530306-003-18-3::2.5::HTS,BRD-K98530306-003-18-3,clonidine,2.5,HTS,DEM2_SAA1 (6288),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, neurology/psychiatry","hypertension, attention-deficit/hyperactivity disorder (ADHD)",Launched,0.254594774339934,0.0122202563303,clonidine,,,0,0
BRD-K98548675-001-05-9::2.5::HTS,BRD-K98548675-001-05-9,parthenolide,2.5,HTS,DEM2_GZF1 (64412),DEMETER2_COM,targeted cancer,NFkB pathway inhibitor,,,,Phase 1,0.33926857977245695,0.127202053291,parthenolide,NFKB PATHWAY INHIBITOR,0.34111410608747256,0.4436799617656748,-3.9832957359039303
BRD-K98557884-001-01-6::2.5::MTS004,BRD-K98557884-001-01-6,suritozole,2.5,MTS004,Exp_NLRP11 (ENSG00000179873),GE,noncancer,GABA receptor inverse agonist,GABBR1,,,Phase 2,0.296167988441011,0.101905822815,suritozole,,,0,0
BRD-K98572433-001-02-9::2.5::HTS,BRD-K98572433-001-02-9,AZD8931,2.5,HTS,Exp_MARVELD3 (ENSG00000140832),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB3",,,Phase 2,0.49567019791760103,0.538199163953,AZD8931,EGFR INHIBITOR,0.4653878098519101,1.076845857063517,-5.136897609427157
BRD-K98684188-001-02-9::2.5::HTS,BRD-K98684188-001-02-9,GSK-0660,2.5,HTS,METHYL_FLYWCH2,METHYL,noncancer,PPAR receptor antagonist,PPARD,,,Preclinical,0.262477753833824,0.0838532325337,GSK-0660,,,0,0
BRD-K98763141-001-30-8::2.5::HTS,BRD-K98763141-001-30-8,niflumic-acid,2.5,HTS,METHYL_DCTN5,METHYL,noncancer,cyclooxygenase inhibitor,"ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9","rheumatology, neurology/psychiatry","joint pain, muscle pain",Launched,0.22272625181205202,0.135211451256,niflumic-acid,,,0,0
BRD-K98769987-001-23-7::2.5::HTS,BRD-K98769987-001-23-7,flumazenil,2.5,HTS,MIRNA_hsa-miR-95,MIRNA,noncancer,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,sedative,Launched,0.275819789040187,0.0965462775485,flumazenil,,,0,0
BRD-K98795921-001-01-7::2.5::HTS,BRD-K98795921-001-01-7,SB-2343,2.5,HTS,Exp_EML6 (ENSG00000214595),GE,targeted cancer,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.350603657327445,0.18149064893,SB-2343,MTOR INHIBITOR,0.35165475946111874,2.7146587380723357,-1.220520328702252
BRD-K98963219-001-01-2::2.5::HTS,BRD-K98963219-001-01-2,ezatiostat,2.5,HTS,Exp_PRAC1 (ENSG00000159182),GE,targeted cancer,glutathione transferase inhibitor,GSTP1,,,Phase 2,0.23367026789092102,0.139792579693,ezatiostat,,,0,0
BRD-K99023089-001-03-7::2.5::HTS,BRD-K99023089-001-03-7,AZD5363,2.5,HTS,Exp_MSANTD4 (ENSG00000170903),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.458985352177641,0.409270156243,AZD5363,AKT INHIBITOR,0.4413405794192759,0.5501228502405617,-2.1156922189823604
BRD-K99048103-001-18-4::2.5::HTS,BRD-K99048103-001-18-4,acetarsol,2.5,HTS,MUTpool_CPNE6 (9362),MUTpool,noncancer,,,gastroenterology,diarrhea,Launched,0.30380265998099604,0.105645363257,acetarsol,,,0,0
BRD-K99063460-001-13-1::2.5::HTS,BRD-K99063460-001-13-1,didanosine,2.5,HTS,METHYL_BRD8,METHYL,noncancer,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1),Launched,0.284222091722957,0.00879459327123,didanosine,,,0,0
BRD-K99077012-001-01-9::2.332734192::MTS004,BRD-K99077012-001-01-9,befuraline,2.332734192,MTS004,PROT_ATM,PROT,noncancer,,,,,Phase 2,0.271370033811337,0.0673147117746,befuraline,,,0,0
BRD-K99092662-001-01-1::2.5::HTS,BRD-K99092662-001-01-1,PS178990,2.5,HTS,METABOL_3-methyladipate/pimelate,METABOL,noncancer,androgen receptor modulator,AR,,,Phase 1,0.225640986914265,0.0589610883511,PS178990,,,0,0
BRD-K99107520-001-24-1::2.5::HTS,BRD-K99107520-001-24-1,felbamate,2.5,HTS,METHYL_RTBDN,METHYL,noncancer,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,Launched,0.287972380108136,0.0912141002432,felbamate,,,0,0
BRD-K99113996-001-02-0::2.5::HTS,BRD-K99113996-001-02-0,AZD2014,2.5,HTS,DEM2_MTOR (2475),DEMETER2_COM,targeted cancer,mTOR inhibitor,MTOR,,,Phase 2,0.32905706719421,0.178492765532,AZD2014,MTOR INHIBITOR,0.3277067716469897,2.7108829098412697,-1.0474096841838592
BRD-K99121711-003-19-7::2.5::HTS,BRD-K99121711-003-19-7,cinchocaine,2.5,HTS,DEM2_KCTD5 (54442),DEMETER2_COM,noncancer,sodium channel blocker,"CALM1, SCN10A, SCN5A",neurology/psychiatry,local anesthetic,Launched,0.23466138016192897,0.126095516841,cinchocaine,,,0,0
BRD-K99149715-001-01-6::2.5::HTS,BRD-K99149715-001-01-6,plurisin-